2021-01-18 18:19:00 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': False, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': '/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_fr_underscore/checkpoint_best.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': './out_fp32_best/fr_underscore_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 768, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 768, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_underscore', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=False, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=768, max_tokens_valid=768, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_fr_underscore/checkpoint_best.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='./out_fp32_best/fr_underscore_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-18 18:19:01 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-18 18:19:01 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-18 18:19:01 | INFO | fairseq_cli.generate | loading model(s) from /global/lv71502/clang/fairseq/mBART_termeval/checkpoint_fr_underscore/checkpoint_best.pt
2021-01-18 18:19:31 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.src
2021-01-18 18:19:31 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.label
2021-01-18 18:19:31 | INFO | fairseq.tasks.translation | ./postprocessed/en_underscore test src-label 2024 examples
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-1.7992855310440063	
D-1685	-1.7992855310440063	
P-1685	-3.2340 -0.3645
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.6262142062187195	
D-664	-0.6262142062187195	
P-664	-1.1153 -0.1371
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.20487220585346222	▁EH
D-1528	-0.20487220585346222	EH
P-1528	-0.2085 -0.2077 -0.1984
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-1.1406865119934082	
D-1451	-1.1406865119934082	
P-1451	-1.9947 -0.2867
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.19143176078796387	
D-133	-0.19143176078796387	
P-133	-0.3042 -0.0787
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.4075741171836853	▁Clinic al
D-228	-0.4075741171836853	Clinical
P-228	-1.0445 -0.1879 -0.2650 -0.1329
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-0.848353922367096	▁d XA
D-1496	-0.848353922367096	dXA
P-1496	-0.6962 -0.5491 -1.7099 -0.4382
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.3886626362800598	▁FM
D-18	-0.3886626362800598	FM
P-18	-0.7804 -0.2738 -0.1118
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf pna
H-1699	-0.8688229918479919	▁ HF ▁p na
D-1699	-0.8688229918479919	HF pna
P-1699	-1.9878 -1.2929 -0.7543 -0.7591 -0.3079 -0.1110
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-1.1574289798736572	▁molecular
D-1607	-1.1574289798736572	molecular
P-1607	-0.8985 -2.3679 -0.2059
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.35219138860702515	
D-307	-0.35219138860702515	
P-307	-0.5731 -0.1312
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal_artery_stenosis
H-1592	-0.5101653337478638	▁Ren al ▁arter y _ ▁sten osis
D-1592	-0.5101653337478638	Renal artery_ stenosis
P-1592	-0.1137 -0.3103 -1.3059 -0.5086 -1.4681 -0.3911 -0.1241 -0.1845 -0.1850
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise cardiovascular health
H-1897	-1.6210352182388306	▁exercise ▁cardiovascular ▁health
D-1897	-1.6210352182388306	exercise cardiovascular health
P-1897	-5.0167 -0.3222 -2.1407 -0.4637 -0.1618
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-0.6569105982780457	▁tertia ry _ ▁refer ral
D-1497	-0.6569105982780457	tertiary_ referral
P-1497	-0.6741 -0.3407 -1.0182 -0.4879 -0.0114 -1.8660 -0.2000
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart_failure
H-1066	-1.8899037837982178	▁devices ▁heart _ ▁failure
D-1066	-1.8899037837982178	devices heart_ failure
P-1066	-5.0046 -2.8183 -1.0330 -2.0564 -0.1947 -0.2324
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse_events
H-1916	-1.010573148727417	
D-1916	-1.010573148727417	
P-1916	-1.7606 -0.2606
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver_disease
H-233	-0.9082027077674866	▁Live r _ ▁disease
D-233	-0.9082027077674866	Liver_ disease
P-233	-1.6936 -0.0200 -1.1709 -2.1027 -0.2704 -0.1916
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary_end_point inhospital mortality
H-190	-0.8413383364677429	hospital _ ▁mortal ity
D-190	-0.8413383364677429	hospital_ mortality
P-190	-3.0461 -0.6847 -0.2430 -0.5508 -0.2889 -0.2346
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective_cohort_study
H-1712	-0.9072413444519043	▁DESIGN
D-1712	-0.9072413444519043	DESIGN
P-1712	-2.1043 -0.4037 -0.2137
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute_care_surgery heart_transplant
H-1279	-1.3718122243881226	▁surgery ▁heart ▁transplant ▁recipient s
D-1279	-1.3718122243881226	surgery heart transplant recipients
P-1279	-3.5309 -1.4186 -1.1304 -2.5044 -0.5436 -0.3271 -0.1477
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-1.043104648590088	▁EC
D-256	-1.043104648590088	EC
P-256	-2.6745 -0.3059 -0.1489
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic_breathing heart_beat
H-1345	-1.538063645362854	▁breath ing ▁heart _ beat
D-1345	-1.538063645362854	breathing heart_beat
P-1345	-3.6683 -1.1058 -1.2765 -2.3492 -1.1409 -1.0521 -0.1738
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational_cohort_study
H-811	-0.8046743273735046	
D-811	-0.8046743273735046	
P-811	-1.4204 -0.1889
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective_cohort
H-211	-1.2544384002685547	▁DESIGN
D-211	-1.2544384002685547	DESIGN
P-211	-2.4315 -1.0633 -0.2686
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart_failure latin_america
H-1788	-1.0257489681243896	▁heart _ ▁failure ▁Latin ▁America
D-1788	-1.0257489681243896	heart_ failure Latin America
P-1788	-2.5802 -0.4551 -2.2272 -0.4738 -1.0477 -0.2251 -0.1712
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-0.7386586666107178	
D-1982	-0.7386586666107178	
P-1982	-1.3018 -0.1755
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-0.8114614486694336	▁ HF
D-346	-0.8114614486694336	HF
P-346	-2.2776 -0.4208 -0.2999 -0.2475
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.8450575470924377	▁mortal ity
D-589	-0.8450575470924377	mortality
P-589	-2.5696 -0.4631 -0.1962 -0.1514
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-0.7888224720954895	
D-796	-0.7888224720954895	
P-796	-1.3638 -0.2139
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.21286854147911072	
D-1944	-0.21286854147911072	
P-1944	-0.3438 -0.0819
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate_models
H-241	-1.123600721359253	
D-241	-1.123600721359253	
P-241	-1.7968 -0.4504
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.2825208902359009	▁doctor s
D-1686	-0.2825208902359009	doctors
P-1686	-0.5077 -0.1933 -0.3412 -0.0879
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.7690426111221313	
D-44	-0.7690426111221313	
P-44	-1.2890 -0.2491
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-0.6295334696769714	
D-1846	-0.6295334696769714	
P-1846	-1.0603 -0.1988
S-422	Heart rate was minimally altered.<unk>
T-422	heart_rate
H-422	-0.6424119472503662	▁Heart
D-422	-0.6424119472503662	Heart
P-422	-0.4254 -1.1712 -0.3307
S-1620	SETTING: Northwest United States.<unk>
T-1620	united_states
H-1620	-0.9920544028282166	
D-1620	-0.9920544028282166	
P-1620	-1.8715 -0.1126
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart_failure
H-1356	-1.264301061630249	▁Nutrition ▁heart _ ▁failure
D-1356	-1.264301061630249	Nutrition heart_ failure
P-1356	-2.5878 -1.9878 -0.7832 -1.8421 -0.1817 -0.2033
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-1.2126120328903198	▁Cross - sec tional
D-795	-1.2126120328903198	Cross-sectional
P-795	-3.2753 -0.1224 -0.9995 -2.0726 -0.4588 -0.3471
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.77761310338974	▁unilateral
D-1595	-0.77761310338974	unilateral
P-1595	-1.5748 -0.4501 -0.3079
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.6150235533714294	
D-363	-0.6150235533714294	
P-363	-1.0673 -0.1627
S-1683	She is going into heart failure.<unk>
T-1683	heart_failure
H-1683	-1.2402629852294922	▁heart _ ▁failure
D-1683	-1.2402629852294922	heart_ failure
P-1683	-2.1114 -1.1290 -2.4901 -0.2031 -0.2677
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-0.790256679058075	▁inter ven tions
D-798	-0.790256679058075	interventions
P-798	-2.5449 -0.7627 -0.3153 -0.2105 -0.1178
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.35015973448753357	
D-1249	-0.35015973448753357	
P-1249	-0.4008 -0.2995
S-979	Heart failure in the young.<unk>
T-979	heart_failure
H-979	-0.9159598350524902	▁Heart
D-979	-0.9159598350524902	Heart
P-979	-0.4279 -1.9479 -0.3721
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.2477393001317978	
D-1687	-0.2477393001317978	
P-1687	-0.4081 -0.0874
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.4431684911251068	▁c lin
D-1246	-0.4431684911251068	clin
P-1246	-0.9824 -0.2058 -0.3677 -0.2167
S-1248	Sci.<unk>
T-1248	
H-1248	-1.0450716018676758	
D-1248	-1.0450716018676758	
P-1248	-1.5921 -0.4980
S-1247	Trans.<unk>
T-1247	
H-1247	-1.3303511142730713	▁trans
D-1247	-1.3303511142730713	trans
P-1247	-0.6190 -3.0562 -0.3159
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end_point
H-1763	-0.48165568709373474	
D-1763	-0.48165568709373474	
P-1763	-0.8351 -0.1282
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.4305243492126465	
D-392	-0.4305243492126465	
P-392	-0.6986 -0.1625
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.850431501865387	▁inter media te _ fra il ty
D-1005	-0.850431501865387	intermediate_frailty
P-1005	-0.7742 -0.2282 -0.6147 -0.3065 -0.6343 -0.2434 -4.4955 -0.1762 -0.1808
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.5184199810028076	
D-1963	-0.5184199810028076	
P-1963	-0.7764 -0.2604
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.3984673321247101	▁CHF
D-222	-0.3984673321247101	CHF
P-222	-0.2085 -0.8745 -0.1124
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.12813815474510193	▁do d son
D-205	-0.12813815474510193	dodson
P-205	-0.2427 -0.0485 -0.0511 -0.2041 -0.0944
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.6184133291244507	
D-575	-0.6184133291244507	
P-575	-1.1147 -0.1221
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.705967366695404	
D-126	-0.705967366695404	
P-126	-1.2327 -0.1792
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air heart_failure
H-1805	-0.542935311794281	▁air ▁pollution ▁heart _ ▁failure
D-1805	-0.542935311794281	air pollution heart_ failure
P-1805	-0.0234 -0.5268 -0.4196 -0.8943 -1.3934 -0.2900 -0.2531
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients cardiovascular_disease
H-247	-1.3827682733535767	▁cardiovascular ▁disease
D-247	-1.3827682733535767	cardiovascular disease
P-247	-1.9214 -3.0744 -0.3643 -0.1711
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients followed_up
H-825	-0.8446362018585205	
D-825	-0.8446362018585205	
P-825	-1.5263 -0.1630
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective_matched_cohort_study
H-1619	-0.6325433254241943	
D-1619	-0.6325433254241943	
P-1619	-1.0934 -0.1717
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal_support
H-1296	-0.41430091857910156	
D-1296	-0.41430091857910156	
P-1296	-0.6939 -0.1347
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf mi
H-1101	-1.4852442741394043	▁temporal es ▁ HF ▁MI
D-1101	-1.4852442741394043	temporales HF MI
P-1101	-2.9457 -3.4433 -1.7411 -0.3477 -1.2053 -0.4529 -0.2607
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart_failure disease therapeutics
H-1073	-0.9500625729560852	▁Heart _ ▁failure
D-1073	-0.9500625729560852	Heart_ failure
P-1073	-0.3176 -1.2277 -1.5538 -1.5156 -0.1356
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary_outcomes hemostasis
H-1116	-0.683954656124115	▁hemos tas is
D-1116	-0.683954656124115	hemostasis
P-1116	-1.7440 -1.0869 -0.1906 -0.2174 -0.1809
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote_ischemic_conditioning patients heart_failure
H-53	-1.4183194637298584	▁Remote ▁ ische mic ▁condition ing ▁heart _ ▁failure
D-53	-1.4183194637298584	Remote ischemic conditioning heart_ failure
P-53	-1.4751 -3.7424 -1.4780 -0.5804 -0.2248 -1.1958 -3.7733 -1.0381 -1.6298 -0.2549 -0.2091
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart_rate_variability risk_stratification cardiac patients
H-1584	-1.5733729600906372	▁Heart _ f ré que nce
D-1584	-1.5733729600906372	Heart_fréquence
P-1584	-0.6692 -1.3515 -5.9514 -0.0478 -0.2782 -0.0701 -3.9038 -0.3149
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart_failure
H-1886	-1.971890926361084	▁Heart _ ▁failure
D-1886	-1.971890926361084	Heart_ failure
P-1886	-1.4964 -0.7345 -4.4227 -2.8443 -0.3615
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-0.6613747477531433	
D-1754	-0.6613747477531433	
P-1754	-1.1385 -0.1842
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-1.0696091651916504	▁rates ▁CHF
D-673	-1.0696091651916504	rates CHF
P-673	-2.3894 -1.5077 -0.1769 -0.2045
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-1.0709649324417114	
D-749	-1.0709649324417114	
P-749	-2.0547 -0.0872
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-1.1915115118026733	▁Sham - opera tion _ animal
D-1339	-1.1915115118026733	Sham-operation_animal
P-1339	-0.4321 -0.5164 -0.0113 -3.0742 -1.1750 -3.2837 -0.5718 -0.4675
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-0.8939492106437683	▁policy
D-312	-0.8939492106437683	policy
P-312	-1.8280 -0.7486 -0.1053
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.21406035125255585	
D-311	-0.21406035125255585	
P-311	-0.3292 -0.0989
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.3899237811565399	
D-885	-0.3899237811565399	
P-885	-0.6521 -0.1278
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.6790155172348022	
D-1399	-0.6790155172348022	
P-1399	-1.1457 -0.2123
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-1.4044609069824219	▁tax ono my
D-1125	-1.4044609069824219	taxonomy
P-1125	-4.7193 -0.1821 -1.6513 -0.3120 -0.1575
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse_events
H-1988	-0.5083898305892944	
D-1988	-0.5083898305892944	
P-1988	-0.8954 -0.1214
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin injected
H-957	-0.1798071563243866	▁do xor ubi cin
D-957	-0.1798071563243866	doxorubicin
P-957	-0.2299 -0.0715 -0.1679 -0.1071 -0.2655 -0.2369
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting cell anand
H-1037	-0.8046433329582214	▁cell ▁Anand
D-1037	-0.8046433329582214	cell Anand
P-1037	-2.9908 -0.0205 -0.1038 -0.1034
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox_proportional_hazards_models
H-712	-0.8569892644882202	▁co x ▁proportion al _ ▁hazard s
D-712	-0.8569892644882202	cox proportional_ hazards
P-712	-2.5676 -0.0705 -1.4539 -0.6011 -0.6727 -0.8238 -0.6009 -0.6393 -0.2831
S-949	No major complications occurred during follow-up.<unk>
T-949	complications follow-up
H-949	-0.36761248111724854	▁complica tions
D-949	-0.36761248111724854	complications
P-949	-0.8363 -0.1874 -0.3074 -0.1393
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient hf
H-364	-1.0274865627288818	▁ HF
D-364	-1.0274865627288818	HF
P-364	-3.2303 -0.4058 -0.2126 -0.2612
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors blood_transfusions
H-1684	-1.345441460609436	▁blood ▁trans fusion s
D-1684	-1.345441460609436	blood transfusions
P-1684	-5.9616 -0.7302 -0.0160 -0.5989 -0.4336 -0.3322
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart_failure patients bisphosphonates
H-1534	-0.9335355162620544	▁Heart _ ▁failure ▁bis phos phon ates
D-1534	-0.9335355162620544	Heart_ failure bisphosphonates
P-1534	-0.3806 -1.6007 -1.5748 -0.6807 -0.0541 -0.1663 -3.3244 -0.3729 -0.2473
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic heart_failure outcomes
H-1198	-1.2835649251937866	▁di ure tic _ utilisation ▁heart _ ▁failure
D-1198	-1.2835649251937866	diuretic_utilisation heart_ failure
P-1198	-0.3894 -0.1209 -3.2876 -2.4103 -2.1935 -1.4368 -0.9950 -1.6369 -0.1768 -0.1884
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 gene_expression heart_failure
H-169	-2.529942750930786	▁cas pas e ▁heart ▁failure
D-169	-2.529942750930786	caspase heart failure
P-169	-4.6666 -1.1915 -1.3722 -3.5997 -6.0716 -0.4282 -0.3799
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute_right_heart_failure pulmonary_hypertension
H-1090	-1.0417206287384033	▁right _ ▁heart _ ▁failure ▁pulmonar y ▁hyper tension
D-1090	-1.0417206287384033	right_ heart_ failure pulmonary hypertension
P-1090	-5.6326 -1.7605 -1.7010 -0.6861 -0.7068 -0.0020 -0.0926 -0.5388 -0.0004 -0.2031 -0.1352
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise cardiovascular
H-1900	-1.2951983213424683	▁benefits ▁cardiovascular
D-1900	-1.2951983213424683	benefits cardiovascular
P-1900	-1.4725 -1.0106 -2.5806 -0.1171
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american hf
H-1843	-0.9428647756576538	▁ HF
D-1843	-0.9428647756576538	HF
P-1843	-2.3381 -0.6587 -0.6737 -0.1009
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.7659963369369507	▁Interna l _ ▁reli ability ▁cro n bach
D-786	-0.7659963369369507	Internal_ reliability cronbach
P-786	-2.8434 -0.0895 -0.5054 -2.1847 -0.8086 -0.1039 -0.0380 -0.0809 -0.8371 -0.1685
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients hypertension
H-1889	-0.6394150853157043	▁hyper tension
D-1889	-0.6394150853157043	hypertension
P-1889	-2.1112 -0.0036 -0.2339 -0.2090
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-0.5003529787063599	
D-1616	-0.5003529787063599	
P-1616	-0.8655 -0.1352
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-0.8327664732933044	
D-32	-0.8327664732933044	
P-32	-1.4566 -0.2089
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.7385278940200806	
D-804	-0.7385278940200806	
P-804	-1.3119 -0.1651
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths strokes
H-778	-0.8133934736251831	▁per i pro ced ural
D-778	-0.8133934736251831	periprocedural
P-778	-2.4889 -0.2104 -0.0691 -0.0637 -0.1325 -2.6101 -0.1190
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty heart_failure
H-1000	-1.61871337890625	▁fra il ty _ ▁in _ ▁heart _ ▁failure
D-1000	-1.61871337890625	frailty_ in_ heart_ failure
P-1000	-4.3711 -1.1329 -3.4953 -2.1725 -1.3011 -1.6898 -1.3772 -0.4386 -1.0184 -0.5653 -0.2437
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea afterload
H-518	-1.5334270000457764	▁h z ▁after load _ ▁burde n
D-518	-1.5334270000457764	hz afterload_ burden
P-518	-5.3261 -2.3424 -3.3309 -0.0491 -0.7989 -1.0696 -0.0819 -0.5292 -0.2727
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.7437736392021179	
D-1469	-0.7437736392021179	
P-1469	-1.4116 -0.0760
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard_ratios cox_regression_analysis
H-1770	-0.8650564551353455	▁Hazard ▁co x
D-1770	-0.8650564551353455	Hazard cox
P-1770	-1.7942 -1.0346 -0.0658 -1.0295 -0.4011
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras atherosclerosis
H-1594	-0.8757830262184143	▁ RAS ▁at hero sc ler osis
D-1594	-0.8757830262184143	RAS atherosclerosis
P-1594	-1.4977 -0.0704 -0.5045 -0.4955 -2.5082 -2.1461 -0.3330 -0.1925 -0.1342
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient conditions
H-0	-1.1091114282608032	▁patient _ ▁safety ▁conditions
D-0	-1.1091114282608032	patient_ safety conditions
P-0	-2.2988 -1.3527 -2.2936 -0.0170 -0.3390 -0.3537
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss exercise training outcomes
H-1932	-0.560960590839386	▁PS SS
D-1932	-0.560960590839386	PSSS
P-1932	-0.9036 -0.5545 -0.6279 -0.1578
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas heart_failure disease
H-1479	-0.7917681932449341	▁Micro RNA s ▁heart _ ▁failure ▁disease
D-1479	-0.7917681932449341	MicroRNAs heart_ failure disease
P-1479	-1.0616 -0.0110 -0.0499 -1.3033 -0.6279 -1.5424 -0.2985 -2.0966 -0.1350
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise quality_of_life heart_failure
H-612	-1.9234415292739868	▁heart _ ▁failure
D-612	-1.9234415292739868	heart_ failure
P-612	-5.9201 -1.0526 -2.2002 -0.2943 -0.1500
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology bromodomain halts heart_failure
H-1033	-1.0077381134033203	▁Card i ology ▁inhibi tion ▁heart _ ▁failure
D-1033	-1.0077381134033203	Cardiology inhibition heart_ failure
P-1033	-0.1875 -0.6091 -0.8180 -4.4421 -0.0718 -0.6535 -1.2657 -1.6646 -0.2681 -0.0968
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart_failure_with_preserved_ejection_fraction
H-1885	-0.9196785092353821	▁heart _ ▁failure ▁e je ction _ fraction
D-1885	-0.9196785092353821	heart_ failure ejection_fraction
P-1885	-2.9858 -0.9044 -1.9552 -0.7508 -0.5395 -0.0945 -1.3216 -0.0087 -0.4154 -0.2210
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.705567479133606	▁implant ed _ ▁monitoring ▁devices
D-156	-0.705567479133606	implanted_ monitoring devices
P-156	-0.0019 -0.6135 -1.0398 -0.5205 -2.4439 -0.1941 -0.1253
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-0.7580960988998413	▁Media n _ ▁age
D-677	-0.7580960988998413	Median_ age
P-677	-0.5626 -0.0596 -0.7769 -2.3387 -0.6292 -0.1816
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.7299225926399231	
D-1759	-0.7299225926399231	
P-1759	-1.2603 -0.1996
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart_failure mortality
H-204	-0.47060129046440125	▁Heart _ ▁failure ▁cognitive ▁im pair ment ▁mortal ity
D-204	-0.47060129046440125	Heart_ failure cognitive impairment mortality
P-204	-0.2245 -1.0126 -0.5674 -0.6738 -1.2042 -0.0090 -0.1793 -0.4123 -0.4598 -0.2658 -0.1679
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv_fibrosis
H-280	-0.9363620281219482	▁LV ▁fibro sis
D-280	-0.9363620281219482	LV fibrosis
P-280	-0.0356 -1.1628 -0.3229 -3.0542 -0.1063
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology hospital
H-812	-0.8473294377326965	▁card i ology ▁university _ hospital
D-812	-0.8473294377326965	cardiology university_hospital
P-812	-2.1843 -0.9141 -0.6630 -1.0320 -1.1047 -0.5053 -0.2950 -0.0802
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.5442075133323669	▁ HF p EF
D-1078	-0.5442075133323669	HFpEF
P-1078	-1.4998 -0.8876 -0.0526 -0.6052 -0.1317 -0.0885
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf hf
H-1309	-1.3492096662521362	▁fréquence ▁ HF
D-1309	-1.3492096662521362	fréquence HF
P-1309	-2.6861 -3.0422 -0.2943 -0.4621 -0.2614
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic_balance
H-1375	-0.3952523171901703	▁autonomi c ▁balance
D-1375	-0.3952523171901703	autonomic balance
P-1375	-0.5001 -0.3242 -0.7534 -0.2253 -0.1732
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty hf
H-624	-1.359911561012268	▁ HF
D-624	-1.359911561012268	HF
P-624	-4.0369 -0.6074 -0.6092 -0.1862
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient hospital heart_failure
H-1960	-1.8064335584640503	
D-1960	-1.8064335584640503	
P-1960	-3.3826 -0.2303
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 functional_capacity
H-702	-1.6003761291503906	
D-702	-1.6003761291503906	
P-702	-2.9931 -0.2076
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient medical conditions
H-1688	-0.8124191761016846	▁in patient ▁medical ▁conditions
D-1688	-0.8124191761016846	inpatient medical conditions
P-1688	-1.6595 -0.0695 -2.6452 -0.0540 -0.2238 -0.2225
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral_stenosis medical_treatment heart_failure
H-332	-1.2642641067504883	▁Mit ral _ ▁sten osis ▁heart _ ▁failure
D-332	-1.2642641067504883	Mitral_ stenosis heart_ failure
P-332	-1.2243 -0.0160 -1.2998 -1.5945 -0.6083 -3.3184 -0.9963 -2.9006 -0.4866 -0.1978
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up_duration
H-495	-0.4978508949279785	▁media n _ ▁follow - up
D-495	-0.4978508949279785	median_ follow-up
P-495	-1.2898 -0.0741 -0.6642 -0.9765 -0.4457 -0.0189 -0.3581 -0.1555
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral_growth
H-511	-0.9373822212219238	▁competitive
D-511	-0.9373822212219238	competitive
P-511	-1.9498 -0.6322 -0.2302
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated mixed_linear_models
H-325	-1.0278923511505127	▁CO
D-325	-1.0278923511505127	CO
P-325	-1.3059 -1.4828 -0.2950
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart_failure hospitalization cardiovascular_death
H-410	-1.5092122554779053	▁heart _ ▁failure ▁cardiovascular ▁death
D-410	-1.5092122554779053	heart_ failure cardiovascular death
P-410	-1.6432 -0.8779 -2.8115 -1.5806 -3.2157 -0.3117 -0.1239
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary_outcomes quality_of_life
H-1654	-0.9574719667434692	▁cognitive _ fon ction nel
D-1654	-0.9574719667434692	cognitive_fonctionnel
P-1654	-1.4140 -2.1254 -1.3356 -0.1388 -0.5543 -0.9532 -0.1809
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin congestive_heart_failure
H-633	-0.624499499797821	▁vaso press in ▁con ges tive _ ▁heart _ ▁failure
D-633	-0.624499499797821	vasopressin congestive_ heart_ failure
P-633	-0.1638 -0.1189 -1.2278 -0.7159 -0.1577 -0.3305 -0.7532 -1.4952 -0.9016 -1.3301 -0.1858 -0.1137
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended_criteria_cardiac_transplantation
H-707	-0.6093210577964783	▁cardiac ▁transplant ation
D-707	-0.6093210577964783	cardiac transplantation
P-707	-0.5827 -2.0276 -0.0387 -0.2549 -0.1428
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness anemia
H-1679	-1.1210938692092896	▁Jehovah _ s _ ▁Wit ness ▁an emia
D-1679	-1.1210938692092896	Jehovah_s_ Witness anemia
P-1679	-0.0775 -2.2809 -1.5882 -1.3368 -0.1320 -1.3728 -3.2998 -0.3872 -0.5231 -0.2126
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 hf
H-1211	-0.28678181767463684	▁p de 2 ▁ HF
D-1211	-0.28678181767463684	pde2 HF
P-1211	-0.4592 -0.0226 -0.0709 -0.7249 -0.4241 -0.1769 -0.1288
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-0.7743292450904846	
D-1839	-0.7743292450904846	
P-1839	-1.4402 -0.1084
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-0.9442024827003479	
D-1998	-0.9442024827003479	
P-1998	-1.7340 -0.1544
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-1.7526856660842896	▁black
D-1634	-1.7526856660842896	black
P-1634	-2.3331 -2.6021 -0.3229
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.48963335156440735	
D-1261	-0.48963335156440735	
P-1261	-0.8021 -0.1772
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-0.9560786485671997	▁ metric _ ▁choice ▁read mission _ ▁metri cs
D-134	-0.9560786485671997	metric_ choice readmission_ metrics
P-134	-1.5963 -0.4239 -1.0456 -2.8819 -0.7155 -0.2358 -1.7630 -0.4504 -1.0348 -0.2310 -0.1386
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-2.2381060123443604	▁ET ▁CHF
D-261	-2.2381060123443604	ET CHF
P-261	-6.8037 -1.5900 -0.3706 -0.1881
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-0.5336156487464905	▁read mission _ metric
D-145	-0.5336156487464905	readmission_metric
P-145	-0.6218 -0.0991 -1.2116 -0.1326 -1.0337 -0.1028
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-0.7947381138801575	
D-958	-0.7947381138801575	
P-958	-1.4327 -0.1568
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician hospital physician
H-1726	-1.3375520706176758	▁physician
D-1726	-1.3375520706176758	physician
P-1726	-0.5224 -3.1829 -0.3074
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-0.47536665201187134	▁Media n _ ▁follow - up
D-1758	-0.47536665201187134	Median_ follow-up
P-1758	-0.7580 -0.1054 -0.9931 -1.1860 -0.3303 -0.0122 -0.2530 -0.1650
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs expenditures
H-1238	-1.0992239713668823	▁Ar rhythm ia - related ▁costs
D-1238	-1.0992239713668823	Arrhythmia-related costs
P-1238	-1.3731 -0.3067 -1.5835 -0.4575 -0.2939 -2.6076 -1.9777 -0.1939
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication sst2
H-403	-0.6773899793624878	▁Medica tion ▁s ST 2
D-403	-0.6773899793624878	Medication sST2
P-403	-0.2380 -0.0382 -0.8787 -1.7738 -0.9066 -0.6659 -0.2406
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable_hf
H-481	-1.047486424446106	▁reli ability ▁ HF
D-481	-1.047486424446106	reliability HF
P-481	-2.6948 -0.4003 -2.7704 -0.2114 -0.1135 -0.0945
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality sts
H-159	-1.090987205505371	▁mortal ity ▁s ts ▁h m
D-159	-1.090987205505371	mortality sts hm
P-159	-3.9289 -0.5326 -1.6496 -0.3757 -1.6981 -0.1322 -0.2466 -0.1642
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-1.0947608947753906	▁réseau _ meta - analys is
D-150	-1.0947608947753906	réseau_meta-analysis
P-150	-2.8797 -2.4210 -2.2074 -0.4976 -0.0988 -0.1657 -0.3201 -0.1678
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.4138428866863251	▁pro pens ity
D-1837	-0.4138428866863251	propensity
P-1837	-0.3831 -0.0949 -1.1750 -0.1817 -0.2345
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed mortality random-effects_models
H-64	-0.5813125967979431	▁mortal ity ▁random - effect s
D-64	-0.5813125967979431	mortality random-effects
P-64	-0.1407 -0.7512 -1.8983 -0.1690 -0.1653 -0.1186 -1.1251 -0.2824
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary_outcomes functional_capacity quality_of_life
H-616	-1.5753904581069946	
D-616	-1.5753904581069946	
P-616	-2.9678 -0.1830
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end_point
H-266	-0.3716922402381897	
D-266	-0.3716922402381897	
P-266	-0.6423 -0.1011
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical hypothermic_circulatory_arrest
H-598	-0.6304212808609009	▁sur g ical _ ▁tac tiques ▁circula tory _ ▁arrest
D-598	-0.6304212808609009	surgical_ tactiques circulatory_ arrest
P-598	-0.5866 -0.1458 -1.2164 -0.6452 -0.8380 -1.1607 -1.1681 -0.5333 -0.3101 -0.5191 -0.2722 -0.1694
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf patients intubated
H-219	-0.6676950454711914	▁CHF
D-219	-0.6676950454711914	CHF
P-219	-0.1095 -1.7154 -0.1782
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection_fraction bnp
H-194	-0.31068137288093567	▁e je ction _ fraction ▁sex ▁b NP
D-194	-0.31068137288093567	ejection_fraction sex bNP
P-194	-0.3987 -0.3375 -0.0046 -0.4599 -0.0081 -0.9367 -0.1066 -0.3508 -0.3554 -0.1485
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic_hf death
H-1796	-0.6551868319511414	▁Chro nic _ HF
D-1796	-0.6551868319511414	Chronic_HF
P-1796	-0.8312 -0.3246 -0.2865 -1.7355 -0.5622 -0.1910
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology diagnosed
H-352	-0.5463301539421082	▁MR ▁MS
D-352	-0.5463301539421082	MR MS
P-352	-1.1228 -0.4945 -0.4634 -0.1046
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients hfpef
H-787	-0.7228824496269226	▁ HF p EF
D-787	-0.7228824496269226	HFpEF
P-787	-2.4776 -0.7318 -0.1608 -0.6402 -0.1637 -0.1632
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac_amyloidosis
H-997	-0.4011758863925934	▁Card iac _ a my lo idos is
D-997	-0.4011758863925934	Cardiac_amyloidosis
P-997	-0.1315 -0.0963 -0.1217 -0.4839 -0.9756 -0.4190 -0.8680 -0.6813 -0.1517 -0.0827
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic medication death
H-507	-0.43288594484329224	▁Pig s ▁anti ar rhythm ic ▁medication
D-507	-0.43288594484329224	Pigs antiarrhythmic medication
P-507	-0.2557 -0.1138 -0.3124 -1.2855 -0.0654 -0.5330 -0.6884 -0.4095 -0.2322
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training heart_failure patients
H-1911	-1.307220458984375	▁Robot - assist ed _ training ▁heart _ ▁failure
D-1911	-1.307220458984375	Robot-assisted_training heart_ failure
P-1911	-1.2476 -0.5929 -0.0031 -0.8660 -2.4409 -2.1619 -2.9631 -0.6538 -2.4986 -0.6093 -0.3423
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients functional_capacity symptoms
H-550	-1.2337669134140015	
D-550	-1.2337669134140015	
P-550	-2.3008 -0.1667
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up patients
H-1009	-0.4315304458141327	
D-1009	-0.4315304458141327	
P-1009	-0.7700 -0.0931
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic biomarkers chronic_heart_failure
H-1471	-0.9325008392333984	▁bio mark ers ▁chronic _ heart _ ▁failure
D-1471	-0.9325008392333984	biomarkers chronic_heart_ failure
P-1471	-0.7251 -0.0117 -0.1267 -3.4658 -0.6703 -1.9881 -0.8308 -1.1581 -0.2211 -0.1275
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart_rate arterial_pressure
H-424	-0.7572911381721497	▁Heart _ ▁rate ▁arterial _ tension
D-424	-0.7572911381721497	Heart_ rate arterial_tension
P-424	-0.4484 -2.4011 -1.0722 -0.3370 -0.6764 -0.7452 -0.2279 -0.1501
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients therapy beta_blockade
H-1736	-1.696576476097107	▁beta ▁block ade
D-1736	-1.696576476097107	beta blockade
P-1736	-4.0567 -3.2406 -0.8281 -0.2035 -0.1539
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb correlated baseline hrqol
H-840	-0.7379164099693298	▁h gb ▁HR Qo L
D-840	-0.7379164099693298	hgb HRQoL
P-840	-0.0188 -0.1379 -3.6576 -0.0417 -0.9721 -0.2089 -0.1284
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients cardiac inflammatory biomarkers
H-1914	-0.816774308681488	▁cardiac ▁infla mma tory ▁bio mark ers
D-1914	-0.816774308681488	cardiac inflammatory biomarkers
P-1914	-0.1965 -4.2873 -0.5703 -0.9323 -0.7364 -0.0085 -0.1752 -0.2422 -0.2023
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected patients systolic_dysfunction
H-1069	-1.5606783628463745	▁sy sto lique _ ▁dys function
D-1069	-1.5606783628463745	systolique_ dysfunction
P-1069	-4.3057 -1.2421 -3.9037 -0.4879 -0.3022 -1.6751 -0.4344 -0.1344
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved_ejection_fraction outcomes
H-1464	-0.5938719511032104	▁e je ction _ fraction
D-1464	-0.5938719511032104	ejection_fraction
P-1464	-1.3143 -0.8306 -0.0334 -0.9825 -0.0768 -0.6762 -0.2433
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated_hf cardiovascular hospitalization
H-1797	-1.0751103162765503	▁ HF ▁cardiovascular
D-1797	-1.0751103162765503	HF cardiovascular
P-1797	-2.3488 -0.2597 -0.3966 -2.1907 -0.1798
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes patients heart_failure emergency_department
H-461	-1.9242258071899414	▁heart _ ▁failure
D-461	-1.9242258071899414	heart_ failure
P-461	-3.9058 -1.0956 -2.9651 -1.3868 -0.2680
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-1.497012972831726	▁US _ ▁health care
D-603	-1.497012972831726	US_ healthcare
P-603	-3.4190 -1.8939 -1.5161 -0.1663 -1.8416 -0.1451
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-0.6564230918884277	
D-591	-0.6564230918884277	
P-591	-1.0745 -0.2384
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.4334319531917572	
D-1923	-0.4334319531917572	
P-1923	-0.7193 -0.1475
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.5812872648239136	
D-800	-0.5812872648239136	
P-800	-1.0379 -0.1247
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.67098468542099	▁ab normal ▁cardiac
D-746	-0.67098468542099	abnormal cardiac
P-746	-0.9941 -0.0147 -1.4826 -0.7172 -0.1463
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug japan
H-1197	-0.9857480525970459	▁drug ▁Japan
D-1197	-0.9857480525970459	drug Japan
P-1197	-2.3746 -1.3484 -0.1222 -0.0979
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-0.6280919313430786	
D-1028	-0.6280919313430786	
P-1028	-1.1624 -0.0938
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-0.8867120742797852	▁risk
D-1206	-0.8867120742797852	risk
P-1206	-2.3328 -0.2170 -0.1103
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max significance
H-1255	-0.4922800660133362	▁VO 2 max
D-1255	-0.4922800660133362	VO2max
P-1255	-1.5664 -0.1575 -0.0326 -0.5004 -0.2045
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients esrd
H-394	-0.8775164484977722	▁ES RD
D-394	-0.8775164484977722	ESRD
P-394	-2.5363 -0.2331 -0.3702 -0.3703
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.3183935284614563	▁bio mark ers
D-70	-0.3183935284614563	biomarkers
P-70	-1.0333 -0.0325 -0.1281 -0.2522 -0.1458
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated hf
H-608	-0.7117372155189514	▁HR ▁ HF
D-608	-0.7117372155189514	HR HF
P-608	-0.6477 -2.3375 -0.1403 -0.2924 -0.1407
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome tug_test
H-799	-0.8532177805900574	▁m AIN _ o UTC OME _ me as ures ▁tu g
D-799	-0.8532177805900574	mAIN_oUTCOME_measures tug
P-799	-1.3530 -0.1210 -0.4059 -2.6726 -0.0139 -0.0925 -1.0936 -0.3155 -0.4180 -1.6741 -0.9986 -2.2601 -0.4441 -0.0823
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart_failure
H-1204	-1.844633936882019	▁heart _ ▁failure
D-1204	-1.844633936882019	heart_ failure
P-1204	-4.0225 -1.0725 -3.6167 -0.3647 -0.1468
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.38582608103752136	
D-1854	-0.38582608103752136	
P-1854	-0.6594 -0.1123
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality_of_life
H-1919	-1.2476253509521484	
D-1919	-1.2476253509521484	
P-1919	-2.3538 -0.1415
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart_failure_with_preserved_left_ventricular_ejection_fraction
H-1299	-0.659122109413147	▁Heart ▁vent ri cular _ ▁e je ction _ fraction
D-1299	-0.659122109413147	Heart ventricular_ ejection_fraction
P-1299	-0.1551 -1.1706 -0.2376 -0.2701 -1.3266 -1.5898 -0.7429 -0.2665 -1.4976 -0.0061 -0.4369 -0.2098
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet aortic_pressure
H-581	-1.3265225887298584	▁a or tic _ tension _ cur ve
D-581	-1.3265225887298584	aortic_tension_curve
P-581	-5.2967 -0.3332 -2.1838 -0.4293 -1.4019 -1.8389 -1.0067 -0.1507 -0.3188 -0.3053
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart_failure hf therapy
H-1067	-1.3504151105880737	▁heart _ ▁failure HF ▁ therapy
D-1067	-1.3504151105880737	heart_ failureHF therapy
P-1067	-5.3164 -0.6518 -2.5517 -0.1978 -1.6072 -0.0300 -0.2759 -0.1725
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician outcomes discharge
H-1414	-0.4270338714122772	▁physician _ continu ity ▁dis charge
D-1414	-0.4270338714122772	physician_continuity discharge
P-1414	-0.1241 -0.7118 -0.7523 -0.8080 -0.5418 -0.0029 -0.3200 -0.1553
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart_failure public health
H-1606	-1.087241530418396	▁Heart _ ▁failure ▁public _ ▁health
D-1606	-1.087241530418396	Heart_ failure public_ health
P-1606	-1.8741 -0.7666 -2.3134 -0.1113 -0.4658 -1.3449 -1.5413 -0.2805
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity patients breast_cancer
H-669	-0.44154563546180725	▁Tras tuz um ab - related _ ▁cardio toxic ity ▁breast ▁cancer
D-669	-0.44154563546180725	Trastuzumab-related_ cardiotoxicity breast cancer
P-669	-0.3591 -0.0069 -0.0537 -0.3245 -0.5231 -0.4173 -0.6582 -0.0942 -0.3440 -1.1800 -0.4184 -1.2081 -0.4270 -0.1673
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital coprimary_outcome
H-1651	-1.2619404792785645	▁Night s ▁hospital ▁co prima ry ▁outcome
D-1651	-1.2619404792785645	Nights hospital coprimary outcome
P-1651	-1.2366 -0.0723 -5.1594 -0.4554 -0.0004 -1.0660 -2.7112 -0.3661 -0.2899
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac symptoms congenital lesions
H-983	-0.713342547416687	▁Card iac
D-983	-0.713342547416687	Cardiac
P-983	-0.3870 -0.3903 -1.9046 -0.1715
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative albumin
H-539	-1.057937741279602	▁Post operativ e _ ▁normal ization ▁album in
D-539	-1.057937741279602	Postoperative_ normalization albumin
P-539	-3.4873 -0.1408 -0.4272 -1.4389 -1.7603 -0.9442 -1.1473 -0.8197 -0.2836 -0.1299
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan vasopressin_type_2_receptor_antagonist
H-1195	-0.41102927923202515	▁Tol va p tan ▁vaso press in ▁receptor
D-1195	-0.41102927923202515	Tolvaptan vasopressin receptor
P-1195	-0.3026 -0.0296 -0.2930 -0.0710 -0.0987 -0.1186 -1.8414 -0.2165 -0.9856 -0.1534
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular_scaffolds heart pathology
H-989	-1.2485036849975586	▁molecular _ ▁sc af fold s ▁heart _ path ologie
D-989	-1.2485036849975586	molecular_ scaffolds heart_pathologie
P-989	-2.7656 -2.4350 -2.6536 -2.4212 -0.3349 -0.1231 -0.4567 -1.4880 -0.3639 -1.2284 -0.4849 -0.2270
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional_ms reported patients degenerative_mr
H-339	-0.4054892957210541	▁Fun ction al ▁MS ▁de genera tive ▁MR
D-339	-0.4054892957210541	Functional MS degenerative MR
P-339	-0.3402 -0.0016 -0.0883 -0.6912 -1.7427 -0.4881 -0.0298 -0.2567 -0.3170 -0.0993
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart_failure hf leading mortality society
H-1034	-0.8125101923942566	▁Heart _ ▁failure HF ▁mortal ity
D-1034	-0.8125101923942566	Heart_ failureHF mortality
P-1034	-0.7198 -0.3591 -1.4946 -1.2501 -1.0848 -0.3884 -1.0176 -0.1857
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone systolic_heart_failure
H-437	-0.8699665665626526	▁spi rono lac tone ▁sy sto lique _ ▁heart _ ▁failure
D-437	-0.8699665665626526	spironolactone systolique_ heart_ failure
P-437	-0.9961 -0.0421 -0.1428 -0.1071 -1.6791 -0.2718 -2.8493 -0.4147 -1.8007 -1.2620 -1.3709 -0.2421 -0.1307
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology chronic_heart_failure bisoprolol
H-645	-1.1518577337265015	▁chronic _ heart _ ▁failure ▁bis o pro lol
D-645	-1.1518577337265015	chronic_heart_ failure bisoprolol
P-645	-6.9773 -0.8566 -1.8410 -0.7099 -1.2938 -0.3167 -0.1361 -0.0246 -0.1181 -0.2736 -0.1227
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate_adjustment cox_proportional_hazards_models
H-785	-0.6081392168998718	▁co x ▁proportion al _ ▁hazard s
D-785	-0.6081392168998718	cox proportional_ hazards
P-785	-0.8166 -0.3319 -0.4145 -0.5808 -0.8660 -0.5812 -0.7294 -0.8771 -0.2757
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic hf
H-1072	-1.485289454460144	▁ HF
D-1072	-1.485289454460144	HF
P-1072	-4.2013 -1.3645 -0.2615 -0.1139
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician hf
H-1732	-0.9342665672302246	▁clinic ian ▁expertise ▁ HF
D-1732	-0.9342665672302246	clinician expertise HF
P-1732	-1.9708 -1.6590 -1.2557 -0.8573 -0.1973 -0.4742 -0.1255
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-0.593113124370575	
D-1576	-0.593113124370575	
P-1576	-0.9641 -0.2221
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.5938442349433899	▁ therapy
D-1965	-0.5938442349433899	therapy
P-1965	-1.9042 -0.1924 -0.1402 -0.1386
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient circulation
H-1824	-0.43765145540237427	▁circulation
D-1824	-0.43765145540237427	circulation
P-1824	-0.9460 -0.2162 -0.1507
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north_america
H-75	-0.9200456738471985	▁en roll ment
D-75	-0.9200456738471985	enrollment
P-75	-2.6948 -0.0120 -0.1211 -1.6755 -0.0968
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.35561469197273254	▁c PG s
D-1848	-0.35561469197273254	cPGs
P-1848	-0.3496 -0.9765 -0.0845 -0.2192 -0.1482
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.4562254250049591	▁ms ▁surgery
D-372	-0.4562254250049591	ms surgery
P-372	-1.0181 -0.5209 -0.2077 -0.0781
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis pathophysiological
H-1276	-0.7198126316070557	▁pat ho phy si ological
D-1276	-0.7198126316070557	pathophysiological
P-1276	-2.6386 -0.3244 -0.0306 -0.2389 -0.6486 -1.0212 -0.1364
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity outcomes
H-709	-0.6599301695823669	
D-709	-0.6599301695823669	
P-709	-1.1835 -0.1364
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha esc
H-1908	-0.8342623114585876	▁ AHA ▁ESC
D-1908	-0.8342623114585876	AHA ESC
P-1908	-1.8772 -0.0979 -0.9139 -1.0970 -0.1852
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income expenditure health
H-1792	-1.617822527885437	▁gross _ ▁income ▁ex pendi ture ▁health
D-1792	-1.617822527885437	gross_ income expenditure health
P-1792	-7.9290 -1.1158 -0.3540 -0.3778 -0.0019 -1.3177 -1.6270 -1.5497 -0.2874
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients heart_failure
H-1821	-1.6488182544708252	▁heart _ ▁failure
D-1821	-1.6488182544708252	heart_ failure
P-1821	-4.9271 -0.9736 -1.9871 -0.2101 -0.1462
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients lvad implantation
H-545	-0.40677741169929504	▁implant ation
D-545	-0.40677741169929504	implantation
P-545	-0.8538 -0.0390 -0.5871 -0.1473
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.4266946315765381	
D-1881	-0.4266946315765381	
P-1881	-0.7251 -0.1283
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis patients implantation
H-913	-0.13395166397094727	▁di al ysis ▁implant ation
D-913	-0.13395166397094727	dialysis implantation
P-913	-0.0697 -0.1563 -0.0501 -0.1404 -0.0300 -0.3579 -0.1332
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive_statistics cox_proportional_hazards_models
H-675	-0.5936516523361206	▁co x ▁proportion al _ ▁hazard s
D-675	-0.5936516523361206	cox proportional_ hazards
P-675	-0.5887 -0.0190 -0.8948 -0.2858 -0.4838 -0.6780 -0.9110 -1.1838 -0.2980
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle_heart_failure_model
H-2011	-1.018932819366455	▁sur vi val ▁Seattle _ ▁Heart _ ▁Fail ure
D-2011	-1.018932819366455	survival Seattle_ Heart_ Failure
P-2011	-2.2023 -0.0119 -1.9280 -2.6351 -1.0852 -0.2296 -0.9085 -0.0755 -0.0578 -1.8957 -0.1787
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping baseline heart_failure
H-1059	-1.7570984363555908	▁heart _ ▁failure
D-1059	-1.7570984363555908	heart_ failure
P-1059	-3.9435 -1.0699 -3.0766 -0.4290 -0.2665
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise life_expectancy
H-1902	-0.6991556286811829	
D-1902	-0.6991556286811829	
P-1902	-1.2030 -0.1954
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate_analyses
H-826	-0.46141713857650757	
D-826	-0.46141713857650757	
P-826	-0.7724 -0.1504
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary_angiography lesions
H-349	-0.8195050358772278	▁Corona ry _ ▁ang i ography
D-349	-0.8195050358772278	Coronary_ angiography
P-349	-0.1178 -0.9304 -0.5300 -2.1751 -1.7113 -0.2673 -0.6677 -0.1565
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient surgery echocardiography
H-358	-0.38711127638816833	▁MS ▁surgery ▁e cho card i ography
D-358	-0.38711127638816833	MS surgery echocardiography
P-358	-0.4883 -1.1981 -0.3165 -0.2014 -0.1932 -0.5633 -0.2666 -0.1929 -0.0636
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic_phenotype fontan
H-223	-0.7766018509864807	▁Hem o dynamic _ ▁ph eno type ▁Font an
D-223	-0.7766018509864807	Hemodynamic_ phenotype Fontan
P-223	-0.2451 -0.0796 -0.0499 -1.6470 -2.2549 -0.2683 -0.1119 -2.4699 -0.8315 -0.4802 -0.1044
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal heartmate_ii
H-772	-0.7646567225456238	▁off - pump _ ▁ster nal _ ▁spar ing ▁Heart Mate
D-772	-0.7646567225456238	off-pump_ sternal_ sparing HeartMate
P-772	-0.1890 -0.0658 -0.1069 -4.3054 -0.6445 -0.0534 -0.4264 -0.3382 -0.0839 -1.3011 -0.3089 -1.9441 -0.1729
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart_failure cox_proportional_hazard_analyses
H-1537	-1.0430262088775635	▁heart _ ▁failure ▁co x ▁proportion al _ ▁hazard
D-1537	-1.0430262088775635	heart_ failure cox proportional_ hazard
P-1537	-3.4706 -0.9725 -2.3239 -0.1729 -0.0074 -1.9387 -0.1865 -0.7199 -0.6487 -0.8174 -0.2147
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized walking patients severe_heart_failure
H-567	-2.1317384243011475	▁Nordic _ ▁walking
D-567	-2.1317384243011475	Nordic_ walking
P-567	-1.2200 -2.0615 -2.8464 -4.2108 -0.3200
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient postoperatively multiorgan_failure sepsis
H-551	-0.7588867545127869	▁multi organ _ ▁failure ▁se psis
D-551	-0.7588867545127869	multiorgan_ failure sepsis
P-551	-2.6808 -0.0065 -2.2097 -0.7293 -0.1222 -0.0087 -0.1647 -0.1492
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological acute_heart_failure
H-1465	-1.2032618522644043	▁Pharma c ological _ ▁treatment ▁a cute _ heart _ ▁failure
D-1465	-1.2032618522644043	Pharmacological_ treatment acute_heart_ failure
P-1465	-3.3098 -0.0292 -0.6174 -2.7559 -1.6676 -1.6923 -0.0601 -0.1741 -2.7659 -0.7605 -1.4512 -0.1775 -0.1808
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients acute_kidney_injury postoperatively
H-975	-1.1054977178573608	▁ki dne y ▁injury
D-975	-1.1054977178573608	kidney injury
P-975	-3.7530 -1.0190 -0.1310 -1.3066 -0.2760 -0.1474
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial_function flow-mediated_dilatation
H-253	-0.9338728189468384	▁en dot heli al _ fon ction nel ▁di la tation
D-253	-0.9338728189468384	endothelial_fonctionnel dilatation
P-253	-0.7276 -1.8156 -0.2764 -0.0344 -2.0263 -1.3914 -0.1179 -0.3316 -4.4943 -0.3708 -0.0390 -0.3855 -0.1296
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric self-care_of_heart_failure_index_version_6.2
H-1503	-0.6812222599983215	▁Psycho metric _ ▁testing ▁Self - Car e _ de _ ▁Heart _ ▁Fail ure
D-1503	-0.6812222599983215	Psychometric_ testing Self-Care_de_ Heart_ Failure
P-1503	-1.4494 -0.0569 -2.0606 -0.5818 -1.1769 -0.0275 -1.5013 -0.1401 -0.4562 -1.6223 -0.1583 -0.3887 -0.6431 -0.2222 -0.0876 -0.7129 -0.2949
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse_events
H-1263	-0.5202719569206238	
D-1263	-0.5202719569206238	
P-1263	-0.9690 -0.0715
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients surgical
H-547	-1.164578914642334	▁AI ▁sur g ical
D-547	-1.164578914642334	AI surgical
P-547	-4.0243 -1.1876 -0.0569 -0.3938 -1.1396 -0.1853
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-1.5048154592514038	▁gr LS ▁CV
D-810	-1.5048154592514038	grLS CV
P-810	-0.6875 -2.4544 -2.0664 -2.2064 -0.1094
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-0.8261892795562744	▁mortal ity
D-1696	-0.8261892795562744	mortality
P-1696	-2.4125 -0.5615 -0.2001 -0.1307
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit_index
H-1006	-0.4167267680168152	▁deficit s
D-1006	-0.4167267680168152	deficits
P-1006	-0.3223 -1.0369 -0.1795 -0.1281
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.2118600308895111	
D-1855	-0.2118600308895111	
P-1855	-0.3448 -0.0789
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.408286988735199	
D-1165	-0.408286988735199	
P-1165	-0.7481 -0.0685
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients hospitals
H-3	-0.6943362951278687	
D-3	-0.6943362951278687	
P-3	-1.2588 -0.1299
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing nursing
H-1397	-0.8787063956260681	▁nur sing
D-1397	-0.8787063956260681	nursing
P-1397	-1.4593 -0.5963 -1.2930 -0.1662
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise training outcomes
H-1640	-1.3913285732269287	▁race
D-1640	-1.3913285732269287	race
P-1640	-2.3720 -1.6508 -0.1513
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs_duration
H-888	-0.7092777490615845	▁QR s ▁benefit
D-888	-0.7092777490615845	QRs benefit
P-888	-0.7534 -1.7156 -0.7756 -0.1411 -0.1607
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-0.6957045793533325	▁ms ▁surgery
D-370	-0.6957045793533325	ms surgery
P-370	-1.3433 -1.1644 -0.1793 -0.0958
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal_muscle exercise_capacity fontan_circulation
H-1491	-0.8949291706085205	▁s kelet al _ ▁muscle _ ▁ab normal ités ▁Font an _ ▁circulation
D-1491	-0.8949291706085205	skeletal_ muscle_ abnormalités Fontan_ circulation
P-1491	-4.4704 -0.0314 -0.1262 -0.6527 -0.5842 -0.8639 -0.2541 -0.0551 -0.9622 -3.3059 -0.8081 -0.3365 -0.4859 -0.3716 -0.1156
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone_system_inhibitors heart_failure
H-1486	-0.9265427589416504	▁re nin - angi oten sin - al do ster one ▁heart _ ▁failure
D-1486	-0.9265427589416504	renin-angiotensin-aldosterone heart_ failure
P-1486	-0.3294 -0.7057 -0.0579 -0.0288 -0.0464 -2.4009 -0.3611 -0.0689 -1.7631 -0.0641 -2.5240 -1.4486 -1.1757 -3.4306 -0.2160 -0.2036
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf unilateral_renal_dnx cardiac autonomic_balance
H-1372	-0.4607580304145813	▁CHF ▁unilateral ▁renal ▁DN x ▁cardiac _ ▁autonomi c ▁balance
D-1372	-0.4607580304145813	CHF unilateral renal DNx cardiac_ autonomic balance
P-1372	-0.0188 -0.8713 -0.5136 -0.3005 -0.0094 -0.0285 -1.7548 -0.3346 -0.4810 -0.8913 -0.2409 -0.0843
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute_heart_failure
H-1014	-0.9543076157569885	▁a cute _ ▁heart _ ▁failure
D-1014	-0.9543076157569885	acute_ heart_ failure
P-1014	-2.0493 -0.0330 -0.2584 -2.5092 -0.6030 -1.5308 -0.4621 -0.1887
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic anaerobic_threshold heart_failure
H-1752	-1.5399410724639893	▁ana ero bic _ ▁thre s hold
D-1752	-1.5399410724639893	anaerobic_ threshold
P-1752	-1.2361 -1.2777 -0.9774 -2.9935 -0.5796 -0.0510 -0.5732 -6.0028 -0.1682
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr_variability cardiac_death
H-1589	-1.2276521921157837	▁ab normal ▁HR _ ▁variabil ity ▁cardiac _ ▁death
D-1589	-1.2276521921157837	abnormal HR_ variability cardiac_ death
P-1589	-3.1304 -0.0121 -1.7621 -2.8737 -0.7619 -0.6995 -0.6748 -2.3984 -0.7065 -0.3084 -0.1764
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome all-cause_readmissions
H-1580	-0.9246991872787476	▁m AIN _ o UTC OME
D-1580	-0.9246991872787476	mAIN_oUTCOME
P-1580	-1.3104 -0.2530 -0.4178 -2.8764 -0.0242 -0.2803 -2.1386 -0.0969
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac cardiac_hypertrophy
H-1782	-0.5647007822990417	▁a ac ▁cardiac _ ▁hyper trop hy
D-1782	-0.5647007822990417	aac cardiac_ hypertrophy
P-1782	-0.2466 -1.2383 -0.2931 -1.6348 -0.9779 -0.0169 -0.1146 -0.3534 -0.2067
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation postsystolic_function
H-331	-1.625435471534729	▁indice s ▁posts y sto lique
D-331	-1.625435471534729	indices postsystolique
P-331	-4.1156 -0.0571 -0.3835 -0.4595 -2.1131 -4.5131 -1.2266 -0.1350
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician outcomes patients heart_failure
H-1720	-1.7031551599502563	▁Physic ian ▁heart _ ▁failure
D-1720	-1.7031551599502563	Physician heart_ failure
P-1720	-1.0113 -1.4373 -5.5339 -1.3476 -2.0441 -0.3057 -0.2421
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication resting_hemodynamics
H-828	-1.1304070949554443	▁medication ▁hem o dynamic s
D-828	-1.1304070949554443	medication hemodynamics
P-828	-1.0456 -5.7129 -0.4927 -0.1168 -0.1452 -0.3137 -0.0859
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic_blood_pressure
H-1048	-1.1576507091522217	▁ toxic ity ▁blood _ tension
D-1048	-1.1576507091522217	toxicity blood_tension
P-1048	-0.1388 -0.3630 -0.7263 -5.4181 -1.3403 -0.9258 -0.2037 -0.1452
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary_outcome patient post
H-617	-1.1169512271881104	▁patient _ ▁satisfaction
D-617	-1.1169512271881104	patient_ satisfaction
P-617	-2.1993 -1.6024 -0.7041 -0.8482 -0.2306
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral_regurgitation hf symptoms surgery
H-362	-0.6270235180854797	▁Mit ral _ re gur gi tation ▁ HF
D-362	-0.6270235180854797	Mitral_regurgitation HF
P-362	-2.3294 -0.0555 -0.3664 -1.1205 -0.2321 -0.1157 -0.4312 -1.2804 -0.2358 -0.5153 -0.2151
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations hospital longitudinal change
H-143	-0.9603800177574158	▁hospital _ ▁longitud in al ▁change
D-143	-0.9603800177574158	hospital_ longitudinal change
P-143	-2.7380 -1.2951 -0.8292 -0.4777 -0.5348 -1.1434 -0.3676 -0.2973
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence systolic_hf
H-1798	-1.2854236364364624	▁sy sto lic ▁ HF
D-1798	-1.2854236364364624	systolic HF
P-1798	-3.2799 -0.5932 -1.7444 -2.9348 -0.1650 -0.1428 -0.1378
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission hospital heart_failure discharge
H-147	-1.5086278915405273	▁hospital ▁heart _ ▁failure ▁dis charge
D-147	-1.5086278915405273	hospital heart_ failure discharge
P-147	-4.2079 -4.0985 -0.7408 -1.8361 -0.6529 -0.0035 -0.3240 -0.2051
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end_stage_heart_failure
H-1669	-1.5945364236831665	▁heart _ ▁failure
D-1669	-1.5945364236831665	heart_ failure
P-1669	-4.5821 -0.9891 -2.2274 -0.1094 -0.0647
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease lead hypertension kidney_failure
H-1598	-0.6567424535751343	▁progressive ▁hyper tension ▁ki dne y _ ▁failure
D-1598	-0.6567424535751343	progressive hypertension kidney_ failure
P-1598	-1.0291 -2.7927 -0.0005 -0.2001 -0.2830 -0.1165 -1.1515 -0.6431 -0.2442 -0.1066
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients chronic_kidney_disease ckd
H-898	-1.060171365737915	▁chronic _ ▁ki dne y _ ▁disease CK d
D-898	-1.060171365737915	chronic_ kidney_ diseaseCKd
P-898	-1.3221 -0.7008 -1.9644 -1.0447 -0.3554 -1.7683 -1.4288 -1.2447 -1.3025 -0.3169 -0.2132
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-0.9957365989685059	▁ HF
D-556	-0.9957365989685059	HF
P-556	-3.0497 -0.5895 -0.2563 -0.0875
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu mortality
H-582	-0.7543489336967468	▁ ICU ▁mortal ity
D-582	-0.7543489336967468	ICU mortality
P-582	-0.6693 -0.1210 -2.7761 -0.4116 -0.4318 -0.1164
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses patients disease
H-2020	-0.942845344543457	▁Nur ses ▁disease
D-2020	-0.942845344543457	Nurses disease
P-2020	-1.9473 -0.0556 -2.3798 -0.2271 -0.1046
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt patients
H-905	-0.7326408624649048	▁c RT ▁di al ysis - dependent ▁patients
D-905	-0.7326408624649048	cRT dialysis-dependent patients
P-905	-0.2659 -2.3780 -0.7634 -0.4675 -0.0439 -0.2212 -0.1663 -2.6505 -0.2478 -0.1221
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf patients
H-217	-0.5113031268119812	▁CHF
D-217	-0.5113031268119812	CHF
P-217	-0.6245 -0.8149 -0.0946
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-1.2064770460128784	▁RM
D-163	-1.2064770460128784	RM
P-163	-3.2365 -0.2269 -0.1560
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic accounting cost
H-1582	-1.3079533576965332	▁économique ▁sav ings ▁coût
D-1582	-1.3079533576965332	économique savings coût
P-1582	-0.7987 -5.1656 -0.3691 -0.9233 -0.4635 -0.1274
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western_blot immunohistochemistry electron_microscopy
H-1252	-0.5504975318908691	▁immun oh isto che mist ry ▁electro n ▁micro s copy
D-1252	-0.5504975318908691	immunohistochemistry electron microscopy
P-1252	-1.9078 -0.1477 -0.8233 -0.1931 -0.6280 -0.2846 -0.0044 -0.0150 -1.6838 -0.7794 -0.2384 -0.2897 -0.1613
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic_cardiomyopathy mortality
H-67	-0.5490702390670776	▁i sche mic _ ▁cardio my o pathy ▁sex ▁mortal ity
D-67	-0.5490702390670776	ischemic_ cardiomyopathy sex mortality
P-67	-1.2729 -0.0154 -0.4422 -0.2619 -0.1300 -0.7687 -0.6538 -0.0132 -2.3989 -0.2131 -0.4907 -0.3032 -0.1740
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence idiopathic_dilated_cardiomyopathy
H-1741	-0.5150192379951477	▁ idio pathi c ▁dil ated _ ▁cardio my o pathy
D-1741	-0.5150192379951477	idiopathic dilated_ cardiomyopathy
P-1741	-0.7159 -0.0699 -0.0483 -0.1664 -1.3484 -0.4468 -0.7318 -0.0937 -1.9531 -0.6908 -0.0197 -0.2917 -0.1186
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf chromatin_hyperacetylation
H-1036	-1.3960459232330322	▁ HF ▁chr omat in _ ▁hyper ace ti lation
D-1036	-1.3960459232330322	HF chromatin_ hyperacetilation
P-1036	-2.4575 -0.1774 -0.1846 -0.0689 -3.3868 -0.7320 -0.9837 -1.7893 -6.5151 -0.0567 -0.2889 -0.1116
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic_dysfunction patients peripheral_artery_disease
H-1566	-0.9141867756843567	▁dia sto lic _ ▁dys function ▁per i pher al _ ▁arter y ▁disease
D-1566	-0.9141867756843567	diastolic_ dysfunction peripheral_ artery disease
P-1566	-0.0904 -0.9660 -3.5944 -1.3914 -0.1331 -0.6164 -0.7464 -0.5251 -0.0975 -0.3283 -0.8242 -0.7640 -1.0050 -2.9760 -0.4390 -0.1299
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded_protein_response cardiac_sodium systolic heart_failure
H-1079	-1.4041789770126343	▁cardiac _ so dium _ ▁current ▁heart _ ▁failure
D-1079	-1.4041789770126343	cardiac_sodium_ current heart_ failure
P-1079	-6.8027 -0.7569 -0.3141 -0.0192 -0.1565 -0.9189 -1.4895 -1.3925 -3.0482 -0.2947 -0.2526
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin_receptor_neprilysin_inhibitor heart_failure
H-1461	-1.0299320220947266	▁ang io ten sin ▁receptor _ ▁nepri ly sin _ ▁inhibi tor ▁heart _ ▁failure
D-1461	-1.0299320220947266	angiotensin receptor_ neprilysin_ inhibitor heart_ failure
P-1461	-0.4463 -3.3264 -0.4866 -1.7999 -0.8648 -3.1196 -0.4638 -0.0705 -1.0772 -0.9073 -0.0743 -0.1517 -0.6233 -1.0617 -2.6662 -0.2272 -0.1419
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient diagnosed hypertensive_lv_dysfunction
H-350	-0.3675139248371124	▁hyper tensi ve ▁LV ▁dys function ▁MR ▁MS
D-350	-0.3675139248371124	hypertensive LV dysfunction MR MS
P-350	-0.2833 -0.4724 -0.2801 -0.8419 -0.3698 -0.3173 -0.4225 -0.4507 -0.1738 -0.0632
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians patients hf
H-1724	-0.9342662692070007	▁physician s ▁ HF
D-1724	-0.9342662692070007	physicians HF
P-1724	-1.5803 -0.0337 -3.5350 -0.1460 -0.2378 -0.0728
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia prognostic patients heart_failure
H-529	-1.1292228698730469	▁hypo album in emia ▁heart _ ▁failure
D-529	-1.1292228698730469	hypoalbuminemia heart_ failure
P-529	-1.3226 -0.7357 -0.8261 -0.3109 -2.6717 -1.3150 -2.4482 -0.3291 -0.2037
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute_heart_failure
H-468	-1.0491951704025269	▁a cute _ heart _ ▁failure
D-468	-1.0491951704025269	acute_heart_ failure
P-468	-1.9136 -0.0485 -0.2893 -3.3408 -0.8012 -1.3981 -0.3354 -0.2667
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia patients heart_disease
H-39	-1.9969713687896729	▁avantages ▁an emia
D-39	-1.9969713687896729	avantages anemia
P-39	-2.4845 -1.9544 -0.6171 -4.7609 -0.1680
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort_study
H-1829	-1.1996190547943115	
D-1829	-1.1996190547943115	
P-1829	-2.2357 -0.1635
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad_ai
H-543	-1.2249760627746582	▁l VAD
D-543	-1.2249760627746582	lVAD
P-543	-3.8991 -0.1025 -0.7276 -0.1707
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative operative outcomes
H-299	-0.27843788266181946	
D-299	-0.27843788266181946	
P-299	-0.4512 -0.1057
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth longitudinal medicare
H-1617	-1.1366080045700073	▁services _ management ▁tele health ▁medica re
D-1617	-1.1366080045700073	services_management telehealth medicare
P-1617	-6.7564 -0.6342 -0.3980 -1.0380 -0.5631 -0.0632 -0.0230 -0.5837 -0.1699
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public_reporting patients hospitals
H-1689	-1.2710473537445068	▁public ▁report ing
D-1689	-1.2710473537445068	public reporting
P-1689	-1.4017 -2.2029 -0.1955 -2.4005 -0.1546
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control outcomes
H-1232	-1.0128995180130005	▁ Rhythm - ▁and _ ▁rate - control
D-1232	-1.0128995180130005	Rhythm- and_ rate-control
P-1232	-0.3345 -0.1073 -0.1818 -5.3793 -1.9723 -0.8019 -0.0889 -0.0181 -1.0249 -0.2200
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus_rhythm adverse_outcomes
H-1644	-0.469200998544693	▁sinus ▁ rhythm ▁AF
D-1644	-0.469200998544693	sinus rhythm AF
P-1644	-1.2871 -0.6805 -0.1326 -0.4896 -0.1237 -0.1018
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal diagnostic filling_pressures
H-490	-1.6445848941802979	
D-490	-1.6445848941802979	
P-490	-3.1578 -0.1314
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial_infarction
H-1137	-0.7539920806884766	▁My o card ial ▁in far ction ▁Wi star ▁rat s
D-1137	-0.7539920806884766	Myocardial infarction Wistar rats
P-1137	-0.1937 -0.1735 -0.1462 -0.3723 -1.2219 -3.3409 -0.0606 -1.1944 -0.7743 -1.7895 -0.0480 -0.3404 -0.1459
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis hf etiologies
H-1795	-0.592367947101593	▁c d ▁ HF
D-1795	-0.592367947101593	cd HF
P-1795	-0.8807 -0.6325 -0.9304 -0.3294 -0.6285 -0.1528
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients heart_failure cardiac_rehabilitation
H-568	-1.3175554275512695	▁heart _ ▁failure ▁cardiac ▁rehabilita tion
D-568	-1.3175554275512695	heart_ failure cardiac rehabilitation
P-568	-3.5515 -0.8642 -2.4817 -0.2626 -2.7911 -0.0557 -0.3952 -0.1384
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity_pathway_analysis
H-875	-0.5314264297485352	▁ingen u ity
D-875	-0.5314264297485352	ingenuity
P-875	-0.4558 -0.4249 -0.6087 -0.9444 -0.2234
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone severe_heart_failure
H-1701	-0.8166342973709106	▁Race ▁spi rono lac tone ▁heart _ ▁failure
D-1701	-0.8166342973709106	Race spironolactone heart_ failure
P-1701	-0.4869 -3.0386 -0.0921 -0.5485 -0.5685 -1.0096 -0.9041 -1.1102 -0.2448 -0.1630
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins tac
H-872	-1.0398812294006348	▁ TAC
D-872	-1.0398812294006348	TAC
P-872	-2.7012 -0.8581 -0.4858 -0.1144
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery mva
H-361	-0.3814791440963745	▁MS ▁m va
D-361	-0.3814791440963745	MS mva
P-361	-1.0298 -0.2070 -0.2157 -0.3571 -0.0978
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-0.3316688537597656	▁c RF
D-1769	-0.3316688537597656	cRF
P-1769	-0.4673 -0.5995 -0.1967 -0.0632
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.4945095479488373	▁Mediterrane an ▁DAS h
D-688	-0.4945095479488373	Mediterranean DASh
P-688	-0.1968 -0.0259 -0.0686 -0.2181 -2.2638 -0.1939
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise exercise
H-1931	-2.3338096141815186	▁social _ support ▁exercise
D-1931	-2.3338096141815186	social_support exercise
P-1931	-2.7637 -2.2778 -2.4512 -5.1022 -1.1952 -0.2127
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-0.5904200673103333	▁re hospital ization
D-1711	-0.5904200673103333	rehospitalization
P-1711	-2.0113 -0.0482 -0.5899 -0.1743 -0.1284
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate_models odds_ratios accounting hospital
H-191	-1.1837959289550781	▁odds ▁ratio s ▁hospital _ ▁cluster ing
D-191	-1.1837959289550781	odds ratios hospital_ clustering
P-191	-3.5769 -3.8178 -0.0978 -0.1924 -0.7573 -0.8028 -0.7861 -0.4307 -0.1925
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk_stratification death all-cause_hospitalization heart_failure clinic outpatients
H-377	-1.7587432861328125	▁risk ▁hospital ization ▁heart _ ▁failure
D-377	-1.7587432861328125	risk hospitalization heart_ failure
P-377	-5.1471 -3.2931 -1.3971 -0.6834 -0.4871 -2.2156 -0.5752 -0.2714
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl hno acute heart_failure
H-412	-0.8079559206962585	▁ni tro x yl ▁h no ▁heart _ ▁failure
D-412	-0.8079559206962585	nitroxyl hno heart_ failure
P-412	-2.0296 -0.0518 -0.0145 -0.2032 -0.3126 -0.2809 -2.6959 -0.9627 -2.0600 -0.1786 -0.0977
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref hfpef patients regression_line
H-497	-0.6704112887382507	▁h f f ▁ HF p f
D-497	-0.6704112887382507	hff HFpf
P-497	-0.2523 -0.2882 -1.5469 -1.0990 -0.5579 -0.1454 -1.1227 -0.7707 -0.2507
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart_block pulmonary_artery bivp
H-322	-0.7669422626495361	▁Heart _ block ▁pulmonar y ▁arter y ▁bi VP
D-322	-0.7669422626495361	Heart_block pulmonary artery biVP
P-322	-0.8959 -2.2752 -1.2363 -0.0151 -0.0891 -1.0115 -0.6595 -1.9224 -0.0517 -0.1709 -0.1088
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute_walk_distance peak_vo2 baseline
H-1636	-0.7839810848236084	▁Black s ▁VO 2
D-1636	-0.7839810848236084	Blacks VO2
P-1636	-1.3983 -0.1059 -2.1345 -0.1156 -0.6760 -0.2736
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home hospital readmission congestive_heart_failure
H-1573	-1.227799654006958	▁Hospital _ to - Home ▁hospital _ ▁read mission _ re duction _ program ▁con ges tive _ ▁heart _ ▁failure
D-1573	-1.227799654006958	Hospital_to-Home hospital_ readmission_reduction_program congestive_ heart_ failure
P-1573	-4.2574 -0.5840 -1.0572 -0.1221 -0.1187 -2.8002 -0.9843 -2.9754 -0.0915 -0.2320 -0.7695 -0.0316 -2.5578 -2.4976 -1.3310 -0.3425 -0.5662 -0.4763 -2.3709 -1.4311 -2.0587 -0.3948 -0.1884
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization_therapy heart_failure narrow_qrs_complex
H-844	-0.8508179187774658	▁Card iac - re syn chron ization _ therapy ▁heart _ ▁failure
D-844	-0.8508179187774658	Cardiac-resynchronization_therapy heart_ failure
P-844	-0.2553 -0.4169 -0.1812 -0.1654 -0.0416 -0.0006 -1.6326 -1.6511 -0.7612 -1.1442 -0.8475 -3.7928 -0.8666 -0.1544
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician death readmission discharge patients heart_failure
H-1412	-1.5504409074783325	▁physician _ ▁continu ity ▁urgent _ ▁read mission _ de _ dis charge ▁heart _ ▁failure
D-1412	-1.5504409074783325	physician_ continuity urgent_ readmission_de_discharge heart_ failure
P-1412	-0.4852 -1.5812 -1.4946 -0.4137 -4.9862 -0.9301 -2.7759 -0.0578 -2.7752 -4.8284 -0.2947 -0.0534 -0.0163 -3.0048 -1.0342 -2.6151 -0.4093 -0.1519
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance attrition
H-1319	-1.0328037738800049	
D-1319	-1.0328037738800049	
P-1319	-2.0020 -0.0636
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients diabetes eo-cfus functional_capacity
H-132	-0.5191433429718018	▁diabetes ▁e - c FU s
D-132	-0.5191433429718018	diabetes e-cFUs
P-132	-0.2598 -1.1114 -0.3856 -0.2783 -0.6172 -0.6246 -0.7186 -0.1578
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life patients
H-161	-0.8997901082038879	
D-161	-0.8997901082038879	
P-161	-1.5990 -0.2006
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients patients echocardiographic
H-813	-1.2226343154907227	▁af ▁pacientes ▁e cho car dio graphic
D-813	-1.2226343154907227	af pacientes echocardiographic
P-813	-0.7757 -2.1380 -0.7937 -0.7448 -0.1757 -2.1377 -2.2093 -1.8892 -0.1396
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf surgical
H-353	-0.412606805562973	▁MS HF ▁sur g ical ▁indica tion ▁MS
D-353	-0.412606805562973	MSHF surgical indication MS
P-353	-0.7953 -0.3588 -0.4002 -0.0343 -0.5735 -0.8861 -0.0372 -0.7603 -0.1977 -0.0826
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac_function catheter
H-1143	-0.9132082462310791	▁Card iac _ fon ction nel ▁pressure - volu me _ ▁conduct ance ▁cat heter
D-1143	-0.9132082462310791	Cardiac_fonctionnel pressure-volume_ conductance catheter
P-1143	-0.1306 -0.4168 -2.6026 -1.7659 -0.0701 -0.6299 -1.8925 -0.1889 -0.2013 -0.0799 -1.6558 -3.6285 -0.1765 -0.5723 -0.0062 -1.3871 -0.1197
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 therapy
H-401	-0.8641784191131592	▁BB ▁ therapy
D-401	-0.8641784191131592	BB therapy
P-401	-2.4868 -1.3577 -0.0792 -0.2348 -0.1624
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf pb
H-1349	-0.5242763757705688	▁PV f ▁ PB ▁amplitud e
D-1349	-0.5242763757705688	PVf PB amplitude
P-1349	-0.1060 -0.0604 -2.8877 -0.2537 -0.3937 -0.1418 -0.2839 -0.0671
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital heart lesions
H-985	-0.8928303122520447	▁con geni tal _ ▁heart _ ▁les ions
D-985	-0.8928303122520447	congenital_ heart_ lesions
P-985	-2.7660 -0.0184 -0.2775 -0.8892 -1.5861 -1.3774 -1.5082 -0.2322 -0.1633 -0.1101
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.24639590084552765	▁beta - block ers
D-865	-0.24639590084552765	beta-blockers
P-865	-0.7208 -0.0668 -0.2215 -0.1471 -0.2169 -0.1054
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up cardiovascular_events deaths
H-974	-1.1385459899902344	▁cardiovascular ▁events
D-974	-1.1385459899902344	cardiovascular events
P-974	-0.7969 -3.1398 -0.5080 -0.1095
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical patients functional_ms
H-373	-1.2539626359939575	▁MS
D-373	-1.2539626359939575	MS
P-373	-3.4126 -0.2434 -0.1059
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic outcomes hf
H-1202	-1.0047416687011719	▁di ure tic _ utilisation ▁ HF
D-1202	-1.0047416687011719	diuretic_utilisation HF
P-1202	-0.3597 -0.1989 -2.4773 -1.4138 -2.0418 -2.2105 -0.1600 -0.0918 -0.0889
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad systolic_hf prognostic
H-1183	-0.8398154377937317	▁CAD ▁sy sto lic ▁ HF
D-1183	-0.8398154377937317	CAD systolic HF
P-1183	-0.0952 -2.5971 -0.2694 -1.5327 -1.8052 -0.0362 -0.3091 -0.0736
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray genes heart_failure
H-1605	-1.2633863687515259	▁bio informati c
D-1605	-1.2633863687515259	bioinformatic
P-1605	-0.5572 -0.0741 -0.6532 -4.8452 -0.1871
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change lvet admission follow-up outcome
H-588	-1.1537754535675049	▁l VET ▁follow - up
D-588	-1.1537754535675049	lVET follow-up
P-588	-3.9823 -2.2040 -1.2977 -0.1048 -0.0137 -0.3196 -0.1543
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin inflammation metabolism heart_disease
H-940	-0.9647101163864136	▁resist in ▁ inflammation ▁metabolism ▁heart
D-940	-0.9647101163864136	resistin inflammation metabolism heart
P-940	-2.3711 -1.1409 -0.1724 -0.1193 -0.2222 -1.2867 -2.1765 -0.2287
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary_disease leading heart_failure
H-981	-0.968230128288269	▁corona ry _ ▁disease ▁heart _ ▁failure
D-981	-0.968230128288269	coronary_ disease heart_ failure
P-981	-1.2465 -0.6655 -1.3468 -1.6509 -1.5527 -0.4480 -1.4212 -0.2626 -0.1197
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative hypoalbuminemia prognosis lvad surgery
H-538	-0.4977448284626007	▁hypo album in emia ▁l VAD
D-538	-0.4977448284626007	hypoalbuminemia lVAD
P-538	-1.0048 -0.8238 -0.5285 -0.3985 -0.5949 -0.0370 -0.4829 -0.1114
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling_pathways cardiac_remodelling
H-992	-1.562480092048645	▁signal ling _ path ways ▁adapt ive ▁cardiac ▁remodel ling
D-992	-1.562480092048645	signalling_pathways adaptive cardiac remodelling
P-992	-2.9188 -3.0825 -2.5276 -1.1501 -0.7630 -3.5986 -0.0207 -2.3007 -1.3034 -0.6383 -0.3027 -0.1434
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia right_ventricle heart_failure
H-1457	-1.1911066770553589	▁Fat ▁cache xia ▁vent ric le ▁heart _ ▁failure ▁complici ty
D-1457	-1.1911066770553589	Fat cachexia ventricle heart_ failure complicity
P-1457	-1.7233 -3.0685 -0.0461 -1.1390 -3.3495 -0.4152 -1.2853 -0.9978 -1.1128 -0.1511 -1.6325 -0.4386 -0.1246
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial_fibrillation patients heart_failure
H-1231	-0.8879897594451904	▁at rial _ ▁fi bril lation AF ▁heart _ ▁failure
D-1231	-0.8879897594451904	atrial_ fibrillationAF heart_ failure
P-1231	-1.1324 -0.0767 -0.5650 -3.6357 -0.0495 -0.0282 -1.0771 -0.4526 -1.2299 -1.9918 -0.3145 -0.1024
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit_index biological_phenotype mortality
H-1012	-0.8958184719085693	▁deficit ▁bi ological _ ▁ph eno type ▁mortal ity
D-1012	-0.8958184719085693	deficit biological_ phenotype mortality
P-1012	-2.8187 -1.9670 -0.3474 -1.3022 -1.4238 -0.6311 -0.0878 -0.3527 -0.6099 -0.1725 -0.1408
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical connected elevated resistin heart_failure
H-929	-1.7593681812286377	
D-929	-1.7593681812286377	
P-929	-3.3990 -0.1197
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd vvd free_wall_rs
H-328	-1.055632472038269	▁av d ▁VVD ▁free ▁wall
D-328	-1.055632472038269	avd VVD free wall
P-328	-0.3914 -0.2181 -1.8193 -0.9825 -2.0567 -1.7963 -0.1251
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence esrd outpatients hf
H-388	-0.828160285949707	▁ES RD ▁out patient s HF
D-388	-0.828160285949707	ESRD outpatientsHF
P-388	-1.5788 -0.3451 -2.3462 -0.0342 -0.0735 -1.9072 -0.2208 -0.1196
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise_intolerance chronic_heart_failure prognosis
H-1273	-1.1069259643554688	▁Exerci se _ ▁in tolerance ▁chronic _ ▁heart _ ▁failure
D-1273	-1.1069259643554688	Exercise_ intolerance chronic_ heart_ failure
P-1273	-2.7131 -0.1895 -0.2837 -0.5930 -0.0701 -2.5524 -0.8737 -2.1390 -0.9789 -2.3198 -0.4087 -0.1613
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical atherosclerosis linear_models
H-1557	-1.284571647644043	▁sub clin ical _ at hero sc ler osis
D-1557	-1.284571647644043	subclinical_atherosclerosis
P-1557	-0.4953 -0.2854 -2.2611 -0.4895 -1.9018 -1.6052 -2.8351 -2.7058 -0.5459 -0.7888 -0.2164
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling hf haemodynamic neuronal_stressors
H-1039	-0.682083785533905	▁remodel ling ▁ HF ▁ha emo dynamic ▁neuron al ▁stress ors
D-1039	-0.682083785533905	remodelling HF haemodynamic neuronal stressors
P-1039	-0.8948 -1.0517 -1.2921 -0.1075 -0.0859 -0.1690 -0.0874 -1.8416 -0.3400 -2.1807 -0.4210 -0.2987 -0.0967
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right_ventricular_function prognosis heart_failure
H-1157	-1.1457051038742065	▁vent ri cular _ f ré que nce
D-1157	-1.1457051038742065	ventricular_fréquence
P-1157	-0.6440 -0.2985 -0.3349 -2.9918 -3.1738 -0.0340 -0.2562 -0.0344 -3.5265 -0.1629
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart_transplantation left_ventricular_assist_device
H-306	-1.0574183464050293	▁heart _ ▁transplant ation ▁left ▁vent ri cular _ assist ▁device
D-306	-1.0574183464050293	heart_ transplantation left ventricular_assist device
P-306	-3.1545 -2.7993 -0.4430 -0.0390 -0.8181 -0.9566 -0.3971 -0.2290 -0.4971 -0.3125 -3.0783 -0.9104 -0.1116
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ecgs electrocardiographers
H-884	-0.3572241961956024	▁e CG s ▁electro car dio graph ers
D-884	-0.3572241961956024	eCGs electrocardiographers
P-884	-1.0023 -0.3352 -0.3339 -0.0861 -0.0626 -0.8737 -0.0773 -0.2659 -0.4176 -0.1177
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart_rate
H-1446	-1.9554965496063232	▁heart _ ▁rate
D-1446	-1.9554965496063232	heart_ rate
P-1446	-3.2264 -1.8474 -3.8933 -0.6568 -0.1535
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end_point neurological cardiovascular_events
H-1872	-1.8137606382369995	▁safety _ ▁end ▁point
D-1872	-1.8137606382369995	safety_ end point
P-1872	-2.4336 -1.4953 -1.9060 -1.2698 -3.5704 -0.2075
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications dialysis patients
H-908	-0.4748765230178833	▁di al ysis
D-908	-0.4748765230178833	dialysis
P-908	-1.1418 -0.5384 -0.0979 -0.4661 -0.1303
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ffm stable
H-20	-0.6191035509109497	f f f f f f f f f f f ▁body _ weight cc
D-20	-0.6191035509109497	fffffffffff body_weightcc
P-20	-0.3746 -0.0947 -0.0619 -0.0620 -0.0848 -0.1126 -0.1514 -0.2227 -0.3707 -0.6582 -1.0974 -4.1332 -0.6087 -0.7650 -1.3419 -0.2619 -0.1230
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty hf
H-632	-1.2473766803741455	▁Fra il ty ▁ HF
D-632	-1.2473766803741455	Frailty HF
P-632	-2.1958 -1.0144 -3.2751 -1.4638 -0.2264 -0.4470 -0.1091
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac_cachexia
H-9	-0.5415337085723877	▁Card iac _ ca xia cc
D-9	-0.5415337085723877	Cardiac_caxiacc
P-9	-0.5600 -0.0528 -0.3957 -0.9414 -0.3725 -0.3914 -1.5172 -0.1013
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota hf
H-1003	-0.8373664021492004	▁South e a stern ▁Minnesota ▁h f
D-1003	-0.8373664021492004	Southeastern Minnesota hf
P-1003	-3.5611 -0.0383 -0.1478 -0.1091 -0.8280 -2.0885 -0.4588 -0.2072 -0.0975
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart_failure nurse
H-84	-1.4451366662979126	▁multi hospital _ ▁study ▁heart _ ▁failure
D-84	-1.4451366662979126	multihospital_ study heart_ failure
P-84	-2.1737 -0.0139 -3.5038 -2.0047 -1.2443 -0.5600 -1.8016 -1.4895 -0.2147
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical hfpef
H-943	-0.7753707766532898	▁h f f
D-943	-0.7753707766532898	hff
P-943	-2.2274 -0.1091 -0.1227 -1.3013 -0.1163
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome hdl
H-254	-0.9251642227172852	▁prote ome _ de _ ▁HD L ▁parti cles ▁shot gun ▁ LC - MS
D-254	-0.9251642227172852	proteome_de_ HDL particles shotgun LC-MS
P-254	-0.8798 -2.5391 -1.5604 -1.0102 -0.2062 -1.0988 -2.0223 -0.5940 -0.0398 -0.1654 -0.1405 -3.2851 -0.5213 -0.0476 -0.4314 -1.0683 -0.1176
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left_bundle_branch_block
H-1153	-1.2230172157287598	▁bran ch _ block _ electric al _ activa tion _ se que nce
D-1153	-1.2230172157287598	branch_block_electrical_activation_sequence
P-1153	-5.1675 -0.3456 -1.0870 -3.4453 -0.1641 -2.7039 -0.3505 -0.3632 -1.9416 -0.0732 -1.3543 -1.7734 -0.1133 -0.0037 -0.5104 -0.1710
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients heart_transplant ecct
H-714	-1.5519839525222778	▁transplant ▁EC CT
D-714	-1.5519839525222778	transplant ECCT
P-714	-5.5573 -1.3184 -0.5433 -0.2282 -0.1127
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise training endothelial_function
H-248	-1.2076092958450317	▁ Protect ive ▁effects ▁ed ▁en dot heli al
D-248	-1.2076092958450317	Protective effects ed endothelial
P-248	-1.7865 -0.3939 -0.0304 -3.7458 -2.7020 -0.9429 -1.1218 -0.0909 -0.0410 -2.3146 -0.1140
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death stroke hospitalisation heart_failure
H-815	-1.0496923923492432	▁CV ▁death _ non - fa tal _ ▁stroke ▁heart _ ▁failure
D-815	-1.0496923923492432	CV death_non-fatal_ stroke heart_ failure
P-815	-1.4985 -3.6421 -4.0321 -0.0748 -0.0129 -0.0218 -0.1686 -0.8191 -0.1700 -1.1370 -0.7670 -1.6427 -0.4529 -0.2563
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct heart_failure therapy patients
H-718	-1.3717657327651978	▁EC CT ▁advanced _ heart _ ▁failure
D-718	-1.3717657327651978	ECCT advanced_heart_ failure
P-718	-0.8802 -2.0601 -3.1831 -0.6368 -2.2076 -0.4243 -1.8899 -0.9166 -0.1473
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4_inhibitors drugs
H-1834	-0.5274856090545654	▁h f ▁d p -4 ▁inhibi tors ▁drugs
D-1834	-0.5274856090545654	hf dp-4 inhibitors drugs
P-1834	-0.0049 -1.0169 -0.1436 -0.7281 -0.3039 -0.4561 -1.1902 -1.1667 -0.1800 -0.0844
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade holosystolic_murmur third_heart_sound apex
H-342	-1.1824893951416016	▁holo sy sto lique _ ▁mur mur ▁heart
D-342	-1.1824893951416016	holosystolique_ murmur heart
P-342	-0.0916 -0.6541 -1.2082 -1.9801 -1.1002 -1.3803 -0.0703 -4.2876 -0.9116 -0.1410
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain_proteins
H-1042	-0.9935171604156494	bro modo main _ ▁protein s
D-1042	-0.9935171604156494	bromodomain_ proteins
P-1042	-5.1942 -0.0803 -0.0385 -1.0383 -1.1092 -0.1135 -0.2509 -0.1232
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart_failure readmission outcome
H-1030	-0.8401431441307068	▁heart _ ▁failure
D-1030	-0.8401431441307068	heart_ failure
P-1030	-0.8602 -0.4664 -1.6429 -1.1095 -0.1217
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up hf
H-288	-1.099317193031311	▁ HF
D-288	-1.099317193031311	HF
P-288	-3.3500 -0.7350 -0.2194 -0.0929
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.5794999003410339	▁ pharma ce ut ically _ assist ed
D-948	-0.5794999003410339	pharmaceutically_assisted
P-948	-0.3543 -0.0475 -0.3096 -1.1129 -0.6118 -1.3869 -0.2523 -1.0211 -0.5812 -0.1174
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse_event hypotension
H-1970	-0.3240276873111725	▁hypo tension
D-1970	-0.3240276873111725	hypotension
P-1970	-0.4119 -0.0086 -0.7920 -0.0837
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt dt implantation
H-315	-0.3098057508468628	▁b t ▁ DT ▁implant ation
D-315	-0.3098057508468628	bt DT implantation
P-315	-0.1204 -0.2148 -1.0825 -0.3749 -0.0075 -0.0306 -0.5667 -0.0811
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient mortality therapeutic
H-1667	-0.7252833247184753	▁mortal ity
D-1667	-0.7252833247184753	mortality
P-1667	-1.6401 -0.5102 -0.6382 -0.1126
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak_vo2
H-1498	-1.2799404859542847	▁Peak ▁VO 2
D-1498	-1.2799404859542847	Peak VO2
P-1498	-1.4017 -4.2419 -0.1140 -0.4363 -0.2059
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 patients plasma
H-699	-1.2885289192199707	▁ST 2
D-699	-1.2885289192199707	ST2
P-699	-1.8527 -0.9830 -2.1987 -0.1196
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients discharge follow-up medication
H-730	-0.7853174209594727	▁dis charge ▁medication
D-730	-0.7853174209594727	discharge medication
P-730	-1.2712 -0.0119 -2.0073 -0.5184 -0.1178
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions septal surgical
H-984	-0.611312747001648	▁sept al ▁defect s ▁sur g ical
D-984	-0.611312747001648	septal defects surgical
P-984	-0.5755 -0.1879 -2.9075 -0.1086 -0.1766 -0.0538 -0.4911 -0.8980 -0.1029
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients extubated blood transfusion
H-777	-0.9518511891365051	▁ex tuba ted ▁blood _ ▁loss ▁trans fusion
D-777	-0.9518511891365051	extubated blood_ loss transfusion
P-777	-1.4760 -0.0305 -3.1760 -1.1995 -1.4620 -1.1240 -0.0272 -0.0247 -0.8652 -0.1334
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis mortality patients
H-61	-0.6659473180770874	▁mortal ity ▁i CD - HF
D-61	-0.6659473180770874	mortality iCD-HF
P-61	-2.2695 -0.8975 -0.3417 -0.4692 -0.0720 -0.2055 -0.7824 -0.2898
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas cardiac pathogenesis
H-1484	-0.4599383473396301	▁mi RNA s ▁cardiac _ path ogen es is
D-1484	-0.4599383473396301	miRNAs cardiac_pathogenesis
P-1484	-0.8958 -0.0622 -0.0396 -0.0563 -1.8916 -0.6564 -0.2671 -0.2192 -0.7202 -0.1754 -0.0755
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers hf
H-1475	-0.2681623101234436	▁bio mark ers ▁ HF
D-1475	-0.2681623101234436	biomarkers HF
P-1475	-0.1427 -0.0099 -0.1006 -1.2154 -0.1927 -0.1125 -0.1033
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative clinical mortality
H-532	-0.906287670135498	▁pre operativ e _ ▁clinic al ▁mortal ity
D-532	-0.906287670135498	preoperative_ clinical mortality
P-532	-2.8076 -0.0538 -0.3077 -0.8897 -1.4960 -0.0944 -2.2740 -0.8324 -0.1546 -0.1526
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes hospitalization
H-566	-0.8508210182189941	
D-566	-0.8508210182189941	
P-566	-1.5526 -0.1491
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-0.6416075229644775	▁FIN DING s
D-1955	-0.6416075229644775	FINDINGs
P-1955	-0.3866 -0.9108 -0.8428 -0.9631 -0.1048
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals outcome
H-1690	-0.9893314838409424	
D-1690	-0.9893314838409424	
P-1690	-1.7989 -0.1798
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf patients
H-671	-0.5224364399909973	▁tras tuz um ab - related ▁CHF
D-671	-0.5224364399909973	trastuzumab-related CHF
P-671	-1.8172 -0.0117 -0.1436 -0.4509 -0.3757 -1.0211 -0.4111 -0.2514 -0.2192
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients transplants
H-2000	-0.5871433019638062	▁transplant s
D-2000	-0.5871433019638062	transplants
P-2000	-1.8168 -0.3132 -0.1541 -0.0644
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy engage exercise
H-1903	-1.9539977312088013	▁Health y
D-1903	-1.9539977312088013	Healthy
P-1903	-3.6162 -0.3788 -3.6254 -0.1956
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-0.23167972266674042	▁hospital s
D-1694	-0.23167972266674042	hospitals
P-1694	-0.5052 -0.1816 -0.1672 -0.0727
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients condition economic
H-1575	-0.5964924097061157	▁économique
D-1575	-0.5964924097061157	économique
P-1575	-1.1329 -0.5303 -0.1262
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-1.1388264894485474	▁patient _ ▁safety
D-1	-1.1388264894485474	patient_ safety
P-1	-2.2707 -0.9336 -2.1332 -0.1899 -0.1667
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon_matched-pairs_signed-rank_tests
H-923	-0.38731932640075684	▁Wil co xon ▁signed - rank
D-923	-0.38731932640075684	Wilcoxon signed-rank
P-923	-0.7198 -0.0174 -0.3193 -1.3160 -0.0181 -0.0068 -0.4809 -0.2203
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left_ventricular_assist_device right_ventricular_support
H-293	-0.761050283908844	▁vent ri cular _ assist ▁device ▁vent ri cular _ support
D-293	-0.761050283908844	ventricular_assist device ventricular_support
P-293	-0.0615 -0.1561 -0.1917 -1.0067 -0.1446 -1.8990 -1.6260 -0.1533 -0.1959 -0.8563 -2.8902 -0.5480 -0.1643
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis atherosclerosis cardiovascular_events rotterdam_study
H-1554	-0.8496124148368835	▁p sori asis ▁at hero sc ler osis ▁cardiovascular ▁events ▁Rotterdam
D-1554	-0.8496124148368835	psoriasis atherosclerosis cardiovascular events Rotterdam
P-1554	-1.3957 -0.1055 -0.5263 -0.0902 -0.1927 -1.6800 -1.8573 -0.1268 -2.3757 -1.7766 -0.4426 -0.3954 -0.0803
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal_artery_stenosis ras peripheral_arterial_disease
H-1593	-0.43662938475608826	▁Ren al _ ▁arter y _ ▁sten osis RAS ▁per i pher al _ ▁arterial
D-1593	-0.43662938475608826	Renal_ artery_ stenosisRAS peripheral_ arterial
P-1593	-0.0999 -0.0718 -1.1963 -0.4812 -0.3164 -0.4998 -0.5146 -0.0966 -0.1124 -0.4793 -0.1728 -0.0550 -0.0900 -0.2672 -1.1068 -1.7178 -0.1448
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart_failure patients rheumatoid_arthritis tnf_antagonist
H-600	-0.9200131893157959	▁Heart _ ▁failure ▁rhe um ato id _ ar thri tis ▁t NF
D-600	-0.9200131893157959	Heart_ failure rheumatoid_arthritis tNF
P-600	-0.2418 -1.0185 -1.2874 -1.4018 -0.1371 -0.4627 -2.0081 -0.1972 -2.6521 -0.4010 -1.9934 -0.8176 -0.1658 -0.8567 -0.1593
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary_artery_disease cad systolic_heart_failure hf
H-1182	-0.9291970729827881	▁Corona ry _ ▁arter y ▁disease CAD ▁sy sto lique _ ▁heart _ ▁failure HF
D-1182	-0.9291970729827881	Coronary_ artery diseaseCAD systolique_ heart_ failureHF
P-1182	-0.2199 -0.2232 -0.9444 -0.2879 -0.1885 -2.1359 -1.9465 -1.0286 -0.0442 -2.6715 -0.2792 -1.6084 -0.7192 -2.7360 -0.4442 -0.2111 -0.1077
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality hf hospital admissions transplant ventricular_assist_device
H-125	-0.6492269039154053	▁mortal ity HF ▁hospital _ ad missions ▁transplant ▁vent ri cular _ assist ▁device
D-125	-0.6492269039154053	mortalityHF hospital_admissions transplant ventricular_assist device
P-125	-1.9966 -0.4681 -1.0131 -0.9972 -2.0918 -0.7737 -0.0127 -0.2628 -0.0210 -0.2800 -0.1713 -0.3121 -0.1794 -1.5014 -0.2027 -0.1037
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-0.7378144264221191	▁valid ity
D-154	-0.7378144264221191	validity
P-154	-1.7698 -0.8412 -0.2433 -0.0970
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.5752034783363342	▁hospital s
D-1713	-0.5752034783363342	hospitals
P-1713	-1.2593 -0.5715 -0.3240 -0.1461
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient heart_failure_with_reduced_ejection_fraction
H-1203	-1.053261399269104	▁heart _ ▁failure ▁e je ction _ fraction
D-1203	-1.053261399269104	heart_ failure ejection_fraction
P-1203	-4.3497 -0.8685 -2.1865 -1.1824 -0.5906 -0.0787 -0.8515 -0.0105 -0.3050 -0.1092
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral_renal_denervation autonomic_balance chronic_heart_failure
H-1369	-1.0132607221603394	▁renal _ ▁den er va tion ▁autonomi c _ ▁balance ▁rabbi ts ▁heart _ ▁failure
D-1369	-1.0132607221603394	renal_ denervation autonomic_ balance rabbits heart_ failure
P-1369	-2.6484 -2.7699 -2.1916 -0.0982 -0.1223 -0.0598 -0.2219 -0.3729 -1.3650 -0.4156 -0.2903 -0.0156 -3.4600 -0.7480 -2.0569 -0.2489 -0.1401
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression type_i_regulatory_subunit ri hf
H-1429	-0.7681529521942139	▁regulator y _ sub un it RI ▁ HF
D-1429	-0.7681529521942139	regulatory_subunitRI HF
P-1429	-1.6592 -0.1352 -0.5424 -0.3035 -0.4048 -0.1966 -2.1790 -2.3759 -0.3540 -0.1694 -0.1296
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat mir-25 transcription_factor hand2 heart_failure
H-638	-0.9566478729248047	▁N fat ▁mi r -25 ▁tran scription _ factor ▁Hand 2 ▁heart _ ▁failure
D-638	-0.9566478729248047	Nfat mir-25 transcription_factor Hand2 heart_ failure
P-638	-4.5137 -0.6315 -0.9046 -0.7228 -0.0649 -0.0645 -0.0212 -1.7346 -1.6329 -0.2407 -0.4224 -0.9400 -0.9415 -1.8934 -0.3024 -0.2752
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf_inhibition cardiac_function remodeling
H-458	-0.8840837478637695	▁VE GF _ ▁inhibi tion ▁b ▁cardiac ▁remodel ing
D-458	-0.8840837478637695	VEGF_ inhibition b cardiac remodeling
P-458	-0.1837 -0.1151 -3.8711 -0.1250 -0.0146 -0.3417 -0.1346 -4.5750 -0.1180 -0.1873 -0.0587
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas right_atrium embolize pulmonary_arterial_vasculature
H-594	-0.7477326393127441	▁My xo mas ▁right _ ▁at rium ▁pulmonar y _ ▁arterial
D-594	-0.7477326393127441	Myxomas right_ atrium pulmonary_ arterial
P-594	-0.9321 -0.0318 -0.4239 -2.4712 -0.6272 -0.9164 -0.0383 -0.0025 -0.2669 -1.1846 -0.6418 -2.0040 -0.1799
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right_atrial_myxoma pulmonary_embolism right_heart_failure
H-592	-0.7508279085159302	▁Right _ ▁at rial _ My xo ma ▁pulmonar y _ ▁e mbol ism ▁right _ ▁heart _ ▁failure
D-592	-0.7508279085159302	Right_ atrial_Myxoma pulmonary_ embolism right_ heart_ failure
P-592	-0.1710 -0.5623 -0.7579 -0.0820 -0.6573 -2.9196 -0.0622 -0.2017 -0.0032 -0.0713 -1.2085 -0.7109 -0.0016 -1.3449 -0.6272 -0.6390 -1.8829 -1.0244 -2.4399 -0.3068 -0.0928
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic_heart_transplantation oht end-stage_heart_failure
H-1280	-0.776563823223114	▁Ort ho topic _ ▁heart _ ▁transplant ation ▁o HT ▁end - s tage _ heart _ ▁failure
D-1280	-0.776563823223114	Orthotopic_ heart_ transplantation oHT end-stage_heart_ failure
P-1280	-0.6326 -0.0481 -0.0805 -0.8159 -1.5710 -2.0259 -0.2199 -0.0172 -0.0366 -1.1155 -4.2241 -0.0515 -0.1810 -0.0028 -0.4956 -1.5298 -0.9403 -1.2767 -0.1816 -0.0848
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary_heart_disease stroke heart_failure
H-1564	-0.9395179748535156	▁corona ry _ ▁heart _ ▁disease ▁stroke ▁heart _ ▁failure
D-1564	-0.9395179748535156	coronary_ heart_ disease stroke heart_ failure
P-1564	-0.4109 -0.3543 -0.6783 -1.4331 -1.3204 -3.0876 -0.0838 -0.2767 -0.5102 -2.7967 -0.1994 -0.1229
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing β-blocker sst2
H-400	-0.4626303017139435	▁β - block er BB ▁s ST 2
D-400	-0.4626303017139435	β-blockerBB sST2
P-400	-0.3352 -0.0243 -0.2238 -0.0959 -1.9370 -0.1695 -1.0146 -0.2913 -0.4226 -0.1122
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone primary_composite_endpoint
H-1227	-0.9856277704238892	▁e pler en one
D-1227	-0.9856277704238892	eplerenone
P-1227	-0.3423 -0.0466 -0.3693 -4.3937 -0.6116 -0.1502
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet exercise_rehabilitation patients chf
H-1884	-1.132846713066101	▁c PET _ gu iding _ ▁exercise ▁CHF
D-1884	-1.132846713066101	cPET_guiding_ exercise CHF
P-1884	-0.1798 -2.9505 -3.5068 -0.9529 -0.0417 -0.1503 -1.0241 -2.2798 -0.1680 -0.0744
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline outcomes ecct cardiac_transplant
H-711	-1.0943868160247803	▁EC CT ▁cardiac ▁transplant
D-711	-1.0943868160247803	ECCT cardiac transplant
P-711	-0.9712 -1.3946 -0.1319 -1.1915 -2.7603 -0.1169
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate_ii lvads patients
H-776	-1.2039985656738281	▁technique ▁mal function ing ▁Heart Mate _ ▁II ▁l VAD s
D-776	-1.2039985656738281	technique malfunctioning HeartMate_ II lVADs
P-776	-1.1114 -4.6813 -1.1447 -0.7986 -0.5603 -0.3702 -1.0306 -1.0041 -3.5523 -0.0272 -0.5902 -0.5051 -0.2760
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart_failure hf cardiovascular hospitalization
H-1074	-0.9030519723892212	▁Heart _ ▁failure HF ▁cardiovascular
D-1074	-0.9030519723892212	Heart_ failureHF cardiovascular
P-1074	-0.9512 -0.4938 -1.7984 -0.5904 -0.3169 -2.0306 -0.1403
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing medications heart_failure
H-1121	-1.4790596961975098	▁medication s ▁heart _ ▁failure
D-1121	-1.4790596961975098	medications heart_ failure
P-1121	-4.1019 -0.0696 -2.6044 -1.2285 -1.7362 -0.4211 -0.1918
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient asymptomatic follow-up
H-599	-0.8041377067565918	
D-599	-0.8041377067565918	
P-599	-1.5089 -0.0993
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality_of_life mlhf_questionnaire
H-1991	-1.2154724597930908	▁ ML HF
D-1991	-1.2154724597930908	MLHF
P-1991	-2.1117 -1.5183 -1.5874 -0.7130 -0.1470
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients heart_failure diagnostic medication follow-up
H-732	-1.5256803035736084	▁Patient s ▁heart _ ▁failure ▁medication
D-732	-1.5256803035736084	Patients heart_ failure medication
P-732	-3.2073 -0.1923 -2.9571 -1.4154 -2.4605 -1.3935 -0.3759 -0.2033
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation resistin correlated ejection_fraction
H-938	-0.5972192287445068	▁resist in ▁decline ▁e je ction _ fraction
D-938	-0.5972192287445068	resistin decline ejection_fraction
P-938	-0.4434 -1.4918 -0.9889 -0.4563 -0.5072 -0.1832 -0.8696 -0.0102 -0.8113 -0.2102
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart_failure hf morbidity mortality
H-199	-0.6109614968299866	▁Pediatri c ▁heart _ ▁failure HF ▁morbi d ity ▁mortal ity
D-199	-0.6109614968299866	Pediatric heart_ failureHF morbidity mortality
P-199	-0.4415 -0.0205 -2.4453 -0.5053 -1.1894 -0.4080 -0.9049 -0.0809 -0.3667 -0.6767 -0.3297 -0.4251 -0.1486
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change readmissions follow-up heart_failure readmission
H-720	-1.3876243829727173	▁read missions ▁heart _ ▁failure
D-720	-1.3876243829727173	readmissions heart_ failure
P-720	-4.4324 -0.0187 -1.2735 -0.5285 -1.6229 -1.6841 -0.1534
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic inflammatory abdominal
H-1285	-1.1036728620529175	▁ ische mic _ in flam ma tory _ ▁abdominal
D-1285	-1.1036728620529175	ischemic_inflammatory_ abdominal
P-1285	-1.4321 -3.0235 -1.1733 -0.6129 -0.2401 -0.3573 -1.0194 -1.1555 -0.2162 -0.4293 -3.3397 -0.2448
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase myocardium
H-171	-0.9067192077636719	▁cas pas e ▁pace d _ My o car dium
D-171	-0.9067192077636719	caspase paced_Myocardium
P-171	-3.5036 -0.9159 -0.9690 -0.2752 -0.2288 -0.2753 -3.6363 -0.1327 -0.0057 -0.3785 -0.4526 -0.1069
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations acr cms
H-140	-0.7722789645195007	▁a CR ▁CMS
D-140	-0.7722789645195007	aCR CMS
P-140	-0.1918 -2.8449 -0.2934 -0.3898 -0.1414
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline embase cinahl
H-62	-0.6841403245925903	▁Med Line ▁ EMBA se ▁c INA HL
D-62	-0.6841403245925903	MedLine EMBAse cINAHL
P-62	-0.6850 -0.2523 -1.1109 -0.0138 -1.6395 -0.3102 -1.9167 -0.5837 -0.2683 -0.0610
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal_dysfunction morbidity
H-719	-0.8939602971076965	▁renal _ ▁dys function ▁trans plant ▁morbi d ity
D-719	-0.8939602971076965	renal_ dysfunction transplant morbidity
P-719	-1.0805 -1.7499 -0.3143 -1.1753 -2.4775 -0.2062 -1.3401 -0.2101 -0.8857 -0.2694 -0.1245
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia heart_disease
H-40	-1.7768970727920532	▁an emia ▁heart _ ▁disease
D-40	-1.7768970727920532	anemia heart_ disease
P-40	-3.2935 -0.8770 -3.1455 -2.1989 -2.5701 -0.2493 -0.1041
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart_failure disease medical
H-2008	-1.5273497104644775	▁Heart _ ▁failure _ ▁disease
D-2008	-1.5273497104644775	Heart_ failure_ disease
P-2008	-0.6326 -0.7723 -2.8858 -1.3884 -2.4154 -2.4505 -0.1464
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin sitagliptin
H-1828	-0.369611918926239	▁h f ▁sax ag lip tin ▁si tag lip tin
D-1828	-0.369611918926239	hf saxagliptin sitagliptin
P-1828	-0.0016 -0.6318 -0.0719 -0.4098 -0.6971 -1.1811 -0.1814 -0.0010 -0.1785 -0.8070 -0.1893 -0.0849
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based therapies patients fes
H-1333	-1.674312710762024	
D-1333	-1.674312710762024	
P-1333	-3.2344 -0.1143
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction pump driveline pump curative
H-774	-0.7664772868156433	▁dys function ▁pump _ ▁failure ▁drive line _ ▁injury ▁pump
D-774	-0.7664772868156433	dysfunction pump_ failure driveline_ injury pump
P-774	-1.2691 -0.6035 -0.7758 -1.9278 -0.3170 -0.0821 -0.2261 -0.9535 -0.1507 -1.2074 -1.5729 -0.1117
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up hf deaths
H-1771	-0.8329816460609436	▁ HF
D-1771	-0.8329816460609436	HF
P-1771	-2.1130 -0.4069 -0.6234 -0.1887
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital discharge
H-302	-1.0372780561447144	▁hospital _ dis charge
D-302	-1.0372780561447144	hospital_discharge
P-302	-4.6813 -0.9704 -0.0676 -0.0477 -0.2981 -0.1585
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal_dnx plasma
H-1381	-0.5689312815666199	▁Ren al ▁DN x ▁circula tion _ ▁plasma ▁CHF - in v ▁rabbi ts
D-1381	-0.5689312815666199	Renal DNx circulation_ plasma CHF-inv rabbits
P-1381	-0.0728 -0.0134 -1.0834 -0.0058 -0.0897 -3.3925 -0.6387 -1.1190 -0.2387 -0.0499 -0.4216 -1.5172 -0.0504 -0.0112 -0.2661 -0.1326
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna genotyped
H-1454	-0.7496989369392395	▁h ct ▁germ line _ DNA ▁geno type d
D-1454	-0.7496989369392395	hct germline_DNA genotyped
P-1454	-0.3439 -1.7486 -0.2065 -0.1816 -0.8306 -0.7113 -0.3709 -0.0304 -2.3860 -1.2798 -0.1570
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients lvad implantation
H-531	-0.4535914957523346	▁implant ation
D-531	-0.4535914957523346	implantation
P-531	-0.8177 -0.0227 -0.8279 -0.1461
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients cad cad
H-1189	-1.559173345565796	▁CAD
D-1189	-1.559173345565796	CAD
P-1189	-3.7937 -0.7955 -0.0884
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients randomized
H-1874	-0.6647549271583557	
D-1874	-0.6647549271583557	
P-1874	-1.2151 -0.1144
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient clinical symptoms
H-1468	-0.7627360224723816	
D-1468	-0.7627360224723816	
P-1468	-1.4495 -0.0760
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients blood medication
H-729	-1.5018973350524902	
D-729	-1.5018973350524902	
P-729	-2.8633 -0.1405
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.6399125456809998	▁HD L - bound _ ▁malo ndi alde hy de ▁HD L - indu ced ▁EC
D-252	-0.6399125456809998	HDL-bound_ malondialdehyde HDL-induced EC
P-252	-0.1095 -1.6516 -0.0640 -0.0403 -0.5854 -2.1219 -0.2837 -0.1689 -0.5827 -0.0456 -0.0846 -0.9976 -0.0310 -0.0008 -3.1624 -1.1910 -0.2548 -0.1426
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients trastuzumab
H-676	-0.15646050870418549	▁tras tuz um ab
D-676	-0.15646050870418549	trastuzumab
P-676	-0.4349 -0.0163 -0.0546 -0.1562 -0.1798 -0.0970
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses patients
H-1021	-1.133349061012268	▁ NP
D-1021	-1.133349061012268	NP
P-1021	-1.4411 -0.0854 -2.8014 -0.2055
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow_up hf
H-627	-1.2809187173843384	▁ HF
D-627	-1.2809187173843384	HF
P-627	-3.8572 -0.8810 -0.2710 -0.1145
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical outcomes hfpef
H-1525	-0.6262775659561157	▁EH ▁h p EF
D-1525	-0.6262775659561157	EH hpEF
P-1525	-0.2372 -2.3377 -0.0184 -0.8539 -0.1664 -0.1440
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ambulatory patients heart_failure functional_capacity outcomes
H-695	-1.2924199104309082	▁Solu ble _ ▁ST 2 ▁ambula tory ▁patients ▁heart _ ▁failure
D-695	-1.2924199104309082	Soluble_ ST2 ambulatory patients heart_ failure
P-695	-1.5329 -0.0357 -1.3661 -1.7269 -0.0645 -3.6704 -0.5110 -1.8804 -2.8675 -0.6309 -1.9261 -0.3949 -0.1941
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote_monitoring hospital discharge patients heart_failure meta-analysis
H-146	-1.3860458135604858	▁hospital _ dis charge ▁patients _ with _ heart _ ▁failure
D-146	-1.3860458135604858	hospital_discharge patients_with_heart_ failure
P-146	-4.0598 -0.8087 -0.1020 -0.0158 -1.7966 -0.9504 -4.7599 -0.4233 -1.6652 -0.6402 -1.9173 -0.6705 -0.2087
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline echocardiograms evidence reverse_remodeling
H-907	-0.3010607659816742	▁e cho card i ogram s ▁rever se ▁remodel ing
D-907	-0.3010607659816742	echocardiograms reverse remodeling
P-907	-0.4249 -0.2633 -0.2121 -0.3549 -0.0101 -0.2388 -0.2092 -0.0101 -1.0038 -0.3801 -0.3470 -0.1583
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin_hypophosphorylation myocardial_dd
H-771	-0.5744379758834839	▁Tit in _ hy phos phor y lation ▁my o card ial ▁ DD
D-771	-0.5744379758834839	Titin_hyphosphorylation myocardial DD
P-771	-0.0532 -1.8637 -1.3140 -0.5518 -0.3811 -0.2039 -0.9101 -0.0251 -0.6798 -0.2120 -0.2052 -0.1451 -2.2283 -0.0403 -0.1983 -0.1791
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac_overexpression mammalian_enabled mena heart_failure
H-1809	-0.7041126489639282	▁Card iac ▁Mamma lian ▁men a ▁heart _ ▁failure ▁mi ce
D-1809	-0.7041126489639282	Cardiac Mammalian mena heart_ failure mice
P-1809	-0.1694 -0.1929 -0.1987 -0.2132 -3.5430 -0.2064 -0.2030 -0.9355 -1.6105 -1.4949 -0.0424 -0.2399 -0.1036
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis chronic_heart_failure tachycardia
H-164	-1.2589235305786133	▁can ine _ model _ de _ ▁chronic _ ▁heart _ ▁failure ▁ta chy car dia
D-164	-1.2589235305786133	canine_model_de_ chronic_ heart_ failure tachycardia
P-164	-1.5510 -0.1257 -2.2779 -1.0583 -1.6010 -1.2903 -0.2236 -3.6718 -0.4309 -2.0225 -0.7518 -2.5207 -1.3230 -0.3231 -0.0262 -1.1820 -2.1078 -0.1729
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker uptitration hfpef
H-183	-0.640083372592926	▁ RAS - ▁β - block er _ up tit ration ▁ HF p EF
D-183	-0.640083372592926	RAS- β-blocker_uptitration HFpEF
P-183	-1.9747 -0.0675 -0.5852 -1.3421 -0.0125 -0.1247 -0.1468 -1.7380 -0.3657 -1.1739 -0.0701 -1.6449 -0.4851 -0.0300 -0.8184 -0.1559 -0.1457
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise adverse_events coronary_artery_disease cad
H-1899	-1.2322219610214233	▁corona ry _ ▁arter y ▁disease CAD
D-1899	-1.2322219610214233	coronary_ artery diseaseCAD
P-1899	-3.5127 -0.5820 -1.6278 -0.4761 -0.3074 -2.2732 -1.8993 -0.2905 -0.1209
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv_filling_pressure stable severe_systolic_hf
H-489	-0.6466464400291443	▁LV ▁fill ing _ tension ▁h z
D-489	-0.6466464400291443	LV filling_tension hz
P-489	-0.1265 -0.9592 -0.2545 -0.7615 -0.6751 -1.7399 -1.0176 -0.1649 -0.1208
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal_bleeding patients ventricular_assist_devices cardiac nurse
H-1656	-0.5692999362945557	▁Gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ assist ▁devices ▁cardiac _ ▁nurse
D-1656	-0.5692999362945557	Gastrointestinal_ bleeding ventricular_assist devices cardiac_ nurse
P-1656	-0.1646 -0.0296 -0.8621 -0.2310 -0.6213 -0.5656 -0.5398 -0.4312 -0.0277 -0.1244 -0.1356 -0.3201 -0.1237 -2.7790 -0.0394 -2.7939 -0.4988 -0.4248 -0.1041
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas bridge_to_transplantation destination_therapy
H-1999	-0.8749959468841553	▁l VAS ▁implant ation
D-1999	-0.8749959468841553	lVAS implantation
P-1999	-0.7602 -0.2141 -3.4660 -0.0105 -0.7027 -0.0965
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 prognosis heart_failure
H-399	-1.704747200012207	
D-399	-1.704747200012207	
P-399	-3.3479 -0.0616
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs functional_capacity peak_vo2
H-123	-1.0205057859420776	▁c PC s ▁functional _ ▁capacity ▁VO 2
D-123	-1.0205057859420776	cPCs functional_ capacity VO2
P-123	-0.0817 -1.3910 -0.0421 -1.2711 -2.1695 -2.5673 -1.3234 -0.6315 -0.5335 -0.1939
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac_hypertrophy energy_metabolism
H-1778	-0.6631155014038086	▁Card iac _ ▁hyper trop hy ▁énergétique
D-1778	-0.6631155014038086	Cardiac_ hypertrophy énergétique
P-1778	-0.6393 -0.3614 -0.3180 -0.6488 -0.0287 -0.0991 -2.3331 -1.4165 -0.1232
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east rhythm_control_therapy cardiovascular complications
H-1648	-0.5231797099113464	▁e AST ▁ rhythm _ control _ therapy ▁cardiovascular ▁complica tions ▁AF
D-1648	-0.5231797099113464	eAST rhythm_control_therapy cardiovascular complications AF
P-1648	-0.3394 -0.2550 -0.1609 -0.8655 -0.5180 -0.0497 -1.1874 -0.3243 -0.7627 -0.6741 -0.0737 -1.8341 -0.1492 -0.1304
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty heart_failure health
H-621	-1.6282638311386108	▁Fra il ité ▁heart _ ▁failure ▁ aging
D-621	-1.6282638311386108	Frailité heart_ failure aging
P-621	-4.5081 -0.1200 -2.2434 -3.1063 -0.7216 -1.9625 -2.1269 -0.7846 -0.5955 -0.1140
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil orally doxorubicin
H-959	-0.19099028408527374	▁Nico rand il ▁do xor ubi cin
D-959	-0.19099028408527374	Nicorandil doxorubicin
P-959	-0.0051 -0.0939 -0.4388 -0.1622 -0.0659 -0.1027 -0.1486 -0.6284 -0.0734
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients clinical radiological hf hospitalization
H-560	-1.1224054098129272	▁ HF
D-560	-1.1224054098129272	HF
P-560	-3.7839 -0.2213 -0.3538 -0.1306
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart heart_failure arrhythmias
H-747	-1.813042402267456	▁Heart _ t 2 ▁heart _ ▁failure
D-747	-1.813042402267456	Heart_t2 heart_ failure
P-747	-0.8089 -3.5343 -1.6275 -0.0469 -3.9595 -1.2141 -1.5209 -3.4572 -0.1482
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham_heart_study hf ef
H-1103	-0.5801994204521179	▁Fram ing ham _ ▁Heart _ ▁Study ▁h f
D-1103	-0.5801994204521179	Framingham_ Heart_ Study hf
P-1103	-0.0734 -0.1390 -0.0643 -1.2259 -0.1485 -0.8605 -0.0379 -3.2854 -0.0458 -0.4059 -0.0955
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations congestive_heart_failure
H-208	-0.5369651317596436	▁ED ▁in tuba tions ▁con ges tive _ ▁heart _ ▁failure
D-208	-0.5369651317596436	ED intubations congestive_ heart_ failure
P-208	-0.8373 -0.0572 -0.1574 -0.0739 -0.6644 -0.1197 -0.3008 -0.5225 -1.5902 -0.9570 -1.3024 -0.2510 -0.1467
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics symptoms patients heart_failure hf
H-1199	-0.920412540435791	▁di ure tics ▁con ges tive _ ▁symptoms ▁heart _ ▁failure HF
D-1199	-0.920412540435791	diuretics congestive_ symptoms heart_ failureHF
P-1199	-0.1759 -0.2695 -1.3271 -4.1606 -0.1911 -0.2009 -1.7750 -0.6237 -1.3130 -0.5694 -1.3211 -0.5204 -0.2864 -0.1518
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence acp clinical_practice_guidelines
H-35	-1.008758306503296	▁a CP
D-35	-1.008758306503296	aCP
P-35	-0.4328 -0.2840 -3.2215 -0.0967
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck_stent chronic_myocardial_ischemia heart_failure
H-502	-0.7801685929298401	▁bottle ne ck ▁sten t ▁chronic _ My o card ial _ ische mia ▁heart _ ▁failure ▁pig s
D-502	-0.7801685929298401	bottleneck stent chronic_Myocardial_ischemia heart_ failure pigs
P-502	-0.2398 -0.0120 -0.3037 -1.1563 -0.0304 -3.4344 -0.6279 -2.5916 -0.5157 -0.2636 -0.1960 -0.1851 -3.3210 -0.8309 -0.2089 -1.1313 -0.6064 -0.2007 -0.1289 -0.2876 -0.1113
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis mortality patients
H-68	-0.6874504685401917	▁mortal ity ▁i CD - HF
D-68	-0.6874504685401917	mortality iCD-HF
P-68	-2.0471 -1.0816 -0.5808 -0.5094 -0.0383 -0.2268 -0.8252 -0.1903
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient patients discharged hf
H-1400	-0.9037150740623474	▁in patient ▁records ▁ HF
D-1400	-0.9037150740623474	inpatient records HF
P-1400	-0.2769 -0.2159 -2.4219 -2.6193 -0.4209 -0.2054 -0.1656
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report aric hf
H-290	-0.957956850528717	▁a RIC ▁ HF
D-290	-0.957956850528717	aRIC HF
P-290	-0.7872 -1.0688 -2.7654 -0.3149 -0.6042 -0.2073
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients therapy hospitalized cardiovascular
H-1223	-1.1214641332626343	▁cardiovascular
D-1223	-1.1214641332626343	cardiovascular
P-1223	-2.7093 -0.4784 -0.1767
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients pneumonia surgical conditions
H-5	-0.7645664215087891	▁pneu monia ▁conditions
D-5	-0.7645664215087891	pneumonia conditions
P-5	-0.0369 -1.4576 -2.0223 -0.2047 -0.1013
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis therapy
H-1467	-0.5895926356315613	▁ therapy
D-1467	-0.5895926356315613	therapy
P-1467	-1.8327 -0.2088 -0.1547 -0.1622
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-0.35985681414604187	
D-1852	-0.35985681414604187	
P-1852	-0.6315 -0.0882
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease accounting cardiac_transplants
H-982	-1.302338719367981	▁pa e dia tric ▁cardiac ▁transplant s
D-982	-1.302338719367981	paediatric cardiac transplants
P-982	-3.0222 -0.0680 -3.0680 -0.5186 -2.5163 -1.0036 -0.3259 -1.0417 -0.1569
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter_ablation sinus_rhythm
H-945	-0.6562061905860901	▁AF - free _ ▁probabil ity ▁cat heter ▁ab lation ▁sinus ▁ rhythm
D-945	-0.6562061905860901	AF-free_ probability catheter ablation sinus rhythm
P-945	-0.2822 -0.0920 -0.3278 -2.8852 -2.8212 -0.5002 -0.1631 -0.0194 -0.8227 -0.0279 -0.4065 -0.6948 -0.2969 -0.3115 -0.1915
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc outcomes outcome admission discharge
H-1401	-1.0756144523620605	▁NO c
D-1401	-1.0756144523620605	NOc
P-1401	-1.0328 -0.6959 -2.4056 -0.1681
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients implantation crt
H-848	-0.44290587306022644	▁implant ation ▁c RT
D-848	-0.44290587306022644	implantation cRT
P-848	-0.0576 -0.0195 -0.1167 -1.6530 -0.7126 -0.0981
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol exercise training baseline hgb
H-843	-0.6400904655456543	▁HR Qo L ▁h gb
D-843	-0.6400904655456543	HRQoL hgb
P-843	-1.3920 -0.0671 -0.7841 -1.5705 -0.3657 -0.2377 -0.0635
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs osprey
H-1611	-0.674033522605896	▁de g s ▁o spre y ▁network s
D-1611	-0.674033522605896	degs osprey networks
P-1611	-1.6196 -2.4748 -0.2788 -0.0313 -0.0257 -0.1041 -1.7517 -0.0821 -0.3004 -0.0719
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.42076337337493896	▁ir on
D-49	-0.42076337337493896	iron
P-49	-0.0935 -0.0586 -1.4094 -0.1216
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-1.1095993518829346	▁ED ▁CHF
D-216	-1.1095993518829346	ED CHF
P-216	-2.6330 -1.4780 -0.2159 -0.1114
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit_index
H-1008	-0.6851983070373535	▁deficit SD
D-1008	-0.6851983070373535	deficitSD
P-1008	-0.6373 -1.8158 -0.1514 -0.1363
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare policy
H-1716	-0.9454206228256226	▁Medica re ▁post - a cute _ care _ ▁transfer
D-1716	-0.9454206228256226	Medicare post-acute_care_ transfer
P-1716	-0.1557 -0.0108 -2.5944 -0.0104 -0.0214 -0.0334 -0.3453 -2.1743 -0.9026 -2.0180 -2.8598 -0.2187
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-1.2279995679855347	▁QR s
D-892	-1.2279995679855347	QRs
P-892	-2.3168 -1.7042 -0.7956 -0.0954
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical change
H-792	-0.6539738774299622	▁clinic al ▁change
D-792	-0.6539738774299622	clinical change
P-792	-2.5480 -0.0587 -0.4921 -0.0988 -0.0723
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-1.1962922811508179	▁vegetables ▁nu ts ▁grain _ ▁in take ▁mortal ity
D-692	-1.1962922811508179	vegetables nuts grain_ intake mortality
P-692	-4.5732 -0.4833 -0.0127 -3.7185 -1.2970 -0.7283 -1.4733 -0.1391 -0.3583 -0.2349 -0.1408
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-0.574743390083313	▁benefit
D-619	-0.574743390083313	benefit
P-619	-1.3218 -0.2371 -0.1653
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-1.5337512493133545	
D-1508	-1.5337512493133545	
P-1508	-2.9383 -0.1292
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt_intervals sd_of_all_qt_intervals sdqt
H-1439	-1.0231883525848389	▁ QT _ ▁interval s ▁SD QT
D-1439	-1.0231883525848389	QT_ intervals SDQT
P-1439	-0.9864 -1.0657 -3.3182 -0.1472 -0.0547 -0.1151 -2.9392 -0.4480 -0.1342
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic right_ventricular_contractile_reserve patients pulmonary_hypertension
H-821	-0.3639247417449951	▁vent ri cular _ contract ile _ ▁reserve ▁pulmonar y ▁hyper tension
D-821	-0.3639247417449951	ventricular_contractile_ reserve pulmonary hypertension
P-821	-0.3081 -0.3366 -0.2826 -0.3584 -0.1777 -0.9047 -0.3295 -0.3420 -0.1084 -0.3027 -1.2121 -0.0006 -0.3103 -0.1213
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart_rate aortic blood_flow doxorubicin
H-960	-0.7185452580451965	▁Heart _ de _ a or tic _ ▁blood _ ▁flow ▁do xor ubi cin
D-960	-0.7185452580451965	Heart_de_aortic_ blood_ flow doxorubicin
P-960	-0.6210 -1.3457 -3.5883 -0.1228 -0.5113 -0.2240 -2.4332 -0.3340 -0.3922 -1.1623 -0.6644 -0.0947 -0.0683 -0.1967 -0.1240 -0.2245 -0.1079
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute autonomic_nervous_system qtv hf patients
H-1447	-0.8916747570037842	▁a cute _ ▁autonomi c _ ▁ner vous _ system _ ▁modul ation ▁Q TV HF
D-1447	-0.8916747570037842	acute_ autonomic_ nervous_system_ modulation QTVHF
P-1447	-1.2310 -0.0064 -0.2933 -0.3899 -0.2184 -0.4980 -2.0158 -3.6890 -1.8530 -0.5147 -1.7182 -0.8532 -0.0207 -0.5585 -0.3196 -1.3563 -0.4212 -0.0930
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular_death hf hospitalization exercise training patients btes
H-1933	-0.7939132452011108	▁cardiovascular _ ▁death HF ▁b tes
D-1933	-0.7939132452011108	cardiovascular_ deathHF btes
P-1933	-0.9677 -2.1061 -0.6679 -0.3456 -1.7476 -0.2318 -0.1956 -0.0889
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac_resynchronization_therapy patients heart_failure
H-903	-0.8838813304901123	▁cardiac _ re syn chron ization _ therapy ▁di al ysis - dependent ▁patients ▁heart _ ▁failure
D-903	-0.8838813304901123	cardiac_resynchronization_therapy dialysis-dependent patients heart_ failure
P-903	-0.6200 -1.0324 -0.7012 -0.0373 -0.0016 -1.4328 -2.6772 -0.2605 -0.1849 -0.1615 -0.0332 -1.0270 -0.1525 -2.4429 -1.5056 -1.3671 -2.6914 -0.2871 -0.1775
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo bivp correlated rs_synchrony
H-327	-0.9413793683052063	▁ RV PO ▁Bi VP ▁co ▁rs ▁synchron y ▁CS
D-327	-0.9413793683052063	RVPO BiVP co rs synchrony CS
P-327	-0.5060 -0.7446 -2.3261 -1.1955 -0.0402 -3.0950 -1.6764 -0.4476 -0.5334 -0.3283 -0.2359 -0.1675
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ventricular-arterial_coupling
H-526	-0.3606800436973572	▁vent ri cular - arte rial ▁coup ling ▁SV
D-526	-0.3606800436973572	ventricular-arterial coupling SV
P-526	-0.0070 -0.1613 -0.0815 -0.1771 -0.0423 -0.1178 -0.4883 -2.5081 -0.0414 -0.2087 -0.1339
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial pde2 expression activity hf
H-1213	-0.9472830891609192	▁My o card ial _ p de 2 ▁expression ▁ HF
D-1213	-0.9472830891609192	Myocardial_pde2 expression HF
P-1213	-1.4445 -0.1473 -0.0609 -0.1425 -1.5456 -1.6873 -0.1044 -1.6546 -0.5198 -2.8610 -1.7135 -0.2389 -0.1943
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1_mapping clinically myocardial_fibrosis
H-1065	-0.8934816718101501	▁ma pping ▁my o card ial _ ▁fibro sis
D-1065	-0.8934816718101501	mapping myocardial_ fibrosis
P-1065	-2.7666 -0.5419 -2.9812 -0.5311 -0.6291 -0.3929 -0.5879 -0.0847 -1.0461 -0.1516 -0.1151
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat sympathetic_outflow parasympathetic_activity
H-1869	-1.2074658870697021	▁BAT ▁sympa the tic _ ▁out flow ▁para sy mpa the tic _ ▁activity
D-1869	-1.2074658870697021	BAT sympathetic_ outflow parasympathetic_ activity
P-1869	-0.3490 -1.2522 -0.7716 -2.9508 -0.5791 -1.2967 -0.7477 -0.2251 -0.9069 -1.0490 -2.9117 -3.4850 -1.4514 -0.7643 -0.3981 -0.1807
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin acute anthracycline-induced_cardiotoxicity
H-931	-0.8486640453338623	▁resist in ▁a cute ▁an thra cycli ne _ indu ce _ ▁cardio toxic ity
D-931	-0.8486640453338623	resistin acute anthracycline_induce_ cardiotoxicity
P-931	-0.8942 -0.4246 -1.4687 -0.0385 -0.7833 -0.0656 -1.3644 -1.3668 -0.9873 -0.0003 -4.6067 -0.3549 -0.3020 -0.2498 -1.0285 -0.3323 -0.1595
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal_muscle correlated vo2_max
H-1500	-0.9158253073692322	▁skelet al _ ▁muscle _ ▁mass ▁VO 2
D-1500	-0.9158253073692322	skeletal_ muscle_ mass VO2
P-1500	-1.1945 -0.3363 -1.2190 -1.5732 -1.1916 -1.8748 -1.3514 -0.0735 -0.2457 -0.0982
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized double-blind active placebo
H-77	-0.637946605682373	▁double - blind ▁active
D-77	-0.637946605682373	double-blind active
P-77	-1.5985 -0.0144 -0.0023 -0.1679 -1.9071 -0.1375
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac_catheterization patient extubated transferred
H-1297	-0.9849063754081726	▁cardiac _ ▁cat heter ization ▁ex tuba ted
D-1297	-0.9849063754081726	cardiac_ catheterization extubated
P-1297	-1.2436 -2.9062 -0.9323 -0.0053 -1.3017 -0.2460 -0.0050 -2.4130 -0.7199 -0.0760
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients atrial_fibrillation pacemaker
H-883	-0.6574801802635193	▁at rial _ ▁fi bril lation ▁pace maker
D-883	-0.6574801802635193	atrial_ fibrillation pacemaker
P-883	-1.4999 -0.1026 -0.6046 -3.0629 -0.0577 -0.0639 -0.6502 -0.1128 -0.3384 -0.0819
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump pump pump_thrombosis hemolysis
H-2004	-0.8464893698692322	▁pump _ change s ▁pump ▁ thro mbo sis ▁hem ol ysis
D-2004	-0.8464893698692322	pump_changes pump thrombosis hemolysis
P-2004	-0.1045 -1.4433 -2.5485 -0.0542 -0.4556 -2.5313 -0.6809 -0.9102 -1.5641 -0.7160 -0.1053 -0.0887 -0.5639 -0.0841
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world_health_organization hf
H-1791	-1.4148982763290405	▁World _ ▁Health ▁Organization ▁ HF
D-1791	-1.4148982763290405	World_ Health Organization HF
P-1791	-5.4130 -0.1498 -1.5222 -0.7754 -2.2021 -0.3107 -0.8515 -0.0946
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial_tissue pka
H-1426	-0.8427382707595825	▁my o card ial _ ▁tissu e ▁p KA
D-1426	-0.8427382707595825	myocardial_ tissue pKA
P-1426	-4.3976 -0.1569 -0.1107 -0.1197 -0.7398 -0.8713 -0.4933 -0.2565 -1.2765 -0.7728 -0.0751
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body_mass_index crf exercise
H-1768	-0.6840225458145142	▁body _ ▁Mass ▁index ▁c RF ▁tre ad m ill
D-1768	-0.6840225458145142	body_ Mass index cRF treadmill
P-1768	-1.2620 -0.6869 -2.0809 -1.5458 -0.0432 -0.2113 -0.1244 -0.0315 -0.0377 -0.3987 -1.6803 -0.1054
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition compliance exercise injections patients
H-1321	-0.8411182761192322	▁implant ions
D-1321	-0.8411182761192322	implantions
P-1321	-2.9197 -0.1340 -0.2373 -0.0734
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic_failure cardiomyopathic
H-986	-0.8278800249099731	▁dia sto lic _ ▁failure ▁cardio my o pathi c ▁restriction
D-986	-0.8278800249099731	diastolic_ failure cardiomyopathic restriction
P-986	-1.2215 -0.4054 -2.4026 -0.8945 -0.4523 -0.2682 -1.7693 -0.8883 -0.0149 -0.1395 -0.9858 -1.2229 -0.0973
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic_nervous_system activity qtv
H-1436	-0.8469032645225525	▁autonomi c _ ▁ner vous _ system _ ▁activity ▁Q TV
D-1436	-0.8469032645225525	autonomic_ nervous_system_ activity QTV
P-1436	-0.2049 -0.1873 -0.4104 -2.5273 -2.7626 -1.5030 -0.6191 -0.7641 -0.8580 -0.5705 -0.4120 -0.1054 -0.0852
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial exercise training heart_failure hf patients
H-1925	-1.274872064590454	▁psycho social ▁factors ▁heart _ ▁failure HF
D-1925	-1.274872064590454	psychosocial factors heart_ failureHF
P-1925	-1.4584 -0.0191 -1.6905 -4.6641 -0.7957 -1.6804 -0.4760 -0.5063 -0.1833
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical outcomes hospitalisations readmissions mortality
H-1850	-0.5916590690612793	▁hospital isation s ▁read missions ▁mortal ity
D-1850	-0.5916590690612793	hospitalisations readmissions mortality
P-1850	-2.8749 -0.0293 -0.1356 -1.2211 -0.0369 -0.1467 -0.5140 -0.2526 -0.1139
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise training patients chronic_heart_failure high-density_lipoprotein
H-245	-1.4547008275985718	▁heart _ ▁failure ▁high - dens ity _ ▁lipo prote in
D-245	-1.4547008275985718	heart_ failure high-density_ lipoprotein
P-245	-7.5284 -1.0168 -1.5263 -4.3450 -0.0854 -0.0074 -0.2217 -0.4907 -0.2030 -0.3220 -1.7683 -1.2097 -0.1865
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf intubation
H-221	-0.4931674599647522	▁ed ▁visit s ▁CHF ▁in tub ation
D-221	-0.4931674599647522	ed visits CHF intubation
P-221	-1.2731 -1.8268 -0.0665 -0.0886 -0.0070 -0.0436 -0.0197 -1.0226 -0.0905
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty health outcomes
H-623	-1.0749354362487793	▁Fra il ité ▁el der ly
D-623	-1.0749354362487793	Frailité elderly
P-623	-1.7309 -0.8588 -3.5620 -0.1248 -0.2571 -0.6565 -1.3431 -0.0662
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical therapeutic
H-1368	-0.69647616147995	
D-1368	-0.69647616147995	
P-1368	-1.2834 -0.1096
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare hospitalizations
H-1714	-0.3138790726661682	▁Medica re ▁fee - for - service
D-1714	-0.3138790726661682	Medicare fee-for-service
P-1714	-0.0615 -0.0109 -0.9249 -0.0643 -0.0305 -0.1052 -0.0205 -1.4480 -0.1590
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician conditions hospital discharge
H-1422	-0.3919793367385864	▁physician _ continu ity ▁conditions ▁hospital _ dis charge
D-1422	-0.3919793367385864	physician_continuity conditions hospital_discharge
P-1422	-0.3032 -0.7087 -0.5638 -0.5697 -0.0179 -0.6418 -1.0270 -0.0863 -0.0041 -0.2616 -0.1278
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-1.075002908706665	SD
D-1983	-1.075002908706665	SD
P-1983	-1.4612 -1.6197 -0.1441
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-0.6999583840370178	
D-1862	-0.6999583840370178	
P-1862	-1.3116 -0.0883
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol mortality
H-650	-0.5061591863632202	▁bis o pro lol ▁mortal ity
D-650	-0.5061591863632202	bisoprolol mortality
P-650	-1.4614 -0.1147 -0.0236 -0.5997 -1.1210 -0.4636 -0.1863 -0.0790
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss btes exercise
H-1928	-0.8622841238975525	▁PS s ▁social _ support ▁b tes
D-1928	-0.8622841238975525	PSs social_support btes
P-1928	-1.6099 -1.3813 -0.2823 -1.1330 -2.2390 -0.1230 -0.1739 -0.6750 -0.1433
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics_rounds
H-1681	-0.45830339193344116	▁e thi cs _ ▁Round s
D-1681	-0.45830339193344116	ethics_ Rounds
P-1681	-0.9979 -0.0400 -0.5789 -1.1896 -0.1430 -0.0575 -0.5827 -0.0768
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients prognosis
H-1315	-0.9113914370536804	▁high - risk
D-1315	-0.9113914370536804	high-risk
P-1315	-2.7755 -0.0245 -0.0546 -1.5603 -0.1421
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac_stress β-ar drive
H-1219	-1.090205192565918	▁cardiac _ ▁stress ▁β - AR
D-1219	-1.090205192565918	cardiac_ stress β-AR
P-1219	-2.4085 -2.0262 -1.8420 -1.1645 -0.0247 -0.2529 -0.8689 -0.1339
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-1.0352075099945068	
D-626	-1.0352075099945068	
P-626	-1.9446 -0.1258
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.7187281847000122	
D-2013	-0.7187281847000122	
P-2013	-1.3070 -0.1304
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart_rate_reduction ivabradine left_ventricle heart_failure patients
H-515	-1.267406702041626	▁heart _ ▁rate ▁i va bra dine ▁vent ric le ▁heart _ ▁failure
D-515	-1.267406702041626	heart_ rate ivabradine ventricle heart_ failure
P-515	-2.8819 -2.2261 -1.3778 -0.2390 -0.0350 -1.3250 -0.1210 -0.6408 -3.7787 -0.9184 -1.3764 -1.2541 -1.9025 -0.7156 -0.2189
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic reverse_remodeling cardiac_resynchronization_therapy
H-426	-0.6708354949951172	▁e cho car dio graphic ▁remodel ing ▁cardiac _ re syn chron ization
D-426	-0.6708354949951172	echocardiographic remodeling cardiac_resynchronization
P-426	-0.3262 -1.2781 -0.1879 -1.0479 -0.8086 -1.3132 -0.3971 -0.0700 -0.9289 -0.8670 -0.0054 -0.0004 -1.4442 -1.2836 -0.1041
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers neurohormonal_stimulation inflammation endothelial_dysfunction
H-13	-0.29611021280288696	▁bio mark ers ▁neuro hormon al ▁stimul ation ▁ inflammation ▁en dot heli al ▁dys function
D-13	-0.29611021280288696	biomarkers neurohormonal stimulation inflammation endothelial dysfunction
P-13	-0.2517 -0.0103 -0.0301 -0.7248 -0.1147 -0.1674 -0.5530 -0.0138 -0.0541 -0.0694 -0.1091 -1.2239 -0.1024 -0.0454 -0.7591 -0.7684 -0.2343 -0.0980
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis medical heart_failure canadian_cardiovascular_society
H-198	-1.3497037887573242	▁heart _ ▁failure ▁Canadian _ ▁Card io vas cular _ ▁Society
D-198	-1.3497037887573242	heart_ failure Canadian_ Cardiovascular_ Society
P-198	-5.2874 -0.4901 -1.2559 -2.9147 -0.7602 -1.6300 -1.7553 -0.6224 -0.5197 -1.0932 -0.3978 -0.7052 -0.1142
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal pathophysiology congestive_heart_failure chf
H-634	-0.6198815107345581	▁Neuro hormon al ▁ab normal ités ▁pat ho phy si ology ▁con ges tive _ ▁heart _ ▁failure ▁ch f
D-634	-0.6198815107345581	Neurohormonal abnormalités pathophysiology congestive_ heart_ failure chf
P-634	-0.6679 -0.1051 -0.0515 -0.8340 -0.0425 -0.8828 -0.6398 -0.0299 -0.0056 -0.4650 -1.1538 -0.8791 -0.1357 -0.3539 -0.3952 -2.4483 -0.4723 -1.5156 -2.3263 -0.0334 -0.1121 -0.0874
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart_failure pathophysiology diagnosis medical_treatment nursing
H-2018	-0.4801112413406372	▁Heart _ ▁Fail ure ▁Path o phy si ology ▁Medical ▁Treatment
D-2018	-0.4801112413406372	Heart_ Failure Pathophysiology Medical Treatment
P-2018	-0.1907 -0.7048 -0.1216 -0.0469 -0.5771 -0.3317 -0.0027 -0.2646 -0.4701 -0.6895 -0.2303 -2.5172 -0.0944
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic_neurotransmission acetylcholinesterase_inhibition
H-1135	-0.5543100237846375	▁para sy mpa the tic _ ▁neuro trans mission ▁a ce tyl cho line ster ase
D-1135	-0.5543100237846375	parasympathetic_ neurotransmission acetylcholinesterase
P-1135	-0.0415 -0.2583 -0.3054 -0.7800 -1.7732 -0.4706 -0.1156 -0.0014 -0.0419 -0.0649 -0.0348 -0.2666 -1.8385 -0.1580 -0.2285 -2.5073 -0.9743 -0.1168
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence end-stage_renal_disease outpatients systolic_heart_failure
H-386	-0.8590495586395264	▁end - s tage _ ▁renal ▁disease ▁out patient s ▁sy sto lique _ ▁heart _ ▁failure
D-386	-0.8590495586395264	end-stage_ renal disease outpatients systolique_ heart_ failure
P-386	-0.2592 -0.0903 -0.2331 -0.0040 -1.0244 -0.1051 -1.4521 -3.5142 -0.0239 -0.0305 -1.0594 -0.1419 -4.0572 -0.3813 -1.3045 -1.2392 -1.0121 -0.2574 -0.1324
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia patients heart_disease clinical_practice_guideline american_college_of_physicians
H-29	-1.0790361166000366	▁an emia ▁heart _ ▁disease ▁College _ de _ phy s iques
D-29	-1.0790361166000366	anemia heart_ disease College_de_physiques
P-29	-1.6676 -0.1680 -2.4604 -1.0363 -2.3039 -2.7895 -0.1655 -1.5655 -0.0769 -0.7760 -1.4533 -0.2976 -0.2412 -0.1049
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal_dnx cardiac autonomic_balance chf sympathetic_tone
H-1382	-0.4691677689552307	▁renal ▁DN x ▁cardiac _ ▁autonomi c ▁balance ▁CHF ▁sympa the tic _ ▁tone
D-1382	-0.4691677689552307	renal DNx cardiac_ autonomic balance CHF sympathetic_ tone
P-1382	-0.0645 -0.5967 -0.0078 -0.0186 -1.2677 -0.1122 -0.2410 -0.6235 -0.0171 -0.0570 -0.4945 -2.1779 -1.3581 -0.1047 -0.2915 -0.0741
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right_ventricle rv cardiac_function medical
H-1091	-1.2320928573608398	▁vent ric le ▁ RV ▁cardiac
D-1091	-1.2320928573608398	ventricle RV cardiac
P-1091	-0.5379 -2.5160 -0.4342 -2.6624 -0.6781 -0.1209 -2.8089 -0.0984
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical radiological hf quality_of_life
H-565	-0.7199013829231262	▁radi ological ▁sign s ▁ HF
D-565	-0.7199013829231262	radiological signs HF
P-565	-0.7501 -0.6527 -2.2395 -0.0316 -1.3049 -0.1113 -0.5342 -0.1349
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive_heart_failure chf
H-209	-0.7845904231071472	▁con ges tive _ ▁heart _ ▁failure ▁ch f
D-209	-0.7845904231071472	congestive_ heart_ failure chf
P-209	-2.0546 -0.1226 -0.0722 -0.3863 -1.3854 -0.5181 -1.0314 -2.8064 -0.0564 -0.0999 -0.0972
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri_scanner baseline heart_failure
H-1057	-1.864820957183838	▁m ri ▁scanner ▁heart
D-1057	-1.864820957183838	mri scanner heart
P-1057	-1.5869 -3.0837 -2.5988 -0.4567 -3.2383 -0.2244
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness sickle_cell_disease anemia
H-1682	-0.5730060935020447	▁Jehovah _ s ▁Wit ness ▁sick le _ cell _ ▁disease ▁an emia
D-1682	-0.5730060935020447	Jehovah_s Witness sickle_cell_ disease anemia
P-1682	-0.0056 -2.0685 -0.6934 -0.8001 -0.5654 -0.1653 -0.0666 -0.2768 -0.5725 -0.9839 -0.7308 -1.0442 -0.0911 -0.3308 -0.2001
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin_subproteome diseased heart
H-99	-0.8519171476364136	▁chr omat in _ sub prote ome ▁mouse _ ▁heart
D-99	-0.8519171476364136	chromatin_subproteome mouse_ heart
P-99	-1.1390 -0.0427 -2.6264 -0.2617 -0.1868 -0.1694 -1.7454 -1.8986 -1.0375 -0.8343 -0.1757 -0.1055
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash mortality heart_failure health
H-684	-0.7628365159034729	▁Mediterrane an ▁DAS h ▁mortal ity ▁women ▁heart _ ▁failure ▁Women s _ ▁Health ▁Initiative
D-684	-0.7628365159034729	Mediterranean DASh mortality women heart_ failure Womens_ Health Initiative
P-684	-0.2577 -0.0182 -0.0489 -0.3275 -0.5383 -0.2764 -2.7615 -0.7239 -0.4900 -1.1581 -1.0710 -1.6673 -0.5692 -1.4074 -1.2626 -0.2608 -0.1293
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad_variant congestive_heart_failure
H-1670	-1.1084022521972656	▁l - type _ ca 2 _ ▁current s ▁Rad ▁con ges tive _ ▁heart _ ▁failure
D-1670	-1.1084022521972656	l-type_ca2_ currents Rad congestive_ heart_ failure
P-1670	-4.4279 -0.4237 -0.0818 -0.9688 -0.0407 -0.0817 -3.3999 -1.9582 -0.1347 -0.8955 -1.7070 -0.1525 -0.2282 -0.7103 -1.8983 -1.4651 -1.9700 -0.3471 -0.1683
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary exercise prognostically heart_failure
H-1274	-1.3608944416046143	▁cardio pul mon ary _ ▁exercise ▁heart _ ▁failure
D-1274	-1.3608944416046143	cardiopulmonary_ exercise heart_ failure
P-1274	-0.3871 -0.4472 -4.0121 -1.3860 -1.5609 -1.8139 -1.7864 -1.1451 -2.0908 -0.2308 -0.1096
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity mortality quality_of_life patients hf
H-2023	-0.6026414036750793	▁morbi d ity ▁mortal ity ▁ HF
D-2023	-0.6026414036750793	morbidity mortality HF
P-2023	-0.3096 -0.1839 -0.5318 -0.6991 -0.3304 -3.0425 -0.1534 -0.0810 -0.0921
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes costs patients heart_failure hf
H-1721	-1.6011182069778442	▁coût ▁heart _ ▁failure HF
D-1721	-1.6011182069778442	coût heart_ failureHF
P-1721	-2.2830 -5.2926 -0.9329 -1.7557 -0.6363 -0.2009 -0.1065
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome heart_failure fontan
H-1493	-0.7360637187957764	▁muscle - was ting _ ▁syndrome ▁acquire d _ ▁heart _ ▁failure ▁Font an
D-1493	-0.7360637187957764	muscle-wasting_ syndrome acquired_ heart_ failure Fontan
P-1493	-0.8569 -0.1272 -0.9773 -0.7473 -3.0342 -0.2444 -1.0713 -0.0602 -0.3110 -1.3565 -0.4712 -2.0384 -0.1081 -0.1476 -0.1121 -0.1133
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas therapeutic heart_failure
H-1485	-0.7218539118766785	▁mi RNA s ▁heart _ ▁failure
D-1485	-0.7218539118766785	miRNAs heart_ failure
P-1485	-1.3988 -0.0647 -0.0604 -1.1812 -0.8293 -1.9983 -0.1476 -0.0945
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health_buddy_program telehealth
H-1622	-1.1399686336517334	▁Health ▁Budd y _ program ▁content - driv en _ ▁tele health _ system ▁care ▁management
D-1622	-1.1399686336517334	Health Buddy_program content-driven_ telehealth_system care management
P-1622	-1.2791 -1.0063 -0.0403 -3.6399 -1.4241 -1.9167 -0.0291 -0.0159 -0.3112 -0.4462 -1.2733 -0.2555 -3.0967 -0.7441 -2.8495 -1.5496 -0.4862 -0.1559
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin breast_cancer patients cardiotoxicity
H-936	-0.7009717226028442	▁an thra cycli ne - tre ated ▁breast ▁cancer ▁cardio toxic ity
D-936	-0.7009717226028442	anthracycline-treated breast cancer cardiotoxicity
P-936	-1.7318 -0.0671 -1.4256 -0.4605 -0.3140 -0.0156 -3.1205 -0.0621 -0.6954 -0.3155 -0.1126 -0.9589 -0.4210 -0.1130
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine furosemide outcome
H-586	-0.6112751364707947	▁do bu tamine ▁fur os em ide ▁oxygen
D-586	-0.6112751364707947	dobutamine furosemide oxygen
P-586	-0.2816 -0.6688 -0.0718 -0.3987 -0.4775 -0.0808 -0.0548 -2.5441 -1.4513 -0.0832
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic patients heart_failure
H-1740	-1.5983728170394897	▁ therapeut ic
D-1740	-1.5983728170394897	therapeutic
P-1740	-3.4481 -0.3350 -0.3849 -3.7188 -0.1050
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality deaths acs consultation operation
H-1287	-0.6364465355873108	▁Mor t ality ▁a CS ▁consultation
D-1287	-0.6364465355873108	Mortality aCS consultation
P-1287	-1.7101 -0.0403 -0.0623 -0.6122 -1.5141 -0.7544 -0.2723 -0.1258
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs outcomes patients diabetes
H-130	-0.5017223358154297	▁c PC s ▁diabetes
D-130	-0.5017223358154297	cPCs diabetes
P-130	-0.2142 -1.6802 -0.0883 -0.5737 -0.2679 -0.1861
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential_effect lvef mortality
H-118	-0.5830802917480469	▁LV EF ▁long - term _ ▁mortal ity
D-118	-0.5830802917480469	LVEF long-term_ mortality
P-118	-0.2992 -0.6888 -0.7623 -0.1003 -1.9964 -0.4351 -0.4378 -0.5593 -0.3978 -0.1538
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health_buddy_program hospital hospitalized
H-1626	-1.1809160709381104	▁Health ▁Budd y _ ▁Program ▁ED ▁hospital
D-1626	-1.1809160709381104	Health Buddy_ Program ED hospital
P-1626	-1.1157 -0.2977 -0.0570 -3.0812 -1.5565 -0.8322 -0.4841 -3.0753 -0.1285
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital mortality patients bnp mortality
H-195	-0.4811304807662964	▁in hospital ▁mortal ity ▁b NP ▁mortal ity
D-195	-0.4811304807662964	inhospital mortality bNP mortality
P-195	-0.6561 -0.0458 -1.3565 -0.3054 -0.0569 -0.6531 -0.8971 -0.4558 -0.3005 -0.0840
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt nt-probnp hf
H-291	-0.2714371681213379	▁c t n t ▁NT - pro b NP ▁ HF
D-291	-0.2714371681213379	ctnt NT-probNP HF
P-291	-0.0716 -0.0570 -0.0866 -0.0952 -0.2301 -0.0116 -0.0095 -0.4255 -0.1913 -0.9274 -0.3313 -0.9101 -0.1815
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv_dysfunction correlated lean_body_mass
H-1164	-1.5114705562591553	▁ RV _ ▁dys function ▁weight _ ▁loss ▁fat
D-1164	-1.5114705562591553	RV_ dysfunction weight_ loss fat
P-1164	-1.5386 -0.5188 -1.5931 -0.5344 -1.0046 -1.1055 -1.7599 -4.3435 -1.6790 -2.3578 -0.1909
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-1.2528119087219238	▁fut ility
D-850	-1.2528119087219238	futility
P-850	-0.5675 -0.1206 -4.2392 -0.0841
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients consultation abdominal
H-1284	-1.1755598783493042	▁MT ▁consultation ▁abdominal
D-1284	-1.1755598783493042	MT consultation abdominal
P-1284	-1.7941 -1.0538 -0.6749 -2.2049 -0.1501
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic complication
H-1661	-0.19643445312976837	▁complica tion
D-1661	-0.19643445312976837	complication
P-1661	-0.4043 -0.1775 -0.1139 -0.0899
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-0.4512960612773895	▁mortal ity
D-2001	-0.4512960612773895	mortality
P-2001	-1.0385 -0.4735 -0.2045 -0.0886
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-0.8450186252593994	▁fréquence
D-727	-0.8450186252593994	fréquence
P-727	-1.3710 -1.0953 -0.0687
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection_fraction clinical cardiac_resynchronization_therapy mild_heart_failure
H-750	-0.6657726764678955	▁e je ction _ fraction ▁cardiac _ re syn chron ization _ therapy ▁heart _ ▁failure
D-750	-0.6657726764678955	ejection_fraction cardiac_resynchronization_therapy heart_ failure
P-750	-0.5288 -0.2291 -0.0114 -0.6570 -0.0016 -0.1194 -0.8123 -1.0566 -0.0433 -0.0028 -1.4167 -1.4929 -0.1512 -2.3745 -0.8986 -1.8967 -0.1874 -0.1037
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular_pacing left_heart_twist strain right_heart_failure
H-318	-1.0063589811325073	▁bi ven tri cular _ pa cing _ ▁on _ ▁left _ ▁heart _ ▁twist ▁por cine _ model _ de _ ▁right _ ▁heart _ ▁failure
D-318	-1.0063589811325073	biventricular_pacing_ on_ left_ heart_ twist porcine_model_de_ right_ heart_ failure
P-318	-1.2694 -0.5070 -0.2451 -0.9250 -1.2184 -0.6912 -0.2294 -3.7105 -1.1457 -0.6011 -0.3283 -1.0460 -1.0209 -1.2209 -0.3044 -1.8694 -0.6541 -2.9555 -1.1774 -1.2054 -1.1888 -0.2225 -1.4691 -0.7500 -0.9387 -0.7492 -1.2001 -0.1820 -0.1589
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress_doppler_echocardiography prognostic pulmonary_hypertension patients
H-832	-0.5180515050888062	▁Stress ▁do pp ler ▁e cho card i ography ▁pulmonar y ▁hyper tension
D-832	-0.5180515050888062	Stress doppler echocardiography pulmonary hypertension
P-832	-0.4069 -0.8739 -0.0894 -0.5122 -1.3670 -1.0217 -0.3325 -0.7363 -0.3236 -0.0183 -0.1267 -1.2872 -0.0024 -0.5371 -0.1355
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical aortic_valve_insufficiency left_ventricular_assist_device implantation
H-541	-0.6358052492141724	▁a or tic ▁val ve ▁vent ri cular ▁implant ation
D-541	-0.6358052492141724	aortic valve ventricular implantation
P-541	-1.0256 -0.0700 -1.7073 -2.1627 -0.2056 -0.7779 -0.2698 -0.2175 -0.8207 -0.0284 -0.2551 -0.0890
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left_ventricular_ejection_time acute_heart_failure precapillary_pulmonary_hypertension
H-576	-0.6211040019989014	▁vent ri cular ▁e je ction _ f ré que ction _ f ré que nce ▁heart _ ▁failure ▁pre cap illa ry _ ▁pulmonar y ▁hyper tension
D-576	-0.6211040019989014	ventricular ejection_fréquection_fréquence heart_ failure precapillary_ pulmonary hypertension
P-576	-0.0655 -0.4646 -0.1260 -1.3989 -0.2146 -0.0190 -1.2918 -3.1229 -0.0328 -0.0959 -0.3459 -0.9341 -2.0044 -0.0105 -0.0745 -1.1814 -1.9228 -0.6666 -1.0493 -0.0679 -1.1019 -0.0032 -0.5079 -0.6147 -0.0809 -0.1409 -0.5530 -0.0003 -0.3583 -0.1828
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial_diastolic_dysfunction dd collagen_deposition titin
H-761	-0.5493552088737488	▁my o card ial _ ▁dia sto lic _ ▁dys function DD ▁collage n _ de position
D-761	-0.5493552088737488	myocardial_ diastolic_ dysfunctionDD collagen_deposition
P-761	-0.2780 -0.1119 -0.0910 -0.1492 -0.1794 -1.7680 -0.6825 -2.7665 -0.8702 -0.0967 -0.8229 -0.7874 -0.3757 -0.0538 -0.5746 -0.0337 -0.2105 -0.4915 -0.0941
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated septal wall avd free_wall_cs vvd
H-329	-1.1228464841842651	▁sept al _ ▁wall ▁av d ▁free ▁wall _ ▁CS ▁VVD
D-329	-1.1228464841842651	septal_ wall avd free wall_ CS VVD
P-329	-1.7245 -0.1891 -1.3194 -1.5834 -1.1108 -0.2395 -0.4156 -1.7130 -2.0115 -2.0010 -1.8910 -0.2415 -0.1566
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic acute_rv_failure left_ventricular_dysfunction
H-1092	-1.0106050968170166	▁ RV ▁vent ri cular _ ▁dys function
D-1092	-1.0106050968170166	RV ventricular_ dysfunction
P-1092	-2.1709 -1.9088 -1.6251 -0.3590 -0.2784 -1.9126 -0.3033 -0.8579 -0.5022 -0.1878
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left_pulmonary_artery right_pulmonary_artery
H-597	-0.8018918037414551	▁pulmonar y ▁arter y
D-597	-0.8018918037414551	pulmonary artery
P-597	-0.7141 -0.1559 -0.6521 -0.6464 -2.4903 -0.1526
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student_t_test confidence_intervals cis regression_analyses
H-215	-1.2720099687576294	▁c s ▁re gression
D-215	-1.2720099687576294	cs regression
P-215	-3.8649 -0.9614 -1.9623 -0.0438 -0.6897 -0.1100
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv_strain strain echocardiography baseline ablation
H-946	-0.6253847479820251	▁LV ▁strain ▁e cho card i ography ▁ab lation
D-946	-0.6253847479820251	LV strain echocardiography ablation
P-946	-0.1424 -2.1298 -1.7807 -0.8215 -0.3688 -0.6281 -0.4286 -0.1636 -0.0296 -0.2669 -0.1193
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr_reduction beta_blockers exercise_capacity hfref
H-1937	-0.7028830051422119	▁HR _ re duction ▁beta _ block ers ▁h f f
D-1937	-0.7028830051422119	HR_reduction beta_blockers hff
P-1937	-0.4179 -3.5244 -0.6818 -0.0116 -0.4227 -0.8424 -0.7352 -0.0429 -0.1925 -1.0991 -0.8829 -0.1915 -0.0927
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle_cohort_study canada
H-1951	-0.7867950201034546	
D-1951	-0.7867950201034546	
P-1951	-1.4842 -0.0894
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs functional_capacity outcomes heart_failure hf
H-121	-0.983849287033081	▁c PC s ▁functional _ ▁capacity ▁heart _ ▁failure HF
D-121	-0.983849287033081	cPCs functional_ capacity heart_ failureHF
P-121	-0.0533 -1.2187 -0.0815 -1.9915 -2.0730 -2.7461 -0.4606 -0.6128 -1.8788 -0.3472 -0.1903 -0.1523
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed_up adverse_events death transplantation circulatory_assist_device
H-1162	-0.6824069619178772	▁implant ation ▁circula tory _ assist ▁device
D-1162	-0.6824069619178772	implantation circulatory_assist device
P-1162	-2.3201 -0.0144 -0.1617 -0.2227 -0.2169 -0.1741 -2.6233 -0.2886 -0.1198
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary_outcome sympathetic_activity myocardial_washout
H-1115	-1.8877936601638794	▁i - m g _ ▁my o card ial
D-1115	-1.8877936601638794	i-mg_ myocardial
P-1115	-0.6765 -4.8932 -1.9302 -1.8250 -2.7123 -2.7221 -1.1810 -0.4556 -0.1081 -3.9365 -0.3252
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating_progenitor_cells outcome heart_failure patients longitudinal
H-119	-0.867666482925415	▁circula tion _ pro gen itor _ cell s ▁heart _ ▁failure
D-119	-0.867666482925415	circulation_progenitor_cells heart_ failure
P-119	-1.0950 -2.6344 -0.4195 -0.2306 -0.2490 -0.7421 -1.8898 -0.4760 -0.1996 -0.6919 -0.7830 -2.1835 -0.3894 -0.1635
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic diastolic_mitral_leaflet_motions organic lesion
H-351	-1.0649758577346802	▁sy sto lic ▁dia sto lic _ met ral ▁le a flet
D-351	-1.0649758577346802	systolic diastolic_metral leaflet
P-351	-1.2945 -0.1644 -1.3634 -3.1197 -0.4440 -1.7472 -1.3086 -1.3659 -0.0210 -2.0732 -0.2688 -0.0144 -1.5769 -0.1475
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein_kinase_a guanylate_cyclase contractile_response
H-418	-0.8200156092643738	▁inhibi tion ▁protein _ ▁kina se ▁solu ble _ ▁gua ny late _ ▁cy cla se ▁contract ile
D-418	-0.8200156092643738	inhibition protein_ kinase soluble_ guanylate_ cyclase contractile
P-418	-0.8199 -0.0239 -1.4872 -1.4904 -0.1536 -0.0945 -2.1460 -0.0309 -0.5400 -0.4523 -0.2369 -3.1796 -1.0697 -0.9158 -0.1706 -1.2774 -0.0489 -0.5650 -1.4879 -0.2099
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta_blockers mortality patients heart_failure
H-649	-1.5473984479904175	▁beta _ block ers ▁heart _ ▁failure
D-649	-1.5473984479904175	beta_blockers heart_ failure
P-649	-1.8568 -2.8678 -0.9157 -0.1986 -4.4956 -0.9263 -2.3844 -0.1713 -0.1101
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd congestive_heart_failure chf
H-902	-0.8425776362419128	▁PD ▁re frac tory ▁end - s tage _ con ges tive _ ▁heart _ ▁failure CH f
D-902	-0.8425776362419128	PD refractory end-stage_congestive_ heart_ failureCHf
P-902	-2.9208 -0.9205 -0.0596 -0.5589 -2.6377 -0.0360 -0.1565 -0.0020 -0.4298 -0.0954 -0.7363 -0.1794 -1.0227 -1.3436 -0.8731 -1.6549 -2.7733 -0.1129 -0.2048 -0.1332
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype perioperative deaths
H-279	-0.5307128429412842	▁per i operativ e
D-279	-0.5307128429412842	perioperative
P-279	-1.9516 -0.3711 -0.2538 -0.1614 -0.3299 -0.1165
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients trastuzumab cardiac comorbidities
H-682	-0.5501881837844849	▁tras tuz um ab ▁cardiac
D-682	-0.5501881837844849	trastuzumab cardiac
P-682	-0.5494 -0.0066 -0.0183 -0.1186 -0.0318 -3.0042 -0.1226
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic patients heart_failure québec canada
H-1233	-1.3698718547821045	▁économique ▁af ▁heart _ ▁failure ▁Québec
D-1233	-1.3698718547821045	économique af heart_ failure Québec
P-1233	-0.3909 -3.6262 -2.9154 -0.9860 -1.5589 -0.4863 -0.9031 -0.0921
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression_models comorbidities
H-662	-1.195818543434143	▁multi vari able _ hier archi cal _ re gression
D-662	-1.195818543434143	multivariable_hierarchical_regression
P-662	-2.7971 -0.0025 -0.0816 -0.3222 -3.1397 -0.2786 -1.5351 -0.3615 -0.9938 -0.0389 -4.6064 -0.1923
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline st2 interquartile_range
H-701	-1.513135313987732	▁st 2
D-701	-1.513135313987732	st2
P-701	-4.3357 -0.2132 -1.3428 -0.1610
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac mena_deletion cardiac_dysfunction hypertrophy
H-1811	-0.476740300655365	▁cardiac _ ▁Men a ▁dele tion ▁cardiac _ ▁dys function ▁hyper trop hy
D-1811	-0.476740300655365	cardiac_ Mena deletion cardiac_ dysfunction hypertrophy
P-1811	-0.1797 -1.2826 -1.3771 -0.1290 -0.5620 -0.0301 -0.0384 -1.1077 -0.3806 -0.8284 -0.6379 -0.0121 -0.2047 -0.2610 -0.1199
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left_bundle-branch_block lbbb
H-886	-0.46312955021858215	▁bund le - bran ch _ block LB BB LB BB
D-886	-0.46312955021858215	bundle-branch_blockLBBBLBBB
P-886	-0.0142 -0.0843 -0.0440 -0.0083 -0.2233 -0.6784 -1.7244 -0.5298 -0.5973 -0.5434 -0.7476 -0.7358 -0.0899
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf atrial_explants cells explants
H-1341	-0.5103341937065125	▁CHF ▁at rial _ ▁ex plant s ▁c - K it _ cell s ▁sham ▁ex plant s
D-1341	-0.5103341937065125	CHF atrial_ explants c-Kit_cells sham explants
P-1341	-0.0235 -2.5141 -0.1194 -1.7574 -0.5592 -0.0398 -0.3373 -0.1808 -0.2006 -0.5332 -0.0151 -0.9622 -0.6936 -0.2702 -0.1964 -1.2551 -0.0101 -0.2028 -0.2444 -0.0918
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf valve_plasty mva
H-369	-0.5256408452987671	▁ HF ▁val ve ▁plast y ▁MS ▁m va
D-369	-0.5256408452987671	HF valve plasty MS mva
P-369	-1.4936 -0.2056 -0.6462 -0.0686 -0.9509 -0.5414 -1.0502 -0.1765 -0.2416 -0.3378 -0.0697
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms patients nyha
H-1893	-0.9706961512565613	▁NY HA
D-1893	-0.9706961512565613	NYHA
P-1893	-2.1153 -0.6897 -0.9637 -0.1141
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure_ulcers surgical patients
H-6	-0.6696475744247437	▁pressure _ ▁ul cer s ▁sur g ical
D-6	-0.6696475744247437	pressure_ ulcers surgical
P-6	-1.3370 -0.9436 -0.1431 -0.1948 -0.8542 -0.7251 -0.0600 -0.4633 -1.7978 -0.1777
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients chronic_organ_failure
H-793	-1.2856980562210083	▁Time d _ up _ go
D-793	-1.2856980562210083	Timed_up_go
P-793	-2.6052 -0.4189 -0.4470 -0.6506 -0.7708 -1.8516 -3.3407 -0.2008
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome change hospitalized heart_failure
H-1395	-1.4758766889572144	▁Nur sing - sensitiv e _ ▁outcome _ change _ ▁score s ▁hospital ized _ ▁older ▁adults ▁heart _ ▁failure
D-1395	-1.4758766889572144	Nursing-sensitive_ outcome_change_ scores hospitalized_ older adults heart_ failure
P-1395	-0.8533 -0.6433 -0.1463 -0.0409 -0.3874 -3.0915 -2.4302 -2.1122 -0.4631 -4.4207 -1.6573 -0.0243 -2.6784 -1.3242 -2.5960 -1.6756 -3.2028 -0.9615 -0.7705 -2.5138 -0.2292 -0.2470
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation heart_iron
H-748	-1.0269832611083984	▁che lation ▁heart _ ▁ir on
D-748	-1.0269832611083984	chelation heart_ iron
P-748	-1.3275 -0.0187 -4.9375 -0.6200 -0.1160 -0.0515 -1.0292 -0.1154
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter invasive surgery
H-553	-0.3811834156513214	▁trans cat heter
D-553	-0.3811834156513214	transcatheter
P-553	-0.0282 -0.3356 -0.0238 -1.4153 -0.1029
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up outcomes mortality
H-1637	-0.558167040348053	▁black _ race ▁mortal ity
D-1637	-0.558167040348053	black_race mortality
P-1637	-0.2367 -1.1530 -1.3561 -0.3439 -0.4070 -0.2548 -0.1557
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise clinical outcomes
H-1926	-1.3297404050827026	▁social _ support
D-1926	-1.3297404050827026	social_support
P-1926	-0.9838 -1.4368 -1.9660 -2.1166 -0.1455
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin heart_failure breast_cancer
H-927	-0.9452769756317139	▁Human ▁resist in ▁che mo therapy - indu ced ▁heart _ ▁failure
D-927	-0.9452769756317139	Human resistin chemotherapy-induced heart_ failure
P-927	-2.6971 -1.8795 -0.4613 -0.2667 -0.0464 -0.0161 -1.0163 -0.0003 -2.2182 -0.3595 -0.6051 -0.2394 -3.2275 -0.2004
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic diagnostic fluid_overload
H-1071	-0.9490963220596313	▁ therapeut ic ▁fluid _ Over load
D-1071	-0.9490963220596313	therapeutic fluid_Overload
P-1071	-0.9793 -0.0387 -0.3602 -3.5133 -0.5978 -1.8851 -0.7314 -0.3175 -0.1186
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing outcomes hospitalized hf
H-1402	-1.5118781328201294	▁hospital ized _ ▁older _ ▁adults HF
D-1402	-1.5118781328201294	hospitalized_ older_ adultsHF
P-1402	-5.1058 -1.0966 -1.9103 -0.5962 -2.1210 -1.4325 -1.0722 -0.1639 -0.1083
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome death hospitalization heart_failure
H-849	-1.730181097984314	
D-849	-1.730181097984314	
P-849	-3.2576 -0.2027
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical echocardiographic invasive hemodynamic outcome
H-1527	-0.4676264524459839	▁e cho car dio graphic ▁invasi ve _ hem o dynamic
D-1527	-0.4676264524459839	echocardiographic invasive_hemodynamic
P-1527	-0.2805 -0.3495 -0.1084 -1.0820 -0.4225 -0.0822 -0.4830 -0.5349 -2.1312 -0.2300 -0.0218 -0.2752 -0.0777
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right_atrium prolapse tricuspid_valve stenotic_physiology
H-596	-0.8151185512542725	▁right _ ▁at rium _ ▁mass ▁pro lapse ▁tri cus pid ▁val ve ▁ste no tic _ ▁physio log y
D-596	-0.8151185512542725	right_ atrium_ mass prolapse tricuspid valve stenotic_ physiology
P-596	-1.6526 -1.1482 -0.9937 -0.0706 -2.0253 -1.5097 -0.0591 -0.0818 -2.7621 -0.1933 -0.2214 -1.8552 -0.6014 -0.0025 -0.0756 -1.5509 -0.5498 -0.5035 -0.4062 -1.0945 -0.4938 -0.0814
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis pacing-induced_dilated_cardiomyopathy
H-165	-0.9380449652671814	▁apo pto sis ▁pa cing - indu ce _ ▁dil ated _ ▁cardio my o pathy
D-165	-0.9380449652671814	apoptosis pacing-induce_ dilated_ cardiomyopathy
P-165	-3.5951 -0.1414 -1.4741 -0.3364 -2.0048 -0.1585 -0.0006 -3.0152 -1.1070 -0.2644 -0.7509 -0.8300 -0.2145 -1.7263 -0.7964 -0.0370 -0.2660 -0.1662
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative serum_albumin patients left_ventricular_assist_device implantation
H-528	-0.6474995613098145	▁vent ri cular ▁implant ation
D-528	-0.6474995613098145	ventricular implantation
P-528	-1.8700 -0.4258 -0.1591 -1.6139 -0.0320 -0.2797 -0.1520
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac_catheterization thrombotic_obstruction right_coronary_artery
H-1292	-0.8633469343185425	▁cardiac _ ▁cat heter ization ▁ thro mbo tic _ ▁ob struct ion ▁right _ ▁corona ry ▁arter y
D-1292	-0.8633469343185425	cardiac_ catheterization thrombotic_ obstruction right_ coronary artery
P-1292	-1.4827 -2.0751 -0.3240 -0.0041 -1.1720 -0.1156 -0.1795 -0.2494 -2.9799 -1.0670 -1.0559 -0.0512 -0.0242 -2.6460 -1.0898 -0.4410 -0.9149 -0.8621 -0.8907 -0.3717 -0.1335
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western_blots monoclonal_antibodies ser83 phosphorylation hf
H-1431	-0.6829319596290588	▁Western ▁blot s ▁mono clo nal _ anti bo dies ▁Ser 83 ▁ phos phor y lation HF
D-1431	-0.6829319596290588	Western blots monoclonal_antibodies Ser83 phosphorylationHF
P-1431	-0.0779 -1.2503 -0.1681 -0.6644 -0.0457 -0.4940 -1.1709 -0.1483 -0.0869 -1.9742 -1.1795 -0.6802 -0.2812 -0.4147 -0.8066 -2.2020 -0.0791 -1.5308 -0.2516 -0.1524
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan_failure systolic_ventricular_function liver_disease
H-224	-1.0532617568969727	▁Font an _ f ré que nce ▁vent ri cular ▁ liver
D-224	-1.0532617568969727	Fontan_fréquence ventricular liver
P-224	-0.1377 -1.2278 -0.6028 -5.0720 -0.0806 -0.0789 -0.0121 -1.4472 -0.3952 -0.2596 -1.3927 -1.4241 -2.5123 -0.1029
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary_outcome functional_capacity 6-minute_walk_test 6mwt
H-571	-1.3250447511672974	▁m t
D-571	-1.3250447511672974	mt
P-571	-4.7062 -0.0417 -0.3892 -0.1632
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine dilated_cardiomyopathy patients heart_failure
H-1257	-0.8623051047325134	▁Chinese _ ▁herbal ▁medicine ▁dil ated _ ▁cardio my o pathy ▁heart _ ▁failure
D-1257	-0.8623051047325134	Chinese_ herbal medicine dilated_ cardiomyopathy heart_ failure
P-1257	-2.0290 -1.0257 -0.4135 -1.2167 -0.4430 -0.6890 -0.4743 -0.2837 -2.1577 -0.9648 -0.0257 -1.0057 -0.8615 -1.6896 -0.3507 -0.1663
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic_heart_failure chf sympathetic_tone autonomic_imbalance
H-1370	-0.8535704612731934	▁chronic _ ▁heart _ ▁failure ▁ch f ▁sympa the tic _ ▁tone ▁autonomi c _ ▁im balance
D-1370	-0.8535704612731934	chronic_ heart_ failure chf sympathetic_ tone autonomic_ imbalance
P-1370	-2.6302 -0.8482 -1.2926 -0.5338 -1.0635 -2.6025 -0.0280 -0.8426 -0.4923 -1.8202 -0.8291 -0.1904 -0.0168 -0.3485 -1.1054 -1.0720 -0.0163 -0.3429 -0.1426
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient implantable_cardioverter-defibrillator
H-1856	-0.6007308959960938	▁implant able ▁implant able ▁cardio ver ter - de _ fi br illa tor _ de _ activa tion
D-1856	-0.6007308959960938	implantable implantable cardioverter-de_fibrillator_de_activation
P-1856	-0.0003 -0.0536 -1.3702 -0.0725 -0.9737 -0.2081 -0.0211 -0.1972 -0.0046 -2.7294 -3.3406 -0.8131 -0.0070 -0.3261 -0.3924 -0.0355 -1.4937 -0.0482 -0.1014 -0.2531 -0.1732
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical_delay dyssynchronous_heart_failure
H-1146	-0.9996519684791565	▁electro me chan ical _ de lay ▁dys syn chron ous _ ▁heart _ ▁failure
D-1146	-0.9996519684791565	electromechanical_delay dyssynchronous_ heart_ failure
P-1146	-1.6621 -0.0107 -0.7553 -2.1153 -0.9232 -0.0473 -1.2750 -0.1960 -0.0067 -0.0013 -2.6721 -0.9761 -2.6443 -1.1617 -1.5086 -0.7419 -0.2965
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated cardiac_filling_pressures adverse_outcomes
H-1532	-0.7006407976150513	▁EH ▁cardiac _ ▁fill ing _ tension s
D-1532	-0.7006407976150513	EH cardiac_ filling_tensions
P-1532	-0.1592 -1.7037 -1.9294 -0.8172 -0.3221 -1.2181 -0.3352 -0.1943 -0.2287 -0.0986
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef sodium ventricular vascular_stiffness
H-917	-0.8630267381668091	▁h f f f ▁dieta ry _ so dium ▁vent ri cular
D-917	-0.8630267381668091	hfff dietary_sodium ventricular
P-917	-0.1988 -0.2976 -0.1155 -2.5950 -2.9690 -0.1557 -0.3868 -0.1261 -0.0292 -0.9261 -0.1575 -0.2610 -3.7577 -0.1065
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart_failure leading mortality western society cardiovascular_diseases
H-1480	-1.4185113906860352	▁Heart _ ▁failure ▁mortal ity
D-1480	-1.4185113906860352	Heart_ failure mortality
P-1480	-0.9015 -0.4524 -1.4178 -2.8467 -0.6076 -3.5541 -0.1494
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein genes western_blot dna_fragmentation tunel
H-167	-0.8102917671203613	▁protein s ▁Western ▁blot ▁DNA _ ▁fragment ation ▁tu nel ▁auto psy
D-167	-0.8102917671203613	proteins Western blot DNA_ fragmentation tunel autopsy
P-167	-1.2760 -2.9863 -1.5869 -0.5117 -0.3399 -2.2832 -0.1766 -0.0256 -1.0830 -0.2793 -0.2635 -0.0139 -0.4163 -0.1019
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully_magnetically_levitated_left_ventricular_assist_system hf
H-1992	-0.8605309128761292	▁magnet ically _ ▁Lev itate d _ le ft _ vent ri cular _ ▁Assist ▁ HF
D-1992	-0.8605309128761292	magnetically_ Levitated_left_ventricular_ Assist HF
P-1992	-1.7296 -0.4024 -0.8156 -0.1228 -1.8456 -1.0619 -1.1983 -1.2695 -0.1687 -1.0983 -0.2826 -1.3248 -0.1473 -0.6887 -1.3074 -1.9515 -0.2900 -0.4835 -0.1617
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological cardiovascular bound
H-1875	-0.9672178030014038	▁neurologi cal ▁cardiovascular
D-1875	-0.9672178030014038	neurological cardiovascular
P-1875	-0.6699 -0.5313 -1.7924 -1.7367 -0.1058
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart_failure
H-1539	-1.3865886926651	▁heart _ ▁failure
D-1539	-1.3865886926651	heart_ failure
P-1539	-2.9923 -1.1400 -2.5307 -0.1339 -0.1361
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up patients hf
H-1106	-0.7108609676361084	▁h f
D-1106	-0.7108609676361084	hf
P-1106	-1.8463 -0.7603 -0.1295 -0.1074
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients madit-crt
H-858	-0.6832770705223083	▁MAD it - c RT
D-858	-0.6832770705223083	MADit-cRT
P-858	-0.2380 -1.5432 -0.0230 -0.3267 -1.2816 -1.2593 -0.1111
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical nitrite vascular
H-414	-0.5982695817947388	▁chemical ▁in st ability ▁co genera tion _ de _ ▁nit rite ▁vas cular
D-414	-0.5982695817947388	chemical instability cogeneration_de_ nitrite vascular
P-414	-2.3700 -0.6056 -0.2358 -0.1111 -0.4014 -0.3565 -0.0677 -1.1347 -1.0631 -0.2212 -0.3370 -0.6800 -0.1866 -0.0787 -1.6256 -0.0973
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech_republic
H-1972	-0.5352756977081299	▁Czech ▁Republic
D-1972	-0.5352756977081299	Czech Republic
P-1972	-0.3364 -1.3356 -0.2892 -0.1799
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets tac hf
H-1050	-0.8402663469314575	BET s ▁mouse ▁ TAC ▁h f
D-1050	-0.8402663469314575	BETs mouse TAC hf
P-1050	-0.7202 -1.0525 -0.9621 -0.8110 -0.0211 -2.0165 -1.6322 -0.2044 -0.1424
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized dopamine nesiritide
H-76	-0.5403437614440918	▁dop amine ▁nesi riti de
D-76	-0.5403437614440918	dopamine nesiritide
P-76	-1.9353 -0.2846 -0.0722 -0.0607 -0.2292 -1.0936 -0.1068
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c_statistics
H-383	-1.2137783765792847	▁u e - va - RT
D-383	-1.2137783765792847	ue-va-RT
P-383	-4.5860 -0.9431 -1.0829 -0.9920 -0.2216 -1.6014 -0.1438 -0.1394
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion mortality
H-50	-0.8290551900863647	▁trans fusion ▁mortal ity
D-50	-0.8290551900863647	transfusion mortality
P-50	-0.1118 -0.3067 -3.1815 -0.4585 -0.7752 -0.1407
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations patients patients
H-1282	-0.21230484545230865	▁consultation s
D-1282	-0.21230484545230865	consultations
P-1282	-0.0261 -0.0397 -0.6791 -0.1044
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac nurses
H-1662	-0.8464687466621399	▁cardiac ▁nurse s
D-1662	-0.8464687466621399	cardiac nurses
P-1662	-0.1179 -3.7922 -0.0630 -0.1707 -0.0886
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients randomization
H-851	-0.7449492812156677	▁ closure
D-851	-0.7449492812156677	closure
P-851	-1.8292 -0.0485 -0.9786 -0.1235
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-0.8243618607521057	▁coût - effect ive
D-614	-0.8243618607521057	coût-effective
P-614	-1.2989 -0.0263 -0.0247 -0.0191 -3.4615 -0.1157
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california_office_of_statewide_health_planning_and_development_patient_discharge_data_nonpublic_file
H-136	-0.897213876247406	▁California ▁office _ de _ ▁State _ wide _ ▁Health _ plan ning _ de _ ▁Development ▁Patient _ dis charge
D-136	-0.897213876247406	California office_de_ State_wide_ Health_planning_de_ Development Patient_discharge
P-136	-1.1738 -0.0996 -0.3739 -1.3891 -0.1703 -2.9375 -1.2979 -0.4033 -0.0753 -1.2121 -1.7468 -1.4110 -0.0813 -1.5553 -2.7229 -0.2016 -0.6878 -0.3509 -1.5047 -0.0159 -0.0076 -1.1058 -0.1115
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal_membrane_oxygenation refractory_right_heart_failure
H-1290	-0.8621749877929688	▁extra corp o real ▁membran e _ ▁oxygen ation ▁in far ction _ related ▁re frac tory _ ▁right ▁heart _ ▁failure
D-1290	-0.8621749877929688	extracorporeal membrane_ oxygenation infarction_related refractory_ right heart_ failure
P-1290	-1.3955 -0.0172 -0.2904 -0.3398 -0.4945 -0.1794 -1.2697 -0.3643 -0.0104 -0.5958 -2.1974 -0.0152 -1.3207 -0.2514 -0.4031 -0.0133 -1.2248 -1.1964 -3.7829 -2.2344 -1.2971 -1.4281 -0.2475 -0.1229
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation therapy heart_disease rate_control
H-1652	-1.1168432235717773	▁antico ag ulation ▁ therapy ▁heart
D-1652	-1.1168432235717773	anticoagulation therapy heart
P-1652	-1.2571 -0.8250 -0.0182 -2.1281 -0.0185 -1.6180 -2.9602 -0.1096
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality_of_life seattle_heart_failure_model
H-2012	-0.6307470798492432	▁temps - var ying ▁Seattle ▁Heart _ ▁Fail ure
D-2012	-0.6307470798492432	temps-varying Seattle Heart_ Failure
P-2012	-3.3880 -0.1399 -0.3399 -0.4946 -0.0304 -0.8299 -0.9405 -0.3498 -0.0418 -0.2465 -0.1370
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change paco2 cerebral blood_flow perfusion carotid
H-1350	-0.5110543370246887	▁Paco 2 ▁cerebral _ ▁blood _ ▁flow ▁caro tid ▁bo dies
D-1350	-0.5110543370246887	Paco2 cerebral_ blood_ flow carotid bodies
P-1350	-0.2895 -0.0612 -0.2273 -1.9125 -0.5294 -0.8140 -0.3853 -0.4198 -0.2295 -1.2441 -0.2494 -0.1778 -0.1041
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology hf diagnosis medical nursing
H-2021	-0.5565316081047058	▁pat ho phy si ology ▁ HF ▁medical ▁management
D-2021	-0.5565316081047058	pathophysiology HF medical management
P-2021	-1.4829 -0.2272 -0.0180 -0.3618 -0.9070 -1.2203 -0.2154 -0.4857 -0.6389 -0.4759 -0.0887
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients physicians hospitals new_jersey new_york
H-212	-0.7842193841934204	▁ed ▁physician s ▁subur ban _ hospital s ▁New ▁Jersey ▁New ▁York
D-212	-0.7842193841934204	ed physicians suburban_hospitals New Jersey New York
P-212	-1.0008 -2.0377 -0.0722 -0.8297 -0.0221 -1.7984 -0.5123 -0.3914 -0.8819 -0.5917 -1.2504 -1.1480 -0.3616 -0.0811
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart_failure protein_kinase_a expression
H-1423	-0.9980198740959167	▁heart _ ▁failure ▁protein _ ▁kina se
D-1423	-0.9980198740959167	heart_ failure protein_ kinase
P-1423	-2.0728 -1.3388 -1.9282 -0.5327 -2.0832 -0.1583 -0.1031 -0.5657 -0.1994
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox_regression cardiovascular_events psoriasis
H-1558	-0.6441779732704163	▁co x _ re gression ▁cardiovascular ▁events ▁psoriasis
D-1558	-0.6441779732704163	cox_regression cardiovascular events psoriasis
P-1558	-0.3403 -0.0183 -1.2709 -1.1084 -0.0277 -1.0452 -1.7935 -0.1679 -0.5459 -0.1238
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy_metabolism heart_failure hypertrophied heart
H-1779	-1.123894453048706	▁ énergie _ ▁metabolism ▁heart ▁hyper trop hi ed _ ▁heart
D-1779	-1.123894453048706	énergie_ metabolism heart hypertrophied_ heart
P-1779	-3.5561 -0.3203 -1.0073 -0.0720 -0.9126 -3.8813 -0.0359 -0.0340 -1.3725 -1.6081 -1.4924 -0.1643 -0.1538
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients clinical echocardiography baseline shunt implantation
H-1954	-0.2367907017469406	▁e cho card i ography ▁shu nt ▁implant ation
D-1954	-0.2367907017469406	echocardiography shunt implantation
P-1954	-0.2872 -0.2458 -0.3360 -0.4980 -0.2923 -0.4664 -0.0512 -0.0088 -0.0296 -0.2640 -0.1255
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic_effect beta_blockers heart_failure
H-648	-0.9573447704315186	▁in o tropi c ▁effect ▁beta _ block ers ▁heart _ ▁failure
D-648	-0.9573447704315186	inotropic effect beta_blockers heart_ failure
P-648	-1.0758 -0.5606 -0.0378 -0.2748 -2.5967 -0.5656 -2.9704 -0.7709 -0.1233 -1.1506 -1.1100 -1.8366 -0.2045 -0.1253
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline mechanical_cardiac_support renal_function
H-1388	-1.1406453847885132	▁mechanic al _ ▁cardiac _ ▁support ▁renal
D-1388	-1.1406453847885132	mechanical_ cardiac_ support renal
P-1388	-1.4854 -0.0451 -0.3527 -0.8528 -2.7347 -1.7889 -0.0747 -2.7721 -0.1593
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ecmo patients vad ecmo vad
H-1390	-1.5017906427383423	▁EC mo ▁ VAD
D-1390	-1.5017906427383423	ECmo VAD
P-1390	-1.7820 -0.5196 -1.3739 -0.2679 -4.7431 -0.3244
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional_ms lv_dilatation functional_ms
H-368	-1.3767248392105103	▁functional ▁MS ▁LV ▁di la tation ▁functional ▁MS
D-368	-1.3767248392105103	functional MS LV dilatation functional MS
P-368	-4.2099 -1.8630 -0.4308 -3.1143 -0.0939 -0.0079 -2.3683 -1.3954 -0.1370 -0.1468
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp circulation hf patients
H-1513	-0.45711228251457214	▁NT - pro b NP ▁circulation ▁ HF
D-1513	-0.45711228251457214	NT-probNP circulation HF
P-1513	-0.5502 -0.0384 -0.0123 -0.7108 -0.1294 -0.2106 -1.8022 -0.3518 -0.5709 -0.1944
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality morbidity health-care budget
H-1075	-0.4873591363430023	▁mortal ity ▁morbi d ity ▁cancer s ▁budget
D-1075	-0.4873591363430023	mortality morbidity cancers budget
P-1075	-0.2596 -0.6172 -1.4189 -0.1141 -0.5969 -0.0941 -0.2224 -1.1527 -0.2920 -0.1057
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp sensitivity
H-271	-0.4412458539009094	▁NT - pro b NP
D-271	-0.4412458539009094	NT-probNP
P-271	-1.3143 -0.0251 -0.0333 -0.5815 -0.2339 -0.7224 -0.1782
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation flow-mediated_dilatation
H-259	-0.8879086375236511	▁HD l - indu ced ▁production ▁flow - media ted _ di la tation ▁ET
D-259	-0.8879086375236511	HDl-induced production flow-mediated_dilatation ET
P-259	-0.8721 -1.3300 -0.3858 -0.0006 -2.1204 -1.2991 -0.8148 -0.0459 -0.2821 -3.2175 -0.4000 -1.8308 -0.1046 -0.0357 -2.0213 -0.2186 -0.1152
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients systolic_function therapeutic
H-1070	-1.5897501707077026	▁ therapeut ic
D-1070	-1.5897501707077026	therapeutic
P-1070	-5.1161 -1.1426 -0.6539 -0.9334 -0.1028
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ahf risk_stratification
H-58	-0.7684529423713684	▁a HF
D-58	-0.7684529423713684	aHF
P-58	-1.4078 -0.4293 -1.0222 -0.2145
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients pad ankle-brachial_index
H-1568	-0.6498481035232544	▁ PAD ▁an kle - bra chi al ▁index
D-1568	-0.6498481035232544	PAD ankle-brachial index
P-1568	-3.6285 -0.1482 -0.4672 -0.2860 -0.1758 -1.3646 -0.1591 -0.1916 -0.2426 -0.3268 -0.1579
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective_studies cpg hf
H-1845	-1.3341659307479858	▁c p
D-1845	-1.3341659307479858	cp
P-1845	-0.8825 -1.3154 -3.0334 -0.1052
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr_reduction ivabradine tac ea
H-525	-0.5696317553520203	▁HR ▁i va bra dine TAC
D-525	-0.5696317553520203	HR ivabradineTAC
P-525	-1.3473 -0.3122 -0.0377 -0.7868 -0.0890 -0.9448 -0.9078 -0.1315
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause_hospitalisations sts
H-160	-1.2341848611831665	▁TM ▁s ts
D-160	-1.2341848611831665	TM sts
P-160	-1.6089 -2.6838 -1.1718 -0.5548 -0.1516
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol linear_mixed_models intention-to-treat
H-838	-0.9519686102867126	▁HR Qo L
D-838	-0.9519686102867126	HRQoL
P-838	-3.1828 -0.0188 -0.7722 -0.6739 -0.1121
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic clinicians patients
H-1124	-0.6971889138221741	▁Reason s _ non tre at ment
D-1124	-0.6971889138221741	Reasons_nontreatment
P-1124	-0.5193 -0.0939 -0.7029 -2.8657 -0.0120 -0.4710 -0.0422 -1.4716 -0.0961
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions hospital
H-144	-0.6847328543663025	▁computing _ ▁read missions ▁hospital ▁pay - for - per form ance
D-144	-0.6847328543663025	computing_ readmissions hospital pay-for-performance
P-144	-2.7021 -0.9862 -2.5762 -0.0248 -0.4143 -1.8918 -0.0189 -0.0654 -0.0840 -0.0351 -0.1388 -0.0214 -0.4575 -0.1699
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd patients
H-65	-0.7224650382995605	▁i CD
D-65	-0.7224650382995605	iCD
P-65	-0.2190 -1.6482 -0.8830 -0.1396
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-0.8083500266075134	▁ HF
D-1002	-0.8083500266075134	HF
P-1002	-2.4080 -0.4059 -0.3334 -0.0861
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients patients
H-267	-0.9025930762290955	
D-267	-0.9025930762290955	
P-267	-1.7021 -0.1030
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular_assist_device extracorporeal_membrane_oxygenation renal_function heart_failure
H-1383	-0.7032367587089539	▁vent ri cular _ assist ▁device ▁extra corp o real _ ▁membran e ▁oxygen ation ▁pediatr ic ▁heart _ ▁failure
D-1383	-0.7032367587089539	ventricular_assist device extracorporeal_ membrane oxygenation pediatric heart_ failure
P-1383	-0.0035 -0.1699 -0.1726 -0.6182 -0.1237 -2.2161 -0.3024 -0.0308 -0.3581 -0.3462 -1.1133 -0.2866 -0.1966 -1.0711 -0.0396 -2.5866 -0.4720 -2.1611 -0.9838 -1.8989 -0.1870 -0.1331
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory_fitness body_mass_index heart_failure mortality cooper_center_longitudinal_study
H-1765	-1.068086862564087	▁Card i ore spira tory _ ▁fitness ▁body _ ▁mass _ ▁index ▁heart _ ▁failure
D-1765	-1.068086862564087	Cardiorespiratory_ fitness body_ mass_ index heart_ failure
P-1765	-0.2594 -0.9467 -3.1391 -0.3515 -0.6493 -1.2564 -0.2667 -1.1744 -0.4075 -1.8835 -0.7825 -0.2896 -0.5396 -0.4972 -3.7273 -1.8620 -0.1247
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations cox_models st2 functional_capacity outcomes
H-700	-1.1740602254867554	▁co x
D-700	-1.1740602254867554	cox
P-700	-0.4451 -0.0107 -4.1290 -0.1115
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new_york_heart_association_classification 6-min_walk_test quality-of-life
H-2005	-1.3140558004379272	▁New ▁York _ ▁Heart _ association
D-2005	-1.3140558004379272	New York_ Heart_association
P-2005	-3.4112 -1.4928 -1.1977 -0.8807 -0.7705 -0.9236 -1.6793 -0.1567
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise_intolerance heart_failure exercise diagnosis prognosis therapeutic
H-1272	-0.9660800099372864	▁Exerci se _ ▁in tolerance ▁heart _ ▁failure
D-1272	-0.9660800099372864	Exercise_ intolerance heart_ failure
P-1272	-2.3570 -0.5968 -0.6522 -0.8681 -0.0190 -1.8343 -0.7459 -1.9243 -0.5489 -0.1143
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse_correlation pro-adrenomedullin mr-proadm ffm
H-15	-0.44356241822242737	▁pro - ad re nom edu llin MR - pro AD m f m
D-15	-0.44356241822242737	pro-adrenomedullinMR-proADmfm
P-15	-0.7105 -0.0236 -0.0360 -0.0480 -0.2956 -1.6298 -0.8152 -0.4231 -0.0119 -0.0096 -0.4940 -0.0292 -0.7788 -1.0926 -0.5938 -0.1052
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin_receptor_antagonist tolvaptan heart_failure patients
H-1194	-0.7868377566337585	▁vaso press in _ ▁receptor _ ▁anta gon ist ▁to lv ap tan ▁Japanese _ heart _ ▁failure
D-1194	-0.7868377566337585	vasopressin_ receptor_ antagonist tolvaptan Japanese_heart_ failure
P-1194	-0.0596 -0.0659 -1.3075 -0.8572 -0.0488 -1.0543 -0.4658 -0.0644 -3.0297 -0.4199 -0.5636 -0.0807 -0.0172 -1.0197 -1.1475 -2.9280 -0.6418 -1.4466 -0.4169 -0.1018
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional_ms ring_annuloplasty ischemic_mr lv_dilatation
H-366	-0.5210005640983582	▁functional ▁MS ▁ring _ ▁ann ulo plast y ▁ ische mic ▁MR ▁LV
D-366	-0.5210005640983582	functional MS ring_ annuloplasty ischemic MR LV
P-366	-0.7966 -0.4524 -0.1941 -0.5066 -1.7256 -0.4885 -0.0242 -0.4958 -0.7064 -0.4547 -0.1532 -0.0625 -0.0792 -1.5938 -0.0813
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp nt-probnp diagnostic prognostic biomarkers patients heart_failure
H-1365	-0.7269601821899414	▁b NP ▁NT - pro b NP ▁bio mark ers ▁heart _ ▁failure
D-1365	-0.7269601821899414	bNP NT-probNP biomarkers heart_ failure
P-1365	-0.0460 -0.3409 -1.9060 -0.0165 -0.0035 -0.3791 -0.1614 -2.5498 -0.0165 -0.1597 -1.7761 -1.2048 -2.0202 -0.2171 -0.1066
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis patients diastolic_blood_pressure body_mass_index
H-1560	-1.0741766691207886	▁p sori asis ▁smo ked ▁dia sto lic _ ▁blood _ tension ▁body
D-1560	-1.0741766691207886	psoriasis smoked diastolic_ blood_tension body
P-1560	-1.3616 -0.0579 -0.8465 -2.3854 -0.4937 -0.6930 -0.2732 -2.6050 -0.9947 -0.4840 -1.2955 -0.4204 -0.5677 -3.4541 -0.1797
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin_receptor st2 beta-blocker therapy chronic_heart_failure
H-398	-1.0165735483169556	▁inter le u kin _ ▁receptor ▁ST 2 ▁beta - block er _ therapy ▁heart _ ▁failure
D-398	-1.0165735483169556	interleukin_ receptor ST2 beta-blocker_therapy heart_ failure
P-398	-0.0153 -0.9789 -0.4824 -4.0773 -1.2406 -0.0400 -2.7231 -0.0157 -0.0817 -0.0290 -0.0812 -0.0644 -2.0077 -0.1590 -3.4278 -1.0134 -2.5952 -0.1990 -0.0832
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf symptom cardiac_murmurs blood_pressure
H-356	-0.744292676448822	▁ HF ▁cardiac _ mur mur s ▁blood _ tension ▁h g
D-356	-0.744292676448822	HF cardiac_murmurs blood_tension hg
P-356	-1.6760 -0.1650 -0.8343 -1.7560 -0.9693 -0.1894 -0.3313 -2.6516 -0.9509 -0.4135 -0.0861 -0.0063 -0.2283 -0.1622
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular_dysfunction outcome patients heartmate_ii
H-305	-1.028172254562378	▁bi ven tri cular _ ▁dys function ▁Heart Mate
D-305	-1.028172254562378	biventricular_ dysfunction HeartMate
P-305	-0.9927 -0.7107 -0.3938 -1.6486 -0.8493 -0.3793 -2.2419 -2.9290 -0.1778 -0.8067 -0.1800
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal_dysfunction mechanical_cardiac_support
H-1394	-0.9026282429695129	▁renal _ ▁dys function ▁mechanic al _ ▁cardiac
D-1394	-0.9026282429695129	renal_ dysfunction mechanical_ cardiac
P-1394	-1.6453 -1.3625 -0.7192 -1.1246 -1.1306 -0.0238 -0.1410 -0.6145 -2.1652 -0.0995
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular_assist_devices therapies
H-203	-0.40673062205314636	▁vent ri cular _ assist ▁devices ▁device ▁ therapie s
D-203	-0.40673062205314636	ventricular_assist devices device therapies
P-203	-0.0366 -0.1249 -0.1053 -0.5896 -0.1240 -1.1580 -1.0043 -1.2683 -0.0514 -0.0441 -0.2519 -0.1222
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional_ms medical_treatment surgical
H-376	-0.627914309501648	▁Fun ction al ▁MS
D-376	-0.627914309501648	Functional MS
P-376	-0.3218 -0.0017 -0.0865 -0.8584 -2.3884 -0.1107
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients left_ventricular_dilatation dysfunction
H-1746	-0.6376833915710449	▁vent ri cular _ di la tation ▁dys function
D-1746	-0.6376833915710449	ventricular_dilatation dysfunction
P-1746	-0.4088 -0.4433 -0.3025 -0.7019 -1.8765 -0.4189 -0.1184 -1.0312 -1.1121 -0.4725 -0.1284
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade evidence anemia patients heart_disease
H-38	-1.6295645236968994	▁an emia ▁heart _ ▁disease
D-38	-1.6295645236968994	anemia heart_ disease
P-38	-3.3042 -0.5030 -2.6612 -1.9538 -2.6393 -0.2348 -0.1106
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients heart_failure systolic_heart_failure
H-725	-1.46499502658844	▁heart _ ▁failure ▁sy sto lique _ ▁heart _ ▁failure
D-725	-1.46499502658844	heart_ failure systolique_ heart_ failure
P-725	-4.9850 -1.2776 -1.6286 -0.5209 -0.2061 -4.0476 -0.5331 -1.8448 -1.1160 -0.9983 -0.2529 -0.1691
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients hf spontaneous_vt qt_intervals
H-1445	-0.6775771379470825	▁ HF ▁ VT ▁beat - to - beat ▁ QT
D-1445	-0.6775771379470825	HF VT beat-to-beat QT
P-1445	-1.8376 -0.3356 -2.6924 -0.8828 -0.6731 -0.0504 -0.5503 -0.0470 -0.0556 -0.7022 -0.4437 -0.3734 -0.1645
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol cxl-1020 myocytes hearts
H-419	-1.015020489692688	▁c XL -10 20 ▁my o cy tes ▁heart s
D-419	-1.015020489692688	cXL-1020 myocytes hearts
P-419	-2.3037 -0.7056 -1.6913 -0.3465 -2.0577 -0.1433 -0.1505 -0.1438 -3.9205 -0.2046 -0.3961 -0.1167
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted patients adverse_events follow-up
H-1956	-0.8799775838851929	▁implant ed
D-1956	-0.8799775838851929	implanted
P-1956	-0.0091 -1.5983 -1.7885 -0.1240
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb patients hf
H-1351	-1.6662031412124634	PB ▁ PB ▁ HF
D-1351	-1.6662031412124634	PB PB HF
P-1351	-0.5766 -2.1514 -2.6370 -2.3088 -0.6626 -3.1249 -0.2021
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug_test patients copd chf crf
H-806	-0.9998739957809448	▁tu g ▁tests ▁COP d ▁CHF ▁c RF
D-806	-0.9998739957809448	tug tests COPd CHF cRF
P-806	-1.2929 -1.0745 -3.9215 -2.3116 -0.6800 -0.0230 -0.1432 -0.3201 -0.1607 -0.0713
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart_failure hf chronic disease
H-2019	-0.9097716212272644	▁Heart _ ▁failure HF
D-2019	-0.9097716212272644	Heart_ failureHF
P-2019	-0.4855 -0.5936 -1.2553 -0.7630 -2.1983 -0.1630
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline rhythm-control rate-control
H-1237	-0.313666433095932	▁ rhythm - control ▁rate - control
D-1237	-0.313666433095932	rhythm-control rate-control
P-1237	-0.3011 -0.7763 -0.2086 -0.0168 -0.7109 -0.1321 -0.0196 -0.4741 -0.1835
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf epidemiology health hf
H-1790	-1.1497085094451904	▁ HF ▁health ▁service _ ▁provision ▁ HF
D-1790	-1.1497085094451904	HF health service_ provision HF
P-1790	-1.1541 -0.1588 -3.3272 -0.4007 -0.7106 -2.9851 -1.2651 -0.1656 -1.1502 -0.1795
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin health outcomes
H-43	-0.8934105038642883	▁hem o glob in
D-43	-0.8934105038642883	hemoglobin
P-43	-2.0868 -0.1178 -0.1152 -1.6167 -1.3254 -0.0985
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes heart_failure hf
H-555	-1.2824198007583618	▁heart _ ▁failure HF
D-555	-1.2824198007583618	heart_ failureHF
P-555	-4.0709 -0.8553 -1.7993 -0.6131 -0.1917 -0.1642
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates coagulability
H-1113	-1.1899739503860474	
D-1113	-1.1899739503860474	
P-1113	-2.2501 -0.1298
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up lvad patients heart_failure
H-548	-1.213454246520996	▁CF ▁l VAD ▁AI ▁heart _ ▁failure
D-548	-1.213454246520996	CF lVAD AI heart_ failure
P-548	-0.1592 -3.7299 -0.0533 -2.1160 -0.5301 -1.6728 -2.2474 -0.2862 -0.1261
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory_factor_analysis cfa
H-1506	-0.49074599146842957	▁c fa
D-1506	-0.49074599146842957	cfa
P-1506	-0.6563 -0.9638 -0.1605 -0.1824
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical patient hemodynamically cpr
H-1294	-0.744989275932312	▁hem o dynamic ally _ ▁uns table ▁c PR
D-1294	-0.744989275932312	hemodynamically_ unstable cPR
P-1294	-3.7428 -0.0793 -0.0977 -0.8087 -0.4730 -1.6358 -0.0093 -0.2390 -0.8008 -0.2436 -0.0649
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing mandate accountable outcomes nursing
H-1396	-1.1056482791900635	▁social ▁mandat e
D-1396	-1.1056482791900635	social mandate
P-1396	-2.6038 -0.0463 -0.7663 -1.8649 -0.2469
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical activity cardiovascular obesity diabetes_mellitus hypertension hyperlipidaemia
H-1898	-0.8003817200660706	▁cardiovascular _ risk s ▁diabetes ▁mell itus ▁hyper tension ▁hyper li pida emia
D-1898	-0.8003817200660706	cardiovascular_risks diabetes mellitus hypertension hyperlipidaemia
P-1898	-2.2904 -3.1771 -0.7414 -3.6197 -0.5730 -0.1529 -0.1599 -0.0074 -0.0095 -0.0812 -0.0830 -0.4283 -0.3161 -0.2504 -0.1153
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-1.0953941345214844	
D-1979	-1.0953941345214844	
P-1979	-2.0979 -0.0929
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.919563353061676	▁long - ter me
D-272	-0.919563353061676	long-terme
P-272	-1.8690 -0.2048 -1.4773 -0.9513 -0.8608 -0.1542
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac_death
H-1905	-0.9380558729171753	▁sud den _ ▁cardiac ▁death
D-1905	-0.9380558729171753	sudden_ cardiac death
P-1905	-0.9296 -0.0656 -0.2123 -0.1163 -4.4029 -0.6769 -0.1627
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital mortality
H-1692	-0.6846630573272705	▁hospital _ ▁mortal ity
D-1692	-0.6846630573272705	hospital_ mortality
P-1692	-2.1337 -0.6070 -0.3364 -0.6257 -0.2346 -0.1706
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration chf
H-683	-0.41072380542755127	▁administration ▁tras tuz um ab ▁CHF
D-683	-0.41072380542755127	administration trastuzumab CHF
P-683	-0.2879 -0.2958 -0.0071 -0.0738 -0.2230 -2.1634 -0.1477 -0.0873
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital rehospitalization
H-1719	-0.8228016495704651	▁re hospital ization
D-1719	-0.8228016495704651	rehospitalization
P-1719	-2.6377 -0.3007 -0.7799 -0.2688 -0.1269
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-0.43252721428871155	▁hospital s
D-142	-0.43252721428871155	hospitals
P-142	-0.8209 -0.1886 -0.5545 -0.1662
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.4827122986316681	▁bio mark er - guide d _ ▁clinic al
D-1476	-0.4827122986316681	biomarker-guided_ clinical
P-1476	-0.0877 -0.0266 -0.0531 -0.2268 -0.0079 -0.6607 -0.8710 -0.8722 -0.1323 -2.1427 -0.2289
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-1.53862726688385	▁medical ▁records
D-1131	-1.53862726688385	medical records
P-1131	-1.6390 -4.0604 -0.3359 -0.1192
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal_pro-b-type_natriuretic_peptides plasma heart_failure patients
H-1510	-1.079964280128479	▁Circula tion _ pro - b - type _ na tri ure _ pe pti des ▁heart _ ▁failure
D-1510	-1.079964280128479	Circulation_pro-b-type_natriure_peptides heart_ failure
P-1510	-0.1699 -0.9677 -3.5384 -1.9162 -0.0452 -1.9056 -0.1035 -0.5468 -0.8049 -1.5855 -0.0406 -0.0749 -4.3899 -0.7280 -0.5575 -0.3840 -2.3978 -0.7026 -1.1157 -0.5403 -0.1643
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients heart_failure hf preserved_left_ventricular_ejection_fraction hfpef
H-1300	-0.7090635299682617	▁heart _ ▁failure HF ▁vent ri cular _ ▁e je ction _ fraction HF p EF
D-1300	-0.7090635299682617	heart_ failureHF ventricular_ ejection_fractionHFpEF
P-1300	-2.4115 -0.7280 -1.9850 -0.4622 -0.6040 -0.3444 -0.3852 -0.5904 -1.5988 -0.6953 -0.2431 -0.5425 -0.0240 -1.2753 -0.0452 -0.4589 -0.2572 -0.1119
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine myocyte collagen left_ventricle
H-1141	-0.40266653895378113	▁Pyr ido stig mine ▁my o cy te ▁collage n _ dens ity ▁vent ric le
D-1141	-0.40266653895378113	Pyridostigmine myocyte collagen_density ventricle
P-1141	-0.0033 -0.3648 -0.0020 -0.1115 -0.6118 -0.0794 -0.0854 -0.3044 -0.8455 -0.0633 -0.2902 -1.0441 -0.5242 -0.2437 -1.8289 -0.5840 -0.1913 -0.0701
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac_angiogenesis in_vivo_coronary_perfusion cardiac_fibrosis
H-454	-0.6820619106292725	▁cardiac _ ▁ang io gene sis ▁corona ry _ per fusion ▁cardiac _ ▁fibro sis
D-454	-0.6820619106292725	cardiac_ angiogenesis coronary_perfusion cardiac_ fibrosis
P-454	-0.2140 -0.8023 -1.8427 -1.7301 -0.2759 -2.4234 -1.2881 -0.5354 -0.3663 -0.1673 -0.0185 -0.0414 -1.1127 -0.1143 -0.3843 -0.2057 -0.0724
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality patients implantable_cardiac_defibrillator meta-analysis
H-59	-0.6888790130615234	▁implant able _ ▁cardiac _ de _ fi br illa tor
D-59	-0.6888790130615234	implantable_ cardiac_de_fibrillator
P-59	-0.0242 -0.0991 -0.7069 -0.1193 -1.0357 -0.0368 -3.2270 -2.3274 -0.6786 -0.0089 -0.3595 -0.1968 -0.1353
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors adenylyl_cyclase g-protein_coupling
H-1406	-0.6581486463546753	▁a den yl yl _ ▁cy cla se ▁g - prote in _ ▁coup ling
D-1406	-0.6581486463546753	adenylyl_ cyclase g-protein_ coupling
P-1406	-0.2037 -0.0351 -0.2634 -0.7332 -1.0019 -0.2445 -0.0079 -0.7375 -0.8827 -0.1707 -0.2515 -1.7834 -1.6187 -0.0954 -2.5611 -0.4352 -0.1627
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization patients heart_failure ventricular_tachycardia
H-1434	-1.3432217836380005	▁implant ation ▁heart _ ▁failure ▁vent ri cular _ ta chy car dia
D-1434	-1.3432217836380005	implantation heart_ failure ventricular_tachycardia
P-1434	-3.9329 -0.1410 -4.7188 -1.1647 -1.1539 -0.0028 -0.3801 -0.1958 -1.4024 -2.7542 -0.4382 -0.0153 -1.4708 -2.2179 -0.1594
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling_pathways pressure-overload-induced_heart_failure
H-877	-1.3420432806015015	▁signal ing _ path ways ▁pressure - over load - indu ce ▁heart _ ▁failure
D-877	-1.3420432806015015	signaling_pathways pressure-overload-induce heart_ failure
P-877	-6.1233 -1.0781 -1.0197 -0.7155 -0.5802 -1.2961 -0.1430 -0.3559 -0.2792 -0.8298 -0.0031 -5.3839 -1.0844 -1.2213 -2.1948 -0.2701 -0.2363
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise_intolerance symptom chronic_hfpef quality_of_life qol
H-1975	-0.7061201333999634	▁Exerci se _ ▁in tolerance ▁h f f
D-1975	-0.7061201333999634	Exercise_ intolerance hff
P-1975	-2.0070 -0.2245 -0.1206 -0.6357 -0.0227 -0.2068 -0.2301 -0.1756 -3.3359 -0.1023
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients systolic_hf etiology coronary_angiography
H-1184	-0.9248161315917969	▁sy sto lic ▁ HF ▁un clear _ ▁et i ology ▁corona ry _ ▁ang i ography
D-1184	-0.9248161315917969	systolic HF unclear_ etiology coronary_ angiography
P-1184	-3.3182 -0.1371 -1.5614 -1.5903 -0.0349 -3.0100 -0.0195 -1.6838 -0.6004 -0.1115 -0.5699 -0.0514 -1.0460 -0.9223 -1.8681 -0.4172 -0.1398 -0.3694 -0.1201
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart_failure hf elevated sympathetic_activity parasympathetic_control heart
H-1133	-1.1078498363494873	▁Heart _ ▁failure HF ▁sympa the tic _ ▁activity ▁para sy mpa the tic _ control ▁heart
D-1133	-1.1078498363494873	Heart_ failureHF sympathetic_ activity parasympathetic_control heart
P-1133	-0.5281 -0.5987 -1.3009 -0.7415 -1.1409 -0.6361 -2.4256 -1.4732 -0.9719 -0.8064 -0.2454 -0.2484 -1.4983 -2.5246 -0.8569 -0.0361 -4.6381 -0.2224 -0.1555
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp xo-mediated_ros mitochondrial_respiration contractile_function
H-471	-0.42546799778938293	▁ATP ▁demand ▁ XO - media ted ▁ ROS ▁mito cho ndri al _ ▁respira tion ▁contract ile
D-471	-0.42546799778938293	ATP demand XO-mediated ROS mitochondrial_ respiration contractile
P-471	-0.1005 -2.3928 -0.5501 -0.1672 -0.0172 -0.1378 -0.5142 -0.3181 -0.3897 -0.2029 -0.9283 -0.4355 -0.1537 -0.7286 -0.2459 -0.0229 -0.0355 -0.0759 -0.9928 -0.0998
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients end-stage_heart_failure implantation ventricular_assist_device
H-1657	-0.7037785649299622	▁implant ation ▁vent ri cular _ assist ▁device
D-1657	-0.7037785649299622	implantation ventricular_assist device
P-1657	-1.2387 -0.0210 -1.6645 -0.4033 -0.1479 -0.7768 -0.1206 -1.7988 -0.5828 -0.2835
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial_fibrillation congestive_heart_failure cost rhythm-control rate-control
H-1230	-0.5565900206565857	▁at rial _ f bril lation ▁con ges tive ▁heart _ ▁failure ▁ rhythm - control ▁rate - control
D-1230	-0.5565900206565857	atrial_fbrillation congestive heart_ failure rhythm-control rate-control
P-1230	-1.1251 -0.0240 -0.8531 -1.5426 -0.4326 -0.0084 -0.4477 -0.1236 -0.0720 -1.1887 -1.0810 -0.9719 -0.4694 -0.7307 -0.1210 -0.0051 -1.2302 -0.1088 -0.0081 -1.0293 -0.1150
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection_fraction ef infarct collateral_growth myocardial_perfusion
H-506	-0.5199919939041138	▁e je ction _ fraction ▁ef ▁col lateral _ ▁growth ▁my o card ial _ per fusion
D-506	-0.5199919939041138	ejection_fraction ef collateral_ growth myocardial_perfusion
P-506	-0.3286 -0.3250 -0.0098 -0.3658 -0.0034 -1.0402 -3.3651 -0.0044 -1.2158 -0.6033 -0.5897 -0.3422 -0.2088 -0.3117 -0.3698 -0.2810 -0.0348 -0.3160 -0.1642
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf_antagonists nbdmard
H-607	-0.5205493569374084	▁HR ▁t NF ▁n b DM ARD
D-607	-0.5205493569374084	HR tNF nbDMARD
P-607	-0.2398 -0.4565 -0.4317 -1.6386 -0.0314 -1.1155 -0.4050 -0.2706 -0.0958
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical revascularization revascularization
H-1603	-0.7765605449676514	▁sur g ical _ re vas cular ization ▁cat heter - based ▁re vas cular ization
D-1603	-0.7765605449676514	surgical_revascularization catheter-based revascularization
P-1603	-0.7262 -0.4336 -4.2087 -1.0145 -0.5026 -0.5966 -0.4437 -0.7809 -0.0666 -0.0033 -0.1086 -0.0952 -2.6349 -0.6001 -0.3694 -0.9532 -0.2582 -0.1821
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based nucleolin protein_expression
H-96	-0.7158077955245972	▁Mor pho lino - based ▁knock down ▁nucleo lin ▁protein ▁expression
D-96	-0.7158077955245972	Morpholino-based knockdown nucleolin protein expression
P-96	-0.5121 -0.3056 -0.6239 -0.1901 -0.1907 -0.4534 -0.1549 -2.0563 -1.6657 -0.6676 -1.6168 -0.7884 -0.0800
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence bnp patients pad bnp hf
H-1572	-0.9508187174797058	▁b NP ▁ PAD ▁b NP ▁ HF
D-1572	-0.9508187174797058	bNP PAD bNP HF
P-1572	-0.4175 -0.2271 -4.0763 -0.2274 -0.3206 -0.2050 -2.7821 -0.9490 -0.2088 -0.0943
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd psoriasis hazard_ratio confidence_interval
H-1563	-0.7422363758087158	▁CV d ▁psoriasis
D-1563	-0.7422363758087158	CVd psoriasis
P-1563	-2.4000 -0.5148 -0.0589 -0.5777 -0.1598
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam_study psoriasis cardiovascular outcomes
H-1556	-1.207880973815918	▁Rotterdam ▁psoriasis ▁cardiovascular ▁outcome s
D-1556	-1.207880973815918	Rotterdam psoriasis cardiovascular outcomes
P-1556	-1.3732 -3.0789 -0.3585 -3.3399 -0.0174 -0.2211 -0.0661
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes exercise training patients ambulatory hf
H-1631	-1.3540464639663696	▁race ▁ HF
D-1631	-1.3540464639663696	race HF
P-1631	-1.7248 -4.4524 -0.3194 -0.1476 -0.1260
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients hfpef adverse_outcomes
H-237	-0.5064666867256165	▁ HF p EF
D-237	-0.5064666867256165	HFpEF
P-237	-1.6838 -0.4290 -0.0574 -0.3030 -0.4296 -0.1360
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence parasympathetic therapeutic hf
H-1134	-0.8268386721611023	▁para sy mpa the tic _ fon ction nel ▁ HF
D-1134	-0.8268386721611023	parasympathetic_fonctionnel HF
P-1134	-0.9330 -0.8049 -0.3795 -0.7371 -1.8917 -1.3106 -1.9381 -0.4094 -0.3197 -1.1702 -0.4955 -0.2718 -0.0873
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes_mellitus cardiovascular_disease baseline
H-630	-1.1097116470336914	▁diabetes ▁mell itus ▁cardiovascular ▁disease
D-630	-1.1097116470336914	diabetes mellitus cardiovascular disease
P-630	-2.0969 -0.9973 -0.1089 -0.1378 -4.0135 -0.2473 -0.1662
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical rule cad systolic_hf
H-1185	-0.8159944415092468	▁clinic al _ ▁predict ion _ ▁rule ▁CAD ▁cause _ de _ ▁sy sto lic _ HF
D-1185	-0.8159944415092468	clinical_ prediction_ rule CAD cause_de_ systolic_HF
P-1185	-0.6166 -0.0299 -0.8070 -0.6776 -0.0151 -1.8692 -0.5464 -0.1111 -0.4614 -0.7538 -1.7197 -0.2458 -2.5763 -0.7236 -1.4804 -0.6007 -1.9359 -0.2347 -0.0986
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality readmission
H-207	-0.7229586243629456	▁cognitive ▁im pair ment ▁mortal ity
D-207	-0.7229586243629456	cognitive impairment mortality
P-207	-0.5138 -1.9725 -0.1679 -0.1576 -0.6477 -0.9648 -1.2611 -0.0981
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence schfi_v.6.2 clinical
H-1509	-1.2576377391815186	▁ SCH f
D-1509	-1.2576377391815186	SCHf
P-1509	-1.7624 -1.2714 -2.7680 -0.4202 -0.0662
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo egfr egfr
H-1392	-0.9230597615242004	▁EC mo ▁e g FR ▁e g FR
D-1392	-0.9230597615242004	ECmo egFR egFR
P-1392	-0.5600 -0.4958 -0.7837 -1.4764 -1.4156 -0.6927 -2.0651 -1.3662 -0.2703 -0.1050
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise haemodynamic pulmonary
H-1277	-0.38586264848709106	▁ha emo dynamic ▁pulmonar y
D-1277	-0.38586264848709106	haemodynamic pulmonary
P-1277	-0.3406 -0.2746 -0.0425 -0.0116 -0.1692 -1.7415 -0.1211
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic rule prospectively
H-1188	-0.9842541813850403	▁predict ion _ ▁rule
D-1188	-0.9842541813850403	prediction_ rule
P-1188	-3.1785 -0.0454 -0.9599 -1.2537 -0.3116 -0.1564
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule patients cad patients cad
H-1191	-1.4240485429763794	▁CAD
D-1191	-1.4240485429763794	CAD
P-1191	-2.4963 -1.6862 -0.0896
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia rv_function
H-1159	-0.787642240524292	▁ HF - related ▁cache xia ▁ RV
D-1159	-0.787642240524292	HF-related cachexia RV
P-1159	-1.4707 -0.4030 -0.4778 -0.8298 -2.1238 -0.1307 -0.4172 -0.1605 -1.7789 -0.0840
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute_hf
H-1018	-0.667617917060852	▁a cute _ HF
D-1018	-0.667617917060852	acute_HF
P-1018	-1.6872 -0.0087 -0.4981 -1.4620 -0.2176 -0.1321
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline hgb exercise training kccq
H-841	-0.6694223880767822	▁h gb ▁k cc q
D-841	-0.6694223880767822	hgb kccq
P-841	-0.5466 -0.2938 -2.0266 -0.0527 -1.0984 -0.5537 -0.1143
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital cardiac hospital south_dakota
H-1577	-0.9122694730758667	▁hospital ▁cardiac _ special ty _ hospital
D-1577	-0.9122694730758667	hospital cardiac_specialty_hospital
P-1577	-2.5191 -0.2511 -1.4332 -0.2284 -0.3419 -0.5109 -0.1353 -2.6815 -0.1092
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications acs patients patients vad
H-1286	-1.094146966934204	▁a CS ▁techniques ▁MT ▁ VAD
D-1286	-1.094146966934204	aCS techniques MT VAD
P-1286	-0.1465 -0.7323 -4.6162 -1.8267 -1.0141 -0.0280 -0.2450 -0.1443
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic histological gastrointestinal
H-1359	-0.9094470143318176	▁sono graphic ▁his t ological ▁functional _ ▁ab normal ités ▁gastro inte stin al
D-1359	-0.9094470143318176	sonographic histological functional_ abnormalités gastrointestinal
P-1359	-1.5845 -2.1791 -2.9804 -0.0680 -0.2960 -1.5008 -1.7119 -0.6790 -0.0259 -1.2036 -0.5528 -0.0281 -0.6642 -0.4077 -0.5724 -0.0968
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy_substrate_metabolism hearts aac
H-1781	-0.8706297278404236	▁energie _ ▁substrat e _ ▁metabolism
D-1781	-0.8706297278404236	energie_ substrate_ metabolism
P-1781	-3.1406 -0.6752 -0.1038 -0.6518 -0.2590 -0.0720 -1.9554 -0.1073
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular_venous_pressure peripheral_oedema patient
H-1895	-0.579673707485199	▁jugu lar _ ve nous _ tension ▁per i pher al _ ▁oed ema ▁volume
D-1895	-0.579673707485199	jugular_venous_tension peripheral_ oedema volume
P-1895	-0.0249 -0.2237 -0.3559 -1.6264 -2.1012 -0.8851 -0.2951 -0.0797 -0.1716 -0.0381 -0.1681 -0.5320 -1.4277 -0.1719 -1.1821 -0.4761 -0.0948
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone hyperkalemia acute_kidney_injury
H-445	-0.5791457891464233	▁Spir ono lac tone ▁hyper kal emia ▁ki dne y ▁injury
D-445	-0.5791457891464233	Spironolactone hyperkalemia kidney injury
P-445	-0.1910 -0.3522 -0.2305 -0.2927 -0.0449 -0.9275 -0.7536 -3.0022 -0.6617 -0.0963 -0.6925 -0.2022 -0.0817
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up deaths heart_transplantations lv_assist_device_implantations heart_failure admissions
H-434	-0.879458487033844	▁heart ▁implant ations LV ▁implant ations ▁heart _ ▁failure
D-434	-0.879458487033844	heart implantationsLV implantations heart_ failure
P-434	-2.6444 -0.9879 -0.0602 -0.5189 -1.1113 -0.0669 -0.5069 -0.8918 -2.5181 -0.2344 -0.1331
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-333	-0.5933265686035156	▁functional _ met ral _ ▁sten osis ▁ring _ ▁ann ulo plast y ▁ ische mic _ ▁mit ral _ re gur gi tation
D-333	-0.5933265686035156	functional_metral_ stenosis ring_ annuloplasty ischemic_ mitral_regurgitation
P-333	-0.7919 -0.8972 -1.8432 -0.0533 -1.1481 -0.3612 -0.0775 -0.1429 -0.7530 -1.6055 -0.6557 -0.0523 -0.3035 -1.0635 -0.2379 -0.2093 -0.5312 -2.5227 -0.0408 -0.6231 -0.8200 -0.0087 -0.0296 -0.0700 -0.4650 -0.1192
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants antiplatelet_drugs heart_failure atrial_fibrillation
H-1352	-0.6825985908508301	▁do a gul ants ▁anti plate let ▁drugs ▁heart _ ▁failure ▁at rial _ f bril lation
D-1352	-0.6825985908508301	doagulants antiplatelet drugs heart_ failure atrial_fbrillation
P-1352	-1.1954 -0.2858 -0.2828 -0.0205 -0.0556 -1.1300 -0.2889 -1.1599 -1.2107 -0.9005 -1.4184 -0.0761 -0.1805 -0.4613 -3.1099 -0.8090 -0.0099 -0.2889 -0.0852
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical_cardiac_support renal_function end-stage_heart_failure
H-1384	-1.1490263938903809	▁mechanic al _ ▁cardiac _ ▁support ▁renal _ fon cti onnement ▁end - s tage _ heart _ ▁failure
D-1384	-1.1490263938903809	mechanical_ cardiac_ support renal_fonctionnement end-stage_heart_ failure
P-1384	-1.1740 -0.0275 -0.5794 -0.7706 -2.5169 -1.7424 -0.5111 -2.9014 -2.3594 -1.6254 -0.2694 -3.5982 -0.0494 -0.1485 -0.0029 -0.3237 -2.2752 -1.1273 -1.6010 -0.3555 -0.1702
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic_peptide biomarkers point_of_care poc
H-1023	-0.7709580659866333	▁na tri ure tic _ pe pti de ▁bio mark ers ▁point _ de _ care
D-1023	-0.7709580659866333	natriuretic_peptide biomarkers point_de_care
P-1023	-0.1741 -0.0110 -0.0563 -3.4069 -1.1291 -0.4617 -0.1352 -0.4155 -0.4860 -0.0102 -0.1031 -0.6728 -0.1869 -1.5488 -0.0898 -2.7204 -2.1582 -0.1114
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart_failure hf condition morbidity mortality
H-1487	-0.8104867339134216	▁Heart _ ▁failure HF
D-1487	-0.8104867339134216	Heart_ failureHF
P-1487	-0.9082 -0.5089 -1.6083 -0.6918 -1.0204 -0.1253
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients systolic_blood_pressure renal_impairment hypertension
H-1529	-1.550777554512024	▁EH ▁h z ▁renal ▁im pair ment ▁hyper tension
D-1529	-1.550777554512024	EH hz renal impairment hypertension
P-1529	-0.5740 -6.0690 -4.5737 -3.2857 -1.6821 -0.0148 -0.1772 -0.2506 -0.0025 -0.2757 -0.1534
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo_sternotomy cardiopulmonary_bypass
H-775	-0.8788750171661377	▁pump - ex change ▁technique ▁redo ▁ster no to my ▁cardio pul mon ary _ ▁by pass
D-775	-0.8788750171661377	pump-exchange technique redo sternotomy cardiopulmonary_ bypass
P-775	-3.3318 -0.0531 -0.0856 -0.0016 -0.2597 -0.0811 -1.7247 -0.0304 -0.2612 -1.3525 -0.0779 -0.2758 -3.8960 -1.6259 -1.1475 -1.9219 -0.0043 -0.4189 -0.1489
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic_myocardial_ischemia heart_failure therapeutic
H-503	-1.1451867818832397	▁chronic _ My o card ial _ ische mia ▁heart _ ▁failure
D-503	-1.1451867818832397	chronic_Myocardial_ischemia heart_ failure
P-503	-4.4293 -0.3053 -3.6085 -0.4034 -0.1500 -0.2098 -0.1983 -3.3960 -0.6676 -0.3863 -0.9669 -0.9753 -0.2329 -0.1030
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf transition compensated_lv_hypertrophy hf hhd
H-283	-0.9536494016647339	▁mouse ▁ HF ▁transition ▁compensa ted ▁LV _ ▁hyper trop hy ▁ HF ▁h HD
D-283	-0.9536494016647339	mouse HF transition compensated LV_ hypertrophy HF hHD
P-283	-2.2426 -1.5376 -0.2741 -0.7682 -1.8305 -2.4966 -1.2576 -1.8158 -0.4260 -0.0154 -0.1486 -1.6546 -0.1699 -0.0677 -1.1442 -0.2490 -0.1138
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical_treatment hf functional_ms medical_treatment
H-354	-1.2581896781921387	▁MS ▁ HF ▁functional ▁MS
D-354	-1.2581896781921387	MS HF functional MS
P-354	-0.7559 -2.7599 -0.1314 -3.5033 -0.6431 -0.9379 -0.0759
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic parasympathetic_activity hf symptoms disease
H-1868	-0.9137895703315735	▁sympa the tic ▁para sy mpa the tic ▁ HF
D-1868	-0.9137895703315735	sympathetic parasympathetic HF
P-1868	-0.7143 -0.4902 -1.3547 -0.3800 -0.7232 -0.4823 -1.3846 -1.7707 -2.3917 -0.2526 -0.9486 -0.0726
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical_treatment hf hf symptom mva
H-371	-0.9855318665504456	▁ HF ▁ HF ▁ms ▁m va
D-371	-0.9855318665504456	HF HF ms mva
P-371	-2.4398 -0.5188 -3.1171 -0.3335 -1.1341 -0.5331 -0.2700 -0.4394 -0.0840
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis heart_failure_with_preserved_ejection_fraction clinical doppler_echocardiography
H-21	-0.7866944074630737	▁heart _ ▁failure ▁e je ction _ fraction ▁do pp ler _ ▁e cho card i ography
D-21	-0.7866944074630737	heart_ failure ejection_fraction doppler_ echocardiography
P-21	-2.1800 -0.7552 -1.9186 -2.3870 -0.7512 -0.0599 -0.8543 -0.0010 -0.5978 -0.0560 -1.2529 -0.5231 -1.3478 -0.6247 -0.2420 -0.6983 -0.2661 -0.3026 -0.1286
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based patient outcomes
H-85	-1.0483019351959229	
D-85	-1.0483019351959229	
P-85	-1.9854 -0.1112
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular conditions patients hf
H-694	-0.909724235534668	▁cardiovascular ▁conditions ▁h f
D-694	-0.909724235534668	cardiovascular conditions hf
P-694	-2.1899 -0.2024 -1.1242 -1.7102 -0.1141 -0.1176
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health health u.s. drug administration
H-1830	-1.2708539962768555	▁health _ ▁insurance ▁health _ system _ de _ ca pit aux ▁Food _ de _ ▁Drug ▁Administration
D-1830	-1.2708539962768555	health_ insurance health_system_de_capitaux Food_de_ Drug Administration
P-1830	-0.4615 -1.7769 -0.2635 -0.7754 -1.5546 -1.0827 -1.1054 -2.2909 -0.1978 -5.0887 -0.1620 -0.3364 -3.4999 -1.6296 -3.2728 -0.2545 -0.3520 -0.3938 -0.6977 -0.2210
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary congenital heart death
H-1906	-0.9963827729225159	▁her edit ary _ con geni tal _ ▁ab normal ités ▁heart ▁non trau matic _ ▁death
D-1906	-0.9963827729225159	hereditary_congenital_ abnormalités heart nontraumatic_ death
P-1906	-5.2884 -0.5577 -1.5728 -3.0821 -0.0377 -0.0200 -0.1665 -1.0103 -0.2235 -0.0945 -1.1066 -1.2854 -1.2514 -0.0295 -0.6072 -0.6995 -0.7005 -0.9704 -0.2272
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling_pathway remodelling
H-994	-1.268269658088684	▁Raf - MEK _ 1/2 - er k 1/2 ▁signal ling ▁remodel ling
D-994	-1.268269658088684	Raf-MEK_1/2-erk1/2 signalling remodelling
P-994	-0.1333 -0.0578 -0.0346 -6.0376 -0.8207 -0.0356 -0.6486 -0.1300 -3.8715 -2.1520 -1.7663 -2.1655 -0.8219 -0.2539 -0.0946
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin lvad postoperative
H-536	-1.3090481758117676	▁album in ▁l VAD
D-536	-1.3090481758117676	albumin lVAD
P-536	-2.8600 -1.2231 -2.6675 -0.1112 -0.8077 -0.1848
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients heartmate_ii lvad
H-303	-1.1520241498947144	▁Heart Mate _ ▁II ▁l VAD
D-303	-1.1520241498947144	HeartMate_ II lVAD
P-303	-2.5182 -0.7135 -1.1212 -0.9447 -3.5092 -0.0437 -0.1683 -0.1974
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate heart_failure
H-1544	-1.1455280780792236	bis phos phon ate ▁heart _ ▁failure
D-1544	-1.1455280780792236	bisphosphonate heart_ failure
P-1544	-1.5260 -0.0989 -0.2535 -3.6901 -1.5296 -1.1009 -1.6623 -0.3306 -0.1180
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary_outcomes
H-620	-0.9184437394142151	▁sustain ability ▁commission ing ▁hospital - based
D-620	-0.9184437394142151	sustainability commissioning hospital-based
P-620	-0.0732 -0.5048 -0.5379 -0.3245 -0.3073 -0.5000 -4.2341 -1.6195 -0.1646
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling emd
H-1151	-0.5614601969718933	▁ HF - indu ce ▁remodel ing ▁EM d ▁prolong ation
D-1151	-0.5614601969718933	HF-induce remodeling EMd prolongation
P-1151	-0.5687 -0.3721 -0.4471 -0.0005 -2.8622 -0.2194 -0.1709 -0.3643 -0.2199 -1.8033 -0.0209 -0.1688 -0.0809
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi mi hf
H-1104	-1.1755236387252808	▁early - ons et ▁MI ▁ HF
D-1104	-1.1755236387252808	early-onset MI HF
P-1104	-1.9730 -0.0679 -0.4149 -0.4950 -0.5350 -5.4978 -1.1290 -0.2761 -0.1908
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs outcomes
H-2009	-0.7438756227493286	▁coût
D-2009	-0.7438756227493286	coût
P-2009	-1.6738 -0.4550 -0.1029
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-0.8852588534355164	▁mal adapt ive _ ▁molecular
D-1473	-0.8852588534355164	maladaptive_ molecular
P-1473	-2.2128 -0.0569 -0.0271 -0.6353 -0.3247 -2.8285 -0.1116
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-0.9410140514373779	▁patient _ ▁safety
D-7	-0.9410140514373779	patient_ safety
P-7	-0.8882 -0.7629 -2.3716 -0.5235 -0.1589
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine_oxidase_inhibition left_ventricular systolic diastolic_function cardiac_volume_overload
H-469	-1.0098105669021606	▁Xan thi ne _ ▁oxid ase ▁vent ri cular _ syn chron ▁dia sto lic ▁cardiac
D-469	-1.0098105669021606	Xanthine_ oxidase ventricular_synchron diastolic cardiac
P-469	-0.0014 -0.0446 -0.4776 -0.7717 -1.6396 -2.4769 -0.7863 -0.4515 -0.4307 -0.6120 -0.5061 -1.0422 -1.8494 -0.5973 -2.2244 -2.2772 -1.8272 -0.1605
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global_left_ventricular_longitudinal_systolic_strain cardiovascular_events patients atrial_fibrillation
H-808	-1.0249505043029785	▁vent ri cular _ ▁longitud in al _ syn chron e _ stat ionnaires ▁at rial _ f ré bril lation
D-808	-1.0249505043029785	ventricular_ longitudinal_synchrone_stationnaires atrial_frébrillation
P-808	-0.2648 -0.3077 -0.1348 -0.6702 -1.0236 -0.1946 -0.0680 -0.3645 -1.4089 -0.1354 -2.2398 -0.8848 -3.8859 -3.0535 -1.2033 -0.2305 -0.6072 -3.6786 -1.3276 -1.1777 -0.0307 -0.4914 -0.1903
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart_failure clinical medicine prevalence coronary_disease
H-980	-0.9496899843215942	▁Heart _ ▁failure ▁medicine ▁a ther omat ous _ ▁corona ry ▁disease
D-980	-0.9496899843215942	Heart_ failure medicine atheromatous_ coronary disease
P-980	-0.6265 -0.9176 -1.0390 -3.0876 -0.0199 -0.0058 -0.0481 -2.7878 -0.2549 -0.4688 -0.8877 -2.6729 -0.3276 -0.1513
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications outpatients heart_failure ncdr_pinnacle
H-658	-1.0397721529006958	▁medication s ▁heart _ ▁failure ▁NC DR _ ▁PIN NA CLE
D-658	-1.0397721529006958	medications heart_ failure NCDR_ PINNACLE
P-658	-2.2998 -0.0439 -1.9332 -1.0747 -2.4218 -0.1407 -0.3388 -1.7709 -1.1193 -1.0984 -0.6175 -0.4975 -0.1605
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart hr_reduction patients systolic_heart_failure
H-527	-1.3703837394714355	▁un load ing _ de _ the _ heart ▁HR ▁sy sto lique _ ▁heart _ ▁failure
D-527	-1.3703837394714355	unloading_de_the_heart HR systolique_ heart_ failure
P-527	-1.5480 -0.0342 -0.1156 -1.5385 -1.7149 -0.5128 -3.4526 -0.5587 -1.7653 -1.3350 -4.7320 -0.4121 -3.9928 -0.6713 -1.5167 -1.0002 -0.7815 -0.2092 -0.1457
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic hfpef medical_history physical_examination
H-1892	-0.8998247385025024	▁ HF p EF
D-1892	-0.8998247385025024	HFpEF
P-1892	-1.5124 -0.9591 -0.2203 -0.4557 -2.1623 -0.0892
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical symptoms hfpef symptoms breathlessness fluid_retention
H-1891	-0.8252785205841064	▁h p f ▁breath less ness ▁fatigue ▁fluid _ re tention
D-1891	-0.8252785205841064	hpf breathlessness fatigue fluid_retention
P-1891	-2.2694 -0.1058 -0.5331 -1.5486 -0.0327 -3.3236 -0.7890 -0.0268 -0.9880 -0.5917 -0.0342 -0.3408 -0.1450
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin insulin_resistance monocytes inflammatory
H-928	-0.6867927312850952	▁circula tion _ media tor _ de _ ▁insulin _ ▁resist ance ▁mono cy tes ▁infla mma tory ▁stimul i
D-928	-0.6867927312850952	circulation_mediator_de_ insulin_ resistance monocytes inflammatory stimuli
P-928	-1.4870 -2.0221 -0.5772 -0.6487 -0.3980 -0.2680 -0.7511 -0.1315 -0.2510 -1.0359 -0.9474 -0.0425 -2.8451 -0.0498 -0.1800 -0.3068 -0.4901 -0.6065 -1.2680 -0.2647 -0.3591 -0.1789
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp patients acute_heart_failure
H-262	-0.9062463045120239	▁NT - pro b NP
D-262	-0.9062463045120239	NT-probNP
P-262	-0.6825 -0.0238 -0.0073 -0.7847 -0.1044 -4.6043 -0.1366
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report patients aortic_valve surgery post-lvad_ai
H-544	-0.6321970820426941	▁a or tic _ ▁val ve ▁surgery ▁new - ons et ▁l VAD
D-544	-0.6321970820426941	aortic_ valve surgery new-onset lVAD
P-544	-0.1319 -0.0327 -1.7847 -0.5376 -0.8678 -0.0566 -1.0732 -2.1202 -0.0736 -0.1891 -0.1239 -2.0366 -0.0314 -0.3394 -0.0842
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking cardiac_rehabilitation functional_capacity outcomes patients heart_failure
H-574	-1.3021706342697144	▁Nordic _ ▁walking ▁cardiac ▁rehabilita tion
D-574	-1.3021706342697144	Nordic_ walking cardiac rehabilitation
P-574	-0.8302 -1.3952 -2.1904 -0.3958 -1.2245 -0.0196 -4.2342 -0.1274
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone diagnosed systolic_heart_failure clinical
H-439	-0.7610418200492859	▁spi rono lac tone ▁sy sto lique _ ▁heart _ ▁failure
D-439	-0.7610418200492859	spironolactone systolique_ heart_ failure
P-439	-0.8479 -0.0492 -0.1607 -0.1947 -0.7712 -0.3701 -3.1104 -0.2345 -2.0545 -0.7492 -1.0180 -0.2513 -0.0819
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape functional_enrichment_analysis david
H-1612	-0.7080590724945068	▁réseau ▁Cy to scape ▁functional _ en rich ment ▁DA VID
D-1612	-0.7080590724945068	réseau Cytoscape functional_enrichment DAVID
P-1612	-1.9928 -0.5540 -0.1036 -0.2864 -1.9324 -0.6243 -1.0890 -0.0035 -0.3022 -1.8309 -0.0035 -0.3782 -0.1040
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension diabetes ischemic etiology
H-1635	-0.6215987205505371	▁black s ▁hyper tension ▁diabetes ▁ ische mic _ ▁et i ology ▁socio economic ▁status
D-1635	-0.6215987205505371	blacks hypertension diabetes ischemic_ etiology socioeconomic status
P-1635	-1.5965 -0.0702 -0.0249 -0.0012 -0.0911 -0.1057 -0.3573 -0.2023 -0.4686 -1.0075 -0.2316 -1.4019 -0.1784 -0.4986 -2.7918 -1.4139 -0.1257
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection nt-probnp antibodies terminal
H-1521	-0.28439509868621826	▁immun o det ection ▁NT - pro b NP ▁anti bo dies
D-1521	-0.28439509868621826	immunodetection NT-probNP antibodies
P-1521	-0.1430 -0.1059 -0.1893 -0.1798 -0.6922 -0.0273 -0.0064 -0.6743 -0.1093 -0.0503 -0.0309 -1.4447 -0.2262 -0.1019
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients fontan_circulation svr cardiac_index
H-232	-0.7593490481376648	▁Font an _ ▁circulation ▁s VR ▁cardiac ▁index ▁pediatr ic
D-232	-0.7593490481376648	Fontan_ circulation sVR cardiac index pediatric
P-232	-0.9726 -0.7798 -0.8691 -0.5352 -0.7774 -0.2650 -0.3144 -3.1732 -0.0586 -0.4842 -0.8130 -0.0698
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid_receptor_antagonists
H-1709	-0.9780464172363281	▁mineral o cor tico id ▁receptor _ ▁anta gon ists
D-1709	-0.9780464172363281	mineralocorticoid receptor_ antagonists
P-1709	-1.4304 -0.1298 -0.1611 -2.7993 -1.5356 -1.7605 -1.5659 -0.4788 -0.0477 -0.8378 -0.8733 -0.1163
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization medicare discharged nursing
H-1710	-0.43754932284355164	▁re hospital ization ▁medica re ▁fee - for - service
D-1710	-0.43754932284355164	rehospitalization medicare fee-for-service
P-1710	-1.5435 -0.0071 -0.1956 -0.0330 -0.0087 -0.1321 -0.0829 -0.0432 -0.0945 -0.0034 -2.9901 -0.1165
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative_care patients terminal disease therapeutic
H-1820	-1.1344612836837769	▁palli ative
D-1820	-1.1344612836837769	palliative
P-1820	-0.1240 -0.2563 -4.0749 -0.0827
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death hf hospitalization crt hazard_ratio
H-755	-0.9063125252723694	▁ HF ▁c rte haz ard
D-755	-0.9063125252723694	HF crtehazard
P-755	-1.8228 -0.3513 -1.2109 -2.3476 -0.5656 -0.0456 -0.7538 -0.1528
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients lvad patients biventricular_support
H-297	-0.5331364274024963	▁l VAD ▁bi ven tri cular
D-297	-0.5331364274024963	lVAD biventricular
P-297	-1.3640 -0.1153 -0.7287 -0.2540 -0.1024 -0.4305 -1.1187 -0.1516
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative_stress gtpase rac1 activity hearts
H-281	-0.8319371938705444	▁o xi da tive ▁stress ▁GT Pas e _ ▁Rac 1 ▁heart s ▁ ANS _ mi ce
D-281	-0.8319371938705444	oxidative stress GTPase_ Rac1 hearts ANS_mice
P-281	-1.9372 -0.2147 -0.2872 -0.0533 -1.2791 -1.4366 -0.2580 -0.3703 -0.3884 -0.3999 -0.1207 -1.2444 -0.0925 -3.8570 -1.3571 -2.2541 -0.4495 -0.3150 -0.2121 -0.1116
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan_circulation skeletal_muscle metabolic
H-1494	-0.8574625849723816	▁Font an _ ▁circulation ▁skelet al _ ▁muscle _ ▁mass ▁metabol ic
D-1494	-0.8574625849723816	Fontan_ circulation skeletal_ muscle_ mass metabolic
P-1494	-0.2550 -0.6917 -0.9135 -0.4646 -0.3385 -0.5028 -0.6202 -2.7595 -1.6750 -1.9756 -0.0347 -0.2544 -1.4403 -0.0786
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right_heart_circulation right_heart_failure
H-1459	-1.7939852476119995	▁vent _ ▁circulation ▁right _ ▁heart _ ▁failure
D-1459	-1.7939852476119995	vent_ circulation right_ heart_ failure
P-1459	-7.0014 -2.1819 -1.3937 -1.9650 -1.2116 -1.7548 -0.4783 -1.6397 -0.1983 -0.1151
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart_failure hf latin_america health hf
H-1789	-1.3494452238082886	▁Heart _ ▁failure ▁ HF ▁Latin ▁America LA ▁ HF
D-1789	-1.3494452238082886	Heart_ failure HF Latin AmericaLA HF
P-1789	-0.8719 -0.3995 -1.8860 -3.2574 -0.1735 -1.5069 -1.0540 -3.1686 -3.1160 -0.4761 -0.1806 -0.1028
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd clinical hospitalizations complications therapy end-stage_hf
H-895	-1.175520420074463	▁PD ▁complica tions ▁ therapy ▁h f
D-895	-1.175520420074463	PD complications therapy hf
P-895	-1.9660 -2.8267 -0.1033 -1.8393 -0.0921 -2.5706 -1.0150 -0.0767 -0.0900
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-0.559799075126648	▁transform ed
D-86	-0.559799075126648	transformed
P-86	-0.6847 -1.2746 -0.1843 -0.0956
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.5871706604957581	
D-158	-0.5871706604957581	
P-158	-1.0569 -0.1174
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients heart_failure hf heart_failure_adherence_and_retention_trial hart
H-238	-0.9179239273071289	▁heart _ ▁failure HF ▁Heart _ ▁Fail ure _ ad her ence HAR t
D-238	-0.9179239273071289	heart_ failureHF Heart_ Failure_adherenceHARt
P-238	-2.0019 -0.6513 -1.8060 -0.5234 -0.4965 -0.6575 -0.2822 -0.1225 -2.3361 -0.2435 -0.0957 -0.0061 -4.7158 -0.4291 -0.2081 -0.1109
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic_receptor_blockade mortality all-cause_hospitalizations patients heart_failure hf
H-1424	-1.1451419591903687	▁β - Ad r energi c _ ▁receptor _ block ade ▁heart _ ▁failure HF
D-1424	-1.1451419591903687	β-Adrenergic_ receptor_blockade heart_ failureHF
P-1424	-3.2064 -0.1528 -0.9934 -0.0835 -0.2289 -0.1020 -1.9131 -0.0173 -1.8273 -2.1601 -0.7177 -4.2208 -0.7915 -2.1267 -0.2502 -0.4469 -0.2288
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial_infarction left_anterior_descending_coronary_artery_occlusion
H-1338	-0.8406229019165039	▁My o card ial _ ▁in far ction ▁left _ ▁anterior ▁descend ing ▁corona ry ▁arter y ▁oc clusi on
D-1338	-0.8406229019165039	Myocardial_ infarction left_ anterior descending coronary artery occlusion
P-1338	-1.7851 -0.3254 -0.1619 -0.3132 -1.3486 -0.7031 -3.4348 -0.0315 -2.4500 -1.2469 -1.4131 -0.7184 -0.1501 -0.8977 -0.7099 -0.7175 -1.2272 -0.1371 -0.0399 -0.2369 -0.3140 -0.1314
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right_ventricle leads stroke_volume shortens left_ventricular_ejection_time lvet
H-578	-0.9323500394821167	▁vent ric le _ over load ▁stroke ▁vent ri cular _ ▁e je ction _ ▁time ▁l VET
D-578	-0.9323500394821167	ventricle_overload stroke ventricular_ ejection_ time lVET
P-578	-0.1673 -4.0586 -0.6926 -1.5440 -1.7924 -0.1213 -0.2440 -0.0831 -0.4372 -0.1535 -0.8397 -1.2156 -0.8124 -0.1619 -1.5553 -2.7017 -0.9728 -0.7538 -0.2145 -0.1254
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective_beta-blockers cardiac_sympathetic_activity hemostasis patients heart_failure
H-1110	-1.1741660833358765	▁non sel ective ▁beta - block ers ▁cardiac _ syn chron e _ ▁activity ▁hemos tas is ▁heart _ ▁failure
D-1110	-1.1741660833358765	nonselective beta-blockers cardiac_synchrone_ activity hemostasis heart_ failure
P-1110	-7.3096 -0.0153 -0.4035 -1.2480 -0.0455 -0.1783 -0.1767 -0.0969 -0.8912 -4.1221 -0.1482 -2.0560 -0.8713 -1.7689 -0.9422 -0.3396 -0.4231 -1.3068 -1.1707 -1.9261 -0.2503 -0.1415
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end_point cardiovascular_death cardiac_transplant secondary_end_point death
H-1757	-1.2397031784057617	▁cardiovascular ▁death ▁urgent _ ▁cardiac ▁transplant
D-1757	-1.2397031784057617	cardiovascular death urgent_ cardiac transplant
P-1757	-1.4838 -4.4581 -0.1939 -0.9674 -0.0814 -1.9344 -0.6451 -0.1534
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated_proteins chromatin_structure changing dna gene_expression_profile
H-90	-0.871325671672821	▁Chro mat in - as soci ated ▁protein s ▁chr omat in _ ▁structure ▁DNA
D-90	-0.871325671672821	Chromatin-associated proteins chromatin_ structure DNA
P-90	-1.0134 -0.0070 -1.4863 -0.7309 -0.1034 -0.0063 -1.0462 -2.1222 -0.1038 -0.0454 -0.0423 -2.5019 -1.1201 -3.0854 -0.3853 -0.8737 -0.1388
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis clinical prognostic diastolic_dysfunction leading hfpef
H-26	-1.1897716522216797	▁h f f f
D-26	-1.1897716522216797	hfff
P-26	-4.4337 -0.3103 -0.1243 -1.4060 -0.7255 -0.1389
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade cardiac_angiogenesis heart_failure vegf_signaling_pathway
H-459	-1.199325442314148	▁β - Block ade ▁cardiac _ ▁ang io gene sis ▁heart _ ▁failure ▁VE GF
D-459	-1.199325442314148	β-Blockade cardiac_ angiogenesis heart_ failure VEGF
P-459	-1.7642 -0.0649 -0.2611 -2.5378 -0.2877 -2.0584 -1.7763 -2.9240 -0.9644 -3.3969 -0.3503 -0.8572 -1.8533 -0.1508 -0.0352 -0.9380 -0.1679
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp hf patient plasma immunoprecipitation mass_spectrometric_analysis
H-1515	-0.4453031122684479	▁NT - pro b NP ▁ HF ▁immun o preci pit ation
D-1515	-0.4453031122684479	NT-probNP HF immunoprecipitation
P-1515	-0.0930 -0.0582 -0.0216 -0.4896 -0.1092 -1.6403 -0.2410 -1.0449 -0.2456 -0.2671 -0.0669 -0.0381 -1.7465 -0.1722
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic_tone pyridostigmine ventricular_dysfunction heart_failure
H-1132	-0.565277636051178	▁para sy mpa the tic ▁tone ▁py rido stig mine ▁vent ri cular _ ▁dys function ▁heart _ ▁failure
D-1132	-0.565277636051178	parasympathetic tone pyridostigmine ventricular_ dysfunction heart_ failure
P-1132	-0.1891 -0.7212 -0.1243 -0.5718 -1.1776 -0.6893 -0.5219 -0.0914 -0.0020 -0.2867 -0.0052 -0.2581 -0.4422 -1.4541 -0.1453 -0.6432 -0.7679 -0.9421 -2.4568 -0.2716 -0.1089
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes myocardial_ischemic_events patients cardiac_resynchronization_therapy
H-101	-0.896939218044281	▁my o card ial _ ische mic ▁events ▁cardiac _ re syn chron ization
D-101	-0.896939218044281	myocardial_ischemic events cardiac_resynchronization
P-101	-2.4973 -0.3826 -0.1198 -0.3246 -0.3283 -3.0087 -0.6382 -1.4096 -0.0645 -1.3098 -0.7843 -0.0040 -0.0007 -1.3003 -2.0306 -0.1479
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf_with_preserved_ejection_fraction hfpef hypertension
H-1076	-0.6707112193107605	HF HF ▁e je ction _ fraction HF p EF ▁hyper tension
D-1076	-0.6707112193107605	HFHF ejection_fractionHFpEF hypertension
P-1076	-0.5465 -2.4066 -3.0715 -0.7955 -0.0913 -0.2958 -0.0139 -0.7879 -0.1369 -0.8013 -0.0373 -0.0008 -0.2800 -0.1246
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end_points nyha_functional_class quality-of-life 6-minute_hall_walk
H-1873	-0.9161255359649658	▁NY ha _ fon ction nel _ ▁class ▁quality - of - life
D-1873	-0.9161255359649658	NYha_fonctionnel_ class quality-of-life
P-1873	-2.1297 -1.0073 -2.7159 -1.1388 -0.1512 -0.2878 -0.9282 -1.9025 -1.0772 -0.0567 -0.0295 -0.1136 -0.3458 -1.6631 -0.1944
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ischemic_heart_failure
H-1613	-1.3299585580825806	▁dé g s ▁non - ische mic ▁ ische mic ▁heart _ ▁failure
D-1613	-1.3299585580825806	dégs non-ischemic ischemic heart_ failure
P-1613	-4.2141 -0.8503 -0.2374 -3.6954 -0.0258 -2.7584 -0.3525 -2.1632 -0.9783 -0.5787 -1.5950 -1.1793 -0.9458 -0.2301 -0.1452
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv_dysfunction prognosis hf
H-1160	-1.3419314622879028	RV _ ▁dys function ▁weight _ ▁loss ▁body _ ▁composition ▁h z
D-1160	-1.3419314622879028	RV_ dysfunction weight_ loss body_ composition hz
P-1160	-0.9253 -2.0761 -0.5079 -1.1059 -1.1286 -1.4201 -2.3948 -2.7841 -0.5928 -1.8321 -1.9340 -1.7986 -0.0976 -0.1890
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart_failure emergency_department patient outcomes
H-462	-0.9353896379470825	▁he art _ ▁failure ▁Emer gen cy _ ▁Department ▁ed ▁ed
D-462	-0.9353896379470825	heart_ failure Emergency_ Department ed ed
P-462	-3.3728 -0.1602 -0.7290 -0.4688 -0.9833 -0.0567 -0.0804 -1.0162 -0.5291 -2.4602 -0.7156 -1.4402 -0.1476
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut inflammation heart_failure patients heart_failure
H-1363	-0.7501835227012634	▁gut ▁ inflammation ▁heart _ ▁failure
D-1363	-0.7501835227012634	gut inflammation heart_ failure
P-1363	-0.9215 -0.0591 -0.1286 -2.2566 -1.1435 -0.8270 -0.5298 -0.1354
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf patients emergency_department intubated
H-210	-0.9477424025535583	▁CHF ▁emergency _ ▁department ED ▁in tuba ted
D-210	-0.9477424025535583	CHF emergency_ departmentED intubated
P-210	-0.0494 -2.2587 -2.4373 -0.4002 -1.7379 -0.1247 -0.1003 -1.9104 -0.3407 -0.1180
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait therapy lokomat heart_failure patients
H-1912	-0.8571092486381531	▁robot - assist ed _ ▁ga it _ therapy ▁Lok omat _ system ▁heart _ ▁failure
D-1912	-0.8571092486381531	robot-assisted_ gait_therapy Lokomat_system heart_ failure
P-1912	-1.3633 -0.2377 -0.0056 -0.4708 -1.3424 -1.0396 -0.0652 -0.9681 -0.1224 -0.1233 -0.0926 -2.8110 -3.0268 -1.3755 -0.7645 -0.9828 -0.5182 -0.1182
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient symptomatic therapeutic exercise hemodynamic
H-1179	-1.7040481567382812	
D-1179	-1.7040481567382812	
P-1179	-3.2888 -0.1193
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-0.9496542811393738	
D-609	-0.9496542811393738	
P-609	-1.7559 -0.1434
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet sensitivity specificity death icu
H-584	-1.5759464502334595	▁l VET ▁ ICU
D-584	-1.5759464502334595	lVET ICU
P-584	-1.4009 -1.8717 -1.7184 -4.1299 -0.2296 -0.1052
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission patients
H-1581	-1.4394447803497314	
D-1581	-1.4394447803497314	
P-1581	-2.7130 -0.1659
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous symptoms patients heart_failure
H-51	-0.8886616826057434	▁Intra ven ous ▁ir on ▁heart _ ▁failure ▁ir on _ de fici en cy
D-51	-0.8886616826057434	Intravenous iron heart_ failure iron_deficiency
P-51	-0.3668 -0.0345 -3.4943 -1.6341 -0.1463 -2.2204 -0.8396 -1.3734 -0.0188 -0.1152 -1.5315 -0.0734 -0.6300 -1.1019 -1.1580 -0.2185 -0.1506
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr acr cms correlated
H-141	-0.8501418828964233	▁p p ▁a cr ▁CMS
D-141	-0.8501418828964233	pp acr CMS
P-141	-0.3787 -1.4007 -0.0730 -3.0374 -0.3423 -0.6009 -0.1179
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality lcx lad disease
H-513	-0.6029665470123291	▁mortal ity ▁ LC x ▁ LAD ▁two - ves sel ▁disease
D-513	-0.6029665470123291	mortality LCx LAD two-vessel disease
P-513	-0.9981 -0.3447 -1.1018 -0.0679 -0.1641 -0.5363 -0.0431 -2.5247 -0.0478 -0.0456 -0.0271 -1.6584 -0.7710 -0.1108
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions remodelling leading heart_failure
H-991	-0.5671859979629517	▁stress ▁conditions ▁mal adapt ive ▁remodel ling ▁heart _ ▁failure
D-991	-0.5671859979629517	stress conditions maladaptive remodelling heart_ failure
P-991	-1.5537 -0.0303 -0.3137 -0.0266 -0.0237 -0.8449 -0.3481 -0.2958 -1.4117 -1.6515 -0.1842 -0.1219
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis systemic followed_up
H-1559	-0.8510280251502991	▁psoriasis UV
D-1559	-0.8510280251502991	psoriasisUV
P-1559	-0.0525 -2.4522 -0.7790 -0.1205
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients diagnosis congestive_heart_failure
H-1578	-0.8774125576019287	▁con ges tive _ ▁heart _ ▁failure
D-1578	-0.8774125576019287	congestive_ heart_ failure
P-1578	-2.4170 -0.1122 -0.2052 -0.4663 -1.9607 -1.0250 -1.3156 -0.2654 -0.1294
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker patients resting_hr bpm p_value
H-1941	-0.7144157290458679	▁Beta - block er
D-1941	-0.7144157290458679	Beta-blocker
P-1941	-0.1405 -0.0205 -0.0625 -0.1791 -3.7877 -0.0962
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive patients pulmonary_hypertension heart_failure
H-577	-0.9205675721168518	▁pulmonar y _ hy tension PH ▁heart _ ▁failure
D-577	-0.9205675721168518	pulmonary_hytensionPH heart_ failure
P-577	-2.7884 -0.0944 -1.2021 -1.0932 -0.0128 -1.2401 -1.0609 -0.8017 -1.5036 -0.2211 -0.1079
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new_zealand renal_dnx pacing-induced_chf
H-1373	-0.5316765904426575	▁White ▁rabbi ts ▁renal ▁DN x ▁pa cing - indu ced ▁CHF
D-1373	-0.5316765904426575	White rabbits renal DNx pacing-induced CHF
P-1373	-4.6739 -0.4879 -0.0384 -0.1179 -0.0191 -0.0032 -0.2027 -0.1425 -0.0959 -0.0002 -1.3342 -0.0634 -0.1574 -0.1068
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 healthy heart_muscle cells phenotype pathological hypertrophy
H-641	-0.9220605492591858	▁mu tant _ mi ce _ ▁over express ing ▁Hand ▁heart _ ▁muscle s ▁path ological _ ▁hyper trop hy
D-641	-0.9220605492591858	mutant_mice_ overexpressing Hand heart_ muscles pathological_ hypertrophy
P-641	-0.1184 -0.1471 -1.3308 -0.3027 -0.1875 -4.4354 -0.6574 -0.2842 -0.1121 -0.2164 -3.9696 -0.8345 -2.8804 -0.7943 -1.0398 -0.7953 -0.8960 -0.8326 -0.0034 -0.0593 -0.2538 -0.1344
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis patients adverse_events echocardiographic outcomes
H-914	-0.7181577682495117	▁di al ysis ▁e cho car dio graphic
D-914	-0.7181577682495117	dialysis echocardiographic
P-914	-0.1650 -0.4407 -0.1117 -1.9135 -0.6963 -0.0895 -0.6734 -1.7188 -1.2356 -0.1370
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients heart_failure_and_reduced_ejection_fraction
H-668	-1.553422451019287	▁heart _ ▁failure ▁e je ction fraction
D-668	-1.553422451019287	heart_ failure ejectionfraction
P-668	-5.0930 -1.1208 -1.2012 -0.6471 -0.7010 -0.0436 -4.7895 -0.2227 -0.1619
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt_variability qtv repolarization qtv cardiac_death
H-1435	-1.4387685060501099	▁ QT _ ▁variabil ity ▁Q TV ▁Q TV ▁cardiac _ ▁death
D-1435	-1.4387685060501099	QT_ variability QTV QTV cardiac_ death
P-1435	-1.9102 -0.4516 -2.7450 -2.4307 -0.6127 -2.1458 -0.6428 -3.0259 -0.7769 -1.9230 -2.5875 -0.5861 -0.1920 -0.1125
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial_structure sarcomeric_microstructure
H-1250	-1.1173688173294067	▁mito cho ndri al ▁structure ▁sar come _ micro structure
D-1250	-1.1173688173294067	mitochondrial structure sarcome_microstructure
P-1250	-0.2402 -1.8743 -0.2122 -0.1432 -2.0164 -0.5303 -1.8770 -4.4404 -1.2362 -0.5386 -0.2119 -0.0876
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory hf patients left_ventricular_ejection_fraction
H-122	-0.7079076170921326	▁consenti ng ▁ambula tory ▁ HF ▁vent ri cular ▁e je ction fraction
D-122	-0.7079076170921326	consenting ambulatory HF ventricular ejectionfraction
P-122	-1.8293 -1.2131 -0.3488 -0.2203 -0.9913 -0.1297 -0.4825 -0.3715 -0.4143 -1.5703 -0.6673 -0.2450 -1.6532 -0.3638 -0.1183
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy hdl chf-nyha-iiib hdl
H-258	-0.9780777096748352	▁ET ▁HD L _ fon cti onnement ▁CHF - NY ha - III b ▁HD L _ fon cti onnement
D-258	-0.9780777096748352	ET HDL_fonctionnement CHF-NYha-IIIb HDL_fonctionnement
P-258	-3.9797 -3.6740 -1.4979 -1.5171 -1.2967 -0.4900 -0.4147 -1.8693 -0.0964 -0.5087 -1.0855 -0.2389 -0.0769 -0.0825 -0.5639 -1.0700 -1.3516 -0.5634 -0.5763 -0.3023 -0.2018 -0.0603
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient implantable_cardioverter-defibrillator
H-1859	-0.8210613131523132	▁a im ▁implant able _ ▁cardio ver ter - de _ f ré br illa tor _ de activa tion
D-1859	-0.8210613131523132	aim implantable_ cardioverter-de_frébrillator_deactivation
P-1859	-0.4782 -0.6940 -0.0011 -0.0555 -2.3456 -0.6375 -0.1447 -0.0219 -0.1374 -0.0059 -3.1787 -1.8650 -0.6333 -4.5115 -0.0095 -0.2469 -0.8828 -0.0173 -1.7238 -0.0390 -0.3091 -0.1248
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence micrornas mirnas pathogenesis heart_failure
H-1481	-0.7019977569580078	▁micro RNA s mi RNA s ▁heart _ ▁failure
D-1481	-0.7019977569580078	microRNAsmiRNAs heart_ failure
P-1481	-0.6288 -0.0344 -0.0410 -2.2319 -0.0462 -0.0368 -1.3795 -0.9638 -2.1236 -0.1535 -0.0826
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients uptitration heart_rate renal_function spironolactone
H-180	-1.4726265668869019	▁implant ation ▁heart _ ▁rate ▁renal ▁fonction ▁spi rono lac tone
D-180	-1.4726265668869019	implantation heart_ rate renal fonction spironolactone
P-180	-3.5502 -1.0314 -3.9588 -2.5585 -0.3941 -0.0877 -5.7244 -0.9557 -0.0457 -0.2656 -0.1705 -0.2125 -0.1890
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis patients chf therapeutic neurohormonal_systems
H-635	-0.75323086977005	▁CHF ▁ therapeut ic _ ▁interrupt ion ▁neuro hormon al
D-635	-0.75323086977005	CHF therapeutic_ interruption neurohormonal
P-635	-0.9792 -1.7547 -0.0673 -0.4476 -1.4148 -0.0207 -0.0166 -1.9055 -0.3271 -0.1218 -1.9062 -0.0772
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician follow-up discharge death readmission patients heart_failure
H-1413	-1.3603649139404297	▁physician _ ▁follow - up _ ▁after _ dis charge
D-1413	-1.3603649139404297	physician_ follow-up_ after_discharge
P-1413	-0.4945 -2.6535 -3.0419 -0.2091 -0.0096 -1.3005 -1.9183 -0.2968 -0.0260 -0.0105 -6.2446 -0.1189
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter_ablation antiarrhythmic_drugs rhythm_control_therapy
H-1647	-0.3985845446586609	▁cat heter ▁ab lation ▁anti ar rhythm ic ▁drugs ▁ rhythm _ control ▁ therapy
D-1647	-0.3985845446586609	catheter ablation antiarrhythmic drugs rhythm_control therapy
P-1647	-0.0433 -0.0136 -0.3478 -0.0111 -0.0211 -1.7553 -0.5162 -0.4595 -0.3082 -0.0799 -0.5525 -1.1548 -0.0289 -1.0727 -0.0521 -0.2081 -0.1507
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage poc
H-1029	-1.6594557762145996	▁po c ▁technologie
D-1029	-1.6594557762145996	poc technologie
P-1029	-3.7866 -2.1689 -2.0438 -0.1532 -0.1447
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac_dysfunction subcellular metoprolol heart_failure myocardial_infarction
H-1546	-0.44760510325431824	▁cardiac _ ▁dys function ▁sub cel lular _ ▁altera tions ▁met o pro lol ▁heart _ ▁failure ▁my o card ial _ ▁in far ction
D-1546	-0.44760510325431824	cardiac_ dysfunction subcellular_ alterations metoprolol heart_ failure myocardial_ infarction
P-1546	-0.1744 -1.0214 -0.1911 -0.9566 -0.0607 -0.2564 -0.0574 -2.9386 -0.2582 -0.0221 -0.0920 -0.0837 -0.0080 -0.1992 -0.3662 -0.5795 -0.4030 -0.1608 -0.2635 -0.3104 -0.1593 -1.0814 -0.5635 -1.1433 -0.1246 -0.4752 -0.1348
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac_magnetic_resonance_postcontrast_t1_time outcome patients heart_failure preserved_ejection_fraction
H-733	-0.6453574299812317	▁Card iac _ ▁magnetic _ ▁res on ance _ ▁post contra st ▁heart _ ▁failure ▁e je ction _ fraction
D-733	-0.6453574299812317	Cardiac_ magnetic_ resonance_ postcontrast heart_ failure ejection_fraction
P-733	-0.1622 -0.2924 -0.2804 -0.7508 -1.5446 -1.5188 -0.1432 -0.0374 -1.8273 -1.3775 -0.0344 -0.1766 -2.0056 -0.6649 -1.3210 -0.5331 -0.3359 -0.0478 -0.7693 -0.0069 -0.2631 -0.1049
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv_diastolic_dysfunction filling_pressures non-invasively doppler_echocardiography
H-28	-0.7198362350463867	▁LV ▁dia sto lic _ ▁dys function ▁fill ing _ tension s ▁do pp ler _ ▁e cho card i ography
D-28	-0.7198362350463867	LV diastolic_ dysfunction filling_tensions doppler_ echocardiography
P-28	-0.0684 -2.7993 -0.9779 -2.7600 -0.9669 -0.1651 -0.7734 -0.7136 -0.1437 -0.7411 -0.3194 -0.1807 -0.3281 -0.0561 -0.9812 -0.6160 -1.6888 -0.6205 -0.2877 -0.5760 -0.3494 -0.2687 -0.1742
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart_magnetic_resonance_imaging chelation compliance heart_disease patients thalassaemia_major
H-744	-1.018889307975769	▁heart _ ▁magnetic _ ▁res on ance _ ▁imagin g ▁che lation _ ▁choice s ▁heart _ ▁disease ▁tha lassa emia
D-744	-1.018889307975769	heart_ magnetic_ resonance_ imaging chelation_ choices heart_ disease thalassaemia
P-744	-1.0253 -1.0769 -1.1899 -2.7704 -1.5607 -0.1581 -0.0922 -0.8529 -0.4698 -0.0466 -0.5290 -0.0119 -2.4211 -2.1608 -0.0108 -1.9264 -1.3745 -3.7188 -0.1417 -0.5788 -0.7177 -0.5193 -0.0809
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial_collagen collagen_cross-linking titin isoforms phosphorylation
H-764	-0.45054930448532104	▁My o card ial ▁collage n ▁collage n _ ▁cross - link ing ▁titi n ▁ phos phor y lation
D-764	-0.45054930448532104	Myocardial collagen collagen_ cross-linking titin phosphorylation
P-764	-0.5234 -0.0732 -0.0849 -0.5718 -0.9785 -0.1269 -1.0404 -0.0640 -2.3280 -1.0189 -0.0045 -0.0161 -0.1296 -0.0631 -0.1983 -0.5602 -0.1023 -0.2884 -1.3136 -0.0512 -0.2810 -0.0938
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping mri tidal_respiration myocardial_t1 heart_failure
H-1054	-0.6703149080276489	▁m ri ▁tid al _ ▁respira tion ▁my o card ial ▁s win e ▁heart _ ▁failure
D-1054	-0.6703149080276489	mri tidal_ respiration myocardial swine heart_ failure
P-1054	-0.2188 -2.8403 -2.0758 -0.0216 -1.1994 -0.1135 -0.0099 -0.1311 -0.1727 -0.0788 -0.0205 -1.5620 -0.2648 -0.1146 -1.2738 -1.1219 -1.0299 -0.3426 -0.1440
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker uptitration clinical outcome patients hfref hfpef
H-185	-0.4713577926158905	RAS - block er ▁h f f ▁ HF p EF
D-185	-0.4713577926158905	RAS-blocker hff HFpEF
P-185	-0.2390 -0.0675 -0.1983 -0.2088 -0.5600 -0.6905 -0.3048 -1.9683 -0.6046 -0.0655 -0.8927 -0.1880 -0.1396
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems_proteomics cardiac_chromatin nucleolin cellular_plasticity cardiomyocytes
H-88	-0.9326944351196289	▁Systems _ protec o mics ▁cardiac _ ▁chr omat in ▁nucleo lin ▁regulator _ de _ ▁growth ▁cardio my o cy tes
D-88	-0.9326944351196289	Systems_protecomics cardiac_ chromatin nucleolin regulator_de_ growth cardiomyocytes
P-88	-0.8542 -0.1940 -1.4702 -2.9246 -0.0048 -0.6829 -1.3623 -0.1423 -0.0164 -1.2432 -0.3197 -1.3393 -2.8424 -1.6178 -1.2013 -0.1920 -1.7699 -1.4225 -0.7745 -0.9266 -0.1329 -0.6554 -0.2221 -0.0735
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac_failure death patients type_2_diabetes diabetes heart_failure
H-652	-0.8269631862640381	▁Card iac _ ▁failure ▁diabetes ▁heart _ ▁failure
D-652	-0.8269631862640381	Cardiac_ failure diabetes heart_ failure
P-652	-0.8808 -0.2980 -0.5588 -1.4786 -0.5401 -1.8051 -0.9420 -1.5084 -0.1425 -0.1153
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese zsf1 heart_failure_with_preserved_ejection_fraction
H-770	-0.8248804807662964	▁z f 1 ▁rat s ▁heart _ ▁failure ▁e je ction _ fraction
D-770	-0.8248804807662964	zf1 rats heart_ failure ejection_fraction
P-770	-1.5100 -0.5397 -1.1939 -1.4687 -0.0730 -1.3211 -0.9646 -2.0860 -1.3149 -0.6648 -0.0763 -0.7092 -0.0151 -0.2544 -0.1817
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin exercise training health patients chronic_heart_failure hf-action randomized
H-833	-1.1232937574386597	▁Hem o glob in ▁ HF - ac tion
D-833	-1.1232937574386597	Hemoglobin HF-action
P-833	-0.1604 -0.0502 -0.0287 -1.3569 -5.3536 -2.3039 -0.3360 -1.1088 -0.6285 -0.8662 -0.1630
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf shift chronic_heart_failure chronic_heart_failure cardiology
H-1964	-0.9639027118682861	▁passage _ f ré que nce _ f ré que nce _ f ré que nce _ f ré que nce ▁heart _ ▁failure ▁card i ology
D-1964	-0.9639027118682861	passage_fréquence_fréquence_fréquence_fréquence heart_ failure cardiology
P-1964	-6.6358 -0.8893 -0.3224 -3.8319 -0.0356 -0.0059 -0.6403 -0.9977 -0.0914 -0.0184 -0.0058 -1.0924 -1.3422 -0.0282 -0.0169 -0.0068 -1.9694 -2.4125 -0.0225 -0.0170 -0.0079 -4.0459 -0.9667 -0.6440 -0.6867 -0.2802 -0.5355 -0.2457 -0.1583
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial_tonometry lvet prognostic patients precapillary_ph heart_failure
H-579	-0.751920759677887	▁arterial _ ▁ton ometr y ▁l VET ▁pre cap illa ry _ ▁PH ▁heart _ ▁failure
D-579	-0.751920759677887	arterial_ tonometry lVET precapillary_ PH heart_ failure
P-579	-0.2519 -0.3544 -1.4738 -0.0599 -0.3243 -1.7864 -2.1079 -0.0658 -0.8477 -0.0055 -0.4636 -0.9377 -0.9784 -0.9964 -0.9457 -1.4701 -0.3178 -0.1473
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal_echocardiography shunts thrombosis
H-1957	-0.522640585899353	▁trans o es op hage al _ ▁e cho card i ography ▁shu nts ▁ thro mbo sis ▁migration
D-1957	-0.522640585899353	transoesophageal_ echocardiography shunts thrombosis migration
P-1957	-0.0731 -0.2894 -0.3732 -2.2084 -0.0278 -0.8443 -0.2652 -1.2074 -0.1374 -0.1015 -0.3848 -0.2064 -0.6303 -0.0786 -1.1777 -0.5781 -0.2245 -1.6529 -0.0481 -0.3678 -0.0984
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk heart adipose_tissue cachectic_heart_failure patients prospective_study
H-8	-0.9366146922111511	▁Cross - talk ▁heart ▁adi pose _ ▁tissu e ▁cache ctic _ ▁heart _ ▁failure
D-8	-0.9366146922111511	Cross-talk heart adipose_ tissue cachectic_ heart_ failure
P-8	-1.5830 -0.0578 -0.0172 -4.4139 -0.1468 -0.1844 -0.6885 -1.7440 -0.4843 -0.0497 -1.4426 -1.1574 -1.1938 -0.4189 -1.3987 -0.7773 -0.1643
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause_readmissions
H-726	-0.7526928186416626	
D-726	-0.7526928186416626	
P-726	-1.4367 -0.0687
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular_disease baseline
H-1767	-1.8642442226409912	▁cardiovascular _ ▁disease
D-1767	-1.8642442226409912	cardiovascular_ disease
P-1767	-3.0485 -3.1075 -2.8129 -0.2244 -0.1278
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal hospital hf patients cms conditions
H-139	-0.9192502498626709	▁PRI n ci pal _ ▁FIN DING s ▁ HF ▁conditions
D-139	-0.9192502498626709	PRIncipal_ FINDINGs HF conditions
P-139	-1.3113 -1.0854 -1.0521 -0.6074 -0.5052 -1.5344 -0.1580 -0.2571 -2.4721 -0.4849 -1.9662 -0.4075 -0.1087
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal likelihood_ratio
H-487	-1.3668437004089355	▁e sept al
D-487	-1.3668437004089355	eseptal
P-487	-5.2704 -0.6829 -0.1364 -0.5760 -0.1686
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis cardiovascular_disease cvd
H-1555	-1.0194231271743774	▁p sori asis ▁cardiovascular ▁disease CV d
D-1555	-1.0194231271743774	psoriasis cardiovascular diseaseCVd
P-1555	-1.9579 -0.1535 -0.5096 -0.3670 -3.2051 -2.2159 -0.4675 -0.2120 -0.0864
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs patients oht transplant vad
H-1288	-1.0129133462905884	▁a CS ▁problems ▁o HT ▁transplant ▁MT ▁ VAD
D-1288	-1.0129133462905884	aCS problems oHT transplant MT VAD
P-1288	-0.1257 -1.2960 -4.5760 -0.1364 -0.4908 -0.7801 -2.6677 -0.8523 -0.0094 -0.1230 -0.0846
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients beta-blocker therapy
H-1939	-1.2838466167449951	▁beta - block er
D-1939	-1.2838466167449951	beta-blocker
P-1939	-4.7578 -0.0236 -0.1570 -0.0839 -2.3998 -0.2809
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs clinical
H-2015	-1.52073073387146	▁coût
D-2015	-1.52073073387146	coût
P-2015	-3.5484 -0.9242 -0.0897
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital_compare ami mortality
H-1697	-0.7593070864677429	▁Hospital ▁ AMI ▁mortal ity
D-1697	-0.7593070864677429	Hospital AMI mortality
P-1697	-1.7436 -1.3154 -0.1893 -0.7758 -0.2446 -0.8736 -0.1728
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins subproteome
H-94	-1.2000070810317993	▁protein s
D-94	-1.2000070810317993	proteins
P-94	-2.9777 -0.2184 -1.5639 -0.0401
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma collected hf patients
H-1514	-0.7815467119216919	▁Plas ma ▁ HF
D-1514	-0.7815467119216919	Plasma HF
P-1514	-0.4520 -0.3057 -2.3985 -0.3239 -1.1242 -0.0850
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician patient admission admission
H-1417	-1.082909345626831	▁index _ ad mission
D-1417	-1.082909345626831	index_admission
P-1417	-3.7373 -0.9880 -0.6305 -0.0139 -0.8648 -0.2630
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis medical hf
H-200	-1.1847398281097412	▁ HF
D-200	-1.1847398281097412	HF
P-200	-3.1937 -0.9186 -0.5189 -0.1078
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm_control_therapy
H-1645	-0.43600744009017944	▁ Rhythm _ control _ therapy
D-1645	-0.43600744009017944	Rhythm_control_therapy
P-1645	-0.1291 -0.1126 -0.5940 -0.0518 -1.5049 -0.2225 -0.7644 -0.1089
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy patients follow-up
H-861	-1.02146577835083	▁ therapy
D-861	-1.02146577835083	therapy
P-861	-3.4137 -0.3541 -0.1959 -0.1222
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients cardiovascular_disease drs
H-1838	-1.1635099649429321	▁cardiovascular ▁disease ▁d RS
D-1838	-1.1635099649429321	cardiovascular disease dRS
P-1838	-1.5311 -3.4733 -0.1193 -0.8445 -0.9121 -0.1008
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported heart_failure clcnka snp
H-1804	-1.2698074579238892	▁heart _ ▁failure ▁CL CN KA _ s NP
D-1804	-1.2698074579238892	heart_ failure CLCNKA_sNP
P-1804	-4.4115 -1.0793 -2.1873 -0.8132 -0.8739 -0.9570 -2.4703 -0.7532 -0.0422 -0.2723 -0.1077
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas cardiac_remodeling heart_failure
H-1483	-0.2927597165107727	▁mi RNA s ▁cardiac ▁remodel ing ▁heart _ ▁failure
D-1483	-0.2927597165107727	miRNAs cardiac remodeling heart_ failure
P-1483	-0.4268 -0.0121 -0.0239 -0.0210 -0.4466 -0.0972 -0.2829 -0.8257 -0.8950 -0.1300 -0.0591
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa immunoassays nt-probnp
H-1516	-0.4811878502368927	▁sandwich ▁Alpha LIS a ▁immun o assa ys ▁NT - pro b NP
D-1516	-0.4811878502368927	sandwich AlphaLISa immunoassays NT-probNP
P-1516	-1.8710 -0.7371 -0.4409 -0.6896 -0.0952 -0.3187 -0.2157 -1.8384 -0.1407 -0.0162 -0.0135 -0.4709 -0.0439 -0.2452 -0.0808
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf patients rheumatoid_arthritis ra
H-602	-0.9904557466506958	▁h f ▁rhe um ato id _ ar thri tis ra
D-602	-0.9904557466506958	hf rheumatoid_arthritisra
P-602	-1.5226 -0.7056 -2.0157 -0.1119 -0.2710 -2.2988 -0.2129 -1.3826 -0.2079 -1.0739 -2.7300 -0.2183 -0.1248
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction_pathways engage signalling_proteins
H-993	-0.9816186428070068	▁trans duction _ path ways ▁signal ling ▁protein s
D-993	-0.9816186428070068	transduction_pathways signalling proteins
P-993	-0.0511 -0.2440 -1.5515 -0.7154 -0.8809 -0.6160 -2.6233 -3.7375 -0.1203 -0.1476 -0.1103
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical diastolic_dysfunction mortality
H-25	-0.874970555305481	▁clinic al _ dia sto lique _ ▁dys function ▁cause _ ▁mortal ity
D-25	-0.874970555305481	clinical_diastolique_ dysfunction cause_ mortality
P-25	-2.3580 -0.0158 -0.2603 -2.4908 -0.7755 -3.5422 -0.2982 -0.6118 -1.0078 -0.4472 -0.1957 -0.3049 -0.5613 -0.1687 -0.0866
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation anti-inflammatory chf
H-1362	-0.7667590975761414	▁regula tion _ de _ ▁feed ing ▁nutrition al ▁anti - in flam ma tory ▁effects ▁CHF
D-1362	-0.7667590975761414	regulation_de_ feeding nutritional anti-inflammatory effects CHF
P-1362	-1.6686 -0.0131 -0.1552 -1.1173 -0.0750 -2.2770 -0.0931 -0.4030 -0.5864 -0.6286 -0.0611 -0.8442 -0.0934 -1.1169 -1.4272 -3.5187 -0.2860 -0.1182 -0.0854
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes hypertrophic
H-1217	-0.5933918952941895	▁p de 2- over express ing ▁cardio my o cy tes ▁no re pine ph rine ▁hyper trop hic
D-1217	-0.5933918952941895	pde2-overexpressing cardiomyocytes norepinephrine hypertrophic
P-1217	-0.4418 -0.0193 -1.9021 -0.3735 -0.4074 -0.0943 -0.7296 -0.9491 -0.8497 -0.3571 -0.4621 -0.0615 -0.0464 -0.3053 -2.8682 -0.5064 -0.8488 -0.0034 -0.2675 -0.8003 -0.1672
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate alendronate heart_failure
H-1545	-1.824405550956726	▁ale ndr onate ▁dose - dependent _ re duction
D-1545	-1.824405550956726	alendronate dose-dependent_reduction
P-1545	-4.0804 -0.1998 -1.7388 -5.7743 -0.0239 -0.0495 -1.8047 -0.5757 -0.0082 -5.6939 -0.1194
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty heart_failure hf
H-622	-1.4490420818328857	▁fra il ty ▁risk ▁heart _ ▁failure HF
D-622	-1.4490420818328857	frailty risk heart_ failureHF
P-622	-2.0675 -0.9062 -3.7186 -1.9635 -1.9458 -0.7679 -1.7882 -0.9245 -0.3026 -0.1056
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression bax bcl-2 proteins pacing
H-170	-0.44956186413764954	▁Bax ▁b cl -2 ▁protein s
D-170	-0.44956186413764954	Bax bcl-2 proteins
P-170	-0.3442 -0.0843 -0.0910 -0.6285 -1.0664 -0.2106 -1.0444 -0.1271
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients β-blocker patients uptitration
H-179	-0.7538482546806335	▁ RAS - ▁β - block er
D-179	-0.7538482546806335	RAS- β-blocker
P-179	-0.4793 -0.0441 -0.4045 -3.3938 -0.0411 -0.1500 -0.2192 -1.8391 -0.2135
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt gdmt bat
H-1871	-0.6366210579872131	▁GD MT ▁GD MT ▁BAT
D-1871	-0.6366210579872131	GDMT GDMT BAT
P-1871	-0.3213 -0.4847 -2.9565 -0.3247 -0.1969 -0.1078 -0.0645
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart_failure patients bisphosphonates
H-1535	-0.8478521704673767	▁heart _ ▁failure ▁bis phos phon ates
D-1535	-0.8478521704673767	heart_ failure bisphosphonates
P-1535	-2.5208 -1.0654 -1.2604 -0.9779 -0.0602 -0.2416 -1.1612 -0.2052 -0.1380
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline patients resting_hr bpm
H-1940	-0.902964174747467	▁h z
D-1940	-0.902964174747467	hz
P-1940	-2.1891 -1.0562 -0.2855 -0.0811
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac_angiogenesis therapy cardiac_function remodeling
H-460	-0.9237042665481567	▁β - Block er - indu ce ▁cardiac _ ▁ang io gene sis ▁ therapy ▁cardiac ▁remodel ing
D-460	-0.9237042665481567	β-Blocker-induce cardiac_ angiogenesis therapy cardiac remodeling
P-460	-1.0690 -0.0864 -0.2040 -0.0559 -0.7380 -0.0006 -2.7792 -0.8301 -0.9072 -1.6334 -1.6424 -0.2438 -1.4740 -2.6278 -0.0609 -0.1159 -3.6205 -0.1058 -0.1918 -0.0873
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil cytotoxic doxorubicin ehrlich_carcinoma
H-966	-0.3734350800514221	▁nic oran dil ▁cy to toxic ▁do xor ubi cin ▁Eh r lich _ car cino ma
D-966	-0.3734350800514221	nicorandil cytotoxic doxorubicin Ehrlich_carcinoma
P-966	-0.0648 -0.0475 -0.5345 -0.4309 -0.0262 -0.0376 -1.6000 -0.1177 -0.0354 -0.0370 -1.8906 -0.0109 -0.3240 -0.7523 -0.5581 -0.1099 -0.2041 -0.2241 -0.0897
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death c-statistics biological_phenotype deficit_index
H-1011	-0.38670814037323	▁c - stat istic s ▁bi ological _ ▁ph eno type ▁deficit
D-1011	-0.38670814037323	c-statistics biological_ phenotype deficit
P-1011	-0.2736 -0.3108 -0.0004 -0.0925 -0.0173 -0.1391 -0.3046 -1.9106 -0.8854 -0.1021 -0.0551 -0.1062 -1.0640 -0.1522
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas cardiac benign_tumors left_atrium right_atrium
H-593	-0.5302352905273438	▁My xo mas ▁cardiac _ ▁benign ▁tumor s ▁left ▁at rium
D-593	-0.5302352905273438	Myxomas cardiac_ benign tumors left atrium
P-593	-1.3757 -0.0260 -0.1592 -0.3534 -1.5120 -0.0277 -0.3050 -0.0780 -1.3455 -1.0132 -0.0095 -0.5960 -0.0918
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic_peptides point_of_care ambulatory
H-1019	-0.8494909405708313	▁na tri ure tic _ pe pti des
D-1019	-0.8494909405708313	natriuretic_peptides
P-1019	-0.0200 -0.0303 -0.0750 -3.9316 -1.2297 -0.6605 -0.0835 -0.3257 -2.0407 -0.0979
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv_diastolic_dysfunction combination figure hfpef
H-24	-0.9400351643562317	▁LV _ ▁dia sto lic _ ▁dys function ▁h f f
D-24	-0.9400351643562317	LV_ diastolic_ dysfunction hff
P-24	-0.1103 -2.8554 -1.9440 -0.7227 -3.3695 -0.2787 -0.1629 -0.9417 -0.1592 -0.3723 -0.3145 -0.8461 -0.1431
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal_denervation dnx chf patients symptomatic
H-1371	-0.5911096334457397	▁Ren al _ den er va tion ▁d x ▁CHF
D-1371	-0.5911096334457397	Renal_denervation dx CHF
P-1371	-0.3998 -0.1608 -0.2187 -3.1121 -0.4425 -0.2050 -0.1376 -0.9958 -0.0673 -0.1474 -1.0989 -0.1075
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported patient implantable_cardioverter-defibrillator
H-1858	-0.6474425792694092	▁implant able ▁cardio ver ter - de _ fi br illa tor _ de _ activa tion
D-1858	-0.6474425792694092	implantable cardioverter-de_fibrillator_de_activation
P-1858	-0.0022 -0.0589 -1.3184 -0.1562 -0.0091 -0.0972 -0.0036 -3.3244 -2.9714 -0.7909 -0.0068 -0.2098 -0.9143 -0.0207 -1.9326 -0.0293 -0.0596 -0.2865 -0.1094
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic_adult_fontan saf patients catheterization
H-226	-0.7107975482940674	▁Font an SAF ▁cat heter ization
D-226	-0.7107975482940674	FontanSAF catheterization
P-226	-0.9221 -0.3638 -0.5664 -1.1662 -0.0158 -2.0576 -0.4410 -0.1535
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients heart_failure left_ventricular ejection_fraction
H-22	-0.9007854461669922	▁heart _ ▁failure ▁vent ri cular LV ▁e je ction _ fraction
D-22	-0.9007854461669922	heart_ failure ventricularLV ejection_fraction
P-22	-4.1368 -0.9507 -1.9735 -2.6863 -0.3685 -0.1714 -0.1467 -0.8022 -0.2347 -0.0252 -0.5888 -0.0046 -0.3858 -0.1359
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory icd patients mortality multivariable_regression
H-63	-0.39580297470092773	▁ambula tory ▁i CD ▁mortal ity ▁multi vari able _ re gression
D-63	-0.39580297470092773	ambulatory iCD mortality multivariable_regression
P-63	-0.0896 -0.2647 -1.3695 -0.4075 -1.0517 -0.4177 -0.5291 -0.0010 -0.0485 -0.4417 -0.3962 -0.0484 -0.3047 -0.1710
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients sinus_rhythm antiplatelet_agents anticoagulants
H-1354	-0.43373847007751465	▁sinus ▁ rhythm ▁anti plate let ▁agents ▁antico a gul ants
D-1354	-0.43373847007751465	sinus rhythm antiplatelet agents anticoagulants
P-1354	-1.0719 -0.5113 -0.1440 -0.0591 -0.6901 -0.8189 -0.5668 -0.5387 -0.4421 -0.2468 -0.0318 -0.4153 -0.1019
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician follow-up discharge physician outcomes patients heart_failure
H-1421	-0.8715924024581909	▁physician _ ▁follow - up _ ▁after _ dis charge ▁physician _ continu ity ▁heart _ ▁failure
D-1421	-0.8715924024581909	physician_ follow-up_ after_discharge physician_continuity heart_ failure
P-1421	-0.1820 -1.6025 -2.0842 -0.2144 -0.0134 -1.3924 -1.5861 -0.3556 -0.0256 -0.0086 -0.0095 -1.0290 -0.5765 -0.5157 -2.8124 -1.3820 -2.4096 -0.2357 -0.1253
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence vad acs consultations operations mortality morbidity
H-1289	-0.5087112188339233	▁MT ▁ VAD ▁a CS ▁mortal ity ▁morbi d ity
D-1289	-0.5087112188339233	MT VAD aCS mortality morbidity
P-1289	-0.5447 -0.6142 -0.0460 -0.6893 -1.0856 -1.0361 -0.7049 -0.1037 -0.1517 -0.7664 -0.2510 -0.1109
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity doxorubicin anti-neoplastic_agent
H-955	-0.3248179852962494	▁cardio toxic ity ▁do xor ubi cin ▁anti - neo plast ic ▁cancer s
D-955	-0.3248179852962494	cardiotoxicity doxorubicin anti-neoplastic cancers
P-955	-0.0224 -0.2977 -1.1064 -0.0187 -0.0259 -0.0563 -0.0353 -0.0422 -0.1071 -0.1685 -0.0496 -0.1609 -2.5943 -0.2298 -0.2030 -0.0790
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes patients preserved_ejection_fraction hfpef
H-1328	-0.8154508471488953	▁f es ▁pres er ved _ ▁e je ction _ fraction HF p EF
D-1328	-0.8154508471488953	fes preserved_ ejection_fractionHFpEF
P-1328	-3.5389 -0.5816 -0.6146 -0.0438 -1.7013 -0.5547 -2.0708 -1.1969 -0.1211 -0.3373 -0.0137 -1.4463 -0.0255 -0.4980 -0.1780 -0.1248
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs hf_with_reduced_ejection_fraction hfref
H-1077	-0.7677820324897766	▁life sa ving ▁drugs HF ▁e je ction _ fraction ▁h r EF
D-1077	-0.7677820324897766	lifesaving drugsHF ejection_fraction hrEF
P-1077	-2.6261 -0.3391 -1.3751 -0.8353 -1.4859 -1.6791 -0.5309 -0.0343 -0.3667 -0.0154 -1.2702 -0.0320 -0.7342 -0.1151 -0.0772
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations refractory_congestive_heart_failure peritoneal_dialysis
H-893	-0.5673070549964905	▁re frac tory _ con ges tive _ heart _ ▁failure ▁per ito ne al _ di al ysis
D-893	-0.5673070549964905	refractory_congestive_heart_ failure peritoneal_dialysis
P-893	-0.2148 -0.0801 -2.3495 -0.2726 -0.0733 -1.1031 -0.1969 -0.2936 -1.5767 -0.6744 -0.4019 -0.0606 -0.6675 -0.2638 -0.2695 -0.2469 -2.5256 -0.2663 -0.0251 -0.1855 -0.1657
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened lvet icu admission prognostic patients precapillary_ph heart_failure
H-590	-1.1058539152145386	▁ ICU _ ad mission ▁pre cap illa ry _ ▁PH ▁heart _ ▁failure
D-590	-1.1058539152145386	ICU_admission precapillary_ PH heart_ failure
P-590	-1.8808 -1.2140 -4.0704 -1.0505 -0.0197 -0.2527 -1.3076 -0.0140 -0.7424 -1.1549 -1.2457 -1.3145 -1.2490 -1.5683 -0.4242 -0.1849
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial irs1 irs2 heart_failure p38alpha mapk insulin_resistance
H-651	-0.615371823310852	▁My o card ial _ ▁loss ▁i RS 1 ▁i RS 2 ▁heart _ ▁failure ▁MA PK ▁insulin _ ▁resist ance
D-651	-0.615371823310852	Myocardial_ loss iRS1 iRS2 heart_ failure MAPK insulin_ resistance
P-651	-1.0262 -0.1079 -0.0671 -0.0659 -2.1650 -0.3567 -0.6858 -0.1332 -0.4358 -0.3879 -0.3600 -0.1660 -0.6961 -1.0260 -0.6978 -1.6568 -0.0515 -0.0417 -1.8229 -1.7367 -0.0075 -0.2989 -0.1601
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni_inhibitors angiotensin-receptor_neprilysin_inhibitors
H-1966	-0.6957083344459534	▁AR NI ▁inhibi tors angi oten sin - recept or _ ▁nepri ly sin
D-1966	-0.6957083344459534	ARNI inhibitorsangiotensin-receptor_ neprilysin
P-1966	-0.8670 -0.4348 -1.4363 -0.9255 -0.1464 -0.3254 -2.6452 -0.6104 -0.0332 -0.1785 -0.6115 -0.8226 -0.0744 -0.7638 -1.1422 -0.1141
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-337	-0.5385121703147888	▁Fun ction al _ met ral _ ▁sten osis MS ▁ring _ ▁ann ulo plast y ▁ ische mic _ met ral _ re gur gi tation MR
D-337	-0.5385121703147888	Functional_metral_ stenosisMS ring_ annuloplasty ischemic_metral_regurgitationMR
P-337	-1.2229 -0.0024 -0.1675 -0.2284 -2.1780 -0.0347 -0.7955 -0.5065 -0.1044 -1.2817 -1.1858 -0.8897 -1.2353 -0.6544 -0.0222 -0.2158 -0.5721 -0.1663 -0.2263 -0.4127 -2.2742 -0.0380 -0.4072 -0.8030 -0.0187 -0.0345 -0.0429 -0.0795 -0.2404 -0.1144
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence heart_failure_with_preserved_ejection_fraction hfpef prognosis
H-23	-0.6603990197181702	▁heart _ ▁failure ▁e je ction _ fraction ▁h f f
D-23	-0.6603990197181702	heart_ failure ejection_fraction hff
P-23	-1.1787 -0.6645 -1.3024 -3.2616 -0.6691 -0.0581 -0.3557 -0.0073 -0.0952 -0.1832 -0.2719 -0.4241 -0.1134
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_reserve
H-916	-0.7913060784339905	▁Heart _ ▁failure ▁e je ction _ fraction ▁h f f ▁cardiovascular _ ▁reserve
D-916	-0.7913060784339905	Heart_ failure ejection_fraction hff cardiovascular_ reserve
P-916	-1.0146 -1.1185 -1.3842 -4.0441 -1.0026 -0.0431 -0.2678 -0.0046 -0.0723 -0.1719 -0.1665 -1.4708 -0.6800 -0.8853 -0.2490 -0.0855
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 hypertensive obese zsf1 hypertensive diabetic
H-766	-0.8926979303359985	▁lean ▁Z SF 1 ▁obes e ▁Z SF 1 ▁diabet ic
D-766	-0.8926979303359985	lean ZSF1 obese ZSF1 diabetic
P-766	-0.2013 -2.2937 -0.5619 -1.3134 -2.0907 -0.2100 -1.2794 -0.3645 -0.2969 -1.9095 -0.8382 -0.1752 -0.0704
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian_enabled mena cytoskeletal_actin_dynamics heart_failure hf
H-1810	-0.7642960548400879	▁Mamma lian _ ▁enabled ▁men a ▁cy tos kelet al _ act in _ ▁dynamic s ▁heart _ ▁failure HF
D-1810	-0.7642960548400879	Mammalian_ enabled mena cytoskeletal_actin_ dynamics heart_ failureHF
P-1810	-0.5729 -0.2782 -0.7186 -0.8606 -1.2213 -0.0303 -3.7207 -0.4613 -0.1161 -0.0774 -0.4391 -0.6671 -2.5429 -0.9650 -0.7764 -0.0127 -0.1466 -0.5541 -2.0814 -0.3518 -0.1135 -0.1065
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal_bleeding reported patients ventricular_assist_devices
H-1659	-0.4822859466075897	▁Gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ assist ▁devices
D-1659	-0.4822859466075897	Gastrointestinal_ bleeding ventricular_assist devices
P-1659	-0.4517 -0.0612 -0.9080 -0.2379 -0.7829 -0.6537 -0.6629 -0.6411 -0.0171 -0.1356 -0.1163 -0.3556 -0.1380 -2.3121 -0.1464 -0.0961
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart hospitalization death patients preserved_left_ventricular_ejection_fraction
H-235	-1.1367570161819458	▁heart _ f ré que nce ▁vent ri cular _ ▁e je ction _ fraction
D-235	-1.1367570161819458	heart_fréquence ventricular_ ejection_fraction
P-235	-1.5981 -0.9526 -6.5086 -0.0401 -0.1694 -0.0566 -1.9246 -0.6281 -0.6267 -0.9960 -2.5597 -0.8253 -0.1612 -1.4200 -0.0071 -0.5663 -0.2847
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial pde2 intracellular antiadrenergic therapeutic hf
H-1220	-0.6098641157150269	▁my o card ial ▁p de 2 ▁intra cel lular ▁anti ad r energi c ▁ therapeut ic ▁ HF
D-1220	-0.6098641157150269	myocardial pde2 intracellular antiadrenergic therapeutic HF
P-1220	-2.0312 -0.1511 -0.0719 -0.1426 -1.0582 -0.0432 -0.2702 -0.3977 -0.6265 -0.0566 -1.1456 -0.5026 -0.1412 -0.2360 -0.4880 -1.2248 -0.2798 -0.6701 -2.9462 -0.6203 -0.1487 -0.1645
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic bnp nt-probnp patients coronary_artery_disease cad
H-1366	-0.613199770450592	▁b NP ▁NT - pro b NP ▁corona ry _ ▁arter y ▁disease CAD
D-1366	-0.613199770450592	bNP NT-probNP coronary_ artery diseaseCAD
P-1366	-0.0751 -0.5939 -0.7502 -0.0124 -0.0041 -0.6049 -0.1680 -0.1430 -0.8207 -0.9702 -0.4998 -0.4690 -2.1436 -2.1912 -0.2526 -0.1124
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients heart_failure elevated left_atrial_pressure symptoms hospital admission
H-1949	-1.3695725202560425	▁heart _ ▁failure ▁left _ at rial _ tension ▁hospital
D-1949	-1.3695725202560425	heart_ failure left_atrial_tension hospital
P-1949	-1.8325 -0.8795 -1.3323 -2.9323 -0.3641 -3.1721 -0.5016 -1.2463 -0.6332 -0.9935 -2.4143 -0.1333
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia acute_kidney_injury spironolactone clinical
H-444	-0.46904316544532776	▁hyper kal emia ▁ki dne y ▁injury ▁spi rono lac tone
D-444	-0.46904316544532776	hyperkalemia kidney injury spironolactone
P-444	-0.4744 -0.6084 -0.4058 -1.4204 -0.6188 -0.1586 -1.5189 -0.0303 -0.0359 -0.2880 -0.1304 -0.3319 -0.0757
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_morbidity mortality
H-236	-0.578307032585144	▁Heart _ ▁failure ▁e je ction _ fraction HF p EF ▁cardiovascular _ ▁morbi d ity ▁mortal ity
D-236	-0.578307032585144	Heart_ failure ejection_fractionHFpEF cardiovascular_ morbidity mortality
P-236	-0.4110 -0.5113 -1.5153 -3.4927 -0.8880 -0.0299 -0.2243 -0.0080 -0.6155 -0.0412 -0.7784 -0.1083 -1.3885 -0.2987 -0.1274 -0.4260 -0.1216 -0.3159 -0.1614 -0.1028
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg crt clinical
H-881	-0.5905102491378784	▁e CG ▁c RT
D-881	-0.5905102491378784	eCG cRT
P-881	-0.4868 -0.2229 -0.7893 -1.4353 -0.5335 -0.0752
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.715864360332489	▁NT - pro b NP
D-1512	-0.715864360332489	NT-probNP
P-1512	-3.8764 -0.0290 -0.0125 -0.7627 -0.1310 -0.1057 -0.0938
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions patients heart_disease
H-48	-0.745086133480072	▁trans fusion s ▁heart _ ▁disease
D-48	-0.745086133480072	transfusions heart_ disease
P-48	-0.1105 -0.0406 -0.0866 -1.6194 -1.9326 -1.8728 -0.1889 -0.1093
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone clinical medications
H-447	-0.7962661385536194	▁benefits ▁spi rono lac tone
D-447	-0.7962661385536194	benefits spironolactone
P-447	-1.6648 -1.9387 -0.0576 -0.1963 -0.4013 -1.1936 -0.1216
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination exercise peak_vo2 joint
H-1985	-1.2197858095169067	▁VO 2 ▁jo int _ ▁effect
D-1985	-1.2197858095169067	VO2 joint_ effect
P-1985	-4.5618 -0.0646 -0.9403 -0.0859 -2.1149 -1.4152 -0.4323 -0.1432
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up hf hospitalization
H-690	-0.8263781666755676	▁ HF
D-690	-0.8263781666755676	HF
P-690	-1.6991 -0.2021 -1.3049 -0.0993
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients sst2 cardiovascular_event
H-407	-1.5967243909835815	▁s st 2 ▁low - dos e ▁b ▁cardiovascular ▁event
D-407	-1.5967243909835815	sst2 low-dose b cardiovascular event
P-407	-0.1480 -2.4853 -0.8091 -5.9559 -0.0056 -1.1902 -0.1857 -3.3895 -0.5391 -2.9024 -1.4135 -0.1365
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast_cancer patients chf reported clinical
H-681	-0.7886703014373779	▁breast ▁cancer ▁patients ▁tras tuz um b - related ▁CHF
D-681	-0.7886703014373779	breast cancer patients trastuzumb-related CHF
P-681	-1.3227 -1.7090 -3.7560 -0.8051 -0.0039 -0.0341 -0.0481 -0.9718 -0.1125 -0.2763 -0.3362 -0.0883
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf pb bp
H-1348	-0.7155875563621521	▁PV f ▁ PB ▁BP
D-1348	-0.7155875563621521	PVf PB BP
P-1348	-0.1786 -0.0505 -0.8074 -0.1156 -3.4327 -0.3278 -0.0964
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant exercise
H-1883	-0.47647103667259216	
D-1883	-0.47647103667259216	
P-1883	-0.8357 -0.1172
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ecct
H-713	-1.617491364479065	
D-713	-1.617491364479065	
P-713	-3.1293 -0.1056
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.7823991179466248	▁aero bic _ ▁capacity ▁left - hand _ ▁grip _ ▁strength ▁body _ weight ▁wa ist _ ▁circum ferenc e ▁anxiety
D-573	-0.7823991179466248	aerobic_ capacity left-hand_ grip_ strength body_weight waist_ circumference anxiety
P-573	-1.8052 -0.2065 -2.2458 -2.9028 -1.6543 -0.0287 -0.1285 -0.4892 -0.5148 -1.4941 -1.0751 -0.7229 -0.6856 -1.0679 -0.8885 -0.1627 -0.6663 -0.2755 -0.0512 -0.1358 -0.5172 -0.1546 -0.1220
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-0.7792935967445374	▁Process _ re design
D-1851	-0.7792935967445374	Process_redesign
P-1851	-3.0398 -0.4090 -0.1795 -0.4778 -0.4674 -0.1023
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue_doppler left_ventricular_filling_pressure patients stable severe_systolic_heart_failure
H-479	-0.8920497298240662	▁do pp ler _ ▁imagin g ▁left ▁vent ri cular _ ▁fill ing _ tension ▁sy sto lique _ ▁heart _ ▁failure
D-479	-0.8920497298240662	doppler_ imaging left ventricular_ filling_tension systolique_ heart_ failure
P-479	-1.2351 -0.0631 -0.4352 -2.4294 -0.3082 -0.0164 -0.3261 -0.5717 -0.7039 -0.1789 -2.1134 -0.7566 -0.2889 -0.6948 -0.7561 -1.4049 -0.3131 -3.6647 -0.4781 -1.5895 -1.4327 -1.2007 -0.3257 -0.1220
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart_failure hypertensive_heart_disease angiotensin_ii infusion nephrectomy salt_loading
H-273	-0.6020923852920532	▁heart _ ▁failure ▁hyper tensi ve _ ▁heart _ ▁disease ▁ang io ten sin _ ▁II ▁in fusion ▁nep hr ecto my ▁salt
D-273	-0.6020923852920532	heart_ failure hypertensive_ heart_ disease angiotensin_ II infusion nephrectomy salt
P-273	-0.4330 -0.5666 -0.5681 -0.3003 -0.6412 -0.9013 -0.6790 -1.3946 -0.9836 -1.9961 -0.0266 -1.0238 -0.2537 -0.8887 -1.3618 -0.6068 -0.0130 -0.0147 -0.0827 -0.1224 -0.1662 -1.0610 -0.0089 -0.8466 -0.1114
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas_city_cardiomyopathy_questionnaire patients heart_failure reduced_ejection_fraction
H-779	-0.6772931218147278	▁Kansas ▁City ▁Card i om yo pathy _ ▁Question naire ▁heart _ ▁failure ▁e je ction _ fraction
D-779	-0.6772931218147278	Kansas City Cardiomyopathy_ Questionnaire heart_ failure ejection_fraction
P-779	-0.0499 -0.9645 -1.7088 -0.1088 -0.1000 -2.3568 -0.0922 -3.6492 -0.2587 -0.0002 -0.9079 -0.6150 -0.8383 -0.2879 -0.2783 -0.0274 -0.9025 -0.0039 -0.2526 -0.1431
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians patient anemic patients heart_disease
H-34	-0.9895045757293701	▁a ne mic ▁ir on - d eficient
D-34	-0.9895045757293701	anemic iron-deficient
P-34	-1.7340 -0.0926 -0.9563 -0.7379 -0.0460 -0.1018 -0.1385 -0.4103 -5.5499 -0.1276
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence prevalence heart_failure leading death hospitalisation
H-1664	-1.2074068784713745	▁heart _ ▁failure
D-1664	-1.2074068784713745	heart_ failure
P-1664	-1.3348 -0.7777 -2.3785 -1.4037 -0.1422
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab chf nontrastuzumab_users
H-678	-0.34508180618286133	▁tras tuz um ab ▁CHF ▁non tras tuz um ab
D-678	-0.34508180618286133	trastuzumab CHF nontrastuzumab
P-678	-0.4000 -0.0058 -0.0459 -0.1731 -0.5081 -1.3235 -0.2373 -0.0067 -0.0526 -0.3020 -1.0212 -0.0649
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration patients hr_reduction beta-blocker therapy
H-1947	-0.9909903407096863	▁HR ▁beta - block er ▁ therapy
D-1947	-0.9909903407096863	HR beta-blocker therapy
P-1947	-3.4187 -3.3862 -0.0252 -0.1047 -0.0758 -1.5912 -0.0581 -0.1253 -0.1337
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary_occlusion collateral_growth stent
H-510	-0.44391050934791565	▁corona ry ▁oc clusi on ▁col lateral _ ▁growth ▁sten t ▁oc clusi on
D-510	-0.44391050934791565	coronary occlusion collateral_ growth stent occlusion
P-510	-0.4878 -1.1564 -0.4010 -0.1256 -0.3939 -0.3943 -0.0052 -1.2438 -1.1900 -0.0721 -0.0293 -0.9192 -0.0469 -0.2420 -0.2756 -0.1194
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis patients disease atherosclerosis cardiovascular_events psoriasis
H-1565	-1.0896071195602417	▁psoriasis ▁patients ▁at hero sc ler osis ▁cardiovascular ▁events ▁psoriasis
D-1565	-1.0896071195602417	psoriasis patients atherosclerosis cardiovascular events psoriasis
P-1565	-0.3073 -5.0229 -1.9901 -0.1528 -1.4491 -1.1300 -0.1651 -0.4561 -1.8753 -0.0996 -0.2745 -0.1525
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid_intima-media_thickness psoriasis
H-1561	-0.7026978135108948	▁caro tid _ ▁intim a - media _ ▁thi ck ness ▁psoriasis
D-1561	-0.7026978135108948	carotid_ intima-media_ thickness psoriasis
P-1561	-0.3821 -0.3174 -2.4901 -0.4468 -0.1805 -0.0584 -0.0925 -0.5904 -2.3358 -0.9080 -1.7741 -0.0261 -0.1129 -0.1228
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 hearts acute β-ar
H-1218	-0.6018637418746948	▁p de 2 ▁fail ing ▁heart s ▁β - AR
D-1218	-0.6018637418746948	pde2 failing hearts β-AR
P-1218	-0.4958 -0.0138 -0.2313 -0.4341 -0.6061 -1.4796 -0.0750 -2.6913 -0.0060 -0.1957 -0.7374 -0.2561
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients narrow_qrs_complex crt patients
H-846	-0.6661096215248108	▁Mechanic al _ syn chron y ▁QR s ▁c RT
D-846	-0.6661096215248108	Mechanical_synchrony QRs cRT
P-846	-0.2499 -0.0283 -0.1802 -0.9405 -0.0004 -1.3094 -1.1865 -1.9391 -0.5313 -1.1329 -0.3421 -0.1528
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote_monitoring rm heart_failure
H-148	-1.2518179416656494	▁Remote _ ▁monitoring RM ▁heart _ ▁failure
D-148	-1.2518179416656494	Remote_ monitoringRM heart_ failure
P-148	-0.5815 -1.7804 -1.1101 -0.6998 -4.3483 -0.8347 -1.5182 -0.2956 -0.0977
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart_failure hf death crt-d
H-105	-1.0994229316711426	▁i ▁heart _ ▁failure ▁h c rte - d
D-105	-1.0994229316711426	i heart_ failure hcrte-d
P-105	-1.4292 -3.7564 -0.8471 -0.7292 -0.5693 -1.1441 -2.5839 -0.1099 -0.3417 -0.4232 -0.1597
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv_dysfunction cardiac_cachexia
H-1168	-0.8073537349700928	▁ RV ▁dys function ▁cardiac _ ▁cache xia
D-1168	-0.8073537349700928	RV dysfunction cardiac_ cachexia
P-1168	-1.1268 -0.8506 -1.2415 -0.8672 -0.0569 -1.0348 -1.8570 -0.3315 -0.5734 -0.1339
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr diuretics hypertension patients esrd
H-397	-0.3450717329978943	▁e g f ▁di ure tics ▁hyper tension ▁ES RD
D-397	-0.3450717329978943	egf diuretics hypertension ESRD
P-397	-0.1472 -1.2953 -0.7799 -0.1020 -0.0670 -1.0161 -0.0511 -0.0006 -0.3324 -0.1052 -0.1729 -0.0712
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence chronic_heart_failure hungary
H-646	-1.7263351678848267	▁chronic _ heart _ ▁failure ▁Hungary
D-646	-1.7263351678848267	chronic_heart_ failure Hungary
P-646	-3.7449 -0.5970 -2.9214 -0.9501 -2.2943 -2.6642 -0.4482 -0.1906
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic clinical pharmacologic
H-1470	-0.5708791017532349	▁ pharma c ologic
D-1470	-0.5708791017532349	pharmacologic
P-1470	-0.1751 -0.0491 -0.0760 -0.1334 -2.9037 -0.0880
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care outpatient acute_heart_failure
H-1026	-0.9812138080596924	▁point - of - care s ▁ NP ▁ed ▁out patient s ▁a cute _ heart _ ▁failure
D-1026	-0.9812138080596924	point-of-cares NP ed outpatients acute_heart_ failure
P-1026	-0.9533 -0.1138 -0.0320 -0.0405 -0.2557 -1.8905 -2.2928 -0.0318 -2.0780 -3.2801 -0.0371 -1.7150 -0.5269 -0.0783 -0.2303 -3.1385 -1.4914 -0.9333 -0.3103 -0.1949
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal_dysfunction all-cause_mortality cardiovascular_events postoperative cabg
H-978	-0.7927709817886353	▁Ren al _ ▁dys function ▁mortal ity ▁cardiovascular ▁events ▁ca BG
D-978	-0.7927709817886353	Renal_ dysfunction mortality cardiovascular events caBG
P-978	-0.1399 -0.1425 -0.2598 -0.5073 -0.9083 -1.7504 -0.6858 -0.0179 -3.0855 -2.1203 -0.4345 -0.1500 -0.1038
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea total_arterial_compliance tac end-systolic_elastance ees baseline
H-520	-0.6579642295837402	▁arterial _ ▁compliance TAC ▁end - sy sto lic _ ▁elastan ce ▁e es
D-520	-0.6579642295837402	arterial_ complianceTAC end-systolic_ elastance ees
P-520	-0.5919 -2.1121 -1.0783 -0.2356 -0.2545 -0.0238 -1.1096 -0.4047 -2.3586 -1.2335 -0.0125 -0.3064 -0.3049 -0.0049 -0.3734 -0.1228
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal_dysfunction mortality myocardial_infarction coronary_artery_bypass_grafting cabg
H-969	-0.830602765083313	▁Ren al _ ▁dys function ▁my o card ial _ ▁in far ction ▁corona ry _ ▁arter y _ ▁by pass ▁graf t ca BG
D-969	-0.830602765083313	Renal_ dysfunction myocardial_ infarction coronary_ artery_ bypass graftcaBG
P-969	-0.1209 -0.1929 -0.4779 -0.4637 -0.8834 -3.6485 -0.1975 -0.1473 -0.2072 -1.4363 -0.3797 -2.0819 -0.0473 -0.1375 -0.5296 -1.3142 -0.3388 -1.0085 -0.6937 -1.5078 -0.0075 -0.1005 -3.2944 -2.4884 -0.3795 -0.2252 -0.1162
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular diabetes_mellitus atrial_fibrillation coronary_artery_disease hfpef
H-1890	-0.8496010899543762	▁cardiovascular _ risk ▁factors ▁diabetes ▁mell itus ▁at rial _ f bril lation ▁corona ry _ ▁arter y _ ▁disease ▁ HF p EF
D-1890	-0.8496010899543762	cardiovascular_risk factors diabetes mellitus atrial_fbrillation coronary_ artery_ disease HFpEF
P-1890	-0.2894 -3.1572 -1.0163 -2.1430 -0.2082 -0.5265 -0.2314 -0.0356 -0.0151 -0.3827 -2.2320 -0.8457 -0.0047 -0.0895 -0.7384 -0.8664 -0.4811 -0.7879 -1.6737 -3.6449 -1.7595 -0.2677 -0.0576 -0.2346 -0.2568 -0.1435
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical coronary_artery_disease patients systolic_heart_failure etiology
H-1181	-0.9191058874130249	▁corona ry _ ▁arter y ▁disease ▁sy sto lic _ ▁heart _ ▁failure
D-1181	-0.9191058874130249	coronary_ artery disease systolic_ heart_ failure
P-1181	-0.4969 -0.8594 -1.2907 -0.4488 -0.4031 -1.8680 -0.2068 -0.1492 -3.1817 -0.5646 -1.2977 -1.0348 -0.6568 -1.2109 -0.1172
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic congestive_heart_failure haematopoietic_cell_transplantation
H-1448	-0.683918297290802	▁an thra cycli ne ▁con ges tive _ heart _ ▁failure ▁ha e mato po ie tique _ cell ▁transplant ation
D-1448	-0.683918297290802	anthracycline congestive_heart_ failure haematopoietique_cell transplantation
P-1448	-0.5618 -0.2095 -1.9994 -0.2809 -2.7471 -0.1056 -0.1394 -0.7269 -1.4611 -1.1229 -0.4518 -0.0537 -0.0467 -0.0335 -0.4556 -0.4673 -2.8157 -1.0856 -0.1997 -0.2819 -0.0169 -0.3414 -0.1255
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular_support heartmate_ii lvad centrimag rvad mortality hospital discharge
H-304	-0.896727442741394	▁bi ven tri cular _ ▁support ▁Heart Mate _ ▁II ▁l VAD ▁Centri Mag _ r VAD ▁mortal ity ▁hospital _ dis charge
D-304	-0.896727442741394	biventricular_ support HeartMate_ II lVAD CentriMag_rVAD mortality hospital_discharge
P-304	-3.1128 -0.5741 -0.2403 -1.2343 -1.8205 -1.4034 -1.8498 -0.2877 -0.9192 -0.7559 -2.2430 -0.0169 -0.3074 -1.0187 -0.7682 -1.8014 -0.1042 -1.3248 -0.4989 -0.6246 -0.7651 -0.1376 -0.0061 -0.3937 -0.2097
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus mortality hazard_ratio confidence_interval
H-129	-0.7305067181587219	▁e - c fu s ▁mortal ity haz ard
D-129	-0.7305067181587219	e-cfus mortalityhazard
P-129	-1.0923 -0.1301 -0.3249 -2.1061 -1.3174 -1.3749 -0.6127 -0.2394 -0.0090 -0.7112 -0.1176
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart_failure preserved_ejection_fraction myocardial_infarction
H-1098	-0.6459859013557434	▁heart _ ▁failure ▁e je ction _ fraction ▁my o card ial _ ▁in far ction
D-1098	-0.6459859013557434	heart_ failure ejection_fraction myocardial_ infarction
P-1098	-1.1994 -0.7977 -1.0820 -0.1090 -0.2763 -0.0540 -1.1651 -0.0039 -1.5608 -0.4104 -0.3851 -0.3464 -0.6986 -0.6743 -2.1269 -0.1567 -0.4287 -0.1527
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline isoprenaline infusion sdqt hf patients
H-1443	-0.5234668254852295	▁iso pren a line _ ▁in fusion ▁SD QT ▁h Nor m ▁ HF
D-1443	-0.5234668254852295	isoprenaline_ infusion SDQT hNorm HF
P-1443	-0.4156 -0.0548 -0.4061 -0.1289 -0.6655 -0.4800 -0.1184 -0.0316 -1.1752 -0.0574 -2.4836 -0.0034 -1.5277 -0.2970 -0.4218 -0.1085
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis post-myocardial_infarction heart heart_failure
H-449	-1.0835740566253662	▁ang io gene sis ▁post - my o card ial _ ▁in far ction ▁heart _ ▁failure
D-449	-1.0835740566253662	angiogenesis post-myocardial_ infarction heart_ failure
P-449	-0.2596 -4.4872 -0.3695 -2.7141 -0.3552 -0.0096 -2.9113 -0.7244 -0.3489 -0.2248 -0.7804 -0.6077 -2.4580 -0.1206 -0.2877 -2.6544 -0.9699 -0.2024 -0.1023
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical clinical outcomes aldosterone_antagonist heart_failure
H-1734	-0.9617719650268555	▁al do ster one _ ▁anta gon ist ▁heart _ ▁failure
D-1734	-0.9617719650268555	aldosterone_ antagonist heart_ failure
P-1734	-0.9316 -0.7972 -0.1327 -2.5081 -0.6864 -0.1291 -0.0755 -2.8307 -0.6262 -1.2256 -2.2071 -0.2529 -0.0999
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute_heart_failure ahf symptoms heart_failure hf
H-1466	-0.9597406387329102	▁a cute _ ▁heart _ ▁failure ▁h f
D-1466	-0.9597406387329102	acute_ heart_ failure hf
P-1466	-0.5647 -0.0941 -0.2925 -1.5036 -0.5302 -1.5161 -3.0234 -1.7543 -0.1586 -0.1599
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery medical_treatment hf hypertension vasodilators diuretics
H-355	-0.5634108781814575	▁surgery ▁ HF ▁hyper tension ▁vaso dila tors ▁di ure tics
D-355	-0.5634108781814575	surgery HF hypertension vasodilators diuretics
P-355	-1.7349 -2.1924 -0.0693 -0.0347 -0.0010 -0.0703 -0.0450 -1.5034 -0.1956 -0.1374 -1.0132 -0.2561 -0.0711
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf remodeling emd dyssynchronous_failing_heart
H-1150	-0.6997228264808655	▁ HF ▁remodel ing ▁EM d ▁dys syn chron ous _ ▁fail ing _ ▁heart
D-1150	-0.6997228264808655	HF remodeling EMd dyssynchronous_ failing_ heart
P-1150	-0.4439 -0.2585 -1.9394 -0.0257 -0.7142 -0.1412 -0.0129 -0.0033 -0.0023 -3.5792 -0.6848 -0.7857 -0.1556 -1.3081 -1.4842 -0.2143 -0.1418
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt implants transseptal_catheterisation transoesophageal_echocardiographic general_anaesthesia
H-1953	-0.676963746547699	▁Shu nt ▁implant s ▁trans sept al ▁cat heter isation ▁trans o es op hage al ▁e cho car dio graphic
D-1953	-0.676963746547699	Shunt implants transseptal catheterisation transoesophageal echocardiographic
P-1953	-0.4408 -0.0296 -0.0045 -0.0931 -0.0085 -0.0653 -0.8739 -1.0395 -0.0014 -0.1392 -0.0030 -1.8383 -0.4631 -1.5947 -0.0109 -1.4252 -1.4200 -0.4530 -0.1099 -0.5449 -2.6410 -2.2043 -0.1660
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine nesiritide placebo
H-78	-0.2011110931634903	▁dop amine ▁nesi riti de
D-78	-0.2011110931634903	dopamine nesiritide
P-78	-0.0411 -0.0721 -0.0691 -0.0642 -0.1390 -0.9382 -0.0840
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients hfpef prospective
H-736	-0.27859145402908325	▁h f f
D-736	-0.27859145402908325	hff
P-736	-0.2636 -0.1368 -0.2335 -0.6668 -0.0923
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline embase cochrane clinical
H-41	-0.7654172778129578	▁MED line ▁ EMBA se ▁co ch rane _ ▁database s ▁clinic al _ ▁trial
D-41	-0.7654172778129578	MEDline EMBAse cochrane_ databases clinical_ trial
P-41	-0.4166 -1.0183 -0.8001 -0.0055 -0.6045 -0.1720 -0.1557 -0.0193 -1.8357 -2.4060 -0.0860 -0.5027 -0.0963 -0.2542 -1.8345 -2.6834 -0.1210
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr vad ecmo vad ecmo
H-1393	-0.9922146797180176	▁e g f ▁ VAD ▁EC mo
D-1393	-0.9922146797180176	egf VAD ECmo
P-1393	-0.0705 -0.8984 -1.1028 -0.2425 -0.1348 -1.8370 -1.5124 -2.9056 -0.2259
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf hospitalization cardiovascular_mortality
H-1639	-0.7284902334213257	▁black _ race ▁ HF ▁cardiovascular ▁mortal ity
D-1639	-0.7284902334213257	black_race HF cardiovascular mortality
P-1639	-0.8955 -1.0079 -1.0270 -1.6758 -0.0752 -0.8107 -0.9730 -0.3711 -0.2654 -0.1835
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical nonprescribing patients
H-1128	-0.3729378283023834	▁bio medic al ▁reasons
D-1128	-0.3729378283023834	biomedical reasons
P-1128	-0.0339 -0.0420 -0.0064 -0.4708 -1.5636 -0.1210
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician nonprescribing patient
H-1127	-1.370234489440918	▁Clinic ian
D-1127	-1.370234489440918	Clinician
P-1127	-0.8874 -2.5545 -1.8934 -0.1457
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients severe_hf prognostic hf
H-1764	-1.0545494556427002	▁ HF
D-1764	-1.0545494556427002	HF
P-1764	-2.1164 -0.4232 -1.5153 -0.1633
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth health outcomes medicare
H-1628	-0.9907654523849487	▁Care _ management ▁content - driv en _ ▁tele health ▁technologies ▁high - co st ▁Medica re ▁beneficiar ies
D-1628	-0.9907654523849487	Care_management content-driven_ telehealth technologies high-cost Medicare beneficiaries
P-1628	-2.6044 -2.3986 -0.2700 -2.6443 -0.0097 -0.0171 -0.0944 -0.5231 -2.1410 -0.2828 -2.8947 -3.4536 -0.0140 -0.0261 -0.1617 -0.5150 -0.0060 -2.1350 -0.2447 -0.2528 -0.1171
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective lvas
H-1995	-0.9408594369888306	▁l VAS
D-1995	-0.9408594369888306	lVAS
P-1995	-3.1125 -0.4202 -0.1185 -0.1122
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant erc epicatechin muscle
H-1256	-0.7344207763671875	▁ ERC ▁epi cate chin
D-1256	-0.7344207763671875	ERC epicatechin
P-1256	-0.6020 -0.1433 -1.3714 -0.0050 -0.7981 -2.1159 -0.1052
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ea tac ees patients
H-522	-0.6380321383476257	▁Ea ▁ TAC ▁HR ▁e es ▁i va bra dine
D-522	-0.6380321383476257	Ea TAC HR ees ivabradine
P-522	-1.6646 -0.9929 -0.0455 -0.9081 -1.7111 -0.0393 -0.0180 -0.0201 -0.4633 -0.0485 -1.6322 -0.1127
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician hf cpgs
H-1853	-0.8293426632881165	▁physician ▁ad her ence ▁ HF _ c PG s
D-1853	-0.8293426632881165	physician adherence HF_cPGs
P-1853	-1.5379 -3.0849 -0.1953 -0.0073 -1.1430 -0.1906 -2.4765 -0.6643 -0.2063 -0.0631 -0.2030 -0.1800
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf hf mortality
H-1774	-1.0634775161743164	▁ HF ▁h f ▁mortal ity
D-1774	-1.0634775161743164	HF hf mortality
P-1774	-0.9317 -0.2253 -3.2740 -0.6920 -1.8173 -0.5680 -0.8759 -0.1236
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl chf vascular
H-260	-1.0853087902069092	▁HD l _ fon cti onnement ▁CHF ▁ET ▁HD L - media ted _ ▁vas cular
D-260	-1.0853087902069092	HDl_fonctionnement CHF ET HDL-mediated_ vascular
P-260	-1.7853 -2.2187 -2.2819 -0.4632 -0.6506 -0.4236 -0.1620 -3.5897 -0.6961 -1.5373 -0.1346 -0.2160 -1.8648 -0.1767 -1.4348 -0.0630 -1.7370 -0.1002
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine vascular_endothelial_growth_factor protein left_ventricle myocardial_angiogenesis
H-1142	-0.8257618546485901	▁Pyr ido stig mine ▁vas cular _ en dot heli al _ ▁growth _ factor _ ▁protein ▁left ▁vent ric le ▁my o card ial _ ▁ang io gene sis
D-1142	-0.8257618546485901	Pyridostigmine vascular_endothelial_ growth_factor_ protein left ventricle myocardial_ angiogenesis
P-1142	-0.0253 -0.3990 -0.0010 -0.2859 -0.1427 -0.0942 -0.3620 -0.7981 -2.3637 -0.1363 -0.0278 -1.9470 -0.6345 -1.5757 -1.0644 -0.8071 -1.2428 -0.3138 -0.8168 -3.3401 -0.6366 -1.1493 -0.1421 -0.3187 -0.2406 -0.3575 -3.4287 -1.7159 -0.3460 -1.3001 -0.2766 -0.1343
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis idiopathic_dilated_cardiomyopathy
H-1742	-0.5490283966064453	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy
D-1742	-0.5490283966064453	idiopathic_ dilated_ cardiomyopathy
P-1742	-0.7643 -0.4209 -0.2064 -0.3710 -0.8170 -0.1564 -0.4212 -0.5091 -0.1537 -2.4226 -0.9043 -0.0308 -0.3524 -0.1565
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics chromatin-associated_proteins disease
H-93	-0.6846641302108765	▁prote o mics ▁chr omat in - as soci ated _ ▁protein s ▁detergent
D-93	-0.6846641302108765	proteomics chromatin-associated_ proteins detergent
P-93	-0.3726 -1.5034 -0.0096 -0.1426 -0.0270 -1.4406 -0.3715 -0.0826 -0.0045 -1.5684 -1.6651 -1.4076 -0.1272 -0.6637 -1.4820 -0.0860
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf_antagonists hf hospital admissions nbdmards ra
H-611	-0.7130767703056335	▁t NF ▁anta gon ists ▁ HF ▁n b DM ARD s ▁RA
D-611	-0.7130767703056335	tNF antagonists HF nbDMARDs RA
P-611	-0.4440 -0.4824 -4.2489 -0.0996 -1.1054 -0.5158 -0.1248 -2.2590 -0.0366 -0.3280 -0.0521 -0.1226 -0.5495 -0.2128 -0.1148
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic acute_hf adverse_event chronic_hf
H-1016	-0.6049256920814514	▁ pharma c ologic ▁management ▁a cute ▁ HF
D-1016	-0.6049256920814514	pharmacologic management acute HF
P-1016	-0.3373 -0.0484 -0.0405 -0.1712 -0.6254 -1.3677 -0.0250 -1.9286 -0.0570 -1.9567 -0.0965
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients heartmate_ii biventricular_support heartmate_ii implantation
H-300	-0.7460333704948425	▁Heart Mate _ ▁II ▁implant ation
D-300	-0.7460333704948425	HeartMate_ II implantation
P-300	-2.1398 -0.4485 -1.1219 -0.8461 -0.9116 -0.0291 -0.3140 -0.1572
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv_dysfunction body_mass_index fat_mass cachexia
H-1163	-1.2502577304840088	▁ RV _ ▁dys function ▁body _ ▁mass _ ▁index ▁figure ▁cache xia
D-1163	-1.2502577304840088	RV_ dysfunction body_ mass_ index figure cachexia
P-1163	-0.6777 -0.7207 -1.3802 -0.3081 -0.8636 -3.6517 -0.5293 -1.7188 -1.1275 -0.2108 -5.6414 -1.1403 -0.2407 -0.4160 -0.1272
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy atrial_fibrillation patients carvedilol metoprolol
H-867	-0.6405554413795471	▁at rial _ f bril lation ▁car vedi lol ▁met o pro lol
D-867	-0.6405554413795471	atrial_fbrillation carvedilol metoprolol
P-867	-2.3494 -0.1876 -0.7795 -1.9801 -1.8719 -0.0306 -1.0404 -0.2670 -0.0938 -0.2016 -0.1327 -0.0060 -0.1112 -0.4624 -0.0941
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline crf hf mortality hf
H-1775	-0.8175668716430664	▁c f ▁ HF ▁mortal ity _ risk ▁ HF
D-1775	-0.8175668716430664	cf HF mortality_risk HF
P-1775	-0.6041 -0.8677 -0.3683 -0.3924 -2.2460 -0.2238 -2.9438 -0.5581 -0.5312 -0.3478 -0.6146 -0.1130
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients chf international_classification_of_diseases
H-213	-0.20900225639343262	▁CHF ▁Disease s ▁code s
D-213	-0.20900225639343262	CHF Diseases codes
P-213	-0.5255 -0.4402 -0.0288 -0.1506 -0.0306 -0.1912 -0.0961
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise health cardiac_disease heart_failure
H-1904	-2.175370454788208	▁cardiac _ ▁disease ▁heart _ ▁failure
D-1904	-2.175370454788208	cardiac_ disease heart_ failure
P-1904	-6.5563 -3.3145 -3.1565 -1.3459 -0.7988 -1.8922 -0.2339 -0.1049
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 hno cxl-1051 t1
H-416	-0.44913867115974426	▁c XL -10 20 ▁h no ▁in active ▁c XL -10 51
D-416	-0.44913867115974426	cXL-1020 hno inactive cXL-1051
P-416	-0.7576 -1.2576 -0.2994 -0.6684 -0.6765 -0.2106 -0.1207 -0.0246 -0.3502 -0.7428 -0.3189 -0.2454 -0.4747 -0.1407
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium expression pka downstream_signaling
H-1433	-0.953852653503418	▁my o car dium _ ▁display s ▁p KA
D-1433	-0.953852653503418	myocardium_ displays pKA
P-1433	-0.5845 -0.0581 -0.0060 -0.1303 -4.1107 -1.0124 -0.2705 -1.0889 -1.5861 -1.5010 -0.1439
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests cardiac_growth disease chromatin remodeling
H-92	-0.8499241471290588	▁cardiac _ ▁growth ▁plastic ity ▁disease ▁chr omat in _ ▁remodel ing
D-92	-0.8499241471290588	cardiac_ growth plasticity disease chromatin_ remodeling
P-92	-0.1108 -1.9573 -1.3300 -1.0095 -0.4636 -0.2722 -2.2546 -0.0268 -2.2439 -1.2446 -0.0213 -0.1477 -0.7231 -0.0934
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 n2bus s12884 pevk
H-769	-1.194929838180542	▁elastic _ n 2 Bu s _ ▁segment ▁PE V K
D-769	-1.194929838180542	elastic_n2Bus_ segment PEVK
P-769	-0.8998 -0.8035 -0.5212 -0.3923 -2.2242 -0.1812 -3.3469 -0.5200 -0.8392 -3.0759 -2.2285 -0.3557 -0.1455
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait therapy lokomat heart_failure patients
H-1921	-0.7408756017684937	▁Robot - assist ed _ ▁ga it _ therapy ▁Lok omat _ system ▁heart _ ▁failure
D-1921	-0.7408756017684937	Robot-assisted_ gait_therapy Lokomat_system heart_ failure
P-1921	-0.6136 -0.2005 -0.0046 -0.7195 -0.9361 -1.3088 -0.0627 -0.9659 -0.1262 -0.1467 -0.1328 -2.9129 -2.5677 -0.4225 -0.6791 -1.0020 -0.4316 -0.1026
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil mitochondrial_dysfunction heart_failure cardioprotection
H-954	-0.5923707485198975	▁Nico rand il ▁mito cho ndri al _ ▁dys function ▁do xor ubi cin - indu ce ▁heart _ ▁failure ▁cardio protec tion
D-954	-0.5923707485198975	Nicorandil mitochondrial_ dysfunction doxorubicin-induce heart_ failure cardioprotection
P-954	-0.0009 -0.5222 -0.4884 -0.2927 -2.0429 -0.5524 -0.1192 -1.3439 -0.0775 -0.3647 -0.0248 -0.0226 -0.0283 -0.1629 -0.2833 -0.0013 -3.3239 -0.7997 -0.8071 -1.1604 -1.8085 -0.0469 -0.0098 -0.4230 -0.1019
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ras asymptomatic clinically hypertension nephropathy congestive_heart_failure
H-1597	-0.4400768578052521	RAS ▁hyper tension ▁nep hro pathy ▁con ges tive _ ▁heart _ ▁failure
D-1597	-0.4400768578052521	RAS hypertension nephropathy congestive_ heart_ failure
P-1597	-1.3329 -0.3073 -0.0010 -0.1400 -0.0255 -0.0405 -0.0839 -0.1076 -0.1754 -0.7550 -1.3093 -0.9492 -0.9794 -0.2688 -0.1252
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic admission brain_natriuretic_peptide bnp creatinine natremia
H-585	-0.8569127321243286	▁na tri ure tic _ pe pti de ▁b NP ▁creati nine ▁na trem ia
D-585	-0.8569127321243286	natriuretic_peptide bNP creatinine natremia
P-585	-4.9522 -0.0678 -0.0197 -3.2743 -0.5391 -0.2599 -0.2966 -0.4950 -0.1127 -0.3157 -0.1264 -1.0338 -0.1034 -0.0880 -2.4178 -0.3277 -0.1373
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart_failure cardiology-cardiovascular_surgery_consensus_report heart_failure disease
H-1818	-0.8726488351821899	▁heart _ ▁failure ▁mechanic al _ support ▁devices ▁Card i ology - car dio vas cular _ sur ger y _ con en sus _ ▁Report ▁Heart _ ▁failure
D-1818	-0.8726488351821899	heart_ failure mechanical_support devices Cardiology-cardiovascular_surgery_conensus_ Report Heart_ failure
P-1818	-1.3143 -1.0681 -1.0026 -0.4301 -0.0075 -1.6862 -0.8874 -0.6680 -0.2481 -0.1685 -0.9158 -0.2677 -0.7725 -1.4482 -0.9994 -0.3133 -0.7071 -0.0423 -0.1637 -0.1405 -3.9826 -0.8114 -0.3424 -0.2997 -2.2329 -1.2254 -1.1567 -0.7806 -1.4697 -1.3596 -0.1400
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart_rate_reduction exercise heart_failure_with_reduced_ejection_fraction beta-blocker
H-1935	-0.8920608162879944	▁Heart _ re duction ▁exercise ▁heart _ ▁failure ▁e je ction _ fraction ▁beta - block er
D-1935	-0.8920608162879944	Heart_reduction exercise heart_ failure ejection_fraction beta-blocker
P-1935	-0.6592 -1.3300 -1.7766 -0.0536 -3.7163 -2.0912 -0.5646 -1.5382 -1.6588 -0.2807 -0.0315 -0.8822 -0.0013 -0.3767 -0.0152 -0.1280 -0.0508 -1.6629 -0.1313
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt sd_of_rr_intervals sdrr qtv heart_rate_variability
H-1440	-1.5037384033203125	▁SD QT ▁SD ▁ RR ▁gr t ▁Q TV ▁heart ▁rate _ vari able
D-1440	-1.5037384033203125	SDQT SD RR grt QTV heart rate_variable
P-1440	-0.0558 -0.6020 -0.2565 -2.4742 -0.7054 -3.1436 -2.6496 -3.3266 -1.0504 -0.2306 -4.3315 -2.5534 -1.0484 -1.0564 -0.4180 -0.1575
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care_of_heart_failure_index_version_6.2 schfi_v.6.2 psychometric
H-1504	-0.7044156193733215	▁Self - Car e _ of _ ▁Heart _ ▁Fail ure ▁ SCH f ▁psycho metric ▁profile
D-1504	-0.7044156193733215	Self-Care_of_ Heart_ Failure SCHf psychometric profile
P-1504	-0.2896 -0.0161 -1.1455 -0.0622 -0.5724 -1.4506 -0.3036 -0.5191 -0.3289 -0.2844 -0.0622 -3.0721 -1.4788 -2.1087 -0.1181 -0.0134 -1.2248 -0.2337 -0.0996
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric_focusing riα ser77 ser83 in_vivo phosphorylation
H-1430	-1.0266631841659546	▁Iso electric _ ▁focus ing ▁RI α ▁ser 77 ▁ser 83 ▁ phos phor y lation
D-1430	-1.0266631841659546	Isoelectric_ focusing RIα ser77 ser83 phosphorylation
P-1430	-1.8892 -0.5112 -2.5914 -0.4360 -0.0681 -2.2174 -0.9759 -1.1398 -1.1464 -2.1208 -0.7472 -0.9576 -0.3193 -0.5235 -1.8018 -0.0646 -0.8428 -0.1267
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient functional_ms patient valve_plasty degenerative_mr dilated disease
H-367	-0.48832014203071594	▁functional ▁MS ▁val ve ▁plast y ▁de genera tive ▁MR ▁LV
D-367	-0.48832014203071594	functional MS valve plasty degenerative MR LV
P-367	-0.5421 -0.2524 -0.8060 -0.0337 -0.6368 -0.4959 -1.0810 -0.2950 -0.0181 -0.5971 -0.0968 -1.4223 -0.0710
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end_stage_heart_failure heart_failure public health patient europe north_america
H-1663	-1.399404764175415	▁management _ de _ ▁end _ heart _ ▁failure ▁Heart _ ▁failure ▁public _ ▁health
D-1663	-1.399404764175415	management_de_ end_heart_ failure Heart_ failure public_ health
P-1663	-2.9247 -1.0476 -1.1136 -0.1203 -1.3048 -0.3654 -4.6955 -0.8164 -1.2029 -3.1963 -0.8841 -1.3713 -0.2254 -0.5244 -1.0297 -2.8136 -0.1536
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient st-segment-elevation_mis killip_class comorbid conditions
H-1105	-0.27105724811553955	▁st - seg ment - elevat ion ▁MI s ▁Kill ip ▁conditions
D-1105	-0.27105724811553955	st-segment-elevation MIs Killip conditions
P-1105	-1.4440 -0.1358 -0.0080 -0.0521 -0.1403 -0.0262 -0.0361 -1.2929 -0.0520 -0.1479 -0.1616 -0.0145 -0.1538 -0.1298
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology myocardial_infarction mi outcomes heart_failure hf
H-1099	-0.9799133539199829	▁my o card ial _ ▁in far ction ▁m ▁heart _ ▁failure HF
D-1099	-0.9799133539199829	myocardial_ infarction m heart_ failureHF
P-1099	-3.4577 -0.2625 -0.2118 -0.2611 -0.5194 -1.0259 -3.0085 -0.0870 -1.4224 -0.9382 -0.9726 -1.7421 -0.4536 -0.1975 -0.1387
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial_elastance ea pulsatile_afterload heart pressure_volume_relation
H-517	-0.7884123921394348	▁arterial _ ▁elastan ce ▁pulsa tile _ ▁after load ▁heart ▁pressure
D-517	-0.7884123921394348	arterial_ elastance pulsatile_ afterload heart pressure
P-517	-0.8503 -1.6644 -0.1571 -0.4989 -0.2896 -0.1255 -1.2814 -2.1932 -0.0317 -2.2545 -0.3824 -0.4380 -0.0824
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated baseline nt-probnp mr-proanp mr-proadm
H-17	-0.47135111689567566	▁NT - pro b NP ▁MR - pro AN p ▁MR - pro AD m
D-17	-0.47135111689567566	NT-probNP MR-proANp MR-proADm
P-17	-0.8364 -0.0208 -0.0183 -0.6584 -0.3986 -0.1196 -0.0294 -0.0270 -3.1542 -0.4414 -0.1573 -0.0273 -0.0673 -1.7088 -0.0230 -0.2000 -0.1252
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect heart_failure patients implantable_cardioverter-defibrillator
H-1860	-0.7025713324546814	▁implant able _ ▁cardio ver ter - de _ fi br illa tor
D-1860	-0.7025713324546814	implantable_ cardioverter-de_fibrillator
P-1860	-0.5367 -0.0734 -1.7091 -0.4652 -0.1463 -0.0228 -0.1828 -0.0074 -3.4561 -2.4040 -0.5395 -0.0084 -0.3061 -0.5534 -0.1273
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate left_ventricular_assist_system lvas patients heart_failure
H-1993	-1.0673584938049316	▁Heart Mate ▁left _ vent ri cular _ assist _ system ▁l VAS ▁heart _ ▁failure
D-1993	-1.0673584938049316	HeartMate left_ventricular_assist_system lVAS heart_ failure
P-1993	-0.8695 -0.8992 -1.4185 -0.8792 -0.9259 -0.8813 -0.2834 -0.3314 -0.2165 -2.8564 -0.5231 -1.0775 -0.1251 -3.6805 -1.2998 -2.6616 -0.1863 -0.0975
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed patients hf drug_treatment paf biosynthetic_enzymes lyso-paf-at
H-1271	-0.6135645508766174	▁h f ▁PA f ▁bio syn the tic ▁enzym es ▁lys o - pa f - AT
D-1271	-0.6135645508766174	hf PAf biosynthetic enzymes lyso-paf-AT
P-1271	-2.2168 -1.0292 -2.3164 -0.0986 -0.1976 -0.0010 -0.6323 -2.2382 -0.6634 -0.1502 -0.0217 -0.0228 -0.0155 -1.0268 -0.0601 -0.1853 -0.3486 -0.3020 -0.1312
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 sst2 outcomes
H-406	-1.1975191831588745	▁s st 2/ low - dos e ▁BB ▁s st 2/ high - dos e ▁BB
D-406	-1.1975191831588745	sst2/low-dose BB sst2/high-dose BB
P-406	-0.5152 -1.9574 -3.5581 -1.9452 -0.0103 -1.9954 -0.2933 -1.2866 -0.5295 -1.9491 -0.8212 -1.9808 -0.0308 -1.2815 -0.1889 -2.8957 -0.1593 -0.1569
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence hf ami mortality
H-1314	-0.6587222218513489	▁ HF ▁complicat ing ▁ AMI ▁mortal ity
D-1314	-0.6587222218513489	HF complicating AMI mortality
P-1314	-1.7692 -0.3759 -1.7034 -0.1040 -0.8049 -0.0718 -1.1556 -0.3467 -0.1662 -0.0895
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin genomic_reprogramming disease
H-100	-0.5041963458061218	▁zebra fish ▁nu cle olin ▁genom ic _ re programm ing
D-100	-0.5041963458061218	zebrafish nucleolin genomic_reprogramming
P-100	-0.2908 -0.1519 -0.4125 -0.0063 -0.8823 -0.1371 -0.4776 -0.7191 -0.6233 -0.2038 -0.2866 -2.2733 -0.0900
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients t1_times cardiac_events
H-740	-1.4503552913665771	▁cardiac ▁events
D-740	-1.4503552913665771	cardiac events
P-740	-2.2771 -3.2048 -0.2256 -0.0940
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv_ejection_fraction pcwp
H-483	-0.4455011487007141	▁LV ▁e je ction _ fraction ▁PC WP ▁h g
D-483	-0.4455011487007141	LV ejection_fraction PCWP hg
P-483	-0.1203 -1.8183 -0.4893 -0.0529 -0.5341 -0.0018 -1.4550 -0.4923 -0.1379 -0.0223 -0.1359 -0.0858
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf chf patients intubated
H-214	-1.1865514516830444	▁CHF ▁ed ▁visit s ▁CHF ▁patients ▁in tuba ted
D-214	-1.1865514516830444	CHF ed visits CHF patients intubated
P-214	-0.4253 -3.8817 -3.9704 -0.2322 -0.3801 -1.6252 -1.4527 -0.0233 -0.7464 -0.2365 -0.0782
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate_analysis gls
H-817	-1.4811028242111206	▁gr s ▁h ▁CV
D-817	-1.4811028242111206	grs h CV
P-817	-0.4883 -2.7251 -2.8330 -1.9267 -0.6810 -0.2326
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr vad ecmo vad renal_function
H-1391	-1.1670631170272827	▁e g f ▁ VAD ▁EC mo + VAD ▁renal
D-1391	-1.1670631170272827	egf VAD ECmo+VAD renal
P-1391	-0.0735 -0.7732 -0.9966 -0.4554 -0.0597 -2.2980 -1.7854 -3.3707 -0.0464 -0.7507 -3.2371 -0.1580
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician mortality hf physicians
H-1731	-0.7079939246177673	▁Physic ian _ ▁volume ▁h f ▁non car dio logist ▁physician s
D-1731	-0.7079939246177673	Physician_ volume hf noncardiologist physicians
P-1731	-0.7328 -1.0586 -0.7321 -0.9335 -1.6222 -0.5885 -1.2201 -0.0320 -0.6265 -0.1961 -1.7523 -0.0466 -0.2867 -0.0839
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ejection_fraction
H-1236	-0.5234462022781372	▁e je ction _ fraction
D-1236	-0.5234462022781372	ejection_fraction
P-1236	-1.4841 -1.2529 -0.0624 -0.4523 -0.0056 -0.2561 -0.1507
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality hospitals
H-1695	-0.7121714949607849	▁risk - ad just ed ▁mortal ity
D-1695	-0.7121714949607849	risk-adjusted mortality
P-1695	-2.8317 -0.0489 -0.0145 -0.0013 -0.3769 -0.8655 -0.5467 -1.5503 -0.1738
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized exercise exercise
H-1981	-1.1844216585159302	
D-1981	-1.1844216585159302	
P-1981	-2.2867 -0.0821
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses magnet
H-87	-1.8670306205749512	
D-87	-1.8670306205749512	
P-87	-3.6070 -0.1271
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician evidence
H-1842	-0.7270745038986206	▁physician ▁ad her ence
D-1842	-0.7270745038986206	physician adherence
P-1842	-0.4409 -2.0367 -0.1267 -0.0186 -1.6254 -0.1141
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-868	-0.4769222140312195	▁m ADI t - c RT ▁multi center _ automat ic _ de ib rilla tor ▁implant ation ▁Card iac _ re syn chron ization _ ▁Therapy
D-868	-0.4769222140312195	mADIt-cRT multicenter_automatic_deibrillator implantation Cardiac_resynchronization_ Therapy
P-868	-0.6856 -0.7780 -0.1090 -0.0078 -0.1647 -1.5997 -0.4351 -0.0220 -0.1201 -0.1418 -0.1546 -0.5778 -0.7194 -1.8370 -0.2350 -0.1033 -0.0733 -0.0149 -0.3425 -0.1173 -0.5789 -0.3417 -0.0118 -0.0004 -1.0859 -1.7502 -0.7135 -1.0209 -0.0885
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic tests cardiac_magnetic_resonance_imaging t1_mapping invasive_hemodynamic_assessments baseline
H-737	-0.8459670543670654	▁cardiac _ ▁magnetic _ ▁res on ance _ ▁imagin g ▁invasi ve _ hem o dynamic ▁assessment s
D-737	-0.8459670543670654	cardiac_ magnetic_ resonance_ imaging invasive_hemodynamic assessments
P-737	-0.1052 -1.1719 -1.0528 -1.4844 -1.7891 -0.0997 -0.0590 -1.3785 -0.2559 -0.0229 -2.0118 -0.7602 -0.3753 -2.7639 -0.2927 -0.0459 -2.6221 -0.1216 -0.3880 -0.1185
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity mortality hfpef patients hf reduced_ef
H-1301	-0.7346610426902771	▁Morbi d ity ▁mortal ity ▁ HF p EF ▁ HF ▁ef
D-1301	-0.7346610426902771	Morbidity mortality HFpEF HF ef
P-1301	-0.1183 -0.0873 -0.4515 -2.5240 -0.2879 -1.1413 -0.1126 -0.1620 -0.3282 -2.0089 -0.2265 -2.3043 -0.4617 -0.0709
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic_regression primary_outcome secondary_outcome death
H-973	-0.7943999171257019	▁Log istic _ re gression
D-973	-0.7943999171257019	Logistic_regression
P-973	-0.1796 -0.0779 -0.5514 -0.6642 -0.0171 -3.9543 -0.1164
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence intravenous exercise_tolerance quality_of_life patients heart_failure
H-46	-1.7000292539596558	▁intra ven ous _ ▁ir on
D-46	-1.7000292539596558	intravenous_ iron
P-46	-3.7451 -0.0510 -4.0534 -1.3903 -0.4233 -0.0820 -3.7717 -0.0833
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency_department acute_heart_failure clinical patient collins
H-56	-1.0132465362548828	▁emergency ▁department ▁a cute _ heart _ ▁failure
D-56	-1.0132465362548828	emergency department acute_heart_ failure
P-56	-1.0778 -1.4768 -0.1951 -0.0182 -0.1668 -2.6337 -0.6241 -1.5794 -2.2323 -0.1281
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence biomarkers pathophysiology chronic_hf therapeutic
H-1474	-0.6243420839309692	▁molecular ▁bio mark ers ▁pat ho phy si ology ▁chronic ▁ HF
D-1474	-0.6243420839309692	molecular biomarkers pathophysiology chronic HF
P-1474	-0.7924 -1.1660 -0.0183 -0.0802 -0.5902 -0.1239 -0.0217 -0.3704 -0.7939 -2.7587 -0.6757 -0.0918 -1.1230 -0.1345
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet bromodomain-containing_protein_4 brd4 cardiac
H-1045	-0.8518040180206299	▁ BET _ bro modo main - conta ining _ ▁protein BR d 4 ▁cardiac
D-1045	-0.8518040180206299	BET_bromodomain-containing_ proteinBRd4 cardiac
P-1045	-2.0050 -0.1318 -3.3542 -1.0162 -0.0125 -0.1248 -0.2139 -0.2617 -0.2886 -1.0169 -0.3801 -0.3031 -0.3289 -2.1776 -0.0415 -2.7053 -0.1184
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission hospital congestive_heart_failure united_states
H-1574	-1.061914086341858	▁hospital _ ▁stay ▁con ges tive _ ▁heart _ ▁failure
D-1574	-1.061914086341858	hospital_ stay congestive_ heart_ failure
P-1574	-5.2047 -0.5486 -2.8896 -0.3572 -0.1301 -0.1567 -0.2235 -1.4060 -0.5226 -0.7919 -0.3838 -0.1284
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs septal qrs resynchronization
H-486	-0.9748126864433289	▁a UC s ▁e sept al ▁e eme an sept al ▁QR s ▁re syn chron ization
D-486	-0.9748126864433289	aUCs eseptal eemeanseptal QRs resynchronization
P-486	-1.7033 -0.1763 -0.1961 -0.8606 -0.4532 -0.2596 -1.8975 -5.7759 -0.3950 -0.0816 -0.1805 -0.4482 -1.9581 -2.2323 -0.0120 -0.0003 -1.2905 -0.3893 -0.2113
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart_failure hf risk_stratification inpatient outpatient
H-378	-1.092323660850525	▁heart _ ▁failure HF ▁in patient
D-378	-1.092323660850525	heart_ failureHF inpatient
P-378	-0.6886 -0.7209 -1.6207 -0.6348 -2.0715 -0.0599 -2.8222 -0.1200
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective diuretics morbidity mortality
H-1200	-0.6805374622344971	▁di ure tics ▁ HF
D-1200	-0.6805374622344971	diuretics HF
P-1200	-0.1248 -0.1366 -1.2867 -1.4927 -0.1208 -1.5168 -0.0852
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc_occlusion correlated rs rs_synchrony
H-326	-0.46644991636276245	▁IV c ▁oc clusi on ▁co ▁cor related ▁twist ▁ap ical ▁ro tation ▁RS ▁synchron y ▁CS
D-326	-0.46644991636276245	IVc occlusion co correlated twist apical rotation RS synchrony CS
P-326	-0.0506 -0.5096 -0.0286 -0.0214 -0.1662 -1.7616 -0.1296 -0.6105 -1.6142 -0.5802 -0.1998 -0.6642 -0.0031 -0.1594 -0.1829 -0.1815 -1.7725 -0.1308 -0.0960
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol metoprolol therapy heart_failure patients
H-857	-0.4332033395767212	▁car vedi lol ▁met o pro lol ▁heart _ ▁failure ▁devices
D-857	-0.4332033395767212	carvedilol metoprolol heart_ failure devices
P-857	-0.8332 -0.1895 -0.0881 -0.0841 -0.1440 -0.0073 -0.2478 -1.1332 -0.9538 -0.8444 -0.8567 -0.1581 -0.0914
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health_care clinically gastrointestinal_bleeding
H-1658	-0.7811409831047058	▁devices ▁gastro inte stin al _ ▁ble ed ing
D-1658	-0.7811409831047058	devices gastrointestinal_ bleeding
P-1658	-3.4782 -1.2701 -0.0289 -0.6943 -0.2053 -0.9583 -0.5090 -0.6477 -0.4549 -0.2840 -0.0619
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital readmission patients heart_failure follow-up
H-731	-1.8573744297027588	▁read mission _ ▁rate ▁patients _ with _ ▁heart _ ▁failure
D-731	-1.8573744297027588	readmission_ rate patients_with_ heart_ failure
P-731	-8.3040 -0.0564 -2.3594 -1.0740 -2.2967 -0.9535 -4.4328 -0.4028 -1.6629 -0.4418 -1.4852 -0.5092 -0.1673
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians public health air cardiovascular health lead hospitalisation death
H-1808	-0.9674146771430969	▁public _ ▁health ▁air ▁pollution
D-1808	-0.9674146771430969	public_ health air pollution
P-1808	-1.0141 -0.9604 -1.0299 -0.0169 -0.3171 -3.2568 -0.1767
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare inpatient hf admissions acute hospitals united_states
H-1723	-0.6903087496757507	▁Medica re ▁in patient ▁ HF ▁a cute _ care ▁hospital s
D-1723	-0.6903087496757507	Medicare inpatient HF acute_care hospitals
P-1723	-0.0447 -0.0070 -1.0528 -0.0922 -1.8219 -0.3924 -1.9183 -0.0955 -0.4781 -1.6745 -0.9265 -0.0733 -0.9799 -0.1074
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping tidal_respiration administration gadolinium-chelate_contrast_agent
H-1058	-0.7553315162658691	▁t 1- ma pping _ se que nce ▁tid al _ ▁respira tion ▁ gado lini um - che late _ ▁contrast
D-1058	-0.7553315162658691	t1-mapping_sequence tidal_ respiration gadolinium-chelate_ contrast
P-1058	-3.6188 -0.9910 -0.5255 -0.3236 -0.7071 -1.5155 -0.1469 -0.0007 -0.2888 -0.0350 -0.8272 -0.2109 -0.0177 -0.2333 -0.2702 -0.2341 -0.2409 -0.1363 -0.1189 -2.3795 -0.5659 -2.4221 -2.1324 -0.1857
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf heart_failure t2d type_2_diabetes skm skeletal_muscle
H-1244	-0.6211930513381958	HF heart _ ▁failure ▁t 2 d ▁diabetes ▁Sk m ▁muscle
D-1244	-0.6211930513381958	HFheart_ failure t2d diabetes Skm muscle
P-1244	-0.2378 -1.7727 -0.5780 -0.1364 -0.7587 -0.0165 -0.2589 -0.3815 -0.1651 -0.0272 -3.1963 -0.4544 -0.0918
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction
H-941	-0.6257596611976624	▁cat heter ▁ab lation ▁at rial _ ▁fi bril lation ▁heart _ ▁failure ▁e je ction _ fraction
D-941	-0.6257596611976624	catheter ablation atrial_ fibrillation heart_ failure ejection_fraction
P-941	-0.2596 -0.0786 -0.9786 -0.0147 -1.2542 -0.4583 -0.7401 -3.5260 -0.0879 -0.0125 -0.4721 -0.8076 -0.9151 -1.0141 -0.6370 -0.0791 -0.7384 -0.0069 -0.2842 -0.1503
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine nesiritide acute_heart_failure renal_dysfunction rose acute_heart_failure randomized
H-71	-0.6036357283592224	▁dop amine ▁nesi riti de ▁a cute _ ▁heart _ ▁failure ▁renal ▁dys function ▁RO se ▁a cute _ ▁heart _ ▁failure
D-71	-0.6036357283592224	dopamine nesiritide acute_ heart_ failure renal dysfunction ROse acute_ heart_ failure
P-71	-1.9044 -0.0832 -0.1093 -0.0573 -0.0691 -0.5011 -0.0253 -0.4757 -1.9648 -0.5627 -0.5259 -0.1670 -0.9533 -0.3721 -1.4713 -0.4449 -0.2330 -0.0390 -0.0895 -2.4204 -0.3406 -1.3071 -0.2550 -0.1152
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary_exercise_test quality_of_life muscular peak_quadriceps_force
H-1915	-1.3143208026885986	▁cardio pul mon ary _ ▁exercise ▁muscular _ ▁strength ▁pe ak _ ▁quadri cep s _ force
D-1915	-1.3143208026885986	cardiopulmonary_ exercise muscular_ strength peak_ quadriceps_force
P-1915	-0.0514 -0.2959 -3.2442 -1.9672 -1.4522 -1.8401 -4.4772 -1.5910 -1.5615 -2.9337 -0.3489 -0.3521 -1.6090 -0.0089 -0.0926 -1.1727 -1.5061 -0.3232 -0.1442
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report dapc dystrophin-associated_protein_complex sarcomeric_microstructure baseline
H-1253	-0.7153860926628113	▁DAP c dys trop hin - as soci ated ▁protein _ ▁complex ▁sar come ric _ micro structure
D-1253	-0.7153860926628113	DAPcdystrophin-associated protein_ complex sarcomeric_microstructure
P-1253	-0.1703 -0.4890 -1.1979 -0.0226 -1.1180 -0.2300 -0.0936 -0.0033 -1.1280 -1.5551 -0.7662 -0.2286 -0.0200 -1.0414 -3.2086 -1.2644 -0.8686 -0.6075 -0.2057 -0.0888
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf pyridostigmine basal_heart_rate sympathetic_control_of_heart_rate
H-1140	-0.7965272068977356	▁ HF ▁rat s ▁py rido stig mine ▁bas al _ ▁heart _ ▁rate ▁va gal ▁sympa the tic _ control _ de _ ▁heart
D-1140	-0.7965272068977356	HF rats pyridostigmine basal_ heart_ rate vagal sympathetic_control_de_ heart
P-1140	-1.6756 -0.6210 -4.0035 -0.0461 -0.0581 -0.0214 -0.0016 -0.2330 -0.2022 -0.0617 -0.7874 -1.8564 -1.7550 -0.5760 -0.0176 -0.0078 -0.3251 -0.3706 -1.1811 -1.0678 -0.0842 -1.0485 -1.2823 -0.1834 -1.7829 -2.1019 -0.1539
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg congenital accessory ion_channelopathies cardiomyopathy
H-1909	-0.7042075991630554	▁e CG ▁ion _ ▁channel o pathi es ▁cardio my o pathy
D-1909	-0.7042075991630554	eCG ion_ channelopathies cardiomyopathy
P-1909	-0.2061 -0.6534 -3.5714 -0.8055 -1.0055 -1.2017 -0.0846 -0.1021 -0.2290 -1.3353 -0.2471 -0.0463 -0.2713 -0.0996
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras neprilysin_inhibition change stable chronic_heart_failure systolic_dysfunction
H-1971	-0.8896462321281433	▁ RAS ▁nepri ly sin _ ▁inhibi tion ▁chronic ▁heart _ ▁failure ▁sy sto lic _ ▁dys function
D-1971	-0.8896462321281433	RAS neprilysin_ inhibition chronic heart_ failure systolic_ dysfunction
P-1971	-0.8991 -0.0315 -0.8396 -0.1236 -0.9570 -1.2253 -0.0655 -0.0231 -3.5323 -1.5755 -1.1321 -0.8977 -0.2118 -0.2827 -4.0146 -0.5091 -0.2889 -0.3261 -0.6517 -0.2056
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf hhd salt_loading uninephrectomy ang_ii_infusion
H-275	-0.7027899622917175	▁mouse ▁ HF ▁h h ▁h d ▁salt _ ▁load ing ▁un ine ph r ecto my ▁ANG _ ▁II ▁in fusion
D-275	-0.7027899622917175	mouse HF hh hd salt_ loading uninephrectomy ANG_ II infusion
P-275	-0.4659 -1.7749 -0.0587 -0.0966 -1.3164 -0.3911 -1.8348 -1.5225 -1.9685 -0.0998 -0.0344 -0.1205 -0.1878 -3.1247 -0.1315 -0.0880 -1.3313 -0.1481 -0.8817 -0.7856 -0.0893 -0.0356 -0.2798 -0.0995
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf_with_preserved_ejection_fraction pef uptitration hospitalization
H-176	-0.5650320053100586	▁Bene fit s ▁ HF ▁e je ction _ fraction ▁p EF
D-176	-0.5650320053100586	Benefits HF ejection_fraction pEF
P-176	-2.3947 -0.1049 -0.0154 -0.6974 -0.1631 -0.6905 -0.8046 -0.1362 -0.3760 -0.0110 -0.5149 -0.5367 -1.3459 -0.1192
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs québec_health_insurance_board costs ontario_case_costing_initiative
H-1235	-0.8062689304351807	▁in - t rial ▁costs ▁Québec ▁Health ▁Insurance ▁Board ▁disease - specific ▁costs ▁Ontario ▁Case _ ▁Cost ing
D-1235	-0.8062689304351807	in-trial costs Québec Health Insurance Board disease-specific costs Ontario Case_ Costing
P-1235	-0.0853 -0.8600 -0.2818 -0.0491 -3.4464 -0.3929 -1.4105 -0.5159 -0.5135 -3.9582 -0.0597 -0.1151 -0.3488 -0.2663 -0.1849 -1.2868 -0.2124 -0.2973 -1.7555 -0.0848
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients idiopathic_dilated_cardiomyopathy tuscany evidence-based
H-1739	-0.49723583459854126	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁tu sca ny
D-1739	-0.49723583459854126	idiopathic_ dilated_ cardiomyopathy tuscany
P-1739	-1.3714 -0.1213 -0.1329 -0.1698 -0.5219 -0.2643 -0.4585 -0.3164 -0.2133 -2.2103 -0.8329 -0.0277 -0.5342 -0.0092 -0.0689 -1.1128 -0.0871
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating_agents patients anemia heart_disease
H-52	-0.9100059270858765	▁Er y thro po ies is - stimul ating ▁agents ▁an emia ▁heart
D-52	-0.9100059270858765	Erythropoiesis-stimulating agents anemia heart
P-52	-4.1120 -0.1402 -0.8944 -1.8947 -1.3863 -0.3043 -0.1261 -0.0333 -1.5411 -0.4447 -0.6570 -0.1613 -0.3664 -1.4914 -0.0967
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report mitral_valve_plasty degenerative_mitral_regurgitation
H-335	-0.5860095620155334	▁mit ral _ ▁val ve ▁plast y ▁de genera tive _ ▁mit ral _ re gur gi tation
D-335	-0.5860095620155334	mitral_ valve plasty degenerative_ mitral_regurgitation
P-335	-1.4172 -0.0187 -1.0000 -0.9082 -0.1694 -0.4464 -0.4469 -1.4084 -0.6551 -0.0437 -1.2995 -1.9973 -0.0392 -0.4570 -0.8632 -0.0140 -0.0308 -0.0906 -0.3020 -0.1126
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial titin_hypophosphorylation heart_failure_with_preserved_ejection_fraction metabolic
H-759	-0.49339497089385986	▁My o card ial ▁titi n ▁hypo phos phor y lation ▁heart _ ▁failure ▁e je ction _ fraction ▁rat ▁metabol ic
D-759	-0.49339497089385986	Myocardial titin hypophosphorylation heart_ failure ejection_fraction rat metabolic
P-759	-0.3577 -0.0688 -0.0532 -0.1785 -2.3549 -0.0574 -0.1248 -0.3393 -0.3166 -1.2273 -0.0173 -0.0904 -0.8799 -0.9480 -0.9495 -0.1420 -0.0170 -0.6030 -0.0048 -0.0534 -0.1298 -0.0402 -2.7231 -0.1644
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients hfpef kccq health prognostic
H-791	-0.7374529242515564	▁ HF p EF ▁k cc q
D-791	-0.7374529242515564	HFpEF kccq
P-791	-1.2579 -0.5475 -0.0741 -0.5716 -0.2404 -0.0333 -0.7749 -3.0479 -0.0895
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf mi reduced_ejection_fraction ef
H-1100	-0.911337673664093	▁ HF ▁MI ▁pres er ved ▁e je ction _ fraction EF
D-1100	-0.911337673664093	HF MI preserved ejection_fractionEF
P-1100	-2.8426 -0.2652 -2.6903 -1.6349 -0.0253 -1.5835 -0.5206 -0.7245 -0.1027 -0.6279 -0.0331 -1.2497 -0.2882 -0.1703
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd diuretic peripheral_edema functional_class
H-899	-1.0085840225219727	▁PD ▁di ure tic ▁ed ema ▁functional
D-899	-1.0085840225219727	PD diuretic edema functional
P-899	-0.9743 -4.2042 -0.0683 -1.6977 -0.5031 -0.0305 -0.6305 -0.8717 -0.0969
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients baseline serum_creatinine serum_potassium
H-441	-0.9521811604499817	▁se rum _ ▁creati nine ▁se rum _ ▁po tas s ium
D-441	-0.9521811604499817	serum_ creatinine serum_ potassium
P-441	-3.2428 -0.6168 -0.5597 -2.0534 -1.3668 -0.7079 -0.3770 -0.5918 -2.0413 -0.5473 -0.5147 -0.1798 -0.3663 -0.1651
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv_failure diagnostic left_ventricular_dysfunction
H-1093	-0.882086455821991	▁ RV ▁vent ri cular ▁dys function
D-1093	-0.882086455821991	RV ventricular dysfunction
P-1093	-0.5637 -0.6804 -3.9706 -0.2591 -0.2220 -1.2134 -0.5711 -0.2939 -0.1644
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality inpatient admissions hospital emergency_department
H-1623	-0.8716798424720764	▁Mor t ality ▁in patient _ ad missions ▁hospital _ ▁days ▁emergency ▁department _ de _ ED
D-1623	-0.8716798424720764	Mortality inpatient_admissions hospital_ days emergency department_de_ED
P-1623	-1.0024 -0.0264 -0.2913 -1.1758 -0.2448 -0.9849 -0.1821 -0.0142 -0.5915 -1.7980 -1.7224 -0.2327 -2.1148 -1.4680 -2.5268 -0.4826 -1.2989 -0.2641 -0.1402
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic_heart_failure yield atrial cells
H-1334	-0.8640708327293396	▁Chro nic _ heart _ ▁failure ▁transform ing ▁growth _ factor _ ▁beta - dependent _ ▁yi eld ▁at rial ▁ex plant - der i ved ▁c - K it
D-1334	-0.8640708327293396	Chronic_heart_ failure transforming growth_factor_ beta-dependent_ yield atrial explant-derived c-Kit
P-1334	-0.4138 -0.4156 -0.4424 -2.3978 -1.2110 -1.0396 -0.5086 -0.1443 -1.8506 -2.6012 -1.2031 -1.5247 -1.0816 -0.0096 -0.1347 -1.6592 -2.9480 -0.0027 -4.0160 -0.0465 -0.8514 -0.0064 -0.1511 -0.0551 -0.1001 -0.5503 -0.0398 -0.2357 -1.0067 -0.0381 -0.8139 -0.1508
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia patients chronic_heart_failure hf prevalence outcomes
H-834	-1.1081485748291016	▁an emia ▁chronic _ ▁heart _ ▁failure HF
D-834	-1.1081485748291016	anemia chronic_ heart_ failureHF
P-834	-0.9502 -0.0460 -4.0736 -0.6091 -2.0937 -0.7148 -1.3383 -0.4543 -0.6666 -0.1349
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients heartmate_ii lvad centrimag rvad
H-298	-0.8370230197906494	▁Heart Mate _ ▁II ▁l VAD ▁Centri Mag _ r VAD
D-298	-0.8370230197906494	HeartMate_ II lVAD CentriMag_rVAD
P-298	-1.3302 -0.3027 -0.8411 -1.0712 -3.2085 -0.0128 -0.4503 -0.8709 -0.8815 -1.2411 -0.0255 -0.5114 -0.1341
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change readmission follow-up follow-up
H-724	-1.0648937225341797	▁read mission
D-724	-1.0648937225341797	readmission
P-724	-2.7805 -0.1165 -1.2802 -0.0824
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic crt
H-428	-0.8963277339935303	▁e cho car dio graphic ▁score ▁c RT
D-428	-0.8963277339935303	echocardiographic score cRT
P-428	-2.5118 -1.3435 -0.0902 -0.5843 -0.6570 -1.7751 -0.2281 -1.2518 -0.3800 -0.1414
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence economic lvad outcomes
H-317	-0.8297208547592163	▁économique ▁models ▁l VAD
D-317	-0.8297208547592163	économique models lVAD
P-317	-0.2781 -1.7169 -2.5388 -0.0516 -0.3042 -0.0887
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection_fraction patients
H-909	-0.8959173560142517	▁e je ction _ fraction
D-909	-0.8959173560142517	ejection_fraction
P-909	-3.4098 -1.4973 -0.0682 -0.5237 -0.0032 -0.6241 -0.1451
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized af_ablation
H-953	-0.4312764108181	▁AF ▁ab lation
D-953	-0.4312764108181	AF ablation
P-953	-1.4061 -0.3720 -0.0370 -0.1877 -0.1535
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac insulin-resistance mitochondrial_energy_production systolic_heart_failure pressure-overload_hypertrophy
H-1777	-0.5654937624931335	▁Card iac ▁insulin - re si stance ▁mito cho ndri al _ énergie ▁heart _ ▁failure ▁pressure - over load ▁hyper trop hy
D-1777	-0.5654937624931335	Cardiac insulin-resistance mitochondrial_énergie heart_ failure pressure-overload hypertrophy
P-1777	-0.1600 -0.0745 -0.6230 -0.0569 -0.1060 -0.2271 -0.0002 -0.0398 -1.3780 -0.2808 -0.0822 -1.0505 -0.4217 -4.5134 -1.0626 -1.9653 -0.0901 -0.1955 -0.2687 -0.0839 -0.9897 -0.0016 -0.0484 -0.2811 -0.1364
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel_inhibition hemodynamic exercise_tolerance heart_failure_with_preserved_ejection_fraction randomized
H-1170	-0.8696048259735107	▁If - chan nel _ ▁inhibi tion ▁hem o dynamic ▁ tolerance ▁heart _ ▁failure ▁e je ction _ fraction
D-1170	-0.8696048259735107	If-channel_ inhibition hemodynamic tolerance heart_ failure ejection_fraction
P-1170	-4.3315 -0.0462 -0.1951 -0.0345 -2.2184 -0.1693 -0.0466 -0.2640 -0.1775 -0.0616 -4.2127 -1.4655 -0.2065 -0.9272 -1.3525 -1.5238 -0.4308 -0.0440 -1.0134 -0.0046 -0.3080 -0.0975
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients heart_failure heart_failure nurses follow-up cardiology mortality
H-1896	-0.7846587300300598	▁heart _ ▁failure ▁nurse s ▁card i ology ▁services ▁mortal ity
D-1896	-0.7846587300300598	heart_ failure nurses cardiology services mortality
P-1896	-2.3205 -0.8047 -0.9794 -2.1465 -0.0268 -0.8181 -0.2453 -0.7691 -0.4276 -0.9392 -0.3159 -0.2436 -0.1639
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline follow-up paf activity metabolic enzymes patients heart_failure healthy
H-1266	-0.7109311819076538	▁PA f ▁metabol ic _ ▁enzym es ▁heart _ ▁failure
D-1266	-0.7109311819076538	PAf metabolic_ enzymes heart_ failure
P-1266	-1.6642 -0.0689 -0.5130 -0.1897 -1.3471 -0.7669 -0.1025 -0.7950 -0.8117 -1.6801 -0.4176 -0.1746
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 hearts beta-adrenergic_responses cardiomyocytes
H-1207	-0.5192874670028687	▁Pho s pho dies tera se -2 ▁fail ing ▁heart s ▁blu nts ▁beta - ad r energi c ▁cardio my o cy tes
D-1207	-0.5192874670028687	Phosphodiesterase-2 failing hearts blunts beta-adrenergic cardiomyocytes
P-1207	-0.3513 -0.1168 -0.7194 -1.3961 -0.1011 -0.0897 -1.8901 -3.3063 -0.4481 -0.9131 -0.0593 -0.3224 -0.0334 -0.1888 -0.0084 -0.1151 -0.0956 -0.2759 -0.2400 -0.3059 -0.6893 -0.3997 -0.1599 -0.7368 -0.3514 -0.1876
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab adjuvant outcomes cardiotoxicity congestive_heart_failure chf
H-670	-0.48451122641563416	▁tras tuz um ab ▁cardio toxic ity ▁con ges tive _ ▁heart _ ▁failure ▁ch f
D-670	-0.48451122641563416	trastuzumab cardiotoxicity congestive_ heart_ failure chf
P-670	-0.1320 -0.0080 -0.0136 -0.1417 -0.0495 -0.3591 -0.7132 -0.1224 -0.0457 -0.2143 -0.5760 -1.4992 -0.6959 -1.2306 -2.6490 -0.0633 -0.1161 -0.0916
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin protein-c phosphorylation troponin_i phosphorylation hf
H-1427	-0.7074117660522461	▁my os in _ binding _ ▁protein - c ▁ phos phor y lation ▁ser 23 /24 ▁trop onin _ ▁I ▁ phos phor y lation HF
D-1427	-0.7074117660522461	myosin_binding_ protein-c phosphorylation ser23/24 troponin_ I phosphorylationHF
P-1427	-0.7334 -0.1823 -1.2646 -1.3414 -0.0553 -1.6987 -0.4379 -0.0948 -0.6743 -0.2471 -0.0446 -0.4402 -2.2943 -0.0467 -2.0276 -1.2182 -0.1031 -0.0497 -0.2292 -1.4104 -1.7701 -0.2740 -0.2476 -0.4531 -1.7744 -0.0675 -1.0639 -0.1320 -0.1386
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative renal_dysfunction stroke myocardial_infarction heart_failure cabg
H-970	-0.6010711789131165	▁renal ▁dys function ▁stroke ▁my o card ial _ ▁in far ction ▁heart _ ▁failure ▁CA BG
D-970	-0.6010711789131165	renal dysfunction stroke myocardial_ infarction heart_ failure CABG
P-970	-1.2090 -1.0177 -0.4945 -0.2811 -1.3006 -0.2346 -0.1320 -0.1906 -1.0990 -0.5771 -1.6152 -0.0782 -0.5902 -0.8854 -0.5490 -0.9200 -0.0704 -0.0723 -0.1038
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine administration methylatropine propranolol cardiac sympathovagal_balance
H-1138	-0.5289134383201599	▁py rido stig mine ▁met hy la tropi ne ▁propra no lol ▁cardiac
D-1138	-0.5289134383201599	pyridostigmine methylatropine propranolol cardiac
P-1138	-0.1268 -0.0591 -0.0015 -0.0910 -0.4525 -0.0269 -0.1421 -0.0191 -1.6148 -0.0111 -0.0057 -0.0816 -0.0552 -5.1813 -0.0649
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic cardiac_resynchronization_therapy crt
H-427	-0.6830033659934998	▁e cho car dio graphic _ ▁predict ors ▁cardiac _ re syn chron ization _ therapy ▁c RT
D-427	-0.6830033659934998	echocardiographic_ predictors cardiac_resynchronization_therapy cRT
P-427	-0.0476 -0.6273 -0.0925 -0.7670 -0.3933 -4.3432 -0.6270 -0.3997 -0.7738 -0.7248 -0.8925 -0.0160 -0.0008 -1.0695 -0.8621 -0.2631 -0.4485 -1.0199 -0.2093 -0.0822
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin_subproteomes heart_failure proteins chromatin_structure
H-91	-0.8879658579826355	▁chr omat in _ sub prote om es ▁heart _ ▁failure
D-91	-0.8879658579826355	chromatin_subproteomes heart_ failure
P-91	-2.3917 -0.0564 -1.5465 -0.4681 -0.2685 -0.2080 -0.4774 -0.2283 -0.2612 -0.5143 -2.0062 -3.0031 -0.1136
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp antibodies nonterminal_epitopes
H-1519	-0.7056148052215576	▁NT - pro b NP ▁anti bo dies ▁non gly cos yla ted
D-1519	-0.7056148052215576	NT-probNP antibodies nonglycosylated
P-1519	-1.3046 -0.0246 -0.0116 -0.7642 -0.1715 -0.0356 -0.0488 -2.1144 -1.9961 -0.5146 -0.0791 -0.2411 -2.3983 -0.7796 -0.1000
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac_mrna inflammatory cell_adhesion_genes retn
H-934	-0.5541061758995056	▁Hum - re t n ▁mi ce ▁cardiac ▁m RNA ▁infla mma tory ▁cell _ a dhe sion ▁Ret n
D-934	-0.5541061758995056	Hum-retn mice cardiac mRNA inflammatory cell_adhesion Retn
P-934	-0.3362 -0.0792 -1.1319 -0.0480 -0.0194 -3.2770 -0.1427 -0.2341 -0.0236 -0.0154 -1.8915 -0.2818 -0.9822 -0.9620 -0.1657 -0.8698 -0.0102 -0.0335 -0.5332 -0.0102 -1.0238 -0.1188
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard tnf_antagonist baseline covariates
H-606	-0.6101924180984497	▁n b DM ARD ▁t NF
D-606	-0.6101924180984497	nbDMARD tNF
P-606	-0.0928 -0.1247 -1.1915 -0.4120 -0.9649 -0.5209 -1.4830 -0.0917
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage_heart_failure mechanical_cardiac_support
H-1386	-0.9575923085212708	▁end - s tage _ heart _ ▁failure ▁pediatr ic ▁mechanic al _ ▁cardiac
D-1386	-0.9575923085212708	end-stage_heart_ failure pediatric mechanical_ cardiac
P-1386	-5.2818 -0.0694 -0.2608 -0.0053 -0.7193 -1.9196 -0.9895 -1.0256 -0.1736 -0.6124 -0.7242 -0.0290 -0.3851 -0.1220 -2.8749 -0.1291
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref exercise resting_hr bpm beta-blocker therapy
H-1946	-1.090637445449829	▁h f f ▁h f ▁h f ▁h f ▁HR ▁beta - block er ▁ therapy
D-1946	-1.090637445449829	hff hf hf hf HR beta-blocker therapy
P-1946	-0.1023 -0.3689 -0.9425 -2.4637 -0.2372 -3.3883 -0.2222 -3.0138 -1.0576 -5.4114 -0.9523 -0.0272 -0.0751 -0.0328 -1.0285 -0.0230 -0.1829 -0.1018
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods_study exercise patients heart_failure
H-615	-2.2141356468200684	
D-615	-2.2141356468200684	
P-615	-4.3052 -0.1231
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox_hazard_models esrd death composite_end_point esrd death esrd
H-391	-1.1377427577972412	▁co x ▁hazard ▁models ▁temps ▁ES RD ▁death ▁ES RD
D-391	-1.1377427577972412	cox hazard models temps ESRD death ESRD
P-391	-1.9396 -0.0011 -0.3321 -1.2173 -1.3375 -0.7790 -0.3568 -4.4724 -1.2308 -0.5243 -1.3145 -0.1476
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-0.626075029373169	
D-557	-0.626075029373169	
P-557	-1.1701 -0.0820
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery rheumatic surgery mva
H-359	-0.8381578922271729	▁rhe u matic ▁MS ▁m va
D-359	-0.8381578922271729	rheumatic MS mva
P-359	-3.9477 -0.0185 -0.0378 -1.9331 -0.2555 -0.3269 -0.1024 -0.0833
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior_vena_cava ivc
H-321	-0.9135020971298218	▁pig s ▁inferior ▁ve na _ ca va ▁i c ▁co
D-321	-0.9135020971298218	pigs inferior vena_cava ic co
P-321	-2.3659 -0.0606 -0.3951 -2.4921 -0.1264 -0.5261 -0.0546 -0.0337 -0.6661 -1.1311 -2.7345 -1.2012 -0.0881
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin resistin
H-932	-0.5727320909500122	▁do xor ubi cin ▁i p ▁se rum _ ▁resist in ▁Hum - re t n _ mi ce
D-932	-0.5727320909500122	doxorubicin ip serum_ resistin Hum-retn_mice
P-932	-0.0039 -0.0606 -0.0944 -0.0347 -1.5006 -0.0153 -1.8466 -0.2736 -0.5651 -1.2866 -1.3305 -0.4360 -0.0784 -1.3457 -0.1926 -0.0399 -1.9262 -0.4049 -0.1799 -0.2827 -0.1288
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf proteins
H-1361	-0.626013457775116	▁nutrition al _ ▁ab normal ities ▁CHF ▁fat ▁car bo hydrat es ▁protein s
D-1361	-0.626013457775116	nutritional_ abnormalities CHF fat carbohydrates proteins
P-1361	-2.9086 -0.0887 -0.8431 -0.3674 -0.0118 -0.7915 -0.4791 -1.0376 -0.2420 -0.0086 -0.1898 -0.0821 -0.7986 -0.0663 -2.0326 -0.0682
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs physicians hospital
H-1729	-0.7334866523742676	▁costs ▁high - volu me ▁physician s
D-1729	-0.7334866523742676	costs high-volume physicians
P-1729	-0.8457 -2.4371 -0.0326 -0.2140 -0.0184 -1.7675 -0.0527 -1.1256 -0.1077
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.5165748596191406	▁de activa tion
D-1864	-0.5165748596191406	deactivation
P-1864	-2.1361 -0.1161 -0.0268 -0.2280 -0.0759
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university_of_connecticut_heart_failure_center heart_failure nurse_practitioner
H-728	-0.6349127888679504	▁University _ of _ connect i cut ▁Heart _ ▁Fail ure ▁Center ▁cardio logist ▁heart _ ▁failure
D-728	-0.6349127888679504	University_of_connecticut Heart_ Failure Center cardiologist heart_ failure
P-728	-0.9219 -0.4653 -1.3288 -0.8802 -1.5667 -0.1437 -0.3894 -0.8783 -0.4370 -0.2103 -0.0914 -1.7443 -0.0447 -0.0467 -0.3477 -0.3510 -1.4538 -0.6221 -0.1402
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone_receptor_antagonists randomized morbidity mortality symptomatic_systolic_heart_failure
H-438	-0.921847403049469	▁al do ster one _ ▁receptor _ ▁anta gon ists ▁morbi d ity ▁mortal ity ▁sy sto lic _ ▁heart _ ▁failure
D-438	-0.921847403049469	aldosterone_ receptor_ antagonists morbidity mortality systolic_ heart_ failure
P-438	-0.2802 -0.4831 -0.0811 -1.9578 -0.7993 -0.0357 -1.2831 -0.4734 -0.0865 -2.0697 -1.6310 -0.0993 -0.5625 -2.4402 -0.2265 -1.0379 -0.2460 -3.7982 -0.3437 -1.7344 -0.9277 -1.2131 -0.2244 -0.0896
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo_inhibition cardiomyocyte_bioenergetics lv_function chronic_acf
H-472	-0.4917181134223938	▁ XO ▁inhibi tion ▁cardio my o cy te _ ▁bio ener ge tics ▁LV ▁a CF ▁rat
D-472	-0.4917181134223938	XO inhibition cardiomyocyte_ bioenergetics LV aCF rat
P-472	-1.8060 -0.0369 -1.0153 -0.0365 -0.0128 -0.7503 -0.3904 -0.3672 -0.9833 -0.4058 -0.0922 -0.0208 -0.2743 -1.2744 -0.0798 -1.1376 -0.5792 -0.3267 -0.1799 -0.0651
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory
H-1324	-0.7970162630081177	▁e car dio graphic ▁measure s ▁N - termin al _ pro - bra in ▁na tri ure tic _ pe pti de ▁infla mma tory ▁marker s
D-1324	-0.7970162630081177	ecardiographic measures N-terminal_pro-brain natriuretic_peptide inflammatory markers
P-1324	-0.6389 -1.8425 -0.3556 -0.3375 -2.7352 -0.0133 -3.5267 -0.0105 -0.0468 -0.0101 -0.5486 -0.7148 -0.0388 -1.3837 -0.3374 -1.2298 -0.0109 -0.0510 -3.7061 -0.9131 -0.3451 -0.1670 -0.3170 -0.1154 -0.4515 -1.0334 -2.5941 -0.0284 -0.2589 -0.1484
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf pyridostigmine stroke_volume ejection_fraction cardiac_output contractility left_ventricle
H-1144	-0.8974586129188538	▁h f ▁ HF ▁py rido stig mine ▁stroke ▁e je ction _ fraction ▁cardiac _ ▁output ▁contract ility ▁vent ric le
D-1144	-0.8974586129188538	hf HF pyridostigmine stroke ejection_fraction cardiac_ output contractility ventricle
P-1144	-1.5271 -1.0493 -3.8180 -0.5995 -2.5566 -0.0294 -0.0019 -0.3188 -0.9569 -2.0272 -0.3855 -0.0354 -0.6389 -0.0008 -0.0406 -2.6609 -0.1377 -0.1313 -0.4184 -0.8316 -2.0078 -1.1087 -0.1767 -0.0798
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol thromboembolic_events patients heart_failure β2-receptor_haplotype
H-1120	-0.672784149646759	▁car vedi lol ▁ thro mbo e mbol ic ▁events ▁heart _ ▁failure ▁β 2- recept or _ ha plo type
D-1120	-0.672784149646759	carvedilol thromboembolic events heart_ failure β2-receptor_haplotype
P-1120	-0.4484 -0.2033 -0.6333 -0.2560 -0.3587 -0.9552 -1.3051 -0.0594 -1.5560 -2.9721 -0.9221 -1.1960 -1.3811 -0.1452 -0.2951 -0.0318 -0.1038 -0.4141 -1.0356 -0.1489 -0.1533 -0.7642 -0.1353
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr protein_kinase_r-like_er_kinase perk calreticulin chop hf
H-1084	-0.5963730812072754	▁u PR ▁protein ▁kina se ▁ER ▁kina se per k ▁cal ret icul in ▁CHO p ▁ HF
D-1084	-0.5963730812072754	uPR protein kinase ER kinaseperk calreticulin CHOp HF
P-1084	-0.1619 -0.0609 -1.9695 -1.5235 -0.0253 -1.0859 -2.1148 -0.0117 -0.6070 -0.7209 -0.0132 -0.6510 -0.0093 -1.0557 -0.0342 -0.3221 -1.0096 -0.2175 -0.2633 -0.0701
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients heart_failure hf cardiopulmonary_exercise_test anaerobic_threshold
H-1753	-0.9924305081367493	▁heart _ ▁failure HF ▁cardio pul mon ary _ ▁exercise ▁ana ero bic _ ▁thre s hold
D-1753	-0.9924305081367493	heart_ failureHF cardiopulmonary_ exercise anaerobic_ threshold
P-1753	-1.5493 -0.6735 -1.9991 -0.1895 -0.1481 -0.1648 -4.1775 -1.6721 -1.0908 -2.0403 -0.7774 -0.1788 -0.6768 -1.4883 -0.8702 -0.0271 -0.3923 -0.6573 -0.0829
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled_trials rcts observational_cohort_studies contemporaneous_control_group
H-152	-0.710297167301178	▁random ised - control led ▁trial s RC t s
D-152	-0.710297167301178	randomised-controlled trialsRCts
P-152	-0.7326 -1.0470 -0.0844 -0.0043 -0.8452 -2.2464 -0.0364 -2.0721 -0.6712 -0.3598 -0.3203 -0.1040
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic biomarkers molecular_dysfunction chronic_hf
H-1477	-0.6491394639015198	▁ therapeut ic ▁bio mark ers ▁molecular _ ▁dys function ▁ HF
D-1477	-0.6491394639015198	therapeutic biomarkers molecular_ dysfunction HF
P-1477	-1.0530 -0.1346 -0.8194 -0.8397 -0.0132 -0.1019 -0.0954 -1.6631 -0.1249 -0.3563 -3.3950 -0.2800 -0.1204 -0.0910
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths stroke hospitalisations heart_failure follow-up
H-816	-1.0129197835922241	▁CV _ ▁death s ▁non - fa tal _ ▁stroke ▁heart _ ▁failure
D-816	-1.0129197835922241	CV_ deaths non-fatal_ stroke heart_ failure
P-816	-3.4081 -3.5390 -2.0604 -0.1043 -0.9508 -0.0098 -0.0320 -0.3402 -0.5602 -0.2117 -1.3767 -0.5961 -1.7279 -0.1512 -0.1254
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective patients rule sensitivity specificity cad sensitivity cad
H-1192	-1.4317973852157593	▁ sensitiv ity ▁CAD
D-1192	-1.4317973852157593	sensitivity CAD
P-1192	-4.7406 -1.7819 -0.2867 -0.3793 -1.3197 -0.0825
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected clinical death medical hospitalization hf clinic outpatients
H-379	-1.3682868480682373	▁ HF
D-379	-1.3682868480682373	HF
P-379	-3.9956 -0.6348 -0.6582 -0.1845
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a upr downregulation cardiac genes hf
H-1089	-0.9530285000801086	▁s CN 5 a ▁tran script ▁u PR ▁down regul ation ▁cardiac _ ▁gene s ▁ HF
D-1089	-0.9530285000801086	sCN5a transcript uPR downregulation cardiac_ genes HF
P-1089	-1.3040 -1.6109 -0.4750 -0.1283 -2.8553 -0.0366 -0.0689 -0.8423 -2.5433 -0.1679 -0.0106 -2.9302 -2.6850 -1.3791 -0.0392 -0.7072 -0.1365 -0.1044 -0.0829
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east rhythm_control_therapy diagnosis cardiovascular complications
H-1655	-0.41531673073768616	▁e AST ▁ rhythm _ control ▁ therapy ▁AF ▁cardiovascular ▁complica tions ▁AF
D-1655	-0.41531673073768616	eAST rhythm_control therapy AF cardiovascular complications AF
P-1655	-0.5279 -0.6357 -0.0331 -0.4036 -0.3774 -0.0412 -1.3262 -0.0280 -1.0468 -0.1343 -0.2949 -0.0723 -1.0944 -0.0959 -0.1180
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air cardiovascular health acute_myocardial_infarction
H-1806	-0.9454212188720703	▁air ▁pollution ▁cardiovascular _ ▁health ▁a cute _ mé o card ial _ ▁in far ction
D-1806	-0.9454212188720703	air pollution cardiovascular_ health acute_méocardial_ infarction
P-1806	-0.6757 -0.4253 -0.2346 -2.6166 -0.9587 -1.9249 -0.0399 -0.1784 -4.6210 -0.7392 -0.3743 -0.3529 -0.6733 -0.6207 -1.8422 -0.2916 -0.2804 -0.1677
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic nhs chronic disease exercise acute hospital
H-613	-1.095218300819397	▁économique _ ▁climate ▁NH s ▁behaviour al - change ▁chronic _ ▁disease
D-613	-1.095218300819397	économique_ climate NHs behavioural-change chronic_ disease
P-613	-0.3488 -2.7094 -2.1728 -0.5080 -0.9151 -1.2732 -0.1449 -0.0353 -0.0012 -3.6522 -1.0621 -1.3117 -1.0486 -0.1498
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac_deaths atherosclerotic_cad
H-1907	-0.541486918926239	▁middle - a ged _ ▁recrea tional _ ▁ath letes ▁sud den _ ▁cardiac ▁death s ▁a ther os cle ro tic ▁CAD
D-1907	-0.541486918926239	middle-aged_ recreational_ athletes sudden_ cardiac deaths atherosclerotic CAD
P-1907	-3.4441 -0.0822 -0.0672 -0.1360 -0.6572 -0.7411 -0.5221 -1.8884 -0.9924 -0.0308 -0.3796 -0.0288 -0.3216 -0.0837 -1.8635 -0.0713 -0.8117 -0.0059 -0.2778 -0.1009 -0.0567 -0.5573 -0.1675 -0.1362 -0.1131
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients hf crt implantation complications
H-912	-0.36249014735221863	▁di al ysis - dependent ▁patients ▁ HF ▁c RT ▁implant ation
D-912	-0.36249014735221863	dialysis-dependent patients HF cRT implantation
P-912	-0.1382 -0.1189 -0.0489 -0.0581 -0.0902 -1.0278 -1.5376 -0.0471 -0.3814 -0.6646 -0.0523 -0.0374 -0.8002 -0.0723
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak_oxygen_consumption pulse patients
H-1918	-0.7305960655212402	▁Peak _ ▁oxygen _ ▁consum p tion ▁oxygen _ ▁puls e
D-1918	-0.7305960655212402	Peak_ oxygen_ consumption oxygen_ pulse
P-1918	-0.5244 -0.4884 -1.2522 -0.7558 -3.3124 -0.2109 -0.1907 -0.7717 -0.6420 -0.4074 -0.5227 -0.2829 -0.1363
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv pathophysiologic rv_dysfunction
H-1094	-0.9174501299858093	▁ RV ▁pat ho phy si ologic ▁mécanisme s ▁ RV
D-1094	-0.9174501299858093	RV pathophysiologic mécanismes RV
P-1094	-0.5844 -0.6735 -2.5166 -0.2296 -0.0656 -0.3910 -0.3033 -3.5704 -0.0260 -0.9678 -0.2542 -2.1810 -0.1634
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf patients hct city_of_hope
H-1452	-0.8014430403709412	▁h ct _ f ré que nce ▁h ct ▁City _ of _ ▁Hope
D-1452	-0.8014430403709412	hct_fréquence hct City_of_ Hope
P-1452	-0.4152 -0.9621 -2.0678 -1.3106 -1.5950 -0.0470 -0.0133 -1.2376 -0.7207 -1.6056 -0.2766 -1.1456 -0.2466 -0.9665 -0.1543 -0.0588
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health followed_up hf hospitalization death contact
H-687	-1.0566949844360352	▁Women _ s _ ▁Health ▁Initiative ▁ HF
D-687	-1.0566949844360352	Women_s_ Health Initiative HF
P-687	-2.1177 -1.9004 -0.9141 -0.7631 -1.1023 -1.7079 -1.0558 -0.2697 -0.5600 -0.1760
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients vad patients ecmo vad patients ecmo
H-1389	-1.325175166130066	▁ VAD ▁EC mo + VAD ▁EC mo
D-1389	-1.325175166130066	VAD ECmo+VAD ECmo
P-1389	-1.0007 -0.1445 -1.9101 -1.1298 -4.3949 -0.0675 -2.6916 -0.7512 -0.9959 -0.1656
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin inflammation hepatic prognosis patients lvad implantation
H-540	-0.3250100314617157	▁album in ▁ inflammation ▁he pati c ▁implant ation
D-540	-0.3250100314617157	albumin inflammation hepatic implantation
P-540	-0.2983 -0.3659 -0.9661 -0.2274 -0.1115 -0.3683 -0.1276 -0.6511 -0.0204 -0.3014 -0.1371
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right_ventricular rv left_ventricular_assist_device lvad outcomes
H-294	-0.7043942809104919	▁vent ri cular ▁ RV ▁left ▁vent ri cular _ assist ▁device ▁l VAD
D-294	-0.7043942809104919	ventricular RV left ventricular_assist device lVAD
P-294	-1.7329 -0.2409 -0.2108 -1.8537 -0.6061 -1.6714 -0.3586 -0.2216 -0.1943 -1.2001 -0.1579 -1.5473 -0.8601 -0.0219 -0.2862 -0.1064
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration neurohumoral_blockers hf hospitalization patients co-morbidity
H-184	-0.5047702789306641	▁neuro hu moral ▁block ers ▁ HF ▁co - mor bid ity _ ▁burde n
D-184	-0.5047702789306641	neurohumoral blockers HF co-morbidity_ burden
P-184	-0.3738 -0.5095 -0.0231 -2.5455 -0.1396 -1.2077 -0.0294 -0.5202 -0.0789 -0.2171 -0.3688 -0.2438 -1.6389 -0.1438 -0.0701 -0.3741 -0.0967
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 c_statistic net_reclassification_improvement integrated_discrimination_improvement
H-705	-1.072821021080017	▁st 2 ▁re class ification _ de _ risk ▁c ▁statistic ▁discrimina tion
D-705	-1.072821021080017	st2 reclassification_de_risk c statistic discrimination
P-705	-2.3339 -0.0748 -4.4632 -0.1008 -0.0193 -0.8474 -1.2709 -0.1769 -0.5941 -0.1485 -3.0961 -1.8656 -0.0496 -0.8877 -0.1637
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ami complications heart_failure kidney_infection uti complications rehospitalization
H-1718	-0.576931893825531	AMI ▁heart _ ▁failure ▁ki dne y ▁infection ▁ UTI
D-1718	-0.576931893825531	AMI heart_ failure kidney infection UTI
P-1718	-1.0737 -1.5234 -1.1297 -0.3003 -0.2298 -0.1110 -0.0928 -0.4437 -1.5332 -0.0117 -0.3549 -0.1190
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox_proportional_hazards_models health health hazard_ratios confidence_intervals
H-689	-0.9297283291816711	▁co x ▁proportion al _ ▁hazard s
D-689	-0.9297283291816711	cox proportional_ hazards
P-689	-1.3546 -0.0092 -0.6183 -0.1274 -0.5593 -0.7805 -0.1743 -4.6237 -0.1202
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone_therapy exercise_rehabilitation patients chronic_heart_failure testosterone double-blind randomized
H-1316	-1.3565423488616943	▁Test o ster one _ therapy ▁exercise _ ▁rehabilita tion ▁heart _ ▁failure ▁testosteron e
D-1316	-1.3565423488616943	Testosterone_therapy exercise_ rehabilitation heart_ failure testosterone
P-1316	-1.0032 -0.1318 -0.0309 -1.6673 -2.9766 -0.1414 -5.6874 -0.7757 -0.6098 -0.0206 -6.7835 -0.9267 -1.2925 -0.5245 -0.0572 -0.3191 -0.1130
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence adjusted_odds_ratio hazard_ratio death hf ami admission discharge
H-1308	-1.1688153743743896	▁odds haz ard ▁ HF AMI ▁dis charge
D-1308	-1.1688153743743896	oddshazard HFAMI discharge
P-1308	-3.3061 -2.7399 -0.0231 -2.4761 -0.4109 -0.8886 -1.4222 -0.0093 -0.2706 -0.1413
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse pasp downward regression_line shift pasp tapse
H-496	-2.1766164302825928	▁pas p
D-496	-2.1766164302825928	pasp
P-496	-4.5445 -1.3752 -2.6827 -0.1040
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq kaplan-meier_curves death all-cause_hospitalization
H-784	-0.6467307209968567	▁k cc q ▁Ka plan - me ier ▁cur ves
D-784	-0.6467307209968567	kccq Kaplan-meier curves
P-784	-0.6123 -0.0499 -0.8920 -0.6446 -0.0475 -0.0122 -0.7541 -0.1514 -1.4842 -0.2264 -2.7009 -0.1853
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome gls beat cox_proportional_hazards_analyses
H-814	-1.091493010520935	▁m AIN _ ▁o UTC OME _ me a su RES ▁gr LS ▁index _ ▁beat ▁CV ▁co x ▁proportion al _ ▁hazard s
D-814	-1.091493010520935	mAIN_ oUTCOME_measuRES grLS index_ beat CV cox proportional_ hazards
P-814	-2.1214 -0.0134 -0.3110 -2.6731 -0.0091 -0.0433 -3.2758 -0.3328 -1.0675 -0.5943 -2.6361 -0.7268 -2.9506 -0.6655 -0.3491 -0.4584 -3.7280 -2.6031 -0.0034 -1.4601 -0.0838 -1.0315 -0.6180 -0.1697 -0.3274 -0.1255
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis expenditure b_natriuretic_peptides nps
H-10	-0.7543348073959351	▁Li poly sis ▁ énergie _ ▁ex pendi ture ▁na tri ure tic _ pe pti des NP s ▁CC
D-10	-0.7543348073959351	Lipolysis énergie_ expenditure natriuretic_peptidesNPs CC
P-10	-1.1489 -0.0586 -1.1909 -3.0920 -0.1261 -1.1775 -0.1692 -0.0027 -0.7118 -1.0526 -0.0281 -0.1251 -3.8121 -1.3748 -0.5564 -0.2171 -0.1808 -0.2004 -0.0071 -1.1048 -0.1480 -0.1105
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ischemic_heart_failure biomarkers heart_failure
H-1615	-1.2356644868850708	▁bio mark ers ▁heart _ ▁failure
D-1615	-1.2356644868850708	biomarkers heart_ failure
P-1615	-5.8138 -0.0423 -0.0773 -1.6495 -1.0076 -0.9404 -0.2022 -0.1523
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted left_ventricle_end-diastolic_pressure
H-1340	-0.7575799822807312	▁CHF ▁in far cted ▁animals ▁left ▁vent ric le _ ▁end - dia sto lic _ tension ▁h g ▁scar
D-1340	-0.7575799822807312	CHF infarcted animals left ventricle_ end-diastolic_tension hg scar
P-1340	-0.0093 -0.5186 -0.3080 -1.5771 -1.0735 -0.6800 -0.1059 -2.0471 -0.9206 -1.7371 -1.2106 -0.0821 -0.5920 -0.8789 -1.8992 -1.3166 -0.6695 -0.0326 -0.0074 -0.2838 -0.6392 -0.0780
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted_county minnesota mi diagnosed hf followed-up
H-1102	-0.4551093280315399	▁Ol m sted ▁County ▁Minnesota ▁MI ▁ HF
D-1102	-0.4551093280315399	Olmsted County Minnesota MI HF
P-1102	-0.2896 -0.0039 -0.2654 -0.1648 -1.3673 -0.5862 -1.4551 -0.1447 -0.1975 -0.0766
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts mena cardiac_injury mena hf pathophysiology
H-1817	-0.8428328037261963	▁heart s ▁Men a ▁cardiac _ ▁injury ▁Men a ▁ HF
D-1817	-0.8428328037261963	hearts Mena cardiac_ injury Mena HF
P-1817	-1.6999 -0.1066 -1.4970 -0.2374 -0.2013 -2.7438 -0.3575 -2.1587 -0.1350 -0.3755 -0.0872 -1.2243 -0.1326
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ras doppler_ultrasonography tomographic_angiography magnetic_resonance_angiography
H-1599	-0.5121963620185852	RAS ▁do pp ler _ ▁ultra son ography ▁to mo graphic _ ang i ography ▁magnetic ▁res on ance _ ang i ography
D-1599	-0.5121963620185852	RAS doppler_ ultrasonography tomographic_angiography magnetic resonance_angiography
P-1599	-1.0451 -0.3532 -0.1034 -0.7530 -0.4157 -0.2169 -0.0225 -0.2722 -0.2596 -0.2604 -0.6419 -0.8454 -0.8485 -0.6765 -0.1900 -0.1081 -3.1503 -0.1210 -0.1442 -0.4960 -0.6153 -0.5510 -0.1614 -0.3922 -0.1610
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence lvad transplantation patients budget
H-316	-0.9222792983055115	▁l VAD ▁transplant ation _ é ligi bility
D-316	-0.9222792983055115	lVAD transplantation_éligibility
P-316	-0.8888 -0.1058 -1.8136 -0.0247 -1.4337 -1.5160 -0.0057 -0.8488 -2.5044 -0.0813
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients terminal diagnostic follow-up
H-1819	-1.0671004056930542	
D-1819	-1.0671004056930542	
P-1819	-2.0172 -0.1170
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d therapy
H-107	-0.724712610244751	▁c RT - d ▁IE ▁de fi br illa tor - on ly ▁ therapy
D-107	-0.724712610244751	cRT-d IE defibrillator-only therapy
P-107	-0.1805 -1.8365 -0.0408 -0.5330 -0.5074 -2.9075 -3.1481 -0.7227 -0.0110 -0.1067 -0.0906 -0.1227 -0.7133 -0.6470 -0.0571 -0.5718 -0.1234
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ic multicenter_automatic_defibrillator_implantation_trial-cardiac_resynchronization_therapy
H-103	-0.4475732743740082	▁IC ▁multi center _ automat ic _ de ib rilla tor ▁implant ation ▁Tri al - Card iac _ re syn chron ization ▁Therapy
D-103	-0.4475732743740082	IC multicenter_automatic_deibrillator implantation Trial-Cardiac_resynchronization Therapy
P-103	-1.6828 -0.4511 -0.0513 -0.1094 -0.1998 -0.2624 -0.2509 -0.6863 -1.9403 -0.4022 -0.1816 -0.1340 -0.0138 -1.3624 -0.0253 -0.1345 -0.2039 -0.5359 -0.5589 -0.3474 -0.0041 -0.0001 -0.6645 -1.0956 -0.2082 -0.1303
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health_buddy_program admissions chronic_obstructive_pulmonary_disease mortality congestive_heart_failure
H-1627	-0.9705005884170532	▁Health ▁Budd y _ program ▁chronic _ ▁ob struct ive _ ▁pulmonar y ▁disease ▁con ges tive _ ▁heart _ ▁failure
D-1627	-0.9705005884170532	Health Buddy_program chronic_ obstructive_ pulmonary disease congestive_ heart_ failure
P-1627	-0.9274 -0.9892 -0.0300 -3.9000 -1.4933 -1.8600 -0.5349 -2.0201 -0.1287 -0.0833 -1.0529 -0.0543 -0.1039 -2.3164 -0.9055 -0.0725 -0.1256 -0.3011 -3.1082 -0.8570 -1.0185 -0.3066 -0.1321
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary_exercise_testing echocardiographic myocardial_function left_ventricular_filling exercise
H-1174	-0.8985757827758789	▁Card io pul mon ary ▁e cho car dio graphic ▁my o card ial ▁vent ri cular ▁fill ing
D-1174	-0.8985757827758789	Cardiopulmonary echocardiographic myocardial ventricular filling
P-1174	-0.1443 -2.8492 -0.1562 -2.8916 -1.8486 -1.2490 -0.0853 -0.0173 -0.1987 -0.6314 -4.4430 -0.1037 -0.1831 -0.2277 -1.7490 -0.1254 -0.1130 -1.4173 -0.1048 -0.2588 -0.0726
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle_tracking_echocardiography ste bivp acute right_ventricular_pressure_overload rvpo
H-320	-0.5920977592468262	▁e cho card i ography ▁ste ▁bi VP ▁vent ri cular _ tension RV PO
D-320	-0.5920977592468262	echocardiography ste biVP ventricular_tensionRVPO
P-320	-1.0516 -0.2069 -0.0906 -0.2220 -0.1519 -0.6932 -1.0184 -0.1772 -0.7932 -0.1555 -0.1502 -1.4702 -0.7006 -1.7193 -1.1665 -0.1767 -0.1216
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia postoperative mortality patients left_ventricular_assist_device lvad implantation
H-530	-0.4737829566001892	▁hypo album in emia ▁post operativ e ▁mortal ity ▁left ▁vent ri cular _ assist ▁device ▁l VAD ▁implant ation
D-530	-0.4737829566001892	hypoalbuminemia postoperative mortality left ventricular_assist device lVAD implantation
P-530	-0.0207 -0.4934 -0.6240 -0.3959 -0.9230 -0.5604 -0.3204 -1.0050 -0.2737 -0.5451 -0.4616 -0.4124 -0.1376 -0.5255 -0.1557 -1.8129 -1.2750 -0.0139 -0.0619 -0.0353 -0.2328 -0.1368
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular_endothelial_growth_factor vegf transition compensatory_hypertrophy cardiac_failure
H-450	-0.8528370261192322	▁inhibi tion ▁vas cular _ en dot heli al _ ▁growth _ factor ve GF ▁transition ▁compensa tory _ ▁hyper trop hy ▁cardiac _ ▁failure
D-450	-0.8528370261192322	inhibition vascular_endothelial_ growth_factorveGF transition compensatory_ hypertrophy cardiac_ failure
P-450	-2.4444 -0.0167 -0.9120 -0.1222 -0.3064 -0.6627 -2.2586 -0.1468 -0.0269 -0.8310 -0.6984 -2.2894 -1.6050 -3.6471 -0.4920 -0.2958 -0.2239 -0.3879 -0.9774 -0.5296 -0.0037 -0.0808 -0.0389 -1.7052 -2.0915 -0.1579 -0.0746
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left_ventricular_ejection_fraction mortality patients heart_failure heart_failure_survey israel
H-110	-0.9997735619544983	▁vent ri cular ▁e je ction _ fraction ▁heart _ ▁Fail ure ▁IS ra el
D-110	-0.9997735619544983	ventricular ejection_fraction heart_ Failure ISrael
P-110	-3.0529 -0.7314 -0.4441 -2.7358 -0.4009 -0.1116 -1.5602 -0.0048 -2.7095 -0.8203 -1.0112 -0.1112 -2.7723 -0.0109 -0.0077 -0.2935 -0.2177
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity diabetes_mellitus metabolic comorbidities heart_failure_with_preserved_ejection_fraction
H-760	-0.9245786070823669	▁obes ity ▁diabetes ▁mell itus ▁metabol ic _ risk _ ▁factors ▁heart _ ▁failure ▁e je ction _ fraction
D-760	-0.9245786070823669	obesity diabetes mellitus metabolic_risk_ factors heart_ failure ejection_fraction
P-760	-1.9037 -1.6165 -0.1854 -0.5546 -0.1434 -1.2290 -0.1043 -1.6914 -0.6455 -2.5385 -2.0408 -1.5397 -0.6739 -2.2113 -1.0757 -0.2150 -0.0439 -0.5419 -0.0071 -0.2852 -0.1694
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil cardioprotection apoptotic_signaling_pathway dna_fragmentation mitochondrial
H-965	-0.50880366563797	▁nic oran dil ▁cardio protec tion ▁apo pto tic ▁signal ing ▁path way ▁DNA ▁fragment ation ▁mito cho ndri al _ ▁ultra struct ural ▁changes
D-965	-0.50880366563797	nicorandil cardioprotection apoptotic signaling pathway DNA fragmentation mitochondrial_ ultrastructural changes
P-965	-0.0945 -0.0413 -0.5942 -0.0649 -0.0279 -0.0110 -0.1412 -0.0141 -0.8225 -0.3998 -0.8148 -1.7416 -0.4292 -0.1018 -0.6114 -0.0154 -0.0317 -1.1624 -0.1279 -0.0772 -0.6602 -3.4508 -0.1859 -0.0460 -1.8005 -0.1721 -0.0973
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous coronary_revascularization hemodynamically stable patient intensive_care_unit icu
H-1293	-0.7771927714347839	▁per cuta ne ous _ ▁corona ry _ re vas cular ization ▁hem o dynamic ally
D-1293	-0.7771927714347839	percutaneous_ coronary_revascularization hemodynamically
P-1293	-1.7370 -0.0072 -0.0711 -2.8108 -0.8104 -0.4757 -0.9515 -0.4997 -0.7526 -0.4933 -0.3442 -0.8666 -0.2147 -0.0695 -0.0577 -1.3940 -2.3327 -0.1005
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary_endpoints therapy atrial_fibrillation atrial_tachyarrhythmias atp shock_therapy
H-860	-0.8269148468971252	▁at rial _ ▁fi bril lation ▁at rial _ ta chy ar rhythm ias ▁ATP ▁shock ▁ therapy
D-860	-0.8269148468971252	atrial_ fibrillation atrial_tachyarrhythmias ATP shock therapy
P-860	-2.0097 -0.0746 -0.9183 -2.9922 -0.0237 -0.0341 -0.0995 -0.1022 -1.0100 -4.1263 -0.4755 -0.6755 -0.2136 -2.1109 -0.2547 -0.0339 -0.9911 -0.0201 -0.2644 -0.1079
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic renal_underperfusion renin-_angiotensin-aldosterone_pathway
H-1596	-0.9462164640426636	▁pat ho phy si ologic ▁mechanism ▁renal _ ▁under per fusion ▁re nin - ▁ang io ten sin - al do ster one
D-1596	-0.9462164640426636	pathophysiologic mechanism renal_ underperfusion renin- angiotensin-aldosterone
P-1596	-3.8876 -0.2140 -0.0386 -0.5487 -0.5145 -3.5966 -1.0270 -0.7846 -1.6765 -0.0820 -0.5618 -0.0132 -0.5441 -0.0680 -1.4558 -1.3555 -0.2173 -1.4184 -0.7880 -0.1666 -1.7624 -0.0392 -2.0046 -0.6660 -0.2242
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics pressure-overload-induced_heart_failure mitochondrial-targeted_peptides
H-869	-0.6026973128318787	▁prote o mics ▁pressure - over load - indu ce ▁heart _ ▁failure ▁mito cho ndri al - tar get ed _ pe pti des
D-869	-0.6026973128318787	proteomics pressure-overload-induce heart_ failure mitochondrial-targeted_peptides
P-869	-1.2002 -1.0835 -0.0069 -0.3913 -0.0660 -0.1396 -0.1249 -0.3636 -0.0032 -4.1061 -0.6908 -1.2832 -1.2816 -0.0064 -1.0584 -0.4114 -0.0653 -0.1355 -0.0985 -0.1371 -0.2259 -1.9773 -0.6311 -0.1077 -0.2695 -0.2663 -0.1414
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration hr_reduction bpm p_value
H-1942	-1.274849534034729	▁HR
D-1942	-1.274849534034729	HR
P-1942	-2.5851 -1.0835 -0.1560
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv_fractional_shortening lung incidence
H-278	-0.8567666411399841	▁av _ mi ce ▁LV _ fraction al _ short en ing ▁lung _ weight
D-278	-0.8567666411399841	av_mice LV_fractional_shortening lung_weight
P-278	-3.2269 -2.5929 -0.4024 -0.2405 -0.1852 -2.4923 -0.0010 -0.2397 -0.2178 -1.6807 -0.1130 -0.6961 -0.1290 -0.8596 -1.1221 -0.2579 -0.1078
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional_enrichment_analysis regulation cell_death degs
H-1614	-0.7689180970191956	▁functional _ en rich ment _ analyse ▁programme d _ cell _ ▁death ▁DE G s
D-1614	-0.7689180970191956	functional_enrichment_analyse programmed_cell_ death DEGs
P-1614	-2.1684 -0.4117 -1.1697 -0.0026 -0.0846 -2.8112 -2.0603 -0.3402 -0.1579 -0.1654 -0.4589 -0.2158 -0.2804 -1.7651 -1.4061 -0.0495 -0.1850 -0.1079
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction rad_variant q66p congestive_heart_failure
H-1673	-0.9781172871589661	▁dys function ▁rad _ variant ▁q 66 p ▁con ges tive _ ▁heart _ ▁failure
D-1673	-0.9781172871589661	dysfunction rad_variant q66p congestive_ heart_ failure
P-1673	-1.8725 -0.6998 -0.5566 -3.2275 -1.0560 -4.5355 -0.3733 -0.2245 -0.0638 -0.1274 -0.1334 -0.3929 -1.3552 -0.8219 -0.5701 -0.5278 -0.0897
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk scn5a kv4.3 mrna mrna_splice
H-1087	-1.101183533668518	▁PER K ▁inhibi tion ▁s CN 5 a ▁kv ▁m RNA ▁sp lice
D-1087	-1.101183533668518	PERK inhibition sCN5a kv mRNA splice
P-1087	-1.8032 -1.4053 -4.1670 -0.0137 -1.1125 -1.2812 -1.5096 -0.1568 -0.1438 -1.6432 -0.1108 -2.6377 -0.0079 -0.4253 -0.0998
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic_heart_failure spironolactone hospitalization death
H-446	-1.034470558166504	▁heart _ ▁failure ▁spi rono lac tone ▁hospital ization
D-446	-1.034470558166504	heart_ failure spironolactone hospitalization
P-446	-5.7422 -0.8478 -1.1360 -0.0676 -0.0207 -0.2141 -0.2682 -0.7775 -1.0890 -1.0942 -0.1218
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg atherosclerotic_cad cardiac_death
H-1910	-0.4994227886199951	▁e CG ▁a ther os cle ro tic ▁CAD ▁sud den _ ▁cardiac ▁death
D-1910	-0.4994227886199951	eCG atherosclerotic CAD sudden_ cardiac death
P-1910	-0.7280 -0.6863 -0.3780 -0.0113 -0.2575 -0.0846 -0.0531 -0.4580 -0.4377 -0.7695 -0.0424 -0.7384 -0.0140 -2.8408 -0.3454 -0.1458
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr_variability risk_stratification
H-1587	-0.8412612080574036	▁HR ▁dynamic s ▁temps - doma in ▁HR ▁variabil ity ▁risk
D-1587	-0.8412612080574036	HR dynamics temps-domain HR variability risk
P-1587	-0.4176 -2.8140 -0.0300 -1.0380 -0.0663 -0.0076 -0.0931 -0.8903 -1.7513 -1.0795 -1.2986 -1.2662 -0.1838
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef bnp hf patients prognostic significance bnp ef
H-188	-1.2282288074493408	▁sex ▁EF ▁b NP ▁ HF ▁b NP ▁sex ▁ef
D-188	-1.2282288074493408	sex EF bNP HF bNP sex ef
P-188	-3.7912 -2.1571 -0.1783 -0.3716 -1.7494 -0.1922 -0.7413 -0.7316 -1.9465 -2.4786 -0.2546 -0.1464
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ami hazard_ratio mortality
H-1313	-1.1698613166809082	▁ HF ▁index ▁ AMI ▁mortal ity
D-1313	-1.1698613166809082	HF index AMI mortality
P-1313	-2.5974 -0.6813 -0.1547 -1.4214 -0.1555 -3.6231 -1.4863 -0.2840 -0.1250
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets transcriptional_pause_release pathological
H-1052	-0.9910765886306763	▁ BET s ▁tran scription al _ ▁pause _ release ▁tran scription
D-1052	-0.9910765886306763	BETs transcriptional_ pause_release transcription
P-1052	-2.8377 -0.0748 -0.9991 -0.8832 -0.0307 -1.7865 -0.4645 -2.0085 -0.2376 -1.0816 -0.4250 -0.0122 -2.8792 -0.1543
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis pathogenesis heart_failure
H-173	-1.0519068241119385	▁apo pto sis ▁heart _ ▁failure
D-173	-1.0519068241119385	apoptosis heart_ failure
P-173	-1.6722 -0.1283 -1.5429 -2.5553 -0.8367 -1.1860 -0.3494 -0.1445
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic neurohormonal symptoms fluid_overload
H-1201	-0.6923103928565979	▁di ure tic _ ▁ef fica cy ▁neuro hormon al _ activa tion ▁fluid _ Over load
D-1201	-0.6923103928565979	diuretic_ efficacy neurohormonal_activation fluid_Overload
P-1201	-0.1926 -0.1162 -2.8384 -1.1452 -0.0997 -0.0015 -1.1778 -0.1927 -0.1896 -0.1119 -0.4292 -1.2490 -0.0422 -2.3017 -0.4246 -2.0468 -0.2178 -0.2736 -0.1036
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr mrna_splice cardiac hf
H-1088	-0.9611450433731079	▁u PR ▁channel _ m RNA ▁sp lice ▁cardiac ▁na + ▁current ▁h z
D-1088	-0.9611450433731079	uPR channel_mRNA splice cardiac na+ current hz
P-1088	-0.0871 -1.0866 -2.0396 -1.8369 -0.4810 -0.1255 -0.1268 -0.0087 -0.2079 -2.0136 -3.6970 -1.2663 -0.9019 -1.1164 -0.2774 -0.1056
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients preserved_lvef lvef
H-114	-0.4301111400127411	▁LV EF
D-114	-0.4301111400127411	LVEF
P-114	-0.1214 -0.3800 -1.1516 -0.0675
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated mena_expression correlates hf mena cardiac pathophysiology
H-1812	-0.8430616855621338	▁Men a ▁expression ▁ HF ▁cardiac _ ▁pat ho phy si ology
D-1812	-0.8430616855621338	Mena expression HF cardiac_ pathophysiology
P-1812	-1.4871 -0.1733 -0.2980 -0.7380 -0.1573 -4.4746 -0.6937 -1.6073 -0.3100 -0.0297 -0.4934 -0.9874 -0.2079 -0.1450
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc nps clinical
H-1024	-1.1372108459472656	▁ NP ▁PO c ▁ NP s ▁clinic al _ care _ ▁delivery
D-1024	-1.1372108459472656	NP POc NPs clinical_care_ delivery
P-1024	-1.8480 -0.1170 -3.6107 -1.1535 -2.9298 -0.0699 -0.3779 -1.5694 -0.1118 -0.3338 -2.8022 -1.4438 -0.2731 -0.3067 -0.1104
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence intestinal patients chf
H-1358	-0.7150142192840576	▁REC ENT ▁FIN DING s ▁intestinal ▁ morph ologie ▁per me ability ▁ab sor p tion _ f ré que nce
D-1358	-0.7150142192840576	RECENT FINDINGs intestinal morphologie permeability absorption_fréquence
P-1358	-0.1660 -0.5033 -1.9822 -0.2576 -0.3397 -4.3331 -0.9123 -0.0275 -0.7220 -0.3537 -0.0157 -0.7501 -0.2230 -0.0230 -0.8681 -0.1333 -1.1288 -2.3673 -0.0994 -0.0435 -0.0156 -1.0951 -0.0851
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized follow-up
H-1751	-0.8013362884521484	▁benefits
D-1751	-0.8013362884521484	benefits
P-1751	-0.8352 -1.4670 -0.1018
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis heart_failure myocardial_tissue left_ventricular trichrome_blue_histologic_analysis
H-1060	-0.7908860445022583	▁fibro sis ▁heart _ ▁failure ▁my o card ial _ ▁tissu e ▁left ▁vent ri cular _ ▁tissu e ▁tri ch rom e _ ▁blue
D-1060	-0.7908860445022583	fibrosis heart_ failure myocardial_ tissue left ventricular_ tissue trichrome_ blue
P-1060	-0.0112 -0.4348 -1.7087 -0.5534 -0.6137 -3.8727 -0.1806 -0.0947 -0.2371 -1.1764 -1.3733 -0.9008 -0.5441 -1.0635 -0.2881 -0.1848 -1.0916 -2.0833 -0.4845 -1.1055 -0.0101 -0.0506 -0.0994 -0.7389 -0.2451 -2.0470 -0.1599
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid_annular_plane_systolic_excursion pulmonary_arterial_systolic_pressure heart_failure right_ventricular_contractile_function prognosis
H-491	-1.020045518875122	▁pulmonar y ▁arterial _ syn chron e _ tension ▁heart _ ▁failure ▁vent ri cular _ contract ile
D-491	-1.020045518875122	pulmonary arterial_synchrone_tension heart_ failure ventricular_contractile
P-491	-3.9714 -0.0872 -1.4325 -0.9946 -1.9907 -0.6326 -2.2232 -0.6191 -0.5018 -0.6365 -1.1346 -3.4324 -0.5900 -0.2313 -0.1347 -0.4587 -0.2064 -0.1388 -0.7681 -0.2163
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes patients atrial_fibrillation early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial
H-1642	-0.9031142592430115	▁at rial _ f ré que nce ▁at rial _ ▁fi bril lation ▁Stro ke
D-1642	-0.9031142592430115	atrial_fréquence atrial_ fibrillation Stroke
P-1642	-1.9930 -0.1985 -0.8095 -1.9623 -0.8518 -0.6525 -0.0083 -2.8475 -0.2715 -0.6690 -3.3169 -0.0785 -0.0535 -0.1119 -0.7627 -0.6738 -0.0919
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas_city_cardiomyopathy_questionnaire kccq hf_with_reduced_ef patients hfpef
H-781	-0.8334192037582397	▁Kansas ▁City _ card i om yo pathy ▁k cc q ▁ HF ▁ef ▁ HF p EF
D-781	-0.8334192037582397	Kansas City_cardiomyopathy kccq HF ef HFpEF
P-781	-0.0113 -1.0187 -1.3015 -3.1000 -0.1331 -0.0760 -1.9723 -0.0964 -1.4886 -0.0269 -0.4439 -0.9425 -0.3789 -2.0594 -2.0514 -0.5458 -0.2088 -0.5553 -0.1677 -0.0897
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab chf nontrastuzumab_users hazard_ratio
H-679	-0.8432477712631226	▁Tras tuz um ab ▁CHF ▁non tras tuz um ab
D-679	-0.8432477712631226	Trastuzumab CHF nontrastuzumab
P-679	-1.2979 -0.0082 -0.0732 -0.1987 -0.1822 -3.4158 -0.0683 -0.0028 -0.0414 -0.6367 -4.0963 -0.0975
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood_pressure arm_cuff stroke_volume ejection_fraction end-diastolic_volume echocardiography
H-521	-0.7649779319763184	▁Blood _ tension ▁arm _ ▁cu ff ▁stroke ▁e je ction _ fraction ▁end - dia sto lique ▁e cho card i ography
D-521	-0.7649779319763184	Blood_tension arm_ cuff stroke ejection_fraction end-diastolique echocardiography
P-521	-0.3748 -1.2580 -0.3756 -0.4862 -0.4085 -0.9641 -0.2118 -0.0664 -4.4428 -0.2668 -0.0129 -0.3322 -0.0011 -1.5485 -0.0351 -1.8368 -1.3970 -3.4035 -0.4027 -0.2373 -0.1405 -0.2802 -0.3292 -0.1936 -0.1187
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients atrial_fibrillation heart_failure hf stroke anticoagulation patients
H-1353	-0.7929112911224365	▁at rial _ ▁fi bril lation AF ▁heart _ ▁failure HF ▁stroke ▁antico ag ulation
D-1353	-0.7929112911224365	atrial_ fibrillationAF heart_ failureHF stroke anticoagulation
P-1353	-0.8728 -0.0639 -0.6331 -3.5254 -0.0133 -0.0124 -1.1340 -0.2847 -0.7897 -0.6214 -0.6593 -1.1600 -2.2470 -0.8242 -0.0178 -0.5372 -0.0834
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt_loading uninephrectomy ang_ii_infusion cardiac_function hf
H-282	-0.788912296295166	▁salt _ ▁load ing ▁un ine ph r ecto my ▁ANG _ ▁II ▁in fusion ▁cardiac _ fon cti onnement ▁mi ce HF
D-282	-0.788912296295166	salt_ loading uninephrectomy ANG_ II infusion cardiac_fonctionnement miceHF
P-282	-0.2013 -3.5664 -0.1352 -0.0212 -0.0832 -0.1203 -1.6509 -0.0728 -0.0723 -1.4014 -0.4305 -1.3556 -0.5390 -0.0162 -0.1363 -0.7897 -2.4083 -1.4712 -0.8454 -0.6313 -1.7032 -0.0509 -1.8143 -0.1283 -0.0773
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck_stent myocardial_infarction antiplatelet_medication
H-508	-0.6448356509208679	▁bottle ne ck ▁sten t ▁my o card ial _ ▁in far ction ▁anti plate let
D-508	-0.6448356509208679	bottleneck stent myocardial_ infarction antiplatelet
P-508	-0.5426 -0.0418 -0.4925 -0.9574 -0.0333 -1.2687 -0.4076 -0.4319 -0.2895 -1.3335 -0.5030 -2.6213 -0.0370 -0.0264 -0.4803 -0.4016 -1.6056 -0.1333
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential_effect lvef mortality hospitalization acute decompensated_hf
H-112	-0.7336488366127014	▁LV EF ▁mortal ity ▁a cute _ de com pensa ted _ HF
D-112	-0.7336488366127014	LVEF mortality acute_decompensated_HF
P-112	-0.1161 -0.9680 -2.0089 -0.5265 -1.0454 -0.0651 -0.2648 -0.0428 -0.3291 -0.0059 -2.9648 -1.2005 -1.2364 -0.0903 -0.1401
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination echocardiographic lv_reverse_remodeling sensitivity specificity
H-433	-0.3875212073326111	▁e cho car dio graphic ▁score ▁LV ▁rever se _ ▁remodel ing
D-433	-0.3875212073326111	echocardiographic score LV reverse_ remodeling
P-433	-0.0848 -0.3474 -0.0792 -0.4837 -0.6911 -0.7806 -0.0344 -0.7073 -0.0119 -1.2135 -0.0741 -0.3498 -0.4019 -0.1656
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan_failure circulatory hemodynamic portal_hypertension cardiac_output
H-234	-0.48998504877090454	▁Font an _ ▁failure ▁circula tory _ de rang ement ▁hem o dynamic ▁portal _ ▁hyper tension ▁cardiac
D-234	-0.48998504877090454	Fontan_ failure circulatory_derangement hemodynamic portal_ hypertension cardiac
P-234	-0.2060 -0.2519 -0.4409 -0.7250 -0.2162 -0.5109 -0.3202 -0.0715 -0.3969 -0.0089 -0.6817 -0.0971 -0.0221 -1.4276 -0.7009 -0.6072 -0.0003 -0.2658 -2.7608 -0.0878
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients biventricular_support heartmate_ii lvad centrimag right_ventricular_assist_device rvad
H-296	-0.683326005935669	▁bi ven tri cular ▁support ▁Heart Mate _ ▁II ▁l VAD ▁Centri Mag ▁vent ri cular _ assist ▁device r VAD
D-296	-0.683326005935669	biventricular support HeartMate_ II lVAD CentriMag ventricular_assist devicerVAD
P-296	-0.4607 -0.2474 -0.1449 -0.8690 -2.1756 -2.5191 -0.2346 -1.4636 -0.6589 -1.1313 -0.0101 -0.1420 -0.3292 -0.6682 -0.0747 -0.0895 -0.2676 -0.1779 -1.0730 -2.6210 -0.0392 -0.1690 -0.1500
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action correlation baseline hgb baseline hrqol kccq
H-842	-0.4878690242767334	▁ HF - ac tion ▁h gb ▁HR Qo L ▁k cc q
D-842	-0.4878690242767334	HF-action hgb HRQoL kccq
P-842	-1.2052 -0.4466 -0.0248 -1.2536 -0.3730 -0.2770 -0.3011 -1.9757 -0.0335 -0.4737 -0.1301 -0.0620 -0.4098 -0.2816 -0.0705
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional_ms patients valve_plasty degenerative_mr dilated disease
H-340	-0.5899804830551147	▁functional ▁MS ▁val ve ▁plast y ▁ann ular _ size _ re duction ▁de genera tive ▁MR ▁LV
D-340	-0.5899804830551147	functional MS valve plasty annular_size_reduction degenerative MR LV
P-340	-0.1604 -0.2745 -0.9580 -0.0714 -0.5833 -0.4133 -0.0521 -0.0024 -1.1643 -1.8499 -0.3446 -0.4644 -0.0027 -1.8089 -0.7324 -0.0139 -1.1341 -0.0683 -1.6276 -0.0730
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined_training peak_work_rate peak_quadriceps_force
H-1917	-1.7895264625549316	
D-1917	-1.7895264625549316	
P-1917	-3.4224 -0.1566
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological remodelling heart cardiac_hypertrophy hf death fibrosis inflammation
H-1035	-0.4797538220882416	▁path ological ▁remodel ling ▁heart ▁cardiac ▁hyper trop hy ▁ HF ▁fibro sis ▁ inflammation
D-1035	-0.4797538220882416	pathological remodelling heart cardiac hypertrophy HF fibrosis inflammation
P-1035	-2.3309 -0.4549 -0.1472 -0.8834 -1.3537 -0.0550 -1.2242 -0.0034 -0.0243 -0.6928 -0.0835 -0.0733 -0.2375 -0.1043 -0.0425 -0.3285 -0.1163
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based prognosis idiopathic_dilated_cardiomyopathy
H-1750	-0.580782413482666	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy
D-1750	-0.580782413482666	idiopathic_ dilated_ cardiomyopathy
P-1750	-1.5569 -1.5758 -0.2282 -0.1849 -1.3423 -0.1575 -0.3174 -0.3788 -0.2460 -1.4564 -0.4069 -0.0246 -0.1595 -0.0957
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report functional_ms patient valve_plasty degenerative_mr dilated disease
H-375	-0.503425121307373	▁functional ▁MS ▁val ve ▁plast y ▁de genera tive ▁MR ▁LV ▁disease
D-375	-0.503425121307373	functional MS valve plasty degenerative MR LV disease
P-375	-0.5035 -0.4111 -0.8258 -0.0320 -0.5630 -0.4301 -1.1413 -0.5051 -0.0135 -0.6227 -0.0786 -1.6009 -0.2518 -0.0685
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty prognostic heart_failure hf biological_phenotype
H-1001	-1.045165777206421	▁Fra il ty ▁heart _ ▁failure HF ▁bi ological _ ▁ph eno type
D-1001	-1.045165777206421	Frailty heart_ failureHF biological_ phenotype
P-1001	-2.5057 -0.7421 -2.5398 -1.3931 -0.6181 -1.1352 -1.8719 -0.2791 -0.2134 -2.2514 -1.1171 -0.1115 -0.0443 -0.7511 -0.1036
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients physicians readmission hospital
H-1728	-1.4072990417480469	▁high - volu me ▁physician s
D-1728	-1.4072990417480469	high-volume physicians
P-1728	-4.9681 -0.0383 -0.1704 -0.0202 -2.3593 -0.0681 -3.5180 -0.1161
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus cells functional_capacity mortality nondiabetic patients
H-131	-1.5269838571548462	▁e - c FU s ▁CD 34 _ ve g f
D-131	-1.5269838571548462	e-cFUs CD34_vegf
P-131	-1.2311 -0.2382 -0.2403 -1.8187 -0.3770 -0.9948 -0.1639 -4.3392 -3.3749 -0.4780 -1.1948 -5.2692 -0.1307
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology comorbidities patients outcomes
H-564	-1.1624597311019897	
D-564	-1.1624597311019897	
P-564	-2.2530 -0.0719
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni cardiovascular_mortality hospitalization heart_failure quality_of_life
H-1969	-0.9026864171028137	▁AR NI ▁cardiovascular ▁mortal ity ▁hospital ization ▁heart _ ▁failure
D-1969	-0.9026864171028137	ARNI cardiovascular mortality hospitalization heart_ failure
P-1969	-3.2212 -0.8205 -0.0748 -1.1152 -0.2735 -0.3872 -0.8705 -1.3317 -0.6127 -1.5078 -0.4662 -0.1510
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right_ventricular rv prognosis patients heart_failure hf
H-1158	-1.3759409189224243	▁vent ri cular RV
D-1158	-1.3759409189224243	ventricularRV
P-1158	-2.1375 -0.2280 -0.1624 -1.3346 -4.3039 -0.0893
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial_dd muscle titin_hypophosphorylation
H-768	-0.7795963883399963	▁my o card ial ▁ DD ▁muscle _ ▁strip _ ▁sti ff ness ▁titi n ▁hypo phos phor y lation
D-768	-0.7795963883399963	myocardial DD muscle_ strip_ stiffness titin hypophosphorylation
P-768	-1.2781 -0.0917 -0.0566 -0.0810 -1.2070 -0.0533 -1.9849 -1.2698 -1.2439 -0.7388 -2.0177 -1.3176 -2.9546 -0.1465 -0.1988 -0.1205 -0.2622 -0.2811 -1.4477 -0.0639 -0.2286 -0.1071
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins expression cardiac_hypertrophy proteins nucleolin
H-95	-0.8095633387565613	▁cardiac _ ▁hyper trop hy ▁nu cle olin
D-95	-0.8095633387565613	cardiac_ hypertrophy nucleolin
P-95	-1.0053 -0.8808 -0.3920 -0.0222 -0.0827 -4.6530 -0.0134 -0.6327 -0.2666 -0.1469
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise training outcomes hf patients exercise training therapy clinical
H-1934	-1.121089220046997	▁ HF
D-1934	-1.121089220046997	HF
P-1934	-2.6644 -0.1588 -1.5369 -0.1243
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients exercise anaerobic_metabolism peak_respiratory_quotient
H-1756	-0.9886370301246643	▁ana ero bic ▁metabolism ▁respirator y
D-1756	-0.9886370301246643	anaerobic metabolism respiratory
P-1756	-4.3860 -0.6645 -0.3112 -1.4225 -0.3507 -0.0866 -0.5684 -0.1191
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ef
H-192	-1.7183235883712769	
D-192	-1.7183235883712769	
P-192	-3.3182 -0.1184
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-1.3371151685714722	▁virtual ▁co hor ts ▁coût - effect ive ness
D-2014	-1.3371151685714722	virtual cohorts coût-effectiveness
P-2014	-5.9457 -1.0522 -0.0803 -0.0773 -3.2946 -0.4071 -0.3007 -0.0748 -2.9774 -0.3740 -0.1242
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac_magnetic_resonance amyloidotic diagnosis multiple_myeloma osteomedullary_biopsy
H-999	-0.6862676739692688	▁cardiac _ ▁magnetic _ ▁res on ance ▁a my lo ido tic _ ▁pattern ▁multiple ▁mye loma ▁osteo me dulla ry ▁bio psy
D-999	-0.6862676739692688	cardiac_ magnetic_ resonance amyloidotic_ pattern multiple myeloma osteomedullary biopsy
P-999	-0.0198 -1.0342 -0.5810 -1.7565 -0.1393 -0.0244 -0.0137 -0.0168 -0.3395 -0.4325 -0.5088 -2.8203 -1.8251 -0.6056 -2.3446 -2.9560 -0.1985 -0.0177 -0.0350 -0.0957 -0.8674 -0.1262 -0.0369 -0.2985 -0.0626
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash diastolic_function ventricular-arterial_coupling hypertensive_heart_failure_with_preserved_ejection_fraction
H-915	-0.6597647070884705	▁DAS h ▁vent ri cular - arte rial ▁coup ling ▁hyper tensi ve ▁heart _ ▁failure ▁e je ction _ fraction
D-915	-0.6597647070884705	DASh ventricular-arterial coupling hypertensive heart_ failure ejection_fraction
P-915	-1.0163 -0.3234 -3.2351 -0.1366 -0.1129 -0.2177 -0.1670 -0.1734 -0.0501 -1.7135 -0.1270 -0.8771 -0.7914 -1.5323 -0.8613 -1.3329 -0.6388 -0.1927 -0.0279 -1.1934 -0.0040 -0.3457 -0.1040
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular_endothelial_growth_factor_blockade beta-blocker therapy cardiac_function angiogenesis remodeling heart_failure
H-448	-0.7162748575210571	▁Vas cular _ en dot heli al _ ▁growth _ factor _ block ade ▁beta - block er ▁ therapy ▁cardiac ▁ang io gene sis ▁remodel ing ▁heart _ ▁failure
D-448	-0.7162748575210571	Vascular_endothelial_ growth_factor_blockade beta-blocker therapy cardiac angiogenesis remodeling heart_ failure
P-448	-0.1887 -0.0747 -0.2524 -0.6901 -2.0832 -0.1709 -0.0229 -0.6459 -1.2140 -0.8551 -1.0900 -0.7566 -1.1757 -1.2399 -0.3039 -0.0104 -0.1029 -0.0966 -1.0566 -0.0257 -0.0870 -3.6761 -1.5218 -0.2142 -1.2793 -0.8310 -0.0452 -0.2372 -0.7362 -1.9915 -0.1509 -0.0942
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable_cardioverter-defibrillators icds mortality cardiac_resynchronization_therapy crt symptoms mortality
H-1068	-0.7966325879096985	▁implant able ▁implant able _ ▁cardio ver ter - de fi br illa teurs ▁i d s ▁cardiac _ re syn chron ization _ therapy ▁c RT ▁mortal ity
D-1068	-0.7966325879096985	implantable implantable_ cardioverter-defibrillateurs ids cardiac_resynchronization_therapy cRT mortality
P-1068	-0.0130 -0.0541 -0.6493 -0.1131 -0.7123 -4.1790 -0.1236 -0.0625 -0.2642 -0.0169 -6.5449 -1.0740 -0.0146 -2.0829 -1.0088 -0.6293 -0.1086 -0.0346 -1.0573 -0.6192 -0.0067 -0.0010 -0.8796 -1.4461 -0.2882 -0.3546 -0.8280 -0.7726 -0.4599 -0.2039 -0.0928
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis hfpef clinical echo-doppler_cardiography invasive_haemodynamic_assessment
H-1303	-0.544836163520813	▁ HF p EF ▁e cho - D opp ler _ card i ography ▁invasi ve ▁ha emo dynamic ▁assessment
D-1303	-0.544836163520813	HFpEF echo-Doppler_cardiography invasive haemodynamic assessment
P-1303	-1.3945 -0.6186 -0.1152 -0.8921 -0.3160 -0.1223 -0.0170 -1.2619 -0.0029 -0.4395 -1.1668 -0.8807 -0.1202 -0.2127 -0.2822 -0.4156 -0.9322 -0.5072 -0.0235 -1.9017 -0.2667 -0.0970
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker uptitrations patients hfref hfpef hospital admission
H-177	-0.6229397058486938	▁ RAS - ▁β - block er ▁h f f ▁h f p f ▁hospital _ ad mission
D-177	-0.6229397058486938	RAS- β-blocker hff hfpf hospital_admission
P-177	-0.6844 -0.0521 -0.5556 -1.3593 -0.0212 -0.1988 -0.1046 -0.4108 -1.3231 -0.4136 -2.0001 -0.5220 -0.1472 -1.1653 -0.7551 -1.6383 -0.5205 -0.0593 -0.3299 -0.1977
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular_assist_device vad extracorporeal_membrane_oxygenation ecmo renal_function
H-1385	-0.4591737687587738	▁vent ri cular _ assist ▁device VAD ▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁e mo ▁renal
D-1385	-0.4591737687587738	ventricular_assist deviceVAD extracorporeal_ membrane_ oxygenation emo renal
P-1385	-0.0031 -0.1064 -0.1174 -0.3684 -0.1401 -1.8979 -0.2908 -0.0460 -0.0279 -0.4669 -0.3429 -1.0469 -0.1326 -0.2481 -0.4792 -0.0938 -0.0141 -0.5147 -0.7534 -0.0311 -2.8568 -0.1234
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american_college_of_cardiology american_heart_association patients ras patients ras
H-1604	-0.8220507502555847	▁American ▁College _ de _ ▁Card i ology _ American _ ▁Heart ▁association ▁ RAS
D-1604	-0.8220507502555847	American College_de_ Cardiology_American_ Heart association RAS
P-1604	-2.1536 -0.4794 -0.1354 -1.1812 -0.0747 -0.6804 -0.3729 -0.2986 -3.7095 -0.2728 -0.5083 -0.4493 -2.2355 -0.9735 -0.0673 -0.2906 -0.0920
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv_remodeling diastolic xo_inhibition symptoms hospitalizations patients severe_heart_failure
H-478	-0.8961896300315857	▁LV ▁remodel ing ▁dia sto lic ▁properties ▁ XO
D-478	-0.8961896300315857	LV remodeling diastolic properties XO
P-478	-0.0096 -0.6578 -0.0615 -0.4446 -0.4462 -1.4302 -1.8732 -0.4053 -0.0707 -4.3283 -0.1306
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile_function lv_dilatation lv_end-diastolic_pressure wall_stress lung
H-476	-0.844048798084259	▁contract ile _ fon cti onnement ▁LV ▁di la tation ▁LV ▁end - dia sto lic _ tension wall _ ▁stress ▁lung _ weight
D-476	-0.844048798084259	contractile_fonctionnement LV dilatation LV end-diastolic_tensionwall_ stress lung_weight
P-476	-0.0323 -0.1823 -1.5277 -1.0460 -0.6682 -0.6152 -0.1017 -2.3102 -0.0734 -0.0222 -1.7305 -1.5996 -0.0123 -0.7881 -0.6951 -1.8020 -1.3492 -0.2970 -2.0122 -0.7073 -1.3590 -0.0249 -1.6875 -0.9162 -0.2763 -0.1092
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating_progenitor_cells cpcs endothelial prognostic cardiovascular_diseases
H-120	-0.5422565340995789	▁Circula tion _ pro gen itor ▁cell s ▁c PC s ▁en dot heli al _ ▁repair ▁cardiovascular
D-120	-0.5422565340995789	Circulation_progenitor cells cPCs endothelial_ repair cardiovascular
P-120	-0.2067 -1.3008 -0.3008 -0.1664 -0.3111 -0.2393 -1.8188 -0.0532 -0.0656 -0.7254 -0.1113 -0.0828 -0.6710 -0.0600 -0.0172 -1.5994 -0.0742 -0.1256 -2.8320 -0.0835
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable_cardioverter-defibrillator physicians heart_failure patients
H-1857	-0.9067612290382385	▁implant able ▁implant able _ ▁cardio ver ter - de _ fi br illa tor _ de _ activa tion ▁heart _ ▁failure
D-1857	-0.9067612290382385	implantable implantable_ cardioverter-de_fibrillator_de_activation heart_ failure
P-1857	-0.0005 -0.0462 -1.3089 -0.0736 -1.7330 -0.8174 -0.1990 -0.0271 -0.2362 -0.0054 -3.1035 -4.5248 -1.2913 -0.0069 -0.3106 -0.4273 -0.0387 -1.7179 -0.0748 -0.1645 -2.9146 -1.3255 -1.1883 -0.9554 -0.1775
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp plasma patients dyspnea left_ventricular_dysfunction admission
H-265	-0.519207775592804	▁NT - pro b NP ▁plasma ▁dys pne a ▁left ▁vent ri cular _ ▁dys function ▁ED
D-265	-0.519207775592804	NT-probNP plasma dyspnea left ventricular_ dysfunction ED
P-265	-0.2731 -0.0205 -0.0085 -0.5566 -0.1343 -1.7346 -0.1554 -0.2624 -0.6938 -0.4617 -1.0390 -0.5266 -0.3941 -1.3445 -0.1787 -0.7441 -1.0347 -0.1937 -0.1085
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped snp rs10927887 ka_renal_chloride_channel_gene clcnka
H-1802	-1.0542610883712769	▁Cau ca sian ▁s NP ▁rs 109 27 887 ▁Ka ▁renal _ ▁chlor ide _ ▁channel _ géné ral ▁c CN KA
D-1802	-1.0542610883712769	Caucasian sNP rs10927887 Ka renal_ chloride_ channel_général cCNKA
P-1802	-2.9388 -0.0071 -0.2907 -2.0661 -0.1802 -1.1156 -0.0772 -0.8919 -0.1963 -3.1817 -0.3597 -0.4999 -0.5048 -0.0969 -2.4126 -0.3162 -0.4987 -2.8609 -1.1561 -2.3447 -1.8637 -1.0793 -0.2464 -0.1167
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician outcomes patients outcomes medically diseases hf
H-1722	-0.7990393042564392	▁Physic ian _ ▁volume ▁med ically _ ▁managed ▁disease s ▁ HF
D-1722	-0.7990393042564392	Physician_ volume medically_ managed diseases HF
P-1722	-0.1078 -0.6527 -1.5118 -0.9274 -2.1203 -0.2712 -0.8842 -0.0364 -2.2286 -0.0321 -2.1386 -0.0600 -0.1098 -0.1059
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients frail frail biological_phenotype
H-1007	-1.000957727432251	▁fra il
D-1007	-1.000957727432251	frail
P-1007	-1.9641 -0.2193 -1.7600 -0.0604
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients lbbb implantable primary_outcome primary_outcome
H-887	-0.5491583347320557	LB BB ▁implant able ▁implant able _ ▁cardio ver ter _ de _ fi br illa tor - c RT
D-887	-0.5491583347320557	LBBB implantable implantable_ cardioverter_de_fibrillator-cRT
P-887	-0.5300 -1.0115 -0.0004 -0.0332 -1.1480 -0.0384 -0.8358 -0.4187 -0.1511 -0.0455 -0.1968 -0.0112 -2.7419 -1.9488 -0.8052 -0.0050 -0.1611 -0.1561 -0.4374 -0.8476 -0.4415 -0.1161
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm outcomes discharged admission heart_failure
H-149	-1.1791203022003174	▁RM ▁dis charge d ▁heart _ ▁failure
D-149	-1.1791203022003174	RM discharged heart_ failure
P-149	-0.6446 -3.5686 -0.0026 -0.4588 -3.4168 -1.0078 -1.2152 -0.2068 -0.0910
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients exercise-induced_pasp pasp patients pasp
H-827	-0.8507824540138245	▁exercise - indu ced ▁PAS p ▁h g ▁PAS p
D-827	-0.8507824540138245	exercise-induced PASp hg PASp
P-827	-3.6588 -0.1330 -0.0009 -1.8991 -0.8576 -0.3795 -0.0721 -0.0209 -2.1246 -0.5491 -0.4353 -0.0784
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone patients hf-ref hyperkalemia patients
H-1224	-0.4986479878425598	▁e pler en one ▁ HF - re f ▁hyper kal emia ▁W RF
D-1224	-0.4986479878425598	eplerenone HF-ref hyperkalemia WRF
P-1224	-0.1897 -0.5629 -0.4311 -3.4229 -0.3604 -0.2140 -0.0311 -0.3653 -0.0972 -0.0660 -0.4052 -0.3524 -0.7510 -0.3363 -0.2791 -0.1140
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping myocardial heart_failure
H-1063	-0.8599830865859985	▁t 1- ma pping ▁technique ▁diffuse _ ▁my o card ial ▁changes ▁heart _ ▁failure ▁contrast ▁agent ▁breath - hold ing
D-1063	-0.8599830865859985	t1-mapping technique diffuse_ myocardial changes heart_ failure contrast agent breath-holding
P-1063	-4.8384 -0.4370 -0.2011 -0.4884 -0.6013 -0.3815 -0.8388 -2.9626 -0.3573 -0.1890 -0.1944 -2.0517 -0.2268 -0.7818 -2.2805 -0.5270 -1.7292 -0.0242 -0.0575 -0.0216 -0.0913 -0.3283 -0.1702
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt dt btt patients
H-314	-0.7953715920448303	▁b t ▁ DT ▁coût - effect ive ness ▁b t
D-314	-0.7953715920448303	bt DT coût-effectiveness bt
P-314	-0.1309 -0.4147 -1.1851 -0.2466 -1.6817 -0.1833 -0.3987 -0.1562 -3.4058 -0.7748 -0.4370 -1.2066 -0.1183
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients hfpef longitudinal cardiac_event
H-738	-0.8102201223373413	▁h f f
D-738	-0.8102201223373413	hff
P-738	-0.1415 -0.0952 -0.1088 -3.6062 -0.0994
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure health income hf
H-1800	-1.0606831312179565	▁ex pendi ture ▁health _ per ▁capita ▁gross _ national _ ▁income ▁ HF
D-1800	-1.0606831312179565	expenditure health_per capita gross_national_ income HF
P-1800	-1.5972 -0.0144 -0.5361 -2.3999 -3.3131 -0.2863 -0.8091 -2.2528 -0.4920 -1.4682 -0.7941 -0.2181 -1.6471 -0.3739 -0.6537 -0.1149
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals patients hfpef
H-952	-0.5372188687324524	▁af ▁ pharma ce u tical s ▁h f f f
D-952	-0.5372188687324524	af pharmaceuticals hfff
P-952	-0.4932 -1.7645 -0.0524 -0.1293 -0.3128 -1.6186 -0.0636 -0.0952 -0.3456 -0.3037 -1.0520 -0.6013 -0.1517
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies crt-d heart_failure death
H-108	-1.0775662660598755	▁i s ▁c RT - d ▁heart _ ▁failure
D-108	-1.0775662660598755	is cRT-d heart_ failure
P-108	-2.1614 -0.5359 -0.0464 -1.2857 -0.0575 -0.5533 -3.6160 -1.2899 -1.7743 -0.3967 -0.1361
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt atrial_pacing
H-1442	-0.7903554439544678	▁SD QT ▁ HF VT ▁h nor m ▁fixed - rate _ at rial _ pa cing
D-1442	-0.7903554439544678	SDQT HFVT hnorm fixed-rate_atrial_pacing
P-1442	-0.0185 -0.7821 -0.7552 -0.6149 -0.8478 -0.2123 -2.7064 -0.0024 -3.4170 -0.0460 -0.4264 -0.1346 -1.6099 -0.2116 -1.2957 -0.7958 -0.6120 -0.4000 -0.1283
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical bnp inhospital mortality
H-196	-0.4766632318496704	▁b NP ▁in hospital _ ▁mortal ity
D-196	-0.4766632318496704	bNP inhospital_ mortality
P-196	-0.1049 -1.5126 -0.3846 -0.1767 -0.8868 -0.2188 -0.3710 -0.5481 -0.0865
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood_pressure therapy patients ras
H-1600	-0.5785865783691406	▁blood _ tension ▁lipid - lo wering ▁ therapy ▁smoking ▁ RAS
D-1600	-0.5785865783691406	blood_tension lipid-lowering therapy smoking RAS
P-1600	-1.0731 -1.0082 -0.6448 -0.3921 -0.0783 -0.1093 -0.0284 -1.7947 -0.1336 -0.0336 -2.5727 -0.0549 -0.0669 -0.1096
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs_morphology cardiac_resynchronization_therapy crt
H-880	-0.4841654598712921	▁QR s ▁ morph ologie ▁cardiac _ re syn chron ization _ therapy ▁c RT
D-880	-0.4841654598712921	QRs morphologie cardiac_resynchronization_therapy cRT
P-880	-0.1858 -0.5110 -0.8352 -0.0408 -1.1714 -0.0603 -0.8465 -0.7535 -0.0314 -0.0015 -1.2045 -0.9910 -0.3211 -0.4812 -0.5820 -0.1285 -0.0853
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial_complex_v_activity phosphocreatine atp
H-1786	-0.748518705368042	▁mito cho ndri al _ ▁complex _ V ▁activity ▁a ac ▁ phos pho creati ne ▁ATP
D-1786	-0.748518705368042	mitochondrial_ complex_V activity aac phosphocreatine ATP
P-1786	-0.8401 -2.1678 -0.3240 -0.0930 -0.4067 -0.9484 -0.5653 -2.0122 -1.0253 -0.6142 -1.0311 -0.4572 -0.1164 -0.9515 -0.8912 -1.1903 -0.2435 -0.2370 -0.1065
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire implanted pacemakers ventricularly beats heart_failure
H-1056	-0.7547120451927185	▁York shire ▁s win e ▁implant ed ▁pace makers ▁vent ri cular ly ▁pace d ▁heart _ ▁failure
D-1056	-0.7547120451927185	Yorkshire swine implanted pacemakers ventricularly paced heart_ failure
P-1056	-1.5364 -0.0237 -1.3957 -0.5324 -0.0958 -0.0185 -0.6671 -1.3898 -0.0455 -0.0109 -0.1223 -0.0264 -0.1477 -3.3963 -0.3077 -2.3177 -1.1803 -1.5503 -0.2349 -0.0947
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality heart_failure hf implantable_cardioverter_defibrillators icds
H-60	-0.8341788649559021	▁implant able _ ▁cardio ver ter _ de _ fi br illa teurs IC d s
D-60	-0.8341788649559021	implantable_ cardioverter_de_fibrillateursICds
P-60	-2.2993 -0.1626 -0.9717 -0.8251 -0.1548 -0.0436 -0.2212 -0.0202 -3.4097 -1.7471 -0.7134 -0.0075 -1.7248 -1.8443 -0.2480 -0.0622 -0.4119 -0.1478
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular_outcomes_in_renal_atherosclerotic_lesions coral stenting ras
H-1602	-0.5549704432487488	▁Card io vas cular ▁Out com es ▁Ren al _ ▁Ath eros cle ro tic _ ▁Les ions co RAL ▁sten ting ▁ RAS
D-1602	-0.5549704432487488	Cardiovascular Outcomes Renal_ Atherosclerotic_ LesionscoRAL stenting RAS
P-1602	-0.1266 -2.0137 -0.2107 -0.3459 -2.3643 -0.0133 -0.1672 -0.0572 -0.0331 -0.3736 -0.1194 -0.1714 -0.0602 -0.4555 -0.7731 -0.8674 -0.6682 -0.0668 -2.3638 -0.1429 -0.3512 -1.9731 -0.5245 -0.0229 -0.0965 -0.0665
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi metoprolol elevated plasma_norepinephrine dopamine elevated epinephrine
H-1550	-0.7120152711868286	▁MI ▁met o pro lol ▁plasma ▁no re pine ph rine ▁dop amine ▁e pine ph rine
D-1550	-0.7120152711868286	MI metoprolol plasma norepinephrine dopamine epinephrine
P-1550	-0.8815 -2.1142 -0.0923 -0.0277 -0.3851 -0.1903 -1.0273 -0.2317 -0.3904 -3.8034 -0.9135 -0.0378 -0.1189 -0.0660 -0.0728 -2.2737 -0.5578 -0.2369 -0.1070
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 cardioprotective_signaling myocardium biomarker heart_failure hf
H-696	-0.5761743187904358	▁st 2 ▁cardio protec tive _ ▁signal ing ▁my o car dium ▁bio mark er ▁heart _ ▁failure HF
D-696	-0.5761743187904358	st2 cardioprotective_ signaling myocardium biomarker heart_ failureHF
P-696	-2.8072 -0.0566 -0.1594 -0.0495 -0.0284 -0.6361 -1.2069 -0.6125 -1.4013 -0.0490 -0.0065 -0.0645 -0.0189 -0.0086 -0.1488 -2.1749 -0.6107 -1.4399 -0.3371 -0.1814 -0.1014
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal_muscle sarcomere patients heart_failure type_2_diabetes
H-1243	-0.6682239174842834	▁skelet al _ syn chron e _ ▁structure ▁heart _ ▁failure ▁diabetes ▁e pica tech in - rich ▁coco a
D-1243	-0.6682239174842834	skeletal_synchrone_ structure heart_ failure diabetes epicatechin-rich cocoa
P-1243	-0.7735 -0.2116 -0.9076 -3.5912 -0.1931 -0.6460 -0.4965 -2.5488 -1.6328 -0.9613 -0.6986 -0.0766 -0.2643 -0.0078 -0.0523 -0.3181 -0.1872 -0.0003 -0.6306 -0.0826 -0.3219 -0.0983
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene pathological heart_disease transcription_factors driving gene
H-639	-1.364549160003662	▁em bry o nic _ ▁gene ▁programs ▁path ological _ ▁heart ▁disease
D-639	-1.364549160003662	embryonic_ gene programs pathological_ heart disease
P-639	-0.5242 -0.0881 -0.1324 -2.3815 -2.5616 -1.9590 -2.8307 -0.1334 -0.5392 -1.2091 -1.1205 -3.9461 -1.4311 -0.2468
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart_rate ivabradine afterload patients systolic_heart_failure
H-516	-1.1896456480026245	▁heart _ ▁rate HR ▁i va bra dine ▁sy sto lic _ ▁heart _ ▁failure
D-516	-1.1896456480026245	heart_ rateHR ivabradine systolic_ heart_ failure
P-516	-2.6591 -1.6612 -1.2872 -1.2103 -0.0519 -0.0169 -0.6468 -0.0247 -5.2326 -0.2425 -3.6182 -0.2653 -1.7451 -0.5855 -0.6453 -0.2281 -0.1033
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard_error_of_measurement mdc clinical change
H-807	-0.6856747269630432	▁m d c
D-807	-0.6856747269630432	mdc
P-807	-0.3776 -0.3360 -1.3528 -1.2273 -0.1346
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient emergency_department acute_heart_failure ahf clinical
H-57	-0.9261051416397095	▁a cute _ heart _ ▁failure ▁a HF
D-57	-0.9261051416397095	acute_heart_ failure aHF
P-57	-3.1585 -0.1969 -0.1817 -2.4206 -0.5256 -1.2118 -0.7956 -0.2854 -0.3467 -0.1382
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic patients reverse_remodeling crt clinical outcomes
H-436	-0.529168963432312	▁multi para metric ▁e cho car dio graphic ▁score ▁rever se ▁remodel ing ▁c RT
D-436	-0.529168963432312	multiparametric echocardiographic score reverse remodeling cRT
P-436	-0.8422 -0.1565 -0.2620 -1.4119 -1.0710 -0.0772 -0.5607 -1.0129 -1.0130 -0.1263 -0.0052 -0.6998 -0.0906 -0.3651 -0.7922 -0.4018 -0.1075
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis biomedical biomedical patients dcm heart_failure
H-1264	-0.8062447905540466	▁bio medic al ▁treatment ▁CH m ▁bio medic al ▁treatment ▁d CM ▁heart _ ▁failure
D-1264	-0.8062447905540466	biomedical treatment CHm biomedical treatment dCM heart_ failure
P-1264	-0.1306 -0.2251 -0.0158 -3.0690 -2.7497 -0.0335 -0.1348 -0.0407 -0.0128 -2.9589 -0.3008 -0.3919 -0.6468 -1.0843 -1.3841 -0.3702 -0.1574
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal_flow_pump hemocompatibility blood-flow pulse
H-1994	-0.5649548172950745	▁centri fu gal _ f ré que nce _ pump ▁hem o com pati bility ▁magnet ically ▁le vita ted ▁ro tor ▁blood - flow
D-1994	-0.5649548172950745	centrifugal_fréquence_pump hemocompatibility magnetically levitated rotor blood-flow
P-1994	-0.1883 -0.2164 -0.1320 -0.2511 -2.7012 -0.5615 -0.1101 -0.0392 -0.3841 -1.1635 -0.5779 -0.0690 -0.1706 -0.1083 -0.5016 -0.2013 -0.3905 -0.9460 -0.0426 -2.0652 -0.1457 -0.0232 -0.9172 -0.0702 -0.1200 -3.0762 -0.0809
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients sst2 sst2 odds_ratios cardiovascular_events
H-409	-1.3901287317276	▁s st 2/ low - dos e ▁b ▁s st 2/ high - dos e ▁cardiovascular ▁events
D-409	-1.3901287317276	sst2/low-dose b sst2/high-dose cardiovascular events
P-409	-0.5541 -1.8581 -4.1043 -1.7241 -0.0091 -1.2165 -0.2958 -3.7384 -1.0748 -1.6901 -1.6543 -1.1515 -0.0198 -0.8516 -0.1321 -2.6282 -3.3208 -0.2586 -0.1303
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary_approaches_to_stop_hypertension dash mortality postmenopausal hf
H-686	-0.5945098400115967	▁Mediterrane an ▁Diet ary _ App ro ach es _ ▁to _ ▁Stop _ ▁Hyper tension DAS h ▁mortal ity ▁post meno paus al ▁women HF
D-686	-0.5945098400115967	Mediterranean Dietary_Approaches_ to_ Stop_ HypertensionDASh mortality postmenopausal womenHF
P-686	-0.0726 -0.0191 -0.9794 -0.6762 -0.6231 -0.7310 -0.1452 -1.1271 -0.0659 -0.6211 -2.4364 -0.6271 -0.3321 -0.1419 -1.1951 -0.0016 -0.3066 -0.2547 -0.1650 -0.4750 -0.7620 -0.1576 -0.0120 -0.0372 -3.1369 -1.2519 -0.1702 -0.1226
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc diagnostic
H-1025	-1.3320518732070923	▁PO c ▁ NP
D-1025	-1.3320518732070923	POc NP
P-1025	-1.4534 -1.4365 -3.8973 -0.0662 -0.9977 -0.1411
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality_of_life functional_capacity
H-618	-1.9624338150024414	
D-618	-1.9624338150024414	
P-618	-3.8189 -0.1060
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography cardiac cardiac_function
H-453	-0.7434415221214294	▁e cho card i ography ▁cardiac _ ▁diameter s ▁b - tre ated
D-453	-0.7434415221214294	echocardiography cardiac_ diameters b-treated
P-453	-0.0797 -0.5632 -0.1595 -0.4628 -0.3560 -0.1850 -2.6239 -0.3342 -0.0285 -3.2855 -0.0882 -0.0170 -0.8640 -2.0391 -0.0651
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients lbbb qrs implantable
H-890	-0.5245973467826843	LB BB ▁implant able ▁cardio ver ter _ de _ fi br illa tor - c RT
D-890	-0.5245973467826843	LBBB implantable cardioverter_de_fibrillator-cRT
P-890	-0.5268 -0.8358 -0.6989 -0.0316 -1.3346 -0.1044 -0.0350 -0.3403 -0.0065 -2.7557 -1.0232 -0.4985 -0.0044 -0.1026 -0.0992 -0.4394 -0.7434 -0.2993 -0.0876
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality readmissions costs patient physician hospital
H-1725	-0.7747225165367126	▁mortal ity ▁read missions ▁costs ▁physician ▁hospital
D-1725	-0.7747225165367126	mortality readmissions costs physician hospital
P-1725	-2.8025 -0.4464 -0.5090 -0.0205 -0.4110 -2.1925 -0.1488 -0.3433 -0.0985
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline embase psycinfo
H-151	-0.500985860824585	▁MED line ▁ EMBA se ▁Psy c INFO
D-151	-0.500985860824585	MEDline EMBAse PsycINFO
P-151	-1.5792 -1.2216 -1.2845 -0.0073 -0.4353 -0.0856 -0.0148 -0.0137 -0.3226 -0.0453
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized medical
H-1977	-2.1137213706970215	
D-1977	-2.1137213706970215	
P-1977	-4.1726 -0.0549
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic interatrial_shunting patients heart_failure_with_reduced_ejection_fraction
H-1950	-0.6819055080413818	▁ therapeut ic ▁left - to - right ▁inter at rial _ ▁sh unting ▁heart _ ▁failure ▁e je ction _ fraction
D-1950	-0.6819055080413818	therapeutic left-to-right interatrial_ shunting heart_ failure ejection_fraction
P-1950	-2.8995 -0.1491 -0.4767 -1.7376 -0.0252 -0.7368 -0.0710 -0.2916 -0.2504 -0.2549 -0.2887 -1.8339 -1.1400 -0.1690 -1.1089 -0.9769 -1.4068 -0.4430 -0.3476 -0.0490 -1.3177 -0.0062 -0.2768 -0.1086
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients systolic_hf cxl-1020 right_heart_filling_pressures systemic_vascular_resistance cardiac stroke_volume_index
H-423	-1.181331992149353	▁sy sto lic ▁ HF ▁c XL _ -10 20 ▁left _ ▁right ▁heart _ ▁fill ing _ tension s ▁système ic _ ▁vas cular _ ▁resist ance ▁cardiac ▁stroke
D-423	-1.181331992149353	systolic HF cXL_-1020 left_ right heart_ filling_tensions systèmeic_ vascular_ resistance cardiac stroke
P-423	-3.8663 -0.1674 -1.0767 -1.5448 -0.0845 -0.3926 -0.1353 -3.7895 -0.6008 -0.3655 -1.1807 -2.9800 -3.6816 -2.0139 -4.0731 -0.1314 -0.0771 -1.3900 -0.1785 -0.1349 -0.6607 -3.2615 -0.2611 -1.0462 -0.2340 -1.2659 -1.8673 -0.0106 -0.0788 -0.8090 -0.3335 -0.1096
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart_failure hypertension mitral_regurgitation mitral_stenosis medical_treatment heart_failure
H-336	-0.5678091645240784	▁heart _ ▁failure ▁hyper tension ▁mit ral _ re gur gi tation ▁mit ral ▁sten osis
D-336	-0.5678091645240784	heart_ failure hypertension mitral_regurgitation mitral stenosis
P-336	-0.6941 -0.6769 -1.2206 -0.0975 -0.0008 -0.0947 -0.0118 -0.4598 -0.9755 -0.0368 -0.0438 -0.0357 -0.3711 -0.0141 -1.1857 -0.0751 -4.1310 -0.0956
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk scn5a kv4.3 mrnas transient_receptor_potential_cation_channel_m7 trpm7 mrna
H-1086	-0.9694174528121948	▁PER K _ activa tion ▁s CN 5 a ▁kv 4.3 ▁m RNA s ▁trans ient _ ▁receptor ▁m d p ▁m RNA
D-1086	-0.9694174528121948	PERK_activation sCN5a kv4.3 mRNAs transient_ receptor mdp mRNA
P-1086	-1.6743 -1.0305 -3.9703 -0.4570 -0.0198 -1.4101 -0.7660 -0.8070 -0.0866 -0.1156 -1.5299 -0.4558 -0.1148 -0.5430 -0.0069 -0.0752 -1.6298 -0.1709 -1.7262 -2.2414 -0.6700 -3.9659 -0.3137 -0.3430 -0.1118
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients implantable_cardioverter-defibrillator heart_function_clinic university_health_network toronto canada
H-1861	-0.8500658869743347	▁implant able _ ▁cardio ver ter - de _ f ré br illa tor ▁Heart _ ▁Fun ction ▁Clinic ▁University _ ▁Health _ ▁Network Tor onto
D-1861	-0.8500658869743347	implantable_ cardioverter-de_frébrillator Heart_ Function Clinic University_ Health_ NetworkToronto
P-1861	-0.0003 -0.0348 -1.6777 -0.8509 -0.1932 -0.0680 -0.1353 -0.0132 -3.7936 -1.7969 -1.0599 -2.8146 -0.0062 -0.1080 -1.1338 -0.2060 -0.2552 -0.0015 -0.6759 -2.4342 -0.1310 -1.2744 -1.6207 -0.3006 -1.3178 -0.0049 -1.7905 -0.1030
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients followed_up composite_primary_outcome cardiovascular_death stroke heart_failure myocardial_infarction
H-1650	-0.8134608864784241	▁cardiovascular _ ▁death ▁stroke ▁heart _ ▁failure ▁my o card ial _ ▁in far ction
D-1650	-0.8134608864784241	cardiovascular_ death stroke heart_ failure myocardial_ infarction
P-1650	-1.7935 -2.5812 -0.6323 -1.2005 -0.5494 -0.6825 -1.6765 -0.7557 -0.2139 -0.1648 -0.3371 -0.5467 -0.8656 -1.1580 -0.1779 -0.3271 -0.1661
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced_pasp clinical prognostic pulmonary_hypertension patients right_ventricular_contractile_reserve
H-831	-0.6779668927192688	▁Exerci se - indu ced ▁PAS p ▁pulmonar y ▁hyper tension ▁vent ri cular _ contract ile
D-831	-0.6779668927192688	Exercise-induced PASp pulmonary hypertension ventricular_contractile
P-831	-4.6793 -0.7106 -0.0741 -0.0004 -2.0987 -0.1194 -0.4836 -0.0040 -0.2348 -0.7435 -0.0004 -0.1557 -0.2280 -0.2602 -1.0284 -0.1765 -0.3486 -1.4354 -0.1000
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists renin-angiotensin-aldosterone sympathetic_nervous_systems clinical outcomes chf
H-636	-0.9380993247032166	▁re nin - angi oten sin - al do ster one ▁sympa the tic _ organ s ▁CHF
D-636	-0.9380993247032166	renin-angiotensin-aldosterone sympathetic_organs CHF
P-636	-0.5445 -0.7182 -0.0270 -0.0316 -0.0112 -2.0626 -0.3318 -0.0545 -1.0967 -0.0269 -1.4503 -0.0736 -0.5109 -2.2724 -0.2719 -4.9563 -3.0661 -1.1188 -0.0708 -0.0660
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization_therapy crt morbidity mortality chronic_systolic_heart_failure wide_qrs_complex
H-845	-0.9356725215911865	▁Card iac - re syn chron ization _ therapy ▁c RT ▁mortal ity ▁chronic _ ▁sy sto lic _ ▁heart _ ▁failure ▁QR s
D-845	-0.9356725215911865	Cardiac-resynchronization_therapy cRT mortality chronic_ systolic_ heart_ failure QRs
P-845	-0.5969 -0.2493 -0.0596 -0.1413 -0.0252 -0.0011 -1.0101 -1.0831 -0.6914 -0.4532 -1.1211 -4.4618 -0.3400 -1.1858 -1.3751 -1.5417 -0.1941 -3.6951 -0.2269 -1.2315 -0.8767 -2.5647 -0.0691 -0.8747 -0.1629 -0.0949
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate unfolded_protein_response upr scn5a remodeling hf
H-1081	-0.47076088190078735	▁tru nca ted ▁na + ▁channel s ▁un fold ed _ ▁protein ▁response ▁u PR ▁s CN 5 a ▁electric ▁remodel ing ▁ HF
D-1081	-0.47076088190078735	truncated na+ channels unfolded_ protein response uPR sCN5a electric remodeling HF
P-1081	-0.2299 -0.0652 -1.4112 -0.5461 -2.2697 -0.2859 -0.0379 -0.1575 -0.0027 -0.1210 -0.6961 -0.4308 -1.6146 -0.1292 -0.3001 -1.2432 -0.6332 -0.3219 -0.1189 -0.0648 -0.3557 -0.0420 -0.7591 -0.2075 -0.1208 -0.0746
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international_right_heart_foundation_working_group step syndrome right_heart_failure
H-1458	-1.4659792184829712	▁Right _ ▁Heart _ ▁Foundation ▁defect s ▁right _ ▁Heart _ ▁failure
D-1458	-1.4659792184829712	Right_ Heart_ Foundation defects right_ Heart_ failure
P-1458	-3.7214 -1.6984 -0.3163 -1.3968 -0.0780 -3.7448 -0.1037 -4.4601 -0.7774 -1.6132 -0.8892 -1.4193 -0.1873 -0.1177
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber_dynamics myofiber_shortening emd dyssynchronous_hf
H-1156	-0.7525140047073364	▁changes ▁my o fi ber ▁dynamic s ▁my o fi ber _ ▁short en ing ▁em d ▁dys syn chron ous ▁ HF
D-1156	-0.7525140047073364	changes myofiber dynamics myofiber_ shortening emd dyssynchronous HF
P-1156	-2.1906 -0.7667 -0.2016 -1.1673 -0.2506 -1.8485 -0.0126 -0.2542 -0.0948 -1.4164 -0.2549 -1.8758 -1.0608 -0.0587 -0.4046 -0.9720 -0.1533 -0.0749 -0.0017 -0.0006 -3.3817 -1.9564 -0.1153 -0.1776 -0.1213
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial_index pulse-wave coronary_artery_calcium_scores
H-1562	-0.5158562064170837	▁an kle - bra chi al ▁index ▁puls e - wa ve _ ▁veloci ty ▁corona ry ▁arter y ▁calci um ▁score s
D-1562	-0.5158562064170837	ankle-brachial index pulse-wave_ velocity coronary artery calcium scores
P-1562	-1.5881 -0.4595 -0.0729 -0.8360 -0.1909 -0.0879 -0.4416 -0.2768 -0.2437 -0.0378 -0.4859 -0.0378 -1.3394 -1.6619 -0.9212 -0.0663 -0.4073 -0.8614 -0.3765 -0.4993 -0.0166 -1.5718 -0.0685 -0.2614 -0.0860
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol lv_contractile_function xo-mediated_ros myofilament sensitivity
H-477	-0.6008243560791016	▁allo puri nol ▁LV ▁contract ile _ f ré que nce ▁ ROS ▁my o fila ment
D-477	-0.6008243560791016	allopurinol LV contractile_fréquence ROS myofilament
P-477	-0.2550 -0.0215 -0.2332 -0.3205 -0.1260 -0.2834 -1.1080 -2.5667 -0.1608 -0.0571 -0.0208 -0.3665 -1.9665 -3.0399 -0.0355 -0.0082 -0.0728 -0.6873 -0.0860
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk_stratification antiplatelet_agents combination anticoagulants vascular_diseases
H-1355	-0.9354450106620789	▁anti plate let ▁agents ▁antico a gul ants ▁vas cular ▁disease s
D-1355	-0.9354450106620789	antiplatelet agents anticoagulants vascular diseases
P-1355	-1.5624 -2.6801 -1.6851 -0.4279 -0.2302 -0.4513 -0.2643 -0.0329 -1.3382 -0.1739 -3.8234 -0.0262 -0.3063 -0.0941
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac_hypertrophy pressure-overload abdominal_aortic_constriction aac
H-1780	-0.5329551100730896	▁cardiac _ ▁hyper trop hy ▁pressure - over load ▁abdominal ▁a or tic _ con stri ction ▁a ac
D-1780	-0.5329551100730896	cardiac_ hypertrophy pressure-overload abdominal aortic_constriction aac
P-1780	-1.2604 -0.9470 -0.6987 -0.0199 -0.0832 -0.7924 -0.2126 -0.3652 -0.2460 -0.0753 -0.8587 -0.4643 -1.9026 -0.3783 -0.1144 -0.6525 -0.0596 -0.6441 -1.1016 -0.1876 -0.1276
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf hf epidemiology rheumatic_fever
H-1799	-0.6341795921325684	▁ HF ▁ HF ▁epidemi ologie ▁SH ▁c d ▁rhe u matic ▁fe ver
D-1799	-0.6341795921325684	HF HF epidemiologie SH cd rheumatic fever
P-1799	-1.1585 -0.5210 -1.5356 -0.1963 -1.7467 -1.6392 -0.7430 -0.5455 -0.5861 -0.0995 -0.0782 -0.6246 -0.1956 -0.0423 -0.3009 -0.1338
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications patients heart_failure_and_reduced_ejection_fraction outpatient
H-667	-0.890129566192627	▁medication s ▁heart _ ▁failure ▁e je ction _ fraction
D-667	-0.890129566192627	medications heart_ failure ejection_fraction
P-667	-3.8074 -0.0511 -1.2820 -1.1379 -0.8427 -0.8956 -0.7235 -0.0384 -0.8968 -0.0153 -0.8230 -0.1678
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise training exercise exercise_capacity qol obese patients hfpef
H-1976	-0.7382400631904602	▁calor ic ▁restriction ▁aero bic ▁exercise _ training _ exe rci se ▁Q OL ▁h f f
D-1976	-0.7382400631904602	caloric restriction aerobic exercise_training_exercise QOL hff
P-1976	-0.4811 -0.4639 -0.2651 -3.4116 -0.0696 -1.0395 -1.2999 -0.5228 -2.4899 -0.5413 -0.0573 -0.0554 -0.9586 -0.3097 -0.8511 -0.2528 -0.3447 -0.5159 -0.0962
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic_heart_failure hf hemodynamic syndrome dysfunction molecular_pathways
H-1472	-0.9029720425605774	▁chronic _ ▁heart _ ▁failure HF ▁hem o dynamic _ ▁disorder ▁syndrome ▁dys function
D-1472	-0.9029720425605774	chronic_ heart_ failureHF hemodynamic_ disorder syndrome dysfunction
P-1472	-2.4097 -0.5401 -2.0180 -0.5201 -1.2091 -0.4041 -0.3492 -0.0810 -0.0337 -1.7121 -0.5786 -1.0942 -0.1211 -1.2204 -2.0353 -0.1210
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms hfpef diastolic_filling_time heart_rate symptoms
H-1172	-1.0488214492797852	▁ HF p f ▁dia sto lic ▁fill ing ▁temps ▁heart _ ▁rate
D-1172	-1.0488214492797852	HFpf diastolic filling temps heart_ rate
P-1172	-1.1300 -1.0965 -0.2498 -1.0274 -0.8483 -0.7270 -2.1179 -1.6722 -0.1110 -1.9557 -0.9815 -2.4660 -1.0862 -0.1570 -0.1059
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline hgb correlated baseline kccq hgb exercise training hrqol
H-839	-0.590394914150238	▁h gb ▁k cc q ▁h gb ▁HR Qo L
D-839	-0.590394914150238	hgb kccq hgb HRQoL
P-839	-0.3049 -0.3109 -0.2570 -0.0266 -0.3586 -0.6758 -0.6511 -3.4962 -0.0346 -0.7001 -0.1912 -0.0777
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient patients heart_failure hospital discharge readmissions patient follow-up
H-722	-0.9928416609764099	▁heart _ ▁failure ▁hospital _ dis charge ▁read missions
D-722	-0.9928416609764099	heart_ failure hospital_discharge readmissions
P-722	-4.3615 -0.9161 -1.9630 -0.6957 -0.8386 -0.2235 -0.0172 -1.3091 -0.0477 -0.4135 -0.1355
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac myocyte-specific_mena_overexpression cardiac pathology
H-1813	-0.6735170483589172	▁mi ce ▁cardiac _ My o cy te _ specific ▁Men a _ over expression ▁t g t et Men a ▁cardiac _ path ologie
D-1813	-0.6735170483589172	mice cardiac_Myocyte_specific Mena_overexpression tgtetMena cardiac_pathologie
P-1813	-0.7564 -0.0582 -0.0670 -0.4165 -2.2975 -0.2372 -0.0442 -0.1303 -2.7535 -1.3128 -0.4094 -0.1252 -1.0357 -1.5829 -0.0861 -1.0589 -0.1276 -0.2862 -0.9001 -1.2091 -0.0315 -0.0246 -1.3411 -0.4999 -1.0393 -0.2662 -0.0878
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan_failure hemodynamically heart_failure systemic_vascular_resistance svr cardiac_index
H-225	-0.7914326786994934	▁Font an _ ▁failure ▁hem o dynamic ally ▁heart _ ▁failure ▁système ic _ ▁vas cular _ ▁resist ance ▁s VR ▁cardiac
D-225	-0.7914326786994934	Fontan_ failure hemodynamically heart_ failure systèmeic_ vascular_ resistance sVR cardiac
P-225	-0.1041 -0.4338 -0.7758 -1.5563 -0.6094 -0.0361 -0.0192 -0.2887 -1.4410 -1.0202 -0.3004 -0.6644 -4.3998 -0.2435 -1.4720 -0.4897 -0.9114 -0.9593 -0.0160 -1.1209 -0.4004 -0.2519 -1.3833 -0.0968
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients heart_transplant prospectively ecct
H-710	-2.529134750366211	▁implant
D-710	-2.529134750366211	implant
P-710	-2.4364 -5.0267 -0.1243
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential_analysis cluster_analysis
H-1610	-1.3990415334701538	
D-1610	-1.3990415334701538	
P-1610	-2.7198 -0.0783
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis metabolic_exercise cardiac kidney
H-1762	-0.939672589302063	▁metabol ic _ ▁exercise ▁cardiac ▁ki dne y ▁index
D-1762	-0.939672589302063	metabolic_ exercise cardiac kidney index
P-1762	-2.6301 -0.1462 -1.9363 -0.3625 -0.0132 -3.1634 -0.1980 -0.0907 -0.2680 -1.3511 -0.1769
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart_failure compliance etidronate alendronate
H-1543	-0.7397441267967224	▁heart _ ▁failure ▁re fill _ ▁compliance ▁et id rona te ▁ale ndr onate
D-1543	-0.7397441267967224	heart_ failure refill_ compliance etidronate alendronate
P-1543	-1.2066 -0.9618 -2.1691 -0.4747 -0.0721 -2.9036 -1.2074 -0.1366 -1.4977 -0.0887 -0.0721 -0.5153 -0.0177 -0.1832 -0.2422 -0.0871
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians patients heart_failure equitable therapeutic
H-1823	-1.463476538658142	▁physician s ▁advanced _ ▁heart _ ▁failure
D-1823	-1.463476538658142	physicians advanced_ heart_ failure
P-1823	-2.1588 -0.0148 -4.9484 -0.7135 -2.1019 -0.9262 -1.2984 -0.8899 -0.1194
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic patients severe_heart_failure financial
H-1242	-1.5151923894882202	▁ therapeut ic ▁AF ▁heart _ ▁failure ▁financière
D-1242	-1.5151923894882202	therapeutic AF heart_ failure financière
P-1242	-3.6850 -0.0549 -0.3179 -2.2372 -2.4719 -1.3120 -0.9823 -2.3503 -1.6576 -0.0827
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate_ratio therapy patient comorbidities
H-663	-1.882837176322937	▁ therapy
D-663	-1.882837176322937	therapy
P-663	-3.4848 -0.4355 -3.5070 -0.1040
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular_pathways patients chronic_heart_failure chf
H-249	-1.3138445615768433	▁ET ▁HD L - media ted _ protec tive _ ▁effects ▁molecular ▁path ways ▁chronic _ ▁heart _ ▁failure CH f
D-249	-1.3138445615768433	ET HDL-mediated_protective_ effects molecular pathways chronic_ heart_ failureCHf
P-249	-2.6225 -2.5008 -1.5495 -0.6076 -0.1706 -1.0765 -0.3573 -0.2746 -1.4896 -2.6668 -1.3177 -1.4010 -1.3890 -0.3172 -4.3008 -0.4350 -2.1853 -0.6258 -1.6332 -2.9408 -0.1319 -0.1251 -0.0998
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization medicare hospital medicare policy
H-1715	-0.5618456602096558	▁re hospital ization ▁Medica re ▁hospital _ ▁claims ▁Medica re ▁post - a cute _ care _ transfer _ policy
D-1715	-0.5618456602096558	rehospitalization Medicare hospital_ claims Medicare post-acute_care_transfer_policy
P-1715	-1.3437 -0.0279 -0.2544 -0.0217 -0.0043 -1.3467 -0.8996 -0.1137 -0.0242 -0.0050 -1.1379 -0.0085 -0.0263 -0.0429 -0.1032 -3.2845 -0.2759 -1.0396 -1.3942 -0.4270 -0.3782 -0.2012
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical activity crf hf mortality
H-1776	-0.8373768925666809	▁men ▁c RF ▁ HF ▁mortal ity
D-1776	-0.8373768925666809	men cRF HF mortality
P-1776	-2.3884 -1.3043 -0.7522 -1.0343 -0.2227 -1.2244 -0.3099 -0.2178 -0.0823
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow_up ffm patients
H-16	-1.1809908151626587	▁figure f f f f cc
D-16	-1.1809908151626587	figureffffcc
P-16	-4.4864 -0.8806 -0.0758 -0.2392 -1.4311 -1.3151 -0.8840 -0.1356
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary_endpoint intermacs interagency_registry_for_mechanically_assisted_circulatory_support
H-1996	-0.7445026636123657	▁inter ma cs ▁inter age ncy _ ▁Registr y ▁Mechanic ally _ ▁Assist ed _ ▁Circula tory _ ▁Support
D-1996	-0.7445026636123657	intermacs interagency_ Registry Mechanically_ Assisted_ Circulatory_ Support
P-1996	-0.3700 -2.0916 -2.8703 -1.2823 -0.1280 -0.0046 -0.5177 -0.5362 -0.0927 -0.8443 -1.2961 -0.5854 -0.7587 -0.5476 -0.2130 -0.4387 -0.4416 -1.7548 -0.3882 -0.3270 -0.1457
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence clinical outcomes concentric_left_ventricular_hypertrophy heart_failure_with_preserved_ejection_fraction
H-1523	-0.7968793511390686	▁ecce n tric ▁vent ri cular ▁hyper trop hy ▁heart _ ▁failure ▁e je ction _ fraction
D-1523	-0.7968793511390686	eccentric ventricular hypertrophy heart_ failure ejection_fraction
P-1523	-3.9520 -0.0045 -0.2801 -2.2438 -0.3390 -0.2685 -1.8522 -0.0140 -0.0869 -0.5249 -1.0150 -1.7213 -1.1085 -0.3222 -0.0404 -0.9521 -0.0026 -0.3062 -0.1064
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients left_ventricular_ejection_fraction heart_failure_with_preserved_ejection_fraction hfpef
H-1887	-0.7324154376983643	▁vent ri cular ▁e je ction _ fraction ▁heart _ ▁failure ▁pres er ved _ ▁e je ction _ fraction HF p EF
D-1887	-0.7324154376983643	ventricular ejection_fraction heart_ failure preserved_ ejection_fractionHFpEF
P-1887	-0.3625 -0.3710 -0.2699 -2.1767 -0.7477 -0.1338 -0.7458 -0.0055 -1.0104 -0.6652 -2.0057 -2.7312 -0.1224 -0.9765 -0.6714 -1.9079 -0.9572 -0.0929 -0.3412 -0.0168 -1.1665 -0.0332 -0.3505 -0.2465 -0.2019
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1260	-0.7686476111412048	▁vent ri cular _ ▁e je ction _ fraction ▁left ▁vent ri cular _ ▁dia sto lic _ ▁end _ ▁diameter
D-1260	-0.7686476111412048	ventricular_ ejection_fraction left ventricular_ diastolic_ end_ diameter
P-1260	-0.1411 -0.4805 -0.3707 -1.0910 -2.5267 -0.8712 -0.0794 -0.5454 -0.0020 -0.5944 -0.2340 -0.3564 -0.1753 -0.4392 -1.8823 -0.3754 -2.3114 -0.8171 -0.5406 -0.7963 -2.6894 -0.2258 -0.1334
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic_receptor_blocker_therapy myocardial_perfusion neoangiogenesis heart
H-451	-0.3942132890224457	▁β - ad r energi c ▁receptor _ block er ▁ therapy ▁my o card ial _ per fusion ▁neo angi ogen es is ▁fail ing _ heart
D-451	-0.3942132890224457	β-adrenergic receptor_blocker therapy myocardial_perfusion neoangiogenesis failing_heart
P-451	-0.0322 -0.0419 -0.0371 -0.0974 -0.2525 -0.0518 -0.8004 -0.7028 -0.8840 -0.0593 -1.4899 -0.0172 -0.6572 -0.1844 -0.2324 -0.3388 -0.4459 -0.2925 -0.0283 -0.0114 -0.1258 -0.3001 -0.1825 -0.4277 -0.8126 -0.1907 -1.3236 -1.4075 -0.2616 -0.1367
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular_matrix left_ventricular biopsies tissuefaxs correlated t1_time
H-741	-0.6425936818122864	▁extra cel lular _ ▁matri x ▁left ▁vent ri cular ▁bio psi es ▁t issue FAX s ▁technologie
D-741	-0.6425936818122864	extracellular_ matrix left ventricular biopsies tissueFAXs technologie
P-741	-1.5095 -0.1712 -0.0276 -1.4698 -0.9218 -0.0153 -0.8986 -1.1059 -0.2811 -0.2977 -1.1808 -0.2709 -0.1824 -1.4925 -0.0609 -0.1088 -1.2629 -1.1550 -0.3072 -0.1317
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart patients hfpef hf_with_reduced_ejection_fraction hfref
H-240	-1.285685658454895	▁h ART ▁h f ▁h f ▁h f ▁h f ▁h r f
D-240	-1.285685658454895	hART hf hf hf hf hrf
P-240	-0.1753 -0.3049 -1.2185 -2.3736 -1.7828 -0.6741 -2.3827 -0.2078 -2.7044 -0.6171 -3.5154 -1.6530 -0.9820 -0.5694 -0.1243
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced_hf cxl-1020 contractility end-systolic_elastance venoarterial_dilation
H-421	-0.6558257937431335	▁ta chy pac ing - indu ced ▁ HF ▁c XL ▁contract ility ▁end - sy sto lic ▁elastan ce ▁ve no arte rial ▁di lation
D-421	-0.6558257937431335	tachypacing-induced HF cXL contractility end-systolic elastance venoarterial dilation
P-421	-6.1647 -0.3828 -0.0035 -0.1386 -0.0520 -0.0002 -1.2351 -1.3072 -0.0580 -0.5680 -0.0761 -2.5172 -0.1572 -0.5645 -0.0055 -0.8363 -0.4215 -1.1575 -0.0438 -0.2933 -0.0859 -0.0773 -0.0839 -0.0959 -1.5301 -0.0621 -0.3498 -0.0949
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin_cytoskeleton mitochondrial_function metabolism glycolysis gluconeogenesis citrate_cycle
H-873	-0.5356547236442566	▁act in _ ▁cy tos kelet on ▁mito cho ndri al ▁metabolism ▁gly col ysis _ glu cone ogen es is ▁cit rate
D-873	-0.5356547236442566	actin_ cytoskeleton mitochondrial metabolism glycolysis_gluconeogenesis citrate
P-873	-0.1286 -0.6528 -0.2685 -1.3502 -0.5152 -0.0486 -0.1136 -0.0493 -1.5362 -0.3931 -0.1395 -1.3846 -0.0312 -1.0559 -0.1029 -2.6456 -0.8555 -0.1722 -0.2288 -0.1427 -0.3830 -0.0077 -0.1140 -0.9977 -0.0740
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated resistin biomarker anthracycline-induced_cardiotoxicity heart_failure macrophages
H-939	-0.6004272699356079	▁resist in ▁an thra cycli ne - indu ced _ ▁cardio toxic ity ▁heart _ ▁failure
D-939	-0.6004272699356079	resistin anthracycline-induced_ cardiotoxicity heart_ failure
P-939	-0.6321 -0.3297 -0.3634 -0.0310 -1.2048 -0.7361 -0.8131 -0.0006 -2.1607 -0.8047 -0.0856 -0.2071 -0.3845 -0.2010 -0.9714 -1.6656 -0.1293 -0.0871
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone_morphogenetic_protein_4 expression rrna_transcription shift heterochromatic_chromatin
H-98	-0.883606493473053	▁bone _ ▁mor pho gene tic ▁protein ▁r RNA ▁tran scription ▁hetero ch ro matic ▁chr omat in
D-98	-0.883606493473053	bone_ morphogenetic protein rRNA transcription heterochromatic chromatin
P-98	-0.8400 -0.3451 -1.5974 -1.5410 -0.9898 -3.2670 -1.4824 -0.2004 -0.1005 -1.4966 -0.0102 -1.5428 -0.3392 -0.0619 -0.2791 -1.3964 -0.0387 -1.7601 -0.2742 -0.1093
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left_ventricular_assist_devices lvads patients heart_failure incidence pump_dysfunction pump
H-773	-0.7759504318237305	▁vent ri cular _ assist ▁devices ▁l VAD s ▁heart _ ▁failure ▁pump
D-773	-0.7759504318237305	ventricular_assist devices lVADs heart_ failure pump
P-773	-0.1367 -0.2302 -0.0646 -0.5787 -0.1259 -1.3673 -0.7499 -0.0196 -0.8875 -2.7327 -0.8691 -1.2300 -0.2800 -2.2775 -0.0895
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a angii hypoxia expression upr downregulation
H-1085	-0.9188164472579956	▁s cc 5 a ▁ang II ▁hypo xia ▁u PR ▁down regul ation
D-1085	-0.9188164472579956	scc5a angII hypoxia uPR downregulation
P-1085	-1.5020 -2.1756 -1.4719 -0.1138 -0.9490 -1.2640 -0.0275 -0.1050 -0.1006 -0.9699 -2.5770 -0.1379 -0.0136 -2.2267 -0.1476
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf multivariate-adjusted_odds_ratio mortality hazard_ratio mortality
H-1312	-1.5657179355621338	▁fréquence ▁ HF ▁mortal ity ▁hazard
D-1312	-1.5657179355621338	fréquence HF mortality hazard
P-1312	-2.4355 -2.4827 -0.1649 -3.4545 -0.8165 -0.2247 -2.7582 -0.1887
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas hf hyperkalemia hypokalemia spironolactone clinical
H-1708	-0.6751669645309448	▁ HF ▁hyper kal emia ▁hypo kal emia ▁spi rono lac tone
D-1708	-0.6751669645309448	HF hyperkalemia hypokalemia spironolactone
P-1708	-2.2671 -0.7483 -0.4893 -0.6535 -0.4041 -0.0439 -1.1582 -0.5518 -0.1876 -0.0171 -0.1346 -0.1116 -2.6188 -0.0664
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate_logistic_regression_analysis bnp patients diastolic_dysfunction
H-1571	-1.0104992389678955	▁b NP ▁dia sto lic _ ▁dys function
D-1571	-1.0104992389678955	bNP diastolic_ dysfunction
P-1571	-0.2096 -1.4104 -0.8652 -0.4547 -4.3273 -0.9797 -0.2635 -1.2286 -0.2723 -0.0937
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo dopamine nesiritide secondary_end_points renal_function clinical outcomes
H-82	-0.7223070859909058	▁dop amine ▁nesi riti de ▁de con gestion ▁renal
D-82	-0.7223070859909058	dopamine nesiritide decongestion renal
P-82	-3.8035 -0.3846 -0.0442 -0.0893 -0.0764 -1.5838 -0.0104 -0.0038 -0.0079 -1.8703 -0.0713
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp nonterminal_epitopes central_glycosylated_region
H-1522	-0.6936209201812744	▁NT - pro b NP
D-1522	-0.6936209201812744	NT-probNP
P-1522	-0.1837 -0.0293 -0.0162 -0.5498 -0.2590 -3.7186 -0.0987
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors g-protein-coupled_receptor kinase-2 downregulation
H-1407	-0.4527554512023926	▁g - prote in - co up led ▁receptor _ ▁kina se
D-1407	-0.4527554512023926	g-protein-coupled receptor_ kinase
P-1407	-1.4810 -0.2035 -0.2505 -0.4620 -0.1525 -0.0095 -0.0134 -0.5848 -0.0918 -1.3979 -0.6797 -0.0238 -0.8481 -0.1400
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic_function hfpef patients long_axis_function exercise
H-1888	-0.8625941276550293	▁imagin g ▁techniques ▁sy sto lic _ fon cti onnement ▁ HF p EF ▁long _ a xis _ fon cti onnement
D-1888	-0.8625941276550293	imaging techniques systolic_fonctionnement HFpEF long_axis_fonctionnement
P-1888	-3.4153 -0.0398 -0.0555 -1.4117 -0.2373 -3.2000 -1.3313 -1.3727 -0.5686 -1.0153 -0.6981 -0.2571 -0.1504 -0.3698 -0.9149 -0.2696 -0.5721 -0.0832 -0.9599 -2.0222 -0.5017 -0.2716 -0.8578 -0.1265
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable_models st2 outcomes clinical amino-terminal_pro-b-type_natriuretic_peptide
H-704	-0.7254166007041931	▁ST 2 ▁amino - termin al _ pro - B - type ▁na tri ure tic _ pe pti de
D-704	-0.7254166007041931	ST2 amino-terminal_pro-B-type natriuretic_peptide
P-704	-2.1950 -0.1508 -0.3292 -0.0392 -0.0092 -0.0138 -2.5855 -0.2328 -0.0391 -1.0461 -0.1235 -0.1361 -0.9373 -0.0234 -0.0851 -4.8196 -1.7111 -0.4719 -0.2586 -0.3560 -0.2582 -0.1379
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia medline cochrane_library
H-31	-0.6495988965034485	▁an emia ▁ir on _ de fici en cy ▁MED LINE ▁co ch rane _ ▁Library
D-31	-0.6495988965034485	anemia iron_deficiency MEDLINE cochrane_ Library
P-31	-5.3131 -0.3031 -0.0983 -0.0420 -0.3052 -0.0435 -0.2568 -1.0607 -0.9767 -0.3313 -0.8813 -0.2105 -0.2290 -0.0293 -0.9334 -0.2941 -0.2659 -0.1183
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change correlation hospitals longitudinal
H-138	-1.5917152166366577	▁hospital s
D-138	-1.5917152166366577	hospitals
P-138	-5.1004 -0.1448 -1.0306 -0.0911
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine bnp furosemide dobutamine norepinephrine outcome
H-587	-0.5526285171508789	▁creati nine ▁b NP ▁fur os em ide _ ▁dose ▁oxygen _ ▁flow ▁dobu tamine ▁no re pine ph rine
D-587	-0.5526285171508789	creatinine bNP furosemide_ dose oxygen_ flow dobutamine norepinephrine
P-587	-1.3173 -0.7140 -0.0695 -0.5435 -0.1035 -0.1819 -0.0502 -0.0374 -3.8223 -0.7228 -0.4404 -1.5261 -0.2834 -0.0928 -0.0234 -0.0319 -0.0337 -0.0616 -1.2454 -0.1344 -0.6570 -0.0653
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical biomedical patients dcm heart_failure pubmed
H-1259	-0.6861399412155151	▁bio medic al ▁treatment ▁CH m ▁bio medic al ▁treatment ▁d CM ▁heart _ ▁failure ▁Pub Med
D-1259	-0.6861399412155151	biomedical treatment CHm biomedical treatment dCM heart_ failure PubMed
P-1259	-0.4440 -0.0421 -0.0042 -3.1935 -1.7091 -0.0370 -0.1331 -0.0178 -0.0071 -2.3642 -0.3679 -0.4009 -0.8046 -0.7053 -1.3292 -1.0869 -0.1012 -0.2011 -0.0875
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 myocardial_collagen myocardial
H-1064	-0.8795070648193359	▁my o card ial _ ▁collage n
D-1064	-0.8795070648193359	myocardial_ collagen
P-1064	-1.2750 -0.3054 -0.2223 -0.3611 -0.5773 -0.4300 -0.1140 -4.5599 -0.0706
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 sst2 odds_ratio cardiovascular_event
H-408	-1.7526390552520752	▁s st 2/ high - dos e ▁BB ▁s st 2 ▁figure ▁cardiovascular _ ▁event
D-408	-1.7526390552520752	sst2/high-dose BB sst2 figure cardiovascular_ event
P-408	-0.3784 -2.2232 -4.6296 -1.4455 -0.0192 -1.3060 -0.2034 -2.2040 -1.8132 -2.3462 -0.3246 -6.4958 -0.9025 -3.3920 -1.7438 -0.2675 -0.1000
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley randomized acf allopurinol
H-473	-0.33362099528312683	▁Spr a gue - Da w ley ▁sham ▁a CF ▁allo puri nol
D-473	-0.33362099528312683	Sprague-Dawley sham aCF allopurinol
P-473	-0.1208 -0.2749 -0.0272 -0.0329 -1.1394 -0.1352 -0.4713 -0.3907 -0.9356 -0.3933 -0.0578 -0.0251 -0.4981 -0.3825 -0.1197
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular_pacing bivp cardiac_output cardiac surgery patients
H-319	-0.8785544633865356	▁bi ven tri cular _ pa cing ▁bi VP ▁cardiac _ ▁output ▁co ▁cardiac ▁surgery
D-319	-0.8785544633865356	biventricular_pacing biVP cardiac_ output co cardiac surgery
P-319	-1.4648 -0.5504 -0.3742 -0.6942 -0.6289 -0.4048 -0.6529 -1.0900 -0.1520 -0.0886 -2.0732 -3.4040 -1.7752 -0.3197 -0.9276 -0.2532 -0.0818
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin sitagliptin follow-up
H-1833	-0.8916846513748169	▁sax ag lip tin ▁si tag lip tin ▁pair wise
D-1833	-0.8916846513748169	saxagliptin sitagliptin pairwise
P-1833	-0.0794 -0.4291 -0.7559 -2.6075 -0.6851 -0.0016 -0.4639 -2.5277 -1.2276 -1.4549 -0.3843 -0.0833
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq patients hfpef
H-790	-0.8410671949386597	▁k cc q ▁ HF p EF ▁c ron bach
D-790	-0.8410671949386597	kccq HFpEF cronbach
P-790	-0.2591 -0.0285 -0.6766 -2.5591 -1.7390 -0.1009 -0.9845 -2.8855 -0.3305 -0.0723 -0.3855 -0.0713
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable patients qrs_duration
H-891	-0.7229609489440918	▁implant able ▁implant able _ ▁cardio ver ter _ de _ fi br illa tor - c RT LB BB ▁QR s
D-891	-0.7229609489440918	implantable implantable_ cardioverter_de_fibrillator-cRTLBBB QRs
P-891	-0.0004 -0.0333 -1.7753 -0.0503 -0.8711 -0.5030 -0.1810 -0.0294 -0.3976 -0.0095 -3.1304 -2.1202 -0.8734 -0.0043 -0.1637 -0.1827 -0.6653 -1.0272 -1.8764 -1.2415 -0.4960 -1.2231 -0.3932 -0.1030
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up patients
H-1538	-0.8095106482505798	▁ale ndr onate - ▁et id rona te ▁ra lo xi fen e - tre
D-1538	-0.8095106482505798	alendronate- etidronate raloxifene-tre
P-1538	-5.4758 -0.0670 -0.3765 -1.0674 -0.5529 -0.4553 -0.0408 -0.0277 -0.4732 -0.0367 -0.1105 -0.9744 -0.2233 -0.2271 -0.0291 -3.5291 -0.0950
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal diagnostic clinical
H-1304	-0.9516270160675049	▁clinic al _ ▁trial s
D-1304	-0.9516270160675049	clinical_ trials
P-1304	-3.4961 -0.0500 -1.0522 -1.5200 -0.0320 -0.4418 -0.0694
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients systolic_hf the_danish_heart_failure_database esrd danish_registry_on_dialysis
H-389	-0.8347582817077637	▁sy sto lic ▁ HF ▁Danish ▁Heart _ ▁Fail ure _ db ▁new - ons et ▁ES RD ▁Danish ▁Registr y _ ▁on _ Dia lys is
D-389	-0.8347582817077637	systolic HF Danish Heart_ Failure_db new-onset ESRD Danish Registry_ on_Dialysis
P-389	-4.1399 -0.1682 -1.8815 -1.5175 -0.0721 -0.7303 -1.3182 -0.8476 -0.0588 -0.0428 -3.8406 -0.9355 -2.3341 -0.0350 -0.0411 -0.0402 -0.4535 -0.2080 -0.9803 -0.7738 -0.2300 -0.1557 -1.2309 -0.1670 -1.1470 -0.2464 -0.1821 -0.3303 -0.0996
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy trastuzumab comorbidities chf international_classification_of_diseases healthcare_common_procedure_coding_system_codes
H-674	-0.5940857529640198	▁Che mo therapy ▁tras tuz um ab ▁CHF ▁Disease s ▁Health care _ ▁Common _ ▁Procedur e ▁code s
D-674	-0.5940857529640198	Chemotherapy trastuzumab CHF Diseases Healthcare_ Common_ Procedure codes
P-674	-1.3104 -0.1483 -0.0218 -0.0658 -0.0010 -0.0133 -0.0734 -1.2118 -3.5064 -0.0299 -1.1010 -0.1025 -1.8072 -0.2675 -0.6128 -0.8498 -0.2624 -0.7348 -0.0206 -0.2256 -0.1095
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart_failure hf therapies outcomes patients hf preserved_left_ventricular_ejection_fraction lvef
H-111	-0.6098257899284363	▁con tempor ary _ ▁heart _ ▁failure HF ▁ therapie s ▁ HF ▁vent ri cular _ ▁e je ction _ fraction LV EF
D-111	-0.6098257899284363	contemporary_ heart_ failureHF therapies HF ventricular_ ejection_fractionLVEF
P-111	-2.8695 -0.0140 -0.3717 -0.5105 -2.0778 -0.5216 -1.4124 -0.8253 -0.5837 -0.4922 -0.0248 -0.8174 -0.2585 -0.5132 -0.3006 -0.1764 -0.5311 -1.4345 -0.8165 -0.1633 -0.5849 -0.0386 -0.1632 -0.0424 -0.1832 -0.1282
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths crt hazard_ratio
H-853	-1.276721477508545	▁c t ▁hazard
D-853	-1.276721477508545	ct hazard
P-853	-0.1993 -2.5444 -2.4285 -1.0765 -0.1349
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation consultation consultation operation
H-1283	-1.189669132232666	▁transplant ation ▁consultation ▁MT
D-1283	-1.189669132232666	transplantation consultation MT
P-1283	-2.4149 -0.0185 -1.8788 -1.9659 -0.7644 -0.0956
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized heart_failure saxagliptin sitagliptin antihyperglycemic_drugs retrospective_cohort_study
H-1826	-0.6025556921958923	▁Hospital ized _ ▁Heart _ ▁Fail ure ▁Sax ag lip tin ▁si tag lip tin ▁anti hy per gly ce mic ▁Drug s
D-1826	-0.6025556921958923	Hospitalized_ Heart_ Failure Saxagliptin sitagliptin antihyperglycemic Drugs
P-1826	-2.4815 -0.5175 -0.5776 -0.2840 -0.8790 -0.0574 -0.0487 -0.0585 -0.1543 -0.5578 -1.7096 -0.7680 -0.0004 -0.0947 -1.3144 -0.1732 -0.0877 -0.1547 -2.6664 -0.2193 -1.3464 -0.6516 -0.0280 -0.1363 -0.0968
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise training outcomes chronic_heart_failure heart_failure_-_a_controlled_trial_investigating_outcomes_in_exercise_training hf-action
H-1629	-1.4074268341064453	▁Race _ training ▁chronic _ ▁heart _ ▁failure ▁Heart _ ▁Fail ure
D-1629	-1.4074268341064453	Race_training chronic_ heart_ failure Heart_ Failure
P-1629	-0.8084 -4.0741 -0.7651 -3.4355 -1.0427 -0.8778 -0.5698 -1.9165 -1.7098 -0.4734 -0.2852 -0.1055 -3.4932 -0.1469
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass_correlation_coefficient icc kappa_coefficient standard_error_of_measurement minimal_detectable_change mdc
H-801	-0.575062096118927	▁intra class _ ▁corre lation _ co e ffi cient ▁i cc ▁ka ppa ▁co e ffi cient ▁m d c
D-801	-0.575062096118927	intraclass_ correlation_coefficient icc kappa coefficient mdc
P-801	-3.0576 -0.1669 -0.9365 -1.4348 -0.2623 -0.2802 -0.5672 -0.8960 -0.0378 -0.0743 -0.7719 -0.8648 -0.6858 -0.2247 -0.9951 -0.0956 -0.0207 -0.0496 -0.7416 -0.2167 -0.3022 -0.4180 -0.1260
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil phosphocreatine adenine_nucleotides mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity
H-964	-0.4943113625049591	▁Nico rand il ▁ phos pho creati ne ▁a den ine ▁nucleo ti des ▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁creati ne _ ▁kina se
D-964	-0.4943113625049591	Nicorandil phosphocreatine adenine nucleotides mitochondrial oxidative phosphorylation creatine_ kinase
P-964	-0.0012 -0.1953 -0.2102 -0.0473 -0.1284 -0.4853 -0.7750 -1.0482 -0.0482 -0.0102 -0.7894 -1.1885 -0.0095 -0.0494 -0.3940 -1.2789 -0.1365 -0.2200 -1.2835 -0.4397 -0.6504 -0.1492 -0.5435 -1.8921 -0.0208 -1.4927 -0.3696 -1.2057 -0.0498 -0.0237 -0.5835 -0.0984
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox_proportional_hazards_models death transplantation lv_assist_device_implantation heart_failure hospitalization follow-up
H-431	-0.8105074167251587	▁implant ation ▁LV ▁implant ation ▁heart _ ▁failure
D-431	-0.8105074167251587	implantation LV implantation heart_ failure
P-431	-2.2438 -0.0070 -0.1729 -1.1056 -0.0158 -0.3806 -1.2909 -2.6067 -0.1526 -0.1292
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones adipokines fat_free_mass ffm fat_mass
H-11	-0.7886694073677063	▁neuro hormon es ▁adi pok ines cc ▁progressive ▁loss ▁fat _ ▁free ▁mass f m ▁fat ▁mass FM
D-11	-0.7886694073677063	neurohormones adipokinescc progressive loss fat_ free massfm fat massFM
P-11	-0.1284 -0.0629 -0.1249 -0.1363 -0.0483 -0.4925 -1.3080 -0.5915 -2.1188 -2.0811 -1.1837 -0.6610 -0.7693 -1.8184 -0.0148 -0.2425 -3.2346 -0.4085 -0.2575 -0.0904
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient primary_end_point rehospitalization stroke myocardial_infarction heart_failure cabg
H-972	-0.5055825114250183	▁Swedish _ national _ in patient _ ▁Registr y ▁re hospital ization ▁stroke ▁my o card ial _ ▁in far ction ▁heart _ ▁failure ▁ca BG
D-972	-0.5055825114250183	Swedish_national_inpatient_ Registry rehospitalization stroke myocardial_ infarction heart_ failure caBG
P-972	-0.0769 -1.1232 -0.2443 -0.1911 -0.6088 -0.2975 -1.1716 -1.4263 -0.0954 -0.1322 -0.0067 -0.4574 -0.9354 -0.4404 -0.2385 -0.0738 -0.1282 -0.9795 -0.3977 -1.4836 -0.0503 -0.3908 -0.7613 -0.9256 -1.0225 -0.2708 -0.1361 -0.0903
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule expression regulation rad q66p rgk_protein in_vivo
H-1678	-1.0672483444213867	▁mis tar ge ting ▁rad ▁Q 66 p ▁R GK ▁protein ▁ef fica cy
D-1678	-1.0672483444213867	mistargeting rad Q66p RGK protein efficacy
P-1678	-0.3049 -0.0311 -0.0647 -2.5914 -1.3909 -2.8122 -0.3104 -0.4291 -1.9127 -0.2652 -2.6299 -1.9490 -0.0034 -0.9699 -1.3239 -0.0873
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter_ablation patients compensated_hfpef left_ventricular ejection_fraction
H-944	-0.5120680332183838	▁cat heter ▁ab lation ▁AF ▁h f f ▁vent ri cular LV ▁e je ction _ fraction
D-944	-0.5120680332183838	catheter ablation AF hff ventricularLV ejection_fraction
P-944	-1.1424 -0.0307 -0.8474 -0.0233 -1.2874 -0.9693 -0.2710 -0.1637 -1.0463 -0.3530 -0.1434 -0.5911 -0.5183 -0.3218 -0.0226 -1.3527 -0.0013 -0.5524 -0.0912
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte_hypertrophy heart_failure global_gene_expression dna genomic
H-89	-0.6892207264900208	▁My o cy te _ ▁hyper trop hy ▁heart _ ▁failure
D-89	-0.6892207264900208	Myocyte_ hypertrophy heart_ failure
P-89	-0.3661 -0.0668 -0.1372 -0.3942 -1.1282 -0.4765 -0.0137 -0.0698 -0.3852 -0.7308 -1.6671 -3.3711 -0.1532
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully_magnetically_levitated_lvas mortality seattle heart_failure
H-2002	-0.8998746871948242	▁magnet ically _ ▁le vita ted ▁l VAS ▁Seattle ▁Heart _ ▁Fail ure
D-2002	-0.8998746871948242	magnetically_ levitated lVAS Seattle Heart_ Failure
P-2002	-4.8601 -0.3606 -0.8348 -0.5809 -0.0220 -1.4723 -1.7029 -0.1691 -0.4847 -1.6384 -0.8000 -0.1553 -0.0439 -0.2492 -0.1237
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa immunoassays antibodies c_termini nt-probnp
H-1518	-0.7426524758338928	▁Alpha LIS a ▁immun o assa ys ▁anti bo dies ▁circula ting ▁NT - pro b NP
D-1518	-0.7426524758338928	AlphaLISa immunoassays antibodies circulating NT-probNP
P-1518	-0.0355 -0.3388 -1.4959 -0.0566 -0.2432 -0.1862 -2.3720 -0.0190 -0.0166 -1.3991 -4.2833 -2.5022 -0.3193 -0.0218 -0.0152 -0.4881 -0.0976 -0.1390 -0.0810
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac_plasma_membrane s1pr1 β1ar heart_failure
H-1411	-0.9559268355369568	▁cardiac _ ▁plasma ▁membran e ▁s 1 PR 1 ▁delete rious ▁β 1 AR _ ▁over stimul ation ▁heart _ ▁failure
D-1411	-0.9559268355369568	cardiac_ plasma membrane s1PR1 deleterious β1AR_ overstimulation heart_ failure
P-1411	-2.1201 -1.2506 -1.5986 -0.5165 -0.2468 -1.8140 -0.1354 -0.5938 -1.7654 -3.7838 -0.0219 -0.3627 -0.1689 -0.6882 -1.9837 -1.4581 -0.2461 -0.0217 -0.3971 -0.8208 -1.6546 -0.2243 -0.1132
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients new_york_heart_association nyha chronic_heart_failure reduced_ejection_fraction
H-1952	-1.2453019618988037	▁New ▁York _ ▁Heart _ association NY HA ▁class _ ▁III _ chron _ ▁heart _ ▁failure ▁e je ction _ fraction
D-1952	-1.2453019618988037	New York_ Heart_associationNYHA class_ III_chron_ heart_ failure ejection_fraction
P-1952	-2.0544 -0.9619 -1.0926 -1.1233 -0.9367 -1.4088 -1.7182 -0.6646 -2.3400 -0.3488 -0.8808 -1.4641 -3.2808 -2.3898 -1.0936 -0.6040 -1.5243 -3.0147 -0.4143 -0.0480 -0.4750 -0.0259 -1.9024 -0.1202
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological_phenotype clinically deficit_index medical frailty
H-1013	-0.8291170597076416	▁bi ological _ ▁ph eno type
D-1013	-0.8291170597076416	biological_ phenotype
P-1013	-0.1447 -0.3090 -1.8799 -0.6290 -0.2890 -0.0308 -3.2765 -0.0741
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel apoptotic_cells tunel-positive_cells
H-172	-1.8401628732681274	▁tu nel
D-172	-1.8401628732681274	tunel
P-172	-1.4619 -1.3032 -4.4824 -0.1132
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt elevated acute β-adrenoceptor_blockade esmolol
H-1444	-0.7735857963562012	▁SD QT ▁ HF VT ▁h nor m ▁β - ad re no cept or _ block ade ▁es mol ol
D-1444	-0.7735857963562012	SDQT HFVT hnorm β-adrenoceptor_blockade esmolol
P-1444	-0.0298 -0.8016 -2.4834 -0.4741 -3.0095 -0.0708 -1.7622 -0.0017 -1.0114 -0.0072 -0.0240 -0.0265 -0.0838 -1.0336 -0.3903 -1.2249 -1.3885 -1.8504 -1.5827 -0.0793 -0.0415 -0.3242 -0.0910
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically myocardial_infarction heart_failure randomized bisoprolol
H-452	-0.5219892859458923	▁sur g ically _ ▁induc ed ▁my o card ial _ ▁in far ction ▁heart _ ▁failure ▁bis o pro lol ▁vehicle
D-452	-0.5219892859458923	surgically_ induced myocardial_ infarction heart_ failure bisoprolol vehicle
P-452	-0.5149 -0.0278 -0.2089 -1.7449 -0.1425 -0.1924 -1.3058 -0.2020 -0.2426 -0.4419 -0.6644 -0.4100 -2.0921 -0.0580 -0.1936 -0.7804 -0.3203 -0.5232 -0.0490 -0.0185 -0.1694 -1.8560 -0.2761 -0.0929
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts hh medical all-cause_mortality discharged patients heart_failure
H-162	-1.4905869960784912	▁s s ▁ HH ▁TM ▁medical _ support ▁office _ ▁hours ▁mortal ity ▁dis charge d ▁patients ▁heart _ ▁failure
D-162	-1.4905869960784912	ss HH TM medical_support office_ hours mortality discharged patients heart_ failure
P-162	-2.2885 -2.1279 -1.2980 -0.1627 -3.7078 -2.2034 -2.0806 -1.5958 -3.0103 -0.7068 -0.8252 -1.3467 -0.3515 -4.2046 -0.0021 -0.5442 -1.4688 -2.1661 -0.8236 -1.5255 -0.2386 -0.1144
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions readmission patients congestive_heart_failure south_dakota
H-1583	-1.2099114656448364	▁transition s _ de _ ca pit aux ▁con ges tive _ ▁heart _ ▁failure
D-1583	-1.2099114656448364	transitions_de_capitaux congestive_ heart_ failure
P-1583	-0.1871 -0.0192 -0.5049 -1.1111 -0.0866 -3.6235 -1.2028 -0.1727 -5.5646 -0.5248 -0.2300 -0.2489 -1.5879 -0.5687 -0.6465 -4.0731 -0.2162
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia intravenous atropine cardiac vagal_tone
H-1380	-0.6565074920654297	▁ta chy car dia ▁intra ven ous ▁a tropi ne ▁cardiac _ va gal _ ▁tone ▁CHF - DN x ▁CHF - in V
D-1380	-0.6565074920654297	tachycardia intravenous atropine cardiac_vagal_ tone CHF-DNx CHF-inV
P-1380	-1.6594 -0.7587 -0.0245 -0.9147 -0.1813 -0.0436 -4.3830 -0.8850 -0.0517 -1.4563 -0.0134 -0.4865 -1.0637 -0.0452 -1.4337 -0.1679 -0.0633 -0.0221 -1.1890 -0.0077 -0.0786 -0.0120 -0.6495 -0.9355 -0.4686 -0.0743
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes myocardium conditions
H-990	-0.4469212591648102	▁cardio my o cy tes ▁humor al ▁stimul i ▁my o car dium ▁conditions
D-990	-0.4469212591648102	cardiomyocytes humoral stimuli myocardium conditions
P-990	-0.1172 -0.5183 -0.4228 -0.1518 -0.2296 -1.7500 -0.1371 -0.5987 -0.2239 -0.9793 -0.0660 -0.0064 -0.2411 -0.0353 -1.5815 -0.0917
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse pasp step rv_function lv_dysfunction
H-501	-1.1626574993133545	▁passage - force ▁ RV ▁LV _ ▁dys function
D-501	-1.1626574993133545	passage-force RV LV_ dysfunction
P-501	-2.8106 -2.5038 -0.1617 -0.3639 -0.3397 -2.3469 -3.0462 -0.3379 -0.5198 -0.2529 -0.1059
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular_support rvads explanted
H-301	-0.8428349494934082	▁bi ven tri cular _ support ▁R VAD s
D-301	-0.8428349494934082	biventricular_support RVADs
P-301	-1.3846 -0.2714 -0.1010 -0.7011 -1.5966 -1.6222 -2.2320 -0.1458 -0.5872 -0.4799 -0.1495
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno_donor myocardial_function evidence hf
H-425	-0.8416275978088379	▁functional _ ▁ef fica cy ▁h no ▁donor ▁my o card ial _ fon ction nel ▁ HF
D-425	-0.8416275978088379	functional_ efficacy hno donor myocardial_fonctionnel HF
P-425	-4.7311 -0.8867 -0.1645 -0.0034 -0.7527 -0.3137 -0.2951 -1.5900 -2.2354 -0.1717 -0.2103 -0.2786 -0.9736 -1.6102 -0.5898 -0.2478 -1.2592 -0.2950 -0.1232 -0.1006
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions training patients out-patient follow-up patient health_care
H-1579	-0.7955501079559326	▁transition s _ de _ care
D-1579	-0.7955501079559326	transitions_de_care
P-1579	-0.0091 -0.0416 -0.2743 -0.8325 -0.0789 -2.3601 -2.5927 -0.1752
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd outpatients systolic_hf patients egfr
H-396	-1.1200838088989258	▁ES RD ▁out patient s ▁sy sto lic _ f ▁e g f
D-396	-1.1200838088989258	ESRD outpatients systolic_f egf
P-396	-1.4432 -0.2941 -4.9031 -0.0238 -0.0219 -1.6203 -0.1885 -2.5287 -0.8710 -1.0475 -0.4203 -1.5043 -1.3657 -0.3749 -0.1939
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf phenotype cardiac explant progenitors regulation
H-1337	-0.5030028820037842	▁CHF ▁cardiac _ ▁ex plant ▁c - K it
D-1337	-0.5030028820037842	CHF cardiac_ explant c-Kit
P-1337	-0.2674 -0.5359 -1.5647 -0.3639 -0.0394 -0.0329 -0.1009 -0.5414 -0.0210 -2.0099 -0.0557
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy sst2 patients chronic_heart_failure
H-411	-1.87984037399292	▁BB ▁ therapy
D-411	-1.87984037399292	BB therapy
P-411	-1.3879 -2.0093 -0.1381 -5.7265 -0.1374
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission disease heart_failure hf acute_myocardial_infarction ami pneumonia
H-137	-1.3066045045852661	▁implant ations ▁heart _ ▁failure ▁h ▁a cute _ mé o card ial _ ▁in far ction ▁pneu monia
D-137	-1.3066045045852661	implantations heart_ failure h acute_méocardial_ infarction pneumonia
P-137	-6.0922 -3.7634 -3.2737 -0.6098 -0.8807 -1.1154 -1.6080 -0.0030 -0.0767 -4.1822 -0.6724 -0.1494 -0.2663 -0.3736 -0.4169 -2.1243 -0.0937 -0.6882 -0.5587 -0.3918 -0.0984
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed heart_failure left_ventricular_ejection_fraction spironolactone kaiser_permanente northern_california
H-440	-0.7035226225852966	▁heart _ ▁failure ▁left ▁vent ri cular _ ▁e je ction ▁spi rono lac tone ▁Kaiser _ ▁Permanent e _ ▁Northern ▁California
D-440	-0.7035226225852966	heart_ failure left ventricular_ ejection spironolactone Kaiser_ Permanente_ Northern California
P-440	-1.5380 -0.9124 -1.3009 -0.4379 -1.4797 -0.6339 -0.6681 -0.6239 -1.2549 -0.6760 -0.1213 -0.6271 -0.0170 -0.1658 -0.0997 -0.6589 -0.8237 -1.4330 -0.2068 -1.9962 -0.0585 -0.7590 -0.2985 -0.0934
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression_analysis echocardiographic lv_reverse_remodeling lv_end-systolic_volume
H-430	-0.6050704121589661	▁e cho car dio graphic ▁score ▁LV ▁rever se _ ▁remodel ing ▁LV ▁end - sy sto lic
D-430	-0.6050704121589661	echocardiographic score LV reverse_ remodeling LV end-systolic
P-430	-0.1881 -0.6458 -0.0490 -0.4839 -0.6438 -0.4194 -0.0522 -0.5851 -0.0059 -0.7539 -0.0924 -0.2298 -0.3975 -1.4996 -0.0247 -1.7244 -0.7321 -1.6906 -1.7810 -0.1021
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative renal_dysfunction cardiovascular_events stroke myocardial_infarction heart_failure death isolated_coronary_artery_bypass_grafting
H-968	-0.7317523956298828	▁pre operativ e ▁renal ▁dys function ▁cardiovascular ▁events stro ke ▁my o card ial ▁in far ction ▁heart _ ▁failure ▁corona ry _ ▁arter y _ ▁by pass ▁graf t
D-968	-0.7317523956298828	preoperative renal dysfunction cardiovascular eventsstroke myocardial infarction heart_ failure coronary_ artery_ bypass graft
P-968	-3.1180 -0.0971 -0.0721 -0.3783 -0.3897 -0.4218 -0.0862 -0.5238 -3.3386 -0.8388 -0.6725 -0.2290 -0.0626 -0.1024 -0.8134 -1.1912 -0.0361 -0.0613 -0.8461 -0.2558 -0.3030 -0.5719 -1.5793 -0.2365 -0.4677 -0.9502 -1.7813 -0.0061 -0.0485 -3.2379 -0.5989 -0.1000
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone_antagonist therapy chronic_advanced_heart_failure patients post-myocardial_infarction heart_failure patients
H-1738	-0.8241773247718811	▁al do ster one _ ▁anta gon ist _ therapy ▁heart _ ▁failure ▁post - my o card ial _ ▁in far ction _ ▁heart _ ▁failure
D-1738	-0.8241773247718811	aldosterone_ antagonist_therapy heart_ failure post-myocardial_ infarction_ heart_ failure
P-1738	-0.1724 -0.3589 -0.0770 -1.9705 -0.9583 -0.1940 -0.1102 -2.5429 -1.3052 -0.0849 -2.9522 -0.8187 -0.6266 -0.9459 -0.0096 -1.7847 -0.4148 -0.1981 -0.2483 -0.9429 -0.3884 -2.6392 -0.0425 -1.2633 -1.1160 -0.6058 -0.5660 -0.3876 -0.1759
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial_shunting patients heart_failure_with_reduced_ejection_fraction proof-of-principle_cohort_study
H-1948	-0.9809892773628235	▁left - to - right ▁inter at rial _ ▁sh unting ▁heart _ ▁failure ▁e je ction _ fraction
D-1948	-0.9809892773628235	left-to-right interatrial_ shunting heart_ failure ejection_fraction
P-1948	-6.6350 -0.0193 -0.8749 -0.0472 -0.2086 -0.1750 -0.1444 -0.2547 -2.3954 -1.5403 -0.1120 -3.2598 -0.7391 -1.1515 -0.6747 -0.5309 -0.0939 -0.6278 -0.0094 -0.9742 -0.1327
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial_extracellular_matrix cardiac_magnetic_resonance t1_mapping pathobiology pathophysiology prognosis
H-735	-0.6592075824737549	▁my o card ial _ ▁extra cel lular ▁matri x ▁cardiac _ ▁magnetic _ ré on ance
D-735	-0.6592075824737549	myocardial_ extracellular matrix cardiac_ magnetic_réonance
P-735	-0.3513 -0.3407 -0.0743 -0.1724 -0.1506 -0.5195 -0.5782 -0.0389 -1.6901 -0.0720 -0.0195 -0.8965 -1.2131 -1.3368 -2.5421 -0.5215 -0.0275 -1.8620 -0.1181
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical_examination patient bmi heart_rate rhythm blood_pressure auscultation rule valvular_disease pulmonary_congestion
H-1894	-0.9521207213401794	▁b mi ▁heart _ ▁rate ▁ rhythm ▁ly ing ▁blood _ tension ▁val vu lar ▁disease ▁pulmonar y _ con gestion
D-1894	-0.9521207213401794	bmi heart_ rate rhythm lying blood_tension valvular disease pulmonary_congestion
P-1894	-0.1252 -1.0985 -4.8460 -1.5992 -1.5130 -0.3898 -0.0451 -0.0425 -0.1912 -2.3151 -0.8976 -0.4685 -2.2236 -1.0650 -0.2737 -2.9309 -0.0054 -0.1563 -1.0584 -0.0582 -0.0021 -0.4655 -0.1280
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal_dialysis pd diuretic volume_overload heart_failure hf
H-894	-0.7100896835327148	▁Peri tone al _ di al ysis PD ▁di ure tic _ ▁resist ant _ ▁volume _ ▁over load ▁heart _ ▁failure HF
D-894	-0.7100896835327148	Peritoneal_dialysisPD diuretic_ resistant_ volume_ overload heart_ failureHF
P-894	-0.2277 -0.4733 -0.1393 -0.3208 -1.7041 -0.1628 -0.0721 -0.5601 -0.1173 -0.0498 -2.5350 -0.6284 -2.5272 -0.0418 -1.1783 -0.7883 -0.1542 -1.2763 -0.1226 -1.0064 -0.7062 -1.5640 -1.0640 -0.2402 -0.0922
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology national_cardiovascular_disease_registry_practice_innovation_and_clinical_excellence_registry
H-660	-1.0633528232574463	▁Card i ology _ prac tice s ▁national _ ▁Card io vas cular _ ▁Disease _ ▁Registr y ▁Clinic al _ ▁Excellence
D-660	-1.0633528232574463	Cardiology_practices national_ Cardiovascular_ Disease_ Registry Clinical_ Excellence
P-660	-0.5828 -1.0801 -0.8981 -3.2775 -1.5123 -1.4406 -0.0690 -2.4904 -0.6254 -1.7140 -2.0465 -0.2013 -0.5686 -1.0729 -0.0607 -2.4741 -0.7126 -0.0703 -2.9331 -0.0132 -0.1858 -1.0064 -0.3733 -0.1117
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report stable hno_donor cxl-1020 myoctyes hearts patients heart_failure hf
H-415	-0.7569121718406677	▁h no ▁donor ▁c XL -10 20) ▁my oc ty es ▁intact ▁heart s ▁heart _ ▁failure HF
D-415	-0.7569121718406677	hno donor cXL-1020) myoctyes intact hearts heart_ failureHF
P-415	-0.3610 -0.2314 -1.5526 -0.3819 -0.2416 -1.3488 -0.2896 -3.5593 -0.0516 -0.9738 -0.1345 -0.2223 -0.5775 -0.0673 -1.4732 -2.1124 -0.8624 -0.3804 -0.1988 -0.1178
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral_muscle_pump cardiac_filling exercise subpulmonary_ventricle fontan_circulation
H-1492	-0.6471114158630371	▁per i pher al _ ▁muscle _ pump ▁cardiac _ ▁fill ing ▁sub pul mon ary ▁vent ric le ▁Font an _ ▁circulation
D-1492	-0.6471114158630371	peripheral_ muscle_pump cardiac_ filling subpulmonary ventricle Fontan_ circulation
P-1492	-0.6160 -0.2317 -0.0879 -0.0788 -0.5878 -1.8826 -0.9000 -0.6522 -0.5183 -1.5382 -0.1852 -0.0895 -0.0488 -0.0671 -2.3497 -0.7997 -0.7629 -2.3938 -0.3049 -0.0818 -0.5108 -0.2244 -0.8672 -0.2834 -0.1148
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil heart_rate aortic blood_flow mitochondrial oxidative_stress doxorubicin cardiotoxicity
H-963	-0.548348069190979	▁Nico rand il ▁heart _ ▁rate ▁a or tic _ ▁blood _ ▁flow ▁mito cho ndri al _ ▁oxid ative _ ▁stress ▁do xor ubi cin ▁cardio toxic ity
D-963	-0.548348069190979	Nicorandil heart_ rate aortic_ blood_ flow mitochondrial_ oxidative_ stress doxorubicin cardiotoxicity
P-963	-0.0073 -0.1378 -0.1129 -2.4899 -1.6425 -1.2683 -0.0183 -0.0302 -0.6461 -1.0683 -0.2108 -1.3270 -0.2142 -0.0126 -1.2261 -0.2713 -0.0764 -0.4094 -1.2313 -0.2152 -1.2787 -1.2859 -0.0032 -0.0068 -0.0270 -0.0634 -0.7390 -0.2570 -0.3547 -0.2907 -0.0765
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal_dysfunction prognostic heart_failure hf dysfunction end-stage_renal_disease esrd
H-387	-0.7650070190429688	▁Ren al _ ▁dys function ▁heart _ ▁failure HF ▁dys function ▁end - s tage _ ▁renal ▁disease ▁e RD
D-387	-0.7650070190429688	Renal_ dysfunction heart_ failureHF dysfunction end-stage_ renal disease eRD
P-387	-1.5109 -0.1933 -0.9425 -0.4210 -0.7031 -1.6979 -0.6968 -1.2080 -1.1208 -2.6168 -0.4258 -0.1994 -0.0274 -0.1103 -0.0020 -1.1984 -0.0414 -1.5437 -1.5733 -0.2142 -0.2623 -0.1208
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients heart_failure_with_preserved_ejection_fraction hfpef heart_failure obese
H-1974	-1.0280953645706177	▁heart _ ▁failure ▁pres er ved _ ▁e je ction _ fraction ▁h f f ▁heart _ ▁failure
D-1974	-1.0280953645706177	heart_ failure preserved_ ejection_fraction hff heart_ failure
P-1974	-2.6865 -0.8597 -1.7728 -3.1228 -0.0633 -1.1300 -0.3620 -2.2052 -1.1739 -0.0872 -0.2825 -0.0041 -0.1105 -0.1448 -0.2375 -1.7483 -0.8226 -1.7447 -1.8489 -0.1546
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral_artery_disease pad heart_failure hf prevalence hf patients pad
H-1567	-0.7984967827796936	▁Peri pher al _ ▁arter y ▁disease PAD ▁heart _ ▁failure HF ▁ HF PAD
D-1567	-0.7984967827796936	Peripheral_ artery diseasePAD heart_ failureHF HFPAD
P-1567	-0.3563 -0.0413 -0.1496 -0.7637 -1.2552 -0.3834 -1.7321 -0.1699 -0.7230 -0.7238 -1.3904 -0.9643 -1.2371 -0.7859 -2.1791 -0.5751 -0.1443
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical outcomes heart_failure charm candesartan_in_heart_failure_assessment_of_reduction_in_mortality_and_morbidity
H-554	-0.6454229950904846	▁heart _ ▁failure ▁CHA RM ▁can des ar tan _ ▁in _ ▁Heart _ ▁Fail ure ▁Mor t ality ▁Morbi d ity
D-554	-0.6454229950904846	heart_ failure CHARM candesartan_ in_ Heart_ Failure Mortality Morbidity
P-554	-4.5915 -0.7174 -1.3719 -0.4509 -0.5971 -1.9768 -0.0206 -0.4449 -0.0079 -0.8119 -0.8445 -0.6487 -0.5966 -0.4808 -0.1725 -0.0701 -0.4773 -0.0148 -0.0900 -0.0732 -0.0891 -0.4490 -0.3862 -0.1065
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic pediatric_fontan patients catheterization
H-227	-0.8125389218330383	▁pediatr ic ▁Font an PF ▁cat heter ization
D-227	-0.8125389218330383	pediatric FontanPF catheterization
P-227	-2.1183 -0.5591 -0.1854 -0.4257 -1.4969 -0.4771 -0.0133 -2.3593 -0.3592 -0.1310
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet patient subvalvular annular_ms
H-374	-1.1766352653503418	▁ms ▁sub val vu lar ▁dynamic ▁ann ular ▁MS
D-374	-1.1766352653503418	ms subvalvular dynamic annular MS
P-374	-2.5477 -0.8276 -2.1683 -0.3511 -0.1530 -3.0937 -0.3589 -0.0116 -1.2409 -2.0947 -0.0955
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the_lancet anoop_shah air heart_failure morbidity mortality
H-1807	-0.4448891878128052	▁Lance t ▁ano op ▁Shah ▁air ▁pollution ▁heart _ ▁failure ▁morbi d ity ▁mortal ity
D-1807	-0.4448891878128052	Lancet anoop Shah air pollution heart_ failure morbidity mortality
P-1807	-0.0288 -0.0091 -0.2825 -0.0974 -0.4481 -0.0179 -0.3795 -0.3605 -0.5921 -0.8596 -0.8122 -0.1350 -0.3239 -1.4964 -0.2530 -1.3375 -0.1295
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell_therapy chronic_heart_failure chf disease progenitor_cells
H-1336	-0.8901301026344299	▁implant - der i ved _ pro gen itor _ cell s
D-1336	-0.8901301026344299	implant-derived_progenitor_cells
P-1336	-4.9684 -0.9137 -0.2248 -0.0753 -0.6377 -0.9099 -0.0741 -0.1385 -0.2478 -3.2332 -0.3171 -0.1319 -0.4968 -0.0925
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese patients clinically stable hfpef exercise training peak_vo2
H-1990	-0.8175602555274963	▁obes e ▁h f f f ▁calor ic ▁restriction ▁aero bic _ ▁exercise ▁VO 2
D-1990	-0.8175602555274963	obese hfff caloric restriction aerobic_ exercise VO2
P-1990	-4.1401 -0.0943 -0.5206 -0.1491 -0.1569 -0.2076 -0.3446 -0.7473 -0.4519 -0.1399 -0.0579 -1.9946 -0.7587 -3.6840 -0.0193 -0.3131 -0.1185
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia hf health-related_quality_of_life hrqol hf
H-835	-0.6106462478637695	▁an emia ▁ HF ▁health - related ▁quality _ of _ ▁life HR Qo L ▁ HF
D-835	-0.6106462478637695	anemia HF health-related quality_of_ lifeHRQoL HF
P-835	-0.7644 -0.0971 -0.9738 -0.1175 -0.6808 -0.0951 -0.0619 -2.6405 -0.2214 -0.7925 -0.1854 -1.9448 -1.0572 -0.0192 -0.1971 -1.0609 -0.2115 -0.3770 -0.1043
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous_nonfailing hf combinations remodeling
H-1152	-0.42487138509750366	▁m RI ▁dys syn chron ous _ non fail ing ▁ HF ▁can ine _ électro me chan iques ▁remodel ing
D-1152	-0.42487138509750366	mRI dyssynchronous_nonfailing HF canine_électromechaniques remodeling
P-1152	-0.1223 -1.8318 -2.3784 -0.0043 -0.0016 -1.4061 -0.0795 -0.1498 -0.0137 -0.0827 -0.3686 -0.1191 -0.1087 -0.2203 -0.3798 -0.2351 -0.0215 -0.3215 -0.5912 -0.4371 -0.0844 -0.6852 -0.1293
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients hr_variability mortality ami diagnosis chf lv_dysfunction
H-1586	-1.2629952430725098	▁HR _ ▁variabil ity ▁mortal ity ▁ AMI ▁CHF / LV
D-1586	-1.2629952430725098	HR_ variability mortality AMI CHF/LV
P-1586	-1.3909 -2.3876 -0.9018 -0.3518 -1.8090 -0.3147 -1.0653 -0.1620 -0.5226 -4.8247 -1.0833 -1.4937 -0.1115
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes chronic_heart_failure hf exercise training
H-1630	-1.067952275276184	▁race ▁chronic _ ▁heart _ ▁failure HF
D-1630	-1.067952275276184	race chronic_ heart_ failureHF
P-1630	-0.9319 -2.8333 -0.3903 -1.5851 -0.5534 -0.7910 -0.7659 -1.6674 -0.0932
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-0.6799003481864929	▁drug - free
D-947	-0.6799003481864929	drug-free
P-947	-2.1440 -0.2304 -0.3000 -0.6241 -0.1010
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence exercise cell_senescence active osteoporosis
H-1901	-0.5027762055397034	▁cell _ ▁se nesc ence ▁active ▁malign a ncies ▁cancer ▁prostat e ▁colon ▁osteo por osis ▁depression ▁dem entia
D-1901	-0.5027762055397034	cell_ senescence active malignancies cancer prostate colon osteoporosis depression dementia
P-1901	-3.5771 -0.4058 -0.7643 -0.1565 -0.0111 -0.2484 -0.2858 -1.1989 -0.1113 -0.1954 -0.1766 -0.0864 -0.8075 -0.0617 -0.1616 -0.0386 -0.6594 -1.2759 -0.0952 -0.1761 -0.0647
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological capillary coronary_perfusion
H-457	-0.8295354247093201	▁cap illa ry ▁corona ry _ per fusion ▁ad - f lk ▁rat s ▁ad - c ▁rat s
D-457	-0.8295354247093201	capillary coronary_perfusion ad-flk rats ad-c rats
P-457	-4.9595 -0.0064 -0.8013 -2.9209 -0.8371 -1.3023 -0.3419 -0.0386 -1.2999 -0.0488 -0.1648 -0.1534 -0.3654 -0.0357 -2.1469 -0.0401 -0.4769 -0.9295 -0.0260 -0.3834 -0.1414
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle_walk_test hand baseline
H-1322	-0.9856783151626587	▁shu ttle _ ▁walk _ test ▁body _ ▁mass ▁hand _ ▁grip _ ▁strength
D-1322	-0.9856783151626587	shuttle_ walk_test body_ mass hand_ grip_ strength
P-1322	-0.5495 -0.0130 -0.1884 -1.1584 -1.1719 -1.7915 -1.1504 -0.8881 -1.8581 -1.6086 -0.2991 -0.8401 -1.8755 -1.2420 -0.9317 -0.2045
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician mortality internists cardiologists
H-1730	-0.7236003875732422	▁physician _ ▁volume ▁mortal ity ▁intern ists ▁cardio logist s
D-1730	-0.7236003875732422	physician_ volume mortality internists cardiologists
P-1730	-0.2916 -1.4259 -1.1024 -0.9995 -0.8370 -0.3261 -2.5799 -0.2081 -0.1004 -0.3925 -0.3340 -0.0860
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc frame patient consultation patients
H-1027	-0.9779677391052246	▁protocol - driv en ▁PO c ▁ NP ▁consultation ▁ED ▁through put
D-1027	-0.9779677391052246	protocol-driven POc NP consultation ED throughput
P-1027	-2.8252 -0.0789 -0.0051 -0.1757 -0.7181 -1.2304 -2.5364 -0.0682 -0.6541 -2.2072 -0.1577 -0.0154 -2.8502 -0.1691
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin_t n-terminal_pro-b-type_natriuretic_peptide biomarker heart_failure atherosclerosis_risk_in_communities
H-284	-0.7749401330947876	▁Tro ponin _ t ▁n - termin al _ pro - b - type _ na tri ure tic _ pe pti de ▁bio mark er ▁heart _ ▁failure ▁at hero sc ler osis
D-284	-0.7749401330947876	Troponin_t n-terminal_pro-b-type_natriuretic_peptide biomarker heart_ failure atherosclerosis
P-284	-0.1849 -0.0026 -2.5962 -0.8520 -2.6990 -0.0085 -0.0069 -0.0049 -1.5188 -0.5869 -0.0175 -1.0804 -0.0327 -0.5977 -0.3160 -1.3382 -0.0275 -0.0799 -3.5577 -0.8223 -0.4868 -0.3195 -0.3730 -0.6943 -0.0101 -0.1013 -1.1841 -0.5643 -0.9956 -1.2328 -0.2813 -2.3377 -1.8557 -0.1340 -0.8611 -0.1355
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients acute_rv_failure chronic_pulmonary_arterial_hypertension pah acute pulmonary_embolism
H-1095	-0.7283530235290527	▁ RV _ ▁failure ▁pulmonar y _ ▁arterial _ ▁hyper tension PA h ▁pulmonar y _ ▁e mbol ism
D-1095	-0.7283530235290527	RV_ failure pulmonary_ arterial_ hypertensionPAh pulmonary_ embolism
P-1095	-1.5772 -1.0244 -2.3589 -0.5919 -0.6377 -0.0561 -0.5852 -0.3125 -0.2946 -1.6896 -0.0001 -1.3384 -0.3335 -0.2283 -0.0959 -0.2975 -2.1965 -0.0043 -1.1239 -0.4275 -0.1215
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic methylatropine vagal_tone bradycardic propranolol sympathetic_tone
H-1139	-0.8755794167518616	▁ta chy car dic _ ▁response ▁met hy la tropi ne ▁va gal _ ▁tone ▁bra dy car dic _ ▁response ▁propra no lol
D-1139	-0.8755794167518616	tachycardic_ response methylatropine vagal_ tone bradycardic_ response propranolol
P-1139	-2.5004 -1.9977 -0.0983 -0.2615 -3.6088 -0.8697 -0.7918 -0.0708 -0.1682 -0.0425 -1.9593 -0.0627 -0.0183 -1.5330 -0.4311 -1.4707 -0.9511 -0.0524 -0.1012 -1.9257 -0.9221 -0.3308 -0.0108 -0.1195 -2.3811 -0.0855
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin_inhibitors natriuretic_peptide atrial_natriuretic_peptide b-type_natriuretic_peptide
H-1462	-0.9416283965110779	▁Ne pri ly sin _ ▁inhibi tors ▁na tri ure tic _ pe pti de ▁break down ▁at rial ▁na tri ure tic _ pe pti de ▁b - type _ na tri ure tic _ pe pti de
D-1462	-0.9416283965110779	Neprilysin_ inhibitors natriuretic_peptide breakdown atrial natriuretic_peptide b-type_natriuretic_peptide
P-1462	-3.2740 -0.4301 -3.0723 -1.3047 -1.9780 -0.0775 -1.9069 -0.0270 -0.0346 -0.1119 -4.0333 -0.5606 -0.3968 -0.5866 -0.6035 -2.9144 -0.1117 -0.3699 -0.1095 -0.4586 -0.0452 -0.1398 -3.6568 -0.6943 -0.4094 -0.2532 -0.2876 -0.7994 -0.1288 -0.4271 -0.3696 -1.6372 -0.0640 -0.1028 -4.9604 -0.5739 -0.6527 -0.3896 -0.3057 -0.2095 -0.1377
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2007	-1.2868897914886475	▁économique _ analys is ▁Patient _ management _ ▁Interven tions ▁Heart _ ▁Fail ure ▁coût - ef ective ness ▁disease _ management _ ▁programs _ ▁in _ heart _ ▁failure
D-2007	-1.2868897914886475	économique_analysis Patient_management_ Interventions Heart_ Failure coût-efectiveness disease_management_ programs_ in_heart_ failure
P-2007	-0.8231 -4.1433 -0.8411 -0.0309 -3.0419 -1.7173 -1.1228 -1.2584 -1.1415 -0.0169 -0.9218 -0.5100 -0.2945 -0.0574 -1.8438 -0.0684 -3.1207 -0.1860 -1.8100 -3.8316 -1.6387 -0.5355 -2.8816 -1.7752 -1.7762 -1.2050 -0.7092 -1.2079 -0.7576 -1.5500 -0.2241 -0.1379
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional_flow_reserve positron_emission_tomography ischemia bottleneck_stenting left_ventricle lad
H-509	-0.5970864295959473	▁Fra ction al _ f ré que nce _ ▁reserve ▁posi tron _ ▁e mission _ tom ography ▁ ische mia ▁bottle ne ck ▁vent ric le ▁ LAD
D-509	-0.5970864295959473	Fractional_fréquence_ reserve positron_ emission_tomography ischemia bottleneck ventricle LAD
P-509	-1.2827 -0.0009 -0.2481 -0.4051 -1.1868 -0.2869 -0.0969 -0.0175 -1.2026 -1.3566 -0.2177 -0.0359 -1.1287 -0.1741 -0.0531 -0.6688 -0.1393 -0.3635 -1.2397 -0.5431 -0.6859 -0.0573 -0.0426 -0.6138 -0.7615 -3.5311 -0.6653 -1.1303 -0.0196 -0.2788 -0.0754
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac_resynchronization_therapy crt mild_heart_failure hf patients qrs_prolongation ejection_fraction ef
H-751	-0.6664318442344666	▁cardiac _ re syn chron ization _ therapy ▁c RT ▁heart _ ▁failure ▁h z ▁QR s ▁e je ction _ fraction EF
D-751	-0.6664318442344666	cardiac_resynchronization_therapy cRT heart_ failure hz QRs ejection_fractionEF
P-751	-0.5332 -0.8651 -0.7483 -0.0221 -0.0013 -0.9299 -1.3418 -0.5284 -0.3365 -0.8638 -2.0037 -0.6346 -1.3851 -0.6734 -1.8963 -0.4464 -1.0977 -0.2816 -0.3121 -0.0283 -0.5851 -0.0022 -0.7279 -0.2921 -0.1240
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity oxidative_stress dna_fragmentation
H-962	-1.0152385234832764	▁mito cho ndri al _ ▁oxid ative _ phos phor y lation ▁creati ne ▁kina se ▁oxid ative _ tension
D-962	-1.0152385234832764	mitochondrial_ oxidative_phosphorylation creatine kinase oxidative_tension
P-962	-0.0185 -1.4610 -0.2640 -0.1194 -1.2008 -3.1707 -1.0773 -0.3721 -0.1486 -0.3303 -1.4041 -0.0128 -2.9255 -0.3713 -0.8027 -0.0290 -2.4285 -0.4492 -0.5903 -2.5508 -2.5107 -0.0977
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ventricular_assist_devices cardiac nurses gastrointestinal_bleeding
H-1660	-0.39374107122421265	▁vent ri cular _ assist ▁devices ▁cardiac ▁nurse s ▁gastro inte stin al _ ▁ble ed ing
D-1660	-0.39374107122421265	ventricular_assist devices cardiac nurses gastrointestinal_ bleeding
P-1660	-0.0045 -0.3693 -0.1613 -0.5036 -0.1698 -1.4176 -0.5467 -0.9465 -0.0275 -0.5218 -0.0129 -0.3261 -0.0798 -0.4743 -0.6736 -0.5560 -0.3386 -0.2372 -0.1140
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox_regression covariates spironolactone death hospitalization hyperkalemia acute_kidney_injury
H-442	-0.5639057159423828	▁spi rono lac tone ▁death ▁hyper kal emia ▁ki dne y ▁injury
D-442	-0.5639057159423828	spironolactone death hyperkalemia kidney injury
P-442	-0.2919 -0.0429 -0.4098 -0.2486 -3.8764 -0.0987 -0.2389 -0.2074 -0.7667 -0.3796 -0.0807 -0.9359 -0.2214 -0.0957
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended_criteria_cardiac_transplant ecct transplant donors transplant comorbidity
H-708	-1.1558501720428467	▁cardiac ▁transplant ▁e ct ▁transplant
D-708	-1.1558501720428467	cardiac transplant ect transplant
P-708	-0.2279 -0.9367 -1.2490 -1.6360 -0.3998 -3.5653 -0.0763
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum systolic lv_posterior_wall lv_internal_diameter metoprolol
H-1549	-1.0996891260147095	▁MI - indu ced ▁sept um _ syn chron e _ ▁thi ck ness ▁LV ▁posterior _ ▁wall _ ▁thi ck ness ▁LV ▁internal _ ▁diameter ▁met o pro lol
D-1549	-1.0996891260147095	MI-induced septum_synchrone_ thickness LV posterior_ wall_ thickness LV internal_ diameter metoprolol
P-1549	-1.2262 -1.2928 -0.0039 -3.5280 -0.7585 -0.0333 -1.7034 -1.3236 -2.7027 -1.3813 -1.0289 -2.1843 -0.6128 -1.3664 -0.5455 -2.2971 -0.6224 -3.0017 -0.5588 -2.2122 -0.2721 -0.5527 -0.3217 -3.3568 -0.8684 -0.6223 -0.1124 -0.0596 -0.0132 -0.2978 -0.2118 -0.1174
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat n-terminal_pro-brain_natriuretic_peptide hospitalized hf
H-1877	-0.6848656535148621	▁BAT ▁n - termin al _ pro - bra in _ ▁na tri ure tic _ pe pti de ▁ HF
D-1877	-0.6848656535148621	BAT n-terminal_pro-brain_ natriuretic_peptide HF
P-1877	-0.3912 -3.8239 -0.0149 -0.0425 -0.0214 -0.2868 -0.8776 -0.1195 -0.9453 -0.4364 -0.3683 -0.3903 -0.0295 -0.0782 -3.0759 -1.2970 -0.3134 -0.5264 -0.2707 -1.6816 -0.4970 -0.1585 -0.1059
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american_college_of_physicians acp evidence clinical anemia patients heart_disease
H-30	-0.650048553943634	▁American _ ▁College _ of _ phy s iques ▁a CP ▁an emia ▁ir on _ de fici en cy ▁heart
D-30	-0.650048553943634	American_ College_of_physiques aCP anemia iron_deficiency heart
P-30	-1.3636 -1.3510 -0.4493 -0.0559 -1.1653 -0.1746 -0.4485 -0.9702 -0.2209 -0.2617 -0.4338 -1.1485 -0.2545 -0.0315 -0.0359 -0.5115 -0.0466 -0.2453 -0.9049 -0.6578 -1.7252 -2.4129 -0.0818
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes mortality hospitalization mortality cardiovascular_mortality hf hospitalization cox_models exercise training
H-1633	-0.8108105659484863	▁mortal ity ▁cardiovascular ▁mortal ity HF
D-1633	-0.8108105659484863	mortality cardiovascular mortalityHF
P-1633	-1.2059 -0.2943 -0.1640 -0.9638 -0.2343 -1.3980 -2.1134 -0.1130
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective hf patients hf_with_reduced_ef ef hfpef ef
H-782	-1.0231211185455322	▁ HF ▁ HF ▁ef f ▁h p f
D-782	-1.0231211185455322	HF HF eff hpf
P-782	-0.8835 -0.7311 -1.9185 -0.4746 -1.8228 -1.4957 -1.7210 -0.0938 -0.9712 -0.9660 -0.1763
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional_electrical_stimulation peripheral_muscles endothelial_function clinical heart_failure patients preserved_left_ventricular_ejection_fraction
H-1326	-0.7121369242668152	▁electric al ▁stimul ation ▁per i pher al ▁muscle s ▁en dot heli al _ f ré que nce ▁heart _ ▁failure ▁vent ri cular _ ▁e je ction _ fraction
D-1326	-0.7121369242668152	electrical stimulation peripheral muscles endothelial_fréquence heart_ failure ventricular_ ejection_fraction
P-1326	-1.3273 -0.0353 -0.5019 -0.0099 -0.4548 -0.2807 -0.1337 -0.1929 -1.9530 -0.0183 -0.2003 -1.5620 -0.0622 -0.0235 -2.4427 -2.9281 -0.1613 -0.0491 -0.1814 -1.9917 -1.3253 -0.9319 -0.2815 -0.1739 -0.1083 -1.1194 -1.8282 -0.4022 -0.1105 -2.2393 -0.0020 -0.3496 -0.1184
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-0.9082292914390564	▁SD QT - to - SD RR ▁ HF VT ▁h nor m
D-1441	-0.9082292914390564	SDQT-to-SDRR HFVT hnorm
P-1441	-0.2777 -1.9391 -0.2133 -0.3504 -0.0121 -0.2453 -1.8228 -1.8608 -1.1606 -2.1159 -0.1227 -2.9642 -0.0021 -0.4312 -0.1054
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular wall_stiffness
H-1148	-1.1070901155471802	▁vent ri cular ▁structure ▁ge ometr y ▁fiber she et ▁ orientation
D-1148	-1.1070901155471802	ventricular structure geometry fibersheet orientation
P-1148	-0.0064 -0.2823 -0.2093 -2.4167 -4.9658 -0.0403 -0.4649 -0.4200 -1.0022 -0.0397 -2.5244 -0.0194 -2.9847 -0.1233
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad q66p cardiomyopathy
H-1677	-0.926160454750061	▁rad _ q 66 p ▁cardio my o pathy
D-1677	-0.926160454750061	rad_q66p cardiomyopathy
P-1677	-0.3982 -2.4460 -1.1486 -0.2525 -0.1850 -0.0548 -1.9556 -0.5149 -0.0245 -3.1068 -0.1009
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin chemotherapy elevated cardiotoxicity
H-937	-0.8075243234634399	▁se rum _ ▁resist in ▁women ▁an thra cycli ne - conta ining _ che mo therapy ▁cardio toxic ity
D-937	-0.8075243234634399	serum_ resistin women anthracycline-containing_chemotherapy cardiotoxicity
P-937	-0.7072 -0.5196 -0.3687 -1.1764 -0.9480 -3.9906 -0.0407 -0.0883 -2.5544 -1.2784 -0.3541 -0.0716 -0.5325 -0.5661 -2.4357 -0.0651 -0.0484 -0.0626 -0.3106 -1.0796 -0.4369 -0.1302
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients sst2 titrated cardiovascular_event
H-405	-1.8801233768463135	▁s st 2 ▁fréquence ▁cardiovascular
D-405	-1.8801233768463135	sst2 fréquence cardiovascular
P-405	-0.2809 -1.8230 -1.6243 -4.8787 -1.8941 -2.5636 -0.0963
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative patients preoperative hypoalbuminemia albumin
H-533	-1.1887820959091187	▁pre operativ e _ hy album in emia
D-533	-1.1887820959091187	preoperative_hyalbuminemia
P-533	-3.7358 -0.1064 -0.1000 -1.3827 -0.6297 -0.9200 -1.0583 -1.1606 -2.6672 -0.1271
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration renin-angiotensin_system_blocker beta-blocker therapy patients hospitalized heart_failure preserved_left_ventricular_ejection_fractions
H-174	-0.7489283680915833	▁re nin - angi oten sin _ system _ block er ▁beta - block er ▁ therapy ▁heart _ ▁failure ▁vent ri cular _ ▁e je ction
D-174	-0.7489283680915833	renin-angiotensin_system_blocker beta-blocker therapy heart_ failure ventricular_ ejection
P-174	-0.0353 -0.9534 -0.0411 -0.1513 -0.0493 -1.5511 -2.1002 -0.3050 -1.1150 -1.1849 -0.1078 -0.3493 -0.0134 -0.0630 -0.0833 -2.9349 -0.0175 -0.2680 -1.2606 -1.7204 -0.8262 -0.2463 -0.1963 -1.3127 -1.9617 -0.5171 -0.1598 -1.9954 -0.1988
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use_of_exercise_and_medical_therapies_to_improve_cardiac_function_among_patients_with_exertional_shortness_of_breath_due_to_lung_congestion
H-1180	-0.5699273347854614	▁Medical ▁Therapie s ▁Card iac _ ▁Fun ction ▁Breath ▁Lung _ con gestion
D-1180	-0.5699273347854614	Medical Therapies Cardiac_ Function Breath Lung_congestion
P-1180	-3.3748 -0.3806 -0.0284 -0.4700 -0.2351 -0.4021 -0.2315 -0.0026 -1.2400 -0.1764 -1.1262 -0.0597 -0.0032 -0.7379 -0.0805
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective nicorandil hemodynamic mitochondrial_dysfunction administration doxorubicin
H-956	-0.46766889095306396	▁cardio protec tive _ effet ▁nic oran dil ▁hem o dynamic _ ▁altera tions ▁mito cho ndri al _ ▁dys function ▁do xor ubi cin ▁rat s
D-956	-0.46766889095306396	cardioprotective_effet nicorandil hemodynamic_ alterations mitochondrial_ dysfunction doxorubicin rats
P-956	-0.0555 -0.0839 -0.0198 -1.5521 -2.0627 -1.2787 -0.1126 -1.0039 -0.2355 -0.0475 -0.0229 -2.2810 -0.2993 -0.0202 -0.0260 -1.3888 -0.1363 -0.0803 -0.6525 -0.0439 -0.3101 -0.1585 -0.0913 -0.0609 -0.1075 -1.1440 -0.0459 -0.1772 -0.0638
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex_sensitivity heart_rate_variability hrv renal_dnx
H-1376	-0.7196581959724426	▁Baro re flex ▁ sensitiv ity ▁temps ▁heart _ ▁rate _ vari able ▁h v ▁CHF - in v ▁sham - in v ▁sham - in v ▁renal ▁DN x
D-1376	-0.7196581959724426	Baroreflex sensitivity temps heart_ rate_variable hv CHF-inv sham-inv sham-inv renal DNx
P-1376	-0.0960 -0.0411 -0.1032 -1.5231 -0.0525 -0.1114 -1.5530 -3.2664 -1.4202 -1.0324 -1.0940 -0.7794 -0.6387 -1.2324 -1.8293 -0.2172 -0.0415 -0.3679 -1.1589 -0.0374 -0.0533 -0.4754 -0.9924 -0.8775 -1.1217 -1.0082 -0.9887 -0.3803 -0.1430 -0.0151 -0.2540 -0.1233
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic_cell_transplantation hct congestive_heart_failure chf anthracyclines
H-1449	-0.5892593860626221	▁ha e mato po ie tique _ cell ▁transplant ation ▁h ct ▁con ges tive _ ▁heart _ ▁failure ▁ch f ▁h ct ▁an thra cycli nes
D-1449	-0.5892593860626221	haematopoietique_cell transplantation hct congestive_ heart_ failure chf hct anthracyclines
P-1449	-1.5463 -0.1389 -0.1014 -0.3272 -0.5109 -1.8420 -0.9845 -0.7135 -0.4198 -0.0121 -0.1056 -1.5703 -0.8167 -0.2832 -0.1291 -0.3830 -1.1817 -0.7521 -0.4764 -1.4760 -0.0190 -0.4017 -1.2682 -0.3319 -0.0411 -0.7106 -0.2126 -0.2321 -0.1007
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic proteins histone_acetyltransferases epigenetic histone_deacetylases cardiac disease
H-1041	-0.7685754299163818	▁epi gene tic _ writer ▁protein s hi stone _ a ce tyl transfer as es ▁epi gene tic _ eras ers hi stone _ de ace ty las es ▁cardiac
D-1041	-0.7685754299163818	epigenetic_writer proteinshistone_acetyltransferases epigenetic_erasershistone_deacetylases cardiac
P-1041	-2.8931 -0.0471 -0.8037 -1.7867 -0.3105 -2.4755 -0.0196 -0.2276 -0.5324 -0.8083 -0.4089 -0.1603 -0.4454 -0.1516 -0.4624 -0.0637 -0.9200 -0.0420 -1.5623 -1.5041 -0.1503 -0.0769 -0.2936 -1.3080 -0.3690 -0.0386 -2.8925 -2.5089 -0.3791 -0.0325 -0.0353 -1.5152 -0.1380
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated nt-probnp admission all-cause_mortality patients acute_hf admission
H-270	-0.5638008713722229	▁NT - pro b NP ▁mortal ity ▁ HF
D-270	-0.5638008713722229	NT-probNP mortality HF
P-270	-0.0733 -0.0136 -0.0069 -0.4672 -0.1591 -0.8441 -0.4719 -3.6971 -0.2467 -0.0917 -0.1302
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in_vivo mir-25 antagomir cardiac_dysfunction murine myocardium heart_failure
H-643	-0.7743457555770874	▁inhibi tion ▁mi r -25 ▁cardiac _ ▁dys function ▁mur ine _ my o car dium ▁heart _ ▁failure ▁Hand 2- dependent
D-643	-0.7743457555770874	inhibition mir-25 cardiac_ dysfunction murine_myocardium heart_ failure Hand2-dependent
P-643	-2.1473 -0.0379 -0.2235 -0.7433 -0.1404 -0.5094 -1.4224 -0.0666 -0.5328 -0.1596 -1.2160 -0.4083 -3.2123 -0.1359 -0.0073 -0.2541 -0.3245 -0.8528 -2.2616 -0.9092 -1.4352 -0.1011 -1.2896 -0.1933
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left_bundle_branch_block remodeling dyssynchronous_heart_failure hf heart
H-1147	-0.7216213345527649	▁electric al _ activa tion ▁dys syn chron ous _ ▁heart _ ▁failure HF ▁electro me chan ical _ ▁behavior ▁heart
D-1147	-0.7216213345527649	electrical_activation dyssynchronous_ heart_ failureHF electromechanical_ behavior heart
P-1147	-0.9277 -0.0509 -0.6845 -0.7023 -0.0216 -0.0793 -0.0031 -0.0015 -1.9747 -0.9945 -1.5664 -0.6052 -0.9726 -0.9673 -0.0257 -0.0124 -0.1975 -0.7076 -1.1433 -0.9484 -3.5604 -0.3037 -0.1465
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse hospitalization physician discharge patients hospitalized heart_failure
H-206	-0.6998937726020813	▁nurse ▁cognitive ▁im pair ment ▁physician ▁dis charge ▁el der ly ▁patients ▁heart _ ▁failure
D-206	-0.6998937726020813	nurse cognitive impairment physician discharge elderly patients heart_ failure
P-206	-0.8012 -0.7355 -1.2800 -0.1081 -0.1323 -0.6425 -0.6538 -0.0021 -0.3743 -0.1816 -0.5718 -1.2527 -2.1854 -1.0451 -1.5772 -0.2295 -0.1252
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension diabetes_mellitus grade systolic diastolic_murmurs apex
H-347	-0.46257585287094116	▁hyper tension ▁h g ▁diabetes ▁mell itus ▁sy sto lic ▁dia sto lic ▁mur mur s
D-347	-0.46257585287094116	hypertension hg diabetes mellitus systolic diastolic murmurs
P-347	-0.1225 -0.0006 -0.0498 -0.0111 -0.0728 -0.8343 -0.1810 -0.6625 -0.1406 -1.4250 -0.6087 -0.4585 -2.2077 -1.0366 -0.0988 -0.1241 -0.1922 -0.0997
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients heart_failure heart cardiologists cardiovascular surgeons medical patient
H-1822	-1.1920199394226074	▁heart _ team ▁cardio logist s ▁cardiovascular ▁surge ons ▁medical
D-1822	-1.1920199394226074	heart_team cardiologists cardiovascular surgeons medical
P-1822	-3.6901 -1.1608 -3.5355 -0.4374 -0.0995 -0.1956 -0.1862 -2.2506 -0.0877 -0.9377 -1.5964 -0.1269
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine patients dilated_cardiomyopathy dcm heart_failure
H-1258	-0.6241627335548401	▁Chinese _ ▁herbal ▁medicine ▁ch m ▁dil ated _ ▁cardio my o pathy ▁d m ▁heart _ ▁failure
D-1258	-0.6241627335548401	Chinese_ herbal medicine chm dilated_ cardiomyopathy dm heart_ failure
P-1258	-1.5123 -0.7542 -0.2619 -0.5274 -2.3293 -0.0195 -0.5276 -0.3667 -0.2824 -0.1791 -1.3963 -0.6970 -0.0101 -0.9501 -0.0243 -0.4053 -0.9901 -0.9474 -0.1823 -0.1200
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse pasp downward hfref hfpef prognostic resolution
H-500	-0.8183931708335876	▁T AP se ▁PAS p ▁non sur viv ors ▁h f f ▁ HF p EF
D-500	-0.8183931708335876	TAPse PASp nonsurvivors hff HFpEF
P-500	-3.5797 -0.5829 -0.7023 -1.2760 -0.4849 -2.5264 -0.0008 -0.0204 -0.6545 -0.0754 -0.8701 -0.1934 -1.6248 -0.4668 -0.0256 -0.9563 -0.6142 -0.0766
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute_rv_failure pulmonary_embolism mortality diagnostic
H-1097	-0.7663888931274414	▁ RV ▁pulmonar y _ ▁e mbol ism ▁mortal ity
D-1097	-0.7663888931274414	RV pulmonary_ embolism mortality
P-1097	-1.3184 -1.2248 -0.5999 -0.0669 -0.5077 -2.1233 -0.0109 -1.8660 -0.4610 -0.7763 -0.1429 -0.0987
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates alendronate etidronate heart_failure compliance
H-1542	-0.40987855195999146	▁bis phos phon ates ▁ale ndr onate ▁et id rona te ▁heart _ ▁failure ▁re fill
D-1542	-0.40987855195999146	bisphosphonates alendronate etidronate heart_ failure refill
P-1542	-0.5030 -0.0386 -0.1239 -0.4852 -0.6141 -0.0177 -0.1396 -0.0338 -0.6377 -0.0428 -0.0120 -1.1299 -1.0392 -1.0020 -0.1824 -0.0207 -1.2591 -0.0961
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action randomized patients hf ejection_fraction exercise training
H-1632	-0.8811514377593994	▁ HF - ac tion ▁ HF ▁e je ction _ fraction
D-1632	-0.8811514377593994	HF-action HF ejection_fraction
P-1632	-1.0168 -0.6907 -0.3024 -1.2347 -0.5160 -1.3066 -0.6014 -2.0113 -1.6247 -0.0332 -0.9781 -0.0059 -1.9046 -0.1097
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol nonselective_β-blocker selective_β-blocker metoprolol thromboembolic_events heart_failure
H-1111	-0.7605183720588684	▁car vedi lol ▁β - block er ▁β - block er ▁met o pro lol ▁ thro mbo e mbol ic ▁events ▁heart _ ▁failure
D-1111	-0.7605183720588684	carvedilol β-blocker β-blocker metoprolol thromboembolic events heart_ failure
P-1111	-1.3695 -0.0461 -0.2196 -0.8579 -0.0155 -0.2647 -0.2517 -3.3918 -0.0131 -0.2560 -0.3311 -1.9320 -0.1621 -0.0204 -0.2685 -0.1298 -0.6272 -0.4289 -1.1662 -0.0252 -1.0992 -3.1164 -1.1099 -0.7956 -2.3480 -0.1780 -0.1095
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ami pna mortality
H-1700	-0.9136549234390259	▁ HF ▁ AMI ▁p na ▁mortal ity
D-1700	-0.9136549234390259	HF AMI pna mortality
P-1700	-2.7390 -1.3083 -1.7998 -0.6428 -0.8017 -0.6308 -0.3808 -0.4430 -0.2724 -0.1180
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline cardiac_transplant ecct
H-716	-1.383455753326416	▁cardiac ▁transplant
D-716	-1.383455753326416	cardiac transplant
P-716	-0.8094 -2.2302 -2.3864 -0.1078
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients heart_failure hf evidence outcomes hf
H-685	-1.63175368309021	▁heart _ ▁failure HF ▁ HF
D-685	-1.63175368309021	heart_ failureHF HF
P-685	-5.4241 -0.6153 -1.7656 -0.7926 -3.1243 -0.2179 -0.9865 -0.1278
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling arrhythmia ami hr_variability arrhythmia
H-1590	-1.3268790245056152	▁remodel ing ▁ar rhythm ia _ ▁substrat e ▁ AMI ▁HR
D-1590	-1.3268790245056152	remodeling arrhythmia_ substrate AMI HR
P-1590	-2.5438 -0.0735 -4.0815 -0.2381 -1.3456 -1.9112 -0.0697 -0.6084 -1.6948 -0.1095 -0.3580 -4.0988 -0.1168
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients hypertension compensated_hfpef dash sodium
H-919	-1.2374602556228638	▁hyper tension ▁h f EF ▁DAS h _ s RD ▁so dium
D-919	-1.2374602556228638	hypertension hfEF DASh_sRD sodium
P-919	-0.2790 -0.0071 -0.2401 -0.2960 -4.5871 -0.1506 -0.1194 -4.0747 -0.5416 -1.3198 -3.4255 -0.1612 -2.0496 -0.0727
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd dyssynchronous_hf remodeling insignificantly
H-1154	-0.5334793329238892	▁em d ▁dys syn chron ous ▁ HF ▁remodel ing
D-1154	-0.5334793329238892	emd dyssynchronous HF remodeling
P-1154	-1.1237 -0.2638 -0.0532 -0.0028 -0.0014 -2.4796 -1.8655 -0.0756 -0.1023 -0.0837 -0.2339 -0.1162
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ejection_fraction cardiac_index inotropes medical transplant
H-1997	-0.47078707814216614	▁e je ction _ fraction ▁cardiac ▁index ▁in o trop es ▁in ot rope
D-1997	-0.47078707814216614	ejection_fraction cardiac index inotropes inotrope
P-1997	-0.2542 -0.3091 -0.0318 -0.7725 -0.0010 -0.3462 -1.2164 -0.0301 -0.6784 -0.0480 -0.4878 -0.0149 -1.0537 -0.0746 -2.1054 -0.1085
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced_cardiotoxicity resistin retn
H-933	-0.5707838535308838	▁do xor ubi cin - indu ce ▁cardio toxic ity ▁Hum - re t n ▁litt er mate ▁resist in ▁re t n
D-933	-0.5707838535308838	doxorubicin-induce cardiotoxicity Hum-retn littermate resistin retn
P-933	-0.0015 -0.0224 -0.0551 -0.1947 -0.2248 -0.0010 -2.4188 -1.5016 -0.2353 -0.5499 -0.1284 -0.0187 -1.3437 -0.2126 -0.0339 -1.8252 -0.0100 -0.1306 -1.8569 -0.4065 -2.6721 -0.1022 -0.0143 -0.2459 -0.0632
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic_dysfunction pathophysiology hfpef cardiovascular_function
H-1302	-0.9840964078903198	▁dia sto lic _ ▁dys function ▁pat ho phy si ology ▁ HF p EF ▁non - dia sto lic _ ▁ab normal ities ▁cardiovascular
D-1302	-0.9840964078903198	diastolic_ dysfunction pathophysiology HFpEF non-diastolic_ abnormalities cardiovascular
P-1302	-0.3185 -0.8269 -4.6193 -0.4859 -0.3159 -0.7319 -0.4453 -0.0935 -0.0136 -0.5831 -1.5050 -0.7990 -0.4432 -0.0806 -0.4591 -5.2513 -0.0149 -0.9242 -0.9186 -1.9572 -1.4128 -0.1232 -0.0724 -1.2825 -0.3120 -2.4577 -0.1230
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp phosphomimic ser77 ser83 riα proteins riα
H-1432	-0.7763705849647522	▁8- flu o - c AMP ▁ binding ▁ phos pho mi mic ▁Ser 77 ▁ser 83 ▁mu tant ▁RI α ▁double _ mu tant ▁ WT _ ri α
D-1432	-0.7763705849647522	8-fluo-cAMP binding phosphomimic Ser77 ser83 mutant RIα double_mutant WT_riα
P-1432	-2.1806 -0.2826 -0.3180 -0.0261 -0.0337 -0.0725 -0.0821 -0.5923 -0.1306 -0.2263 -0.1600 -0.0479 -1.1758 -0.6619 -1.5040 -2.7115 -0.9751 -0.8141 -0.0740 -2.7988 -0.6197 -2.0208 -0.4649 -0.8932 -0.0488 -1.5245 -0.5729 -2.5190 -0.3361 -0.6686 -0.2094 -0.0981
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density_lipoprotein hdl endothelial_cell nitric_oxide
H-246	-0.6895095705986023	▁high - dens ity _ ▁lipo prote in HD l ▁en dot heli al - protec tive ▁effects ▁en dot heli al _ cell ▁e ▁ni tric ▁oxid e
D-246	-0.6895095705986023	high-density_ lipoproteinHDl endothelial-protective effects endothelial_cell e nitric oxide
P-246	-5.0337 -0.0939 -0.0169 -0.1785 -0.6660 -0.1611 -0.4017 -0.9492 -1.6937 -0.7662 -0.1181 -0.8852 -0.1463 -0.0429 -0.3155 -0.0150 -0.0536 -4.2170 -0.1843 -1.3340 -0.0961 -0.0238 -1.2193 -0.3800 -0.7127 -0.7527 -0.0474 -0.1056 -0.2109 -0.4577 -0.0956
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis patients hf hospitalization all-cause_hospitalization mortality hf hospitalization death
H-910	-0.8150355815887451	▁dia lys is ▁ HF ▁hospital ization ▁mortal ity ▁ HF
D-910	-0.8150355815887451	dialysis HF hospitalization mortality HF
P-910	-1.6468 -0.1338 -0.0699 -2.7696 -0.1045 -1.1465 -0.8763 -0.6346 -0.4726 -2.1629 -0.1898 -0.2668 -0.1214
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome admission discharge hospitalized heart_failure hf nursing_outcomes_classification noc
H-1398	-0.7962474226951599	▁ad mission _ à _ dis charge ▁hospital ized _ ▁older ▁adults ▁heart _ ▁failure HF ▁Nur sing _ out com es _ ▁Classifica tion no c
D-1398	-0.7962474226951599	admission_à_discharge hospitalized_ older adults heart_ failureHF Nursing_outcomes_ Classificationnoc
P-1398	-0.7313 -0.0061 -0.4056 -3.0371 -0.2894 -0.0276 -0.0038 -1.1644 -0.8451 -2.7936 -0.6158 -1.0139 -1.5493 -0.7486 -1.5761 -1.6245 -0.4754 -0.2539 -0.8944 -1.4988 -0.1414 -0.0719 -1.0482 -0.4735 -0.0082 -1.1024 -0.1972 -0.3467 -0.1470
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort_study saxagliptin sitagliptin antihyperglycemic_agents
H-1840	-0.5179561376571655	▁h f ▁sax ag lip tin ▁si tag lip tin ▁anti hy per gly ce mic ▁agents
D-1840	-0.5179561376571655	hf saxagliptin sitagliptin antihyperglycemic agents
P-1840	-0.0037 -0.6532 -0.2434 -0.2055 -0.2817 -1.4155 -0.2584 -0.0005 -0.0866 -1.3814 -0.0242 -0.0838 -0.3144 -1.9562 -0.1905 -1.9394 -0.4857 -0.2263 -0.0909
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate_analysis preoperative albumin mortality lvad implantation hazard_ratio confidence_interval
H-535	-0.6044136881828308	▁pre operativ e ▁album in ▁mortal ity ▁l VAD ▁implant ation
D-535	-0.6044136881828308	preoperative albumin mortality lVAD implantation
P-535	-2.7330 -0.3222 -0.1008 -1.1795 -0.4920 -0.0592 -0.3608 -1.3301 -0.0404 -0.1095 -0.0330 -0.9218 -0.1751
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients systolic_heart_failure qrs_duration crt death hospitalization heart_failure mortality
H-854	-1.312341332435608	▁sy sto lique _ ▁heart _ ▁failure ▁QR s ▁c RT ▁hospital ization ▁heart _ ▁failure ▁mortal ity
D-854	-1.312341332435608	systolique_ heart_ failure QRs cRT hospitalization heart_ failure mortality
P-854	-4.1595 -0.5743 -3.2188 -0.3535 -1.6359 -0.7729 -1.3791 -0.1117 -1.1422 -0.1749 -1.9899 -3.8115 -1.1438 -1.4172 -0.5071 -2.1479 -0.7973 -0.4587 -0.3218 -0.1289
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially_expressed_genes degs ischemic_heart_failure healthy diagnosis heart_failure
H-1608	-1.3568835258483887	▁d g s ▁non - ische mic ▁ ische mic ▁heart _ ▁failure
D-1608	-1.3568835258483887	dgs non-ischemic ischemic heart_ failure
P-1608	-3.4902 -0.6270 -0.2262 -3.8493 -0.0153 -2.3575 -0.2742 -2.6490 -0.9529 -0.4439 -1.5661 -1.4297 -0.6479 -1.6937 -0.1304
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse_events reoperation bleeding driveline infection gastrointestinal_bleeding stroke rankin_score
H-2003	-0.4642145037651062	▁ble ed ing ▁drive line _ ▁infection ▁gastro inte stin al ▁ble ed ing ▁stroke
D-2003	-0.4642145037651062	bleeding driveline_ infection gastrointestinal bleeding stroke
P-2003	-2.0668 -0.4682 -0.4717 -0.1802 -0.2210 -0.5893 -0.8325 -0.0156 -0.0096 -0.3927 -0.1524 -0.5308 -0.3981 -0.2224 -1.0867 -0.1602 -0.0933
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox_regression_models propensity_score oral glucocorticoid hf hospitalisations loop_diuretics
H-605	-0.7518861293792725	▁co x _ re gression ▁models ▁pro pens ity _ ▁score _ de cile ▁oral ▁gluco cor tico id ▁ HF ▁loop _ di ure tics
D-605	-0.7518861293792725	cox_regression models propensity_ score_decile oral glucocorticoid HF loop_diuretics
P-605	-0.0879 -0.0072 -0.9092 -0.8800 -0.0104 -3.2041 -0.0363 -0.0654 -0.5597 -0.9554 -0.9077 -0.6299 -0.0455 -0.4185 -1.2833 -0.0611 -0.0797 -2.0846 -1.0156 -1.6924 -0.0371 -0.9100 -0.5746 -2.4285 -0.2946 -1.3887 -0.3987 -0.0866
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin_resistance type_2_diabetes insulin_receptor_substrates_1 irs1 irs2 cellular_metabolism
H-653	-0.6289664506912231	▁in s ulin _ ▁resist ance ▁diabetes ▁insulin _ ▁receptor ▁substrat es ▁i ▁rs ▁insulin - signal ing
D-653	-0.6289664506912231	insulin_ resistance diabetes insulin_ receptor substrates i rs insulin-signaling
P-653	-0.4187 -0.7623 -0.0918 -0.4299 -1.3332 -0.0075 -0.1302 -0.0139 -1.8798 -0.2512 -1.5902 -0.1601 -1.0342 -1.6261 -0.7404 -0.1596 -0.0314 -0.3418 -1.4643 -0.1129
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous_hf electromechanical_delay emd myocyte_depolarization myofiber_shortening
H-1149	-0.5980785489082336	▁dys syn chron ous ▁ HF ▁electro me chan ical _ de lay ▁e d ▁my o cy te _ de po lar ization ▁my o fi ber
D-1149	-0.5980785489082336	dyssynchronous HF electromechanical_delay ed myocyte_depolarization myofiber
P-1149	-0.7582 -0.0020 -0.0004 -2.1589 -0.8388 -0.0595 -0.0065 -0.0222 -0.7496 -1.3009 -0.2541 -0.0549 -1.6273 -1.1159 -0.5382 -0.9274 -0.1492 -0.8666 -0.5433 -0.6881 -0.0234 -2.1536 -0.0706 -0.3493 -0.5446 -0.0431 -1.6129 -0.1091 -0.2326 -0.1412
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta_blockers all-cause_mortality readmissions heart_failure_with_reduced_ejection_fraction hfref heart_rate
H-1936	-0.7270445227622986	▁Beta _ block ers ▁mortal ity ▁read missions ▁heart _ ▁failure ▁e je ction _ fraction ▁h r f ▁heart _ ▁rate HR
D-1936	-0.7270445227622986	Beta_blockers mortality readmissions heart_ failure ejection_fraction hrf heart_ rateHR
P-1936	-0.5300 -2.1382 -1.1936 -0.0735 -2.2364 -0.2915 -0.2075 -0.0137 -0.6569 -0.3952 -0.9620 -1.0361 -0.4482 -0.0194 -0.4032 -0.0091 -0.9648 -0.1298 -0.8286 -0.4156 -1.3582 -1.9992 -1.5138 -0.2535 -0.0980
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional_electrical_stimulation fes exercise_capacity quality_of_life endothelial_function chronic_heart_failure systolic_function
H-1327	-0.9150442481040955	▁Fun ction al _ electric al ▁stimul ation ▁f es ▁emotional ▁stress ▁en dot heli al _ fon ction nel ▁heart _ ▁failure
D-1327	-0.9150442481040955	Functional_electrical stimulation fes emotional stress endothelial_fonctionnel heart_ failure
P-1327	-2.2781 -0.0010 -0.1168 -0.1574 -2.1453 -0.0240 -1.2670 -0.0140 -3.3116 -0.3329 -1.3972 -1.0885 -0.0675 -0.6765 -0.0546 -0.0073 -2.1614 -1.6599 -0.4215 -0.3422 -2.3093 -0.8085 -0.6354 -1.5272 -0.0708
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report patient right_atrial_myxoma massive_embolism pulmonary_arteries surgically right_atrial pulmonary_embolectomy
H-595	-0.8609508872032166	▁droit _ ▁at rial _ My xo ma ▁pulmonar y _ ▁arteri es ▁right _ ▁at rial _ ▁mass _ ▁remo val ▁pulmonar y _ ▁e mbol ecto my
D-595	-0.8609508872032166	droit_ atrial_Myxoma pulmonary_ arteries right_ atrial_ mass_ removal pulmonary_ embolectomy
P-595	-4.2941 -0.6786 -1.1378 -0.1326 -0.4447 -3.0240 -0.1577 -0.1270 -0.3417 -0.0991 -1.6773 -0.1569 -0.0302 -2.7007 -0.5388 -1.3052 -0.1640 -0.9877 -1.2331 -0.1990 -0.1627 -1.0661 -0.0010 -0.0552 -0.9766 -1.6469 -0.0075 -0.6019 -2.2892 -0.3639 -0.0883
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant patients pd hf clinical
H-896	-1.3153871297836304	▁transplant _ ▁in elig ible ▁patients ▁PD ▁ HF ▁volume _ management PD
D-896	-1.3153871297836304	transplant_ ineligible patients PD HF volume_managementPD
P-896	-0.7550 -2.8720 -1.2704 -0.0045 -1.0129 -0.9912 -3.7854 -1.3957 -0.1050 -2.2357 -0.7453 -0.4782 -2.7405 -1.2445 -0.0945
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker clinical therapeutic
H-1478	-0.6667056679725647	▁bio mark er - guide d _ ▁clinic al _ ▁trial ▁ therapeut ic ▁multi mark er - based
D-1478	-0.6667056679725647	biomarker-guided_ clinical_ trial therapeutic multimarker-based
P-1478	-1.1184 -0.0269 -0.0557 -1.3093 -0.0118 -0.1957 -0.7892 -0.3730 -0.0463 -0.6115 -1.0598 -1.6378 -0.0345 -0.9159 -3.7022 -0.0398 -0.0579 -0.2388 -0.0793 -1.5817 -0.1152
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf incidence liver nodularity
H-231	-1.1704120635986328	▁ SAF ▁ab normal ▁ liver _ ▁texture
D-231	-1.1704120635986328	SAF abnormal liver_ texture
P-231	-2.1207 -0.0770 -1.2384 -0.0753 -0.5808 -1.4078 -1.8507 -1.6787 -2.5073 -0.1673
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty biological_phenotype physical activity
H-1004	-1.0134669542312622	▁Fra il ty ▁bi ological _ ▁ph eno type ▁we ak _ ▁grip _ ▁strength ▁physical _ ▁exhaust ion
D-1004	-1.0134669542312622	Frailty biological_ phenotype weak_ grip_ strength physical_ exhaustion
P-1004	-1.2900 -0.4554 -3.2889 -0.4035 -0.2937 -1.0758 -0.4264 -0.3564 -0.0364 -3.8961 -0.0235 -0.8643 -0.2847 -1.3209 -1.1906 -0.7736 -1.1453 -0.6069 -0.0329 -3.4212 -0.0961
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d patients ic crt-d ies
H-109	-0.7300881743431091	▁c RT - d ▁IE ▁IC ▁c RT - d ▁IE s
D-109	-0.7300881743431091	cRT-d IE IC cRT-d IEs
P-109	-0.4367 -1.2517 -0.0640 -0.6507 -1.3666 -1.2282 -0.2394 -1.4318 -0.0605 -0.6308 -1.7861 -0.7539 -0.2380 -0.0828
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds discharge patients heart_failure outcomes driven readmissions
H-467	-1.7712138891220093	▁ed s ▁dis charge ▁patients ▁heart _ ▁failure ▁ED
D-467	-1.7712138891220093	eds discharge patients heart_ failure ED
P-467	-5.1658 -0.6301 -4.0530 -0.0015 -1.4168 -1.9551 -0.6483 -0.6856 -3.6304 -1.1955 -0.1013
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs_morphology outcomes cardiac_resynchronization_therapy resynchronization-defibrillation_for_ambulatory_heart_failure_trial raft
H-879	-0.4199453890323639	▁QR s ▁ morph ologie ▁cardiac ▁re syn chron ization _ therapy ▁re syn chron ization - Def i bril lation ▁Amb ulator y _ ▁Heart _ ▁Fail ure _ tri al RAF t
D-879	-0.4199453890323639	QRs morphologie cardiac resynchronization_therapy resynchronization-Defibrillation Ambulatory_ Heart_ Failure_trialRAFt
P-879	-0.0778 -0.3890 -1.1911 -0.0510 -1.0724 -0.1773 -0.5748 -0.0078 -0.0020 -0.6087 -0.7780 -2.3030 -0.3464 -0.0054 -0.0043 -0.6009 -0.3990 -1.3520 -0.3617 -0.2137 -0.0132 -0.1006 -0.0112 -0.0703 -0.4986 -0.1714 -0.4471 -0.1010 -0.0673 -0.9038 -0.5523 -0.0347 -0.1011 -1.2817 -0.1314 -0.1159
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute_right_heart_failure therapy refractory_cardiogenic_shock heart extra_corporeal_membrane_oxygenation ecmo cpr icu
H-1295	-0.7742695808410645	▁a cute _ ▁right _ ▁heart _ ▁failure ▁ therapy _ re frac tory _ ▁cardio ge nic _ ▁shock ▁heart ▁corpore al _ ▁membran e _ ▁oxygen ation ▁e mo ▁c PR ICU
D-1295	-0.7742695808410645	acute_ right_ heart_ failure therapy_refractory_ cardiogenic_ shock heart corporeal_ membrane_ oxygenation emo cPRICU
P-1295	-0.7431 -0.0049 -0.4483 -3.1185 -1.0472 -1.2534 -0.7253 -0.5041 -0.5250 -0.0081 -0.6412 -0.6646 -0.0334 -1.3299 -0.0792 -0.3558 -0.1226 -2.3940 -0.7992 -0.0940 -3.3189 -4.7528 -0.1135 -0.6994 -0.2553 -0.2667 -0.3657 -0.2444 -0.0136 -0.6494 -1.0801 -0.0638 -0.1281 -0.7057 -0.2467 -0.0780
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency_room undiagnosed heart_disease symptoms hf surgical_palliation
H-201	-1.4620442390441895	▁office - based ▁emergency ▁room _ prac ti tioner s ▁heart _ ▁disease ▁ HF
D-201	-1.4620442390441895	office-based emergency room_practitioners heart_ disease HF
P-201	-5.1952 -0.0331 -0.0372 -4.3805 -1.0850 -0.6189 -3.2456 -0.2359 -0.0662 -0.6003 -2.4955 -1.1069 -1.5586 -1.2629 -0.0770 -2.7506 -0.1053
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene_expression bax pacing bcl-2 mrna expression heart_failure bcl-2 bax
H-168	-0.6687677502632141	▁Bax ▁b cl -2 ▁m RNA ▁heart _ ▁failure ▁b cl - 2/ Ba x
D-168	-0.6687677502632141	Bax bcl-2 mRNA heart_ failure bcl-2/Bax
P-168	-1.4835 -0.3480 -0.2083 -0.9334 -0.0205 -0.0474 -1.4497 -1.1267 -1.4286 -0.0785 -0.2635 -0.0558 -0.0176 -3.6499 -0.0034 -0.1575 -0.0969
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart_magnetic_resonance_imaging chelation patient compliance heart_failure arrhythmias
H-745	-0.8826334476470947	▁heart _ ▁magnetic _ ▁res on ance _ ▁imagin g ▁che lation _ ▁choice s ▁patient _ ▁compliance ▁heart _ ▁failure ▁ar rhythm ias
D-745	-0.8826334476470947	heart_ magnetic_ resonance_ imaging chelation_ choices patient_ compliance heart_ failure arrhythmias
P-745	-1.0132 -0.7061 -1.2341 -1.7259 -1.2406 -0.0710 -0.0415 -0.8587 -0.1778 -0.0151 -0.0642 -0.0204 -1.6751 -2.2376 -0.0199 -1.6469 -1.0052 -2.2250 -0.9195 -0.8588 -1.0644 -3.2225 -0.1010 -0.4317 -0.2957 -0.0764
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl hno inotropic lusitropic vasodilator in_vivo camp
H-413	-0.28706929087638855	▁ni tro x yl ▁h no ▁Angeli s ▁salt ▁in o tropi c ▁ lusi tropi c ▁vaso dila tor ▁c AMP
D-413	-0.28706929087638855	nitroxyl hno Angelis salt inotropic lusitropic vasodilator cAMP
P-413	-0.2000 -0.0959 -0.0214 -0.1244 -0.2422 -0.1624 -0.2928 -1.7367 -0.0196 -0.5804 -0.5126 -0.0143 -0.1010 -0.3484 -0.0273 -0.0512 -0.1139 -0.0389 -0.0567 -0.0673 -1.6430 -0.0593 -0.2961 -0.0837
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection_fraction ef patients nyha_class_iiib symptoms right_ventricular_dysfunction
H-897	-0.7429007291793823	▁e je ction _ fraction ▁ef ▁pre - PD ▁NY HA ▁vent ri cular _ ▁dys function
D-897	-0.7429007291793823	ejection_fraction ef pre-PD NYHA ventricular_ dysfunction
P-897	-0.4335 -0.7601 -0.0229 -0.6674 -0.0015 -1.0015 -0.8183 -0.0102 -0.8505 -1.1721 -0.7637 -3.8900 -0.3018 -0.4374 -0.8329 -0.6037 -1.0891 -0.3585 -0.1001
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs early-outgrowth_colony-forming_units eo-cfus cells
H-124	-0.8715420365333557	▁c PC s ▁early - out g row th ▁e - c FU s ▁circula ting ▁CD 34 ▁v EG FR
D-124	-0.8715420365333557	cPCs early-outgrowth e-cFUs circulating CD34 vEGFR
P-124	-0.0925 -0.8767 -0.2047 -3.3983 -0.0302 -0.9766 -0.4976 -0.1145 -0.1100 -1.5999 -0.1237 -0.2093 -1.1625 -0.2936 -1.4780 -2.4647 -1.1446 -0.6987 -0.4112 -0.4684 -1.5576 -1.9586 -0.1735
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence clinical continuous-flow_lvads heartmate_ii hm_ii heartware btt dt patients
H-309	-0.9788506627082825	▁coût - effect ive s ▁continuo us - flow ▁l VAD s ▁he art Mate ▁h m _ ▁II ▁Heart War e ▁b t ▁ DT
D-309	-0.9788506627082825	coût-effectives continuous-flow lVADs heartMate hm_ II HeartWare bt DT
P-309	-3.8600 -0.4288 -0.0633 -0.0396 -5.7364 -0.6653 -0.0995 -0.0546 -0.1014 -4.3800 -0.0353 -0.3801 -0.9413 -0.2298 -0.5189 -0.8619 -1.0784 -2.1348 -1.5380 -0.6254 -0.9036 -0.0375 -0.1323 -0.2926 -1.6163 -0.3269 -0.2351 -0.0905
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy anticoagulation rate_control cardiovascular complications stroke cardiovascular_death acute_heart_failure patients atrial_fibrillation
H-1643	-0.9800774455070496	▁antico ag ulation ▁rate _ control ▁cardiovascular ▁complica tions ▁cardiovascular _ ▁death ▁a cute _ ▁heart _ ▁failure ▁at rial _ ▁fi bril lation AF
D-1643	-0.9800774455070496	anticoagulation rate_control cardiovascular complications cardiovascular_ death acute_ heart_ failure atrial_ fibrillationAF
P-1643	-4.3145 -1.0650 -0.0223 -3.0456 -0.7272 -0.0289 -0.4990 -0.2462 -0.1357 -2.3903 -2.6111 -0.3091 -0.0589 -0.0194 -0.1296 -3.4755 -0.4372 -1.3406 -0.2855 -0.1807 -0.2650 -3.9869 -0.0194 -0.0334 -0.5713 -0.1755 -0.0881
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients baseline ef ef core
H-753	-1.1010162830352783	▁EF
D-753	-1.1010162830352783	EF
P-753	-2.0412 -1.1284 -0.1335
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef bnp bnp inhospital mortality
H-197	-1.027275562286377	▁b p ▁b NP ▁in hospital _ ▁mortal ity
D-197	-1.027275562286377	bp bNP inhospital_ mortality
P-197	-2.5182 -1.6260 -2.4818 -1.6467 -1.3244 -0.2959 -0.8199 -0.1231 -0.2414 -0.1226 -0.1001
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash mortality hf nonsignificant
H-693	-0.5500462651252747	▁DAS h ▁mortal ity ▁ HF ▁Mediterrane an _ die t ▁score s
D-693	-0.5500462651252747	DASh mortality HF Mediterranean_diet scores
P-693	-0.0678 -0.2796 -0.5869 -0.3225 -1.6240 -0.0823 -0.2736 -0.3768 -1.4086 -0.6221 -0.4861 -1.7644 -0.0205 -0.2330 -0.1024
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal_muscle lean_mass z-score
H-1499	-1.7835423946380615	▁s kelet al _ ▁muscle _ ▁mass ▁figure
D-1499	-1.7835423946380615	skeletal_ muscle_ mass figure
P-1499	-3.6523 -0.0699 -0.3424 -0.9537 -3.2138 -1.8168 -2.1423 -4.7894 -0.6980 -0.1568
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 functional_capacity outcomes ambulatory patients hf
H-706	-0.8723320960998535	▁ST 2 ▁functional _ ▁capacity ▁well - tre ated ▁ambula tory ▁patients ▁ HF
D-706	-0.8723320960998535	ST2 functional_ capacity well-treated ambulatory patients HF
P-706	-3.0987 -0.2100 -0.5981 -1.7696 -2.1452 -0.6519 -0.0119 -0.0447 -1.5090 -0.5174 -0.4952 -1.1625 -1.2296 -0.0553 -0.2850 -0.1733
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality_of_life all-cause_mortality mortality
H-561	-1.2714158296585083	▁Quality _ of _ ▁life ▁mortal ity
D-561	-1.2714158296585083	Quality_of_ life mortality
P-561	-1.0175 -0.2454 -2.0541 -0.1808 -4.0674 -2.2228 -0.5214 -1.0146 -0.1188
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene_expression cardiomyocytes jq1 drug genes
H-1046	-0.9688506722450256	▁cardio my o cy tes ▁j q 1 ▁drug ▁ phen yle ph rine - indu ce ▁gene s
D-1046	-0.9688506722450256	cardiomyocytes jq1 drug phenylephrine-induce genes
P-1046	-3.2096 -1.6021 -0.8678 -0.2624 -0.2193 -0.4238 -0.7083 -0.8753 -0.1908 -0.3436 -0.4391 -1.6286 -2.0027 -0.3427 -0.4003 -0.0001 -3.5543 -2.9010 -0.0258 -0.2759 -0.0725
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka polymorphism rs10927887 p.arg83gly heart_failure estimated_glomerular_filtration_rate renastur
H-1801	-1.0299768447875977	▁a cc ka ▁poly morph ism ▁heart _ ▁failure ▁glo mer ular _ ▁filtr ation _ ▁rate ▁RE NAS tur
D-1801	-1.0299768447875977	accka polymorphism heart_ failure glomerular_ filtration_ rate RENAStur
P-1801	-2.4191 -0.8888 -2.3664 -0.2468 -0.0209 -0.9702 -3.9097 -1.2605 -2.2531 -0.0434 -0.1284 -0.1182 -1.3810 -0.4975 -0.0197 -2.4074 -0.5192 -1.6211 -0.0381 -1.0213 -0.3531 -0.1756
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular_diseases heart_failure hf incidence hf
H-285	-0.8932033181190491	▁cardiovascular ▁disease s ▁heart _ ▁failure HF
D-285	-0.8932033181190491	cardiovascular diseases heart_ failureHF
P-285	-0.1987 -3.1586 -0.0203 -0.4473 -0.5092 -1.5943 -0.9115 -1.1027 -0.0963
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac_vegf_expression endothelial_no_synthase_activation hearts
H-455	-0.7098791599273682	▁cardiac _ ve GF ▁expression ▁Akt ▁en dot heli al _ no ▁synth ase _ activa tion ▁drug - un tre ated ▁fail ing _ heart s
D-455	-0.7098791599273682	cardiac_veGF expression Akt endothelial_no synthase_activation drug-untreated failing_hearts
P-455	-0.4592 -1.5389 -1.4822 -0.3576 -0.6307 -0.0279 -0.0533 -1.1235 -0.0894 -0.0145 -0.6173 -0.6638 -1.6006 -1.9734 -0.3110 -0.5972 -0.0362 -0.9281 -0.1387 -0.2514 -0.0053 -2.6324 -1.0004 -0.3480 -1.3906 -1.7271 -0.1271 -0.3521 -0.1084
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial exercise outcomes heart_failure patients heart_failure outcomes exercise training hf-action
H-1924	-0.7699307799339294	▁Psycho social ▁Factor s ▁Heart _ ▁Fail ure ▁Heart _ ▁Fail ure ▁h - ac tion
D-1924	-0.7699307799339294	Psychosocial Factors Heart_ Failure Heart_ Failure h-action
P-1924	-0.7291 -0.0039 -1.8836 -0.0367 -2.8945 -1.0544 -0.1896 -0.1076 -1.6180 -0.5015 -0.2184 -0.1425 -2.4281 -0.3664 -0.7385 -0.5724 -0.2636 -0.1099
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart_failure left_ventricular_systolic_dysfunction post_hoc_analysis
H-402	-1.0498418807983398	▁heart _ ▁failure ▁vent ri cular _ syn chron _ ▁dys function ▁BB
D-402	-1.0498418807983398	heart_ failure ventricular_synchron_ dysfunction BB
P-402	-1.9017 -1.4318 -1.2245 -1.1778 -0.3621 -0.1517 -0.4404 -1.4139 -2.2434 -2.7926 -0.3730 -0.9795 -0.9517 -0.2076 -0.0958
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients coronary_angiography diagnosis systolic_hf etiology ejection_fraction
H-1186	-0.7848543524742126	▁deriva tion _ co hor t ▁corona ry _ ▁ang i ography ▁sy sto lic ▁ HF ▁un clear ▁et i ology
D-1186	-0.7848543524742126	derivation_cohort coronary_ angiography systolic HF unclear etiology
P-1186	-3.0368 -0.0104 -1.7534 -0.4589 -0.1162 -0.1448 -0.6859 -1.5042 -0.5015 -1.8068 -0.5530 -0.1936 -0.4524 -0.1752 -1.9566 -1.6265 -0.0481 -0.8357 -0.0076 -0.8170 -0.5203 -0.9698 -0.5402 -0.1217
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac insulin-resistance glycolysis glucose_oxidation plasma_membrane_translocation glucose
H-1784	-0.4570469856262207	▁cardiac ▁insulin - re si stance ▁a ac ▁insulin - stimul ated ▁rates ▁gly col ysis ▁gluco se _ ▁oxid ation ▁plasma ▁membran e ▁trans location ▁gluco se _ transport
D-1784	-0.4570469856262207	cardiac insulin-resistance aac insulin-stimulated rates glycolysis glucose_ oxidation plasma membrane translocation glucose_transport
P-1784	-0.0943 -0.9492 -0.0360 -0.3084 -0.1813 -0.0006 -0.3625 -1.4075 -0.1368 -0.0583 -0.0162 -0.5365 -0.6425 -0.1362 -0.6560 -0.0677 -0.0692 -0.0325 -0.9152 -0.9982 -0.0149 -0.1192 -1.3060 -0.1889 -1.4181 -0.2844 -1.0032 -0.0196 -1.2792 -0.5769 -0.6780 -0.1320
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells angiotensin_ii angii hypoxia scn5a mrna_splicing scn5a
H-1083	-0.804519772529602	▁ang io ten sin _ II ▁ang II ▁hypo xia ▁s CN 5 a ▁m RNA ▁s plic ing ▁s CN 5 a
D-1083	-0.804519772529602	angiotensin_II angII hypoxia sCN5a mRNA splicing sCN5a
P-1083	-0.0736 -3.0003 -0.1984 -0.8794 -1.1325 -0.7738 -0.6513 -0.4818 -0.0219 -0.0420 -2.4611 -2.4232 -0.6787 -0.1656 -0.0084 -0.1360 -1.2465 -1.0863 -0.1883 -1.5352 -1.8408 -0.5186 -0.2432 -0.2225 -0.1036
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced_pasp right_ventricular_contractile_reserve patients exercise-induced_pasp
H-824	-0.7612436413764954	▁vent ri cular _ contract ile _ ▁reserve ▁exercise - indu ced ▁PAS p
D-824	-0.7612436413764954	ventricular_contractile_ reserve exercise-induced PASp
P-824	-2.4553 -0.4294 -0.4581 -0.5734 -0.2089 -0.4630 -0.7562 -0.7054 -2.6097 -0.0765 -0.0009 -1.7416 -0.6811 -0.7142 -0.2041 -0.1022
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial_elastance ea end-systolic_elastance ees ventricular-arterial_coupling ees ea
H-922	-0.6663637757301331	▁arterial _ ▁elastan ce ▁end - sy sto lic ▁elastan ce ▁vent ri cular - arte rial ▁coup ling ▁e es ▁techniques
D-922	-0.6663637757301331	arterial_ elastance end-systolic elastance ventricular-arterial coupling ees techniques
P-922	-1.3365 -2.4923 -0.4284 -0.4330 -0.2283 -0.0362 -1.0877 -0.1874 -2.1157 -1.0839 -0.2920 -0.1143 -0.0908 -0.1041 -0.1795 -0.1207 -0.1050 -0.5793 -2.3851 -1.4137 -0.0176 -0.7974 -0.2403 -0.1239
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline central_blood_pressure radial_arterial_tonometry cardiovascular_function echocardiographic invasively
H-920	-0.9733976125717163	▁post - DAS h ▁rs _ s RD _ ▁bra chi al _ central _ ▁blood _ tension ▁radi al _ ▁arterial _ ▁ton ometr y ▁cardiovascular _ fon ction nel ▁e cho car dio graphic
D-920	-0.9733976125717163	post-DASh rs_sRD_ brachial_central_ blood_tension radial_ arterial_ tonometry cardiovascular_fonctionnel echocardiographic
P-920	-2.6977 -0.0283 -0.3289 -0.2389 -1.7623 -3.3969 -1.3280 -0.9984 -2.4576 -1.5461 -0.0224 -0.0337 -1.8925 -2.8294 -0.4801 -1.1204 -1.3415 -0.9749 -0.0276 -0.0273 -0.6144 -1.1044 -0.2572 -2.1056 -0.0769 -0.3566 -0.1843 -2.5547 -3.4169 -0.5160 -0.3497 -0.0695 -0.0997 -0.0202 -0.2579 -0.6882 -0.6759 -0.1077
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene_expression_profile gse9128 gene_expression_omnibus non-ischemic_heart_failure ischemic
H-1609	-1.0079270601272583	▁Gene ▁expression ▁gr se 91 28 ▁Gene _ ▁Express ion _ ▁Omni bus ▁heart _ ▁failure ▁ ische mic
D-1609	-1.0079270601272583	Gene expression grse9128 Gene_ Expression_ Omnibus heart_ failure ischemic
P-1609	-0.9648 -0.6350 -5.1304 -0.3349 -2.1885 -0.2627 -0.3003 -0.8255 -0.4905 -0.0211 -0.1070 -0.0771 -0.0304 -4.1860 -0.6696 -0.9011 -1.2677 -1.3033 -0.9067 -0.4531 -0.1109
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm_control_therapy rhythm_control_therapy antiarrhythmic_drugs catheter_ablation electrocardiographic rhythm
H-1653	-0.3523648977279663	▁ rhythm _ control ▁ therapy ▁anti ar rhythm ic ▁drugs ▁cat heter ▁ab lation ▁electro car dio graphic ▁device ▁ rhythm
D-1653	-0.3523648977279663	rhythm_control therapy antiarrhythmic drugs catheter ablation electrocardiographic device rhythm
P-1653	-0.1083 -0.3362 -1.2776 -0.0241 -0.8174 -0.0303 -0.2696 -1.4248 -0.1234 -0.3458 -0.1166 -0.0218 -0.0017 -0.4442 -0.0051 -0.0231 -0.0161 -0.1133 -0.3669 -1.4327 -0.3466 -0.3812 -0.2861 -0.1435
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures hospitalizations noncardiovascular diagnoses implantable_cardiac_arrhythmia_devices noncardiovascular drugs rate-control
H-1240	-0.48828479647636414	▁ex pendi tures ▁non car dio vas cular ▁diagnose s ▁implant able ▁cardiac _ ar rhythm ia ▁devices ▁non car dio vas cular ▁drugs
D-1240	-0.48828479647636414	expenditures noncardiovascular diagnoses implantable cardiac_arrhythmia devices noncardiovascular drugs
P-1240	-1.6349 -0.0067 -0.1904 -0.6899 -0.0244 -0.4351 -0.5636 -0.8416 -0.9163 -0.0065 -0.0002 -0.1139 -0.1346 -0.9546 -1.3789 -0.0780 -0.4673 -1.0355 -0.5239 -0.0242 -0.2282 -0.3173 -0.7927 -0.6826 -0.5407 -0.1133
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence hf_with_reduced_ejection_fraction hfref hf_with_preserved_ejection_fraction hfpef
H-1488	-1.0348063707351685	▁ HF ▁reduce d _ ▁e je ction _ fraction ▁h r EF ▁h p f
D-1488	-1.0348063707351685	HF reduced_ ejection_fraction hrEF hpf
P-1488	-1.1427 -0.2256 -4.9021 -0.2013 -0.4701 -1.9680 -1.3514 -0.1231 -0.3950 -0.0171 -1.2544 -0.1938 -0.6350 -3.5860 -1.2730 -0.5258 -0.2732 -0.0888
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal_life_support therapy patients acute_ischemic_right_heart_failure refractory_cardiogenic_shock reperfusion therapy
H-1298	-0.878232479095459	▁extra corp o real _ ▁life _ support ▁ brid ging _ therapy ▁a cute _ ische mic _ ▁right _ ▁heart _ ▁failure ▁re frac tory _ ▁cardio ge nic _ ▁shock ▁reper fusion ▁ therapy
D-1298	-0.878232479095459	extracorporeal_ life_support bridging_therapy acute_ischemic_ right_ heart_ failure refractory_ cardiogenic_ shock reperfusion therapy
P-1298	-4.8196 -0.0342 -0.2565 -0.1271 -0.6158 -0.6292 -0.7650 -1.1510 -0.3671 -0.2693 -0.3508 -1.4189 -0.0798 -3.0161 -0.0454 -0.4891 -4.0449 -0.4456 -0.5555 -2.8344 -0.9384 -1.4710 -0.6156 -0.2252 -0.0151 -0.0277 -1.6763 -0.5000 -0.2720 -0.1418 -3.0934 -0.5751 -0.3394 -0.1249 -0.0119 -1.5084 -0.0282 -0.2118 -0.1593
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart_failure reduced_left_ventricular_ejection_fraction fes exercise_capacity quality_of_life endothelial_function hfpef
H-1332	-0.8278990387916565	▁heart _ ▁failure ▁left ▁vent ri cular _ ▁e je ction _ fraction ▁F es ▁en dot heli al _ fon cti onnement ▁ HF p EF
D-1332	-0.8278990387916565	heart_ failure left ventricular_ ejection_fraction Fes endothelial_fonctionnement HFpEF
P-1332	-0.4629 -1.1785 -0.7426 -0.9788 -0.7352 -0.4119 -0.5980 -0.5231 -1.7528 -0.8820 -0.1104 -0.8282 -0.0029 -2.6764 -0.3107 -4.1479 -1.9548 -0.0895 -0.0124 -0.9585 -1.3842 -0.9094 -0.1898 -1.0274 -0.3996 -0.0981 -0.4617 -0.1013 -0.0802
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-0.2915745675563812	▁in tub ation
D-220	-0.2915745675563812	intubation
P-220	-0.0450 -0.0278 -0.0260 -1.2379 -0.1212
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts heart_mass transgenic
H-1814	-0.8539541363716125	▁heart s ▁t g t et Men a _ mi ce ▁wild - type _ ▁litt er mates ▁heart _ ▁mass ▁trans ge nic _ mi ce
D-1814	-0.8539541363716125	hearts tgtetMena_mice wild-type_ littermates heart_ mass transgenic_mice
P-1814	-1.4117 -0.0827 -2.7634 -1.5352 -0.1593 -1.0617 -0.9783 -0.2321 -1.7810 -0.3997 -0.2837 -1.9812 -0.0508 -0.0623 -1.0968 -0.3173 -0.0216 -0.2513 -1.9763 -1.1881 -2.2001 -0.0596 -0.1485 -2.8847 -0.8787 -0.4976 -0.1713 -0.2204 -0.0692
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene heart_failure
H-1541	-1.1008249521255493	▁ra lo xi fen e
D-1541	-1.1008249521255493	raloxifene
P-1541	-0.6530 -0.0581 -0.1258 -1.3268 -0.4493 -4.9715 -0.1213
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients hfref exercise respiratory_gas_analysis baseline
H-1938	-0.5611680150032043	▁h f f ▁respirator y _ gas
D-1938	-0.5611680150032043	hff respiratory_gas
P-1938	-0.3693 -0.6520 -1.1345 -0.2707 -0.0602 -0.8052 -1.2719 -0.3539 -0.1330
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients drugs heart_failure biomedical nonprescribing patients
H-1126	-0.5447075963020325	▁guide line - re com mend ed ▁drugs ▁heart _ ▁failure ▁bio medic al ▁reasons
D-1126	-0.5447075963020325	guideline-recommended drugs heart_ failure biomedical reasons
P-1126	-4.1712 -0.0425 -0.1807 -0.0230 -0.0325 -0.0083 -0.6511 -0.2379 -1.1599 -0.6695 -0.7364 -0.0623 -0.0374 -0.0143 -0.4651 -0.6274 -0.1406
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients chronic_hf prevalence exercise hf hospitalization mortality exercise training
H-1641	-1.4150665998458862	▁black _ race ▁ HF ▁exercise _ ▁performance ▁ HF
D-1641	-1.4150665998458862	black_race HF exercise_ performance HF
P-1641	-0.8030 -1.7719 -0.9540 -2.0645 -0.2008 -5.6831 -0.9448 -0.9851 -0.5230 -0.0852 -2.7967 -0.1688
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean_mass adverse_outcome adipose_tissue cardioprotective hf
H-1169	-0.6974078416824341	▁Was ting _ de _ ▁fat ▁lean _ ▁mass ▁fat _ ▁loss ▁cata bol ism ▁adi pose _ ▁tissu e ▁cardio protec tive ▁ HF
D-1169	-0.6974078416824341	Wasting_de_ fat lean_ mass fat_ loss catabolism adipose_ tissue cardioprotective HF
P-1169	-3.0364 -0.4550 -0.6304 -1.2314 -0.1203 -1.9043 -0.1715 -1.2767 -0.7321 -0.7189 -1.7871 -1.3761 -0.4808 -0.1594 -0.4976 -0.0175 -0.0484 -0.3982 -0.9895 -0.8551 -0.3309 -0.0343 -0.0166 -1.3512 -0.0708 -0.0644 -0.0751
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads heartmate_ii thoratec_corp pleasanton calif hvad heartware framingham
H-546	-0.6603643298149109	▁l VAD s ▁CF ▁devices ▁Heart Mate _ II ▁devices ▁Thor a tec _ ▁Corp ▁Ple asan ton _ ▁Cali f ▁h VAD ▁h VAD ▁Heart War e ▁in t l ▁Fram ing ham ▁Mass
D-546	-0.6603643298149109	lVADs CF devices HeartMate_II devices Thoratec_ Corp Pleasanton_ Calif hVAD hVAD HeartWare intl Framingham Mass
P-546	-1.0955 -0.0455 -0.1893 -1.1115 -2.5737 -2.0789 -0.2736 -0.3547 -1.0391 -0.4241 -0.2456 -0.0211 -0.0063 -2.2412 -1.0157 -0.4909 -0.0041 -0.0706 -1.4697 -0.1145 -0.0010 -0.0633 -0.1572 -2.2745 -0.6556 -2.6294 -0.5329 -0.0795 -0.9815 -0.0067 -0.0077 -0.3498 -0.0520 -0.0152 -1.3760 -0.2949 -0.0908
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts nucleolin chamber_patterning cardiac_looping myocyte_differentiation
H-97	-0.8112162947654724	▁heart s _ de _ ▁fish _ ▁la cking ▁nu cle olin ▁development al _ ▁im pair ment ▁cha mber _ ▁pattern ing ▁functional ▁defect s ▁cardiac _ ▁loop ing ▁my o cy te
D-97	-0.8112162947654724	hearts_de_ fish_ lacking nucleolin developmental_ impairment chamber_ patterning functional defects cardiac_ looping myocyte
P-97	-0.6526 -0.0333 -1.0991 -1.8096 -0.1267 -1.4596 -1.5269 -0.6643 -0.0644 -0.7744 -0.0122 -0.7501 -4.4976 -0.4095 -1.4952 -0.8588 -0.0036 -0.0529 -0.0555 -0.0220 -0.5259 -0.6738 -1.3764 -3.3778 -2.6697 -0.0344 -0.0592 -0.6821 -1.3330 -0.1288 -1.0558 -0.1116 -0.1592 -0.1802 -0.3822 -0.0852
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma collected hf patients immunoreactive nt-probnp c-terminally nt-probnp
H-1520	-0.820692241191864	▁ HF ▁immun ore active ▁NT - pro b NP ▁c - termin al _ ▁tru nca ted _ ▁fragment s ▁NT - pro b NP
D-1520	-0.820692241191864	HF immunoreactive NT-probNP c-terminal_ truncated_ fragments NT-probNP
P-1520	-2.4924 -0.2496 -0.0859 -3.0638 -0.0556 -0.0513 -0.0437 -0.0451 -1.2248 -0.1454 -1.5557 -0.1546 -0.0929 -1.0343 -0.9840 -0.3970 -0.2315 -1.3448 -2.2261 -3.1238 -0.0667 -1.8793 -0.0472 -0.1773 -1.1137 -0.3191 -0.6350 -0.1387
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma_nps adiponectin baseline ffm correlate nps adiponectin follow_up
H-19	-0.9270409941673279	▁FM ▁plasma ▁ NP s ▁adi pon ect in f f f m ▁ NP s ▁adi pon ect in
D-19	-0.9270409941673279	FM plasma NPs adiponectinfffm NPs adiponectin
P-19	-1.1427 -1.9712 -0.5969 -0.0354 -0.0347 -0.8171 -0.3024 -0.1025 -3.5629 -1.8737 -0.2670 -1.1539 -1.8975 -1.8679 -0.1690 -0.0430 -1.0399 -0.3589 -0.1248 -2.6543 -0.2652 -0.1141
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages cardiomyocytes doxorubicin in_vitro resistin mrna protein_expression
H-935	-0.5603217482566833	▁Mac rop hage s ▁cardio my o cy tes ▁Hum - re t n ▁mi ce ▁do xor ubi cin ▁h re t n ▁m RNA ▁protein ▁expression
D-935	-0.5603217482566833	Macrophages cardiomyocytes Hum-retn mice doxorubicin hretn mRNA protein expression
P-935	-3.3602 -0.0214 -0.0005 -0.0205 -0.0415 -0.4947 -0.5320 -0.1228 -0.1074 -0.4003 -0.0446 -0.9912 -0.4030 -0.0474 -3.7592 -0.0842 -0.2491 -0.1461 -0.1169 -0.0342 -0.0021 -1.7015 -0.0611 -0.0124 -2.4429 -0.0410 -0.8571 -0.2362 -0.3983 -0.0802
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt_interval ecgs baseline atrial_pacing esmolol isoprenaline atropine infusion
H-1438	-0.5440635085105896	▁beat - to - beat ▁ QT _ ▁interval ▁surface ▁e CG s ▁at rial _ pa cing ▁es mol ol ▁iso pren a line ▁a tropi ne ▁in fusion
D-1438	-0.5440635085105896	beat-to-beat QT_ interval surface eCGs atrial_pacing esmolol isoprenaline atropine infusion
P-1438	-0.5624 -0.0189 -0.1736 -0.0189 -0.0265 -0.3591 -0.2341 -3.2466 -0.6376 -0.3715 -2.1741 -0.6533 -0.1755 -1.5145 -0.0979 -1.8289 -0.9583 -0.3569 -0.2363 -0.1132 -0.0420 -0.0901 -0.0216 -0.3831 -0.1652 -0.0762 -0.0539 -1.2309 -0.5481 -0.2409 -0.6554 -0.1441
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic_tone parasympathetic_tone heart_rate intravenous_bolus metoprolol atropine
H-1378	-0.7802925109863281	▁sympa the tic ▁tone ▁para sy mpa the tic _ ▁tone ▁heart _ ▁rate ▁met o pro lol ▁a tropi ne
D-1378	-0.7802925109863281	sympathetic tone parasympathetic_ tone heart_ rate metoprolol atropine
P-1378	-2.0008 -0.6807 -2.1195 -1.0469 -0.1780 -0.3552 -0.8766 -1.2490 -2.2313 -1.2760 -0.1813 -0.6564 -2.0298 -0.6104 -1.0054 -0.1302 -0.0420 -0.2470 -0.0617 -0.0209 -0.6202 -0.2357 -0.0919
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef pathophysiologically hf_with_reduced_ef hfref hfref therapy
H-1533	-0.7449786067008972	▁EH ▁ HF p EF ▁h f f ▁h f f ▁ therapy
D-1533	-0.7449786067008972	EH HFpEF hff hff therapy
P-1533	-0.0051 -0.8654 -0.7883 -0.4220 -0.9090 -2.2062 -0.2236 -0.8730 -1.3370 -0.3695 -0.4222 -2.2974 -0.1121 -0.2683 -0.0758
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse_event acute_myocardial_infarction congestive_heart_failure adverse_events
H-4	-0.8699171543121338	▁a cute _ My o card ial _ ▁in far ction ▁con ges tive _ ▁heart _ ▁failure
D-4	-0.8699171543121338	acute_Myocardial_ infarction congestive_ heart_ failure
P-4	-2.9790 -0.0769 -0.2311 -4.0209 -0.5230 -0.2656 -0.3011 -0.6395 -0.5506 -2.9748 -0.1188 -0.1181 -0.0774 -0.0734 -0.6294 -1.1177 -1.0277 -0.7181 -0.8153 -0.1398
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence_interval
H-803	-0.8302789926528931	
D-803	-0.8302789926528931	
P-803	-1.5472 -0.1134
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change follow-up readmissions hospital follow-up
H-721	-1.3601555824279785	▁hospital _ quality _ ▁improvement
D-721	-1.3601555824279785	hospital_quality_ improvement
P-721	-2.5610 -0.7601 -3.4834 -0.7223 -1.2495 -0.6081 -0.1366
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac jq1 bet pathological cardiac gene_expression
H-1049	-0.9484184384346008	▁cardiac _ ▁tissu e ▁mi ce ▁ TAC - ▁sham - opera ted ▁j q 1 ▁ BET ▁implant ation ▁path ological _ ▁cardiac _ ▁gene ▁expression
D-1049	-0.9484184384346008	cardiac_ tissue mice TAC- sham-operated jq1 BET implantation pathological_ cardiac_ gene expression
P-1049	-0.5695 -2.0372 -2.0364 -0.7621 -2.5561 -0.1292 -0.4224 -0.0247 -1.3482 -0.2423 -0.0179 -0.0011 -0.8965 -0.1978 -0.8695 -0.1081 -1.1108 -0.8000 -4.4605 -0.4826 -0.7700 -0.5790 -0.4243 -0.3574 -1.5623 -2.6291 -0.2845 -1.6540 -0.1707
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power_spectral_analysis hf dnx
H-1377	-1.0086218118667603	▁Power _ ▁spec tral _ analyse ▁low - fre que ncy _ high - fre que ncy f f f ▁CHF - in v ▁sham - in v ▁sham - in v ▁DN x
D-1377	-1.0086218118667603	Power_ spectral_analyse low-frequency_high-frequencyfff CHF-inv sham-inv sham-inv DNx
P-1377	-0.8046 -2.7519 -1.6945 -0.0115 -3.7660 -1.6528 -2.4378 -0.0399 -0.1925 -0.1019 -0.0627 -2.1376 -1.9023 -0.1011 -0.1134 -0.1030 -0.1055 -1.5854 -0.2640 -1.2478 -1.9607 -0.0373 -0.4899 -1.3757 -0.0253 -0.1300 -0.5124 -1.2698 -0.2127 -2.4914 -1.5577 -1.6561 -2.9229 -0.0116 -0.3787 -0.2019
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal_pro-b-type_natriuretic_peptide nt-probnp misdiagnosis heart_failure hf
H-1511	-0.7510271668434143	▁na tri ure tic _ pe pti de NT - pro b NP ▁mis diagnos is ▁heart _ ▁failure HF
D-1511	-0.7510271668434143	natriuretic_peptideNT-probNP misdiagnosis heart_ failureHF
P-1511	-2.3456 -0.0775 -0.0595 -3.3124 -0.9919 -0.4157 -0.1062 -0.3074 -1.5173 -0.0095 -0.0211 -0.5169 -0.2072 -0.0069 -0.1620 -0.0873 -2.3853 -0.6361 -2.3412 -0.6961 -0.1682 -0.1514
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action randomized patients left_ventricular_ejection_fraction new_york_heart_association_class_ii hf exercise training
H-698	-0.8782819509506226	▁ HF - ac tion ▁vent ri cular _ ▁e je ction _ fraction ▁New ▁York _ ▁Heart _ association ▁IV ▁ HF
D-698	-0.8782819509506226	HF-action ventricular_ ejection_fraction New York_ Heart_association IV HF
P-698	-1.7576 -0.7098 -0.3385 -1.4678 -0.7362 -1.6160 -0.4647 -0.2834 -1.0708 -1.2326 -1.2778 -0.1437 -1.7715 -0.0023 -0.8239 -1.4181 -1.3576 -0.6309 -1.0035 -1.0691 -1.8937 -0.2661 -0.1677 -0.3078 -0.1461
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial_dd collagen_deposition titin obese diabetic zsf1 heart_failure_with_preserved_ejection_fraction
H-762	-0.5705968737602234	▁my o card ial ▁ DD ▁collage n _ de position ▁titi n ▁diabet ic ▁z SF 1 ▁rat s ▁heart _ ▁failure
D-762	-0.5705968737602234	myocardial DD collagen_deposition titin diabetic zSF1 rats heart_ failure
P-762	-0.9834 -0.0897 -0.0837 -0.0762 -2.3908 -0.0170 -0.1296 -0.0614 -1.0329 -0.0258 -0.5336 -0.7256 -0.0299 -0.7385 -0.3577 -1.2220 -0.4880 -0.2637 -0.1675 -0.0980 -0.7579 -0.8436 -1.4431 -1.6027 -0.1024
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac_magnetic_resonance_postcontrast_t1_time prognosis hfpef postcontrast_t1 biomarker hfpef
H-743	-0.4743868410587311	▁cardiac _ ▁magnetic _ ▁res on ance ▁h f f ▁bio mark er ▁h f f
D-743	-0.4743868410587311	cardiac_ magnetic_ resonance hff biomarker hff
P-743	-0.1919 -0.7337 -1.1065 -1.3586 -0.9419 -0.1249 -0.0297 -0.0695 -0.5327 -0.3664 -1.1738 -0.0220 -0.0579 -0.2345 -0.3426 -0.4761 -0.6401 -0.1361
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ventricular-arterial_coupling patients
H-524	-0.44451719522476196	▁contract ility ▁vent ri cular - arte rial ▁coup ling ▁SV ▁i va bra dine - tre ated
D-524	-0.44451719522476196	contractility ventricular-arterial coupling SV ivabradine-treated
P-524	-0.3372 -0.7531 -0.0046 -0.1369 -0.1558 -0.1146 -0.0760 -0.1173 -0.2489 -2.8530 -0.5766 -0.0347 -0.0221 -0.3212 -0.0396 -0.1813 -0.0663 -2.1051 -0.6139 -0.1324
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 hypertrophy fibrosis ventricular_dysfunction gene
H-642	-0.6345434188842773	▁condition al _ ▁gene - tar get ed ▁Hand s ▁pression - over load - indu ced ▁hyper trop hy ▁fibro sis ▁vent ri cular _ ▁dys function ▁fet al
D-642	-0.6345434188842773	conditional_ gene-targeted Hands pression-overload-induced hypertrophy fibrosis ventricular_ dysfunction fetal
P-642	-0.0172 -0.2897 -0.9595 -2.3799 -0.1058 -0.0548 -0.1428 -0.3093 -0.3326 -2.9273 -2.7665 -0.1044 -0.2980 -0.1968 -1.3376 -0.0013 -3.0787 -0.1652 -0.0066 -0.0684 -0.0066 -0.2818 -0.0031 -0.1650 -0.1856 -0.6510 -0.3576 -0.2138 -0.0832 -0.0808 -2.5481 -0.1864
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission nt-probnp patients acute_hf diagnosis
H-264	-1.109415054321289	▁NT - pro b NP ▁ed ▁ HF
D-264	-1.109415054321289	NT-probNP ed HF
P-264	-3.7552 -0.0257 -0.0122 -0.5736 -0.1743 -3.0829 -2.1346 -0.6228 -0.5318 -0.1811
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical rule patients cad angiography patients systolic_hf cost
H-1193	-1.046949028968811	▁clinic al _ ▁predict ion _ ▁rule ▁CAD ▁ang i ography ▁sy sto lic _ HF ▁coût
D-1193	-1.046949028968811	clinical_ prediction_ rule CAD angiography systolic_HF coût
P-1193	-3.4532 -0.0175 -1.1676 -1.2613 -0.0083 -1.6770 -0.5767 -1.6667 -0.2703 -0.3001 -0.2396 -1.6338 -0.2494 -1.6900 -0.6353 -1.6589 -1.6975 -1.5722 -0.1167
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic cardiac cardiac gene signal_transduction pathological gene_expression hf
H-1053	-0.6344310641288757	▁epi gene tic ▁readers ▁cardiac _ bi ology ▁cardiac _ ▁gene _ control ▁chr omat in - dependent ▁signal _ trans duction ▁a bro gate _ path ological _ ▁gene ▁expression ▁ HF
D-1053	-0.6344310641288757	epigenetic readers cardiac_biology cardiac_ gene_control chromatin-dependent signal_transduction abrogate_pathological_ gene expression HF
P-1053	-0.6255 -0.0414 -0.7359 -0.1971 -0.1243 -1.2624 -0.2807 -0.7661 -0.4277 -1.2739 -1.9278 -2.2880 -0.0447 -0.0698 -0.0325 -1.4080 -0.1500 -0.0197 -1.7849 -0.5089 -0.1269 -0.1014 -0.2118 -0.0013 -0.0166 -1.5528 -0.8879 -0.5172 -1.1526 -0.5576 -1.5962 -0.8041 -0.0312 -0.5333 -0.1451
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic_blood_pressure elevated left_ventricular hypertrophy
H-277	-0.899560809135437	▁Sy sto lic _ ▁blood _ tension ▁left _ vent ri cular LV ▁hyper trop hy
D-277	-0.899560809135437	Systolic_ blood_tension left_ventricularLV hypertrophy
P-277	-0.5111 -0.4827 -2.3970 -0.4706 -0.8191 -1.6737 -0.3341 -0.3424 -0.9087 -0.6235 -1.1322 -0.3194 -1.0561 -0.8464 -0.0132 -0.0519 -4.1081 -0.1020
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up patients combined_end_point death heart_failure death cardiac_transplant
H-1747	-2.1622462272644043	▁heart _ ▁failure ▁cardiac ▁transplant
D-1747	-2.1622462272644043	heart_ failure cardiac transplant
P-1747	-5.3774 -0.7670 -1.5914 -5.0009 -2.0056 -0.2548 -0.1385
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous revascularization angioplasty stenting clinical patients randomized clinical
H-1601	-0.7996325492858887	▁cat heter - based _ per cuta ne _ re vas cular ization ▁ang io plast y ▁sten ting
D-1601	-0.7996325492858887	catheter-based_percutane_revascularization angioplasty stenting
P-1601	-2.1664 -0.0065 -0.1438 -0.1812 -1.4328 -0.1801 -0.0209 -0.1336 -2.7665 -0.6412 -0.2622 -0.4058 -0.5293 -0.1484 -2.2103 -0.0490 -0.4082 -0.0599 -3.9832 -0.9697 -0.0930
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic_response heart_rate exercise baseline follow-up tests heart_rate exercise
H-1176	-1.4299744367599487	▁load - corre cted ▁chr ono tropi c _ ▁response ▁heart _ ▁rate
D-1176	-1.4299744367599487	load-corrected chronotropic_ response heart_ rate
P-1176	-3.5666 -0.0920 -0.0348 -1.1834 -0.6812 -0.0775 -0.1237 -0.1731 -4.3891 -1.2022 -3.0176 -2.1150 -2.0008 -2.6715 -0.1212
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak_oxygen_consumption vo2max resting_hr bpm p_value
H-1943	-1.0397099256515503	▁Peak _ ▁oxygen _ ▁consum p tion VO 2 max ▁h z
D-1943	-1.0397099256515503	Peak_ oxygen_ consumptionVO2max hz
P-1943	-0.8923 -0.8299 -1.2166 -2.4181 -1.6591 -0.2990 -0.1930 -1.2183 -0.0219 -0.0034 -3.7284 -1.6321 -0.3156 -0.1281
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional_hazard_models negative_binomial_regression_models health
H-1624	-0.6995881199836731	▁co x - propor tional _ ▁hazard ▁models ▁negative _ bi nom ial _ ▁re gression ▁models
D-1624	-0.6995881199836731	cox-proportional_ hazard models negative_binomial_ regression models
P-1624	-0.5460 -0.0041 -0.0125 -0.0424 -0.2782 -1.5099 -1.1431 -2.6693 -0.0980 -1.5529 -0.1679 -0.0596 -0.0039 -0.3817 -1.2358 -0.0051 -0.8537 -2.6127 -0.1153
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients hf t2d erc vo2max maximum_oxygen_consumption skm biopsies
H-1251	-0.6165161728858948	▁ HF ▁t 2 d ▁ ERC ▁tre ad m ill _ ▁testing VO 2 max ▁oxygen ▁bio psi es
D-1251	-0.6165161728858948	HF t2d ERC treadmill_ testingVO2max oxygen biopsies
P-1251	-1.2629 -0.2598 -1.3269 -0.0394 -0.2533 -0.3857 -0.3774 -0.2507 -0.0040 -0.0090 -0.3624 -4.0490 -1.0316 -0.9161 -0.0056 -0.0188 -0.2570 -2.0222 -0.1921 -0.1150 -0.3442 -0.0803
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient hospital gastrointestinal_bleeding patient ventricular_tachycardia terminal_heart_failure
H-1961	-0.7707148790359497	▁hospital ▁gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ ta chy car dia ▁storm ▁heart
D-1961	-0.7707148790359497	hospital gastrointestinal_ bleeding ventricular_tachycardia storm heart
P-1961	-1.8550 -0.4203 -0.0085 -1.1379 -0.0979 -0.8960 -0.5173 -0.2554 -0.1635 -0.0261 -0.2440 -0.0889 -0.8270 -2.1821 -0.1528 -0.0099 -1.5413 -0.9637 -1.9339 -2.7554 -0.1079
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic β-ar catecholamine infusions pde2 expression camp activity correlated cardiac β-ar_responsiveness
H-1214	-0.5282194018363953	▁β - AR ▁stimul ation ▁cate chol amine ▁in fusion s ▁p de 2 ▁c AMP ▁hydro ly tic ▁activity ▁blu n ted _ ▁cardiac ▁β - AR ▁responsive ness
D-1214	-0.5282194018363953	β-AR stimulation catecholamine infusions pde2 cAMP hydrolytic activity blunted_ cardiac β-AR responsiveness
P-1214	-1.2443 -0.0135 -0.2407 -1.6574 -0.0151 -0.0789 -0.0317 -0.1082 -0.1147 -0.0393 -0.0651 -0.6934 -0.0792 -0.0410 -0.3428 -0.0959 -1.3651 -0.1586 -1.8333 -1.5460 -0.0047 -0.0424 -3.9183 -0.6648 -0.0375 -0.2178 -0.0071 -0.0542 -0.4217 -1.2720 -0.3692 -0.1290
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild_hf qrs_prolongation lvef crt reverse_remodeling clinical systolic_dysfunction
H-758	-0.6378403306007385	▁ HF ▁QR s ▁prolong ation ▁LV EF ▁c RT ▁rever se _ ▁remodel ing ▁LV
D-758	-0.6378403306007385	HF QRs prolongation LVEF cRT reverse_ remodeling LV
P-758	-0.4322 -0.1988 -0.0926 -1.3355 -1.7582 -0.0095 -0.1649 -0.5806 -0.1887 -1.7317 -0.1843 -0.0021 -0.4884 -0.0885 -0.0775 -0.9988 -3.0707 -0.0782
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic_pah clinical hospitalized patients acute rv_decompensation pharmacologic therapies rv_failure pah
H-1096	-0.7035914063453674	▁chronic ▁p AH ▁ RV _ de com pensa tion ▁ pharma c ologic ▁ therapie s ▁ RV _ ▁failure _ management ▁p AH
D-1096	-0.7035914063453674	chronic pAH RV_decompensation pharmacologic therapies RV_ failure_management pAH
P-1096	-1.2346 -1.9132 -0.0265 -1.3050 -1.5617 -2.1056 -0.1978 -1.2144 -0.0160 -0.0327 -0.1001 -0.3679 -0.0182 -0.1648 -0.7511 -0.1867 -0.0465 -1.1560 -0.6616 -0.7852 -1.1895 -1.0727 -0.2969 -2.1756 -0.0127 -0.2466 -0.1575
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up patients
H-268	-1.1078054904937744	
D-268	-1.1078054904937744	
P-268	-2.0570 -0.1586
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians patients patient clinician medication patient
H-1129	-0.7658491134643555	▁co management ▁clinic ians ▁medication
D-1129	-0.7658491134643555	comanagement clinicians medication
P-1129	-0.4160 -0.0191 -1.6866 -0.6203 -2.2136 -0.2801 -0.1252
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty gill_index hf
H-628	-1.7684956789016724	▁non - fra il ▁h ▁severe _ fra il ty ▁h ▁Gill ▁ HF
D-628	-1.7684956789016724	non-frail h severe_frailty h Gill HF
P-628	-6.0130 -0.0080 -0.0397 -0.1753 -6.3089 -3.2504 -1.7605 -0.3246 -0.0902 -4.1753 -2.2142 -1.2096 -2.1591 -0.2497 -0.1656 -0.1518
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty health_abc_short_physical_performance_battery habc_battery gill_index hf
H-625	-0.8005900382995605	▁fra il ty ▁Health ▁ABC _ short _ phy al _ ▁Performance ▁Bat tery ▁h ABC _ ▁Bat tery ▁Gill ▁ HF
D-625	-0.8005900382995605	frailty Health ABC_short_phyal_ Performance Battery hABC_ Battery Gill HF
P-625	-2.8296 -0.5815 -3.8182 -1.1376 -0.8071 -0.6658 -0.6333 -0.0277 -0.3726 -1.2877 -0.2222 -0.1008 -0.9040 -0.0079 -0.0871 -0.8805 -1.4957 -0.8710 -0.0084 -0.4004 -1.6841 -0.1655 -0.1548 -0.0708
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients rv_support lvad patients cardiogenic_shock myocardial_infarction chronic_decompensated_heart_failure
H-295	-1.134475827217102	▁ RV _ support ▁l VAD ▁cardio ge nic _ ▁shock ▁my o card ial _ ▁in far ction ▁chronic _ de com pensa tion _ heart _ ▁failure
D-295	-1.134475827217102	RV_support lVAD cardiogenic_ shock myocardial_ infarction chronic_decompensation_heart_ failure
P-295	-1.5620 -0.5113 -3.3795 -2.3491 -1.6489 -0.0321 -1.6234 -0.1677 -2.9661 -0.7472 -0.3275 -1.4115 -0.2609 -0.1848 -0.2447 -1.0679 -0.4548 -2.5474 -0.0637 -3.6649 -0.9642 -0.1105 -0.7200 -0.0158 -2.5253 -0.8138 -1.3716 -1.3260 -1.3919 -0.4629 -0.2515
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic_heart_failure chf multisystem_disease comorbidities anemia insulin_resistance autonomic_dysbalance cardiac_cachexia
H-1357	-0.6044582724571228	▁Chro nic _ ▁heart _ ▁failure ▁ch f ▁multi system _ ▁disease ▁an emia ▁insulin _ ▁resist ance ▁autonomi c _ ▁dys balance ▁cardiac _ ▁cache xia
D-1357	-0.6044582724571228	Chronic_ heart_ failure chf multisystem_ disease anemia insulin_ resistance autonomic_ dysbalance cardiac_ cachexia
P-1357	-1.8539 -1.2758 -0.1087 -2.1295 -0.2279 -0.8291 -1.7297 -0.0374 -0.0875 -0.1101 -0.5323 -2.7581 -0.1836 -0.0738 -0.0220 -0.9254 -1.3421 -0.0059 -0.1185 -0.2239 -0.6414 -0.3485 -0.0509 -0.0167 -0.7211 -0.7413 -0.0792 -0.2618 -0.0933
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine_oxidase xo left_ventricular myocytes volume_overload vo mitral_regurgitation aortocaval_fistula acf
H-470	-0.7456879615783691	▁Xan thi ne ▁oxid ase XO ▁rat ▁vent ri cular LV ▁my o cy tes vo ▁mit ral _ re gur gi tation ▁a orto ca val _ f
D-470	-0.7456879615783691	Xanthine oxidaseXO rat ventricularLV myocytesvo mitral_regurgitation aortocaval_f
P-470	-0.0020 -0.0149 -0.3568 -1.1518 -0.4945 -0.7676 -0.8658 -1.4401 -0.1873 -0.2865 -0.4076 -3.3665 -0.0420 -0.0628 -0.1629 -3.6910 -1.2584 -0.0287 -1.0535 -1.0633 -0.0032 -0.0231 -0.0218 -0.0509 -0.3749 -0.0035 -1.3471 -0.4520 -1.5213 -2.5150 -0.0995
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese zsf1 heart_failure_with_preserved_ejection_fraction lung preserved_left_ventricular_ejection_fraction left_ventricular_dd
H-767	-0.8306041359901428	▁obes e ▁Z SF 1 ▁heart _ ▁failure ▁e je ction _ fraction ▁lung ▁vent ri cular ▁e je ction _ fraction ▁left _ vent ri cular ▁ DD
D-767	-0.8306041359901428	obese ZSF1 heart_ failure ejection_fraction lung ventricular ejection_fraction left_ventricular DD
P-767	-1.9727 -0.0618 -0.9970 -0.3608 -0.8358 -2.9078 -0.5965 -1.4160 -2.4245 -0.4959 -0.0853 -0.2768 -0.0067 -0.8019 -2.1024 -0.2750 -0.1968 -2.2025 -0.6264 -0.1214 -0.4409 -0.0091 -0.7236 -1.0561 -0.6805 -0.7422 -0.1261 -2.6119 -0.2508 -0.2215 -0.1220
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients physicians mortality physicians hospitals
H-1727	-0.8856722712516785	▁high - volu me ▁physician s ▁mortal ity ▁low - volu me
D-1727	-0.8856722712516785	high-volume physicians mortality low-volume
P-1727	-4.9321 -0.0327 -0.2284 -0.0271 -0.9514 -0.0780 -1.3925 -0.8949 -0.4317 -0.0262 -0.2948 -0.0118 -2.9551 -0.1426
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western administrative health patients hf hospitalized ami
H-1307	-1.0002161264419556	▁Western _ ▁Australian _ link ed _ administra tive _ ▁health
D-1307	-1.0002161264419556	Western_ Australian_linked_administrative_ health
P-1307	-1.6886 -1.0993 -0.9542 -2.3386 -0.5325 -0.2081 -0.5138 -0.3839 -0.1703 -0.2504 -1.0093 -3.7207 -0.1331
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report connection patients disease healthcare conditions turkey
H-1825	-1.028647780418396	▁conditions ▁Turkey
D-1825	-1.028647780418396	conditions Turkey
P-1825	-1.0900 -2.7899 -0.1263 -0.1084
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome prospective hospitalized hf nursing outcomes
H-1403	-1.219544529914856	▁nur sing - sensitiv e
D-1403	-1.219544529914856	nursing-sensitive
P-1403	-3.4748 -0.2496 -0.0868 -0.0123 -0.2487 -4.3548 -0.1099
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence hf ami adjusted_odds_ratio
H-1310	-1.4730197191238403	▁ HF ▁am ▁odds
D-1310	-1.4730197191238403	HF am odds
P-1310	-1.8535 -0.5929 -3.2359 -2.1729 -0.8765 -0.1063
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas rnas expression genes messenger_rna repression
H-1482	-0.7767735719680786	▁mi RNA s ▁ RNA s ▁ RNA s ▁ binding ▁messenger ▁ RNA
D-1482	-0.7767735719680786	miRNAs RNAs RNAs binding messenger RNA
P-1482	-0.6339 -0.0401 -0.0467 -2.3609 -0.0957 -0.1188 -2.1959 -0.7122 -0.6938 -2.4693 -0.1369 -0.5237 -0.6621 -0.0721 -1.5831 -0.0831
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse myocardial_t1 heart_failure
H-1055	-0.6169555187225342	▁free - bre a thing ▁puls e _ ▁se que nce ▁my o card ial ▁changes ▁s win e ▁ta chy car dia - indu ce ▁heart _ ▁failure
D-1055	-0.6169555187225342	free-breathing pulse_ sequence myocardial changes swine tachycardia-induce heart_ failure
P-1055	-0.6496 -0.0535 -0.2009 -0.1121 -0.1310 -1.2290 -0.1499 -1.8083 -1.5754 -0.0582 -0.0012 -0.2021 -0.0919 -0.0795 -0.0661 -2.1237 -0.0372 -0.3275 -0.0466 -3.8854 -0.1206 -0.0153 -1.1931 -0.2908 -0.0002 -2.1571 -0.8563 -0.7834 -0.6366 -0.1465 -0.0968
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients hfpef ivabradine placebo double-blind
H-1173	-0.630423367023468	▁ HF p f ▁i va bra dine
D-1173	-0.630423367023468	HFpf ivabradine
P-1173	-1.1487 -0.7982 -0.4658 -1.1275 -0.0089 -0.0244 -0.7469 -0.0263 -1.8706 -0.0869
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic new_york_heart_association_classes saf
H-229	-1.291530728340149	▁ PF _ co hor t ▁New ▁York _ ▁Heart _ association
D-229	-1.291530728340149	PF_cohort New York_ Heart_association
P-229	-1.9940 -1.1743 -5.4736 -0.5869 -0.1131 -0.0592 -2.5474 -1.5498 -0.7653 -0.6080 -0.6224 -1.0429 -1.4331 -0.1114
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective_cohort eds diagnosis heart_failure
H-463	-1.3606879711151123	▁ed s ▁responsable ▁ diagnos is _ de _ ▁heart _ ▁failure
D-463	-1.3606879711151123	eds responsable diagnosis_de_ heart_ failure
P-463	-1.5588 -0.4535 -4.3383 -2.0841 -0.7175 -0.1117 -1.6867 -0.6459 -0.4059 -1.8891 -0.7621 -2.6306 -1.5334 -0.2320
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac cells cardiac cells cardiac_functions myocardial_infarction
H-1335	-0.7057416439056396	▁Card iac ▁c - K it ▁cardiac ▁ex plant - der i ved ▁cell s ▁cardiac _ organ s ▁my o card ial _ ▁in far ction
D-1335	-0.7057416439056396	Cardiac c-Kit cardiac explant-derived cells cardiac_organs myocardial_ infarction
P-1335	-0.6014 -0.1560 -0.3910 -0.0206 -0.6162 -0.0428 -0.7044 -0.6120 -0.0191 -0.0769 -0.1878 -0.0938 -0.3163 -1.7837 -0.0467 -0.4054 -2.3799 -3.1066 -1.4330 -2.6137 -0.1765 -0.1681 -0.2676 -1.0642 -0.6403 -2.0831 -0.1083 -0.2449 -0.1064
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses pathophysiology hf nursing medical symptoms pathophysiologic
H-2022	-0.6636877655982971	▁pat ho phy si ology ▁ HF ▁medical ▁management ▁pat ho phy si ologic
D-2022	-0.6636877655982971	pathophysiology HF medical management pathophysiologic
P-2022	-2.3351 -0.2523 -0.0157 -0.2231 -1.2806 -1.1560 -0.1019 -1.0977 -1.1528 -1.3882 -0.1742 -0.0515 -0.1813 -0.2199 -0.8838 -0.1048
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 bets chromatin downstream_signalling rna polymerase_ii pol_ii
H-1043	-0.7395780086517334	▁inhibi tor ▁j q 1 ▁ BET s ▁chr omat in ▁sup pression ▁ RNA _ poly mera se _ ▁II
D-1043	-0.7395780086517334	inhibitor jq1 BETs chromatin suppression RNA_polymerase_ II
P-1043	-1.6019 -0.0328 -0.8335 -0.6027 -0.3653 -1.0150 -0.4974 -1.9670 -0.1078 -0.0526 -1.1679 -1.8023 -0.0021 -1.2035 -0.1555 -1.0709 -0.4335 -0.0793 -0.0318 -1.3023 -0.3523 -2.2273 -0.1055
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps adverse_outcomes patients heart_failure pulmonary_embolism diabetes chemotherapy
H-1022	-0.7807891964912415	NP s ▁pulmonar y _ ▁e mbol ism ▁diabetes ▁che mo therapy
D-1022	-0.7807891964912415	NPs pulmonary_ embolism diabetes chemotherapy
P-1022	-0.9914 -0.0846 -4.0849 -0.0921 -0.7944 -2.0035 -0.0046 -1.7476 -0.1484 -0.5577 -0.0239 -0.0152 -0.2441 -0.1386
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome heart_failure hf acute_myocardial_infarction ami pneumonia pna
H-1691	-0.6922891139984131	▁em pir ically _ ▁deri ved _ com posit e _ quality _ ▁measure ▁heart _ ▁failure ▁h ▁a cute _ mé o card ial _ ▁in far ction ▁pneu monia ▁p na
D-1691	-0.6922891139984131	empirically_ derived_composite_quality_ measure heart_ failure h acute_méocardial_ infarction pneumonia pna
P-1691	-0.6741 -0.0205 -0.2885 -1.2839 -1.1223 -0.1955 -2.4741 -0.6727 -0.0188 -0.0958 -0.2380 -1.7958 -0.6560 -0.9641 -1.5131 -0.4839 -0.4219 -0.5239 -0.4367 -0.0025 -0.0507 -3.6430 -0.5191 -0.1034 -0.1207 -0.4592 -0.3334 -1.7515 -0.0509 -1.0374 -0.7024 -0.5148 -0.7119 -0.2123 -0.1372
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal_dysfunction intestinal lead chronic inflammatory catabolic anabolic cardiac_cachexia terminal chf prognosis
H-1360	-0.77960604429245	▁intestinal _ ▁dys function ▁intestinal _ ▁barrier ▁chronic _ ▁infla mma tory _ ▁state ▁cata bo lic _ ana bo lic _ ▁im balance ▁cardiac _ ▁cache xia ▁CHF
D-1360	-0.77960604429245	intestinal_ dysfunction intestinal_ barrier chronic_ inflammatory_ state catabolic_anabolic_ imbalance cardiac_ cachexia CHF
P-1360	-0.4158 -1.0854 -2.2460 -0.8501 -2.0726 -0.9127 -0.7577 -1.0225 -0.2603 -1.0053 -0.8305 -0.6010 -1.3392 -2.1216 -0.1435 -0.0029 -1.5706 -0.4369 -1.5209 -0.0103 -1.3012 -0.4921 -0.6124 -0.0117 -0.0243 -0.8407 -1.1596 -0.0079 -0.2413 -0.1677 -0.1031
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic heart_failure_with_preserved_ejection_fraction hfpef patients health symptoms quality_of_life
H-780	-0.8401969075202942	▁heart _ ▁failure ▁e je ction _ fraction HF p EF
D-780	-0.8401969075202942	heart_ failure ejection_fractionHFpEF
P-780	-1.6236 -0.6465 -1.2835 -1.2418 -0.5640 -0.0736 -0.3114 -0.0092 -1.5118 -0.0574 -0.6806 -2.8303 -0.0888
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic_adenosine_monophosphate camp cyclic_guanosine_monophosphate cgmp hearts
H-1209	-0.7194463014602661	▁ cycli c _ ad enos ine _ ▁mono phos pha te ▁c AMP ▁ cycli c _ ▁gua no sine _ ▁mono phos pha te ▁c g m ▁fail ing _ ▁heart s
D-1209	-0.7194463014602661	cyclic_adenosine_ monophosphate cAMP cyclic_ guanosine_ monophosphate cgm failing_ hearts
P-1209	-1.2643 -1.6976 -0.1620 -1.5788 -0.8685 -0.9640 -1.4163 -0.2408 -1.3798 -0.0061 -0.1932 -0.1485 -0.1523 -0.0984 -1.6319 -0.3818 -0.1326 -0.7221 -2.6761 -0.0143 -0.4378 -0.2528 -0.5664 -0.0077 -0.1055 -0.0929 -0.2186 -0.9773 -1.3739 -1.6887 -0.4612 -1.0367 -2.2897 -0.1301 -0.3955 -0.1358
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality healthcare telehealth congestive_heart_failure chronic_obstructive_pulmonary_disease diabetes_mellitus
H-1618	-0.6031565070152283	▁mortal ity ▁health care _ ▁utiliza tion ▁tele health ▁con ges tive _ ▁heart _ ▁failure ▁chronic _ ▁ob struct ive _ ▁pulmonar y ▁disease ▁diabetes ▁mell itus
D-1618	-0.6031565070152283	mortality healthcare_ utilization telehealth congestive_ heart_ failure chronic_ obstructive_ pulmonary disease diabetes mellitus
P-1618	-0.1677 -0.3360 -0.1506 -0.0664 -1.1785 -0.2023 -0.0084 -5.8264 -0.2869 -0.2377 -0.0998 -0.0867 -0.4221 -2.0123 -0.8323 -0.1768 -0.1172 -0.5448 -1.6785 -0.0789 -0.0318 -0.3969 -0.1429 -0.2149 -2.1347 -0.1495 -0.2052 -0.0233 -0.1759 -0.1089
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction hfpef
H-942	-0.554471492767334	▁cat heter ▁ab lation ▁at rial _ ▁fi bril lation AF ▁heart _ ▁failure ▁h f f f
D-942	-0.554471492767334	catheter ablation atrial_ fibrillationAF heart_ failure hfff
P-942	-0.1821 -0.1046 -0.7315 -0.0239 -0.4185 -0.1781 -0.4723 -3.1193 -0.0678 -0.0070 -1.1263 -0.4169 -0.6531 -0.7974 -0.6813 -0.1424 -0.2939 -1.1042 -0.4365 -0.1324
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report patient diagnosis ischemic-hypertensive_cardiomyiopathy angina myocardial_ischemia coronary_arteries
H-998	-0.8971944451332092	▁ ische mic - hy per tensi ve _ ▁cardio mio pathy ▁ang ina ▁induc ible _ mé o card ial _ ische mia ▁corona ry _ ▁arteri es
D-998	-0.8971944451332092	ischemic-hypertensive_ cardiomiopathy angina inducible_méocardial_ischemia coronary_ arteries
P-998	-0.9325 -3.4287 -0.9543 -0.0853 -0.0076 -0.0191 -0.5202 -0.6794 -0.5435 -0.1789 -4.6909 -0.5211 -0.0437 -0.6138 -1.1218 -0.6263 -0.3303 -3.9984 -0.2409 -0.1860 -0.2808 -0.3909 -3.0856 -0.4974 -0.4634 -0.7088 -1.8953 -0.3088 -0.0607 -0.2982 -0.1006
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra methotrexate tnf_antagonist non-biological_disease_modifying_antirheumatic_drug nbdmard
H-604	-0.7545645833015442	▁RA ▁met ho tre xa te ▁t NF _ ▁anta gon ist ▁non - bi ological ▁disease ▁anti r heu matic ▁drug n b DM ARD
D-604	-0.7545645833015442	RA methotrexate tNF_ antagonist non-biological disease antirheumatic drugnbDMARD
P-604	-0.7636 -0.3052 -0.2329 -0.0087 -0.1150 -0.0577 -1.1261 -0.5199 -3.9849 -0.1397 -0.0529 -1.2698 -2.5251 -0.0095 -0.0283 -0.4159 -0.4153 -0.7030 -1.0230 -1.6520 -0.7031 -0.7276 -2.9596 -0.0091 -0.6884 -0.1687 -0.3267 -0.1961
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate_cox_proportional_hazards_regression_modeling hospitalization acute_coronary_syndromes coronary_interventions patients
H-104	-0.8400815725326538	▁co x ▁proportion al _ ▁hazard s _ re gression _ modell ing ▁i e ▁a cute _ ▁corona ry ▁syndrome s ▁corona ry
D-104	-0.8400815725326538	cox proportional_ hazards_regression_modelling ie acute_ coronary syndromes coronary
P-104	-2.1346 -0.0119 -0.7816 -0.1143 -0.9258 -0.8193 -0.1499 -0.9447 -0.6125 -0.0054 -2.4925 -2.0337 -0.1891 -1.7895 -2.6311 -0.5736 -0.0102 -0.2446 -0.8457 -0.4573 -1.6456 -0.0359 -0.1494 -0.3933 -1.6607 -0.1899
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate_receptor_1 s1pr1 β1-adrenergic_receptor β1ar g-protein-coupled_receptors heart
H-1405	-0.48676374554634094	▁sp hing os ine -1 - phos pha te ▁receptor ▁s 1 PR ▁β 1- ad r energi c ▁receptor β 1 AR ▁g - prote in - co up led _ ▁receptor s ▁heart
D-1405	-0.48676374554634094	sphingosine-1-phosphate receptor s1PR β1-adrenergic receptorβ1AR g-protein-coupled_ receptors heart
P-1405	-0.0040 -0.2980 -1.5978 -0.8580 -2.4108 -0.0863 -0.0161 -0.0774 -0.0632 -0.6747 -1.9187 -0.0415 -0.2554 -0.6133 -0.1663 -0.1486 -0.0684 -0.3838 -0.1056 -0.1134 -0.8784 -0.0404 -0.2841 -0.6484 -0.0648 -0.1235 -0.5153 -0.3592 -0.0117 -0.0040 -0.1175 -2.7742 -1.1633 -0.1177 -0.6757 -0.2405 -0.0902
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal correlated pcwp p_values
H-484	-0.8534809947013855	sept al ▁PC WP
D-484	-0.8534809947013855	septal PCWP
P-484	-0.0325 -0.2312 -0.9447 -1.1932 -2.4058 -0.3135
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy atrial_fibrillation patients carvedilol metoprolol
H-864	-0.6152439117431641	▁in appropria te ▁ therapy ▁at rial _ ▁fi bril lation ▁car vedi lol ▁met o pro lol
D-864	-0.6152439117431641	inappropriate therapy atrial_ fibrillation carvedilol metoprolol
P-864	-3.9409 -0.0224 -0.2303 -0.7423 -0.0226 -0.4007 -0.1732 -0.6330 -4.2167 -0.1028 -0.0802 -0.3222 -0.1442 -0.1581 -0.0898 -0.1894 -0.0174 -0.3045 -0.3877 -0.1265
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls lvef prognostic clinical echocardiographic systolic
H-820	-1.3154630661010742	▁gr s ▁LV EF ▁sa ▁CV
D-820	-1.3154630661010742	grs LVEF sa CV
P-820	-0.3235 -2.0956 -0.4174 -0.9703 -0.7038 -1.1318 -4.8112 -0.0701
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia intravenous metoprolol cardiac sympathetic_tone
H-1379	-0.5615452527999878	▁Brad y car dia ▁implant ed ▁met o pro lol ▁cardiac _ ▁sympa the tic _ ▁tone ▁CHF - in v ▁rabbi ts ▁sham - in v ▁CHF - DN x
D-1379	-0.5615452527999878	Bradycardia implanted metoprolol cardiac_ sympathetic_ tone CHF-inv rabbits sham-inv CHF-DNx
P-1379	-0.0152 -0.0755 -0.0447 -1.6909 -3.6228 -0.4047 -0.9814 -0.0377 -0.0119 -0.2729 -0.0055 -0.4906 -2.3930 -0.2058 -1.7666 -1.3798 -0.0749 -0.1408 -0.0142 -0.5109 -1.2416 -0.0330 -0.0124 -0.0039 -0.0107 -0.8675 -1.0720 -0.1040 -0.0250 -0.6330 -0.0084 -0.2831 -0.0966
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes patients prescribed pharmacological discharge left_ventricular_function
H-1849	-0.6417364478111267	▁c PG - re com mend ed ▁ pharma c ological ▁treatment ▁device ▁vent ri cular
D-1849	-0.6417364478111267	cPG-recommended pharmacological treatment device ventricular
P-1849	-0.0780 -1.4102 -2.1884 -0.0406 -0.0188 -0.0127 -0.2285 -0.4537 -0.0126 -0.0514 -0.3795 -1.7719 -0.9509 -2.2051 -0.1735 -0.1504 -1.2770 -0.1481
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized walking cardiac_rehabilitation functional_capacity outcomes patients severe_heart_failure
H-569	-1.5114651918411255	▁Nordic _ ▁walking ▁cardiac ▁rehabilita tion _ de _ fon ction nel _ pu issa nce
D-569	-1.5114651918411255	Nordic_ walking cardiac rehabilitation_de_fonctionnel_puissance
P-569	-1.8966 -1.1027 -2.2624 -1.1807 -1.3711 -0.0195 -2.1796 -2.8255 -0.4022 -3.8137 -0.8329 -0.7052 -0.7786 -4.2291 -0.0422 -0.0116 -3.4579 -0.0948
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad q66p rad cav1.2 cav1.3 l-type_channel isoforms heart
H-1674	-1.1616030931472778	▁rad _ q 66 p ▁inhibi tory ▁actions ▁rad ▁ca v 1.3 ▁l - type _ ▁channel _ iso form s ▁heart
D-1674	-1.1616030931472778	rad_q66p inhibitory actions rad cav1.3 l-type_ channel_isoforms heart
P-1674	-0.8059 -3.0282 -1.4602 -0.6171 -0.2341 -0.6581 -0.8848 -0.8918 -0.6578 -1.2920 -1.8353 -5.1584 -1.4361 -0.1826 -0.0250 -0.5763 -4.8705 -0.3582 -1.2707 -0.2331 -0.1358 -0.9349 -0.1985 -0.1334
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef lcx lad stenting infarcted left_ventricle lcx lad
H-512	-1.1203097105026245	▁EF ▁ LC x ▁ LAD ▁sten t ▁in far cted ▁left ▁vent ric le ▁ LC x ▁ LAD
D-512	-1.1203097105026245	EF LCx LAD stent infarcted left ventricle LCx LAD
P-512	-0.6423 -1.5538 -0.4870 -0.3488 -1.3250 -0.7205 -2.6063 -4.9120 -1.5241 -0.7821 -1.3232 -1.1748 -0.6574 -2.7105 -0.1579 -0.9577 -0.8587 -0.3575 -0.9091 -0.1397 -0.3821 -0.1162
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas expression bhlh transcription_factor hand2 myocardium gene heart_failure
H-644	-0.6612797379493713	▁signal ling ▁casca des ▁micro RNA s ▁b HL h ▁tran scription _ factor ▁Hand 2 ▁post na tal _ ▁mamma lian _ ▁my o car dium ▁em bry o nic _ ▁gene s ▁heart _ ▁failure
D-644	-0.6612797379493713	signalling cascades microRNAs bHLh transcription_factor Hand2 postnatal_ mammalian_ myocardium embryonic_ genes heart_ failure
P-644	-0.7116 -2.3097 -0.5874 -0.0088 -0.0624 -0.0095 -0.0258 -0.0058 -0.3135 -0.1953 -0.8536 -0.0129 -1.9988 -2.1208 -0.4375 -0.1451 -0.0463 -0.0568 -0.0918 -0.4478 -0.1863 -0.2776 -0.5060 -2.7370 -0.1045 -0.0065 -0.1994 -0.0185 -0.0088 -0.1104 -3.0955 -0.6886 -1.1448 -2.0006 -0.6815 -1.0867 -2.1029 -0.2718 -0.1215
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc dapc_protein sarcomeric_microstructure skm myofibre_regeneration
H-1254	-0.7534399628639221	ERC ▁ ERC ▁DAP c ▁protein ▁sar come ric _ micro structure ▁Sk m ▁my o fi bre _ ▁regenera tion
D-1254	-0.7534399628639221	ERC ERC DAPc protein sarcomeric_microstructure Skm myofibre_ regeneration
P-1254	-0.3162 -2.4367 -0.0138 -1.0376 -0.4096 -1.4151 -0.9144 -1.3003 -2.3775 -0.5607 -0.7953 -0.2234 -0.2142 -0.0477 -2.4988 -0.0723 -0.7722 -0.0944 -1.1792 -0.2474 -0.0571 -0.2647 -0.0807
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva surgical implantation leaflet leaflet edge-to-edge_anastomosis
H-360	-0.4591224789619446	▁m va ▁implant ation ▁le a flet _ ▁motion ▁le a flet _ ré ection ▁edge - to - ed ge ▁an asto mos is
D-360	-0.4591224789619446	mva implantation leaflet_ motion leaflet_réection edge-to-edge anastomosis
P-360	-0.1520 -0.0855 -1.1168 -0.0280 -0.3035 -0.0577 -0.0072 -1.3666 -0.8586 -0.2469 -0.0313 -0.0316 -1.0415 -2.2593 -0.1317 -1.5999 -0.0558 -0.6077 -0.1139 -0.3589 -0.0344 -1.0987 -0.0113 -0.0818 -0.3796 -0.2305 -0.1057
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart patients new_york_heart_association nyha hospitalized hf primary_outcome death hf hospitalization
H-239	-0.9309275150299072	▁h ART ▁New ▁York _ ▁Heart _ ▁Association NY HA ▁ HF ▁self - management _ ▁counsel ing ▁ HF
D-239	-0.9309275150299072	hART New York_ Heart_ AssociationNYHA HF self-management_ counseling HF
P-239	-0.3358 -0.3102 -5.6644 -1.0085 -0.7338 -0.9233 -0.5324 -1.4836 -2.3589 -0.4638 -1.1758 -0.2647 -1.3819 -0.0177 -0.0039 -1.0113 -0.2249 -0.0646 -1.4901 -0.3376 -0.5534 -0.1398
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet bromodomain_proteins bets acetyl-lysine_reader_proteins hf pathogenesis hf
H-1038	-0.7766991853713989	▁ BET _ bro modo main _ ▁protein s BET s ▁a ce tyl - ly sine _ ▁reader _ ▁protein s ▁ HF
D-1038	-0.7766991853713989	BET_bromodomain_ proteinsBETs acetyl-lysine_ reader_ proteins HF
P-1038	-1.1866 -0.0284 -4.3793 -2.3034 -0.0071 -0.1984 -0.9633 -1.0185 -0.1171 -0.4196 -2.1239 -0.8627 -0.0443 -0.1042 -0.0407 -0.7404 -0.2835 -1.1878 -0.1383 -1.7862 -0.8943 -0.0887 -0.5498 -0.0837 -0.5195 -0.1244
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in_vivo cardiac_function echocardiography diastolic_dysfunction systolic_dysfunction ejection_fraction
H-1783	-0.621406614780426	▁cardiac _ fon ction ▁e cho card i ography ▁dia sto lic _ ▁dys function ▁e je ction _ fraction
D-1783	-0.621406614780426	cardiac_fonction echocardiography diastolic_ dysfunction ejection_fraction
P-1783	-0.2745 -1.9294 -0.7858 -0.9888 -0.1105 -0.5328 -0.1593 -0.2295 -0.3856 -0.0953 -0.3305 -2.7583 -0.8651 -0.1116 -0.3455 -0.3885 -2.4802 -0.0497 -0.4364 -0.0018 -0.3240 -0.0878
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone_antagonism heart_failure aldosterone neurohormone electrolytes heart_failure patients systolic_dysfunction
H-1733	-0.8375954031944275	▁al do ster one _ ▁anta gon ism ▁heart _ ▁failure ▁al do ster one ▁neuro hormon e ▁electro ly tes ▁heart _ ▁failure
D-1733	-0.8375954031944275	aldosterone_ antagonism heart_ failure aldosterone neurohormone electrolytes heart_ failure
P-1733	-0.5571 -0.6956 -0.2243 -1.5350 -2.6038 -0.3062 -0.0699 -1.2448 -2.5205 -0.5330 -1.0038 -1.2383 -0.1088 -0.0418 -0.8919 -0.2666 -0.1480 -0.3274 -0.0168 -0.1135 -0.0364 -2.8358 -1.0016 -1.7019 -1.6581 -0.0967
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv_compliance lv_end-diastolic_volume lv_end-diastolic_pressure β_coefficient
H-1531	-1.4471607208251953	▁EH ▁LV _ comp ▁compliance ▁v LV _ ▁end - dia sto lic _ pu issa nce ▁h g ▁co e ffi cient ▁ml
D-1531	-1.4471607208251953	EH LV_comp compliance vLV_ end-diastolic_puissance hg coefficient ml
P-1531	-0.2483 -0.8488 -3.8905 -2.4233 -2.4738 -4.6927 -3.0060 -2.3967 -1.7358 -0.0470 -1.6493 -1.8074 -2.4825 -1.2104 -3.4300 -0.1530 -0.0328 -3.4312 -0.0329 -0.5937 -0.1212 -0.0090 -0.0229 -0.0996 -0.6323 -0.1553
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade clinical
H-202	-1.0466206073760986	▁Grad e
D-202	-1.0466206073760986	Grade
P-202	-2.7676 -0.3900 -0.9437 -0.0853
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf hospitalization
H-563	-1.150516152381897	▁ HF
D-563	-1.150516152381897	HF
P-563	-2.4766 -0.6437 -1.2849 -0.1969
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right_heart_circulatory_failure disease right_heart
H-1460	-1.8075696229934692	▁vent _ ▁circula tory _ ▁failure
D-1460	-1.8075696229934692	vent_ circulatory_ failure
P-1460	-7.7738 -0.9300 -1.8755 -0.6923 -0.2792 -0.8855 -1.8797 -0.1446
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular_action_potentials excitation-contraction myocardium
H-1671	-0.6120619773864746	▁l - type _ volta ge - ga ted ▁vent ri cular ▁action ▁excita tion - con traction ▁e ▁coup lage ▁my o car dium
D-1671	-0.6120619773864746	l-type_voltage-gated ventricular action excitation-contraction e couplage myocardium
P-1671	-2.3198 -0.2092 -0.0283 -0.8481 -1.3487 -0.1501 -0.0973 -0.0677 -0.3949 -0.5619 -0.5491 -0.3925 -0.2003 -2.3056 -0.0517 -0.0545 -0.0214 -0.0582 -0.7731 -0.1277 -1.8264 -3.0623 -0.0681 -0.0065 -0.3673 -0.4539 -0.1810
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1_receptors neprilysin renin-angiotensin-aldosteron ras vasodilatory diuretic natriuretic_peptides
H-1967	-0.6890871524810791	▁AT 1 ▁receptor s ▁nepri ly sin ▁block s ▁re nin - angi oten sin - al do ster on ▁ RAS ▁vaso dila tory ▁di ure tic
D-1967	-0.6890871524810791	AT1 receptors neprilysin blocks renin-angiotensin-aldosteron RAS vasodilatory diuretic
P-1967	-4.0686 -0.1101 -0.5318 -0.1577 -0.2337 -0.0392 -1.1528 -0.5141 -0.0384 -0.2346 -0.2610 -0.0205 -0.0273 -0.0152 -2.6261 -0.2173 -0.0566 -1.8274 -0.0589 -0.2939 -1.4202 -0.0061 -0.6447 -0.2297 -1.4406 -0.3313 -0.0434 -2.3208 -1.6049 -0.1456
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine exercise_capacity left_ventricular_filling patients heart_failure_with_preserved_ejection_fraction hfpef
H-1171	-0.6126449704170227	▁i va bra dine ▁vent ri cular _ ▁fill ing ▁heart _ ▁failure ▁h p EF
D-1171	-0.6126449704170227	ivabradine ventricular_ filling heart_ failure hpEF
P-1171	-0.0270 -0.0250 -0.8074 -0.0385 -1.2498 -0.1822 -0.1003 -2.2094 -0.4655 -0.0362 -1.3700 -0.4478 -0.9875 -1.9780 -0.0322 -0.8641 -0.0988 -0.1082
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood_transfusions erythropoiesis-stimulating_agents anemia congestive_heart_failure coronary_heart_disease transfusion
H-42	-0.6497195959091187	▁trans fusion s ▁ir on ▁er y thro po ies is - stimul ating ▁agents ▁an emia ▁con ges tive _ ▁heart _ ▁failure ▁corona ry _ ▁heart _ ▁disease ▁trans fusion
D-42	-0.6497195959091187	transfusions iron erythropoiesis-stimulating agents anemia congestive_ heart_ failure coronary_ heart_ disease transfusion
P-42	-4.2537 -0.0354 -0.0675 -0.0116 -0.0200 -1.3188 -0.2246 -0.7861 -1.0104 -1.2273 -0.2218 -0.2903 -0.0322 -1.0956 -0.1233 -0.2982 -0.0411 -0.0969 -0.0720 -0.0681 -1.2281 -0.8771 -0.5127 -0.7971 -0.0101 -0.3244 -0.3533 -1.9940 -1.1138 -3.1378 -0.1107 -0.0288 -0.1953 -0.1126
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate_analysis bnp estimated_glomerular_filtration_rate hypertension transmitral e-wave diastolic_mitral_annular_velocity
H-1570	-0.6019756197929382	▁b NP ▁glo mer ular ▁filtr ation _ ▁rate ▁hyper tension ▁transmit ral ▁e - wa ve ▁dia sto lic _ met ral _ ▁ann ular
D-1570	-0.6019756197929382	bNP glomerular filtration_ rate hypertension transmitral e-wave diastolic_metral_ annular
P-1570	-0.1545 -1.7821 -0.3491 -0.0324 -0.0449 -0.7681 -0.0191 -1.6999 -0.4544 -0.0140 -0.0001 -0.1335 -0.0303 -1.4589 -0.0170 -0.1722 -0.0297 -0.1955 -0.3790 -1.3149 -0.5086 -1.9183 -0.0252 -0.3267 -2.2760 -0.0032 -2.5985 -0.1493
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade halt disease protein_kinase pka β-adrenergic_receptor
H-1425	-0.645025908946991	▁β - block ade ▁disease _ ▁progression ▁c AMP - dependent ▁protein _ ▁kina se ▁p KA ▁β - ad r energi c ▁receptor
D-1425	-0.645025908946991	β-blockade disease_ progression cAMP-dependent protein_ kinase pKA β-adrenergic receptor
P-1425	-0.4574 -0.0417 -0.7134 -1.6201 -1.0281 -2.6759 -0.2596 -0.0039 -0.1125 -0.1697 -0.0242 -1.7321 -2.2269 -0.1677 -0.0485 -0.6179 -0.6409 -0.3533 -0.0169 -0.0901 -0.1139 -0.3040 -0.1050 -0.9999 -2.1024 -0.1448
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence erythropoiesis-stimulating_agent therapy venous_thromboembolism
H-47	-1.089334487915039	▁er y thro po ies is - stimul ation _ agent _ therapy ▁benefits ▁ve nous _ thro mbo e mbol ism
D-47	-1.089334487915039	erythropoiesis-stimulation_agent_therapy benefits venous_thromboembolism
P-47	-4.1869 -0.0852 -0.9690 -1.1968 -1.6060 -0.2720 -0.1309 -0.0430 -1.2748 -2.1753 -1.1028 -0.4071 -0.3108 -2.2476 -3.3793 -1.7255 -1.1508 -0.2214 -1.1384 -0.8676 -0.0084 -1.3245 -0.2486 -0.0713
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical genetic chf area_under_the_curve auc genetic auc clinical auc
H-1456	-1.4137623310089111	▁clinic al ▁genetic ▁CHF
D-1456	-1.4137623310089111	clinical genetic CHF
P-1456	-3.1779 -1.8622 -1.0560 -0.1911 -2.1167 -0.0787
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable_adjustment mortality hospitalization hazard_ratio cardiovascular_mortality hf hospitalization
H-1638	-0.8330333828926086	▁black _ race ▁mortal ity haz ard ▁ratio ▁cardiovascular ▁mortal ity HF
D-1638	-0.8330333828926086	black_race mortalityhazard ratio cardiovascular mortalityHF
P-1638	-0.6034 -2.0068 -0.8406 -1.0950 -0.5258 -1.7224 -0.0254 -1.7175 -0.3254 -1.1816 -0.5277 -0.5452 -0.3217 -0.2242
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous chronic_myocardial_ischemia stent polytetrafluoroethylene
H-504	-0.8695759773254395	▁per cuta ne ous _ ▁one - ves sel _ model _ for _ ▁chronic _ My o card ial _ ische mia ▁sten t ▁poly te tra flu oro e thy lene ▁bottle ne ck
D-504	-0.8695759773254395	percutaneous_ one-vessel_model_for_ chronic_Myocardial_ischemia stent polytetrafluoroethylene bottleneck
P-504	-2.8433 -0.0138 -0.0141 -1.6021 -1.5908 -3.5473 -0.0146 -0.3779 -0.0063 -1.4492 -1.6481 -2.0227 -1.2010 -0.4556 -0.9075 -0.1490 -3.5657 -0.7032 -0.5509 -0.2666 -0.1291 -3.8312 -0.8244 -0.0269 -0.0267 -0.0224 -0.0525 -0.1427 -0.0399 -0.1868 -0.9378 -0.1577 -0.4542 -2.2147 -0.0166 -0.5362 -0.4218 -0.0925
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers_for_medicare_and_medicaid_services cms hospital outcomes reported mortality readmission penalties
H-1031	-0.872251033782959	▁Center s _ for _ ▁Medica re _ ▁and _ ▁Medica id ▁services ▁c ms ▁mortal ity ▁read mission ▁penal ties
D-1031	-0.872251033782959	Centers_for_ Medicare_ and_ Medicaid services cms mortality readmission penalties
P-1031	-0.2289 -0.0190 -0.0926 -2.7927 -0.2156 -0.2763 -0.0090 -1.9228 -1.2577 -1.2711 -0.1802 -0.1565 -1.5118 -0.1609 -1.1949 -3.5990 -0.3454 -1.5114 -0.0258 -1.8145 -1.1049 -0.2619 -0.1088
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart_failure hf tumor_necrosis_factor tnf tnf_antagonists disease severe_hf
H-601	-0.6639368534088135	▁heart _ ▁failure HF ▁tumor _ ▁nec rosi s ▁factor TN f ▁t NF _ ▁anta gon ists ▁ HF
D-601	-0.6639368534088135	heart_ failureHF tumor_ necrosis factorTNf tNF_ antagonists HF
P-601	-0.3425 -0.6607 -1.4768 -0.5513 -0.0219 -0.6314 -1.4703 -0.0434 -0.1696 -1.2495 -1.0257 -0.0983 -0.5100 -0.1150 -3.5248 -0.1709 -0.0511 -0.3546 -1.6497 -0.2701 -0.1511 -0.0679
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate signal_transduction transcription_factors pathological cardiomyocytes transcription_factors epigenetic chromatin_structure
H-1040	-0.8264701962471008	▁signal _ trans duction _ ▁casca de ▁tran scription ▁factors ▁cardio my o cy tes ▁tran scription ▁factors ▁chr omat in _ ▁structure
D-1040	-0.8264701962471008	signal_transduction_ cascade transcription factors cardiomyocytes transcription factors chromatin_ structure
P-1040	-0.2973 -0.6873 -0.2538 -0.5035 -0.6086 -0.2301 -0.0173 -0.9663 -0.0263 -2.2237 -1.2872 -1.4150 -0.9316 -0.3193 -0.3085 -1.0741 -0.0595 -1.6850 -2.1222 -0.0905 -1.8238 -1.1055 -2.0851 -0.3600 -0.1802
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox_proportional_hazard_models covariates follow-up physician discharge primary_outcome death all-cause_readmission
H-1416	-0.8294771313667297	▁hazard _ modellen ▁follow - up ▁physician ▁dis charge ▁death
D-1416	-0.8294771313667297	hazard_modellen follow-up physician discharge death
P-1416	-0.9120 -2.3339 -1.5238 -1.2584 -0.0370 -0.0129 -0.3406 -0.1614 -0.0053 -1.9462 -1.2903 -0.1320
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable_logistic_analysis peak_oxygen_uptake metabolic_exercise cardiac kidney prognostic hf_index
H-1760	-1.1221411228179932	▁multi vari able ▁logistic ▁analysis ▁oxygen _ up take ▁metabol ic ▁exercise ▁cardiac ▁ki dne y ▁ HF
D-1760	-1.1221411228179932	multivariable logistic analysis oxygen_uptake metabolic exercise cardiac kidney HF
P-1760	-4.9104 -0.0004 -0.0140 -0.7944 -3.0218 -3.0909 -1.4221 -0.5822 -0.1644 -0.6455 -0.0895 -1.2714 -0.0178 -2.4079 -0.1323 -0.0581 -3.2459 -0.1119 -0.3360 -0.1260
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular_dilatation
H-334	-0.7449766397476196	▁ann ular ▁size _ re duction ▁surgery ▁dia sto lic _ met ral _ ▁val ve _ ▁te ther ing ▁anterior ▁le a flet _ ▁opening ▁papil lar y _ ▁muscle s ▁vent ri cular _ di la tation
D-334	-0.7449766397476196	annular size_reduction surgery diastolic_metral_ valve_ tethering anterior leaflet_ opening papillary_ muscles ventricular_dilatation
P-334	-1.5212 -0.0022 -2.4211 -0.9350 -0.8198 -0.0038 -0.1234 -0.0142 -0.2563 -2.2696 -0.4843 -2.2473 -0.0110 -1.0822 -2.6476 -0.3656 -1.2664 -1.4580 -0.0099 -0.0486 -0.9142 -0.4218 -0.0679 -0.0050 -2.2162 -0.2942 -1.2011 -0.2642 -0.3640 -1.5455 -1.0242 -0.0179 -0.5416 -0.2400 -0.0686 -0.6855 -2.1093 -0.2091 -0.0189 -0.2322 -0.1150
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients hypertensive_hfpef dash ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling
H-926	-0.550726056098938	▁hyper tensi ve ▁h f f f ▁so dium - re strict ed ▁DAS h ▁vent ri cular _ ▁dia sto lic _ fon cti onnement ▁arterial _ ▁elastan ce ▁vent ri cular - arte rial ▁coup ling
D-926	-0.550726056098938	hypertensive hfff sodium-restricted DASh ventricular_ diastolic_fonctionnement arterial_ elastance ventricular-arterial coupling
P-926	-1.8118 -1.2886 -0.3432 -0.3574 -0.1280 -0.1247 -0.5062 -1.1056 -0.0277 -0.0062 -0.0044 -0.0206 -0.1148 -0.1530 -0.3720 -0.0325 -0.0915 -0.0776 -0.3574 -2.0034 -0.3646 -1.8575 -2.3346 -1.7247 -0.5774 -0.2594 -0.0560 -1.5880 -0.1466 -0.2994 -0.0040 -0.1000 -0.0765 -0.3036 -0.2860 -0.1068 -0.1628 -2.3963 -0.3537 -0.1045
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf hct polymorphisms genes anthracycline metabolism iron_homeostasis anti-oxidant_defence myocardial_remodelling
H-1450	-0.3659714162349701	▁CHF ▁h ct ▁poly morph ism s ▁an thra cycli ne ▁metabolism ▁ir on _ ▁home osta sis ▁anti - oxid ant _ de _ fen ce ▁my o card ial ▁remodel ling
D-1450	-0.3659714162349701	CHF hct polymorphisms anthracycline metabolism iron_ homeostasis anti-oxidant_de_fence myocardial remodelling
P-1450	-0.1862 -0.2050 -1.4463 -1.5571 -0.0053 -0.4246 -0.0406 -0.0800 -0.0197 -0.6931 -0.4649 -0.2440 -0.0044 -0.0062 -0.9535 -0.8214 -0.1129 -0.2018 -0.0103 -0.0627 -0.0018 -0.1895 -0.3619 -0.0398 -2.1007 -0.3790 -0.1180 -0.3242 -0.0984 -0.2911 -0.1345 -0.5241 -0.3547 -0.2791 -0.0724
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate_logistic_regression_analysis rule cad stenosis 3-vessel_cad 2-vessel_cad left_anterior_descending_artery
H-1187	-2.871767282485962	▁figure ▁CAD ▁diameter _ ▁sten osis
D-1187	-2.871767282485962	figure CAD diameter_ stenosis
P-1187	-5.7468 -5.5631 -0.7869 -1.7348 -0.4461 -0.1805 -8.4194 -0.0965
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence mortality outcomes heart_failure acute_myocardial_infarction patients acute_myocardial_infarction western_australia
H-1305	-1.2253611087799072	▁heart _ ▁failure ▁a cute _ mé o card ial _ ▁in far ction
D-1305	-1.2253611087799072	heart_ failure acute_méocardial_ infarction
P-1305	-2.5955 -0.7887 -0.9527 -0.9999 -0.0202 -0.1273 -4.1667 -0.9799 -0.5567 -0.5841 -0.4493 -0.6523 -2.8822 -0.2560 -3.4268 -0.1674
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized_aldactone_evaluation_study symptomatic_chronic_advanced_heart_failure patients aldosterone_antagonist spironolactone mortality placebo
H-1735	-0.809953510761261	▁al da cto ne _ ▁Evalua tion _ ▁Study ▁cardiovascular _ ▁failure ▁al do ster one _ ▁anta gon ist ▁spi rono lac tone ▁mortal ity
D-1735	-0.809953510761261	aldactone_ Evaluation_ Study cardiovascular_ failure aldosterone_ antagonist spironolactone mortality
P-1735	-0.5667 -2.1092 -0.1817 -0.0720 -1.5234 -0.6152 -0.0082 -2.2682 -0.3816 -5.0228 -0.7652 -0.7659 -0.5016 -0.4536 -0.1911 -1.9577 -0.8452 -0.0412 -0.0399 -2.3488 -0.0903 -0.0139 -0.1276 -0.1864 -0.4076 -0.7391 -0.3663 -0.0882
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-1.1359622478485107	▁medication ▁no nadh er ence ▁salt
D-559	-1.1359622478485107	medication nonadherence salt
P-559	-0.3437 -3.2117 -3.4626 -0.0230 -0.4408 -0.7429 -0.7443 -0.1186
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological diagnostic prognostic
H-1278	-0.6061692237854004	▁pat ho phy si ological
D-1278	-0.6061692237854004	pathophysiological
P-1278	-0.5628 -0.5323 -0.0171 -0.4406 -0.7070 -1.8999 -0.0835
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad surgery patients albumin hypoalbuminemia surgery
H-534	-1.4434211254119873	▁l VAD
D-534	-1.4434211254119873	lVAD
P-534	-1.2359 -0.0773 -4.2853 -0.1752
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical hm_ii heartware patients economic hm_ii
H-310	-1.3322399854660034	▁scientific _ ▁literature ▁h m _ ▁II ▁Heart War e _ ▁patients ▁h m ▁II
D-310	-1.3322399854660034	scientific_ literature hm_ II HeartWare_ patients hm II
P-310	-1.5623 -3.4186 -0.9267 -0.4015 -1.4151 -2.0013 -0.8757 -1.0093 -0.2768 -0.0689 -3.4575 -0.9726 -1.6784 -1.2229 -2.3428 -0.8463 -0.1716
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate_model creatinine hazard_ratio confidence_interval mortality
H-717	-0.9310339093208313	▁creati nine haz ard ▁d L
D-717	-0.9310339093208313	creatininehazard dL
P-717	-0.5124 -1.2294 -0.0313 -0.0069 -0.7533 -0.8727 -3.9267 -0.1157
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications implantation lvad_therapy transplantation btt dt medical_therapy
H-313	-0.4647519886493683	▁implant ation ▁l VAD ▁implant ation ▁implant ation ▁implant ation ▁b t ▁d t ▁medical ▁ therapy
D-313	-0.4647519886493683	implantation lVAD implantation implantation implantation bt dt medical therapy
P-313	-0.1259 -0.0182 -0.9782 -0.0328 -0.6261 -0.0098 -0.7213 -0.0096 -1.8387 -0.0107 -1.4160 -0.1754 -1.7986 -0.0689 -0.1158 -0.5725 -0.0289 -0.1882 -0.0946
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical artery_tonometry prospectively admission patients icu clinical
H-580	-0.7688429355621338	▁radi al _ ▁arter y _ ▁ton ometr y
D-580	-0.7688429355621338	radial_ artery_ tonometry
P-580	-0.8599 -0.0405 -0.9187 -0.7535 -0.4179 -0.2681 -1.7931 -0.0435 -0.2422 -3.0316 -0.0883
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized hr_variability hr_variability clinical risk_stratification cardiac patients
H-1591	-1.0646662712097168	▁HR ▁variabil ity _ tur bul ence
D-1591	-1.0646662712097168	HR variability_turbulence
P-1591	-2.3195 -1.8610 -0.6831 -0.5880 -1.0344 -0.0187 -0.1227 -2.7449 -0.2098
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine nesiritide renal_function patients acute_heart_failure renal_dysfunction
H-72	-0.9528607726097107	▁dop amine ▁nesi riti de ▁renal ▁fonction ▁a cute _ ▁heart _ ▁failure ▁renal _ ▁dys function
D-72	-0.9528607726097107	dopamine nesiritide renal fonction acute_ heart_ failure renal_ dysfunction
P-72	-2.6705 -0.2287 -1.4485 -0.1265 -0.0623 -0.0852 -4.1824 -0.9988 -0.0253 -0.3515 -2.0551 -0.7039 -0.5867 -0.0141 -2.5940 -0.7065 -0.7735 -0.3778 -0.1130
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death patients estimated_glomerular_filtration_rate odds_ratio confidence_interval
H-977	-1.0941194295883179	▁risk _ de _ ▁death ▁glo mer ular ▁filtr ation
D-977	-1.0941194295883179	risk_de_ death glomerular filtration
P-977	-3.4071 -1.1124 -0.8808 -0.1356 -1.9718 -0.3328 -0.2112 -0.2413 -2.4357 -0.1188 -1.9977 -0.2843
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast_cancer patients medicare diagnosed breast_cancer chemotherapy seer-medicare texas medicare
H-672	-0.6156705021858215	▁Medica re ▁coverage ▁breast ▁cancer ▁che mo therapy ▁s EER - Medic are ▁Texas ▁Cancer ▁Registr y _ Medic are
D-672	-0.6156705021858215	Medicare coverage breast cancer chemotherapy sEER-Medicare Texas Cancer Registry_Medicare
P-672	-0.9756 -0.0067 -2.5013 -0.1922 -0.4595 -0.2330 -0.0296 -0.0203 -0.8515 -0.0698 -0.0130 -0.0444 -0.7760 -0.0736 -3.0621 -1.8885 -0.0217 -0.6721 -0.1749 -1.0408 -0.3351 -0.1030
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome_complex scaffold_protein drives kinases phosphorylation effector_molecules
H-995	-0.8507969379425049	▁signal o some _ ▁complex ▁sc af fold _ ▁protein ▁kina ses ▁sequenti al _ phos phor y lation
D-995	-0.8507969379425049	signalosome_ complex scaffold_ protein kinases sequential_phosphorylation
P-995	-1.9275 -4.1100 -1.1010 -1.6373 -0.6387 -0.1545 -0.8024 -0.1034 -0.7728 -0.6444 -0.2677 -0.1369 -0.6710 -0.0863 -0.6049 -1.1229 -0.4043 -1.9999 -0.0540 -0.5011 -0.1258
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully_magnetically_levitated_centrifugal-flow_chronic_lvas adverse_event quality_of_life functional_status
H-2006	-0.7212554216384888	▁magnet ically ▁le vita ted ▁centri fu gal - flow _ ▁chronic ▁l VAS
D-2006	-0.7212554216384888	magnetically levitated centrifugal-flow_ chronic lVAS
P-2006	-1.0640 -0.3542 -0.9687 -0.0282 -1.4785 -1.5356 -0.1627 -0.1429 -0.0950 -0.1565 -1.1980 -1.9927 -1.7286 -0.1505 -0.4029 -0.0812
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased cardiomyocytes pde2 activity cgmp_synthesis nitric_oxide donors pde2_inhibition β-ar_responsiveness
H-1215	-0.7372214198112488	▁cardio my o cy tes ▁p de 2 ▁activity ▁c g MP ▁ni tric ▁oxid e ▁p de 2
D-1215	-0.7372214198112488	cardiomyocytes pde2 activity cgMP nitric oxide pde2
P-1215	-0.8006 -1.3901 -0.7989 -0.1819 -0.3071 -0.2753 -0.0580 -0.0510 -1.5482 -0.0089 -0.8849 -2.0546 -1.7669 -0.2866 -0.7414 -0.2475 -0.8616 -0.0497 -0.1396 -2.9492 -0.0797
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection_fraction b-type_natriuretic_peptide patients hospitalized heart_failure inhospital outcomes get_with_the_guideline-heart_failure_registry
H-186	-0.7695208787918091	▁e je ction _ fraction ▁b - type _ na tri ure tic _ pe pti de ▁heart _ ▁Fail ure
D-186	-0.7695208787918091	ejection_fraction b-type_natriuretic_peptide heart_ Failure
P-186	-0.9040 -0.5411 -0.0127 -0.7573 -0.0008 -0.6005 -0.0692 -0.0871 -0.6825 -1.5886 -0.0858 -0.1061 -2.9383 -0.9071 -0.4098 -0.0767 -0.1477 -3.3373 -0.9392 -2.2922 -0.0613 -0.9670 -0.1867
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic_receptor sphingosine-1-phosphate_receptor_1 s1pr1 downregulation cardiac hypertrophic heart_failure s1pr1 cardiac gene therapy
H-1404	-0.7472550868988037	▁beta 1- ad r energi c ▁receptor ▁sp hing os ine - phos pha te ▁receptor ▁s 1 PR ▁cardiac ▁hyper trop hic ▁heart _ ▁failure ▁s 1 PR ▁cardiac ▁gene ▁ therapy
D-1404	-0.7472550868988037	beta1-adrenergic receptor sphingosine-phosphate receptor s1PR cardiac hypertrophic heart_ failure s1PR cardiac gene therapy
P-1404	-2.1659 -1.7578 -0.1116 -0.0445 -0.0453 -0.0952 -0.0748 -0.0093 -0.1100 -0.7780 -0.6354 -2.5448 -0.0512 -0.0706 -0.0960 -0.9533 -1.8428 -0.0539 -0.5136 -0.4152 -1.5687 -0.0024 -0.3276 -2.8788 -0.8052 -2.0524 -2.0320 -0.0463 -0.2825 -1.1102 -1.8087 -0.6805 -0.0191 -0.1006 -0.0696
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs hdl phosphorylation
H-251	-0.5708051919937134	▁EC s ▁HD l ▁ phos phor y lation ▁e NOS - Ser ▁e NOS - Th r ▁PK c - β II - Ser ▁p 70 s 6 k - Ser
D-251	-0.5708051919937134	ECs HDl phosphorylation eNOS-Ser eNOS-Thr PKc-βII-Ser p70s6k-Ser
P-251	-0.4107 -0.5003 -0.8460 -1.9887 -0.0436 -0.0816 -0.0616 -1.3752 -0.0484 -0.0479 -0.0885 -0.0619 -1.6972 -0.0737 -0.0844 -0.0547 -1.7412 -0.0016 -0.6366 -0.1371 -0.0989 -0.3422 -1.7261 -0.0799 -0.2969 -0.7027 -0.6703 -0.5470 -1.2258 -2.3696 -0.0530 -1.0702 -0.1168 -0.1271
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts patients sts hh sts
H-155	-1.2058947086334229	▁R CT s ▁s ts ▁h m ▁s ts ▁TM
D-155	-1.2058947086334229	RCTs sts hm sts TM
P-155	-4.7432 -0.6303 -0.1215 -1.2152 -0.4777 -0.2021 -0.6008 -2.5725 -1.0709 -2.3066 -0.4451 -0.0846
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular_myocytes sarcomere shortening
H-417	-0.6135262250900269	▁mouse ▁vent ri cular _ My o cy tes ▁sar com ere
D-417	-0.6135262250900269	mouse ventricular_Myocytes sarcomere
P-417	-0.6070 -0.3390 -0.2389 -0.2610 -0.4243 -2.3059 -0.2078 -0.1354 -0.5408 -0.2329 -0.1919 -0.9733 -2.0416 -0.0896
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative alberta discharged hospital diagnosis heart_failure
H-1415	-0.6604770421981812	▁administrative ▁database s ▁Albert a ▁dis charge d _ ▁ali ve ▁hospital ▁heart _ ▁failure
D-1415	-0.6604770421981812	administrative databases Alberta discharged_ alive hospital heart_ failure
P-1415	-0.0241 -3.4572 -0.0221 -1.3886 -0.1614 -1.0424 -0.0028 -0.5339 -0.2981 -0.1230 -0.0962 -0.2326 -1.4752 -0.8305 -1.2385 -0.2248 -0.0765
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp 6-minute_walking_distance peak_o2
H-829	-1.4510328769683838	▁PAS p
D-829	-1.4510328769683838	PASp
P-829	-1.5990 -0.9666 -3.1135 -0.1250
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates crt death hf hospitalization hazard_ratio lvef
H-757	-1.3351759910583496	▁c t _ on _ ▁assign ment ▁time _ ▁to _ ▁death ▁h f
D-757	-1.3351759910583496	ct_on_ assignment time_ to_ death hf
P-757	-0.1078 -2.2455 -3.1961 -0.3999 -1.6770 -1.6159 -0.0240 -1.5770 -1.6585 -1.6499 -0.9962 -0.4241 -2.4355 -0.5184 -2.7073 -0.1297
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart_failure histologically myocardial_collagen healthy heart_failure
H-1062	-1.0841344594955444	▁heart _ ▁failure ▁my o card ial _ ▁collage n ▁tissu e
D-1062	-1.0841344594955444	heart_ failure myocardial_ collagen tissue
P-1062	-3.2993 -1.0285 -1.9854 -1.6818 -0.3438 -0.1339 -0.1314 -0.4686 -0.2767 -0.0757 -0.7600 -0.7107 -4.1683 -0.1136
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko cardiac irs1 irs2 proteins heart_failure cardiac_energy_metabolism_gene_expression p38α mitogen-activated_protein_kinase p38
H-656	-0.9191746711730957	▁l - d KO ▁mi ce ▁cardiac ▁i RS 1 ▁i RS 2 ▁heart _ ▁failure ▁im pair ed ▁cardiac _ énergie _ ▁metabolism ▁protein _ ▁kina se
D-656	-0.9191746711730957	l-dKO mice cardiac iRS1 iRS2 heart_ failure impaired cardiac_énergie_ metabolism protein_ kinase
P-656	-1.0043 -0.4248 -0.5026 -1.4962 -3.6547 -0.0959 -0.1741 -1.3052 -0.1627 -1.0837 -0.5912 -0.3322 -0.0947 -2.8676 -0.7483 -1.0102 -0.9496 -0.0048 -0.2119 -0.8871 -1.0559 -1.3881 -1.4792 -0.0560 -3.0083 -2.3608 -0.2592 -0.0184 -0.2301 -0.1174
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil heart_failure hemodynamic mitochondrial_dysfunction antitumor activity
H-967	-0.44897058606147766	▁nic oran dil ▁do xor ubi cin - indu ce ▁heart _ ▁failure ▁hem o dynamic ▁perturba tions ▁mito cho ndri al _ ▁dys function ▁ultra struct ural ▁anti tum or
D-967	-0.44897058606147766	nicorandil doxorubicin-induce heart_ failure hemodynamic perturbations mitochondrial_ dysfunction ultrastructural antitumor
P-967	-0.1158 -0.0138 -0.2719 -0.0093 -0.0269 -0.0354 -0.1751 -0.3651 -0.0003 -2.0838 -1.7569 -0.8764 -0.4269 -1.7505 -0.0310 -0.0480 -1.1402 -0.0131 -0.0487 -0.7554 -0.0855 -0.0862 -0.8355 -0.1735 -0.1673 -1.3871 -0.0495 -0.1475 -0.2513 -0.1086 -0.0274 -1.4811 -0.0710
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm_control_therapy diagnosis atrial sinus_rhythm rhythm_control symptoms rate_control
H-1646	-0.9401382207870483	▁ Rhythm _ control ▁ therapy ▁af ▁at rial ▁structure ▁sinus ▁ rhythm ▁ rhythm
D-1646	-0.9401382207870483	Rhythm_control therapy af atrial structure sinus rhythm rhythm
P-1646	-1.1607 -1.6552 -0.6857 -0.0560 -1.1744 -0.0404 -0.4635 -2.2354 -0.1008 -1.0404 -2.3802 -0.1922 -0.2956 -2.0979 -0.5211 -1.7807 -0.1022
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative_risk rr heart_failure bisphophonates rr confidence_interval hazard_ratio
H-1540	-1.3776371479034424	▁ RR ▁heart _ ▁failure ▁bis pho phon ates ▁cru de ▁ RR
D-1540	-1.3776371479034424	RR heart_ failure bisphophonates crude RR
P-1540	-3.3270 -0.6669 -2.8089 -0.8478 -1.6932 -1.7106 -0.2223 -0.2818 -2.3326 -0.9981 -0.0061 -0.4013 -0.1059 -5.1026 -0.1594
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician heart_failure clinical_practice_guideline cpg outcomes heart_failure hf
H-1841	-0.9496697783470154	▁physician _ ad her ence ▁guide line _ ▁recommendations ▁heart _ ▁failure ▁Clinic al _ ▁Practic e _ ▁Guide line ▁c g ▁heart _ ▁failure HF
D-1841	-0.9496697783470154	physician_adherence guideline_ recommendations heart_ failure Clinical_ Practice_ Guideline cg heart_ failureHF
P-1841	-1.1347 -2.8255 -0.8312 -0.0647 -0.0032 -0.6991 -0.0565 -1.6123 -0.9787 -1.1551 -0.6108 -1.1637 -1.1842 -0.0588 -0.1691 -1.4427 -0.0786 -2.0033 -1.0098 -0.0333 -1.9980 -0.5482 -2.1038 -0.7459 -2.1728 -1.5386 -0.2149 -0.1532
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute_heart_failure renal_dysfunction dopamine nesiritide renal_function diuretic therapy
H-83	-0.8077386021614075	▁a cute _ ▁heart _ ▁failure ▁renal ▁dys function ▁dop amine ▁nesi riti de ▁renal _ fon cti onnement ▁di ure tic ▁ therapy
D-83	-0.8077386021614075	acute_ heart_ failure renal dysfunction dopamine nesiritide renal_fonctionnement diuretic therapy
P-83	-1.1965 -0.0292 -0.4565 -1.8141 -0.7766 -0.3548 -0.0363 -0.7358 -0.4541 -1.6897 -0.3069 -1.3551 -0.1565 -0.0295 -0.1342 -3.6470 -2.0731 -0.8459 -0.7949 -0.0376 -0.1101 -2.6851 -0.9460 -0.0628 -0.1932 -0.0801
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf prospective dual-energy_x-ray_absorptiometry echocardiography blood
H-1161	-0.6544432044029236	▁ HF ▁implant _ ▁thi ck ness ▁dual - ener gy ▁X - ray _ ▁ab sor pti ometr y ▁e cho card i ography ▁blood
D-1161	-0.6544432044029236	HF implant_ thickness dual-energy X-ray_ absorptiometry echocardiography blood
P-1161	-1.9301 -0.3016 -4.4578 -4.6009 -1.3444 -0.3636 -0.3553 -0.3242 -0.0129 -0.0191 -0.0017 -1.0927 -0.0159 -0.0633 -0.6847 -0.5718 -0.0232 -0.0621 -0.0521 -0.1390 -0.0542 -0.1386 -0.2001 -0.3795 -0.2531 -0.1480 -0.6021 -0.1325
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare centers_for_medicare_and_medicaid_services clinics propensity-score
H-1621	-0.6113831996917725	▁high - co st ▁Medica re ▁fee - for - service _ ▁beneficiar ies ▁Center s _ de _ ▁Medica re ▁Medica re ▁Medica id ▁services ▁pro pens ity - s core
D-1621	-0.6113831996917725	high-cost Medicare fee-for-service_ beneficiaries Centers_de_ Medicare Medicare Medicaid services propensity-score
P-1621	-4.2114 -0.0411 -0.1050 -0.4881 -0.4187 -0.0296 -0.5464 -0.0160 -0.0129 -0.0687 -0.0089 -3.0459 -0.3324 -0.7723 -0.3816 -0.0637 -0.1755 -2.6610 -0.1661 -0.5583 -0.0142 -0.3870 -1.4759 -0.9955 -0.2425 -1.2067 -1.1070 -0.0234 -0.3520 -0.1203 -0.0768 -0.2402 -0.2951 -0.1467
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals patients hospitalized heart_failure hf conditions acute_myocardial_infarction pneumonia conditions
H-1032	-0.6406767964363098	▁hospital s ▁heart _ ▁failure HF ▁conditions ▁a cute _ My o card ial _ ▁in far ction ▁pneu monia ▁conditions
D-1032	-0.6406767964363098	hospitals heart_ failureHF conditions acute_Myocardial_ infarction pneumonia conditions
P-1032	-3.0927 -0.1155 -1.4461 -0.5882 -0.5426 -0.9696 -0.2545 -0.6403 -0.0045 -0.1613 -3.6454 -0.3085 -0.0793 -0.1026 -0.9508 -0.2754 -0.8735 -0.0554 -0.0022 -0.1879 -0.1550 -0.1454 -0.1389
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients heart_failure
H-1744	-1.445335865020752	▁Patient s ▁heart _ ▁failure
D-1744	-1.445335865020752	Patients heart_ failure
P-1744	-4.4385 -0.3925 -1.6076 -1.0927 -1.8769 -0.5436 -0.1656
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq new_york_heart_association_class patients hfpef hf_with_reduced_ef
H-788	-0.989314615726471	▁k cc q ▁New ▁York _ ▁Heart _ association ▁ HF p EF ▁ HF ▁ef
D-788	-0.989314615726471	kccq New York_ Heart_association HFpEF HF ef
P-788	-0.3546 -0.0480 -1.1468 -5.1726 -1.2285 -0.8225 -1.0430 -0.5882 -1.1425 -1.3217 -0.4502 -0.3863 -0.4242 -0.4542 -0.6706 -2.1971 -0.2234 -0.1334
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp red_blood_cell_transfusion hemoglobin hemoglobin hospitalized patients coronary_heart_disease
H-36	-1.5026453733444214	▁a CP ▁restrict ive _ ▁red _ ▁blood _ cell _ trans fusion ▁stratégie _ tri gger _ ▁hem o glob in ▁d l ▁hem o glob in
D-36	-1.5026453733444214	aCP restrictive_ red_ blood_cell_transfusion stratégie_trigger_ hemoglobin dl hemoglobin
P-36	-0.4138 -0.9807 -0.0800 -0.0085 -1.2121 -0.6666 -1.6992 -0.9376 -1.2692 -0.7723 -0.8510 -0.4437 -0.0711 -5.0152 -5.1972 -0.6795 -0.0066 -0.5798 -3.4441 -0.6101 -0.3852 -2.2819 -3.9198 -3.1863 -3.6091 -0.4456 -0.4024 -1.8408 -3.8548 -0.2152
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted interatrial_shunt clinical haemodynamic outcomes patients heart_failure_with_reduced_ejection_fraction
H-1962	-0.6356620192527771	▁implant ed ▁left - to - right ▁inter at rial _ ▁shu nt ▁ha emo dynamic ▁heart _ ▁failure ▁e je ction _ fraction
D-1962	-0.6356620192527771	implanted left-to-right interatrial_ shunt haemodynamic heart_ failure ejection_fraction
P-1962	-0.0013 -0.3140 -1.9546 -0.0113 -0.3412 -0.0591 -0.2191 -0.1634 -0.3240 -0.4285 -1.7628 -1.0437 -0.1218 -0.2360 -0.5975 -0.0345 -3.5411 -1.2259 -0.8494 -1.2284 -0.3189 -0.0638 -1.2476 -0.0052 -0.3078 -0.1265
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise training peak_oxygen_consumption quality_of_life obese patients heart_failure_with_preserved_ejection_fraction randomized clinical
H-1973	-0.5521824359893799	▁Cal o ric _ re stri ction ▁Aero bic _ ▁Exerci se ▁Peak ▁o xy gen _ ▁Consum p tion ▁Quality _ of _ ▁Life ▁Heart _ ▁Fail ure ▁e je ction _ fra ction
D-1973	-0.5521824359893799	Caloric_restriction Aerobic_ Exercise Peak oxygen_ Consumption Quality_of_ Life Heart_ Failure ejection_fraction
P-1973	-1.0100 -0.0799 -0.9867 -1.0760 -0.1459 -0.0321 -0.0079 -0.1832 -0.0739 -1.8957 -0.1614 -0.0797 -1.0939 -2.5663 -0.0712 -0.1475 -0.6148 -0.0183 -0.4596 -0.0607 -0.9634 -0.5430 -1.2366 -0.1019 -0.7250 -1.9382 -0.9657 -0.1152 -0.0375 -1.1949 -0.2656 -0.0178 -0.3772 -0.7222 -0.0172 -0.3531 -0.0916
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left_ventricular_assist_devices lvads chronic_end-stage_heart_failure bridge_to_transplantation btt patients destination_therapy dt
H-308	-0.6526501774787903	▁vent ri cular _ assist ▁devices ▁l VAD s ▁chronic ▁end - s tage _ heart _ ▁failure ▁b t ▁transplant - ine ligi ble ▁patients ▁d t
D-308	-0.6526501774787903	ventricular_assist devices lVADs chronic end-stage_heart_ failure bt transplant-ineligible patients dt
P-308	-0.5514 -0.4075 -0.1338 -0.5700 -0.0870 -1.1631 -0.3761 -0.0194 -0.4839 -1.9227 -1.9015 -0.0428 -0.2412 -0.0044 -0.2054 -2.1333 -0.8121 -1.2616 -0.4002 -0.2268 -0.3404 -1.2501 -0.7265 -0.0240 -0.0372 -2.4083 -1.0206 -0.6020 -0.1239 -0.1023
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1_time correlated right_ventricular-pulmonary_arterial_coupling pulmonary_vascular_resistance right_ventricular_ejection_fraction
H-742	-1.0423486232757568	▁vent ri cular - pul mon ary _ ▁arterial ▁coup ling pul mon ary _ ▁vas cular ▁resist ance ▁right ▁vent ri cular _ ▁e je ction _ fraction
D-742	-1.0423486232757568	ventricular-pulmonary_ arterial couplingpulmonary_ vascular resistance right ventricular_ ejection_fraction
P-742	-0.3036 -0.3366 -0.2705 -0.6384 -0.9774 -3.1933 -1.3636 -0.7972 -2.8497 -0.3802 -2.8349 -1.9684 -1.4741 -0.9929 -0.3289 -1.1783 -0.2433 -3.2390 -0.0431 -1.3083 -0.5619 -0.2973 -0.2665 -0.7598 -2.5118 -0.5143 -0.1182 -2.0604 -0.0066 -0.3274 -0.1670
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol metoprolol implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-855	-0.6216272115707397	▁car vedi lol ▁met o pro lol ▁implant able ▁implant able _ ▁cardio ver ter - de _ de _ fis br illa tor _ therapy ▁MAD it - c RT ▁multi center _ automat ic _ de ib rilla tor ▁implant ation ▁Card iac _ re syn chron ization ▁Therapy
D-855	-0.6216272115707397	carvedilol metoprolol implantable implantable_ cardioverter-de_de_fisbrillator_therapy MADit-cRT multicenter_automatic_deibrillator implantation Cardiac_resynchronization Therapy
P-855	-0.3972 -0.0285 -0.0748 -0.0195 -0.0322 -0.0029 -0.2325 -0.0001 -0.0227 -0.3630 -0.0283 -1.8242 -0.7675 -0.1461 -0.0337 -0.1525 -0.0114 -3.3839 -1.2102 -3.8470 -3.1768 -2.5337 -0.0067 -0.4181 -1.6662 -0.1542 -0.0452 -0.8125 -0.0171 -0.2407 -1.2824 -2.7454 -0.0295 -0.1028 -0.2503 -0.3695 -0.2820 -0.3742 -2.1081 -0.1749 -0.1392 -0.1171 -0.0148 -0.4328 -0.1199 -0.2880 -0.6859 -0.0065 -0.0004 -0.5715 -0.8301 -0.2802 -0.0914
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral glucocorticoids hf
H-610	-1.1457711458206177	▁gluco cor tico ids ▁ HF
D-610	-1.1457711458206177	glucocorticoids HF
P-610	-1.7051 -0.0393 -3.1736 -0.5487 -1.2794 -0.1064 -2.2150 -0.0986
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ea tac placebo
H-523	-0.7940847277641296	▁HR ▁i va bra dine ▁Ea ▁ TAC
D-523	-0.7940847277641296	HR ivabradine Ea TAC
P-523	-1.9028 -0.0403 -0.0184 -0.5357 -0.0128 -3.9104 -1.2572 -0.0481 -0.1294 -0.0855
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi death medical hospitalization hf clinic outpatients hf health
H-385	-1.264308214187622	▁ HF PSI ▁risk _ de _ ▁death ▁medical ▁hospital ization ▁ HF ▁ HF
D-385	-1.264308214187622	HFPSI risk_de_ death medical hospitalization HF HF
P-385	-0.7971 -1.0348 -0.9703 -4.8109 -2.0802 -0.8367 -0.1643 -0.9641 -0.3729 -1.3754 -0.6166 -0.4912 -0.0857 -3.2475 -0.4230 -3.0421 -0.1805
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up systemic adverse_events patients dcm heart_failure
H-1265	-1.0677961111068726	▁CH m ▁ad ju nc tive ▁d CM ▁heart _ ▁failure
D-1265	-1.0677961111068726	CHm adjunctive dCM heart_ failure
P-1265	-5.0274 -0.0696 -1.8072 -0.0048 -0.0586 -0.0144 -3.3538 -0.5264 -0.6969 -1.0085 -1.0347 -0.1896 -0.0896
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol therapy metoprolol hazard_ratio confidence_interval
H-862	-0.4913845658302307	▁car vedi lol ▁in appropria te ▁ therapy ▁met o pro lol haz ard
D-862	-0.4913845658302307	carvedilol inappropriate therapy metoprololhazard
P-862	-1.9209 -0.1693 -0.2550 -1.2767 -0.2164 -0.2685 -1.5535 -0.0275 -0.1282 -0.1590 -0.0397 -0.1991 -0.0995 -0.0123 -1.3957 -0.1409
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone_supplementation exercise_rehabilitation health outcomes patients chf testosterone
H-1325	-1.2697789669036865	▁testosteron e ▁rehabilita tion ▁CHF ▁testosteron e
D-1325	-1.2697789669036865	testosterone rehabilitation CHF testosterone
P-1325	-0.7394 -0.0541 -5.2213 -0.0274 -2.8446 -1.5341 -0.0891 -0.8445 -0.0736
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change peak_vo2 correlated change lean_body_mass change thigh muscle
H-1987	-1.2986928224563599	▁VO 2 ▁lean _ ▁body _ ▁Mass ▁change _ ▁in _ ter me _ s yst ème ▁inter mus cular _ ▁fat
D-1987	-1.2986928224563599	VO2 lean_ body_ Mass change_ in_terme_système intermuscular_ fat
P-1987	-0.7223 -0.0248 -2.3319 -1.1320 -1.1947 -0.6989 -1.4451 -0.6913 -3.3854 -1.7465 -1.8408 -3.1663 -1.5875 -1.5723 -2.6803 -0.7935 -0.3331 -2.5272 -0.4818 -0.1660 -0.4992 -1.2542 -0.6949 -0.1984
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals get_with_the_guidelines-heart_failure hf patients ef ef ef ef
H-189	-0.6302908658981323	▁guide lines - He art _ ▁Fail ure ▁h f ▁ef
D-189	-0.6302908658981323	guidelines-Heart_ Failure hf ef
P-189	-1.6135 -0.2080 -0.5046 -1.3981 -0.0770 -0.6055 -0.3080 -0.0587 -0.4929 -0.0360 -2.5612 -0.2240 -0.1064
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate_cox_model pasp exercise peak_o2 prognostic hazard_ratio peak_o2 pasp
H-830	-1.8287657499313354	▁co x _ model
D-830	-1.8287657499313354	cox_model
P-830	-0.1828 -0.0186 -3.0373 -1.6469 -5.9711 -0.1158
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac insulin-resistance mitochondrial_oxidative_metabolism metabolic cardiac_hypertrophy hypertrophy heart_failure
H-1787	-0.5304793119430542	▁cardiac ▁insulin - re si stance ▁mito cho ndri al _ ▁oxid ative ▁metabolism ▁cardiac _ ▁hyper trop hy ▁energie _ ▁deficit ▁hyper trop hy ▁heart _ ▁failure
D-1787	-0.5304793119430542	cardiac insulin-resistance mitochondrial_ oxidative metabolism cardiac_ hypertrophy energie_ deficit hypertrophy heart_ failure
P-1787	-0.2231 -0.7428 -0.0243 -0.0447 -0.6400 -0.0001 -0.1195 -0.9406 -0.1497 -0.0589 -0.6750 -1.1411 -0.2343 -0.2473 -0.3850 -1.5332 -0.3801 -0.0059 -0.0304 -2.3054 -2.2854 -0.2068 -0.0579 -0.0225 -0.0624 -0.6384 -0.7363 -1.7690 -0.1536 -0.1008
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad rgk rem rem2 rad monomeric_g_proteins ventricular_action_potential gain cardiac l-type_channel activity
H-1672	-1.9429774284362793	▁rad ▁rem ▁rem ▁rem 2 ▁rad ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem ▁rem _ g _ g ▁protein s ▁vent ri cular _ action ▁EC ▁coup ling ▁cardiac _ l - type _ active
D-1672	-1.9429774284362793	rad rem rem rem2 rad rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem rem_g_g proteins ventricular_action EC coupling cardiac_l-type_active
P-1672	-0.5815 -0.7646 -0.0169 -0.6899 -0.3740 -0.1194 -2.7970 -0.9115 -1.2009 -1.4710 -1.6415 -1.7249 -1.7536 -1.7490 -1.7297 -1.7000 -1.6702 -1.6319 -1.5947 -1.5654 -1.5404 -1.5202 -1.5023 -1.4897 -1.4802 -1.4745 -1.4743 -1.4766 -1.4809 -1.4868 -1.4958 -1.5057 -1.5173 -1.5327 -1.5465 -1.5628 -1.5760 -1.5939 -1.6097 -1.6293 -1.6461 -1.6643 -1.6792 -1.7004 -1.7180 -1.7368 -1.7558 -1.7731 -1.7932 -1.8094 -1.8275 -1.8450 -1.8644 -1.8820 -1.9006 -1.9191 -1.9382 -1.9570 -1.9755 -1.9937 -2.0115 -2.0317 -2.0491 -2.0697 -2.0892 -2.1092 -2.1263 -2.1472 -2.1677 -2.1881 -2.2072 -2.2266 -2.2464 -2.2672 -2.2848 -2.3074 -2.3268 -2.3474 -2.3671 -2.3867 -2.4063 -2.4215 -2.4427 -2.4610 -2.4818 -2.5017 -2.5182 -2.5403 -2.5581 -2.5744 -2.5958 -2.6126 -2.6331 -2.6490 -2.6671 -2.6854 -2.7010 -2.7164 -2.7376 -2.7502 -2.7688 -2.7837 -2.7981 -2.8134 -2.8278 -2.8444 -2.8603 -2.8723 -2.8890 -2.9010 -2.9148 -2.9280 -2.9415 -2.9561 -2.9679 -2.9789 -2.9930 -3.0026 -3.0164 -3.5639 -2.6863 -3.9200 -1.9710 -0.0894 -1.2491 -0.1470 -0.8610 -0.8380 -1.2186 -2.1568 -0.3118 -0.7900 -1.4698 -1.2657 -3.8837 -0.1447 -0.0455 -0.3461 -3.3216 -0.1333 -0.3141
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular dilatation
H-338	-0.7277494668960571	▁implant ular _ ▁size _ re duction ▁surgery ▁dia sto lic _ met ral _ ▁val ve _ ▁te ther ing ▁anterior ▁le a flet _ ▁opening ▁papil lar y _ ▁muscle s ▁left ▁vent ri cular LV
D-338	-0.7277494668960571	implantular_ size_reduction surgery diastolic_metral_ valve_ tethering anterior leaflet_ opening papillary_ muscles left ventricularLV
P-338	-1.0125 -0.0428 -2.1493 -1.8066 -0.8406 -0.7827 -0.0041 -0.1431 -0.0155 -0.2401 -2.2825 -0.4108 -2.2465 -0.0118 -0.8056 -2.8138 -0.2934 -1.1082 -1.4687 -0.0101 -0.0543 -0.7507 -0.4782 -0.0587 -0.0044 -2.1407 -0.2894 -1.1246 -0.2202 -0.2988 -1.3614 -0.9330 -0.0151 -0.2559 -0.6909 -0.2411 -0.0418 -0.4551 -1.0750 -0.1319
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology heart_failure_with_preserved_ejection_fraction hfpef myocardial_extracellular_matrix
H-734	-0.5787809491157532	▁pat ho phy si ology ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction ▁h f f ▁my o card ial _ ▁extra cel lular _ ▁matri x ▁accumula tion
D-734	-0.5787809491157532	pathophysiology heart_ failure preserved ejection_fraction hff myocardial_ extracellular_ matrix accumulation
P-734	-1.6446 -0.3049 -0.0089 -0.6095 -0.7781 -1.0514 -0.7145 -0.6335 -1.3680 -0.0306 -0.5729 -1.4816 -0.4833 -0.0488 -0.4538 -0.0050 -0.0826 -0.0876 -0.1037 -1.3951 -0.1126 -0.1616 -0.1485 -0.2892 -0.5203 -0.9993 -0.0628 -0.6699 -2.7730 -0.0638 -1.4861 -0.0493 -0.3881 -0.0954
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing cardiac_arrest advantage pulseless_ventricular_fibrillation pvf implanted cardioverter-defibrillator_device
H-1346	-0.6324732303619385	▁breath ing _ control ▁cardiac _ ▁arrest ▁puls e less ▁vent ri cular _ ▁fi bril lation PV f ▁implant ed ▁cardio ver ter - de _ fi br illa tor
D-1346	-0.6324732303619385	breathing_control cardiac_ arrest pulseless ventricular_ fibrillationPVf implanted cardioverter-de_fibrillator
P-1346	-0.6434 -0.2749 -0.6522 -0.0090 -0.0839 -1.4024 -0.1055 -0.4224 -0.1528 -0.2140 -0.7966 -0.2349 -0.1014 -0.1460 -4.4716 -0.0850 -0.0293 -0.8486 -0.0623 -0.0046 -0.4647 -0.8375 -0.1053 -0.0300 -0.1436 -0.0098 -3.1748 -2.5846 -0.5346 -0.0057 -0.1951 -1.9389 -0.1062
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal_probnp nt-probnp midregional_proanp mr-proanp adiponectin elevated chf correlated bmi
H-14	-0.7151432633399963	▁n - termin al ▁pro b NP NT - pro b NP ▁mid region al ▁pro AN p MR - pro AN p ▁adi pon ect in ▁CHF ▁b mi ▁FM
D-14	-0.7151432633399963	n-terminal probNPNT-probNP midregional proANpMR-proANp adiponectin CHF bmi FM
P-14	-3.2964 -0.0328 -0.0774 -0.0060 -0.7363 -1.3830 -0.2356 -1.7102 -0.0028 -0.0145 -0.8332 -0.3090 -1.2305 -0.1189 -0.1009 -0.5297 -4.3604 -0.4795 -0.6694 -0.0082 -0.0030 -3.0485 -0.4136 -0.2328 -0.0390 -0.0193 -0.7454 -0.2998 -0.1421 -1.3607 -0.8279 -0.2455 -0.0873
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase_inhibitor pyridostigmine sympathovagal_balance cardiac_remodeling cardiac_function hf myocardial_infarction
H-1136	-0.5592045783996582	▁a ce tyl cho line ster ase ▁inhibi tor _ ▁py rido stig mine ▁sympa t hova gal _ ▁balance ▁cardiac _ ▁remodel ing ▁cardiac ▁ HF ▁my o card ial _ ▁in far ction
D-1136	-0.5592045783996582	acetylcholinesterase inhibitor_ pyridostigmine sympathovagal_ balance cardiac_ remodeling cardiac HF myocardial_ infarction
P-1136	-0.0771 -0.0852 -0.2199 -2.0502 -0.1624 -0.3618 -1.0023 -0.4148 -0.0442 -0.3008 -1.5057 -0.0267 -0.0005 -0.2228 -0.2490 -0.0630 -0.4833 -0.1307 -0.9377 -0.2812 -0.0036 -1.8090 -0.0878 -0.0525 -0.3019 -3.0503 -0.0480 -1.6421 -0.4948 -0.4412 -0.6456 -0.5841 -0.7554 -1.6160 -0.2287 -0.2252 -0.0850
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac_sympathetic_activity β-blocker
H-1112	-0.5579015612602234	▁cardiac _ ▁sympa the tic ▁activity ▁i - meta - i odob enz yl guan i dine ▁i - m BG ▁β - block er
D-1112	-0.5579015612602234	cardiac_ sympathetic activity i-meta-iodobenzylguanidine i-mBG β-blocker
P-1112	-0.7397 -0.6628 -2.2770 -0.6082 -1.8963 -0.7665 -0.2610 -0.2757 -0.1643 -0.0207 -0.3032 -0.0972 -0.1530 -1.8541 -0.0148 -0.2544 -0.0046 -0.0746 -0.9952 -1.2545 -1.2682 -0.3278 -0.0208 -0.2568 -0.1186 -0.2515 -0.1419
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based heart_disease therapies patients cabg sweden
H-971	-0.771170973777771	▁Swedish web - system ▁e viden ce - based _ care ▁Heart _ ▁disease ▁Reco mmende d ▁Therapie s ▁ca BG ▁Sweden
D-971	-0.771170973777771	Swedishweb-system evidence-based_care Heart_ disease Recommended Therapies caBG Sweden
P-971	-0.1422 -2.1558 -0.0279 -0.0558 -3.9042 -0.1937 -0.0952 -0.0158 -0.0077 -0.8755 -1.6488 -0.6291 -1.4196 -1.1489 -1.1863 -0.0028 -0.2336 -0.8731 -0.0161 -2.3289 -0.2277 -1.0341 -0.2047 -0.0805
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef clinical reverse_remodeling death hf hospitalization hazard_ratio
H-756	-0.6722714304924011	▁LV EF ▁rever se ▁remodel ing ▁temps ▁ HF
D-756	-0.6722714304924011	LVEF reverse remodeling temps HF
P-756	-0.0190 -0.5975 -0.5362 -0.0020 -0.7851 -0.1115 -2.6325 -1.1481 -0.3530 -1.1001 -0.1101
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients brain_natriuretic_peptide bnp bnp patients bnp bnp
H-1569	-0.7395015954971313	▁brain _ ▁na tri ure tic _ pe pti de ▁b NP ▁b NP ▁b NP
D-1569	-0.7395015954971313	brain_ natriuretic_peptide bNP bNP bNP
P-1569	-0.7116 -0.5730 -0.3013 -0.0611 -0.0370 -4.9852 -0.4135 -0.3080 -0.3768 -0.6550 -0.1126 -0.5469 -0.1653 -0.9152 -0.6751 -1.0345 -1.3378 -0.1009
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde pde2 cgmp leading camp_hydrolysis cross_talk cgmp camp_signaling
H-1210	-0.747565507888794	▁p de _ ▁super family ▁p de 2 ▁c g mp ▁c AMP _ hydro lys is ▁negative ▁cross _ talk ▁c g mp ▁c AMP ▁signal ing
D-1210	-0.747565507888794	pde_ superfamily pde2 cgmp cAMP_hydrolysis negative cross_talk cgmp cAMP signaling
P-1210	-0.1861 -0.0220 -1.5810 -0.5699 -0.0426 -0.2421 -0.0263 -0.0900 -0.0378 -2.0326 -1.3334 -0.1458 -3.3881 -1.3640 -0.3344 -0.0789 -0.0929 -1.1096 -2.0544 -1.0236 -1.1524 -0.0084 -1.5288 -1.4553 -0.0503 -0.8366 -1.1170 -0.2502 -0.1729 -0.0997
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse longitudinal_rv_fiber_shortening pasp rv in_vivo rv prognosis
H-493	-0.8574123382568359	▁T AP se long itud in al ▁ RV _ ▁fiber _ ▁short en ing ▁PAS p force ▁ RV ▁in ▁vivo ▁ RV _ ▁length - force
D-493	-0.8574123382568359	TAPselongitudinal RV_ fiber_ shortening PASpforce RV in vivo RV_ length-force
P-493	-4.5529 -0.2824 -0.3209 -0.2100 -0.7021 -0.8104 -0.6067 -1.1093 -0.4411 -1.7851 -0.7702 -0.9449 -0.7382 -0.0602 -0.3615 -0.8574 -0.6321 -1.2978 -0.7663 -0.3189 -1.0651 -0.5092 -0.2176 -0.2774 -3.5389 -1.2873 -0.1108 -0.3249 -0.6916 -0.1312
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides szeto-schiller ss ss20 cardiac_function proteomic_remodeling signaling_pathways
H-870	-0.7553550004959106	▁mito cho ndri al - tar get ed ▁antioxidant ▁protection ive _ pe pti des ▁Sze to - Sch iller ▁SS ▁cardiac ▁fonction ▁prote om ic ▁remodel ing
D-870	-0.7553550004959106	mitochondrial-targeted antioxidant protectionive_peptides Szeto-Schiller SS cardiac fonction proteomic remodeling
P-870	-0.9878 -1.2599 -0.3506 -0.0814 -0.1025 -0.0332 -0.2242 -0.0563 -0.0844 -2.9858 -1.1305 -2.3748 -0.4257 -0.0977 -0.0617 -0.0207 -0.0342 -0.0043 -0.5604 -0.0236 -2.4390 -2.3620 -3.9083 -0.2894 -0.2111 -1.1435 -0.4125 -0.0536 -0.8823 -0.0593
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2017	-1.262461543083191	▁économique _ ▁Analys is ▁Patient _ management _ ▁Interven tions ▁Heart _ ▁Fail ure ▁Cost - E ff ective ness _ ▁Model ▁coût - effect ive ness ▁disease ▁management _ ▁programs _ ▁in _ heart _ ▁failure
D-2017	-1.262461543083191	économique_ Analysis Patient_management_ Interventions Heart_ Failure Cost-Effectiveness_ Model coût-effectiveness disease management_ programs_ in_heart_ failure
P-2017	-0.6666 -4.4685 -1.2851 -0.0462 -1.6734 -1.6713 -1.2525 -1.2489 -1.0934 -0.0181 -0.9118 -0.6296 -0.1912 -0.0642 -0.6785 -0.0515 -3.3006 -2.4368 -0.0287 -0.8607 -2.7316 -1.1496 -4.9631 -0.0993 -0.2259 -0.0692 -3.2422 -1.6178 -0.7277 -2.5331 -2.3180 -1.5502 -0.9483 -0.8178 -1.4761 -0.8072 -1.1084 -0.1397 -0.1334
2021-01-18 18:21:29 | INFO | fairseq.logging.progress_bar | :    101 / 145 wps=194
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization admissions patient
H-900	-0.3083459138870239	▁re - hospital ization ▁ad missions
D-900	-0.3083459138870239	re-hospitalization admissions
P-900	-0.0797 -0.1649 -0.0238 -0.9178 -0.1129 -0.0183 -1.0401 -0.1092
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes coprimary_end_points end_point change serum_cystatin_c renal_function end_point
H-79	-0.8062888979911804	▁co prima ry _ ▁end ▁points ▁cum ul ative _ ▁urin e _ ▁volume ▁dé con gestion ▁se rum _ ▁cyst atin ▁c ren al _ fon ction _ ▁end ▁point
D-79	-0.8062888979911804	coprimary_ end points cumulative_ urine_ volume décongestion serum_ cystatin crenal_fonction_ end point
P-79	-0.2012 -0.0021 -0.3176 -1.2957 -0.7896 -0.4856 -0.9860 -0.0213 -0.1590 -0.7957 -0.5570 -0.3146 -2.6444 -0.6263 -3.2772 -0.0075 -0.0044 -1.1046 -0.3325 -1.2640 -0.1687 -0.6800 -1.2877 -4.0593 -0.0864 -0.3513 -1.0890 -0.3685 -2.1113 -0.3705 -0.3700 -0.3651 -0.1133
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical cardiac_arrest cardiopulmonary_resuscitation cpr diagnosis posterior_wall_infarction hospitalized cardiac
H-1291	-0.9023953080177307	▁cardiac _ ▁arrest ▁cardio pul mon ary _ ▁res uscita tion ▁c PR ▁posterior _ ▁wall _ ▁in far ction ▁cardiac
D-1291	-0.9023953080177307	cardiac_ arrest cardiopulmonary_ resuscitation cPR posterior_ wall_ infarction cardiac
P-1291	-3.3126 -1.1011 -0.1724 -0.0296 -0.0651 -3.7558 -1.0337 -0.3001 -1.8403 -0.0069 -0.0896 -0.1586 -0.2189 -0.1786 -0.5289 -3.3225 -0.2719 -0.9048 -0.9475 -0.0528 -0.0869 -2.2620 -0.1146
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients patients type_2_diabetes therapy saxagliptin sitagliptin pioglitazone second-generation_sulfonylureas insulin
H-1831	-0.36644622683525085	▁diabetes ▁sax ag lip tin ▁si tag lip tin ▁pi og lita zone ▁sul fon yl ure as ▁insulin
D-1831	-0.36644622683525085	diabetes saxagliptin sitagliptin pioglitazone sulfonylureas insulin
P-1831	-1.3562 -0.2710 -0.0686 -0.2434 -0.9583 -0.1001 -0.0001 -0.0766 -1.0400 -0.0040 -0.4777 -0.0394 -0.0411 -1.0805 -0.0049 -0.5711 -0.0624 -0.1173 -0.5169 -0.5537 -0.1121
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence hyperkalemia mineralocorticoid_receptor_antagonists mineralocorticoid_receptor_antagonists heart_failure hf
H-1702	-0.9215077757835388	▁hyper kal emia ▁mineral o cor tico id _ ▁receptor _ ▁anta gon ists ▁race ▁mineral o cor tico id _ ▁receptor _ ▁anta gon ists ▁heart _ ▁failure HF
D-1702	-0.9215077757835388	hyperkalemia mineralocorticoid_ receptor_ antagonists race mineralocorticoid_ receptor_ antagonists heart_ failureHF
P-1702	-0.1418 -1.0010 -0.8463 -0.6561 -0.2136 -0.2285 -3.3825 -1.4191 -1.8411 -0.0410 -1.1808 -0.6225 -0.0764 -0.7670 -1.8633 -1.4134 -0.3048 -0.3101 -3.2184 -1.3397 -1.2134 -0.0967 -1.2350 -0.8684 -0.1048 -1.2646 -1.1336 -0.5046 -1.3398 -0.6374 -0.1185 -0.1040
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade evidence acp erythropoiesis-stimulating_agents patients anemia congestive_heart_failure coronary_heart_disease
H-37	-1.0843896865844727	▁a CP ▁er y thro po ies is - stimul ation ▁agents ▁an emia ▁con ges tive _ ▁heart _ ▁failure ▁corona ry _ ▁heart _ ▁disease
D-37	-1.0843896865844727	aCP erythropoiesis-stimulation agents anemia congestive_ heart_ failure coronary_ heart_ disease
P-37	-1.2563 -1.3386 -3.8154 -0.1609 -1.5434 -1.7687 -2.2496 -0.5173 -0.3175 -0.1144 -1.5255 -0.6237 -0.7803 -0.0772 -0.1980 -0.1001 -0.1788 -1.6107 -1.2892 -1.0013 -1.0243 -0.0201 -0.5468 -0.6374 -2.4994 -2.1733 -3.6631 -0.2868 -0.1292
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory patients heart_failure hf reduced_ejection_fraction renin-angiotensin_system ras β-blockers all-cause_mortality readmissions
H-175	-0.6690938472747803	▁heart _ ▁failure HF ▁e je ction _ fraction r EF ▁re nin - angi oten sin _ system RAS ▁β - block ers
D-175	-0.6690938472747803	heart_ failureHF ejection_fractionrEF renin-angiotensin_systemRAS β-blockers
P-175	-3.0107 -0.5383 -1.2257 -0.6388 -0.6907 -0.5969 -0.0649 -0.5778 -0.0025 -0.2472 -0.1498 -0.0051 -1.6045 -0.0392 -0.0824 -0.0325 -2.0030 -2.5835 -0.4062 -0.9005 -0.1960 -0.0055 -0.0642 -0.0792 -1.5197 -0.1316
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr scn5a ventricular_systolic_hf human_induced_pluripotent_stem_cell-derived_cardiomyocytes hipsc-cms
H-1082	-0.6088403463363647	▁u PR ▁s cc 5 a ▁vent ri cular _ ▁sy sto lic ▁ HF ▁implant ed ▁pluri potent ▁stem _ cell - der i ved _ ▁cardio my o cy tes hi PS c - CM s
D-1082	-0.6088403463363647	uPR scc5a ventricular_ systolic HF implanted pluripotent stem_cell-derived_ cardiomyocyteshiPSc-CMs
P-1082	-0.0897 -0.5545 -1.2832 -1.6203 -0.3434 -0.0821 -0.0298 -0.1705 -0.1016 -0.6651 -2.9960 -0.1488 -1.3888 -1.5212 -0.2453 -3.0408 -0.3058 -0.4358 -0.0029 -0.7834 -0.8687 -0.3586 -0.5034 -0.1118 -0.0798 -0.3974 -1.0697 -0.1607 -1.4562 -0.6513 -0.1179 -0.3453 -1.0169 -0.8019 -0.1122 -0.0294 -0.1466 -0.0154 -0.2210 -0.0800
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd chf crf icc kappa_coefficients
H-802	-0.6689348220825195	▁co PD ▁CHF ▁c RF ▁ICC ▁ka ppa ▁co ef fici ents
D-802	-0.6689348220825195	coPD CHF cRF ICC kappa coefficients
P-802	-1.9268 -1.4558 -0.1142 -0.5705 -0.9034 -0.8761 -0.8583 -0.2103 -1.7728 -0.0232 -0.0214 -0.2598 -0.2715 -0.1009
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient implantable_cardioverter-defibrillator implant change clinical
H-1865	-0.8637831807136536	▁implant able ▁implant able ▁implant able ▁cardio ver ter - de _ fi br illa tor ▁implant ▁end - of - life
D-1865	-0.8637831807136536	implantable implantable implantable cardioverter-de_fibrillator implant end-of-life
P-1865	-0.0013 -0.0882 -1.2726 -0.1408 -2.5812 -0.4452 -1.8253 -0.1307 -0.0250 -0.1349 -0.0043 -3.7043 -4.3225 -0.9093 -0.0045 -0.1924 -0.2171 -3.4915 -0.0384 -0.0794 -0.0777 -0.2614 -0.6493 -0.1334
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients stable_heart_failure left_ventricular_ejection_fraction training training
H-1913	-1.3493144512176514	▁heart _ ▁failure ▁left ▁vent ri cular _ ▁e je ction _ fraction
D-1913	-1.3493144512176514	heart_ failure left ventricular_ ejection_fraction
P-1913	-3.0338 -1.4548 -1.0922 -0.2113 -1.2963 -0.6370 -0.5349 -0.8753 -1.9358 -0.9486 -0.1165 -2.4650 -0.0168 -5.4922 -0.1293
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients heart_failure myocardial_function dilated contracting ventricles aetiologies
H-987	-0.9588271975517273	▁heart _ ▁failure ▁my o card ial _ f ré que nce ▁children ▁dil ated ▁vent ric les
D-987	-0.9588271975517273	heart_ failure myocardial_fréquence children dilated ventricles
P-987	-1.6111 -0.7975 -0.8704 -3.4652 -0.1953 -0.3800 -0.3928 -0.9874 -3.2322 -0.0414 -0.0527 -0.0527 -2.3108 -1.1084 -0.2342 -0.7003 -2.3156 -0.1370 -0.1856 -0.1060
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial cochrane_effective_practice_and_organisation_of_care_taxonomy
H-1847	-0.42166632413864136	▁co ch rane _ ▁Effective _ ▁Practic e ▁Care _ ▁Tax ono my
D-1847	-0.42166632413864136	cochrane_ Effective_ Practice Care_ Taxonomy
P-1847	-1.1590 -0.3790 -0.0659 -0.7608 -0.7033 -0.3302 -0.2158 -0.0111 -0.6077 -0.5491 -0.6690 -0.0266 -0.5818 -0.1838 -0.0820
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad q65p murine rad q66p l-type_currents cav1.2 cav1.3 wild-type_rad
H-1675	-1.6110478639602661	▁mouse _ rad _ q 65 p ▁mur ine _ ▁equivalent _ of _ ▁human ▁rad ▁Q 66 p ▁l - type _ ▁current s ▁ca V
D-1675	-1.6110478639602661	mouse_rad_q65p murine_ equivalent_of_ human rad Q66p l-type_ currents caV
P-1675	-0.1612 -3.1413 -1.6985 -2.9980 -1.6134 -0.2024 -0.2944 -0.1233 -0.8344 -4.3563 -0.8695 -2.5644 -3.0452 -1.1624 -3.4492 -1.3772 -2.4279 -0.2441 -0.2740 -4.3847 -0.1736 -0.0434 -0.5258 -3.0417 -0.2012 -1.3373 -1.5553 -4.5236 -0.0969
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients implantable_cardioverter-defibrillator patients implantable_cardioverter-defibrillator
H-1866	-1.0492496490478516	▁implant able ▁implant able ▁cardio ver ter - de _ f illa tor _ de _ activa tion ▁implant able _ ▁cardio ver ter - de _ f illa tor _ ▁shock s
D-1866	-1.0492496490478516	implantable implantable cardioverter-de_fillator_de_activation implantable_ cardioverter-de_fillator_ shocks
P-1866	-0.0003 -0.0787 -1.0877 -0.1230 -2.8093 -0.2697 -0.0460 -0.1747 -0.0101 -3.4647 -3.0885 -4.6630 -0.4911 -0.3652 -0.0227 -1.8426 -0.1168 -0.1201 -0.3918 -0.2380 -1.0566 -2.9838 -0.4181 -0.0506 -0.1570 -0.0116 -2.6879 -2.8204 -3.4839 -0.3336 -0.9605 -1.8074 -0.1355 -0.2746 -0.1383
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart_failure hf hypertensive_heart_disease hhd pathophysiology therapeutic hhd stable phenotypes
H-274	-0.8913798928260803	▁mouse _ ▁heart _ ▁failure HF ▁hyper tensi ve _ ▁heart _ ▁disease ▁h d h ▁ therapeut ic ▁h d
D-274	-0.8913798928260803	mouse_ heart_ failureHF hypertensive_ heart_ disease hdh therapeutic hd
P-274	-0.0688 -0.6871 -1.4088 -0.4652 -0.4203 -0.5877 -0.4350 -0.4959 -0.6129 -0.1938 -2.3811 -0.6108 -2.1801 -0.2156 -1.3501 -2.4585 -2.6496 -0.2545 -0.6455 -0.7221 -0.6582 -0.9193 -0.0806
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient mi hazard_ratios hf
H-1108	-1.6044154167175293	▁MI ▁h f
D-1108	-1.6044154167175293	MI hf
P-1108	-1.5918 -4.6869 -1.2226 -0.3215 -0.1993
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare patients acute hospital hf ami pna
H-1693	-0.7796176671981812	▁Medica re ▁patients ▁a cute _ care ▁hospital ▁ HF ▁ AMI ▁p na
D-1693	-0.7796176671981812	Medicare patients acute_care hospital HF AMI pna
P-1693	-1.0277 -0.0100 -2.3758 -0.6734 -0.1438 -0.2594 -2.0585 -0.5067 -1.4601 -0.7107 -1.3145 -0.5342 -0.3602 -0.6895 -0.2345 -0.1149
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt nt-probnp aric hf aucs nris
H-289	-0.8507515788078308	▁c t n t ▁NT - pro b NP ▁a RIC _ f f ▁model ▁au c s ▁continuo us ▁NR Is
D-289	-0.8507515788078308	ctnt NT-probNP aRIC_ff model aucs continuous NRIs
P-289	-0.0627 -0.0912 -0.1395 -0.1413 -0.3923 -0.0046 -0.0072 -0.3661 -0.2340 -0.0653 -3.7359 -0.9160 -1.2878 -2.6113 -2.5037 -2.1271 -0.2391 -0.8179 -0.5365 -0.0193 -1.8204 -1.3769 -0.8199 -0.1020
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular_events baseline sst2 metoprolol_succinate
H-404	-1.5064159631729126	▁Card _ vas cular _ ▁events ▁s st 2 ▁m l ▁ml ▁met o pro lol _ ▁suc cina te
D-404	-1.5064159631729126	Card_vascular_ events sst2 ml ml metoprolol_ succinate
P-404	-0.9996 -5.9439 -1.3445 -0.6661 -2.7494 -1.4742 -0.0763 -2.0359 -0.1169 -5.7680 -2.3190 -3.9903 -2.6696 -0.1921 -0.0495 -0.5781 -1.4397 -0.1767 -0.0353 -0.2006 -0.2484 -0.0671
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl nyha-iiib phosphorylation phosphorylation hdl healthy
H-255	-0.8771998286247253	▁in cuba tion _ de _ ▁EC ▁HD l ▁NY ha - III b ▁ phos phor y lation ▁e NOS - Ser ▁ phos phor y lation ▁e NOS - Th r ▁HD L
D-255	-0.8771998286247253	incubation_de_ EC HDl NYha-IIIb phosphorylation eNOS-Ser phosphorylation eNOS-Thr HDL
P-255	-1.4798 -0.0009 -0.0048 -1.9291 -1.8450 -0.7666 -1.9335 -2.9579 -2.0358 -3.2586 -1.1044 -0.3876 -0.0638 -0.0152 -0.3463 -1.0630 -0.5961 -2.0373 -0.0543 -0.1105 -0.0322 -0.0440 -0.7920 -0.2072 -0.9384 -0.5854 -1.3361 -0.0559 -0.8034 -0.0949 -0.2087 -1.1133 -0.0058 -1.3610 -1.9664 -0.7609 -0.1603
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients hospitalized hf preserved_lvef mortality patients lvef lvef mortality
H-117	-0.7228254675865173	▁ HF ▁LV EF ▁long - term _ ▁mortal ity ▁LV EF
D-117	-0.7228254675865173	HF LVEF long-term_ mortality LVEF
P-117	-1.9807 -0.1940 -0.5799 -0.3855 -1.8651 -0.0672 -1.3765 -0.3523 -0.3178 -0.3784 -0.6634 -0.1801 -1.6903 -0.0884
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic_reticular protein phospholamban infarcted hearts metoprolol
H-1551	-0.6077477931976318	▁sar co plas mic _ ▁reti cular SR ▁ca (2 +) - up take ▁protein ▁rs ▁ca (2 +) - pump ▁ phos pho lam ban ▁in far cted _ ▁heart s ▁met o pro lol
D-1551	-0.6077477931976318	sarcoplasmic_ reticularSR ca(2+)-uptake protein rs ca(2+)-pump phospholamban infarcted_ hearts metoprolol
P-1551	-0.0490 -0.0906 -0.1810 -3.2034 -0.1557 -0.2388 -0.4738 -0.7082 -1.9174 -0.4646 -0.0026 -0.0217 -0.0694 -0.1719 -0.9023 -4.1876 -1.9308 -0.3581 -0.0015 -0.0065 -0.0095 -0.1481 -0.1099 -0.2701 -0.7742 -0.0637 -0.0190 -1.1050 -1.8452 -1.5084 -1.3024 -0.0463 -0.2703 -0.0272 -0.0140 -0.2420 -0.1265 -0.0778
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global_left_ventricular_longitudinal_systolic_strain gls left_ventricular cardiovascular atrial_fibrillation
H-809	-0.7060260772705078	▁vent ri cular _ ▁longitud in al _ syn chron e _ ▁strain ▁gr LS ▁left ▁vent ri cular _ ▁mechanic s ▁cardiovascular CV ▁at rial _ ▁fi bril lation AF
D-809	-0.7060260772705078	ventricular_ longitudinal_synchrone_ strain grLS left ventricular_ mechanics cardiovascularCV atrial_ fibrillationAF
P-809	-3.3521 -0.2656 -0.1921 -0.6619 -0.7356 -0.1075 -0.0718 -0.1506 -1.4108 -0.2383 -1.7875 -0.5728 -0.8085 -0.2954 -2.4228 -0.9845 -0.7765 -0.1761 -0.2110 -0.3152 -1.3333 -0.0251 -0.1364 -0.7250 -0.8340 -0.0404 -0.2975 -3.9089 -0.0167 -0.0192 -0.1767 -0.1323 -0.1167
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf hf_with_reduced_ef hf_with_preserved_ef change hf mi
H-1109	-0.9447721242904663	▁early - ons et ▁ HF ▁ HF ▁EF ▁ HF ▁ HF ▁MI
D-1109	-0.9447721242904663	early-onset HF HF EF HF HF MI
P-1109	-4.4025 -0.0566 -0.2117 -0.1957 -1.0090 -0.3957 -1.8551 -0.2482 -0.8338 -0.5303 -0.3105 -1.8185 -0.4767 -2.1793 -0.4937 -0.0991
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol von_willebrand_factor metoprolol β2-adrenergic_receptor_haplotype
H-1118	-0.5827304720878601	▁car vedi lol ▁Will e brand _ ▁factor ▁met o pro lol ▁β 2- ad r energi c ▁receptor _ ha plo type
D-1118	-0.5827304720878601	carvedilol Willebrand_ factor metoprolol β2-adrenergic receptor_haplotype
P-1118	-3.3593 -0.4730 -0.6922 -0.2910 -0.1387 -0.0800 -3.1974 -0.8159 -0.1349 -0.1432 -0.0330 -0.4932 -0.4606 -0.6433 -0.1801 -0.0796 -0.3123 -0.0772 -0.4710 -1.1127 -0.8236 -0.1093 -0.0968 -0.2490 -0.1009
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise intramuscular_testosterone_supplementation patients chronic_heart_failure chf testosterone collected health outcomes
H-1317	-1.5607657432556152	▁in mus cular ▁testosteron e _ ▁supplement ation ▁cardiac _ ▁failure ▁ch f ▁testosteron e
D-1317	-1.5607657432556152	inmuscular testosterone_ supplementation cardiac_ failure chf testosterone
P-1317	-7.2274 -2.4265 -0.3699 -0.7283 -0.0430 -4.6401 -0.3770 -0.0151 -5.1372 -1.7115 -0.4587 -2.1564 -0.0359 -0.5971 -0.0711 -0.4426 -0.0952
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart_failure hf plasma_b-type_natriuretic_peptide bnp preserved_ejection_fraction ef hf
H-187	-0.7659933567047119	▁heart _ ▁failure ▁ HF ▁plasma ▁b - type _ na tri ure tic _ pe pti de ▁b NP ▁e je ction _ fraction ▁ef ▁ HF ▁sex
D-187	-0.7659933567047119	heart_ failure HF plasma b-type_natriuretic_peptide bNP ejection_fraction ef HF sex
P-187	-0.5127 -0.6815 -1.6713 -2.1646 -0.0359 -1.0521 -0.3596 -0.5559 -0.0277 -0.3230 -1.7516 -0.0364 -0.0947 -3.6807 -0.5633 -0.2872 -0.2190 -0.3344 -0.1589 -0.7894 -0.3995 -0.7014 -0.0543 -0.4645 -0.0083 -3.3168 -0.8619 -0.4610 -1.3840 -0.7003 -0.0936
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls left_ventricular_ejection_fraction lvef systolic_mitral_annulus_velocity multivariate_models
H-818	-0.8798596858978271	▁gr LS ▁vent ri cular _ ▁e je ction _ fraction LV EF ▁sy sto lic _ met ral _ ▁ann ulus _ ▁veloci ty ▁CV
D-818	-0.8798596858978271	grLS ventricular_ ejection_fractionLVEF systolic_metral_ annulus_ velocity CV
P-818	-0.3529 -2.0430 -2.3614 -0.4079 -0.3310 -0.4929 -2.0529 -0.9798 -0.2712 -0.4828 -0.0102 -0.3409 -0.3105 -0.1137 -0.1810 -1.9526 -0.2870 -2.1923 -0.0520 -0.3102 -1.1709 -0.5421 -0.8785 -2.8971 -0.5115 -1.9493 -1.0111 -0.1495
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm telemonitoring implanted medical structured_telephone_support sts human-to-human_contact hh human-to-machine_interface
H-153	-1.3904615640640259	▁RM ▁implant ed _ monitor ing ▁implant ed _ ▁implant ed _ monitor ing _ ▁devices ▁medical ▁support ▁st s ▁contact ▁h m
D-153	-1.3904615640640259	RM implanted_monitoring implanted_ implanted_monitoring_ devices medical support sts contact hm
P-153	-0.2495 -1.3018 -0.4161 -1.4613 -0.9734 -0.1542 -0.4213 -0.4538 -0.8697 -4.9898 -0.4459 -0.8095 -2.1333 -1.5265 -3.3164 -1.1392 -3.0357 -2.8390 -4.9743 -0.1850 -0.4037 -0.1558 -1.7245 -0.7101 -0.0718
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug patients chronic_obstructive_pulmonary_disease copd chronic_heart_failure chf chronic_renal_failure crf
H-794	-1.0772634744644165	▁Time d _ up _ go ▁tu g ▁chronic _ ▁ob struct ive _ ▁pulmonar y ▁disease co PD ▁chronic _ ▁heart _ ▁failure ▁ch f ▁chronic _ ▁renal _ ▁failure ▁c f
D-794	-1.0772634744644165	Timed_up_go tug chronic_ obstructive_ pulmonary diseasecoPD chronic_ heart_ failure chf chronic_ renal_ failure cf
P-794	-4.2615 -0.1641 -0.3202 -0.4309 -0.8122 -1.7808 -0.2892 -0.6651 -3.4677 -0.3303 -1.7520 -0.1089 -0.0610 -0.4814 -0.1381 -0.0766 -1.3735 -2.9899 -0.3565 -1.9701 -0.1765 -3.0885 -0.8143 -0.3205 -2.2613 -0.0335 -2.1274 -0.1783 -0.9873 -2.5029 -1.0844 -1.7302 -0.2897 -0.0994 -0.1801
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox_regression_analysis patients beta-blockers beta-blockers primary_endpoint therapy antitachycardia_pacing atp shock_therapy
H-859	-0.5821348428726196	▁temps - dependent ▁co x _ re gression _ analyse ▁beta - block ers ▁beta - block ers ▁in appropria te ▁ therapy ▁anti ta chy car dia _ pa cing ▁a TP ▁shock ▁ therapy
D-859	-0.5821348428726196	temps-dependent cox_regression_analyse beta-blockers beta-blockers inappropriate therapy antitachycardia_pacing aTP shock therapy
P-859	-1.1749 -0.2114 -0.1319 -0.2578 -0.0094 -1.1873 -1.3587 -0.0148 -4.1814 -1.8223 -1.9482 -0.0374 -0.3658 -0.0641 -0.3272 -0.0283 -0.3723 -0.0997 -1.0709 -0.1576 -0.1583 -0.7388 -0.0208 -0.0239 -0.6902 -0.2784 -0.0228 -1.0227 -1.0546 -0.9816 -0.1986 -0.5793 -0.4191 -0.1035 -0.6806 -0.0412 -0.1661 -0.1190
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically legal decisions
H-1680	-0.7950336337089539	▁et h ically _ ▁complex ▁situations ▁pediatr iques ▁families ▁religious _ ▁belief s ▁life - s usta ining
D-1680	-0.7950336337089539	ethically_ complex situations pediatriques families religious_ beliefs life-sustaining
P-1680	-0.2138 -0.1248 -0.8641 -1.9619 -0.7697 -0.6252 -0.2019 -0.6928 -0.8056 -0.2251 -1.3487 -0.4349 -0.0367 -2.4804 -0.0182 -0.4508 -0.2495 -0.4256 -3.8964 -0.0746
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient prescribing medications medical
H-1122	-0.7641531229019165	▁patient _ ▁preference s ▁priorit ies ▁guide line - re com mend ed ▁medication s ▁medical ▁records ▁performance
D-1122	-0.7641531229019165	patient_ preferences priorities guideline-recommended medications medical records performance
P-1122	-4.1874 -1.6529 -0.2736 -0.0156 -0.8041 -1.4318 -1.2270 -0.1352 -0.1550 -0.0255 -0.0643 -0.0349 -0.5146 -0.8467 -0.0242 -1.1728 -1.2613 -0.1524 -1.2046 -0.0993
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost patient rhythm-control rate-control
H-1241	-0.5953284502029419	▁coût ▁ rhythm - control ▁rate - control
D-1241	-0.5953284502029419	coût rhythm-control rate-control
P-1241	-0.8319 -0.3544 -1.5359 -0.1718 -0.0120 -2.0958 -0.1382 -0.0212 -0.5403 -0.2517
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left_ventricular_ejection_fraction egfr
H-393	-1.4317563772201538	▁vent ri cular ▁e je ction _ fraction ▁e g f
D-393	-1.4317563772201538	ventricular ejection_fraction egf
P-393	-4.3012 -0.2711 -0.4048 -1.3002 -2.8277 -0.2261 -0.9801 -0.0132 -2.4157 -2.7703 -1.5271 -1.3061 -0.2693
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells functional_capacity cells peak_vo2
H-127	-1.743545651435852	▁CD 34 _ ve g f 2 _ cell s ▁functional _ pu issa nce ▁CD 34 _ ve g f 2 _ cell s ▁VO 2
D-127	-1.743545651435852	CD34_vegf2_cells functional_puissance CD34_vegf2_cells VO2
P-127	-1.3976 -0.4646 -3.7369 -2.2914 -0.9374 -1.6618 -1.6674 -4.3735 -0.4760 -0.5810 -2.9097 -2.1718 -4.8770 -0.0814 -0.0052 -4.3425 -0.4733 -3.2544 -4.5899 -0.8164 -1.9022 -0.2414 -3.0982 -0.4264 -0.1599 -3.1442 -0.0723 -0.2899 -0.1193
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf hazard_ratios body_mass_index obese
H-1773	-1.365775465965271	▁fit ▁un fit ▁c RF ▁hazard ▁ratio s ▁un fit _ ▁men ▁obes e
D-1773	-1.365775465965271	fit unfit cRF hazard ratios unfit_ men obese
P-1773	-0.2057 -2.7911 -0.1783 -0.0776 -0.5432 -1.0309 -3.4432 -0.0974 -2.1954 -0.1812 -4.4794 -1.5530 -3.1418 -0.3892 -1.4490 -0.0959
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare_patient_safety_monitoring_system mpsms adverse_event patients hospitalized acute_myocardial_infarction congestive_heart_failure pneumonia conditions surgery
H-2	-0.6609506607055664	▁Medica re ▁Patient _ ▁Safety _ monitor ing _ system ▁m SMS ▁advers e _ ▁event _ ▁rates ▁a cute _ mé o card ial _ ▁in far ction ▁con ges tive _ ▁heart _ ▁failure ▁pneu monia ▁conditions ▁surgery
D-2	-0.6609506607055664	Medicare Patient_ Safety_monitoring_system mSMS adverse_ event_ rates acute_méocardial_ infarction congestive_ heart_ failure pneumonia conditions surgery
P-2	-0.0260 -0.0025 -1.1224 -0.2890 -0.1104 -1.0153 -0.8712 -0.0433 -1.2464 -0.4359 -1.3678 -0.2791 -2.6374 -0.0602 -0.8809 -1.0571 -1.9357 -1.8423 -0.5141 -0.0084 -0.1099 -3.1187 -0.4371 -0.1330 -0.2557 -0.6789 -0.3656 -2.1638 -0.0424 -0.1820 -0.0600 -0.0559 -0.5594 -1.1746 -0.7312 -0.2392 -0.0017 -0.2229 -1.0716 -0.1097 -0.1963 -0.1049
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi blood_urea_nitrogen b-type_natriuretic_peptide new_york_heart_association_class diabetes atrial_fibrillation all-cause_hospitalization
H-382	-0.7395161986351013	▁ HF PSI ▁blood _ ▁u rea _ ▁nit rogen ▁b - type _ ▁na tri ure tic _ pe pti de ▁New ▁York _ ▁Heart _ association ▁diabetes ▁at rial _ ▁fi bril lation flu tter
D-382	-0.7395161986351013	HFPSI blood_ urea_ nitrogen b-type_ natriuretic_peptide New York_ Heart_association diabetes atrial_ fibrillationflutter
P-382	-1.4750 -0.6139 -1.3608 -3.1926 -1.5140 -0.3247 -2.5013 -0.3441 -0.1649 -0.0554 -1.0509 -0.0191 -0.0275 -0.5560 -1.1056 -0.0292 -0.0419 -2.6061 -0.7420 -0.4064 -0.1222 -0.1501 -0.6045 -0.8303 -1.1068 -1.0099 -0.5535 -1.1109 -0.3401 -0.1162 -0.0429 -0.2164 -3.1469 -0.0591 -0.0538 -0.5438 -0.0161 -0.5891 -0.0973
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary_outcome patients crt hazard_ratio confidence_interval
H-852	-1.3904300928115845	▁c RT
D-852	-1.3904300928115845	cRT
P-852	-0.3959 -2.2075 -2.8342 -0.1242
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality_rate patients hf hf case-fatality_rate
H-1311	-1.2172608375549316	▁figure - fat ality ▁ HF
D-1311	-1.2172608375549316	figure-fatality HF
P-1311	-4.6603 -1.5622 -0.1378 -0.0717 -1.9977 -0.2374 -0.9733 -0.0978
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients heart_failure_and_reduced_ejection_fraction patient
H-659	-1.152479648590088	▁implant s ▁heart _ ▁failure ▁e je ction _ fraction
D-659	-1.152479648590088	implants heart_ failure ejection_fraction
P-659	-5.1148 -1.1490 -2.5641 -0.7792 -1.0182 -1.3676 -0.3848 -0.0237 -0.6418 -0.0032 -0.6760 -0.1073
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame chf anthracycline stem_cell allogeneic autologous follow-up
H-1453	-1.0835453271865845	▁CHF ▁race _ eth nici ty ▁an thra cycli ne ▁exposure ▁stem _ cell
D-1453	-1.0835453271865845	CHF race_ethnicity anthracycline exposure stem_cell
P-1453	-0.4493 -2.9214 -1.8427 -0.3516 -0.1704 -2.1007 -0.2686 -0.1102 -0.7515 -0.4412 -3.4614 -0.0945 -1.6566 -0.5758 -2.0808 -0.0601
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting_tension fpassive muscle kcl-ki titin titin extracellular_matrix fpassive
H-765	-0.8445256352424622	▁tension _ f pass ive - sar com ere _ long _ ter me ▁muscle _ ▁strip s ▁k c l - KI ▁treatment ▁titi n ▁extra cel lular _ ▁matri x ▁F pass ive
D-765	-0.8445256352424622	tension_fpassive-sarcomere_long_terme muscle_ strips kcl-KI treatment titin extracellular_ matrix Fpassive
P-765	-0.1788 -4.2914 -0.3134 -0.0351 -0.0054 -1.3092 -0.1603 -0.0254 -0.8154 -1.8896 -2.8226 -1.4050 -1.6641 -0.0849 -1.7788 -3.7649 -0.2459 -0.0148 -0.1903 -0.2280 -0.1263 -0.0393 -0.0658 -4.4751 -0.6642 -0.0339 -1.1774 -0.5171 -0.0577 -0.6814 -0.3200 -0.0096 -1.5015 -0.0139 -0.0053 -0.2304 -0.1052
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training exercise_capacity muscle quality_of_life cardiac nt-probnp inflammatory il6 hscrp biomarkers
H-1922	-1.0776422023773193	▁aero bic _ de _ ré que nce _ training ▁avantages ▁exercise _ pu issa nce ▁muscle _ ▁strength ▁cardiac ▁NT - pro b NP ▁infla mma tory ▁i 6 ▁h s CR p
D-1922	-1.0776422023773193	aerobic_de_réquence_training avantages exercise_puissance muscle_ strength cardiac NT-probNP inflammatory i6 hsCRp
P-1922	-0.6877 -0.2711 -2.7863 -2.1599 -0.2455 -1.3804 -1.6376 -0.0813 -2.9337 -0.4583 -4.2894 -1.6225 -1.1834 -2.5991 -0.0581 -0.0081 -0.3868 -1.0882 -1.9809 -0.8118 -4.5701 -0.0194 -0.5623 -0.6660 -0.1697 -0.3058 -0.5049 -1.1190 -1.6227 -0.7732 -0.0034 -0.0198 -1.1584 -0.1759 -0.3489 -0.1054
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital readmission all-cause_readmission acr potential_preventable_readmission ppr medicare medicaid readmission cms
H-135	-0.6979007124900818	▁hospital _ ▁performance ▁read mission ▁a CR ▁Potential _ ▁Prev en table _ ▁Read mission ▁p PR ▁Center s _ de _ ▁Medica re ▁Medica id ▁c m
D-135	-0.6979007124900818	hospital_ performance readmission aCR Potential_ Preventable_ Readmission pPR Centers_de_ Medicare Medicaid cm
P-135	-2.8745 -1.7369 -1.4408 -0.7542 -0.0656 -0.5664 -2.1957 -1.1849 -0.1602 -1.0338 -0.0269 -0.1325 -0.1728 -0.6438 -0.0164 -0.3432 -0.3922 -0.9329 -0.0209 -0.1013 -2.2405 -0.0772 -0.2986 -0.0216 -0.4518 -0.8830 -0.4180 -1.4440 -0.1895 -0.1169
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart_failure myocardial_infarction mi β-adrenoceptor_blockade infarcted metoprolol
H-1547	-0.7800729870796204	▁rever si bility ▁heart _ ▁failure ▁my o card ial _ ▁in far ction ▁m ▁β - ad re no cept or _ block ade ▁in far cted _ ▁rat s ▁met o pro lol
D-1547	-0.7800729870796204	reversibility heart_ failure myocardial_ infarction m β-adrenoceptor_blockade infarcted_ rats metoprolol
P-1547	-1.8966 -0.0799 -0.1192 -1.6322 -0.9345 -0.4643 -0.5070 -0.7108 -0.4526 -0.8260 -0.6628 -0.7801 -3.2250 -0.1176 -0.9519 -2.9604 -0.0064 -0.0218 -0.0301 -0.0935 -1.3350 -0.2436 -0.5830 -1.0512 -0.7305 -0.1052 -1.8668 -1.9500 -3.1987 -0.3340 -0.0240 -0.2775 -0.0826 -0.0255 -0.2833 -0.2079 -0.0912
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise rehabilitation walking minnesota_quality_of_life exercise
H-1882	-2.2531535625457764	▁rehabilita tion
D-1882	-2.2531535625457764	rehabilitation
P-1882	-4.4995 -0.0385 -4.3380 -0.1366
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive_heart_failure correlation_coefficient
H-218	-1.0330157279968262	▁con ges tive _ ▁heart _ ▁failure ▁ed
D-218	-1.0330157279968262	congestive_ heart_ failure ed
P-218	-2.1806 -0.0618 -0.0559 -0.4591 -1.9919 -0.6930 -1.7480 -0.9724 -2.0230 -0.1447
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine_vasopressin avp physiologic chf avp vasopressin_receptor_antagonist therapy therapeutic chf
H-637	-0.7012640237808228	▁argi nine _ ▁vaso press in ▁a VP ▁physio logi que _ process es ▁CHF ▁in hib i tion ▁a VP ▁vaso press in _ ▁receptor _ ▁anta gon ist _ therapy ▁CHF
D-637	-0.7012640237808228	arginine_ vasopressin aVP physiologique_processes CHF inhibition aVP vasopressin_ receptor_ antagonist_therapy CHF
P-637	-3.1075 -0.3697 -0.5785 -0.4273 -0.0588 -0.8756 -0.3338 -0.1081 -0.9177 -1.0200 -1.2812 -1.5664 -1.2390 -0.1736 -0.2728 -2.0757 -0.0335 -0.2683 -0.0251 -0.6272 -0.1212 -0.3142 -0.0441 -0.7005 -1.0244 -0.1520 -1.0364 -1.9162 -0.0310 -1.1837 -1.6483 -0.1729 -0.5155 -0.1953 -0.1288
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies medication physical_therapy implantable_defibrillators circulatory_support transplantation risk_stratification patient heart_failure therapies disease
H-1205	-1.0656930208206177	▁implant able _ de fi br illa tors ▁circula tory _ ▁support ▁transplant ation ▁heart _ ▁failure
D-1205	-1.0656930208206177	implantable_defibrillators circulatory_ support transplantation heart_ failure
P-1205	-0.0864 -0.0954 -1.0470 -0.0396 -5.7932 -1.7081 -0.0154 -2.5607 -0.6508 -0.1303 -1.2232 -1.2458 -0.3329 -0.0079 -1.9097 -0.8892 -1.0557 -1.3401 -0.1170
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts caspase-3 activity phosphocreatine adenine_nucleotides cytochrome_c bcl2 bax caspase_3 expression
H-961	-0.45618078112602234	▁rat s ▁heart s ▁cas pas e ▁ phos pho creati ne ▁a den ine _ ▁nucleo ti des ▁cy to ch rom e ▁b cl 2 ▁Bax ▁cas pas e
D-961	-0.45618078112602234	rats hearts caspase phosphocreatine adenine_ nucleotides cytochrome bcl2 Bax caspase
P-961	-0.7411 -0.1361 -1.5166 -0.0376 -0.0225 -0.9106 -0.4864 -1.9413 -0.1786 -1.0010 -0.8098 -0.5952 -0.0643 -0.0162 -0.2950 -1.9152 -0.1590 -0.0076 -0.0219 -1.1043 -0.0708 -0.3065 -0.0415 -0.1192 -0.1204 -0.0288 -0.2361 -0.0981 -0.0055 -1.2368 -0.3318 -0.3698 -0.1285
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right_ventricular_pacing gene_expressions bax bcl-2 caspase-3 rtq-pcr interventricular_septum biopsies heart_failure
H-166	-0.5922895669937134	▁vent ri cular _ pa cing ▁Bax ▁b cl -2 ▁Cas pas e -3 ▁RT q - PC r ▁interven tri cular _ ▁sept um ▁bio psi es ▁beag le ▁dog s ▁heart _ ▁failure
D-166	-0.5922895669937134	ventricular_pacing Bax bcl-2 Caspase-3 RTq-PCr interventricular_ septum biopsies beagle dogs heart_ failure
P-166	-3.6761 -0.2428 -0.1516 -0.4609 -0.3631 -0.4003 -1.3529 -0.0456 -0.1048 -1.6711 -1.3882 -0.4204 -0.0703 -0.4649 -1.3897 -0.9920 -0.0504 -0.7228 -0.2209 -0.0514 -0.0135 -0.0663 -0.4853 -1.5018 -0.0217 -0.4417 -0.0234 -0.0450 -0.0037 -0.0764 -2.0190 -0.0202 -0.2500 -0.8608 -1.5508 -0.1964 -0.0983
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers β-blockers patients heart_failure_and_reduced_ejection_fraction
H-661	-0.7834672331809998	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi teurs angi oten sin _ ▁receptor ▁block ers ▁β - block ers ▁heart _ ▁failure ▁e je ction _ fraction
D-661	-0.7834672331809998	angiotensin-converting enzyme inhibiteursangiotensin_ receptor blockers β-blockers heart_ failure ejection_fraction
P-661	-1.2342 -2.5122 -0.4907 -1.6438 -0.6375 -0.0030 -0.0867 -3.0822 -0.8536 -0.2290 -0.5454 -1.5142 -1.1318 -0.0379 -1.3633 -1.5896 -0.0315 -2.6590 -0.0443 -0.0515 -0.0092 -0.0889 -0.0531 -1.3943 -0.9314 -1.9837 -0.2240 -0.1609 -0.0223 -0.9483 -0.0036 -0.1848 -0.1082
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary_approaches_to_stop_hypertension dash left_ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling hypertensive_hfpef
H-918	-0.6766197085380554	▁so dium - re strict ed ▁hyper tension ▁die t DAS h ▁s d ▁vent ri cular _ ▁dia sto lic _ fon cti onnement ▁arterial _ ▁elastan ce ▁vent ri cular - arte rial ▁coup ling ▁hyper tensi ve ▁h f f
D-918	-0.6766197085380554	sodium-restricted hypertension dietDASh sd ventricular_ diastolic_fonctionnement arterial_ elastance ventricular-arterial coupling hypertensive hff
P-918	-1.0970 -0.0320 -0.0118 -0.0087 -0.0329 -0.1268 -2.7047 -0.0010 -2.0721 -0.0161 -0.5490 -0.2561 -2.9567 -1.1885 -0.1607 -0.1351 -0.0644 -0.2522 -2.6528 -0.2565 -1.4275 -2.3305 -1.4798 -0.8019 -1.3785 -0.0547 -1.1364 -0.2781 -0.2248 -0.0038 -0.1543 -0.0620 -0.3368 -0.1656 -0.0472 -0.0882 -1.3500 -0.7091 -1.2378 -0.4127 -0.2756 -0.1987 -0.4148 -1.2206 -0.0833
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute_hf relax-ahf astronaut pronto patient patients end_points
H-1017	-0.6892102360725403	▁a cute _ f ▁trial s ▁RELA x - a HF AST RON AUT ▁PR ONTO ▁patient _ en roll ment
D-1017	-0.6892102360725403	acute_f trials RELAx-aHFASTRONAUT PRONTO patient_enrollment
P-1017	-0.4562 -0.0376 -0.5890 -0.8798 -5.5134 -0.0183 -1.0211 -0.1640 -0.0072 -0.0563 -0.4056 -1.4875 -0.2609 -0.1509 -0.1237 -0.0097 -1.8968 -0.8738 -0.9176 -0.0955 -0.0982 -0.6984 -0.0902
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol carvedilol sympathetic_activity von_willebrand_factor
H-1119	-0.9108339548110962	▁met o pro lol ▁car vedi lol ▁sympa the tic _ ▁activity ▁Will e brand _ ▁factor
D-1119	-0.9108339548110962	metoprolol carvedilol sympathetic_ activity Willebrand_ factor
P-1119	-0.1377 -0.0988 -0.0168 -0.2518 -0.1264 -0.7704 -0.7073 -0.4860 -0.6019 -2.6314 -1.4473 -0.6906 -3.3149 -0.3596 -0.1357 -1.6667 -1.2651 -2.4535 -0.1439
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized hf international_classification_of_diseases clinical principal discharge diagnosis
H-1832	-0.605477511882782	▁Hospital ized ▁ HF ▁Disease s ▁Clinic al _ ▁Modifica tion ▁code s ▁principal ▁dis charge
D-1832	-0.605477511882782	Hospitalized HF Diseases Clinical_ Modification codes principal discharge
P-1832	-1.0645 -0.4130 -1.1831 -0.0753 -3.3788 -0.0452 -0.7202 -0.0133 -0.7643 -0.1437 -0.0306 -1.0738 -0.0256 -0.3970 -0.5817 -0.0022 -0.8831 -0.1034
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad q65p movement wild-type_rad q65p l-type_channel rgk_proteins
H-1676	-1.176513671875	▁rad _ q 65 p ▁ga ting _ ▁movement ▁wild - type ▁rad ▁Q 65 p ▁l - type _ ▁channel _ ▁inhibi tion ▁R GK ▁protein s
D-1676	-1.176513671875	rad_q65p gating_ movement wild-type rad Q65p l-type_ channel_ inhibition RGK proteins
P-1676	-0.5631 -4.0680 -1.4941 -0.6979 -0.3596 -3.0464 -1.1196 -0.2108 -0.6733 -3.1481 -0.0066 -0.0093 -1.6973 -1.8871 -0.2369 -0.5012 -5.2144 -0.1859 -0.0285 -0.6168 -2.9179 -0.5690 -0.2866 -0.0613 -1.9979 -0.2489 -3.0739 -0.0812 -0.1996 -0.0942
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 heart_failure proteomics actin_cytoskeleton ss20 mitochondrial metabolic_pathways
H-876	-0.979762852191925	▁heart _ ▁failure ▁prote o mics ▁changes ▁act in _ cy tos kelet on _ path ways ▁SS 20 ▁mito cho ndri al ▁metabol ic ▁path ways
D-876	-0.979762852191925	heart_ failure proteomics changes actin_cytoskeleton_pathways SS20 mitochondrial metabolic pathways
P-876	-3.3568 -0.9095 -2.1217 -0.7749 -1.4575 -0.0119 -3.7400 -0.2859 -0.4463 -0.4382 -2.6464 -0.6109 -0.0429 -0.1573 -2.1829 -0.4969 -0.2657 -2.1349 -1.1714 -0.5306 -0.7740 -0.0819 -0.0938 -0.5502 -0.1645 -2.2871 -0.2536 -0.3090 -0.1164
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms left_ventricular_base midpapillary apex baseline ivc_occlusion bivp ste rs
H-324	-0.6866605877876282	▁e cho card i ogram s ▁left ▁vent ri cular ▁base ▁mid pap illa ry ▁ap ex ▁IV c ▁bi VP ▁ STE ▁twist ▁bas al ▁rota tions ▁CS ▁RS ▁synchron y
D-324	-0.6866605877876282	echocardiograms left ventricular base midpapillary apex IVc biVP STE twist basal rotations CS RS synchrony
P-324	-0.9663 -1.4287 -0.1594 -0.1196 -0.0112 -0.0781 -0.5236 -0.1787 -0.2103 -0.1065 -0.7383 -1.1349 -0.6221 -0.0168 -0.2252 -1.5416 -0.0239 -0.2613 -0.2568 -1.2740 -0.1028 -1.8004 -1.2775 -2.0025 -2.8497 -0.0081 -1.8053 -0.0189 -1.2400 -1.1009 -0.6254 -0.2610 -0.2869 -0.0897
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration pyridostigmine coronary_artery_ligation cardiac sympathetic_tone cardiac_remodeling left_ventricular_dysfunction hf
H-1145	-0.47296226024627686	▁py rido stig mine ▁corona ry _ ▁arter y _ ▁liga tion ▁cardiac _ va gal ▁sympa the tic _ ▁tone ▁cardiac ▁remodel ing ▁vent ri cular _ ▁dys function ▁ HF
D-1145	-0.47296226024627686	pyridostigmine coronary_ artery_ ligation cardiac_vagal sympathetic_ tone cardiac remodeling ventricular_ dysfunction HF
P-1145	-2.4837 -0.0785 -0.0008 -0.1951 -0.1485 -0.2842 -1.7859 -0.1646 -0.3255 -0.6957 -0.2020 -0.1715 -0.0022 -0.7011 -0.6073 -0.0063 -0.3770 -0.2218 -1.2202 -1.4777 -0.0593 -0.0474 -1.3271 -0.1199 -0.4405 -0.1280 -0.1064 -0.8801 -0.1505 -0.3821 -0.6392 -0.1195 -0.4641 -0.0668
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes patients new_york_heart_association nyha heart_failure eplerenone placebo heart_failure medicines emphasis-hf
H-1229	-1.3579243421554565	▁New ▁York _ ▁Heart _ association NY HA ▁class _ ▁II _ ▁Heart _ ▁Fail ure ▁e pler en one ▁implant - HF
D-1229	-1.3579243421554565	New York_ Heart_associationNYHA class_ II_ Heart_ Failure eplerenone implant-HF
P-1229	-6.7639 -1.3944 -1.3551 -3.0211 -0.9998 -1.2037 -3.1746 -1.1305 -1.7481 -0.2715 -0.5607 -1.3863 -0.3972 -0.6288 -0.1121 -0.0748 -0.2831 -0.2011 -0.2102 -2.7670 -4.0592 -1.0662 -0.4014 -0.5770 -0.1604
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge patients follow-up physician physician
H-1418	-0.8320813775062561	▁dis charge ▁follow - up
D-1418	-0.8320813775062561	discharge follow-up
P-1418	-1.3974 -0.0259 -1.7395 -0.1244 -0.0376 -2.4171 -0.0827
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life_expectancy heart_failure patients disease terminal_heart_failure
H-1665	-1.3269376754760742	▁life _ ▁expect an cy ▁heart _ ▁failure
D-1665	-1.3269376754760742	life_ expectancy heart_ failure
P-1665	-4.1191 -0.9761 -0.3977 -0.4540 -0.4668 -2.3545 -0.8487 -1.9196 -1.5668 -0.1659
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart_failure discharges university_of_connecticut_health_center patients follow-up
H-723	-1.0747207403182983	▁heart _ ▁failure _ dis charge s ▁University _ of _ connect i cut _ health ▁Center
D-723	-1.0747207403182983	heart_ failure_discharges University_of_connecticut_health Center
P-723	-2.3926 -0.5637 -1.2693 -3.8257 -0.1575 -0.0044 -0.0385 -0.8903 -0.6021 -1.4035 -0.6256 -1.6192 -0.2059 -0.3493 -0.4631 -1.2430 -2.6776 -1.9782 -0.1101
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary_capillary_wedge_pressure baseline right_atrial_pressure pulmonary_arterial_pressure pulmonary_resistance
H-1959	-0.8437240123748779	▁Pul mon ary _ ca illa ry _ we dge _ tension ▁h g ▁h g ▁right _ ▁at rial _ tension ▁pulmonar y _ ▁arterial _ tension ▁pulmonar y _ ▁resist ance
D-1959	-0.8437240123748779	Pulmonary_caillary_wedge_tension hg hg right_ atrial_tension pulmonary_ arterial_tension pulmonary_ resistance
P-1959	-0.6421 -4.3401 -1.3589 -0.4786 -3.9317 -0.3608 -0.1486 -0.1552 -2.1232 -0.0201 -0.7544 -0.3447 -0.0788 -0.0194 -0.8889 -0.0225 -2.5197 -0.7728 -0.8717 -0.2335 -2.2548 -0.3288 -0.0060 -0.0618 -0.8514 -0.7482 -1.1401 -0.3740 -0.0009 -0.1778 -0.6102 -2.5134 -0.0342 -0.2754 -0.0877
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute_heart_failure hf pharmacologic therapeutics calcium-sensitizing_agents antagonists endothelin vasopressin adenosine
H-1015	-0.44477856159210205	▁a cute _ heart _ ▁failure HF ▁ pharma c ologic ▁studies ▁calci um - sensi t izing ▁agents ▁en do the lin ▁vaso press in ▁ad enos ine
D-1015	-0.44477856159210205	acute_heart_ failureHF pharmacologic studies calcium-sensitizing agents endothelin vasopressin adenosine
P-1015	-0.5423 -0.0890 -0.1906 -1.7557 -0.5359 -1.0956 -0.4757 -0.4041 -0.0494 -0.0576 -0.2425 -1.7376 -0.3484 -0.0206 -0.0435 -0.0082 -2.2190 -0.2178 -0.1148 -0.1121 -0.0980 -0.3206 -1.9638 -0.0332 -0.0217 -0.4135 -0.0121 -0.0467 -0.1840 -0.2951 -0.1386
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic_insufficiency mechanical_circulatory_support continuous_flow left_ventricular_assist_devices lvads pulsatile_devices
H-542	-0.7390108108520508	▁a or tic _ insu ffi cie ncy ▁i ▁mechanic al _ ▁circula tory _ ▁support ▁continuo us _ f ré que nce ▁vent ri cular _ assist ▁devices ▁l VAD s ▁pulsa tile ▁devices
D-542	-0.7390108108520508	aortic_insufficiency i mechanical_ circulatory_ support continuous_fréquence ventricular_assist devices lVADs pulsatile devices
P-542	-1.9596 -0.2095 -2.0951 -0.3396 -0.6252 -0.1359 -1.7612 -0.0905 -2.9312 -2.4159 -0.0165 -0.1964 -1.7795 -0.6506 -0.8045 -1.0050 -1.0258 -0.7625 -0.4243 -2.2115 -0.4970 -0.0334 -0.0185 -0.8668 -0.1410 -0.0946 -0.3760 -0.1595 -0.4284 -0.6286 -0.0166 -0.7815 -0.0104 -0.0556 -1.4968 -0.1725 -0.1257
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in_vivo hf phenylephrine haemodynamic surgical transverse_aortic_constriction tac jq1 pathological cardiac_hypertrophy
H-1047	-0.6365473866462708	▁ HF ▁ HF ▁ phen yle ph rine ▁ha emo dynamic _ ▁stress ▁sur g ical ▁trans verse _ a or tic _ con stri ction TAC ▁j q 1 ▁cardiac _ ▁hyper trop hy
D-1047	-0.6365473866462708	HF HF phenylephrine haemodynamic_ stress surgical transverse_aortic_constrictionTAC jq1 cardiac_ hypertrophy
P-1047	-1.8702 -0.1849 -1.0253 -1.7841 -0.6763 -1.6220 -0.3986 -0.6345 -0.4284 -0.4393 -0.2881 -0.0449 -1.6903 -0.7201 -1.4054 -0.0646 -0.1491 -0.7375 -0.0803 -0.2466 -0.3824 -0.1562 -0.9803 -0.3544 -0.2789 -0.4074 -0.0326 -2.0212 -0.2032 -0.4574 -1.4973 -0.4367 -1.5617 -0.5864 -0.0055 -0.0469 -0.2112 -0.0785
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence drugs drugs raas renin_inhibitors endopeptidase_inhibitors vasopeptidase_inhibitors angiotensin_receptor_blockers
H-1490	-0.7081378102302551	▁drugs ▁RA as ▁direct _ re nin ▁inhibi tors ▁en dop ep tida se ▁inhibi tors ▁vaso pe pti das e ▁inhibi tors ▁ang io ten sin ▁receptor _ block ers
D-1490	-0.7081378102302551	drugs RAas direct_renin inhibitors endopeptidase inhibitors vasopeptidase inhibitors angiotensin receptor_blockers
P-1490	-1.8852 -1.3182 -0.5023 -0.0008 -0.4151 -0.3428 -1.8592 -1.0002 -0.4604 -0.9023 -0.0109 -0.7215 -0.1357 -0.0503 -1.0024 -0.9763 -0.0543 -0.4274 -0.4895 -1.5705 -0.3693 -0.3244 -1.1333 -0.0367 -0.6077 -0.2152 -1.0580 -1.0285 -2.6781 -1.5160 -0.0092 -0.1791 -0.0877
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 healthy cardiomyocytes camp inotropic_effect acute β-ar contractility
H-1216	-0.6902447938919067	▁p de 2 _ over expression ▁healthy _ ▁cardio my o cy tes ▁c AMP ▁l - type _ ca 2 ▁in o tropi c _ ▁effect ▁β - AR ▁bas al _ contract ility
D-1216	-0.6902447938919067	pde2_overexpression healthy_ cardiomyocytes cAMP l-type_ca2 inotropic_ effect β-AR basal_contractility
P-1216	-0.1707 -0.0179 -0.1157 -3.7423 -1.3326 -0.0335 -1.1968 -0.8228 -0.1354 -0.9269 -0.7643 -0.4629 -0.5854 -0.0080 -0.1503 -2.6560 -0.0461 -0.0253 -1.5002 -0.0175 -0.0233 -0.4853 -0.7139 -0.0781 -0.1194 -2.9273 -1.1729 -1.2323 -0.0042 -0.1628 -2.0284 -0.0601 -0.2058 -0.3776 -0.8052 -0.3064 -0.1255
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck_stent implanted lad circumflex_artery lcx lcx lad
H-505	-0.9271169900894165	▁bottle ne ck _ ▁sten t ▁implant ed ▁left _ ▁anterior _ ▁descend ing LAD ▁proxima l _ ▁circum flex ▁arter y ▁l x ▁proxima l ▁ LC x ▁ LAD
D-505	-0.9271169900894165	bottleneck_ stent implanted left_ anterior_ descendingLAD proximal_ circumflex artery lx proximal LCx LAD
P-505	-0.2915 -0.0254 -0.3986 -2.9043 -0.8439 -0.0240 -0.1219 -0.6307 -3.5016 -0.2545 -1.1158 -1.5189 -0.0042 -0.0738 -1.3367 -0.7446 -0.0666 -0.5310 -1.5667 -0.0495 -0.6774 -0.3626 -3.4923 -0.2189 -1.3278 -0.0240 -2.6781 -1.1470 -0.2814 -1.7532 -0.4480 -2.0428 -0.1371
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute_myocardial_infarction ami incidence deaths heart_failure hf ami
H-1306	-1.1135050058364868	▁a cute _ mé o card ial _ ▁in far ction ▁ AMI ▁heart _ ▁failure HF ▁ AMI
D-1306	-1.1135050058364868	acute_méocardial_ infarction AMI heart_ failureHF AMI
P-1306	-1.2039 -0.0722 -0.2019 -3.3645 -0.6472 -0.2706 -0.6263 -0.3235 -0.9626 -2.7069 -0.1006 -2.6451 -0.3719 -2.7321 -0.8626 -1.7634 -1.9303 -2.1461 -0.1449 -0.1985 -0.1087
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac_washout carvedilol metoprolol β2-adrenergic_receptor_haplotype
H-1117	-0.9427775740623474	▁i - m g ▁cardiac _ ▁was hout ▁car vedi lol ▁met o pro lol ▁β 2- ad r energi c ▁receptor
D-1117	-0.9427775740623474	i-mg cardiac_ washout carvedilol metoprolol β2-adrenergic receptor
P-1117	-0.0761 -1.3322 -1.3512 -2.6566 -0.4136 -1.3716 -6.3479 -0.0094 -0.3364 -0.1806 -0.1383 -0.1046 -0.1556 -0.0231 -0.3161 -3.4880 -0.6599 -0.1307 -0.0637 -0.3140 -0.0625 -1.1100 -1.8834 -0.1011
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle_aerobic_capacity postexercise_phosphocreatine_resynthesis fontan
H-1502	-0.7264462113380432	▁Mus cle _ ▁aero bic _ ▁capacity ▁poste xer ci se _ phos pho creati ne _ re syn the sis ▁Font an
D-1502	-0.7264462113380432	Muscle_ aerobic_ capacity postexercise_phosphocreatine_resynthesis Fontan
P-1502	-0.2454 -0.1424 -0.0714 -0.6561 -0.5961 -2.1867 -1.4607 -0.0267 -0.0646 -0.0981 -0.5213 -1.1689 -0.3250 -0.9580 -1.2572 -2.5717 -0.2540 -0.8477 -0.0344 -1.7471 -1.8204 -0.1190 -0.2331 -0.6581 -0.0972
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac_resynchronization_therapy crt patients heart_failure hf outcomes crt dialysis reported
H-904	-0.5405285954475403	▁Card iac _ re syn chron ization _ therapy ▁c RT ▁di al ysis - dependent ▁patients ▁heart _ ▁failure HF ▁c RT ▁di al ysis
D-904	-0.5405285954475403	Cardiac_resynchronization_therapy cRT dialysis-dependent patients heart_ failureHF cRT dialysis
P-904	-0.3312 -0.3511 -0.1515 -0.4097 -0.0310 -0.0008 -1.0271 -0.8330 -0.1708 -0.3767 -0.7263 -0.3002 -0.2427 -0.0997 -0.3167 -0.0988 -1.3077 -1.3469 -0.6934 -1.3511 -0.7814 -0.7748 -1.3060 -1.2843 -0.3827 -0.1754 -0.1623 -0.1016
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone patients hyperkalemia renal_function emphasis-hf eplerenone patients hospitalization heart_failure
H-1221	-1.0759886503219604	▁ef fica cy ▁e pler en one ▁hyper kal emia ▁renal ▁fonction ▁EM PHA SIS - HF ▁e pler en _ in _ ▁Mil d ▁Patient s ▁Hospital ization ▁Heart _ ▁Fail ure
D-1221	-1.0759886503219604	efficacy eplerenone hyperkalemia renal fonction EMPHASIS-HF epleren_in_ Mild Patients Hospitalization Heart_ Failure
P-1221	-3.2602 -0.0201 -1.0208 -0.0867 -2.2925 -0.9551 -5.5267 -0.1870 -1.3863 -0.5700 -0.2039 -4.4600 -0.6367 -0.0336 -0.4107 -0.0227 -0.0703 -0.2322 -1.4570 -0.5760 -5.4987 -2.5737 -0.4871 -0.5667 -0.0314 -0.3237 -0.0673 -0.6896 -1.1091 -0.8366 -1.4849 -0.1148 -0.1068 -0.2141 -0.1466
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ventricular_mass cardiac_apoptosis fibrosis cardiac_metabolic_gene_expression atp
H-655	-0.8285511136054993	▁h - d KO ▁vent ri cular ▁mass ▁cardiac _ ▁apo pto sis ▁fibro sis
D-655	-0.8285511136054993	h-dKO ventricular mass cardiac_ apoptosis fibrosis
P-655	-0.2552 -1.0520 -0.2257 -1.1304 -0.1031 -0.3185 -0.2040 -2.0088 -0.0626 -1.1887 -1.3771 -0.1806 -0.9875 -0.0259 -0.1503 -4.7185 -0.0963
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp shock_therapy
H-863	-0.7808972001075745	▁in appropria te ▁ATP ▁shock ▁ therapy
D-863	-0.7808972001075745	inappropriate ATP shock therapy
P-863	-3.3158 -0.0661 -0.1739 -0.5759 -1.0782 -1.2455 -0.0345 -0.3595 -0.1788
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint cardiorespiratory_fitness crf body_mass_index heart_failure hf mortality cardiovascular hf mortality
H-1766	-0.8725927472114563	▁cardio re spira tory _ ▁fitness ▁cr f ▁body _ ▁mass ▁index ▁heart _ ▁failure HF ▁cardiovascular _ risk ▁factors ▁ HF
D-1766	-0.8725927472114563	cardiorespiratory_ fitness crf body_ mass index heart_ failureHF cardiovascular_risk factors HF
P-1766	-0.4224 -0.0780 -0.4162 -0.5146 -0.6879 -0.1685 -1.4261 -0.0069 -0.0959 -0.6792 -1.3559 -0.2080 -0.2441 -0.4420 -1.5810 -1.4945 -0.3641 -3.1672 -0.3465 -3.0667 -0.5195 -0.4008 -3.1468 -0.1091
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized heart_failure dipeptidyl_peptidase-4 dpp-4 antihyperglycemic_agents
H-1827	-0.9468050599098206	▁hospital ized _ heart _ ▁failure ▁h HF ▁di pe pti dy l _ ▁pep tida se -4 ▁d p -4 ▁anti hy per gly ce mic ▁agents
D-1827	-0.9468050599098206	hospitalized_heart_ failure hHF dipeptidyl_ peptidase-4 dp-4 antihyperglycemic agents
P-1827	-5.3190 -0.6269 -1.0069 -2.4463 -0.8234 -1.4332 -0.1007 -0.8107 -0.0076 -0.0185 -0.0317 -5.7193 -2.3025 -0.6782 -0.0977 -0.0460 -0.0479 -0.4207 -0.0960 -0.7962 -1.2122 -0.0679 -0.1142 -0.0926 -1.5637 -0.1476 -1.7294 -0.3110 -0.2127 -0.1233
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox_modeling heart_failure_patient_severity_index hfpsi university_of_michigan hf clinic primary_outcome
H-380	-0.802045464515686	▁quality _ ▁improvement ▁database ▁multi vari able _ co x ▁model ing ▁Heart _ ▁Fail ure _ ▁Patient _ ▁Sever ity _ ▁Index ▁h PSI ▁University _ de _ ▁Michigan ▁ HF
D-380	-0.802045464515686	quality_ improvement database multivariable_cox modeling Heart_ Failure_ Patient_ Severity_ Index hPSI University_de_ Michigan HF
P-380	-2.6151 -0.6020 -0.3294 -2.3042 -0.2687 -0.0025 -0.0206 -1.0912 -0.0582 -0.0214 -2.6298 -0.1817 -1.7599 -0.3730 -0.1686 -0.0690 -1.3306 -0.2843 -0.2131 -0.6766 -0.2221 -1.0278 -1.6233 -0.8340 -0.8662 -0.4801 -0.4912 -1.9389 -0.2094 -0.2155 -1.2488 -0.6925 -2.3086 -0.1115
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart_rate cardiac patients patients acute_myocardial_infarction ami patients congestive_heart_failure chf left_ventricular dysfunction
H-1585	-0.8421083688735962	▁cardiac ▁patients ▁a cute _ mé o card ial _ ▁in far ction AMI ▁con ges tive _ ▁heart _ ▁failure ▁ch f ▁left _ vent ri cular LV
D-1585	-0.8421083688735962	cardiac patients acute_méocardial_ infarctionAMI congestive_ heart_ failure chf left_ventricularLV
P-1585	-5.2957 -1.5064 -0.1572 -0.0093 -0.1779 -2.0395 -0.4189 -0.1306 -0.4859 -0.5156 -0.5542 -2.1495 -0.0997 -1.8406 -0.4259 -0.0664 -0.0879 -0.7210 -0.9036 -0.6080 -0.3628 -3.6060 -0.0235 -0.0414 -0.7925 -1.1705 -0.8342 -0.0676 -0.2627 -0.5435 -0.2071
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular_cardiomyocytes chronic insulin irs1 irs2 proteins insulin p38 cardiac_dysfunction insulin_resistance type_2_diabetes
H-657	-0.7273908853530884	▁ne ona tal ▁rat ▁vent ri cular _ ▁cardio my o cy tes ▁chronic ▁insulin ▁i RS 1 ▁i RS 2 ▁insulin ▁action ▁cardiac _ ▁dys function ▁insulin _ ▁resist ance ▁diabetes
D-657	-0.7273908853530884	neonatal rat ventricular_ cardiomyocytes chronic insulin iRS1 iRS2 insulin action cardiac_ dysfunction insulin_ resistance diabetes
P-657	-1.9600 -0.0297 -0.0652 -0.6948 -0.1330 -0.1645 -0.2721 -0.4024 -0.1081 -0.7255 -0.3799 -0.1184 -0.4729 -1.1881 -1.1637 -3.6427 -0.0963 -1.0549 -0.8245 -0.3106 -0.0606 -2.5247 -2.7862 -0.3528 -1.7260 -0.2214 -0.1451 -0.0506 -0.9558 -1.5809 -0.0071 -0.2171 -0.2132 -0.0825
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms left_ventricular midpapillary atrioventricular_delay avd interventricular_delay vvd ste circumferential_strain radial_strain rs
H-323	-0.5958559513092041	▁e cho card i ogram s ▁left ▁vent ri cular _ ▁mid pap illa ry ▁at rio ven tri cular _ de lay ▁av d ▁interven tri cular _ de lay ▁v d ▁ste ▁radi al _ ▁strain RS
D-323	-0.5958559513092041	echocardiograms left ventricular_ midpapillary atrioventricular_delay avd interventricular_delay vd ste radial_ strainRS
P-323	-2.4559 -1.2176 -0.1013 -0.1541 -0.0212 -0.0953 -0.6611 -0.1473 -0.3627 -0.2219 -0.3937 -2.0521 -0.8652 -0.0138 -0.1832 -1.8378 -0.4385 -0.1635 -0.2172 -0.3183 -0.3800 -0.0643 -0.4477 -0.6045 -0.0753 -0.0944 -0.1463 -0.0952 -0.3163 -0.0338 -0.7897 -0.6307 -0.0216 -0.7659 -3.9166 -0.0687 -1.1668 -1.0853 -1.4993 -0.2195 -0.0865
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients new_york_heart_association nyha functional_class hf ejection_fractions chronic stable guideline-directed_medical_therapy gdmt united_states canada europe
H-1870	-0.8637879490852356	▁New ▁York _ ▁Heart _ ▁Association NY HA ▁functional ▁class _ ▁III ▁ HF ▁e je ction _ fraction s ▁chronic _ direct ed _ ▁medical ▁ therapy GD MT
D-1870	-0.8637879490852356	New York_ Heart_ AssociationNYHA functional class_ III HF ejection_fractions chronic_directed_ medical therapyGDMT
P-1870	-3.2064 -0.8776 -1.0756 -1.1870 -0.7642 -1.6805 -1.4415 -0.5332 -3.3318 -0.5646 -0.4459 -0.6973 -0.8031 -0.0600 -0.0620 -0.4140 -0.0330 -0.6236 -0.0025 -0.0181 -1.2556 -1.1287 -1.6039 -0.3266 -0.2475 -0.8331 -0.9624 -0.0244 -1.8202 -0.8232 -0.7225 -0.0713
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients qrs hazard_ratio primary_outcome patients qrs hazard_ratio
H-889	-1.498892903327942	▁b b ▁QR s
D-889	-1.498892903327942	bb QRs
P-889	-3.1384 -1.2610 -0.9379 -1.4993 -1.9587 -0.1981
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka change riiα cα expression riiα ser96 cα thr197 phosphorylation hf
H-1428	-0.944886326789856	▁p ka ▁regulator y ▁r II α ▁cata ly tic ▁c α ▁ phos phor y lation ▁h z
D-1428	-0.944886326789856	pka regulatory rIIα catalytic cα phosphorylation hz
P-1428	-0.2419 -1.2252 -2.4113 -0.1563 -4.6737 -1.7389 -0.8966 -0.8413 -0.1136 -0.5750 -0.1246 -0.6798 -0.6149 -0.9620 -0.3931 -1.1540 -0.0530 -1.2678 -1.4320 -0.1732 -0.1145
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous_hf myofiber_shortening septum myofiber_shortening stretch wall
H-1155	-1.3753702640533447	▁dys syn chron ous ▁ HF ▁my o fi ber ▁sept um ▁de press es ▁my o fi ber ▁stretch _ ▁rate
D-1155	-1.3753702640533447	dyssynchronous HF myofiber septum depresses myofiber stretch_ rate
P-1155	-2.3203 -0.0107 -0.0019 -2.7957 -1.5305 -0.1462 -2.6721 -0.1908 -1.9989 -0.4825 -3.0903 -0.0677 -4.9217 -0.1463 -0.9988 -1.8600 -0.1007 -1.7387 -0.3084 -1.3630 -2.0776 -1.7325 -2.3040 -0.1496
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells transforming_growth_factor-β tgf-β epithelial mesenchymal transition expression pluripotency_markers
H-1342	-0.5196065902709961	▁CHF ▁c - K it ▁transform ing _ ▁growth _ factor - β ▁t GF - β ▁epi the li al ▁mes en chy mal ▁transition ▁pluri pote ncy ▁sham s
D-1342	-0.5196065902709961	CHF c-Kit transforming_ growth_factor-β tGF-β epithelial mesenchymal transition pluripotency shams
P-1342	-0.0874 -3.1011 -0.0562 -1.2359 -0.0355 -1.1941 -0.2217 -1.6232 -1.1771 -1.8824 -1.2184 -0.8138 -0.0214 -0.3062 -0.5366 -0.5380 -0.0216 -0.0373 -0.0752 -0.0700 -0.0357 -0.1350 -0.3994 -0.2758 -0.1639 -0.6794 -0.4298 -0.1214 -0.0688 -0.2544 -0.0369 -0.1960 -0.0974
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics proteomics transverse_aortic_constriction tac heart_failure signaling_pathway ingenuity_pathway_analysis
H-871	-0.7774889469146729	▁label - free ▁shot gun ▁prote o mics ▁trans verse _ a or tic _ con stri ction ▁ TAC ▁heart _ ▁failure
D-871	-0.7774889469146729	label-free shotgun proteomics transverse_aortic_constriction TAC heart_ failure
P-871	-0.3470 -0.0437 -0.3462 -0.0895 -0.1439 -2.5316 -1.1935 -0.0060 -3.3906 -0.1767 -0.3796 -0.3698 -0.1695 -1.4281 -0.3862 -0.2526 -1.5805 -0.0416 -1.9729 -0.0897 -0.4423 -1.2013 -1.8730 -0.8994 -0.0818
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients hfref left_ventricular_ejection_fraction hfpef left_ventricular_ejection_fraction β-blocker hf hospitalization
H-178	-0.7191636562347412	▁h f f ▁vent ri cular _ ▁e je ction _ fraction ▁h f p EF ▁left _ vent ri cular _ ▁e je ction _ fraction ▁ RAS - ▁β - block er ▁ HF
D-178	-0.7191636562347412	hff ventricular_ ejection_fraction hfpEF left_ventricular_ ejection_fraction RAS- β-blocker HF
P-178	-0.0571 -0.3273 -0.2922 -1.3846 -0.5630 -0.8290 -0.7494 -2.0027 -1.6035 -0.5522 -1.0800 -0.0048 -1.2246 -0.2281 -0.3264 -0.9660 -0.1291 -0.9836 -1.0754 -1.8172 -0.7612 -0.3975 -1.8310 -1.6196 -0.4352 -1.1814 -0.0065 -0.2897 -0.3238 -0.6620 -0.5781 -0.0261 -0.1134 -0.0593 -2.0089 -0.2299 -0.4178 -0.1908
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated p70s6k pkc-βii hdl nyha-iiib malondialdehyde bound hdl nyha-iiib hdl healthy
H-257	-0.9492594599723816	▁p 70 s 6 ▁k ▁PK c - β II ▁HD l ▁j ha - III b ▁malo ndi alde hy de ▁ bound ▁HD l
D-257	-0.9492594599723816	p70s6 k PKc-βII HDl jha-IIIb malondialdehyde bound HDl
P-257	-0.6790 -0.6083 -0.5709 -0.5020 -1.7004 -1.0880 -0.1207 -0.0667 -0.2267 -0.6362 -1.7856 -1.2031 -4.5232 -0.3141 -0.4471 -0.3363 -0.0348 -0.0753 -0.0505 -0.2156 -0.1964 -0.0172 -3.2896 -0.2048 -3.3323 -1.4294 -2.8163 -0.1088
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross_talk g-protein-coupled_receptors physiological significance regulation hearts chronic β-adrenergic_receptor postischemic_heart_failure
H-1410	-0.8260267376899719	▁g - prote in - co up led ▁receptor s ▁reciproc al _ ▁regula tion ▁mouse ▁heart s ▁β - ad r energi c _ ▁receptor _ stimul ation ▁rat ▁post ische mic _ heart _ ▁failure
D-1410	-0.8260267376899719	g-protein-coupled receptors reciprocal_ regulation mouse hearts β-adrenergic_ receptor_stimulation rat postischemic_heart_ failure
P-1410	-1.1008 -0.1747 -0.6234 -0.8141 -0.1098 -0.0129 -0.0123 -0.2281 -1.0170 -0.1358 -2.0872 -0.0321 -1.1690 -3.3373 -0.0162 -0.3034 -1.9658 -0.0841 -0.7424 -0.0142 -0.0835 -0.1460 -0.1749 -0.0623 -2.5281 -0.0413 -3.2092 -0.6850 -0.0110 -1.3379 -2.3002 -2.7933 -0.3378 -0.3342 -2.1429 -0.8834 -0.7725 -0.2740 -0.1166
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise exercise
H-1989	-1.6921141147613525	▁weight
D-1989	-1.6921141147613525	weight
P-1989	-1.9456 -2.9669 -0.1638
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp inflammatory biomarkers hscrp il6 patients hscrp
H-1920	-0.535162627696991	▁NT - pro b NP ▁infla mma tory _ ▁bio mark ers ▁h s CR p ▁IL
D-1920	-0.535162627696991	NT-probNP inflammatory_ biomarkers hsCRp IL
P-1920	-0.0302 -0.0406 -0.5057 -0.5700 -0.1638 -0.2719 -0.2826 -0.7071 -0.9410 -0.3110 -0.0061 -0.0546 -0.0100 -0.0238 -1.9664 -0.2586 -1.7835 -2.1236 -0.1175
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection_fraction patients frail biological_phenotype death frailty deficit_index death
H-1010	-0.8962663412094116	▁sex ▁e je ction _ fraction ▁fra il ▁bi ological _ ▁ph eno type
D-1010	-0.8962663412094116	sex ejection_fraction frail biological_ phenotype
P-1010	-2.8152 -0.3129 -0.4281 -0.0238 -0.7685 -0.0003 -0.9782 -0.2166 -0.2769 -0.4073 -1.5633 -1.4583 -0.1379 -0.0519 -4.7935 -0.1078
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients resting_hr follow-up baseline vo2max patients resting_hr p_value
H-1945	-1.8613835573196411	▁rest ing _ HR ▁VO 2 max
D-1945	-1.8613835573196411	resting_HR VO2max
P-1945	-4.5284 -0.3381 -1.5330 -1.0458 -5.1599 -0.1247 -0.0053 -3.7889 -0.2282
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β cell phenotype in_vitro cardiac_progenitor_function cell clinical
H-1344	-0.9019575119018555	▁t f - β ▁inhibi tion ▁c - K it _ cell ▁implant ation ▁cardiac _ pro gen itor _ ▁function ▁cell _ ▁exp an sion
D-1344	-0.9019575119018555	tf-β inhibition c-Kit_cell implantation cardiac_progenitor_ function cell_ expansion
P-1344	-1.5362 -1.5279 -0.1628 -0.1356 -1.9879 -0.0718 -0.0029 -0.0663 -1.6307 -0.0254 -0.9303 -1.0069 -3.8592 -0.3157 -0.3344 -1.2012 -0.8528 -0.3036 -0.5656 -1.8279 -2.7708 -1.2048 -0.9004 -0.8029 -0.4544 -0.3472 -0.3574 -0.0716
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets in_vitro neurohormonally heart_disease nanomolar jq1 phenylephrine-mediated_hypertrophy cardiomyocytes pathological gene_induction
H-1044	-0.5379175543785095	BET s ▁neuro hormon ally _ ▁induc ed _ ▁heart _ ▁disease ▁j q 1 ▁ phen yle ph rine - media ted ▁hyper trop hy ▁cardio my o cy tes ▁path ological ▁gene ▁in duction
D-1044	-0.5379175543785095	BETs neurohormonally_ induced_ heart_ disease jq1 phenylephrine-mediated hypertrophy cardiomyocytes pathological gene induction
P-1044	-0.7169 -0.7002 -0.2633 -0.0600 -1.2149 -0.6484 -0.3053 -0.1879 -1.1918 -1.2698 -1.5584 -1.1672 -0.3217 -1.1917 -1.0990 -0.4420 -0.1418 -0.3550 -0.8194 -0.3181 -0.6005 -0.2764 -1.0672 -0.5736 -0.0034 -0.0437 -0.1973 -0.5172 -0.7238 -0.1224 -0.2274 -0.0875 -0.3529 -0.5293 -0.7013 -0.0159 -0.3241 -0.1045
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric_remodeling concentric_hypertrophy left_ventricular remodeling heart_failure_with_preserved_ejection_fraction hfpef eccentric_hypertrophy patients
H-1524	-0.723267674446106	▁concentr ic _ ▁remodel ing ▁cr ▁concentr ic _ ▁hyper trop hy CH ▁left _ ▁vent ri cular LV ▁implant ing ▁heart _ ▁failure ▁e je ction _ fraction ▁h p EF ▁ecce n tric ▁hyper trop hy EH
D-1524	-0.723267674446106	concentric_ remodeling cr concentric_ hypertrophyCH left_ ventricularLV implanting heart_ failure ejection_fraction hpEF eccentric hypertrophyEH
P-1524	-0.5697 -0.1050 -1.0370 -0.4162 -0.0845 -2.3665 -0.9702 -0.0579 -0.2509 -0.8410 -0.0161 -0.0189 -3.5229 -0.4409 -0.8320 -1.8824 -0.2098 -0.1893 -0.1617 -2.7303 -2.4900 -1.2008 -0.5471 -0.8108 -2.8056 -0.3859 -0.0438 -0.4053 -0.0061 -0.8370 -0.0283 -1.0679 -0.1613 -0.0079 -0.3136 -0.9211 -0.0060 -0.0224 -0.3574 -0.3591 -0.1734
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat functional_status quality_of_life exercise_capacity n-terminal_pro-brain_natriuretic_peptide heart_failure hospitalizations patients nyha_functional_class_iii hf
H-1878	-1.0160071849822998	▁BAT ▁implant al _ pro - bra in _ ▁na tri ure tic _ pe pti de ▁burde n ▁heart _ ▁failure ▁GD m - tre ated ▁NY HA
D-1878	-1.0160071849822998	BAT implantal_pro-brain_ natriuretic_peptide burden heart_ failure GDm-treated NYHA
P-1878	-0.5927 -5.1350 -3.8391 -1.8440 -0.2337 -0.1337 -0.4469 -0.2120 -0.7657 -0.3231 -0.0169 -0.0359 -1.9789 -1.2457 -0.4585 -0.1035 -0.0539 -2.6931 -0.0323 -1.3618 -1.0004 -0.8451 -0.7743 -1.5455 -0.8556 -0.0030 -1.9637 -0.7128 -0.3394 -1.8428 -0.1071
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change exercise exercise
H-1986	-1.2511235475540161	▁ ML HF
D-1986	-1.2511235475540161	MLHF
P-1986	-1.7607 -0.3466 -1.3523 -2.6230 -0.1730
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx dnx
H-1374	-1.6124151945114136	▁h - I nner vat ed ▁s ham - in v ▁non pa ce ▁d x ▁s ham - d x ▁pace _ non - d x ▁ch f - in v ▁pace _ ▁DN x ▁ch f - DN x
D-1374	-1.6124151945114136	h-Innervated sham-inv nonpace dx sham-dx pace_non-dx chf-inv pace_ DNx chf-DNx
P-1374	-7.2116 -0.8061 -2.7610 -0.0058 -0.0767 -0.4933 -6.2558 -1.7587 -0.0247 -0.6431 -0.8878 -7.1291 -0.1454 -0.0412 -4.2077 -0.2568 -5.7412 -0.7287 -0.0152 -3.4415 -0.0982 -3.7843 -2.5838 -0.4461 -0.0111 -2.4772 -0.3801 -3.0621 -0.1541 -0.0787 -0.2348 -0.7613 -2.8517 -2.1554 -1.5911 -0.1301 -2.5755 -0.1181 -0.0413 -2.6700 -0.0250 -0.3371 -0.1355
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise correlated psss btes exercise psss btes
H-1929	-1.1718180179595947	▁PS s ▁b tes
D-1929	-1.1718180179595947	PSs btes
P-1929	-4.0665 -1.2939 -0.1227 -0.1598 -1.3028 -0.0852
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin hgb hrqol hrqol patients heart_failure outcomes exercise training hf-action
H-836	-0.5972234010696411	▁hem o glob in ▁h gb ▁HR Qo L ▁training - indu ced ▁changes ▁HR Qo L ▁patients ▁Heart _ ▁Fail ure ▁h f - ac tion
D-836	-0.5972234010696411	hemoglobin hgb HRQoL training-induced changes HRQoL patients Heart_ Failure hf-action
P-836	-0.4554 -0.0597 -0.0503 -0.6474 -0.1243 -0.0946 -0.4631 -0.1026 -0.8928 -3.1503 -0.1780 -0.0002 -0.7805 -0.3389 -1.0658 -0.1702 -0.5963 -1.1347 -1.2362 -0.6322 -0.1764 -0.0448 -1.8630 -1.5567 -0.0308 -0.7172 -0.4846 -0.1822 -0.0903
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv_dysfunction hazard_ratio confidence_interval cachexia hazard_ratio multivariate_analyses
H-1166	-1.5050349235534668	▁Risk ▁ RV _ ▁dys function haz ard ▁figure ▁cache xia haz ard
D-1166	-1.5050349235534668	Risk RV_ dysfunctionhazard figure cachexiahazard
P-1166	-2.0546 -0.8495 -0.3334 -1.1170 -0.5271 -1.3565 -4.3226 -0.0396 -5.0103 -2.0682 -1.0301 -2.6503 -0.0497 -0.9797 -0.1868
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial_fibrillation congestive_heart_failure health_care expenditures patients québec randomized rhythm rate-control
H-1234	-0.8412925004959106	▁at rial _ f bril lation ▁con ges tive _ ▁Heart _ ▁Fail ure ▁ex pendi tures ▁Québec ▁ rhythm ▁rate - control
D-1234	-0.8412925004959106	atrial_fbrillation congestive_ Heart_ Failure expenditures Québec rhythm rate-control
P-1234	-0.6480 -0.0409 -0.7553 -0.5363 -1.1416 -0.0169 -1.1282 -0.1508 -0.1000 -0.5553 -0.3154 -0.7075 -0.1402 -0.0685 -3.7303 -0.0074 -0.5344 -2.8933 -0.1248 -0.7365 -1.6390 -0.1015 -0.0117 -4.8127 -0.1361
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report calcineurin nfat mir-25 expression basic_helix-loop-helix bhlh transcription_factor dhand hand2 diseased myocardium
H-640	-0.7016017436981201	▁calci ne uri n _ n fat ▁m r -25 ▁expression ▁heli x - loop - heli x ▁b HL h ▁Hand
D-640	-0.7016017436981201	calcineurin_nfat mr-25 expression helix-loop-helix bHLh Hand
P-640	-0.0282 -0.3947 -0.0229 -0.0623 -3.1511 -0.2946 -0.1371 -1.5952 -2.2041 -0.0732 -0.1232 -1.4709 -0.0470 -0.0265 -0.1766 -0.0685 -0.0237 -0.0361 -0.1433 -0.5620 -0.0756 -1.1551 -4.8286 -0.1378
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart_failure patient compliance myocardial_ischaemia bradyarrhythmias valvular_regurgitation pulmonary_embolism infection renal_dysfunction
H-1668	-0.677485466003418	▁heart _ ▁failure ▁my o card ial _ is cha emia ▁bra dy ar rhythm ias ▁val vu lar _ re gur gi tation ▁pulmonar y ▁e mbol ism ▁renal ▁dys function
D-1668	-0.677485466003418	heart_ failure myocardial_ischaemia bradyarrhythmias valvular_regurgitation pulmonary embolism renal dysfunction
P-1668	-3.4875 -1.0504 -0.8137 -1.1288 -0.0827 -0.2399 -0.1689 -0.4812 -3.5643 -0.0248 -0.1097 -3.5556 -0.8999 -0.2467 -0.1585 -0.6566 -0.2227 -0.5400 -0.1217 -0.3169 -1.0654 -0.0168 -0.0147 -0.0291 -0.0018 -0.0330 -1.3611 -0.0010 -0.6323 -0.6851 -0.5724 -0.2874 -0.3547 -0.1093
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc_battery hf health_abc_hf_model death
H-629	-1.2686972618103027	▁h ABC _ ▁Bat tery _ ▁score ▁ HF ▁health ▁ABC ▁ HF ▁h f _ model ▁SD ▁death
D-629	-1.2686972618103027	hABC_ Battery_ score HF health ABC HF hf_model SD death
P-629	-0.2125 -1.6930 -2.8618 -1.6088 -0.0085 -1.5489 -0.7172 -0.3292 -0.0569 -2.9946 -0.5574 -0.6804 -0.0908 -2.4748 -1.2744 -3.4720 -1.3376 -0.3705 -3.2348 -0.9834 -0.1352
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp admission sensitivity specificity confidence_interval area_under_the_curve
H-269	-0.7541123628616333	▁NT - pro b NP
D-269	-0.7541123628616333	NT-probNP
P-269	-0.2499 -0.0362 -0.0688 -0.6651 -0.4641 -3.6817 -0.1130
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic r-r_interval hr_variability short-term_fractal_scaling_exponent prognostic
H-1588	-1.2320972681045532	▁prognos tic _ pu issa nce ▁r - r ▁interval _ ▁os cilla tions ▁HR _ ▁variabil ity ▁fra c tal _ ▁scal ing
D-1588	-1.2320972681045532	prognostic_puissance r-r interval_ oscillations HR_ variability fractal_ scaling
P-1588	-2.2048 -1.1516 -0.7488 -3.1626 -0.0894 -0.0222 -2.0147 -0.1710 -0.7727 -1.1519 -1.1366 -2.0708 -0.0026 -0.1849 -3.5637 -4.3317 -1.5014 -0.5842 -4.2875 -0.0548 -1.0086 -0.6747 -0.2787 -0.0902 -0.6791 -0.0952
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart_failure hf patients spontaneous_ventricular_tachycardia hf patients spontaneous_vt hearts
H-1437	-1.2165443897247314	▁heart _ ▁failure ▁ HF ▁vent ri cular _ ta chy car dia ▁h t ▁ VT ▁h nor m
D-1437	-1.2165443897247314	heart_ failure HF ventricular_tachycardia ht VT hnorm
P-1437	-0.9800 -0.7508 -1.5110 -2.9638 -0.2788 -0.1301 -0.5143 -0.1881 -0.3700 -3.4270 -0.4528 -0.0208 -1.3280 -0.7582 -3.2861 -1.8694 -3.1726 -2.5496 -1.7568 -0.0018 -0.3691 -0.0851
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls cox_model chronic_heart_failure hypertension diabetes stroke estimated_glomerular_filtration_rate lvef
H-819	-0.8977332711219788	▁gr LS ▁co x ▁model ▁chronic _ ▁heart _ ▁failure ▁hyper tension ▁diabetes ▁stroke ▁glo mer ular _ ▁filtr ation _ ▁rate ▁LV EF
D-819	-0.8977332711219788	grLS cox model chronic_ heart_ failure hypertension diabetes stroke glomerular_ filtration_ rate LVEF
P-819	-0.3774 -2.4584 -0.1187 -0.0055 -2.2975 -2.4368 -0.5375 -1.5519 -0.4611 -1.0512 -0.0183 -0.0007 -0.0699 -1.9984 -2.4351 -0.0275 -0.0791 -0.8266 -0.5205 -0.0167 -1.7729 -0.2736 -0.0823 -0.1629 -3.6590 -0.1015
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic_function diastolic_filling_formalism relaxation doppler_mitral_inflow_velocity e-wave
H-921	-0.6097493767738342	▁dia sto lic _ ▁fill ing _ ▁formal ism ▁relax ation vis co ela stic ▁passiv e _ sti ff ness ▁do pp ler _ ▁mit ral ▁in flow ▁e - wa ve
D-921	-0.6097493767738342	diastolic_ filling_ formalism relaxationviscoelastic passive_stiffness doppler_ mitral inflow e-wave
P-921	-1.1954 -0.1426 -1.1029 -1.6394 -1.2970 -0.0880 -2.1273 -0.6320 -0.5648 -0.0903 -0.0045 -0.5397 -0.0157 -0.0974 -0.0308 -0.2887 -0.0817 -1.8646 -0.8604 -0.6850 -0.3418 -0.2050 -0.1078 -0.8785 -0.4874 -2.6019 -0.0181 -0.7598 -0.6311 -1.3575 -0.0275 -0.3070 -0.0361 -0.1107 -0.1229
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient vad patients ventricular_assist_device ecmo patients extracorporeal_membrane_oxygenation ecmo vad patients ecmo vad
H-1387	-0.7646135091781616	▁ VAD ▁vent ri cular _ assist _ ▁device _ support ▁EC mo ▁extra corp o real _ ▁membran e _ ▁oxygen ation _ ▁membran e ▁ VAD
D-1387	-0.7646135091781616	VAD ventricular_assist_ device_support ECmo extracorporeal_ membrane_ oxygenation_ membrane VAD
P-1387	-1.4964 -0.1168 -0.0145 -0.2141 -0.2191 -0.3897 -0.1611 -1.6666 -0.5891 -0.9020 -1.4034 -1.3617 -1.4269 -3.8138 -0.1402 -0.4132 -1.0774 -0.6140 -0.7188 -0.2036 -0.4983 -0.2912 -0.0382 -0.3055 -0.1838 -0.0926 -2.8511 -0.3051 -1.1415 -0.2887
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional_status 6-mwt nyha_class patients hfpef hfref prescribed therapy patients hfpef death hf hospitalization
H-244	-0.7937396764755249	▁m t ▁NY ha ▁ HF p EF ▁h f f ▁ HF p EF
D-244	-0.7937396764755249	mt NYha HFpEF hff HFpEF
P-244	-0.8279 -0.0254 -0.9809 -0.6017 -1.0608 -0.8875 -0.1324 -0.3173 -0.0602 -0.6650 -0.2455 -0.9925 -1.2376 -1.9353 -0.5171 -2.8967 -0.1098
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart_failure disease evidence-based health_care
H-2016	-1.2623121738433838	▁cost - effect ive ness ▁heart _ ▁failure _ ▁disease _ management
D-2016	-1.2623121738433838	cost-effectiveness heart_ failure_ disease_management
P-2016	-1.9166 -0.1363 -0.2932 -0.1053 -3.6994 -1.5080 -0.6297 -1.1868 -0.8233 -2.3272 -2.2086 -0.2272 -2.4753 -0.1353
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin heart_failure murine resistin transgenic retn gene resistin
H-930	-0.9183312058448792	▁resist in ▁heart _ ▁failure ▁human ized ▁mouse ▁mur ine _ ▁resist in ▁trans ge nic ▁Ret n _ ▁gene ▁h um - re t n _ mi ce ▁ inflammation - stimul ated ▁resist in
D-930	-0.9183312058448792	resistin heart_ failure humanized mouse murine_ resistin transgenic Retn_ gene hum-retn_mice inflammation-stimulated resistin
P-930	-4.6249 -0.6377 -1.1274 -0.4979 -0.3583 -2.0912 -0.7017 -0.1101 -2.7081 -0.8501 -1.0785 -0.9255 -0.6685 -3.3461 -0.0442 -0.4263 -1.9253 -0.0051 -1.6781 -0.8394 -0.2559 -0.7305 -0.0096 -0.8039 -0.0300 -0.0052 -1.2555 -0.5477 -0.2024 -0.2909 -0.1348 -0.0755 -0.0172 -1.4353 -3.2425 -0.4276 -0.6611 -0.1266
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients angiotensin-converting_enzyme_inhibitors angiotensin_receptors_blockers β-blockers
H-1745	-0.8784038424491882	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi teurs angi oten sin ▁receptor s ▁β - block ers
D-1745	-0.8784038424491882	angiotensin-converting enzyme inhibiteursangiotensin receptors β-blockers
P-1745	-0.4173 -2.4388 -0.7261 -2.1372 -0.6533 -0.0036 -0.1200 -3.7374 -1.3497 -0.2503 -0.9142 -2.0961 -1.3199 -0.0165 -1.6257 -0.5827 -0.2239 -0.4137 -0.0061 -0.0643 -0.0482 -0.9083 -0.1501
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac_injury ejection_fraction fractional_shortening heart_dilatation hypertrophy transverse_aortic_constriction tac
H-1815	-0.7095249891281128	▁t t t Men a _ mi ce ▁cardiac _ ▁injury ▁e je ction _ fraction ▁ fraction ▁heart _ ▁di la tation ▁hyper trop hy ▁trans verse _ a or tic _ con stri ction TAC
D-1815	-0.7095249891281128	tttMena_mice cardiac_ injury ejection_fraction fraction heart_ dilatation hypertrophy transverse_aortic_constrictionTAC
P-1815	-2.4603 -0.3265 -1.3098 -4.4049 -0.3423 -1.6322 -0.3764 -0.2379 -0.1018 -1.9901 -0.1697 -0.1878 -0.1876 -0.0382 -0.5324 -0.0026 -2.0675 -0.0010 -3.5479 -0.5729 -2.2696 -0.2419 -0.0163 -0.0489 -0.0161 -0.0648 -0.0028 -0.1259 -0.1982 -0.3653 -0.3305 -1.4886 -0.3060 -0.2699 -0.7966 -0.1341 -0.2583 -0.1389 -0.1090
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart_failure patients italy confirmatory_factor_analysis cfa schfi_v.6.2 self-care_maintenance self-care_management self-care_confidence
H-1505	-0.7402747869491577	▁heart _ ▁failure ▁Italy ▁c fa ▁ SCH f ▁Self - Car e _ ▁Main ten ance ▁Self - Car e ▁Management ▁Self - Car e _ ▁Confi den ce
D-1505	-0.7402747869491577	heart_ failure Italy cfa SCHf Self-Care_ Maintenance Self-Care Management Self-Care_ Confidence
P-1505	-2.5140 -0.6861 -1.3406 -2.1630 -0.6239 -0.5466 -1.0721 -1.3849 -1.8368 -1.8832 -0.0304 -1.2879 -0.0693 -0.3949 -0.6398 -0.1048 -0.0199 -0.1978 -0.0155 -0.8244 -0.0535 -1.8829 -0.1895 -0.0213 -0.9957 -0.0828 -0.2721 -2.1327 -0.0213 -0.0178 -0.2654 -0.1179
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation_for_ambulatory_heart_failure_trial implantable primary_end_point all-cause_mortality heart_failure hospitalization
H-882	-0.5549384951591492	▁re syn chron ization - Def i bril lation ▁Amb ulator y _ ▁Heart _ ▁Fail ure ▁implant able ▁cardio ver ter _ de _ fi br illa tor - c RT ▁mortal ity ▁heart _ ▁failure
D-882	-0.5549384951591492	resynchronization-Defibrillation Ambulatory_ Heart_ Failure implantable cardioverter_de_fibrillator-cRT mortality heart_ failure
P-882	-0.6066 -0.0008 -0.0004 -0.4021 -0.1044 -1.4204 -0.4947 -0.2300 -0.0136 -0.1183 -0.0354 -0.0928 -0.5997 -0.1541 -1.0114 -0.0618 -0.0740 -0.0267 -0.0381 -1.2792 -0.1240 -0.0167 -0.7271 -0.0146 -3.7983 -0.9578 -0.2735 -0.0017 -0.0916 -0.0782 -0.4395 -0.7844 -2.9443 -0.3118 -0.2567 -1.0697 -2.5933 -0.3039 -0.0905
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic_events ies patients ischemic_cardiomyopathy ic cardiac_resynchronization_therapy defibrillator crt-d
H-102	-0.8569574356079102	▁ ische mic ▁events ▁i e s ▁ ische mic _ ▁cardio my o pathy IC ▁cardiac _ re syn chron ization _ therapy ▁de fi br illa tor ▁c RT - d
D-102	-0.8569574356079102	ischemic events ies ischemic_ cardiomyopathyIC cardiac_resynchronization_therapy defibrillator cRT-d
P-102	-2.1670 -2.1205 -0.6317 -2.7223 -0.7916 -2.3538 -0.6643 -0.9726 -0.9308 -0.2604 -0.3869 -0.2776 -1.4953 -0.7798 -0.0166 -1.8809 -0.0355 -0.6249 -0.8206 -0.0083 -0.0012 -0.7113 -1.5149 -0.1098 -0.5845 -2.3952 -0.4443 -0.0073 -0.1228 -0.4862 -1.4481 -0.1131 -0.6763 -1.3220 -0.1149
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal_dysfunction chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks follow-up mortality ischemic_cardiomyopathy
H-69	-0.4346809983253479	▁renal ▁dys function ▁chronic _ ▁ob struct ive ▁pulmonar y ▁disease ▁diabetes ▁per i pher al _ ▁vas cular ▁disease ▁left ▁vent ri cular _ ▁e je ction _ fraction ▁i CD ▁shock s ▁ ische mic _ ▁cardio my o pathy
D-69	-0.4346809983253479	renal dysfunction chronic_ obstructive pulmonary disease diabetes peripheral_ vascular disease left ventricular_ ejection_fraction iCD shocks ischemic_ cardiomyopathy
P-69	-0.0857 -0.4666 -0.2984 -0.1056 -0.3349 -1.1609 -0.0475 -0.0702 -0.4208 -0.0780 -0.6130 -0.0559 -0.1732 -0.1364 -0.1188 -0.1228 -0.1386 -0.8738 -0.0942 -1.0715 -0.5165 -0.4483 -0.2268 -0.1564 -0.7431 -1.2930 -0.3943 -0.0567 -0.4960 -0.0057 -0.2342 -0.3390 -2.3880 -0.0412 -1.5152 -0.3725 -0.2779 -0.2856 -0.2931 -0.6798 -0.2934 -0.0254 -1.4626 -0.1142
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients chf testosterone exercise testosterone placebo
H-1318	-0.5724510550498962	▁CHF ▁SD ▁testosteron e
D-1318	-0.5724510550498962	CHF SD testosterone
P-1318	-0.2726 -1.1946 -0.2221 -0.0555 -1.6167 -0.0733
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold_proteins cardiac_remodelling field therapeutic
H-996	-0.9031804800033569	▁Raf - MEK _ 1/2 - er k ▁sc af fold _ ▁protein s ▁adapt ive ▁mal adapt ive ▁cardiac ▁remodel ling
D-996	-0.9031804800033569	Raf-MEK_1/2-erk scaffold_ proteins adaptive maladaptive cardiac remodelling
P-996	-0.3160 -0.0585 -0.0613 -5.0521 -1.2659 -0.0359 -0.3849 -0.1850 -5.3160 -0.8726 -0.1207 -1.0741 -0.7335 -0.0472 -1.5450 -0.0114 -3.1122 -0.0442 -0.0178 -0.1921 -0.4986 -0.3056 -0.3754 -0.0503
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional_ms lv_dilatation heart_failure hf functional_ms hf prolapse degenerative_mitral_valve
H-341	-0.9372466802597046	▁functional ▁MS ▁LV ▁di la tation ▁heart _ ▁failure ▁ HF ▁LV ▁functional ▁MS ▁ HF ▁MR ▁pro lapse ▁de genera tive _ m ral ▁val ve
D-341	-0.9372466802597046	functional MS LV dilatation heart_ failure HF LV functional MS HF MR prolapse degenerative_mral valve
P-341	-1.9202 -1.0150 -0.8672 -2.1885 -0.0394 -0.0050 -3.6295 -0.5593 -0.5368 -1.8667 -0.1509 -0.3259 -1.6647 -1.6597 -1.3821 -0.1986 -0.2865 -1.6606 -0.0541 -1.6186 -0.7309 -0.0322 -0.2592 -2.5891 -0.3579 -0.9668 -0.0569 -0.4822 -0.0759
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blockers β-blockers patients heart_failure medications medical
H-1130	-0.8339292407035828	▁ang io ten sin ▁convert ing _ ▁enzym e _ ▁inhibi tor ▁ang io ten sin - recept or _ block ers ▁β - block ers ▁heart _ ▁failure
D-1130	-0.8339292407035828	angiotensin converting_ enzyme_ inhibitor angiotensin-receptor_blockers β-blockers heart_ failure
P-1130	-1.5462 -4.1470 -0.6435 -1.0399 -0.0796 -0.3958 -1.2865 -0.4700 -0.1464 -0.7096 -0.0350 -0.1197 -0.1900 -2.5166 -0.7890 -1.3316 -0.7767 -0.0701 -0.3058 -1.8686 -1.6069 -0.0833 -0.4918 -0.0149 -0.0626 -0.0783 -1.1678 -1.3090 -1.2060 -1.2154 -0.1480
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new_york_heart_association_class kccq symptom spearman_correlations 2-way_anova patients hf_with_reduced_ef hfpef
H-783	-1.0351561307907104	▁New ▁York _ ▁Heart _ association ▁k cc q ▁symptoms ▁ HF ▁ef ▁ HF p EF
D-783	-1.0351561307907104	New York_ Heart_association kccq symptoms HF ef HFpEF
P-783	-3.5931 -0.7338 -1.0985 -0.6545 -0.7863 -0.6845 -0.5101 -0.0443 -0.5508 -3.0711 -1.4157 -1.0759 -3.0204 -1.0537 -0.3863 -0.3498 -0.3125 -0.2146 -0.1121
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic lv_ejection_fraction lv_strain strain systole diastolic lv_strain_rate diastole transmitral_flow patients sinus_rhythm follow-up
H-951	-0.9702111482620239	▁LV ▁e je ction _ fraction ▁LV ▁strain _ de _ stra in _ ▁rate ▁sy stol e ▁dia sto lic ▁indice s ▁LV ▁strain _ ▁rate ▁dia stol e ▁transmission ral _ f ré que nce ▁sinus ▁ rhythm
D-951	-0.9702111482620239	LV ejection_fraction LV strain_de_strain_ rate systole diastolic indices LV strain_ rate diastole transmissionral_fréquence sinus rhythm
P-951	-0.2504 -1.3275 -0.9139 -0.0633 -0.3674 -0.0018 -0.1146 -0.9857 -0.7364 -4.4596 -0.1983 -0.4172 -0.1821 -0.4550 -0.4751 -3.8594 -0.1251 -0.2451 -2.5122 -2.0128 -1.0778 -1.0662 -0.0078 -0.5804 -2.7126 -0.3852 -1.3056 -2.5779 -0.0384 -0.3412 -5.1395 -0.5673 -1.1474 -2.1627 -0.0745 -0.1038 -0.0760 -0.7529 -0.4001 -0.2097 -0.1728 -0.1461
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang_ii_infusion ang_ii_infusion uninephrectomy ang_ii_infusion salt_loading ang_ii_infusion uninephrectomy salt_loading
H-276	-1.397799015045166	▁c 57 b ▁angle _ ▁II ▁in fusion ▁un ine ph r ecto my ▁ANG _ ▁II ▁in fusion ▁salt _ ▁load ing ▁ANG ▁in fusion ▁un ine ph r ecto my ▁salt
D-276	-1.397799015045166	c57b angle_ II infusion uninephrectomy ANG_ II infusion salt_ loading ANG infusion uninephrectomy salt
P-276	-0.3601 -1.3379 -1.1964 -6.3342 -0.9942 -1.7620 -0.0763 -0.1975 -1.3074 -0.5034 -3.4245 -0.1586 -0.2178 -1.0775 -3.3922 -1.6429 -2.2215 -0.1279 -0.3801 -2.6764 -1.0424 -0.1727 -0.0185 -4.4054 -3.7875 -0.8932 -1.4822 -0.4275 -3.6514 -0.1262 -0.4388 -1.3298 -0.2236 -1.4263 -0.1084
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral_blood_flow_velocity tissue_doppler diastolic_mitral_annulus_velocity pulmonary_capillary_wedge_pressure pcwp patients decompensated_systolic_heart_failure hf
H-480	-1.134184718132019	▁transmission ral _ ▁blood _ ▁flow _ f ré que nce ▁do pp ler _ ▁early _ ▁dia sto lic _ met ral _ ▁ann ulus ▁pulmonar y _ ca illa ry _ we dge _ tension ▁p WP ▁sy sto lique _ ▁heart _ ▁failure HF
D-480	-1.134184718132019	transmissionral_ blood_ flow_fréquence doppler_ early_ diastolic_metral_ annulus pulmonary_caillary_wedge_tension pWP systolique_ heart_ failureHF
P-480	-4.9351 -0.8465 -1.0618 -1.2683 -0.9682 -0.2162 -1.9901 -3.2454 -0.0697 -0.1266 -0.0317 -2.2912 -0.0965 -0.3932 -2.8318 -0.5707 -0.1766 -1.4284 -2.0111 -2.6333 -0.2390 -3.0376 -0.0303 -0.6359 -0.3301 -0.4384 -0.7775 -0.0435 -0.6881 -1.1826 -0.6290 -0.3358 -0.0855 -2.4466 -0.0720 -0.5989 -0.5786 -1.2155 -1.7049 -2.3643 -1.2135 -3.8295 -0.2838 -1.5156 -0.8385 -2.7044 -0.2816 -0.1802 -0.1018
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak_vo2 exercise
H-1984	-1.579732894897461	▁VO 2 ▁exercise ▁masse
D-1984	-1.579732894897461	VO2 exercise masse
P-1984	-2.0124 -0.0706 -3.9039 -2.4037 -0.8309 -0.2569
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami patient hospital hospital_compare p-value
H-1698	-1.1850389242172241	▁ AMI ▁hospital
D-1698	-1.1850389242172241	AMI hospital
P-1698	-1.0958 -0.1090 -1.0703 -3.4867 -0.1633
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq patients hfpef log_rank ef
H-789	-1.046360731124878	▁k cc q ▁ HF p EF
D-789	-1.046360731124878	kccq HFpEF
P-789	-0.9815 -0.0410 -1.2158 -1.5926 -1.1083 -0.0727 -1.1048 -3.1578 -0.1428
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt nt-probnp report ctnt nt-probnp clinical hf
H-292	-0.6230165958404541	▁sex - specific ▁model ▁c t n t ▁NT - pro b NP ▁c t n t ▁NT - pro b NP ▁ HF
D-292	-0.6230165958404541	sex-specific model ctnt NT-probNP ctnt NT-probNP HF
P-292	-2.1484 -0.1007 -0.0660 -2.6854 -0.3027 -0.1139 -0.0266 -0.3974 -1.2472 -0.0246 -0.0206 -0.7168 -0.2047 -3.5081 -0.1622 -0.0262 -0.3313 -1.4911 -0.0215 -0.0776 -0.5797 -0.3360 -0.2577 -0.3561 -0.8604 -0.1356
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass_spectrometry c-terminally nt-probnp physiological proteolysis
H-1517	-0.7593188881874084	▁Mass _ spec tro met ry ▁n - ▁c - termin ally _ process ed _ ▁form s ▁circula ting ▁NT - pro b NP ▁physio logic al _ ▁prote ol ysis ▁le u 3- g ly
D-1517	-0.7593188881874084	Mass_spectrometry n- c-terminally_processed_ forms circulating NT-probNP physiological_ proteolysis leu3-gly
P-1517	-1.2048 -1.5618 -1.7518 -0.0635 -0.1351 -0.2972 -1.9707 -0.0394 -2.2901 -0.0337 -0.0187 -0.9749 -1.2594 -0.5288 -0.5635 -2.9902 -0.7513 -0.0403 -0.6068 -1.6753 -0.1065 -0.0191 -0.0482 -0.7707 -0.2135 -0.0187 -1.2478 -0.0514 -0.4970 -1.6122 -0.2569 -0.1561 -1.4527 -0.0157 -0.8381 -1.1319 -0.1560 -2.1700 -0.0941
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef patients new_york_heart_association_class_ii ejection_fraction fes placebo
H-1329	-1.1956815719604492	▁ HF p EF ▁patients ▁New ▁York _ ▁Heart _ association ▁mean _ ▁e je ction _ fraction
D-1329	-1.1956815719604492	HFpEF patients New York_ Heart_association mean_ ejection_fraction
P-1329	-0.5208 -0.7681 -0.2588 -0.5883 -3.7013 -2.2980 -1.0547 -1.1985 -1.1605 -0.5341 -1.1466 -2.8005 -0.1987 -1.9972 -0.9863 -0.0540 -0.5920 -0.0035 -3.9670 -0.0848
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left_ventricular systolic_pressure ejection_fraction fractional_shortening cardiac_output lv_end-diastolic_pressure mi metoprolol
H-1548	-0.926520049571991	▁de press ed _ ▁left _ vent ri cular LV ▁pressure ▁pressure ▁e je ction _ fraction ▁ fraction _ ▁short en ing ▁cardiac _ ▁output ▁LV ▁end - dia sto lic _ tension ▁MI ▁met o pro lol
D-1548	-0.926520049571991	depressed_ left_ventricularLV pressure pressure ejection_fraction fraction_ shortening cardiac_ output LV end-diastolic_tension MI metoprolol
P-1548	-1.2285 -0.0166 -0.4144 -1.6282 -0.7921 -0.4471 -0.5953 -0.9652 -0.1247 -0.4783 -5.0602 -2.6240 -0.4625 -0.2822 -0.0138 -0.8646 -0.0011 -1.2750 -0.0007 -2.0193 -1.3568 -0.0647 -0.9267 -1.2705 -1.9913 -0.2167 -0.2732 -2.6057 -0.0328 -1.7654 -0.9633 -2.0035 -0.7799 -0.6014 -2.3804 -0.9784 -0.0516 -0.0100 -0.1498 -0.1495 -0.1220
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex_activation_therapy_for_the_treatment_of_heart_failure_with_a_reduced_ejection_fraction clinical carotid baroreflex_activation_therapy bat heart_failure hf
H-1867	-0.8655301332473755	bar ore flex _ ▁Activ ation ▁Therapy ▁Heart _ ▁Fail ure ▁Red u ced _ e je ction _ fra ction
D-1867	-0.8655301332473755	baroreflex_ Activation Therapy Heart_ Failure Reduced_ejection_fraction
P-1867	-3.8387 -1.6526 -0.8735 -0.5263 -1.3567 -0.0086 -0.6302 -0.3568 -0.5646 -0.1497 -0.0624 -0.6843 -0.0294 -1.3379 -0.2725 -1.7586 -0.8869 -0.0403 -0.1557 -0.9389 -0.0132 -3.6896 -0.0799
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome hazard_ratio
H-1748	-1.459723711013794	▁en roll ment
D-1748	-1.459723711013794	enrollment
P-1748	-3.2525 -0.0504 -0.1292 -3.6635 -0.2029
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf blood_glucose obesity systemic_hypertension rheumatic_fever disease
H-1793	-0.7943308353424072	▁ HF ▁h f ▁raised ▁blood ▁gluco se ▁levels ▁obes ity ▁to ba cco ▁ aging ▁système ic ▁hyper tension SH ▁rhe u matic ▁fe ver ▁Cha gas ▁disease ▁c d
D-1793	-0.7943308353424072	HF hf raised blood glucose levels obesity tobacco aging systèmeic hypertensionSH rheumatic fever Chagas disease cd
P-1793	-1.4048 -0.1274 -2.3764 -0.3992 -4.1278 -1.2800 -0.5323 -0.0173 -2.6034 -0.1457 -0.5509 -0.0493 -0.0667 -0.0323 -0.1288 -0.0141 -1.0802 -3.2544 -0.8331 -0.0003 -1.0338 -0.0246 -0.0306 -0.2132 -0.1629 -0.0293 -1.2589 -0.0903 -1.8902 -0.6209 -0.9711 -0.7164 -0.1463
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard_ratios confidence_interval hf hf
H-1107	-1.3023028373718262	▁age - de _ sex - ad just ed ▁risk ▁h f
D-1107	-1.3023028373718262	age-de_sex-adjusted risk hf
P-1107	-0.7291 -0.1897 -5.6813 -0.8750 -2.7167 -0.2840 -0.0074 -0.0022 -0.3556 -1.9122 -3.2975 -1.5833 -0.4632 -0.1350
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard_ratios crf obese body_mass_index
H-1772	-1.7981568574905396	▁hazard ▁c RF
D-1772	-1.7981568574905396	hazard cRF
P-1772	-2.6920 -0.9190 -1.5642 -3.7160 -0.0996
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline egfr egfr egfr hypertension diuretics esrd
H-395	-0.935242772102356	▁e g f ▁e g f ▁un control led ▁hyper tension ▁di ure tics ▁temps ▁ES RD
D-395	-0.935242772102356	egf egf uncontrolled hypertension diuretics temps ESRD
P-395	-0.1442 -1.3063 -1.0613 -1.0734 -1.4674 -1.0761 -4.5272 -0.0109 -0.9816 -0.5326 -0.0004 -0.0499 -0.2596 -0.6722 -1.4692 -2.7555 -0.1205 -0.1476 -0.1137
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial phosphodiesterase-2 pde2 heart_failure hf beta-adrenergic_receptor β-ar healthy diseased cardiomyocytes
H-1208	-0.548250138759613	▁my o card ial _ phos pho dies tera se -2 ▁p de 2 ▁heart _ ▁failure HF ▁p de 2 ▁beta - ad r energi c ▁receptor β - AR ▁cardio my o cy tes
D-1208	-0.548250138759613	myocardial_phosphodiesterase-2 pde2 heart_ failureHF pde2 beta-adrenergic receptorβ-AR cardiomyocytes
P-1208	-0.6397 -0.1686 -0.0897 -0.6165 -0.5820 -0.1686 -1.6940 -1.9066 -0.1397 -0.2661 -1.9434 -0.1831 -0.0392 -1.9837 -0.5815 -0.7514 -0.6230 -0.6793 -0.1079 -0.0310 -1.5964 -1.5941 -0.0175 -0.0562 -0.0686 -0.4928 -0.0975 -0.1477 -0.4222 -0.0055 -0.2324 -0.4792 -0.8526 -0.4535 -0.2087 -0.6600 -0.1663 -0.0874
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart_failure patients cardiac_resynchronization_therapy defibrillator implantable_cardioverter-defibrillator carvedilol atp shock_therapy metoprolol
H-866	-0.8367902040481567	▁heart _ ▁failure ▁cardiac _ re syn chron ization _ therapy ▁de fi br illa tor ▁implant able ▁cardio ver ter - de fi br illa tor ▁device ▁car vedi lol ▁ATP ▁shock _ therapy ▁met o pro lol
D-866	-0.8367902040481567	heart_ failure cardiac_resynchronization_therapy defibrillator implantable cardioverter-defibrillator device carvedilol ATP shock_therapy metoprolol
P-866	-1.2648 -0.8020 -0.9251 -0.0823 -0.8133 -1.1388 -0.0330 -0.0023 -1.0316 -2.3160 -0.1660 -0.3569 -4.7847 -2.3509 -0.0170 -0.2336 -0.0006 -0.0107 -0.8890 -0.1322 -0.0331 -0.1487 -0.0043 -6.8074 -1.4504 -0.0167 -0.2642 -2.4586 -0.1881 -0.0439 -0.1060 -0.8332 -1.5680 -2.2119 -0.1081 -0.0684 -0.0588 -0.0088 -0.1511 -0.3267 -0.1012
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich_cocoa skm mitochondrial_structure taub ramirez-sanchez ciaraldi perkins murphy naviaux hogan ceballos maisel henry
H-1245	-0.39111262559890747	ERC ▁e pica tech in - rich ▁coco a ▁Sk m ▁mito cho ndri al _ ▁structure ▁ram i rez - s anche z ▁ci ar aldi ▁per kin s ▁Murphy ▁na vi aux ▁Hoga n ▁ce ball os ▁mais el ▁Henry
D-1245	-0.39111262559890747	ERC epicatechin-rich cocoa Skm mitochondrial_ structure ramirez-sanchez ciaraldi perkins Murphy naviaux Hogan ceballos maisel Henry
P-1245	-0.8314 -0.1831 -0.0166 -0.1062 -0.6792 -0.1500 -0.0015 -0.4857 -0.0246 -0.4019 -0.0530 -1.3368 -1.4402 -0.2275 -0.0301 -0.9500 -1.3651 -3.2073 -0.0666 -0.1430 -0.0077 -1.4242 -0.0038 -0.0009 -0.2153 -0.0298 -0.0024 -0.4549 -0.1162 -0.0134 -0.6063 -0.0898 -0.0052 -0.0035 -0.0363 -0.0034 -0.0340 -0.0424 -0.2682 -0.8990 -0.0010 -0.9492 -0.2072 -0.0950
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up death readmission patients physician physicians
H-1420	-1.778896450996399	▁consultation s ▁urgent _ ▁read mission
D-1420	-1.778896450996399	consultations urgent_ readmission
P-1420	-5.4889 -0.2227 -3.0837 -0.3326 -2.6560 -0.0524 -2.2746 -0.1203
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena_overexpression tac surgery mena cardiac_hypertrophy cardiac
H-1816	-1.2907755374908447	▁men a _ over expression ▁ TTA ▁mi ce ▁ TAC ▁cardiac _ ▁hyper trop hy
D-1816	-1.2907755374908447	mena_overexpression TTA mice TAC cardiac_ hypertrophy
P-1816	-2.4475 -0.7180 -1.0790 -2.9530 -0.0780 -1.8585 -0.2573 -4.0840 -0.1577 -0.7959 -0.1956 -2.9234 -1.3919 -1.2694 -0.0079 -0.0511 -2.8317 -0.1340
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd diuretic hf outcomes clinical hospitalizations pdrelated complications
H-901	-0.8638479709625244	▁p ▁di ure tic _ re frac tory _ ▁severe - end - s tage ▁ HF ▁PD
D-901	-0.8638479709625244	p diuretic_refractory_ severe-end-stage HF PD
P-901	-1.5468 -0.4148 -0.0352 -2.3991 -0.1110 -0.3480 -0.0529 -1.1997 -1.1038 -2.3760 -0.1829 -1.9080 -0.0315 -0.0915 -0.0016 -1.2335 -0.0402 -2.7790 -1.3459 -0.0756
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp mitochondrial_oxidation glucose lactate fatty_acids myocardial glycolysis
H-1785	-0.3925323784351349	▁ATP ▁a ac ▁mito cho ndri al ▁oxid ation ▁gluco se ▁lac tate ▁fa tty ▁acid s ▁my o card ial _ ▁gly col ysis
D-1785	-0.3925323784351349	ATP aac mitochondrial oxidation glucose lactate fatty acids myocardial_ glycolysis
P-1785	-0.1214 -2.9922 -1.2543 -0.0712 -1.0908 -0.1269 -0.0209 -0.3636 -0.0105 -0.0759 -0.0264 -0.0134 -0.0653 -0.0789 -0.4173 -0.4808 -0.0225 -0.4442 -0.0988 -0.1391 -0.4724 -0.4615 -0.5841 -0.6145 -0.0308 -0.3916 -0.1292
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic vegf_pathway intravenously injected adenoviral vegf_receptor adenovirus
H-456	-0.6870294213294983	▁pro angi ogen ic ▁effects ▁b ▁activa tion ▁VE GF _ ▁path way ▁a den ovi ral _ ▁ve ctor ▁de co y ▁VE GF _ ▁receptor ▁ad - f lk ▁ade no virus ▁ad - c
D-456	-0.6870294213294983	proangiogenic effects b activation VEGF_ pathway adenoviral_ vector decoy VEGF_ receptor ad-flk adenovirus ad-c
P-456	-0.3376 -0.2564 -0.0995 -0.8567 -0.8501 -0.5310 -4.3423 -0.0186 -3.1281 -0.1479 -2.0855 -1.1793 -0.1659 -0.3989 -0.0258 -1.3936 -0.0453 -0.7971 -1.8783 -0.2258 -0.1184 -0.0058 -0.0924 -2.5116 -0.2242 -2.4090 -0.0631 -0.6276 -0.0526 -0.0389 -0.0560 -0.0771 -0.0290 -0.0054 -0.3012 -0.0183 -0.0785 -1.2250 -0.0963
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients eplerenone potassium potassium hospitalization hyperkalemia medication adverse_events
H-1226	-0.6600191593170166	▁e pler en one ▁po tas s ium ▁po tas s ium ▁hyper kal emia ▁medication
D-1226	-0.6600191593170166	eplerenone potassium potassium hyperkalemia medication
P-1226	-0.8950 -1.0643 -0.5564 -5.5710 -0.0291 -0.5469 -0.2598 -0.1637 -0.0409 -0.5411 -0.1099 -0.2360 -0.0460 -0.2168 -0.1675 -0.8705 -0.4843 -0.0812
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation bottleneck_stent lad lcx myocardial_ischemia stent ischemic_heart_failure stent therapeutic
H-514	-0.6905400156974792	▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁proxima l ▁ LAD ▁ LC x ▁rever sible _ My o card ial _ ische mia ▁open ▁sten t ▁ ische mic _ ▁heart _ ▁failure ▁sten t
D-514	-0.6905400156974792	implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation proximal LAD LCx reversible_Myocardial_ischemia open stent ischemic_ heart_ failure stent
P-514	-0.0006 -0.0084 -0.9023 -0.0070 -1.4070 -0.0099 -1.4882 -0.0136 -1.4224 -0.0180 -1.2993 -0.0232 -1.1519 -0.0292 -1.0076 -0.0362 -0.8891 -0.0436 -0.8144 -0.0521 -0.7974 -0.0601 -0.8430 -0.0688 -0.9492 -0.0766 -1.1127 -0.0829 -1.3252 -0.0896 -1.5760 -0.0958 -1.8900 -0.0147 -0.9201 -0.0278 -2.4722 -0.8131 -0.3610 -2.1907 -0.0023 -0.4610 -3.6684 -0.3720 -0.1215 -0.0964 -0.3832 -2.4814 -0.3165 -2.9484 -0.0856 -0.0142 -0.3872 -0.7570 -0.2710 -0.8416 -1.3630 -1.0670 -0.7795 -0.4140 -0.0210 -0.1754 -0.0856
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient new_york_heart_association_class_iii heart_failure hf left_ventricular_ejection_fraction periodic_breathing pb report
H-1347	-1.1116989850997925	▁New ▁York _ ▁Heart _ association _ ▁class _ ▁III _ ▁heart _ ▁failure ▁h f ▁vent ri cular _ ▁e je ction ▁p
D-1347	-1.1116989850997925	New York_ Heart_association_ class_ III_ heart_ failure hf ventricular_ ejection p
P-1347	-5.8974 -0.9613 -1.4644 -1.3413 -0.6155 -0.9952 -2.1412 -0.1904 -0.4375 -0.6510 -0.7036 -2.4843 -0.6023 -1.7553 -1.5256 -0.4960 -0.1745 -0.3729 -0.1908 -0.3239 -1.7394 -0.4191 -0.0388 -1.7380 -1.5306 -0.1140
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium spironolactone aas
H-1705	-0.5432679653167725	▁po tas s ium ▁spi rono lac tone ▁AA s ▁race _ de _ ré que nce
D-1705	-0.5432679653167725	potassium spironolactone AAs race_de_réquence
P-1705	-0.3439 -0.5427 -0.0895 -0.1196 -0.1347 -0.0413 -0.3485 -0.3085 -1.0227 -0.1363 -0.5581 -0.4348 -3.5694 -0.1512 -0.6917 -0.8653 -0.0693 -0.7888 -0.1060
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom cpet patients chf patients exercise exercise patients exercise rehabilitation
H-1880	-1.068945050239563	▁c PET ▁CHF ▁exercise ▁rehabilita tion
D-1880	-1.068945050239563	cPET CHF exercise rehabilitation
P-1880	-0.2955 -0.6092 -0.1710 -2.9282 -4.1081 -0.0162 -0.3471 -0.0763
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography lv_end-diastolic_volume mitral_valve_opening mva
H-357	-0.8066347241401672	▁e cho card i ography ▁LV ▁end - dia sto lic ▁ml ▁mit ral ▁val ve ▁m va ▁pressure ▁h g
D-357	-0.8066347241401672	echocardiography LV end-diastolic ml mitral valve mva pressure hg
P-357	-0.0769 -0.7581 -0.1219 -0.2905 -0.2606 -0.9165 -2.6658 -0.0207 -0.8026 -0.6178 -1.1178 -1.9567 -2.9304 -0.0293 -1.4059 -0.2354 -0.2723 -0.2182 -0.7574 -2.5872 -0.0130 -0.4090 -0.0883
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical post-lvad_ai aortic_valve leaflet bioprosthetic_aortic_valve_replacement functional_capacity lvad patients symptomatic
H-552	-0.9035217761993408	▁l VAD ▁a or tic _ ▁val ve ▁le a flet ▁repair ▁bio pro sthetic ▁a or tic _ ▁val ve _ ▁replace ment ▁CF ▁l VAD
D-552	-0.9035217761993408	lVAD aortic_ valve leaflet repair bioprosthetic aortic_ valve_ replacement CF lVAD
P-552	-5.9620 -0.1163 -1.1647 -0.1193 -1.7955 -1.0608 -2.7925 -0.1736 -0.4321 -0.0157 -0.0060 -1.0718 -0.0020 -0.0025 -0.0072 -0.2790 -0.1040 -1.6908 -0.5112 -1.5506 -0.1515 -1.4335 -0.2855 -0.0092 -0.9212 -2.1601 -0.0313 -2.2273 -0.1249
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods_study health_care systolic_heart_failure prescribed β-blocker angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blocker
H-1123	-0.967122495174408	▁veteran s ▁VA ▁health _ care s ▁sy sto lic _ ▁heart _ ▁failure ▁β - block er ▁ang io ten sin _ ▁convert ing ▁enzym e _ ▁inhibi tor ▁ang io ten sin - recept or _ block er
D-1123	-0.967122495174408	veterans VA health_cares systolic_ heart_ failure β-blocker angiotensin_ converting enzyme_ inhibitor angiotensin-receptor_blocker
P-1123	-3.7215 -0.0633 -0.5004 -1.5138 -3.2661 -0.5912 -0.9908 -2.5671 -0.2241 -3.7485 -0.2133 -1.9538 -0.6830 -1.5745 -0.4183 -0.0194 -0.1509 -0.2207 -0.1660 -2.0774 -1.1364 -1.2846 -1.6315 -0.0890 -0.2896 -1.2267 -0.2496 -1.1261 -0.0578 -0.0408 -0.1333 -2.1403 -1.0912 -1.4382 -0.6562 -0.0937 -0.2042 -0.9320 -1.6214 -0.0906 -0.3074 -0.1143
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced_pulmonary_artery_systolic_pressure pasp stress_doppler_echocardiography right_ventricular_contractile_reserve patients pulmonary_hypertension right_heart_failure
H-822	-0.6391607522964478	▁exercise - indu ce ▁pulmonar y _ ▁arter y _ ▁sy sto lic _ tension PAS p ▁stress ▁do pp ler ▁e cho card i ography ▁right ▁vent ri cular _ contract ile _ ▁reserve ▁pulmonar y ▁hyper tension ▁right _ ▁heart _ ▁failure
D-822	-0.6391607522964478	exercise-induce pulmonary_ artery_ systolic_tensionPASp stress doppler echocardiography right ventricular_contractile_ reserve pulmonary hypertension right_ heart_ failure
P-822	-1.8856 -0.2293 -0.0007 -2.3045 -0.0835 -0.1001 -1.4891 -0.2095 -0.2239 -0.6488 -1.9468 -0.3746 -2.5887 -0.7539 -0.2840 -0.3276 -0.1892 -0.1831 -0.4070 -0.0301 -0.3476 -1.1562 -0.6774 -0.1411 -0.1159 -0.2480 -0.3224 -0.2542 -0.3850 -0.1408 -0.1967 -0.2877 -0.2336 -0.4997 -0.2096 -0.0923 -0.0926 -1.1297 -0.0003 -1.8189 -0.6027 -3.0929 -1.1061 -1.6919 -0.2120 -0.0860
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline embase healthstar cinahl cochrane_library campbell_collaboration joanna_briggs_institute_evidence_based_practice centre_for_reviews_and_dissemination evidence_based_practice_centres
H-1844	-0.5902906060218811	▁MED LINE EMBA se ▁HE al th STAR ▁c INA HL ▁co ch rane _ ▁Library ▁Campbell ▁Joan na _ ▁Brig gs ▁Institute ▁e viden ce _ ▁Base d _ ▁Practic e
D-1844	-0.5902906060218811	MEDLINEEMBAse HEalthSTAR cINAHL cochrane_ Library Campbell Joanna_ Briggs Institute evidence_ Based_ Practice
P-1844	-0.6988 -1.0766 -0.7416 -0.3097 -1.2185 -0.9592 -1.3296 -0.7322 -0.3860 -1.7183 -0.2913 -0.2034 -0.1007 -0.0201 -0.7360 -0.2245 -0.0648 -1.5339 -0.0144 -1.3225 -0.0629 -0.1026 -0.9347 -3.1515 -0.0811 -0.0172 -0.2273 -0.5536 -0.0318 -0.1374 -0.7339 -0.0749 -0.1507 -0.1279
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart_failure neuro-hormonal_system angiotensin_converting_enzyme_inhibitors angiotensin_receptor_blockers angiotensin_converting_enzyme_inhibitors beta_receptor_blockers mineralocorticoid_receptor_antagonists
H-647	-0.956061840057373	▁heart _ ▁failure ▁block ade ▁neuro - hormon al ▁système ▁ang io ten sin ▁convert ing _ ▁enzym e _ ▁inhibi teurs angi oten sin ▁convert ing _ ▁enzym e _ ▁inhibi teurs _ ▁in tolerance ▁mineral o cor tico id ▁receptor
D-647	-0.956061840057373	heart_ failure blockade neuro-hormonal système angiotensin converting_ enzyme_ inhibiteursangiotensin converting_ enzyme_ inhibiteurs_ intolerance mineralocorticoid receptor
P-647	-1.7662 -0.7062 -1.2629 -2.6132 -0.3158 -0.4990 -0.1369 -0.0170 -0.0594 -1.7555 -0.2523 -1.4233 -0.8434 -1.8488 -0.4633 -0.5502 -1.5397 -0.7817 -0.3541 -1.1596 -0.1324 -1.5768 -2.5918 -0.2720 -1.5305 -1.4606 -0.8003 -0.5324 -1.3104 -0.3796 -0.7290 -0.2199 -1.2542 -1.5984 -0.9537 -0.0518 -1.2308 -0.0872 -0.1741 -3.5308 -1.3426 -0.5988 -1.2560 -0.1040
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest rs rs_synchrony ste noninvasive rvpo rs_synchrony strain bivp
H-330	-1.1541355848312378	▁open _ ▁che st _ model ▁twist ▁RS ▁RS ▁synchron y ▁CS ▁ STE ▁ rte ▁ rv po ▁RS _ syn chron y ▁CS ▁bi VP
D-330	-1.1541355848312378	open_ chest_model twist RS RS synchrony CS STE rte rvpo RS_synchrony CS biVP
P-330	-0.6346 -0.3122 -1.8138 -0.0486 -1.7013 -1.4445 -0.0266 -0.2401 -0.9227 -0.1842 -0.3893 -1.6547 -1.6335 -2.1993 -2.9411 -1.8825 -1.9199 -1.5544 -1.7222 -2.2045 -2.0840 -0.1261 -0.0495 -1.4587 -1.6609 -1.0183 -0.2113 -1.2945 -0.1369
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse pasp tapse pasp cox_regression kaplan-meier_analyses tapse pasp
H-498	-1.1388225555419922	▁T AP se _ pass p ▁t AP se - to - pass p ▁ratio TA PS e _ pass p ▁co x _ re gression ▁Ka plan - me ier
D-498	-1.1388225555419922	TAPse_passp tAPse-to-passp ratioTAPSe_passp cox_regression Kaplan-meier
P-498	-4.2364 -0.7645 -0.6647 -2.9966 -1.0787 -0.7288 -2.2776 -1.0451 -0.3957 -0.1812 -0.3690 -0.0599 -1.1502 -0.3383 -2.0489 -5.6681 -1.5963 -0.8093 -1.7650 -2.4269 -0.3448 -0.2978 -0.0252 -0.6198 -0.6151 -0.0545 -1.0392 -0.1689 -0.0466 -0.5196 -0.1354 -2.9591 -0.1539
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese body_mass_index chronic stable hfpef
H-1978	-1.0016711950302124	▁obes e SD ▁body _ ▁mass _ ▁index ▁h f f f
D-1978	-1.0016711950302124	obeseSD body_ mass_ index hfff
P-1978	-2.3915 -0.0878 -2.4186 -1.2131 -0.8650 -2.2457 -1.2641 -0.2108 -0.6258 -0.5210 -0.5122 -1.0286 -0.5286 -0.1106
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart_failure hf mrna_splicing cardiac scn5a endoplasmic_reticulum
H-1080	-0.9664682745933533	▁heart _ ▁failure HF ▁m RNA ▁v ▁volta ge - ga ted _ ▁cardiac ▁na + sub un it ▁s cc 5 a ▁tru nca ted _ non function al ▁channel s ▁en do plas mic _ ▁reti culum
D-1080	-0.9664682745933533	heart_ failureHF mRNA v voltage-gated_ cardiac na+subunit scc5a truncated_nonfunctional channels endoplasmic_ reticulum
P-1080	-4.3367 -0.5505 -1.0048 -1.4406 -0.0132 -0.0483 -2.7369 -0.5442 -0.0110 -0.1341 -0.1267 -1.2102 -1.2532 -0.1322 -2.0176 -3.3183 -1.8958 -0.0444 -0.0256 -0.7933 -2.5158 -1.9069 -0.1706 -0.1503 -0.2029 -0.9714 -2.5717 -1.9262 -0.6626 -0.0784 -1.4383 -0.0481 -0.3560 -0.7359 -0.0615 -2.7152 -0.8528 -0.2382 -0.0025 -0.2767 -0.1055
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart_failure diagnosis myocarditis dilated_cardiomyopathy heart_failure heart_failure anthracycline disease
H-988	-0.7272993922233582	▁pa e dia tric _ ▁heart _ ▁failure ▁my o card itis ▁dil ated _ ▁cardio my o pathy ▁heart _ ▁failure ▁an thra cycli ne ▁malign ant _ ▁disease
D-988	-0.7272993922233582	paediatric_ heart_ failure myocarditis dilated_ cardiomyopathy heart_ failure anthracycline malignant_ disease
P-988	-1.2328 -0.0370 -3.7075 -1.8754 -0.8063 -1.4166 -0.6186 -0.4350 -1.0446 -0.2048 -0.2612 -0.4021 -0.1137 -0.1600 -0.7169 -0.0813 -0.6693 -0.3060 -0.0153 -0.5905 -0.7930 -0.5277 -0.1803 -0.1002 -1.3271 -0.3107 -1.3730 -0.1455 -1.1441 -1.6642 -0.9143 -0.0985
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model clinical evidence-based medications costs outcomes
H-2010	-1.1860902309417725	▁économique _ analys is ▁Patient _ management _ ▁Interven tions ▁Heart _ ▁Fail ure ▁Cost - E ffi ective ness _ ▁Model
D-2010	-1.1860902309417725	économique_analysis Patient_management_ Interventions Heart_ Failure Cost-Effiectiveness_ Model
P-2010	-1.1216 -4.1371 -0.9966 -0.0279 -1.7078 -1.8531 -1.0568 -2.1157 -0.9366 -0.0128 -0.5635 -0.6807 -0.1900 -0.0375 -0.6170 -0.0437 -2.9061 -2.0401 -1.0040 -0.8672 -1.7381 -1.4125 -2.3456 -0.0542
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic_peptides nps b-type_np n-terminal_pro-b-type_np diagnosis acute_heart_failure patients emergency_department acute_dyspnea
H-1020	-0.6621804237365723	▁na tri ure tic _ pe pti des NP s ▁b - type _ NP ▁n - termin al _ pro - b - type _ NP ▁a cute _ ▁heart _ ▁failure ▁Emer gen cy _ ▁Department ▁ed ▁a cute _ ▁dys pne a
D-1020	-0.6621804237365723	natriuretic_peptidesNPs b-type_NP n-terminal_pro-b-type_NP acute_ heart_ failure Emergency_ Department ed acute_ dyspnea
P-1020	-0.0024 -0.0273 -0.0741 -3.6331 -1.2676 -0.4511 -0.1421 -0.2585 -0.7516 -0.0561 -0.6470 -0.0661 -0.2003 -0.8563 -1.0558 -2.4391 -0.0176 -0.0050 -0.0048 -1.4960 -0.3043 -0.0172 -1.1484 -0.0392 -0.0697 -0.3903 -1.7132 -0.7343 -0.1129 -0.1529 -2.5781 -0.6099 -0.4440 -0.4508 -0.0541 -0.2105 -1.0969 -0.9306 -2.0891 -1.1986 -0.0254 -0.1048 -2.2168 -0.0512 -0.4735 -0.2784 -0.1755
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak_oxygen_consumption peak_vo2 exercise exercise_oscillatory_ventilation eov partial_pressure_of_end-tidal_co2 petco2 gain cardiopulmonary_exercise_testing
H-1275	-0.7539981603622437	▁oxygen _ ▁consum p tion ▁VO 2 ven ▁v co 2 ▁s lope ▁exercise _ ▁os cilla tory _ ▁ventilation ▁e OV ▁pressure ▁end - ti dal ▁CO 2 PET co 2 ▁cardio pul mon ary
D-1275	-0.7539981603622437	oxygen_ consumption VO2ven vco2 slope exercise_ oscillatory_ ventilation eOV pressure end-tidal CO2PETco2 cardiopulmonary
P-1275	-3.4063 -1.4958 -0.2761 -0.2147 -0.0755 -2.3799 -0.1913 -2.2700 -0.9898 -0.5115 -0.0149 -2.0239 -0.1657 -1.7857 -0.8647 -0.7430 -0.0023 -0.7013 -0.6557 -0.0915 -0.1536 -0.0857 -0.4441 -1.7641 -0.0328 -0.0017 -0.2483 -1.2314 -0.0146 -0.1904 -0.6477 -0.7263 -0.0390 -0.0936 -1.4126 -1.2825 -1.2846 -0.1394
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective_cohort_study denmark bisphosphonates raloxifene
H-1536	-1.1126855611801147	▁Denmark ▁bis phos phon ates ▁ra lo xi fen e
D-1536	-1.1126855611801147	Denmark bisphosphonates raloxifene
P-1536	-5.3803 -2.2834 -0.0521 -0.2535 -1.3885 -0.4489 -0.1794 -0.1805 -1.5076 -0.5208 -1.0745 -0.0827
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal strain left_ventricle echocardiographic patients baseline echocardiography crt follow-up echocardiograms
H-429	-0.900465190410614	▁longitud in al _ ▁strain _ de _ ▁left _ vent ric le ▁e cho car dio graphic _ ▁measure ments ▁patients ▁base line _ ▁e cho card i ography ▁c RT ▁e cho card i ogram s
D-429	-0.900465190410614	longitudinal_ strain_de_ left_ventricle echocardiographic_ measurements patients baseline_ echocardiography cRT echocardiograms
P-429	-3.9460 -0.1767 -0.0937 -1.2325 -1.1406 -1.2013 -1.7618 -0.1274 -1.1468 -0.5561 -0.3335 -4.5338 -0.6743 -0.0783 -0.3343 -0.1084 -0.6446 -0.5754 -3.2913 -1.0938 -0.0304 -3.7479 -0.8734 -0.0383 -0.8569 -0.8727 -0.5494 -0.1586 -0.6610 -0.3773 -0.1700 -1.1337 -1.7192 -0.3456 -0.1960 -0.7779 -0.0433 -0.1897 -0.1487 -0.0780
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension lv_dilatation lv_dysfunction mitral_valve organic lesion systolic diastolic_tethering etiology
H-365	-0.7439356446266174	▁hyper tension ▁LV ▁di la tation ▁LV ▁dys function ▁MR ▁MS ▁mit ral _ ▁val ve ▁ closure ▁organic ▁les ion ▁sy sto lic ▁dia sto lic _ ▁te ther ing ▁MR ▁MS
D-365	-0.7439356446266174	hypertension LV dilatation LV dysfunction MR MS mitral_ valve closure organic lesion systolic diastolic_ tethering MR MS
P-365	-0.3872 -0.0008 -0.0225 -1.2573 -0.0577 -0.0090 -0.0207 -0.1984 -0.3493 -0.7279 -1.0982 -1.8412 -0.0191 -1.2804 -2.3103 -0.1765 -3.4773 -0.1068 -3.2802 -0.3458 -0.0594 -0.2888 -0.0799 -0.7686 -0.6480 -0.4543 -1.4066 -1.0321 -1.0369 -0.0100 -0.0281 -2.0679 -1.0073 -0.1341 -0.0491
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl healthy hdl healthy patients chf-nyha-iii hdl nyha-iiib patients chf-nyha-ii hdl nyha-ii
H-250	-1.6419644355773926	▁HD l ▁healthy _ control s ▁h d l ▁CHF - NY HA - III ▁h d l ▁franc - NY ha - II ▁h d l
D-250	-1.6419644355773926	HDl healthy_controls hdl CHF-NYHA-III hdl franc-NYha-II hdl
P-250	-2.2050 -2.5563 -3.5995 -3.2676 -0.0157 -0.1140 -3.3652 -2.4632 -1.8926 -1.9880 -0.0854 -0.8141 -0.7533 -0.1279 -0.0516 -3.0241 -1.1819 -1.6492 -5.0237 -0.5399 -2.4395 -1.2869 -0.1013 -0.2384 -2.6795 -1.6393 -2.1463 -2.2817 -0.0860
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating_factor paf metabolic enzymes follow-up patients diagnosed heart_failure hf healthy
H-1267	-1.295005202293396	▁plate let - activa tion ▁factor pa f ▁metabol ic _ ▁enzym es ▁heart _ ▁failure ▁b mi
D-1267	-1.295005202293396	platelet-activation factorpaf metabolic_ enzymes heart_ failure bmi
P-1267	-0.7410 -1.0316 -0.1717 -0.0777 -4.6900 -2.8845 -2.3023 -0.0447 -0.0592 -0.1224 -1.9064 -0.4018 -0.0622 -2.7185 -1.2160 -2.0480 -2.8424 -1.6285 -0.8566 -0.0944
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute_care_surgery acs consultations oht transplantation medical_therapy intravenous inotropes ventricular_assist_devices vads
H-1281	-0.6117026209831238	▁a cute _ care _ ▁surgery ▁ac s ▁o HT ▁transplant ation ▁medical ▁ therapy ▁intra ven ous ▁in o trop es ▁vent ri cular _ assist ▁devices VAD s
D-1281	-0.6117026209831238	acute_care_ surgery acs oHT transplantation medical therapy intravenous inotropes ventricular_assist devicesVADs
P-1281	-0.0164 -0.0295 -0.3547 -2.4705 -0.8062 -0.7494 -2.5238 -0.9400 -0.1515 -2.1808 -0.3463 -0.0113 -1.0041 -0.5640 -0.0098 -1.0644 -0.0261 -2.7982 -0.3454 -0.3840 -0.0219 -0.1172 -0.0016 -0.1087 -0.0424 -0.7531 -0.2135 -0.3223 -0.1001 -0.5433 -0.4450 -0.1288
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone_system raas hfref angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers aldosterone_blockade evidence hfpef
H-1489	-0.7685193419456482	▁re nin - angi oten sin - al do ster one _ system _ ra as ▁h f f ▁ang io ten sin - con ver ting ▁enzym e _ ▁inhibi tors ▁ang io ten sin _ ▁receptor _ block ers ▁al do ster one _ block ade ▁ HF p EF
D-1489	-0.7685193419456482	renin-angiotensin-aldosterone_system_raas hff angiotensin-converting enzyme_ inhibitors angiotensin_ receptor_blockers aldosterone_blockade HFpEF
P-1489	-0.0458 -0.5420 -0.0299 -0.0723 -0.0085 -2.7537 -0.1949 -0.0561 -1.4834 -0.0951 -1.5399 -1.7469 -0.3241 -2.0293 -1.7380 -0.5060 -0.1585 -0.8822 -1.1074 -0.0109 -1.6850 -0.6935 -1.4092 -0.7352 -0.0037 -0.1270 -2.6680 -0.5717 -0.1375 -1.6883 -0.0202 -1.4110 -0.0810 -1.6662 -0.6403 -0.8717 -0.7451 -0.0843 -1.9012 -1.8006 -0.0503 -0.0266 -0.3159 -0.1008 -1.2963 -0.8797 -1.1734 -1.5229 -0.5868 -0.5020 -0.0572 -0.5692 -0.0772 -0.0761
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients hfpef ivabradine exercise_capacity left_ventricular_filling_pressure exercise peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1178	-1.0794836282730103	▁ HF p f ▁i va bra dine ▁vent ri cular _ ▁fill ing _ tension
D-1178	-1.0794836282730103	HFpf ivabradine ventricular_ filling_tension
P-1178	-1.2464 -0.8949 -1.0563 -0.5086 -0.0743 -0.0441 -1.2938 -0.0381 -1.2425 -0.4422 -0.1538 -3.2399 -2.3386 -0.1065 -0.4685 -0.6602 -5.5049 -0.1171
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission lvet patients outcome tonometric
H-583	-2.19054913520813	▁ad mission ▁l VET
D-583	-2.19054913520813	admission lVET
P-583	-4.1349 -0.0222 -0.7412 -4.0198 -4.0016 -0.2236
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart_rate blood_pressure renal_function spironolactone ras_blockers β-blockers
H-182	-1.1924396753311157	▁heart _ ▁rate ▁blood _ tension ▁renal _ fon cti onnement ▁spi rono lac tone ▁ RAS
D-182	-1.1924396753311157	heart_ rate blood_tension renal_fonctionnement spironolactone RAS
P-182	-3.2078 -2.1387 -2.2166 -2.1301 -1.0477 -0.5148 -0.1250 -4.8509 -2.3151 -0.2030 -0.1039 -0.0725 -0.0449 -0.4084 -0.3613 -0.5422 -0.1932 -2.0618 -0.1183
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac β-adrenoceptor_blockade heart_failure reverse cardiac_remodeling elevated plasma_catecholamines
H-1553	-0.7657991647720337	▁cardiac _ ▁performance ▁β - ad re no cept or _ block ade ▁heart _ ▁failure ▁SR ▁ca (2 +) - pump ▁cardiac _ ▁remodel ing ▁plasma ▁cate chol amine s
D-1553	-0.7657991647720337	cardiac_ performance β-adrenoceptor_blockade heart_ failure SR ca(2+)-pump cardiac_ remodeling plasma catecholamines
P-1553	-2.2007 -2.5775 -0.3949 -0.1677 -0.0148 -0.0500 -0.0651 -0.1778 -0.7962 -0.3733 -1.0328 -0.9098 -1.3228 -0.2915 -0.5554 -1.1899 -1.9342 -2.2201 -1.8705 -0.0100 -0.0414 -0.0635 -2.0603 -1.6787 -0.0239 -0.2590 -0.3060 -2.0253 -0.0103 -0.1394 -0.0549 -0.3108 -0.1430
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 congestive_heart_failure phenotypes mitochondrial tac mitochondrial_proteome mitochondrial nonmitochondrial_protein
H-874	-0.8985325694084167	▁SS 31 ▁con ges tive _ ▁heart _ ▁failure ▁mito cho ndri al _ ▁damage ▁ TAC ▁mito cho ndri al _ prote ome
D-874	-0.8985325694084167	SS31 congestive_ heart_ failure mitochondrial_ damage TAC mitochondrial_proteome
P-874	-1.0149 -2.0589 -0.5599 -0.2562 -0.1238 -0.4115 -1.6771 -0.6198 -0.5515 -0.2326 -1.7464 -0.6053 -0.0690 -1.3971 -1.1102 -1.0769 -0.0303 -0.2841 -1.3201 -0.2935 -0.0626 -0.9275 -2.2046 -1.2092 -3.4493 -0.0698
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action randomized exercise training patients hf left_ventricular_ejection_fractions hrqol kansas_city_cardiomyopathy_questionnaire kccq baseline
H-837	-0.7007938027381897	▁ HF - ac tion ▁ HF ▁vent ri cular _ ▁e je ction _ fraction s ▁HR Qo L ▁Kansas ▁City ▁Card i om yo pathy ▁k cc q
D-837	-0.7007938027381897	HF-action HF ventricular_ ejection_fractions HRQoL Kansas City Cardiomyopathy kccq
P-837	-1.1780 -0.4123 -0.0482 -0.9083 -0.3051 -1.2444 -0.4351 -1.1599 -0.2784 -0.2854 -0.8753 -1.3922 -1.2134 -0.0909 -1.9321 -0.0017 -0.0093 -0.5327 -0.0554 -1.1477 -0.0131 -1.4960 -1.4889 -0.1260 -0.0975 -2.5056 -0.1452 -2.4315 -0.0707 -0.3455 -0.1012 -0.0982
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan hyponatremia united_states japan congestive_heart_failure patients diuretic therapy serum_sodium systolic_function
H-1196	-0.719653844833374	▁to lv ap tan ▁hypo na trem ia ▁Japan ▁con ges tive _ ▁heart _ ▁failure ▁di ure tic ▁ therapy ▁se rum _ so dium
D-1196	-0.719653844833374	tolvaptan hyponatremia Japan congestive_ heart_ failure diuretic therapy serum_sodium
P-1196	-0.5781 -1.7298 -0.0485 -0.0291 -0.4168 -0.0610 -0.1585 -1.7968 -3.1136 -0.7613 -0.1684 -0.0972 -0.4201 -1.5253 -0.7251 -0.1538 -0.4953 -0.2291 -2.3002 -1.5093 -0.0321 -0.4444 -0.1294 -0.1689 -0.3477 -0.0077 -2.6219 -0.0807
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar atpase activity mrna phospholamban α-myosin_heavy_chain mrna β-myosin_heavy_chain metoprolol
H-1552	-0.6821370720863342	▁dé press ed ▁my o fi bril lar ▁ca (2 +) - stimul ated ▁ATP ase ▁m RNA ▁rs ▁ca (2 +) - pump ▁ phos pho lam ban ▁α - my os in _ ▁heavy _ ▁chain ▁m RNA ▁β - my os in _ ▁heavy _ ▁chain ▁met o pro lol
D-1552	-0.6821370720863342	dépressed myofibrillar ca(2+)-stimulated ATPase mRNA rs ca(2+)-pump phospholamban α-myosin_ heavy_ chain mRNA β-myosin_ heavy_ chain metoprolol
P-1552	-4.1752 -0.0323 -0.3643 -1.8457 -0.1626 -1.6517 -0.0987 -0.4791 -2.3017 -1.0098 -0.0090 -0.0477 -0.0498 -0.6484 -0.7157 -0.9997 -0.0538 -0.0996 -5.4634 -2.2337 -0.3078 -0.0034 -0.0131 -0.1473 -0.2394 -0.1193 -0.2076 -0.4279 -0.0232 -0.7447 -0.0076 -0.6463 -0.6116 -1.4214 -0.2741 -0.6362 -0.5833 -0.1409 -0.0836 -0.2909 -2.6638 -0.0081 -1.0631 -0.6826 -0.8159 -0.1710 -1.1593 -0.2149 -0.2447 -0.4161 -0.0599 -0.0369 -0.2942 -0.2045 -0.1109
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized coronary_microembolization-induced_hf cxl-1020 left_ventricular_end-diastolic_pressure myocardial_oxygen_consumption ejection_fraction maximal_ventricular_power_index
H-420	-0.5726842880249023	▁in est het ized ▁dog s ▁corona ry _ micro e mbol ization - indu ced ▁ HF ▁c XL -10 20 ▁vent ri cular _ ▁end - dia sto lic _ tension ▁my o card ial _ ▁oxygen ▁e je ction _ fraction ▁vent ri cular _ power
D-420	-0.5726842880249023	inesthetized dogs coronary_microembolization-induced HF cXL-1020 ventricular_ end-diastolic_tension myocardial_ oxygen ejection_fraction ventricular_power
P-420	-1.5000 -0.0226 -1.3602 -0.7937 -0.3162 -0.0177 -0.1060 -0.1918 -0.3742 -0.8868 -0.3214 -0.0005 -0.3486 -0.2767 -0.0000 -1.2420 -0.3984 -0.0213 -0.7583 -0.1727 -1.8034 -0.5770 -0.8575 -0.2394 -0.0979 -1.5307 -1.5276 -0.0386 -1.2097 -0.5646 -1.2627 -1.5297 -0.5354 -0.2693 -0.0616 -0.1739 -0.1935 -0.2867 -1.1638 -0.9356 -0.2348 -0.0284 -2.1676 -0.0031 -0.0183 -0.2514 -0.1744 -0.2214 -1.0471 -0.9795 -0.1132
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline heart_failure t1-mapping administration administration
H-1061	-2.1332714557647705	▁heart _ ▁failure ▁t 1- ma pping
D-1061	-2.1332714557647705	heart_ failure t1-mapping
P-1061	-4.5778 -1.1205 -2.5756 -4.5656 -0.5017 -0.2326 -0.1094 -5.4105 -0.1058
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard_error_of_measurement mdc mdc
H-805	-1.2611262798309326	▁m d c ▁m d c ▁m d c
D-805	-1.2611262798309326	mdc mdc mdc
P-805	-0.4509 -0.4391 -2.9902 -1.1715 -0.1920 -1.4503 -2.5225 -0.1656 -1.3648 -2.9591 -0.1663
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies hf idiopathic_dilated_cardiomyopathy ischemic valvular
H-1794	-0.515450119972229	▁ HF ▁ idio pathi c ▁dil ated _ ▁cardio my o pathy ▁c d ▁ ische mic ▁SH ▁val vu lar ▁alcohol
D-1794	-0.515450119972229	HF idiopathic dilated_ cardiomyopathy cd ischemic SH valvular alcohol
P-1794	-1.0067 -0.6210 -1.5033 -2.6695 -0.0415 -0.1011 -0.4942 -0.1783 -1.0152 -0.0885 -0.8331 -0.4938 -0.0064 -0.0421 -2.2087 -0.1758 -0.2868 -0.0592 -0.2302 -0.0271 -0.0680 -0.1050 -0.0964 -0.4560 -0.0783
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 functional_capacity clinical outcomes ambulatory patients hf heart_failure outcomes exercise training hf-action randomized exercise training hf
H-697	-0.795615553855896	▁ST 2 ▁functional _ capaci tation ▁ambula tory ▁patients ▁ HF ▁Heart _ ▁Fail ure ▁Exerci se _ ▁Training ▁h - ac tion ▁exercise _ training ▁ HF
D-697	-0.795615553855896	ST2 functional_capacitation ambulatory patients HF Heart_ Failure Exercise_ Training h-action exercise_training HF
P-697	-0.4224 -0.1784 -1.5314 -1.2966 -1.3784 -2.6560 -1.4840 -0.5270 -0.4893 -0.5617 -0.1214 -1.2245 -0.3617 -0.2277 -0.0344 -2.3039 -0.0705 -0.1981 -0.2281 -2.2719 -0.6514 -0.7640 -0.3975 -1.7449 -0.3581 -0.9034 -0.7983 -0.4035 -0.1635 -0.1166
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol metoprolol endpoint implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-856	-0.6434975266456604	▁implant able _ car vedi lol ▁met o pro lol ▁implant able _ ▁cardio ver ter - de _ fi br illa tor ▁ therapy ▁MAD t - c RT ▁multi center _ automat ic _ de ib rilla tor ▁implant ation ▁Card iac _ re syn chron ization ▁Therapy
D-856	-0.6434975266456604	implantable_carvedilol metoprolol implantable_ cardioverter-de_fibrillator therapy MADt-cRT multicenter_automatic_deibrillator implantation Cardiac_resynchronization Therapy
P-856	-0.2618 -0.0425 -1.9207 -0.8502 -0.2176 -0.3620 -0.2355 -0.0640 -0.0119 -0.3749 -0.0118 -0.0799 -0.6239 -2.3718 -0.1686 -0.0544 -0.1580 -0.0139 -3.1796 -4.4974 -1.0268 -0.0085 -0.3229 -1.8164 -0.0291 -0.0690 -2.3357 -0.0192 -0.1996 -1.4999 -1.4538 -0.0962 -0.0639 -0.2990 -0.3162 -0.1929 -0.4618 -2.3784 -0.3510 -0.1051 -0.0977 -0.0141 -0.6050 -0.1644 -0.2811 -1.0657 -0.0122 -0.0005 -0.5800 -1.8539 -0.1472 -0.0943
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate_ratio confidence_interval angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers therapy confidence_interval β-blockers therapy
H-666	-0.8192757964134216	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors angi oten sin ▁receptor _ block ers ▁β - block ers
D-666	-0.8192757964134216	angiotensin-converting enzyme inhibitorsangiotensin receptor_blockers β-blockers
P-666	-1.6747 -3.1702 -0.4673 -1.4057 -0.4566 -0.0023 -0.1392 -2.5890 -0.4475 -0.2163 -0.3950 -1.5610 -0.9928 -0.0116 -0.8533 -0.8527 -2.3213 -0.7461 -0.0312 -1.0977 -0.0103 -0.1252 -0.0391 -0.7237 -0.1518
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ischemic_hf pathogenesis nyha_functional_class_iv estimated_glomerular_filtration_rate heart_rate hypertension diabetes_mellitus myocardial_infarction
H-1704	-0.7316972613334656	▁ ische mic ▁ HF ▁NY HA _ ▁functional _ ▁class _ ▁IV ▁glo mer ular _ ▁filtr ation _ ▁rate ▁heart ▁hyper tension ▁diabetes ▁mell itus ▁my o card ial _ ▁in far ction
D-1704	-0.7316972613334656	ischemic HF NYHA_ functional_ class_ IV glomerular_ filtration_ rate heart hypertension diabetes mellitus myocardial_ infarction
P-1704	-1.9180 -1.6430 -0.3469 -1.4920 -0.1806 -0.7172 -0.4407 -2.1952 -1.2450 -1.5810 -0.2112 -0.6941 -0.4215 -0.1192 -0.0216 -0.0585 -1.1879 -0.4927 -0.0133 -1.8415 -0.4244 -0.8775 -1.8203 -0.0004 -0.0593 -0.8277 -0.0227 -0.9400 -0.4030 -0.1633 -0.3131 -0.4733 -0.7141 -1.4371 -0.1194 -1.5097 -0.1463
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt systolic_dysfunction outcomes resynchronization_reverses_remodeling_in_systolic_left_ventricular_dysfunction reverse patients left_ventricular ejection_fraction lvef
H-752	-0.7273043990135193	▁c RT ▁sy sto lic _ ▁dys function ▁re syn chron ization _ re ve rse s _ re model ing ▁Sy sto lic _ ▁left _ ▁v _ en tri cular _ ▁dys function ▁left ▁vent ri cular LV ▁e je ction _ fraction LV EF
D-752	-0.7273043990135193	cRT systolic_ dysfunction resynchronization_reverses_remodeling Systolic_ left_ v_entricular_ dysfunction left ventricularLV ejection_fractionLVEF
P-752	-0.1454 -1.7182 -2.5773 -0.4251 -3.9577 -0.3540 -0.8920 -0.7659 -1.0100 -0.0167 -0.0015 -0.7585 -0.3660 -0.4127 -1.8036 -0.0489 -0.0158 -1.2115 -0.1627 -0.7539 -0.0870 -0.4267 -0.0784 -1.8085 -0.5215 -0.2619 -0.6861 -1.2240 -3.3179 -1.3154 -0.1442 -0.1917 -0.6345 -0.1115 -0.4204 -2.0623 -1.3716 -0.1664 -0.0766 -0.6521 -1.1361 -0.2175 -0.0203 -0.4259 -0.0038 -0.1358 -0.4664 -0.1559 -0.1199
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars s1pr1s myocyte camp report receptors g-protein-coupled_receptor kinase-2
H-1408	-0.6498335003852844	▁β 1 AR s ▁s 1 PR 1 s ▁my o cy te ▁c AMP ▁receptor s ▁g - prote in - co up led ▁receptor _ ▁kina se
D-1408	-0.6498335003852844	β1ARs s1PR1s myocyte cAMP receptors g-protein-coupled receptor_ kinase
P-1408	-2.1209 -0.9863 -0.6992 -0.3100 -2.3209 -0.1442 -0.3098 -0.7510 -0.1415 -0.7252 -0.1188 -0.2255 -0.1534 -0.4385 -0.2857 -2.2980 -0.2858 -2.4978 -0.0857 -0.3311 -0.4368 -0.1821 -0.0132 -0.0062 -0.3648 -0.8093 -1.5207 -0.4098 -0.0142 -1.0353 -0.1232
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up paf-cpt paf lyso-paf-at downregulated paf-ah lp-pla2 elevated
H-1270	-0.8956266641616821	▁PA f - c p ▁PA f ▁lys o - pa f - AT ▁p p - PLA 2
D-1270	-0.8956266641616821	PAf-cp PAf lyso-paf-AT pp-PLA2
P-1270	-1.5397 -0.0697 -0.2461 -0.2754 -1.2412 -2.1052 -0.0968 -4.4123 -0.0387 -0.0224 -0.6180 -0.0679 -0.5238 -0.9783 -2.3621 -2.3138 -0.2382 -0.7941 -0.2928 -0.4133 -0.1582
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic patients auc auc
H-488	-1.3814843893051147	▁a UC
D-488	-1.3814843893051147	aUC
P-488	-3.1087 -1.2156 -0.8869 -0.3148
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control patients cardiac driven cardioversions costs antiarrhythmic_drugs cad patient confidence_interval patient
H-1239	-0.943096935749054	▁Rate - control ▁cardiac ▁procedure s ▁cardio version s ▁costs ▁anti ar rhythm ic ▁drugs ▁c
D-1239	-0.943096935749054	Rate-control cardiac procedures cardioversions costs antiarrhythmic drugs c
P-1239	-1.2700 -0.0935 -0.0038 -2.5582 -4.6626 -0.0139 -0.2154 -0.0078 -0.0481 -1.4132 -0.1806 -1.0744 -0.2035 -0.1194 -1.7607 -1.7428 -1.5090 -0.0988
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients follow-up patients spironolactone hospitalization hazard_ratio confidence_interval death hazard_ratio confidence_interval
H-443	-0.9705939888954163	▁spi rono lac tone ▁hospital ization
D-443	-0.9705939888954163	spironolactone hospitalization
P-443	-2.9754 -0.0810 -0.3194 -0.4312 -1.3405 -1.5680 -0.9059 -0.1434
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients bundle_branch_morphology diabetes_mellitus cardiomyopathy β-blocker angiotensin-converting_enzyme_inhibitor angiotensin_ii_receptor_blocker
H-906	-0.682266891002655	▁diabetes ▁mell itus ▁cardio my o pathy ▁β - block er ▁ang io ten sin - con ver ting ▁enzym e _ ▁inhibi tor ▁ang io ten sin _ II ▁receptor _ block er
D-906	-0.682266891002655	diabetes mellitus cardiomyopathy β-blocker angiotensin-converting enzyme_ inhibitor angiotensin_II receptor_blocker
P-906	-1.6444 -1.2063 -0.1299 -0.0120 -0.6481 -0.4213 -0.0174 -1.4027 -0.0106 -0.0959 -0.1458 -0.0710 -1.2128 -0.9312 -1.2976 -0.5113 -0.0099 -0.1220 -3.0815 -0.5667 -0.1912 -1.2402 -0.0537 -0.0650 -0.1435 -1.2203 -0.6975 -0.7690 -0.6062 -1.2705 -0.3432 -1.5822 -1.9824 -0.1053 -0.6186 -0.1347
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone_post_myocardial_infarction_heart_failure_efficacy_and_survival_study ephesus post-myocardial_infarction patients heart_failure mortality hospitalizations patients randomized aldosterone_antagonist eplerenone
H-1737	-1.1624196767807007	▁e pler en _ Post _ my o card ial _ ▁in far ction _ ▁Heart _ ▁failure ▁ef fica cy ▁ed ge SUS ▁post - my o card ial _ ▁in far ction ▁heart _ ▁failure ▁al do ster one _ ▁anta gon ist ▁e pler en
D-1737	-1.1624196767807007	epleren_Post_myocardial_ infarction_ Heart_ failure efficacy edgeSUS post-myocardial_ infarction heart_ failure aldosterone_ antagonist epleren
P-1737	-0.1664 -0.3756 -0.6862 -5.1740 -1.4465 -0.3531 -5.0158 -1.0689 -0.4799 -0.6282 -0.2625 -0.8487 -2.9644 -0.0885 -2.5057 -0.3128 -0.3555 -0.5030 -2.8498 -0.0212 -0.9496 -1.9454 -5.5283 -0.2844 -0.7077 -0.0178 -2.9457 -0.6817 -0.7220 -0.3862 -0.3043 -0.5361 -3.4043 -0.0730 -0.9102 -0.8442 -0.4780 -1.0592 -0.2801 -0.0899 -1.1197 -1.0431 -0.0668 -0.0556 -1.4438 -0.7164 -0.7089 -0.2746 -4.2611 -0.1762
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report cardiopulmonary_exercise_testing exercise_rehabilitation patients chronic_heart_failure exercise_rehabilitation patient chronic_heart_failure chf clinical cardiopulmonary_exercise_testing cpet exercise_rehabilitation china
H-1879	-1.1983232498168945	▁cardio pul man ary _ ▁exercise _ ▁rehabilita tion ▁patients _ ▁with _ chron _ ▁heart _ ▁failure ▁ch f ▁Card io P ul mon ary _ ▁Exerci se _ ▁Test ing ▁c PET ▁exercise _ ▁rehabilita tion
D-1879	-1.1983232498168945	cardiopulmanary_ exercise_ rehabilitation patients_ with_chron_ heart_ failure chf CardioPulmonary_ Exercise_ Testing cPET exercise_ rehabilitation
P-1879	-0.4161 -0.3788 -4.7540 -1.3388 -1.6682 -0.9241 -0.8125 -2.9000 -0.0193 -1.5016 -1.0643 -3.3772 -0.8224 -1.2208 -2.4110 -1.1020 -0.5415 -1.0926 -2.9790 -0.0523 -0.7397 -0.7794 -2.4060 -0.2456 -4.5436 -0.6052 -0.4695 -0.1638 -0.0641 -1.8656 -0.4312 -0.0450 -0.1777 -0.3339 -1.2911 -0.3572 -1.6402 -0.0252 -2.2040 -0.1687
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence_interval heart mortality death
H-1749	-1.3602044582366943	▁risk _ re duction ▁h ▁heart _ ▁failure _ related _ ▁mortal ity
D-1749	-1.3602044582366943	risk_reduction h heart_ failure_related_ mortality
P-1749	-2.9833 -1.3963 -0.5729 -0.0123 -0.5387 -3.6565 -0.5605 -5.0587 -1.4383 -0.1895 -0.7561 -0.7968 -0.4713 -1.8111 -0.1608
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash clinic brachial_systolic_pressure central_end-systolic_pressure
H-924	-1.522973895072937	▁DAS h _ s RD ▁bra chi al _ syn chron e _ syn chron e _ tension ▁central _ en - sy sto lic _ tension ▁h g
D-924	-1.522973895072937	DASh_sRD brachial_synchrone_synchrone_tension central_en-systolic_tension hg
P-924	-0.0110 -0.2687 -4.2609 -0.3215 -0.6491 -4.8605 -0.0825 -0.5253 -0.2406 -1.9648 -1.9363 -2.8562 -0.5436 -4.1471 -1.1093 -1.3849 -0.8837 -1.7385 -2.4311 -0.3517 -6.0300 -0.3305 -1.5300 -1.2921 -4.3139 -1.0797 -1.0674 -0.4732 -0.0319 -0.3663 -0.1300
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause_mortality hospitalization hf lvef patients heart_failure_survey israel
H-113	-0.6971503496170044	▁all - ca use _ ▁mortal ity ▁ HF ▁LV EF ▁Heart _ ▁Fail ure _ ▁Survey ▁IS ra el
D-113	-0.6971503496170044	all-cause_ mortality HF LVEF Heart_ Failure_ Survey ISrael
P-113	-3.4925 -0.0371 -0.0170 -0.1001 -0.4810 -0.1460 -0.2953 -0.7406 -0.2884 -0.1750 -0.4488 -2.4807 -0.7215 -0.2348 -0.1263 -2.5141 -0.4231 -2.2911 -0.0266 -0.0117 -0.1766 -0.1093
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients hf obese body_mass_index idiopathic-dilated_cardiomyopathy
H-558	-0.8135673403739929	▁ HF ▁obes e ▁body _ ▁mass _ ▁index ▁black ▁et hni city ▁ idio pathi c - dila ted _ ▁cardio my o pathy
D-558	-0.8135673403739929	HF obese body_ mass_ index black ethnicity idiopathic-dilated_ cardiomyopathy
P-558	-1.8969 -0.2900 -2.0599 -0.0965 -1.4850 -0.5094 -3.7744 -0.9467 -0.2036 -0.6989 -2.2718 -0.2243 -2.6940 -0.1561 -0.0658 -0.0416 -0.2743 -0.1984 -0.0146 -1.1113 -0.5179 -0.1649 -1.3127 -0.5577 -0.0155 -0.2839 -0.1002
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients left_ventricular_ejection_fraction world_health_organization idiopathic_dilated_cardiomyopathy coronary_angiography followed_up
H-1743	-0.5948600769042969	▁vent ri cular _ ▁e je ction _ fraction ▁World _ ▁Health ▁Organization ▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁negative ▁corona ry _ ▁ang i ography
D-1743	-0.5948600769042969	ventricular_ ejection_fraction World_ Health Organization idiopathic_ dilated_ cardiomyopathy negative coronary_ angiography
P-1743	-0.6176 -0.3206 -0.2479 -0.9288 -1.8953 -0.4705 -0.0520 -0.7618 -0.0003 -0.3703 -0.7444 -1.7029 -1.2899 -1.3864 -0.0552 -0.0731 -0.2068 -0.2359 -0.6550 -0.3238 -0.5999 -0.1905 -1.8853 -0.6566 -0.0293 -0.0757 -0.8060 -0.4614 -0.7786 -1.4121 -0.3011 -0.1887 -0.3889 -0.1126
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european_society_of_cardiology hfpef symptoms heart_failure preserved_lv_ejection_fraction non-dilated_left_ventricle evidence diastolic_dysfunction lv_relaxation lv_diastolic_stiffness elevated lv_filling_pressures
H-27	-0.9345108866691589	▁European ▁Society _ of _ ▁Card i ology ▁h f f f ▁heart _ ▁failure ▁LV ▁e je ction _ fraction _ de _ a _ non - dila ted _ ▁left _ vent ric le ▁dia sto lic _ ▁dys function ▁implant ation ▁LV ▁dia sto lic _ ▁sti ff ness ▁LV ▁fill ing
D-27	-0.9345108866691589	European Society_of_ Cardiology hfff heart_ failure LV ejection_fraction_de_a_non-dilated_ left_ventricle diastolic_ dysfunction implantation LV diastolic_ stiffness LV filling
P-27	-3.8894 -1.0062 -0.0648 -1.3827 -0.2295 -1.0249 -0.2427 -0.7669 -0.3541 -0.1958 -0.1090 -0.2893 -1.2375 -0.4332 -0.9554 -0.5901 -2.2935 -0.2688 -0.0133 -2.0345 -0.0044 -3.5052 -0.9431 -0.3358 -2.3499 -0.9712 -0.9601 -0.0028 -0.0833 -0.2674 -1.0559 -0.3016 -0.9386 -0.3021 -3.1680 -0.2722 -0.5582 -0.5762 -2.3739 -0.2828 -1.3692 -0.1092 -3.4148 -0.3263 -0.0745 -2.0336 -0.4117 -1.9973 -0.2902 -1.0643 -0.6053 -0.7276 -0.9805 -0.4624 -0.0519 -2.6272 -0.0871
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated_glomerular_filtration_rate egfr type_2_diabetes cholesterol ldl-cholesterol clcnka genotype
H-1803	-0.8687089681625366	▁glo mer ular _ ▁filtr ation ▁e g f ▁diabetes ▁cholesterol ▁l DL - ch olesterol ▁CL CN ka _ GG
D-1803	-0.8687089681625366	glomerular_ filtration egf diabetes cholesterol lDL-cholesterol CLCNka_GG
P-1803	-0.3411 -0.1191 -0.0967 -1.1937 -0.8528 -0.0239 -1.3043 -1.9365 -1.2202 -0.2001 -0.3450 -1.4334 -1.4550 -0.4586 -1.4964 -0.0008 -1.0713 -2.1948 -1.3258 -1.9305 -0.3033 -0.5709 -0.1061
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography lv_end-diastolic_dimension lv_end-diastolic_pressure wall_stress lung acf
H-474	-1.1452029943466187	▁e cho card i ography ▁LV ▁end - dia sto lic _ dimension ▁LV ▁end - dia sto lic _ tension _ de _ wall _ ▁stress ▁lung _ ▁weight ▁a CF ▁sham
D-474	-1.1452029943466187	echocardiography LV end-diastolic_dimension LV end-diastolic_tension_de_wall_ stress lung_ weight aCF sham
P-474	-0.2019 -1.9811 -0.7382 -0.3625 -0.2209 -0.8218 -1.3531 -0.0468 -2.0210 -1.3486 -3.0968 -1.6873 -0.0568 -1.1696 -1.4967 -0.0289 -2.1242 -1.1480 -3.5310 -0.6907 -0.3345 -2.0080 -3.1653 -0.2366 -2.8118 -0.5033 -2.0121 -0.0505 -0.8512 -0.9220 -0.5496 -0.9080 -0.6807 -0.7987 -0.1239
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients heart_failure ejection_fraction cardiac_rehabilitation walking exercise
H-570	-0.8988608717918396	▁heart _ ▁failure ▁e je ction _ fraction ▁cardiac _ ▁rehabilita tion _ care ▁Nordic _ ▁walking
D-570	-0.8988608717918396	heart_ failure ejection_fraction cardiac_ rehabilitation_care Nordic_ walking
P-570	-2.2864 -0.8383 -1.6684 -2.7269 -0.5409 -0.0187 -0.6223 -0.0008 -0.6558 -1.1368 -0.6472 -0.0415 -1.0028 -2.2731 -0.2991 -0.8927 -1.0891 -0.2249 -0.1128
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard_ratios sitagliptin pioglitazone sitagliptin sulfonylureas sitagliptin insulin
H-1836	-0.6588207483291626	▁d RS - stra t ified ▁hazard ▁ratio s ▁si tag lip tin ▁pi og lita zone ▁si tag lip tin ▁sul fon yl ure as ▁si tag lip tin ▁insulin
D-1836	-0.6588207483291626	dRS-stratified hazard ratios sitagliptin pioglitazone sitagliptin sulfonylureas sitagliptin insulin
P-1836	-0.1058 -1.8318 -0.2937 -0.0176 -0.0113 -0.0785 -1.1036 -2.4380 -0.0176 -0.9033 -0.0047 -0.8712 -2.0342 -0.0920 -2.8774 -0.1138 -0.1573 -0.1873 -0.0086 -0.4896 -1.6931 -0.5586 -0.0069 -0.3080 -0.0544 -0.1387 -1.9083 -0.0132 -0.7605 -2.2513 -0.1095 -0.2007 -0.1005
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal_muscle t-score fontan sarcopenic_range_muscle_wasting t-score clinically t-score
H-1501	-1.2575312852859497	▁skelet al _ pu issa nce ▁t - s core ▁figure ▁sar co pen ic _ ▁range _ de _ pu issa nce
D-1501	-1.2575312852859497	skeletal_puissance t-score figure sarcopenic_ range_de_puissance
P-1501	-0.1759 -0.1238 -0.7342 -5.9002 -0.0920 -0.0421 -1.1656 -0.0462 -0.0382 -0.4013 -3.2234 -1.1844 -0.0698 -0.7742 -1.5669 -1.2496 -0.7909 -0.3984 -3.7318 -0.2396 -5.0651 -0.0281 -0.0389 -4.2787 -0.0791
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker uptitrations composite_end-point all-cause_mortality hf readmissions hfref hazard_ratio confidence_interval
H-181	-0.756651759147644	▁ RAS - ▁β - block er _ up ti tra tions ▁all - ca use _ ▁mortal ity ▁h f f ▁h f
D-181	-0.756651759147644	RAS- β-blocker_uptitrations all-cause_ mortality hff hf
P-181	-0.8698 -0.0868 -0.8454 -0.7482 -0.0054 -0.0990 -0.0716 -3.3523 -1.1038 -0.0463 -0.1749 -0.0814 -4.2196 -0.0039 -0.0023 -0.0341 -0.4460 -0.0842 -0.2403 -0.2901 -0.2694 -1.2578 -1.1606 -0.2300 -3.7767 -0.1730
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise testosterone baseline peak_oxygen_uptake beck_depression_inventory leg medical_outcomes_study_short-form quality_of_life exercise placebo
H-1323	-0.7004907131195068	▁testosteron e ▁oxygen _ up take ▁Beck _ de pression ▁in ven tory ▁leg _ ▁strength ▁Medical
D-1323	-0.7004907131195068	testosterone oxygen_uptake Beck_depression inventory leg_ strength Medical
P-1323	-0.3562 -0.0274 -0.4119 -2.2004 -0.3919 -0.1060 -0.0370 -1.5656 -0.0252 -0.0363 -1.3316 -0.5795 -0.0619 -0.3091 -0.8583 -1.3541 -0.2600 -3.2885 -0.1084
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients heart_failure outcomes exercise training hf-action exercise perceived_social_support_score psss barriers_to_exercise_score btes
H-1927	-1.2125166654586792	▁Heart _ ▁Fail ure ▁h - ac tion ▁social _ ▁support ▁score ▁p s s ▁b tes
D-1927	-1.2125166654586792	Heart_ Failure h-action social_ support score pss btes
P-1927	-2.3231 -0.6040 -0.3225 -0.0573 -3.8602 -0.4026 -0.5459 -0.4478 -0.1851 -1.3866 -2.3115 -3.8014 -1.9663 -1.1918 -0.5936 -2.5700 -0.2223 -0.1570 -0.0885
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable_analysis st2 death hospitalization hazard_ratio cardiovascular_death hf hospitalization hazard_ratio all-cause_mortality hazard_ratio hazard_ratios
H-703	-1.3331810235977173	▁ST 2 ▁cardiovascular _ ▁death ▁ HF ▁mortal ity
D-703	-1.3331810235977173	ST2 cardiovascular_ death HF mortality
P-703	-1.2934 -0.6565 -2.6994 -2.7723 -0.5028 -1.5139 -0.1070 -2.7316 -0.6399 -1.5186 -0.2296
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients new_york_heart_association_class_i fontan cardiopulmonary_exercise_testing lean_mass_quantification dual_x-ray_absorptiometry dxa calf muscle magnetic_resonance_spectroscopy healthy
H-1495	-1.0489565134048462	▁New ▁York _ ▁Heart _ association ▁cardio pul mon ary _ ▁exercise ▁lean _ ▁mass ▁d XA ▁cal f _ ▁muscle ▁magnetic _ ré on ance _ ▁spec tros copy
D-1495	-1.0489565134048462	New York_ Heart_association cardiopulmonary_ exercise lean_ mass dXA calf_ muscle magnetic_réonance_ spectroscopy
P-1495	-4.1280 -1.2697 -0.8449 -1.5107 -0.6232 -1.0661 -0.3235 -0.3058 -3.6294 -1.6656 -0.9581 -0.3652 -0.0686 -0.3710 -2.5079 -2.7282 -0.6985 -0.5860 -0.0027 -1.2329 -0.3405 -0.1993 -0.9505 -3.1866 -0.6426 -0.0433 -0.9926 -1.0794 -0.1295 -0.3967 -0.6312 -0.0884
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo dopamine nesiritide bolus diuretic therapy renal_function patients acute_heart_failure renal_dysfunction
H-73	-0.9784660339355469	▁low - dos e ▁dop amine ▁nesi riti de ▁di ure tic ▁ therapy ▁renal
D-73	-0.9784660339355469	low-dose dopamine nesiritide diuretic therapy renal
P-73	-4.7387 -0.0291 -0.8133 -0.3136 -1.1222 -0.1621 -0.4083 -0.0708 -0.0563 -0.0941 -0.3316 -2.6422 -0.8653 -0.0617 -0.1088 -4.7148 -0.1007
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized crt patients new_york_heart_association_class_iii heart_failure left_ventricular_ejection_fraction qrs_duration echocardiographic evidence left_ventricular_dyssynchrony
H-847	-0.9661524295806885	▁c RT ▁New ▁York _ ▁Heart _ association ▁heart _ ▁failure ▁left ▁vent ri cular _ ▁e je ction ▁QR s ▁e cho car dio graphic ▁vent ri cular _ ▁dys syn chron y
D-847	-0.9661524295806885	cRT New York_ Heart_association heart_ failure left ventricular_ ejection QRs echocardiographic ventricular_ dyssynchrony
P-847	-0.7218 -2.3079 -3.7414 -1.2107 -1.3316 -0.9059 -0.6559 -1.2268 -2.0078 -0.6564 -2.4783 -0.0942 -1.4135 -0.5436 -0.4668 -0.7100 -1.7856 -0.9400 -0.0961 -0.1223 -0.6652 -0.2696 -0.1323 -0.0553 -0.2978 -0.6260 -2.6494 -1.1756 -0.3972 -0.2936 -2.0721 -0.0149 -0.0014 -2.2018 -0.3949 -0.1180
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients left_ventricular ejection_fraction stable_hf right-sided_cardiac_catheterization transthoracic_echocardiography transmitral_flow mitral_annulus_velocities systole diastole
H-482	-0.5856892466545105	▁vent ri cular LV ▁e je ction ▁ fraction ▁ HF ▁right - side _ ▁cardiac ▁cat heter ization ▁trans t hora cic ▁e cho card i ography ▁transmit ral _ ▁flow ▁mit ral _ ▁ann ulus ▁dia stol e
D-482	-0.5856892466545105	ventricularLV ejection fraction HF right-side_ cardiac catheterization transthoracic echocardiography transmitral_ flow mitral_ annulus diastole
P-482	-1.4138 -0.5927 -0.1797 -0.4219 -2.4704 -0.3148 -0.0398 -0.5347 -0.0225 -0.5228 -0.5675 -2.0884 -0.0100 -0.0332 -1.9847 -0.1429 -0.6580 -0.0020 -0.5448 -0.0011 -0.0358 -0.0286 -0.0822 -0.5202 -0.3716 -0.1018 -0.1652 -0.2935 -0.1386 -0.1423 -0.7883 -0.7675 -2.9806 -0.0263 -0.6179 -0.5570 -0.2347 -3.4650 -0.0076 -0.2802 -0.3334 -0.1149
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients acute_coronary_syndromes patients stable cad bnp nt-probnp cad prognostic clinical outcome
H-1367	-0.6057257056236267	▁a cute _ ▁corona ry ▁syndrome s ▁CAD ▁b NP ▁NT - pro b NP ▁CAD
D-1367	-0.6057257056236267	acute_ coronary syndromes CAD bNP NT-probNP CAD
P-1367	-0.3418 -0.0146 -0.2132 -0.7944 -0.4945 -0.9745 -0.0188 -2.9125 -0.3958 -0.3042 -1.2230 -0.0195 -0.0074 -0.7668 -0.1952 -1.7830 -0.3142 -0.1296
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline patients hf lyso-paf-at paf-cpt paf paf-ah lp-pla2
H-1269	-0.6298953294754028	▁h f ▁lys o - pa f - AT ▁PA f - c p ▁PA f - AH ▁l p - PLA 2
D-1269	-0.6298953294754028	hf lyso-paf-AT PAf-cp PAf-AH lp-PLA2
P-1269	-2.0549 -1.1737 -1.4928 -0.0256 -0.0506 -0.6656 -0.0528 -0.2860 -0.6318 -0.9025 -0.0825 -0.1976 -0.4769 -0.7092 -1.5008 -0.0973 -0.5467 -2.8133 -1.0759 -0.0068 -0.1482 -0.0772 -0.1115 -0.4224 -0.1445
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical_therapy patients redo_sternotomy aortic_valve bioprosthetic_valve_replacement dacron_patch_closure aortic_valve patients transcatheter_aortic_valve_procedure surgery aortic_valve
H-549	-0.7214545011520386	▁ster no to my ▁a or tic _ ▁val ve ▁bio pro sthetic ▁val ve _ ▁replace ment ▁da cro n ▁patch _ closure ▁a or tic _ ▁val ve ▁trans cat heter ▁a or tic _ ▁val ve
D-549	-0.7214545011520386	sternotomy aortic_ valve bioprosthetic valve_ replacement dacron patch_closure aortic_ valve transcatheter aortic_ valve
P-549	-2.1393 -0.0243 -0.2912 -0.6085 -0.0432 -0.0522 -2.8325 -0.9896 -1.5335 -0.0895 -0.2985 -0.0173 -0.0272 -2.2112 -0.1519 -2.4539 -0.5943 -0.0095 -0.2056 -0.4334 -0.0069 -0.8180 -0.4865 -0.1049 -0.0161 -0.0669 -2.1807 -0.7176 -1.6869 -0.1548 -0.3471 -0.2223 -0.0075 -0.9328 -0.0773 -2.4219 -0.6588 -0.9155 -0.0610 -2.5951 -0.0945
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma_n-terminal_pro-b-type_natriuretic_peptide nt-probnp patients acute_heart_failure hf admission emergency_department
H-263	-0.8599914908409119	▁plasma _ n - termin al ▁pro - b - type _ ▁na tri ure tic _ pe pti de NT - pro b NP ▁a cute _ ▁heart _ ▁failure HF ▁emergency ▁department ▁ed
D-263	-0.8599914908409119	plasma_n-terminal pro-b-type_ natriuretic_peptideNT-probNP acute_ heart_ failureHF emergency department ed
P-263	-4.6652 -3.2273 -0.4066 -0.0141 -0.0239 -0.0125 -1.3114 -0.0189 -0.8350 -0.0484 -0.0473 -0.2589 -1.1054 -0.0685 -0.0843 -2.9573 -0.7402 -0.5413 -0.1353 -0.1011 -1.8257 -0.0076 -0.0191 -0.4122 -0.3364 -1.1653 -0.3419 -0.1424 -1.8720 -0.5329 -1.2448 -1.8021 -0.8125 -2.3532 -1.8720 -0.3055 -0.1714
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac_troponin_t ctnt n-terminal_pro-b-type_natriuretic_peptide nt-probnp biomarkers hf hf atherosclerosis_risk_in_communities aric
H-286	-0.7261338829994202	▁cardiac _ ▁trop onin ▁t ▁c t n t ▁n - termin al _ pro - b - type _ na tri ure tic _ pe pti de NT - pro b NP ▁ HF ▁ HF ▁Ath eros cle rosi s _ ▁Risk _ in _ com uni s ARI
D-286	-0.7261338829994202	cardiac_ troponin t ctnt n-terminal_pro-b-type_natriuretic_peptideNT-probNP HF HF Atherosclerosis_ Risk_in_comunisARI
P-286	-0.0405 -1.3462 -0.3492 -0.1499 -0.7905 -1.0373 -0.0507 -0.0067 -0.3046 -3.9148 -0.0262 -0.0203 -0.0046 -1.8762 -0.4342 -0.0192 -0.9236 -0.0748 -0.0869 -0.3952 -1.2019 -0.0328 -0.0451 -2.1151 -0.7608 -0.3860 -0.1674 -0.1525 -2.3481 -0.0097 -0.0103 -0.3585 -0.2199 -0.5122 -0.3044 -1.4004 -0.4448 -2.2811 -0.3334 -0.3945 -1.2214 -0.0344 -0.8357 -0.2979 -1.2773 -1.5933 -0.1562 -0.2773 -3.7813 -2.1349 -0.3685 -1.0521 -0.1244
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body_mass_index fat_mass fat-free_mass
H-1167	-1.780402421951294	▁body _ ▁mass _ ▁index ▁h ▁fat - free _ ▁mass
D-1167	-1.780402421951294	body_ mass_ index h fat-free_ mass
P-1167	-3.4655 -0.7928 -4.4855 -1.8371 -0.9893 -1.2719 -4.2320 -0.6076 -0.5615 -1.9828 -1.0073 -1.7427 -0.1694
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile_range body_mass_index interquartile_range copd chf crf
H-797	-1.3460012674331665	▁p d ▁CHF ▁c RF
D-797	-1.3460012674331665	pd CHF cRF
P-797	-5.4433 -0.0987 -1.5148 -0.1362 -1.6887 -0.3953 -0.1451
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse_remodeling ejection_fraction mortality all-cause_hospitalizations hf hospitalizations dialysis patients
H-911	-0.3524092435836792	▁rever se _ ▁remodel ing ▁e je ction _ fraction ▁mortal ity ▁ HF ▁di al ysis
D-911	-0.3524092435836792	reverse_ remodeling ejection_fraction mortality HF dialysis
P-911	-0.0917 -0.0230 -0.6044 -0.1670 -0.1827 -0.0147 -0.4152 -0.0575 -0.4492 -0.0020 -0.1227 -0.5966 -1.5345 -0.5373 -0.6828 -0.1251 -0.0457 -0.9358 -0.1079
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates lv_contractility lvef β_coefficient confidence_interval systolic_blood_pressure end-systolic_volume β_coefficient
H-1530	-1.689602255821228	▁EH ▁LV _ contract ility ▁h z ▁LV f ▁expression _ de _ tension ▁end - sy sto lic _ ▁volume ▁h g
D-1530	-1.689602255821228	EH LV_contractility hz LVf expression_de_tension end-systolic_ volume hg
P-1530	-0.3063 -1.1178 -2.7319 -1.1571 -0.3783 -4.4746 -1.5644 -2.6204 -1.1063 -6.6559 -1.6958 -1.4615 -0.3000 -4.7006 -2.2322 -0.0528 -1.4490 -1.8952 -3.2712 -1.3310 -0.4628 -0.3742 -0.0409 -0.7185 -0.1414
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography dilated_lv end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mva
H-348	-1.0330967903137207	▁e cho card i ography ▁dil ated ▁LV ▁end - dia sto lic ▁volume _ ▁index ▁ml ▁e je ction _ fraction ▁MR ▁mit ral _ ▁val ve _ ▁opening ▁ms ▁m va ▁pressure
D-348	-1.0330967903137207	echocardiography dilated LV end-diastolic volume_ index ml ejection_fraction MR mitral_ valve_ opening ms mva pressure
P-348	-0.6233 -2.7112 -1.3427 -0.3935 -0.1448 -4.6284 -0.2610 -0.1667 -0.4947 -0.0228 -1.2386 -0.7893 -1.2501 -0.6929 -1.9184 -0.6786 -2.4523 -1.8107 -0.2458 -0.0262 -1.8929 -0.0071 -2.9180 -0.9093 -0.0111 -1.2926 -1.6107 -0.1760 -1.8382 -0.3368 -0.7512 -0.4466 -0.1564 -0.9645 -1.8982 -0.0897
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind clinical renal_optimization_strategies_evaluation rose hospitalized patients acute_heart_failure renal_dysfunction estimated_glomerular_filtration_rate randomized admission
H-74	-0.7456773519515991	▁double - blind ▁place bo - control led ▁clinic al _ ▁trial ROS e ▁a cute _ ▁heart _ ▁failure ▁renal ▁dys function ▁glo mer ular ▁filtr ation
D-74	-0.7456773519515991	double-blind placebo-controlled clinical_ trialROSe acute_ heart_ failure renal dysfunction glomerular filtration
P-74	-2.9880 -0.0062 -0.0070 -1.0745 -0.0080 -0.0061 -0.0016 -1.1636 -0.8325 -0.0499 -1.7250 -0.8082 -2.8409 -0.9738 -1.7044 -0.0164 -0.4744 -2.3736 -1.0321 -0.2394 -0.0222 -1.1410 -0.5113 -0.0191 -0.0801 -0.0718 -0.9243 -0.0290 -1.1190 -0.1268
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets signal_transduction pol_ii transcription_factor hf pathogenesis nuclear_factor_of_activated_t_cells nfat nuclear_factor-κb nf-κb transcription_factor gata4
H-1051	-1.0294924974441528	▁ BET s ▁chr omat in - media ted ▁signal _ trans duction ▁Pol ▁II ▁co - activa tion ▁tran scription _ ▁factor _ de _ activa tion _ ▁T ▁cell s ▁n FAT ▁nuclear _ factor - κ b NF - κ b ▁tran scription _ ▁factor
D-1051	-1.0294924974441528	BETs chromatin-mediated signal_transduction Pol II co-activation transcription_ factor_de_activation_ T cells nFAT nuclear_factor-κbNF-κb transcription_ factor
P-1051	-1.5211 -0.2274 -0.6734 -0.2419 -0.0382 -1.0015 -0.0699 -0.0352 -1.0166 -1.1829 -1.7921 -0.2547 -0.0610 -0.5822 -1.1544 -1.1322 -0.0046 -0.0566 -1.0785 -0.9889 -0.0306 -1.8619 -1.0043 -1.0030 -3.9573 -0.1371 -2.4113 -0.7054 -0.6061 -1.9564 -2.1918 -0.0639 -3.6593 -0.3939 -0.8112 -1.9361 -1.9053 -0.5496 -3.1253 -0.3079 -0.4962 -0.2561 -2.9676 -0.2619 -0.3103 -0.0583 -2.2608 -0.9817 -1.9938 -0.1567
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes mortality hospitalization exercise_tolerance quality_of_life cardiovascular_events myocardial_infarction congestive_heart_failure arrhythmia cardiac_death hypertension venous_thromboembolic_events ischemic_cerebrovascular_events
H-33	-0.8117733001708984	▁mortal ity ▁hospital ization ▁cardiovascular ▁events ▁my o card ial ▁in far ction ▁con ges tive ▁heart _ ▁failure ▁ar rhythm ia ▁cardiac _ ▁death ▁hyper tension ▁ve nous _ thro mbo e mbol ic _ ▁events
D-33	-0.8117733001708984	mortality hospitalization cardiovascular events myocardial infarction congestive heart_ failure arrhythmia cardiac_ death hypertension venous_thromboembolic_ events
P-33	-1.8591 -0.4484 -1.7239 -0.8821 -1.8893 -1.5472 -0.3852 -0.1242 -0.0864 -0.1838 -1.1910 -1.8040 -0.0354 -0.1931 -0.1043 -0.0538 -0.9581 -0.9411 -0.4135 -0.2997 -0.1407 -0.6264 -0.0657 -2.0829 -0.3548 -0.1088 -0.0007 -0.4590 -0.4331 -1.6398 -0.1590 -1.2252 -2.0658 -0.0034 -1.0283 -3.4430 -0.8053 -1.7982 -0.0956
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus diabetes patients diabetes peak_vo2 patients diabetes eo-cfus peak_vo2
H-128	-1.4415762424468994	▁ EO - c FU s ▁diabetes ▁e - c fu
D-128	-1.4415762424468994	EO-cFUs diabetes e-cfu
P-128	-2.4326 -1.0101 -0.0984 -0.6015 -2.0358 -0.7749 -0.1848 -3.0363 -0.5708 -0.6167 -1.7909 -5.3879 -0.1999
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular_mortality multivariable_adjustment hazard_ratio confidence_interval hazard_ratio confidence_interval
H-562	-0.7544461488723755	▁all - ca use ▁cardiovascular ▁mortal ity
D-562	-0.7544461488723755	all-cause cardiovascular mortality
P-562	-2.4529 -0.0662 -0.0050 -0.0348 -0.1695 -1.0367 -0.5429 -2.3537 -0.1283
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting video_edge_detection epifluorescence_microscopy myocardial_tissues cardiomyocytes hf
H-1212	-0.5806998014450073	▁immun o blo tting ▁radio en zy matic - ▁and ▁fluor esc ence _ ré on ance _ énergie _ transfer - based _ as say s ▁video ▁edge _ ▁det ection ▁epi flu o resc ence _ micro s copy ▁l - type _ ca 2 ▁my o card ial _ ▁tissu es ▁cardio my o cy tes ▁ HF
D-1212	-0.5806998014450073	immunoblotting radioenzymatic- and fluorescence_réonance_énergie_transfer-based_assays video edge_ detection epifluorescence_microscopy l-type_ca2 myocardial_ tissues cardiomyocytes HF
P-1212	-0.1115 -0.0547 -0.0572 -0.3617 -0.1456 -0.1070 -0.0064 -0.2661 -0.1573 -3.4938 -1.3047 -1.1927 -0.0174 -1.3648 -2.7063 -0.4276 -0.0518 -0.6975 -0.6603 -0.7635 -0.9790 -0.2587 -0.0706 -3.5056 -0.8687 -0.0123 -0.0426 -1.3227 -1.0487 -2.0758 -0.3012 -0.0035 -0.0521 -0.0074 -0.4738 -0.1377 -0.0224 -0.4030 -1.0628 -0.0648 -0.2018 -1.0061 -0.0465 -0.0184 -0.9385 -0.0123 -0.0228 -1.1136 -0.0886 -0.0706 -0.2393 -1.0532 -1.0354 -0.6702 -0.0166 -0.6902 -0.4557 -0.1574 -0.2340 -1.3598 -0.3407 -0.0946 -0.0566
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes exercise_capacity peak_oxygen_consumption vo2 co-primary_outcome qol minnesota heart_failure heart qol co-primary_outcome
H-1980	-1.0846294164657593	▁Exerci se _ pu issa nce ▁oxygen _ ▁consum p tion VO 2 ▁Q OL ▁Minnesota _ ▁Living _ ▁with _ ▁Heart _ ▁Fail ure ▁ml f ▁heart _ ▁failure
D-1980	-1.0846294164657593	Exercise_puissance oxygen_ consumptionVO2 QOL Minnesota_ Living_ with_ Heart_ Failure mlf heart_ failure
P-1980	-3.7328 -0.1705 -0.8298 -2.1424 -0.1037 -0.0013 -3.3106 -1.8560 -0.3676 -0.2452 -0.0941 -1.0071 -0.2353 -4.5184 -0.6657 -0.1343 -0.8089 -0.2841 -0.1206 -1.6596 -0.1704 -0.2198 -0.3288 -0.2021 -0.2231 -0.9298 -1.0707 -2.9240 -0.6147 -4.8019 -0.7957 -0.1390
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial randomize patients stroke rhythm_control_therapy prospective randomized outcome
H-1649	-0.9360580444335938	▁e AST ▁at rial _ ▁fi bril lation _ for _ ▁Stro ke _ pre vention _ tri al ▁AF ▁stroke
D-1649	-0.9360580444335938	eAST atrial_ fibrillation_for_ Stroke_prevention_trial AF stroke
P-1649	-0.4952 -0.2949 -1.2065 -0.1716 -0.3393 -2.8714 -0.0820 -0.0234 -2.6788 -0.9456 -0.3073 -0.1603 -0.7712 -0.5948 -0.8833 -0.0580 -2.0184 -0.4782 -0.0185 -1.9398 -1.6357 -3.4801 -0.0749
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients left_ventricular_ejection_fraction patients hf preserved_left_ventricular_ejection_fraction hospital physicians acute outpatient epidemic medical financial_costs
H-55	-1.1331676244735718	▁vent ri cular _ é je ction _ fraction ▁patients ▁ HF ▁vent ri cular _ é je ction _ fraction ▁hospital ▁a cute _ ▁out patient s
D-55	-1.1331676244735718	ventricular_éjection_fraction patients HF ventricular_éjection_fraction hospital acute_ outpatients
P-55	-3.4460 -0.4529 -0.3904 -0.5822 -1.6383 -1.7675 -0.1137 -0.9855 -0.0053 -2.1655 -1.4270 -0.1694 -1.3048 -0.4492 -0.2859 -0.3067 -1.7874 -1.9902 -0.0928 -0.8483 -0.0070 -1.6934 -1.1098 -0.0146 -1.4522 -3.3776 -0.0499 -2.5791 -3.3751 -0.1273
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic mitochondrial-targeted_peptide ss31 mitochondrial_function tac clinical mitochondrial-targeted_peptide drugs heart_failure
H-878	-0.9075498580932617	▁ TAC - indu ce _ prote om ic ▁altera tions ▁mito cho ndri al - tar get ed _ pe pti de ▁SS 31 ▁per tur bed _ ▁mito cho ndri al _ fon cti onnement ▁ TAC ▁mito cho ndri al - tar get ed _ pe pti de _ ▁drugs ▁heart _ ▁failure
D-878	-0.9075498580932617	TAC-induce_proteomic alterations mitochondrial-targeted_peptide SS31 perturbed_ mitochondrial_fonctionnement TAC mitochondrial-targeted_peptide_ drugs heart_ failure
P-878	-0.6769 -0.0773 -1.1397 -0.0071 -2.9846 -1.1455 -2.1880 -0.6175 -0.4304 -3.9779 -0.0360 -1.2815 -2.4764 -1.3059 -0.2164 -0.2400 -0.2267 -0.5268 -0.1441 -0.5778 -0.6539 -0.1738 -0.1459 -2.8692 -0.8392 -1.9263 -0.0350 -0.2100 -0.5531 -1.4997 -2.1164 -0.7347 -0.0780 -0.4302 -2.4622 -0.6063 -0.3774 -1.6619 -0.5698 -1.8135 -1.5190 -1.9969 -0.1926 -0.1671 -0.3260 -0.5160 -0.0610 -0.2980 -0.5699 -0.2610 -0.1594 -1.3364 -0.8308 -1.0088 -0.8261 -2.2805 -0.1525 -0.1028
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf patients hfref left_ventricular ejection_fraction hfpef echo-doppler n-terminal_pro-brain-type_natriuretic_peptide adverse_events
H-494	-0.611575186252594	▁h f ▁vent ri cular LV ▁e je ction _ fraction ▁h p f ▁e cho - D opp ler ▁pro - bra in - type _ na tri ure tic _ pe pti de
D-494	-0.611575186252594	hf ventricularLV ejection_fraction hpf echo-Doppler pro-brain-type_natriuretic_peptide
P-494	-2.0492 -0.2210 -1.6051 -0.3395 -0.2791 -0.5004 -0.4152 -0.8629 -0.0403 -0.5669 -0.0027 -0.9530 -0.7108 -0.4948 -0.0636 -0.1974 -0.0155 -0.7972 -0.0009 -0.2196 -1.0241 -0.0178 -0.6517 -0.1124 -0.1765 -0.0207 -1.0122 -1.6674 -0.0126 -0.0454 -4.1089 -1.8732 -0.2566 -0.2276 -0.3603 -0.5711 -0.1547
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds comorbidities hospitalized adjusted_odds_ratio aor confidence_interval eds aor
H-464	-1.340638279914856	▁low - volu me ▁ed s
D-464	-1.340638279914856	low-volume eds
P-464	-2.5081 -0.0345 -0.2421 -0.0252 -2.2225 -0.2737 -5.2465 -0.1725
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc_battery health_abc_hf_risk_model change c-index net-reclassification-improvement hf
H-631	-0.6079108119010925	▁h ABC ▁Bat tery _ ▁score s ▁Health ▁ABC ▁ HF ▁Risk _ Model ▁discrimina tion ▁c - index net - re class ification - improv ement ▁ HF
D-631	-0.6079108119010925	hABC Battery_ scores Health ABC HF Risk_Model discrimination c-indexnet-reclassification-improvement HF
P-631	-0.1594 -1.3703 -1.7404 -0.0023 -1.7969 -1.0729 -0.0031 -1.0035 -0.3026 -0.3820 -0.0682 -3.1209 -0.9782 -0.9743 -1.5701 -0.0518 -0.0780 -0.0651 -0.0369 -1.1769 -0.0363 -0.1035 -0.0601 -0.0199 -0.0727 -0.1152 -0.0107 -0.9754 -1.2253 -0.1717 -0.1009
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients cardiac_transplant ecct patients diabetes_mellitus chronic_kidney_disease estimated_glomerular_filtration_rate
H-715	-0.6479237079620361	▁cardiac ▁transplant ▁EC CT ▁diabetes ▁mell itus ▁chronic _ ▁ki dne y ▁disease ▁glo mer ular _ ▁filtr ation
D-715	-0.6479237079620361	cardiac transplant ECCT diabetes mellitus chronic_ kidney disease glomerular_ filtration
P-715	-0.1782 -0.6850 -0.9278 -1.1467 -0.6597 -0.8315 -0.1106 -0.1377 -0.7299 -1.4845 -0.2931 -0.3703 -2.6362 -0.0336 -0.0580 -0.0450 -1.1840 -0.6445 -0.0345 -1.1839 -0.2317
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi rmsea self-care_maintenance cfi rmsea self-care_management cfi rmsea self-care_confidence
H-1507	-0.9458646774291992	▁c f ▁m se a ▁Self - Car e _ ▁Main ten ance _ ▁Scal e ▁c f ▁m se a ▁Self - Car e _ management _ ▁Scal e ▁c f ▁m se a ▁Self - Car e _ con version _ ▁scale
D-1507	-0.9458646774291992	cf msea Self-Care_ Maintenance_ Scale cf msea Self-Care_management_ Scale cf msea Self-Care_conversion_ scale
P-1507	-2.4486 -2.0316 -2.9997 -0.3135 -0.5409 -1.0791 -0.0405 -1.8690 -0.1345 -0.2555 -1.5034 -0.4619 -0.0190 -1.6966 -0.0738 -0.0534 -0.3767 -1.9792 -2.8303 -0.1519 -0.4582 -0.5871 -0.0502 -1.8900 -0.1006 -0.3210 -0.6956 -1.4881 -0.2184 -0.0308 -0.2946 -1.7643 -2.7179 -0.1705 -0.6233 -0.7865 -0.0494 -2.4758 -0.1563 -0.1532 -2.2355 -2.7611 -0.8575 -1.3376 -0.2836 -0.1432
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients bat patients quality-of-life nyha_functional_class change
H-1876	-1.1549179553985596	▁BAT ▁distance _ ▁walked ▁quality - of - life
D-1876	-1.1549179553985596	BAT distance_ walked quality-of-life
P-1876	-0.3633 -4.0289 -1.3874 -0.5987 -1.6787 -0.0826 -0.0803 -0.1933 -0.7609 -3.3321 -0.1979
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients preoperative hypoalbuminemia postoperative albumin hypoalbuminemia albumin lvad
H-537	-1.3467702865600586	▁pre operativ e ▁hypo album in emia ▁post operativ e _ ▁normal ization _ de _ album in _ ▁levels ▁l VAD
D-537	-1.3467702865600586	preoperative hypoalbuminemia postoperative_ normalization_de_albumin_ levels lVAD
P-537	-2.9656 -0.6810 -0.1070 -0.8463 -1.1120 -1.5409 -0.7126 -1.4069 -0.9712 -0.2680 -2.0674 -3.8998 -0.9726 -2.8891 -1.5329 -0.5147 -0.6333 -1.0450 -4.1071 -0.3945 -2.9609 -0.0992 -0.4752 -0.1190
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization confidence_interval acute_myocardial_infarction ami complications kidney_infection urinary_tract_infection uti complications
H-1717	-1.0141205787658691	▁re hospital ization ▁a cute _ mé o card ial _ ▁in far ction ▁am ▁ki dne y ▁infection ▁urin ary _ ▁tract ▁infection UTI
D-1717	-1.0141205787658691	rehospitalization acute_méocardial_ infarction am kidney infection urinary_ tract infectionUTI
P-1717	-4.2041 -0.0106 -0.7518 -0.9412 -0.3291 -0.1254 -2.9151 -1.6475 -0.3102 -0.2698 -0.4011 -0.8352 -2.3365 -0.1758 -2.0761 -2.5848 -0.5977 -0.0885 -0.6796 -0.0080 -0.3575 -1.1672 -0.5399 -2.7948 -0.7392 -0.2770 -0.2176
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients heart_failure hf ischemic nonischemic_cardiomyopathies pharmacological implantable_cardioverter_defibrillators cardiac_resynchronization_therapy cardiac_transplantation right_ventricular_assist_devices
H-54	-0.7606976628303528	▁heart _ ▁failure HF ▁ ische mic _ non ische mic _ ▁cardio my o pathi es ▁ pharma c ological ▁implant able ▁implant able ▁cardio ver ter _ de fi br illa teurs ▁cardiac ▁re syn chron ization _ therapy ▁cardiac ▁transplant ation ▁vent ri cular _ assist ▁devices
D-54	-0.7606976628303528	heart_ failureHF ischemic_nonischemic_ cardiomyopathies pharmacological implantable implantable cardioverter_defibrillateurs cardiac resynchronization_therapy cardiac transplantation ventricular_assist devices
P-54	-3.1649 -0.5721 -0.9815 -0.4669 -0.5894 -0.8419 -0.2066 -1.1944 -0.1883 -1.7970 -0.6366 -0.8108 -0.5901 -1.5708 -0.9921 -0.0537 -0.1895 -2.6827 -0.0718 -0.0577 -0.4541 -0.4190 -0.0606 -1.3461 -0.0798 -2.0445 -0.1811 -0.0246 -0.3647 -0.0257 -5.3581 -0.9821 -0.0081 -2.3049 -0.0137 -1.3458 -0.0046 -0.0012 -0.5613 -1.7753 -0.1879 -0.0775 -1.2326 -0.0168 -0.4628 -0.0937 -0.0347 -0.6253 -0.1394 -1.3890 -0.2002 -0.0819
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf catheterization central_venous_pressure svr cardiac_index
H-230	-1.9666162729263306	▁ SAF ▁ PF ▁figure _ de _ ca heter ization ▁central _ ve nous _ tension ▁h g ▁s VR ▁dyn ▁cardiac
D-230	-1.9666162729263306	SAF PF figure_de_caheterization central_venous_tension hg sVR dyn cardiac
P-230	-2.6736 -1.2654 -2.8211 -0.8915 -4.4628 -4.8697 -3.4003 -0.6433 -1.4007 -1.4136 -1.6880 -2.9786 -0.4900 -4.3098 -4.2070 -1.1716 -1.1070 -0.0280 -0.0531 -1.3456 -1.4093 -3.8682 -1.3946 -1.0724 -0.2001
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission bnp reduced_ef preserved_ef bnp ef
H-193	-1.3211408853530884	▁ad mission _ media n _ b NP ▁EF ▁b NP ▁b p
D-193	-1.3211408853530884	admission_median_bNP EF bNP bp
P-193	-1.5857 -0.0188 -2.4279 -0.7474 -0.0443 -1.2583 -0.5170 -1.3312 -1.7712 -1.1427 -2.2632 -2.2601 -2.0643 -2.1801 -0.2050
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart_failure admission heart_transplantation lv_assist_device death hazard_ratio confidence_interval death hazard_ratio confidence_interval ischemic functional_class
H-435	-1.2941702604293823	▁heart _ ▁failure ▁implant ation LV _ assist _ ▁device ▁death
D-435	-1.2941702604293823	heart_ failure implantationLV_assist_ device death
P-435	-1.5022 -1.2891 -2.9332 -3.1130 -0.0137 -0.9227 -0.7542 -0.2180 -1.9016 -1.0913 -0.7083 -2.2392 -0.1378
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv_ejection_fraction shortening systolic_elastance contractile_efficiency acf acf allopurinol cardiomyocytes extracellular_flux_analyzer
H-475	-0.5195276737213135	▁LV ▁e je ction _ fraction ▁vitesse _ de _ ▁circum fer ential _ ▁short en ing ▁sy sto lic ▁elastan ce ▁contract ile _ ▁efficiency ▁a CF ▁a CF ▁allo puri nol ▁rat s ▁o 2 ▁consum p tion _ ▁rate ▁cardio my o cy tes ▁extra cel lular ▁flux
D-475	-0.5195276737213135	LV ejection_fraction vitesse_de_ circumferential_ shortening systolic elastance contractile_ efficiency aCF aCF allopurinol rats o2 consumption_ rate cardiomyocytes extracellular flux
P-475	-0.0393 -0.1919 -0.1910 -0.0135 -0.3263 -0.0010 -1.3348 -0.3889 -1.0295 -0.0928 -0.4602 -1.3119 -0.2926 -0.3851 -0.4987 -0.0470 -0.2888 -2.1640 -0.2362 -0.9789 -0.8339 -0.2067 -0.0156 -0.4260 -0.3719 -1.1066 -0.3531 -0.8951 -2.3964 -0.9711 -0.8764 -0.1028 -0.2847 -0.2975 -0.0297 -0.1150 -0.0236 -1.6634 -0.7181 -0.1402 -0.8335 -0.2863 -0.0527 -0.6701 -0.3618 -0.1604 -0.4097 -0.0146 -0.6631 -0.0306 -0.9283 -0.9421 -0.0818
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively patients hfpef lv_hypertrophy lvh relative_wall_thickness rwt lvh rwt lvh rwt lvh rwt
H-1526	-1.4035203456878662	▁ HF p EF ▁LV _ ▁structure ▁normal _ ge ometr y ▁LV ▁hyper trop hy LV h ▁wall _ ▁thi ck ness ▁cr ▁LV h ▁R WT ▁v h
D-1526	-1.4035203456878662	HFpEF LV_ structure normal_geometry LV hypertrophyLVh wall_ thickness cr LVh RWT vh
P-1526	-1.3021 -0.8976 -0.1971 -0.8227 -1.1251 -2.9295 -5.3194 -2.9017 -0.5898 -0.4631 -0.2539 -0.6215 -0.8390 -1.3187 -0.0401 -0.0337 -2.3725 -0.7762 -2.2644 -0.2401 -2.5785 -0.7157 -1.3995 -2.9123 -0.9651 -0.5565 -2.9737 -0.1951 -2.8675 -0.8968 -3.4357 -0.1082
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 angiotensin_receptor_neprilysin_inhibitor neprilysin_inhibitor prodrug angiotensin_receptor_antagonist valsartan hypertension heart_failure_with_preserved_ejection_fraction outcomes heart_failure_with_reduced_ejection_fraction
H-1463	-0.8954719305038452	▁ang ion _ ▁receptor _ pri ly sin _ ▁inhibi tor ▁nepri ly sin _ ▁inhibi tor _ pro drug ▁ang io ten sin _ ▁receptor _ ▁anta gon ist _ ▁val sar tan ▁hyper tension ▁heart _ ▁failure
D-1463	-0.8954719305038452	angion_ receptor_prilysin_ inhibitor neprilysin_ inhibitor_prodrug angiotensin_ receptor_ antagonist_ valsartan hypertension heart_ failure
P-1463	-1.2101 -3.1188 -3.8099 -0.1480 -0.4917 -1.6942 -0.2986 -1.4132 -1.0012 -0.0566 -0.0630 -1.2798 -0.1187 -1.3057 -0.6875 -0.0992 -0.1228 -0.6058 -0.3029 -0.0113 -0.0276 -1.9510 -0.8429 -2.0610 -1.2625 -0.0453 -0.8068 -1.3419 -0.0421 -1.8059 -0.5829 -0.4100 -0.1082 -0.0080 -0.0055 -0.0005 -2.2881 -0.6906 -1.5601 -2.8647 -0.1700
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood_pressure mitral_valve_plasty degenerative_mr p3_prolapse chordal_ruptures triangular_resection edge-to-edge_anastomosis ring_annuloplasty physio_ring_30 edwards_lifesciences irvine
H-343	-0.49889981746673584	▁blood _ tension ▁mit ral ▁val ve ▁plast y ▁de genera tive ▁MR ▁p 3 ▁chor dal ▁rup tures ▁angle - to - ed ge ▁an asto mos is ▁ring _ ▁ann ulo plast y ▁Ph y sio ▁Ring ▁ed ward s _ life science s ▁ir vine
D-343	-0.49889981746673584	blood_tension mitral valve plasty degenerative MR p3 chordal ruptures angle-to-edge anastomosis ring_ annuloplasty Physio Ring edwards_lifesciences irvine
P-343	-0.7154 -1.6146 -0.3575 -1.4827 -0.0087 -1.0208 -0.1575 -0.2657 -0.4522 -0.1798 -0.8722 -0.0284 -0.2380 -0.9961 -0.0220 -2.1045 -0.1833 -0.7543 -0.0865 -2.0799 -0.2521 -1.0392 -0.0851 -0.3098 -0.0188 -0.6988 -0.0170 -0.1720 -0.0718 -0.1106 -0.2801 -1.4472 -0.7546 -0.0163 -0.1068 -0.9588 -0.0086 -0.0602 -0.8179 -0.6265 -0.0977 -0.0063 -0.0988 -1.4140 -0.0587 -0.0014 -0.4334 -0.0066 -1.2611 -0.0946
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes incremental_shuttle_walk_test peak_oxygen_uptake muscular echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory beck_depression_inventory health-related_quality_of_life minnesota_living_with_heart_failure_questionnaire medical_outcomes_study_short-form
H-1320	-0.6127708554267883	▁shu ttle _ walk _ test ▁oxygen _ up take ▁muscular _ ▁strength ▁e cho car dio graphic ▁measure s ▁pro - bra in ▁na tri ure tic _ pe pti de ▁depression ▁be ck _ de pression _ in ven tory ▁min nes ota _ ▁Living _ with _ ▁Heart _ ▁Fail ure ▁Medical
D-1320	-0.6127708554267883	shuttle_walk_test oxygen_uptake muscular_ strength echocardiographic measures pro-brain natriuretic_peptide depression beck_depression_inventory minnesota_ Living_with_ Heart_ Failure Medical
P-1320	-0.3154 -0.0053 -0.1438 -0.8724 -1.3440 -1.5660 -1.2039 -1.1170 -0.5357 -0.0270 -0.0111 -1.3296 -0.8513 -0.0146 -0.1019 -0.0135 -0.2394 -0.3460 -2.5126 -0.0061 -0.4442 -0.0147 -0.7514 -0.1166 -0.6853 -0.0078 -0.0329 -1.8914 -1.1007 -0.2335 -0.1106 -0.0425 -2.3160 -1.8261 -0.2417 -0.3022 -0.0281 -0.1930 -1.1184 -0.4175 -0.9666 -0.1225 -2.5132 -0.1877 -0.5156 -1.4356 -0.5440 -0.5017 -1.2976 -0.1402 -0.6906 -0.3089 -0.1668 -0.1204 -0.4691 -0.3831 -0.1336
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction_term_analysis lvef patients patients mortality lvef p_value
H-116	-0.8691086173057556	▁LV EF ▁long - term _ ▁mortal ity ▁LV EF
D-116	-0.8691086173057556	LVEF long-term_ mortality LVEF
P-116	-2.7170 -0.4797 -1.9314 -0.0680 -1.6907 -0.6665 -0.1705 -0.3806 -1.6081 -0.1292 -0.4918 -0.0959
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto zsf1 obese zsf1 obese zsf1 followed_up metabolic renal echocardiographic hemodynamically euthanization
H-763	-1.0179219245910645	▁ géné ra - K yo to ▁lean ▁Z SF ▁obes e ▁Z SF ▁obes e ▁Z SF ▁high - fat _ die t ▁metabol ic ▁renal ▁e cho car dio graphic ▁evaluation s ▁hem o dynamic ally
D-763	-1.0179219245910645	généra-Kyoto lean ZSF obese ZSF obese ZSF high-fat_diet metabolic renal echocardiographic evaluations hemodynamically
P-763	-4.3872 -3.4312 -0.3941 -0.0219 -3.5842 -0.4043 -0.0604 -0.0696 -2.1195 -0.4544 -0.7224 -0.0702 -1.5693 -0.6863 -5.1920 -0.0609 -1.6627 -0.6395 -3.3611 -0.0087 -0.7229 -1.6580 -0.2920 -0.1730 -0.5048 -0.0415 -0.0474 -0.0292 -0.0423 -0.0176 -0.1580 -0.6415 -4.5390 -0.1013 -0.3440 -0.0569 -0.1061 -0.6425 -1.6324 -0.0666
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier_curves log-rank_testing risk_stratification patients patients
H-384	-1.0923995971679688	▁Ka plan - me ier _ cur ves ▁log - rank
D-384	-1.0923995971679688	Kaplan-meier_curves log-rank
P-384	-1.3163 -0.0704 -0.0152 -0.4900 -0.1735 -2.9275 -3.1801 -0.2888 -0.4893 -0.0246 -0.0150 -4.9857 -0.2247
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate_cox_regression_analyses hypertension sinus_rhythm hazard_ratio confidence_interval
H-950	-0.947089672088623	▁af ▁af ▁hyper tension ▁sinus ▁ rhythm haz ard
D-950	-0.947089672088623	af af hypertension sinus rhythmhazard
P-950	-1.5393 -2.0189 -0.4432 -0.0013 -0.7657 -0.9555 -0.2263 -1.7125 -0.0067 -2.5687 -0.1799
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients chronic hf-ref nyha_functional_class_ii egfr potassium eplerenone hyperkalemia
H-1228	-0.7097616791725159	▁ HF - re f ▁NY HA _ ▁functional _ ▁class _ ▁II ▁e g f ▁po tas s ium ▁e pler en one ▁hyper kal emia ▁W RF
D-1228	-0.7097616791725159	HF-ref NYHA_ functional_ class_ II egf potassium eplerenone hyperkalemia WRF
P-1228	-1.2162 -1.1015 -0.0833 -0.3366 -0.0711 -0.0582 -0.4431 -1.9302 -1.4424 -1.6165 -0.1353 -0.4658 -0.9931 -0.2373 -2.6788 -1.0290 -0.1302 -0.4473 -0.1317 -0.0254 -0.0535 -0.4075 -0.3303 -2.5852 -0.4929 -0.3026 -0.1580 -2.2271 -0.6471 -0.1125 -0.1130
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm dual_energy_x-ray_absorptiometry dxa patients chronic_heart_failure chf non-cachectic_chf myocardial
H-12	-0.8752055764198303	f f f f f f ▁body _ f f ré que nce _ dis tribution ▁dual _ énergie _ ▁X - ray _ ▁ab sor pti ometr y ▁d XA ▁non - dia be tic ▁patients ▁chronic _ ▁heart _ ▁failure cc cc ▁non - ca che ctic ▁CHF ▁my o card ial _ ▁in far ction - bo th
D-12	-0.8752055764198303	ffffff body_ffréquence_distribution dual_énergie_ X-ray_ absorptiometry dXA non-diabetic patients chronic_ heart_ failurecccc non-cachectic CHF myocardial_ infarction-both
P-12	-0.7129 -0.0304 -0.0144 -0.0750 -0.5642 -1.6362 -1.7857 -0.5441 -1.1521 -1.0389 -5.0370 -0.0619 -0.0119 -2.9315 -2.6699 -0.0074 -0.5882 -0.6502 -0.5343 -3.1662 -1.4622 -0.0311 -0.0696 -0.6213 -0.8353 -0.0508 -0.0557 -0.1864 -0.2955 -0.3362 -0.3874 -3.7441 -0.0069 -0.2692 -0.1414 -1.1808 -0.9044 -3.5052 -0.4909 -1.4638 -0.7919 -0.5267 -0.9898 -2.4644 -5.9646 -0.0060 -0.0005 -0.0713 -0.1733 -0.0142 -0.6724 -0.2787 -0.1261 -0.2396 -0.5215 -0.5814 -1.5878 -0.0953 -0.3695 -0.0008 -0.0092 -0.3365 -0.0655
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline drug spironolactone combined_end_point death hospitalization hf hazard_ratio confidence_interval aas hazard_ratio confidence_interval p_value
H-1707	-0.8244228363037109	▁spi rono lac tone ▁end ▁point _ de _ ▁death ▁hospital ization ▁ HF ▁AA s
D-1707	-0.8244228363037109	spironolactone end point_de_ death hospitalization HF AAs
P-1707	-3.0388 -0.0482 -0.3024 -0.5122 -1.3127 -0.2457 -0.5081 -1.0093 -0.1495 -0.9301 -1.4311 -0.7978 -2.0381 -0.0891 -1.2172 -0.1329 -0.9435 -0.1329
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective_study patients invasively diagnosed pulmonary_arterial_hypertension inoperable chronic_thromboembolic_pulmonary_hypertension right_ventricular pump stable pulmonary_arterial_hypertension medication noninvasive stress_echocardiography cardiopulmonary_exercise_testing
H-823	-0.589320957660675	▁pulmonar y _ ▁arterial _ ▁hyper tension ▁in opera ble ▁chronic ▁ thro mbo e mbol ic ▁pulmonar y _ ▁hyper tension ▁im pair ed ▁vent ri cular _ pu issa nce ▁pulmonar y _ ▁arterial _ ▁hyper tension ▁medication ▁stress ▁e cho card i ography ▁cardio pul mon ary _ ▁exercise
D-823	-0.589320957660675	pulmonary_ arterial_ hypertension inoperable chronic thromboembolic pulmonary_ hypertension impaired ventricular_puissance pulmonary_ arterial_ hypertension medication stress echocardiography cardiopulmonary_ exercise
P-823	-0.6499 -0.0844 -1.2039 -0.5217 -1.1126 -1.2556 -0.0003 -0.8558 -0.1024 -0.0399 -0.3596 -0.4746 -0.0817 -0.9808 -0.3456 -0.0067 -0.5755 -0.3062 -0.1045 -0.8767 -0.6135 -0.0004 -1.1789 -0.0126 -0.4074 -2.2492 -0.2551 -0.0718 -0.3655 -2.3567 -0.3786 -0.0400 -0.8423 -0.0559 -0.9066 -0.2164 -0.8197 -1.2929 -0.0005 -2.3967 -0.0926 -0.2705 -0.1290 -0.1167 -0.1959 -0.2344 -0.0310 -0.1317 -1.5298 -1.4054 -0.9757 -1.7234 -0.5011 -0.0868
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular_death hf hospitalization randomization btes btes cardiovascular_death hf hospitalization exercise hazard_ratio confidence_interval hazard_ratio confidence_interval
H-1930	-1.1099562644958496	▁cardiovascular _ ▁death ▁ HF ▁b tes ▁b tes ▁cardiovascular _ ▁death ▁ HF
D-1930	-1.1099562644958496	cardiovascular_ death HF btes btes cardiovascular_ death HF
P-1930	-1.5123 -1.5910 -1.6215 -0.9893 -0.0768 -2.2856 -0.5455 -0.5739 -0.4738 -0.9920 -1.3986 -1.6258 -1.0661 -0.0964 -2.7914 -0.1190
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients hospitalized death all-cause_readmission aor eds aor
H-466	-1.3021761178970337	▁index _ de _ f ré que nce _ de _ f ré que nce _ de _ la _ f ré que nce _ de _ la _ f ré que nce _ de _ la _ f ré que nce _ de _ la _ f ré que nce _ de _ ca use _ de _ la _ f ré que nce
D-466	-1.3021761178970337	index_de_fréquence_de_fréquence_de_la_fréquence_de_la_fréquence_de_la_fréquence_de_la_fréquence_de_cause_de_la_fréquence
P-466	-0.2778 -0.4820 -4.3199 -0.4635 -4.1192 -1.3150 -0.0625 -0.0040 -1.7301 -1.8321 -0.3558 -4.8928 -0.0658 -0.0643 -0.0038 -1.9880 -0.6659 -0.3610 -5.1864 -1.3919 -2.6439 -0.0260 -0.0227 -0.0033 -1.2291 -0.3307 -0.3282 -4.8426 -1.6892 -2.4372 -0.0107 -0.0210 -0.0029 -1.1036 -0.3952 -0.3758 -4.7356 -1.8501 -2.5981 -0.0127 -0.0268 -0.0027 -1.0570 -0.4181 -0.4271 -4.6455 -1.9589 -2.6388 -0.0183 -0.0347 -0.0028 -1.2519 -0.4295 -0.5052 -3.2724 -0.6283 -0.2224 -1.6979 -0.5313 -4.4485 -2.1995 -2.8675 -0.0471 -0.0729 -0.0042 -3.4486 -0.1476
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients implantable_cardioverter-defibrillator implantation engage patients decisions implantable_cardioverter-defibrillator
H-1863	-0.9671646952629089	▁implant able ▁implant able _ ▁cardio ver ter - de _ f illa tor _ de _ activa tion ▁implant ation
D-1863	-0.9671646952629089	implantable implantable_ cardioverter-de_fillator_de_activation implantation
P-1863	-0.0003 -0.0792 -1.6038 -0.2643 -0.8708 -1.8978 -0.2337 -0.1118 -0.2734 -0.0124 -3.0057 -3.3091 -4.4009 -0.4910 -0.4266 -0.0201 -2.0695 -0.1596 -0.1151 -0.0748 -0.3677 -2.3717 -0.0856
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac_magnetic_resonance t1_time hazard_ratio confidence_interval left_atrial_area hazard_ratio confidence_interval pulmonary_vascular_resistance hazard_ratio confidence_interval cardiac_events
H-739	-1.0321751832962036	▁Card iac _ ▁magnetic _ ▁res on ance ▁left _ ▁at rial _ ▁area ▁pulmonar y _ ▁vas cular _ ▁resist ance ▁cardiac
D-739	-1.0321751832962036	Cardiac_ magnetic_ resonance left_ atrial_ area pulmonary_ vascular_ resistance cardiac
P-739	-0.6195 -0.6082 -0.3191 -1.3132 -1.1980 -2.7460 -0.5505 -0.0985 -1.5440 -0.5755 -0.8716 -0.2875 -3.7156 -1.6793 -0.3128 -0.2098 -0.3775 -0.9865 -0.4187 -1.4199 -2.6912 -0.0389 -1.0487 -2.0301 -0.1436
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively followed_up hf patients systolic left_ventricular_ejection_fraction hf stable clinical conditions new_york_heart_association_class_i clinical echocardiographic cardiopulmonary_exercise_test
H-1755	-0.8779951333999634	▁ HF ▁vent ri cular _ ▁e je ction _ fraction ▁ HF ▁New ▁York _ ▁Heart _ association ▁e cho car dio graphic ▁cardio pul mon ary _ ▁exercise
D-1755	-0.8779951333999634	HF ventricular_ ejection_fraction HF New York_ Heart_association echocardiographic cardiopulmonary_ exercise
P-1755	-1.1994 -0.6559 -3.6996 -0.2957 -0.2443 -0.8143 -2.7296 -1.5442 -0.1625 -1.0366 -0.0017 -0.7528 -0.3386 -1.4700 -0.8780 -1.0662 -0.6955 -0.6072 -1.1236 -0.9998 -0.1427 -0.0265 -0.4581 -0.3599 -0.2281 -0.3036 -2.4899 -1.1237 -1.7579 -0.5101 -0.2972 -0.0826
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients end_stage_heart_failure abcd_classification american_college_of_cardiology acc american_heart_association aha new_york_heart_association nyha heart_disease symptoms heart_failure physical medical_treatment
H-1666	-1.3580588102340698	▁heart _ ▁failure ▁ABC d ▁American _ ▁College _ of _ ▁Card i ology ▁a cc ▁American _ ▁Heart _ association ▁ AHA ▁New ▁York _ ▁Heart _ association ▁NY HA ▁structura l _ ▁heart _ de _ ca pit aux
D-1666	-1.3580588102340698	heart_ failure ABCd American_ College_of_ Cardiology acc American_ Heart_association AHA New York_ Heart_association NYHA structural_ heart_de_capitaux
P-1666	-5.8162 -1.0649 -1.8537 -0.2711 -0.1677 -3.8158 -1.6117 -0.2348 -0.1242 -1.3620 -0.2888 -0.8700 -0.1792 -0.4132 -0.1537 -0.0576 -4.1398 -0.2328 -0.7918 -0.8472 -1.1095 -1.2373 -0.0620 -2.2459 -0.8284 -0.7993 -1.5622 -0.7273 -0.9559 -4.2626 -0.1709 -5.2787 -0.0764 -0.7511 -0.7697 -1.1000 -4.8343 -1.3334 -1.8328 -0.2229 -1.2219 -2.5495 -0.1685
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva continuity_equation lv_end-diastolic_volume lv_end-systolic_volume mitral_filling_flow mva mitral_filling_flow continuous_wave_doppler_echocardiography mitral_valve_plasty
H-345	-0.7758569717407227	▁m va ▁continu ity _ ▁e qu ation LV ▁end - dia sto lic ▁volume ▁LV ▁end - sy sto lic ▁volume ▁mit ral _ ▁fill ing _ ▁flow ▁m va ▁veloci ty _ time ▁mit ral _ ▁fill ing _ ▁flow ▁wa ve ▁do pp ler _ ▁e cho card i ography ▁MR ▁mit ral _ ▁val ve ▁plast y
D-345	-0.7758569717407227	mva continuity_ equationLV end-diastolic volume LV end-systolic volume mitral_ filling_ flow mva velocity_time mitral_ filling_ flow wave doppler_ echocardiography MR mitral_ valve plasty
P-345	-1.9831 -0.0866 -0.0249 -0.0710 -1.1137 -0.6646 -0.0351 -0.1288 -1.4803 -1.6893 -0.0107 -3.0992 -0.9643 -1.0108 -1.0285 -0.6175 -0.9292 -0.0111 -1.3034 -0.8228 -1.2194 -1.9200 -1.3079 -0.0385 -1.0051 -1.4032 -0.0724 -0.8934 -0.8906 -0.3144 -0.2007 -2.2015 -0.6827 -0.2646 -2.1897 -1.2599 -0.0212 -0.8912 -1.0555 -0.0507 -0.7043 -0.4353 -2.0843 -0.0121 -0.5320 -0.1232 -0.2735 -0.7164 -0.6850 -0.1495 -0.1031 -0.1808 -0.1899 -0.1397 -1.5804 -0.0156 -0.5899 -3.3538 -0.0751 -0.9507 -0.6155 -0.2508 -0.1607
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance rm all-cause_mortality sts hh cri cri cri
H-157	-1.3329658508300781	▁stati tis tical _ ▁significa nce ▁RM ▁mortal ity ▁s ts ▁h ▁ml ▁office _ ▁hours
D-157	-1.3329658508300781	statitistical_ significance RM mortality sts h ml office_ hours
P-157	-1.0252 -1.0506 -2.2285 -3.0124 -0.0946 -0.0670 -1.0807 -1.4640 -0.2534 -0.6835 -0.6171 -1.0080 -4.4219 -0.6319 -1.1139 -0.9464 -4.1803 -0.1142
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi hf clinic outcomes hfpsi outcomes tracking patients hfpsi
H-381	-1.0542018413543701	▁ HF PSI ▁Ann ▁Ar bor ▁Veteran s _ ▁Affairs ▁ HF _ ▁clinic VA - RT ▁VA ▁patients ▁ HF PSI
D-381	-1.0542018413543701	HFPSI Ann Arbor Veterans_ Affairs HF_ clinicVA-RT VA patients HFPSI
P-381	-0.4956 -1.5505 -1.1086 -0.0812 -0.2311 -0.0508 -0.2220 -0.0631 -0.4779 -0.3480 -0.7617 -0.1880 -2.7931 -3.5075 -1.9199 -0.3658 -0.5801 -1.5141 -5.0417 -0.6509 -0.8998 -1.3084 -1.0336 -0.1075
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas spironolactone hyperkalemia potassium hypokalemia potassium
H-1706	-0.8362650275230408	▁AA s ▁spi rono lac tone ▁hyper kal emia ▁po tas s ium ▁hypo kal emia
D-1706	-0.8362650275230408	AAs spironolactone hyperkalemia potassium hypokalemia
P-1706	-0.1382 -0.1475 -1.5279 -0.0841 -0.7794 -0.6155 -4.0032 -0.6237 -0.3616 -1.7345 -0.6742 -0.0881 -0.2651 -1.4126 -1.3737 -0.3867 -0.7320 -0.1048
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate_analysis patients preserved_lvef mortality patients lvef hazard_ratio lvef preserved_lvef
H-115	-0.9734252095222473	▁LV EF ▁long - term _ ▁mortal ity ▁LV EF haz ard ▁LV EF
D-115	-0.9734252095222473	LVEF long-term_ mortality LVEFhazard LVEF
P-115	-3.4123 -0.7149 -1.6556 -0.0876 -1.9236 -0.6275 -0.1806 -0.4859 -0.9663 -0.3310 -1.7930 -0.0141 -2.0287 -0.3567 -0.8480 -0.1492
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients hfpef primary_outcome odds_ratio nyha_class_iii 6-minute_walk_test 6-mwt feet prescribed medications
H-242	-1.5860671997070312	▁ HF p EF ▁ HF p f ▁gender odd s ▁ratio ▁NY ha _ ▁class _ III ▁distance ▁m t
D-242	-1.5860671997070312	HFpEF HFpf genderodds ratio NYha_ class_III distance mt
P-242	-1.5835 -0.3795 -0.0940 -1.2236 -4.5105 -0.9559 -0.4714 -0.8862 -4.2142 -2.7069 -0.0050 -3.1656 -0.7401 -0.8542 -4.5203 -0.2847 -0.4135 -1.1139 -3.9908 -2.2461 -0.0802 -1.8974 -0.1419
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived_pulmonary_arterial_systolic_pressure pasp right_ventricular rv tricuspid_annular_plane_systolic_excursion tapse diastole end-systole clinical follow-up heart_failure hf patients cardiac
H-492	-0.7756362557411194	▁e cho - der i ved ▁pulmonar y _ ▁arterial _ ▁sy sto lic _ tension PAS p ▁right ▁vent ri cular RV ▁tri cus pid _ ▁ann ular _ ▁plane _ syn chron e _ excursion TA PS e ▁dia stol e ▁end - sy stol e ▁heart _ ▁failure HF ▁cardiac
D-492	-0.7756362557411194	echo-derived pulmonary_ arterial_ systolic_tensionPASp right ventricularRV tricuspid_ annular_ plane_synchrone_excursionTAPSe diastole end-systole heart_ failureHF cardiac
P-492	-1.3024 -0.0505 -0.0120 -0.1663 -0.0671 -0.1991 -0.0488 -0.0894 -0.8976 -0.5520 -0.2483 -2.9155 -0.1669 -2.9556 -0.4403 -0.2316 -0.3764 -0.4173 -0.7625 -0.7977 -0.3705 -0.1214 -1.6265 -2.7020 -0.0414 -0.1069 -0.8145 -0.3125 -0.0087 -0.1528 -1.9966 -0.0989 -0.9665 -2.5101 -1.5213 -1.6561 -0.0291 -3.0366 -1.3041 -1.0214 -1.0451 -0.0272 -0.2246 -1.2277 -0.0175 -0.7795 -0.0412 -0.0926 -1.2154 -0.6092 -2.0067 -0.7150 -0.2526 -1.1969 -0.1139
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad diabetes odds_ratio electrocardiographic_q_waves left_bundle_branch_block odds_ratio nondiabetes dyslipidemia hypertension odds_ratio
H-1190	-0.9469089508056641	▁CAD ▁diabetes ▁electro car dio graphic _ q _ ▁wa ves ▁left ▁bund le _ ▁bran ch _ ▁block ▁non dia bete s ▁dys li pide mia ▁hyper tension ▁to ba cco
D-1190	-0.9469089508056641	CAD diabetes electrocardiographic_q_ waves left bundle_ branch_ block nondiabetes dyslipidemia hypertension tobacco
P-1190	-3.0453 -1.0847 -0.0081 -0.0118 -0.1130 -0.3143 -2.5408 -1.0739 -1.6954 -0.5026 -0.0449 -3.2755 -1.3263 -0.4484 -0.1371 -3.3606 -0.1503 -0.7539 -2.0410 -1.0916 -1.6770 -0.0203 -0.0264 -3.1065 -0.0344 -0.0434 -1.1342 -0.0219 -0.0002 -0.0826 -0.2413 -0.2940 -2.3500 -0.1431
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area_under_the_receiver_operating_characteristic_curve auc pcwp confidence_interval septal p_values
H-485	-1.2798205614089966	▁receive r _ ▁operating _ ▁character istic _ cur ve ▁au c ▁PC p
D-485	-1.2798205614089966	receiver_ operating_ characteristic_curve auc PCp
P-485	-2.9688 -0.0105 -0.6530 -0.7779 -1.1058 -1.4382 -0.1931 -1.2248 -0.3936 -0.0796 -3.7314 -0.7883 -2.5253 -1.7621 -2.6047 -0.2202
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients coronary_artery_disease hypertension trastuzumab administration chf
H-680	-1.023398756980896	▁tras tuz um ab - tre ated ▁patients ▁corona ry _ ▁arter y ▁disease ▁hyper tension
D-680	-1.023398756980896	trastuzumab-treated patients coronary_ artery disease hypertension
P-680	-0.8637 -0.0113 -0.0870 -1.0076 -0.7550 -0.0853 -3.2120 -2.1284 -2.0852 -0.3499 -1.7346 -0.0734 -0.2750 -1.1909 -0.0863 -0.0003 -4.3449 -0.1302
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef clinical crt crt systolic_volume_index lv_mass
H-754	-1.2206244468688965	▁LV EF ▁clinic al _ com posit e _ ▁response ▁c RT _ on ▁c rte _ ▁OFF ▁LV _ ▁end _ syn chron e _ ▁volume _ ▁index ▁LV
D-754	-1.2206244468688965	LVEF clinical_composite_ response cRT_on crte_ OFF LV_ end_synchrone_ volume_ index LV
P-754	-0.1149 -0.8229 -1.8547 -0.0304 -0.8782 -0.5635 -0.0195 -0.1314 -2.3640 -1.1666 -0.1184 -1.0202 -3.3579 -1.3202 -0.2342 -2.6855 -0.9508 -1.2105 -0.6594 -2.2267 -3.2608 -0.1642 -2.7546 -2.3348 -0.7682 -0.4396 -0.5020 -1.1162 -0.7563 -3.0802 -2.0144 -0.1391
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β_signaling tgf-β_receptor_type_i cell yield epithelial mesenchymal transition pluripotency_marker nanog cell cells in_vitro
H-1343	-0.5643320083618164	▁T GF - β ▁signal ing ▁T GF - β ▁receptor ▁s mad ▁small - mo le cule _ ▁inhibi tors ▁c - K it _ cell _ ▁yi eld ▁epi the li al ▁mes en chy mal ▁transition ▁marker s ▁pluri pote ncy _ ▁marker ▁na nog ▁c - K it _ cell _ ▁differenti ation ▁cardio my o cy te
D-1343	-0.5643320083618164	TGF-β signaling TGF-β receptor smad small-molecule_ inhibitors c-Kit_cell_ yield epithelial mesenchymal transition markers pluripotency_ marker nanog c-Kit_cell_ differentiation cardiomyocyte
P-1343	-1.2878 -0.2959 -0.1317 -0.0980 -0.6964 -0.2814 -0.9394 -0.2843 -0.1970 -0.2260 -1.3377 -1.9360 -0.0292 -0.9718 -0.0096 -0.0594 -0.1961 -0.2521 -1.4150 -0.0908 -1.1490 -0.0029 -0.1002 -1.2764 -0.0784 -0.8379 -4.9390 -1.5373 -0.7082 -0.0012 -0.0893 -0.0871 -0.0804 -0.0347 -0.1006 -0.3656 -0.3432 -0.1787 -0.1431 -1.1412 -0.0296 -0.0039 -0.0998 -0.0263 -0.9912 -0.4960 -1.2796 -0.0078 -0.0135 -0.0477 -1.2199 -0.1199 -0.4185 -1.1641 -1.6766 -0.6030 -0.0136 -0.0410 -0.8263 -0.2992 -0.1434 -0.4169 -2.1889 -0.0606
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients hfref diuretics co-morbidities 6-mwt feet nyha_class_iii
H-243	-0.7439907193183899	▁h f f ▁di ure tics ▁co - mor bid ities ▁mw t ▁NY ha
D-243	-0.7439907193183899	hff diuretics co-morbidities mwt NYha
P-243	-0.1538 -0.5799 -2.1103 -0.1906 -0.7930 -1.8353 -0.0340 -0.0379 -0.3593 -0.0467 -1.1845 -1.8723 -0.4493 -0.9620 -1.0418 -0.8784 -0.1187
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery hf postoperative echocardiography end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mitral_valve_area mva
H-344	-0.9822973012924194	▁ HF ▁post operativ e ▁e cho card i ography ▁LV ▁end - dia sto lic ▁volume _ ▁index ▁LV ▁e je ction _ fraction ▁MR ▁mit ral _ ▁val ve ▁m va ▁pressure
D-344	-0.9822973012924194	HF postoperative echocardiography LV end-diastolic volume_ index LV ejection_fraction MR mitral_ valve mva pressure
P-344	-1.2660 -0.1717 -3.5944 -0.6341 -0.0330 -1.1214 -0.6755 -0.2393 -0.3568 -0.1917 -2.1872 -0.4863 -0.0228 -1.3366 -0.7721 -1.4225 -1.2209 -1.5499 -1.0260 -2.0196 -3.0556 -0.5128 -0.0361 -1.5668 -0.0013 -0.5814 -0.4679 -0.0346 -1.5749 -1.3243 -0.2232 -1.9464 -0.1520 -1.5286 -1.9461 -0.0830
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients systolic_heart_failure ejection_fraction randomized placebo ivabradine shift systolic_heart_failure_treatment_with_the_if_inhibitor_ivabradine_trial patients placebo ivabradine echocardiographic
H-519	-0.8779268860816956	▁implant ation _ fraction ▁i va bra dine ▁SHI FT ▁Sy sto lic _ ▁Heart _ ▁Fail ure ▁in hib itor _ ▁i va bra dine _ tri al ▁i va bra dine ▁e cho car dio graphic
D-519	-0.8779268860816956	implantation_fraction ivabradine SHIFT Systolic_ Heart_ Failure inhibitor_ ivabradine_trial ivabradine echocardiographic
P-519	-3.4907 -2.0754 -3.5151 -0.0075 -0.1015 -0.0788 -1.6691 -0.1038 -0.2817 -1.2710 -1.5918 -0.1689 -3.5189 -0.2763 -1.0306 -0.5939 -0.1042 -0.0483 -2.6234 -0.4487 -0.2705 -0.5856 -1.8456 -0.0233 -0.8184 -0.0636 -1.7333 -0.3467 -0.0253 -0.7975 -0.0554 -1.2859 -0.0812 -0.8397 -0.2112 -0.0706 -0.5544 -1.4982 -0.9071 -0.1038
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard_ratios multivariate_regression tapse pasp hazard_ratio tapse new_york_heart_association_functional_class
H-499	-1.6146186590194702	▁Hazard ▁ratio s _ multi varia te _ re gression ▁t AP se _ pass p ▁h g ▁New ▁York _ ▁Heart _ association _ fon ction nel
D-499	-1.6146186590194702	Hazard ratios_multivariate_regression tAPse_passp hg New York_ Heart_association_fonctionnel
P-499	-3.2837 -3.2946 -0.0635 -4.1567 -2.9778 -1.1179 -0.5891 -0.1884 -0.9186 -0.0593 -2.2491 -1.6087 -0.6712 -4.3559 -1.3742 -0.7377 -1.9213 -0.4838 -5.2654 -2.3402 -1.1031 -1.9885 -0.4672 -1.3676 -1.1231 -2.5767 -0.2482 -0.4247 -1.2681 -0.2144
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal_function the_chronic_kidney_disease_epidemiology_collaboration patients estimated_glomerular_filtration_rate egfr
H-390	-0.9593433141708374	▁Ren al _ fon ction nel ▁Chro nic _ ▁Kid ney ▁Disease ▁Epidemi ology ▁glo mer ular _ ▁filtr ation _ ▁rate ▁e g f
D-390	-0.9593433141708374	Renal_fonctionnel Chronic_ Kidney Disease Epidemiology glomerular_ filtration_ rate egf
P-390	-1.0071 -0.2392 -1.4684 -1.9805 -0.2112 -2.2587 -0.3918 -1.3484 -0.2897 -0.2579 -0.4969 -0.4378 -0.3607 -1.7475 -2.6677 -0.4119 -0.3148 -0.7811 -1.0855 -0.0470 -1.6520 -1.3877 -0.1040 -1.7323 -1.6078 -1.3389 -0.2759
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective randomized paradigm-hf chronic_heart_failure systolic_dysfunction lv_ef functional_class nyha elevated bnp nt-pro_bnp primary_endpoint cardiovascular_death hospitalization heart_failure arni lcz696 sacubiltril valsartan
H-1968	-1.0727040767669678	▁para DIG m - HF ▁chronic _ ▁heart _ ▁failure ▁sy sto lic _ ▁dys function LV _ f ▁NY HA ▁b NP ▁b NP car dio vas cular _ ▁death ▁hospital ization ▁heart _ ▁failure ▁l z 696 ▁sa cubi lt ril ▁val sar tan
D-1968	-1.0727040767669678	paraDIGm-HF chronic_ heart_ failure systolic_ dysfunctionLV_f NYHA bNP bNPcardiovascular_ death hospitalization heart_ failure lz696 sacubiltril valsartan
P-1968	-4.6072 -0.5131 -0.0838 -0.0302 -0.9475 -2.9578 -1.0628 -2.1241 -1.3649 -0.8114 -2.2484 -0.2902 -3.4675 -0.3761 -0.2264 -0.1913 -0.3878 -2.0856 -0.5644 -4.6051 -0.6088 -0.5117 -0.6516 -0.3139 -0.9612 -2.3283 -0.0874 -1.5967 -0.4580 -1.3520 -0.8651 -1.4933 -0.7859 -1.6031 -0.8586 -1.4200 -4.5830 -0.3077 -0.3159 -0.0535 -0.1501 -0.0767 -0.0999 -0.5769 -0.0660 -0.0108 -0.3202 -0.0882
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia outcomes african_americans aas new_york_heart_association nyha hf left_ventricular_dysfunction randomized spironolactone titrated placebo randomized_aldactone_evaluation_study rales
H-1703	-0.8960398435592651	▁hyper kal emia ▁African _ American s AA s ▁a s ▁white ▁New ▁York _ ▁Heart _ association NY HA ▁ HF ▁left _ vent ri cular _ ▁dys function ▁spi rono lac tone ▁al da cto ne _ evalua tion RAL es
D-1703	-0.8960398435592651	hyperkalemia African_AmericansAAs as white New York_ Heart_associationNYHA HF left_ventricular_ dysfunction spironolactone aldactone_evaluationRALes
P-1703	-0.5154 -0.7812 -0.5328 -1.7343 -2.9383 -0.8116 -0.1085 -1.4386 -0.0204 -2.5687 -0.2239 -4.9764 -3.9820 -0.5882 -0.9996 -1.4375 -1.0893 -1.1821 -1.6620 -0.6270 -0.8631 -0.2930 -0.2819 -0.7101 -0.7950 -2.2883 -0.2895 -0.4011 -0.1434 -0.5647 -0.0252 -0.0085 -0.0754 -0.1044 -0.7584 -0.1646 -0.0422 -0.1276 -0.8447 -0.6467 -0.0278 -2.3966 -0.0865 -0.0919 -0.0735
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv_reverse_remodeling lv_end-diastolic_dimension longitudinal strain left_ventricle left_atrial_area right_ventricular_end-diastolic_area_index right_atrial right_ventricular_fractional_area change
H-432	-1.5100611448287964	▁LV ▁rever se _ ▁remodel ing ▁pre - c RT ▁LV ▁vent ri cular ▁vent ri cular
D-432	-1.5100611448287964	LV reverse_ remodeling pre-cRT LV ventricular ventricular
P-432	-0.8058 -2.9764 -0.0048 -1.0759 -0.0849 -0.1026 -3.1916 -0.0050 -0.6828 -1.7655 -3.7435 -1.6307 -1.4159 -0.4552 -2.8504 -1.8910 -0.5144 -5.3527 -0.1420
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type_natriuretic_peptide n-terminal_pro-b-type_natriuretic_peptide diagnostic stable coronary_artery_disease b-type_natriuretic_peptide bnp nt-probnp ventricular_cardiomyocytes ventricular wall_stress myocardial_ischemia
H-1364	-0.9308164715766907	▁b - type _ n - termin al _ pro - B - type _ na tri ure tic _ pe pti de ▁corona ry _ ▁arter y ▁disease ▁b n p ▁p ▁vent ri cular _ ▁cardio my o cy tes ▁vent ri cular _ f ré que nce _ ▁stress ▁my o card ial _ ische mia
D-1364	-0.9308164715766907	b-type_n-terminal_pro-B-type_natriuretic_peptide coronary_ artery disease bnp p ventricular_ cardiomyocytes ventricular_fréquence_ stress myocardial_ischemia
P-1364	-0.5453 -1.0299 -0.9526 -0.3637 -4.9755 -0.0335 -1.0254 -0.0099 -2.4750 -0.9544 -0.0283 -1.2178 -0.1384 -0.2100 -0.2621 -1.8133 -0.2507 -0.1661 -4.3570 -0.6848 -0.5305 -0.3591 -0.1426 -2.9269 -0.8568 -1.0960 -0.4513 -0.5250 -2.1432 -0.1565 -1.3768 -1.1385 -3.0786 -0.2107 -0.1248 -0.2644 -0.3039 -0.9440 -0.5469 -0.4491 -0.1177 -0.4575 -0.0041 -0.1833 -0.2337 -0.4294 -5.4910 -0.1830 -0.0898 -0.1486 -2.3409 -1.5200 -0.4375 -0.4562 -0.3098 -0.3294 -0.5400 -3.3429 -0.5510 -0.3551 -0.1395
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 irs2 heart hyperinsulinemia myocardial_insulin_resistance cellular_dysfunction irs1 irs2 heart-specific_irs1_and_irs2_gene_double-knockout h-dko liver-specific_irs1_and_irs2_double-knockout l-dko
H-654	-0.6848876476287842	▁i RS 1 ▁i RS 2 ▁heart ▁hyper insu line mia ▁my o card ial _ ▁insulin _ ▁resist ance ▁cel lular _ ▁dys function ▁i RS 2 ▁heart - specific ▁i RS 2 ▁double - k no ckou t ▁h - d KO ▁ liver - specific ▁i RS 2 ▁double - k no ckou t ▁l - d KO
D-654	-0.6848876476287842	iRS1 iRS2 heart hyperinsulinemia myocardial_ insulin_ resistance cellular_ dysfunction iRS2 heart-specific iRS2 double-knockout h-dKO liver-specific iRS2 double-knockout l-dKO
P-654	-0.5418 -0.4886 -2.5289 -1.0549 -0.5578 -0.3184 -1.7533 -0.3083 -0.0415 -0.3309 -3.3083 -1.6645 -0.1350 -0.2635 -0.2393 -1.1540 -0.0509 -1.1601 -2.0772 -0.0163 -2.5950 -0.0158 -0.5302 -0.1744 -0.2806 -0.4558 -0.2746 -0.8541 -3.8294 -0.1872 -0.4322 -1.1612 -0.1932 -1.7313 -1.5795 -0.0113 -0.9828 -0.0712 -0.0120 -0.0118 -0.7111 -0.3201 -0.2541 -0.2357 -0.1992 -0.9291 -0.2769 -0.5511 -1.0939 -0.2906 -1.3060 -0.7009 -0.0134 -0.8028 -0.0329 -0.0182 -0.0097 -1.0343 -0.1168 -0.1914 -0.3148 -0.2541 -0.1137
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers interquartile_range β-blockers interquartile_range interquartile_range
H-665	-0.8267976641654968	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors angi oten sin ▁receptor _ block ers ▁β - block ers
D-665	-0.8267976641654968	angiotensin-converting enzyme inhibitorsangiotensin receptor_blockers β-blockers
P-665	-1.6323 -3.1383 -0.4960 -1.3107 -0.2787 -0.0030 -0.1686 -2.6306 -0.6312 -0.2122 -0.3783 -1.4443 -1.9733 -0.0175 -0.8344 -0.6586 -2.7860 -0.5482 -0.0485 -0.7676 -0.0081 -0.1043 -0.1244 -0.3186 -0.1561
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ivabradine change peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity correlates exercise_capacity therapy ivabradine correlated peak_oxygen_uptake
H-1177	-1.3018907308578491	▁i va bra dine
D-1177	-1.3018907308578491	ivabradine
P-1177	-0.4997 -0.0351 -1.0718 -0.1001 -5.9803 -0.1244
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence transfusion mortality relative_risk mortality patients acute_coronary_syndrome
H-45	-1.4870038032531738	▁liberal ▁trans fusion ▁mortal ity
D-45	-1.4870038032531738	liberal transfusion mortality
P-45	-2.2088 -0.9121 -0.2344 -3.2095 -0.3997 -3.3304 -0.1142
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death readmission patients physician hazard_ratio confidence_interval physician follow-up patients follow-up
H-1419	-1.497192144393921	▁risk _ de _ ▁death ▁un plan ned _ ▁read mission
D-1419	-1.497192144393921	risk_de_ death unplanned_ readmission
P-1419	-4.4822 -1.5218 -1.1245 -0.1313 -2.9031 -0.7151 -0.3558 -1.1626 -0.1024 -2.5609 -0.0943 -4.1720 -0.1374
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek human_embryonic_kidney cells β1ar s1pr1 β1ar downregulation sphingosine-1-phosphate s1pr1_agonist s1pr1 downregulation isoproterenol β-adrenergic_receptor_agonist
H-1409	-0.7759655117988586	▁h EK ▁em bry o nic _ ▁ki dne y ▁sp hing os ine _ -1 - phos pha te ▁s 1 PR 1 ▁down regul ation ▁iso prot eren ol ▁β - ad r energi c ▁receptor _ ▁ago nist
D-1409	-0.7759655117988586	hEK embryonic_ kidney sphingosine_-1-phosphate s1PR1 downregulation isoproterenol β-adrenergic receptor_ agonist
P-1409	-0.2604 -1.4831 -0.5442 -0.0884 -0.0971 -1.7616 -0.1768 -1.4047 -0.3643 -0.0978 -3.2547 -0.4625 -0.4938 -0.2425 -1.6505 -1.7927 -0.0372 -0.0077 -0.0509 -0.0133 -0.8955 -0.0439 -0.3561 -1.3508 -3.7275 -0.4794 -0.0577 -3.8329 -0.1387 -2.5081 -0.0475 -0.1324 -0.0312 -0.1124 -0.1237 -0.7382 -0.1150 -1.2187 -1.1494 -1.5976 -0.0132 -0.3325 -0.0795
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline training 6-minute_walked_distance quality_of_life kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire symptoms beck_depression_inventory zung_self-rated_depression_scores b-type_natriuretic_peptide endothelial_function flow-mediated_dilatation left_ventricular_diastolic_function
H-1330	-0.7978366017341614	Kan sas ▁City ▁Card i om yo pathy ▁Minnesota ▁Heart _ ▁Fail ure ▁ depressiv e _ ▁symptoms ▁be ck _ de pression ▁in ven tory ▁depression ▁na tri ure tic _ pe pti de ▁en dot heli al _ f ré que nce - media ted _ ▁di la tation ▁vent ri cular _ dia sto lique
D-1330	-0.7978366017341614	Kansas City Cardiomyopathy Minnesota Heart_ Failure depressive_ symptoms beck_depression inventory depression natriuretic_peptide endothelial_fréquence-mediated_ dilatation ventricular_diastolique
P-1330	-4.2146 -0.0546 -1.0646 -1.4831 -0.0626 -0.0854 -2.2915 -0.0645 -0.9919 -1.9252 -0.7199 -0.2462 -0.0730 -1.8416 -0.0078 -0.0334 -2.6243 -0.3282 -1.1502 -0.2489 -0.4444 -0.0417 -0.0850 -1.7175 -0.3670 -0.0488 -0.1956 -0.8853 -0.0164 -0.0338 -1.5990 -1.2867 -0.5506 -0.0702 -0.0705 -0.8546 -2.4207 -0.1806 -0.0151 -1.8765 -2.5373 -0.2097 -0.1985 -0.0763 -1.4166 -0.1585 -1.5911 -0.3566 -2.0108 -0.0412 -0.0116 -0.2847 -0.1001 -0.1329 -0.2800 -2.4247 -0.2181 -2.1851 -1.2104 -0.1544
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds_ratios confidence_intervals cardiovascular_events atrial_fibrillation left_ventricular_ejection_fraction diabetes_mellitus peripheral_vascular_disease myocardial_infarction heart_failure stroke patients estimated_glomerular_filtration_rate nonsignificant acute_kidney_injury
H-976	-0.580722987651825	▁cardiovascular ▁events ▁at rial _ ▁fi bril lation ▁left ▁vent ri cular _ ▁e je ction _ fraction ▁diabetes ▁mell itus ▁per i pher al _ ▁vas cular ▁disease ▁my o card ial ▁in far ction ▁heart _ ▁failure ▁stroke ▁glo mer ular _ ▁filtr ation
D-976	-0.580722987651825	cardiovascular events atrial_ fibrillation left ventricular_ ejection_fraction diabetes mellitus peripheral_ vascular disease myocardial infarction heart_ failure stroke glomerular_ filtration
P-976	-3.6153 -2.1835 -0.1765 -0.0540 -0.7084 -2.2186 -0.0312 -0.0257 -0.1062 -0.5719 -0.2156 -0.1883 -0.6754 -1.2265 -0.2814 -0.0533 -0.9413 -0.0010 -0.0293 -0.4507 -0.0610 -0.4423 -0.0928 -0.4457 -0.0576 -0.0890 -1.7916 -0.0976 -1.9416 -0.1238 -0.1289 -0.1553 -0.1744 -0.6724 -1.4752 -0.0344 -0.1167 -0.9518 -0.2139 -0.2385 -0.0634 -0.0521 -0.0527 -1.0432 -0.2806 -0.0142 -3.1906 -0.1193
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic_function ea ventricular-arterial_coupling ees ea
H-925	-0.9475815892219543	▁in _ con jun ction ▁dia sto lic _ fon cti onnement ▁vent ri cular - arte rial ▁coup ling
D-925	-0.9475815892219543	in_conjunction diastolic_fonctionnement ventricular-arterial coupling
P-925	-0.9180 -3.8462 -0.0646 -0.2767 -0.0201 -1.6004 -0.8909 -2.1798 -2.4862 -0.9095 -0.7380 -0.3000 -0.2477 -0.4362 -0.1155 -0.2461 -0.1280 -0.1208 -0.5338 -3.3244 -1.2440 -0.2198
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard_ratios disease_risk_score drs saxagliptin sitagliptin saxagliptin pioglitazone saxagliptin sulfonylureas saxagliptin insulin
H-1835	-1.1161495447158813	▁disease _ risk ▁score ▁d RS ▁sax ag lip tin ▁si tag lip tin ▁sax ag lip tin ▁pi og lita zone ▁sax ag lip tin ▁sul fon yl ure as
D-1835	-1.1161495447158813	disease_risk score dRS saxagliptin sitagliptin saxagliptin pioglitazone saxagliptin sulfonylureas
P-1835	-1.4576 -1.9361 -0.2863 -1.1170 -0.0917 -1.3086 -4.8039 -1.2665 -1.5826 -2.1414 -1.4579 -0.0042 -0.6435 -1.4539 -1.6189 -1.0784 -1.0936 -2.2399 -0.0423 -1.4211 -0.0648 -0.0471 -0.4201 -1.5837 -1.0850 -2.3256 -0.4041 -0.0114 -0.3605 -0.1246 -0.2231 -3.0347 -0.1030
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients revascularization coronary_artery_bypass_surgery hazard_ratio percutaneous_coronary_intervention systolic_blood_pressure left_bundle_branch_block_pattern baseline electrocardiogram
H-106	-0.8400366306304932	▁re vas cular ization ▁co ron ary _ ▁arter y _ ▁by pass ▁surgery ▁hazard ▁ratio ▁per cuta ne ous _ ▁corona ry ▁intervention ▁sy sto lic _ ▁blood _ tension ▁left ▁bund le _ ▁bran ch _ ▁block _ ▁pattern ▁base line _ ▁electro card i ogram
D-106	-0.8400366306304932	revascularization coronary_ artery_ bypass surgery hazard ratio percutaneous_ coronary intervention systolic_ blood_tension left bundle_ branch_ block_ pattern baseline_ electrocardiogram
P-106	-1.8923 -0.0861 -0.1432 -0.5184 -1.1272 -0.7006 -1.2451 -1.7265 -0.1200 -0.1522 -0.3760 -0.4021 -0.0107 -0.6304 -1.9521 -0.9645 -0.1607 -0.0045 -0.0624 -1.7201 -0.7138 -0.7195 -0.7869 -2.2511 -1.4580 -0.0993 -1.9786 -0.4865 -0.4728 -2.0167 -0.7317 -3.0576 -0.3346 -0.2566 -0.6825 -3.3153 -0.1064 -0.6022 -1.1761 -1.5639 -0.8592 -0.3066 -0.0321 -0.7883 -0.5707 -0.0493 -0.1629 -0.0273 -2.1397 -0.2606
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical biomedical relative_risk confidence_interval left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1262	-1.0846680402755737	▁bio medic al ▁treatment ▁CH m ▁vent ri cular _ é je ction _ fraction ▁left ▁vent ri cular _ ▁dia sto lic _ ▁end _ ▁diameter
D-1262	-1.0846680402755737	biomedical treatment CHm ventricular_éjection_fraction left ventricular_ diastolic_ end_ diameter
P-1262	-0.0359 -0.0603 -0.0082 -2.6352 -3.1765 -0.0464 -1.5189 -0.2325 -0.3277 -1.2824 -3.2568 -1.7316 -0.0980 -1.4554 -0.0036 -1.6589 -0.7367 -0.4473 -0.2860 -0.4799 -3.7711 -0.3139 -2.3039 -0.9701 -0.2340 -1.5236 -2.0861 -0.5781 -0.1963
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective randomized crossover_study outcome stable_heart_failure patients left_ventricular_ejection_fraction homozygous haplotype β2-receptor randomized carvedilol metoprolol
H-1114	-1.0859466791152954	▁heart _ ▁failure ▁vent ri cular _ ▁e je ction _ fraction ▁Ar g _ g n 27 ▁g l 27 _ ha plo type ▁β 2- recept or ▁car vedi lol ▁met o pro lol
D-1114	-1.0859466791152954	heart_ failure ventricular_ ejection_fraction Arg_gn27 gl27_haplotype β2-receptor carvedilol metoprolol
P-1114	-4.5388 -1.0546 -1.1969 -0.4551 -0.3684 -0.2947 -1.0681 -1.4948 -1.4319 -0.1256 -3.1139 -0.0012 -1.9682 -0.0187 -3.4634 -1.2085 -0.7884 -0.1617 -0.9303 -3.9687 -1.7343 -4.3189 -3.0094 -0.1113 -0.4935 -0.3518 -0.2546 -0.0045 -0.2172 -0.9815 -0.1596 -0.4475 -0.4119 -0.2000 -0.0499 -0.6465 -0.1230 -0.0987
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients death hospitalization aor aor aor aor
H-465	-1.5842880010604858	▁low - volu me _ de _ hospital ization ▁ed
D-465	-1.5842880010604858	low-volume_de_hospitalization ed
P-465	-3.6099 -0.0312 -0.2078 -0.0221 -2.2683 -3.5318 -0.8185 -2.9454 -1.4435 -1.2251 -2.6567 -0.2512
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health_buddy_program all-cause_mortality hazard_ratio confidence_interval inpatient admissions baseline
H-1625	-0.9331232309341431	▁health _ bud y _ program ▁risk - ad just ed _ ▁all - ca use _ ▁mortal ity haz ard ▁ratio ▁h z ▁in patient _ ad missions
D-1625	-0.9331232309341431	health_budy_program risk-adjusted_ all-cause_ mortalityhazard ratio hz inpatient_admissions
P-1625	-2.3154 -1.5006 -0.4721 -0.6625 -3.0430 -1.3784 -4.3261 -0.0333 -0.0120 -0.0008 -0.1064 -1.6420 -0.1505 -0.0125 -0.0014 -0.0600 -0.5536 -0.0471 -0.1690 -0.2043 -0.0163 -0.7176 -1.2447 -3.4553 -2.6201 -0.9853 -2.1187 -0.2467 -0.0166 -0.6912 -0.1233
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted_hazard_ratios dash
H-691	-0.7283666133880615	▁multi vari able - ad just ed _ ▁hazard ▁ratio s ▁Mediterrane an _ die t
D-691	-0.7283666133880615	multivariable-adjusted_ hazard ratios Mediterranean_diet
P-691	-0.5774 -0.0021 -0.0776 -0.2417 -0.0421 -0.0066 -0.5151 -1.0086 -0.5634 -2.8097 -0.0371 -1.3260 -0.7994 -1.5164 -0.4073 -0.2734 -2.6844 -0.2224
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt nt-probnp report aric hf systolic_blood_pressure antihypertensive_medication diabetes body_mass_index coronary_heart_disease heart_rate hf area_under_the_receiver_operating_characteristic_curve auc integrated_discrimination_improvement net_reclassification_improvement nri
H-287	-0.8223513960838318	▁c t n t ▁NT - pro b NP ▁a ric _ f h ▁sy sto lic _ ▁blood _ tension ▁anti hy per tensi ve ▁medication ▁smoking ▁diabetes ▁corona ry _ heart _ ▁disease ▁heart _ ▁rate ▁ HF ▁receive r _ ▁operating _ ▁character istic _ cur ve ▁discrimina tion ▁n RI
D-287	-0.8223513960838318	ctnt NT-probNP aric_fh systolic_ blood_tension antihypertensive medication smoking diabetes coronary_heart_ disease heart_ rate HF receiver_ operating_ characteristic_curve discrimination nRI
P-287	-0.0319 -0.0858 -0.8557 -0.1195 -0.3450 -0.0054 -0.0056 -0.2618 -0.2560 -1.0993 -3.4812 -0.5326 -0.5996 -2.2175 -4.8094 -0.2319 -1.2613 -0.5362 -0.4272 -1.1124 -0.8179 -0.0296 -0.0362 -0.0211 -0.1837 -0.3724 -0.1686 -0.5235 -0.2680 -0.3888 -0.0829 -0.3561 -3.1071 -1.0438 -2.3653 -0.4702 -1.2959 -3.0222 -1.4478 -0.4158 -0.6257 -0.0030 -0.3245 -0.3584 -1.0157 -0.4536 -0.0162 -0.7984 -0.2399 -0.0104 -2.9898 -0.0118 -3.8214 -0.3858 -0.2475 -0.0576
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone patients hyperkalemia renal_function emphasis-hf patients heart_failure_and_reduced_ejection_fraction hf-ref new_york_heart_association nyha functional_class estimated_glomerular_filtration_rate egfr serum_potassium
H-1222	-0.8441958427429199	▁e pler en one ▁hyper kal emia ▁renal _ fon cti onnement ▁w RF ▁EM PHA SIS - HF ▁heart _ ▁failure ▁e je ction _ fraction ▁h - re f ▁New ▁York ▁Heart _ association ▁NY HA ▁glo mer ular _ ▁filtr ation _ ▁rate ▁e g f ▁se rum _ po tas s ium
D-1222	-0.8441958427429199	eplerenone hyperkalemia renal_fonctionnement wRF EMPHASIS-HF heart_ failure ejection_fraction h-ref New York Heart_association NYHA glomerular_ filtration_ rate egf serum_potassium
P-1222	-0.2990 -1.3073 -0.4694 -3.3949 -0.0422 -0.9636 -0.1322 -0.4747 -2.5743 -3.8687 -0.4272 -0.1760 -4.8462 -0.8123 -0.8727 -0.0244 -0.4424 -0.0061 -0.1772 -0.7141 -0.5542 -2.2265 -2.0093 -0.7740 -0.0164 -0.4955 -0.0026 -1.2436 -0.1829 -0.2106 -0.0674 -0.3423 -0.4397 -3.1532 -0.8782 -1.3256 -1.9685 -0.2568 -0.1174 -0.0729 -0.1437 -1.0997 -0.2667 -0.0126 -1.8062 -0.6546 -0.0503 -2.0379 -0.6340 -0.3849 -0.5098 -0.4957 -1.3968 -0.3579 -0.2110 -0.0686 -0.3643 -0.1062
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide nesiritide placebo change cystatin_c nesiritide placebo
H-81	-1.4513459205627441	▁low - dos e _ ▁nesi riti de ▁cum ul ative _ ▁urin e _ ▁volume nesi riti de
D-81	-1.4513459205627441	low-dose_ nesiritide cumulative_ urine_ volumenesiritide
P-81	-4.0401 -0.0477 -3.2537 -0.3715 -2.1111 -0.9291 -0.3136 -0.1853 -2.9781 -0.0151 -0.0574 -1.3089 -0.8151 -0.6153 -3.4063 -0.5886 -1.9333 -1.1475 -0.1727 -6.0333 -0.1544
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking functional_capacity 6mwt physical activity symptoms hospital_anxiety_and_depression_scale
H-572	-1.5299043655395508	▁Nordic _ ▁walking _ de _ fon cti onnement ▁m t ▁physical _ ▁activity ▁right _ ▁grip ▁ depressiv e
D-572	-1.5299043655395508	Nordic_ walking_de_fonctionnement mt physical_ activity right_ grip depressive
P-572	-0.9681 -0.8887 -1.2255 -3.0962 -3.1133 -0.4462 -1.9006 -1.0907 -0.0756 -1.0818 -0.1532 -2.2530 -2.7479 -0.4740 -5.3686 -0.4577 -0.3443 -3.8016 -0.4743 -0.1581 -3.3662 -0.1723
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients hyperkalemia patients diabetes egfr systolic_blood_pressure potassium hyperkalemia leading hospitalization hospitalization primary_outcome hospitalization hf cardiovascular_mortality
H-1225	-0.838996171951294	▁hyper kal emia ▁W RF ▁diabetes ▁e g f ▁sy sto lic _ ▁blood _ tension ▁h g ▁po tas s ium ▁hyper kal emia drug _ dis continu ation ▁hospital ization ▁W RF ▁ HF ▁cardiovascular ▁mortal ity
D-1225	-0.838996171951294	hyperkalemia WRF diabetes egf systolic_ blood_tension hg potassium hyperkalemiadrug_discontinuation hospitalization WRF HF cardiovascular mortality
P-1225	-0.5303 -1.1453 -0.4686 -3.1791 -1.0351 -0.2501 -0.0256 -1.1969 -1.1561 -1.8237 -0.2830 -2.4040 -0.3971 -0.5044 -0.7833 -0.4164 -0.0109 -0.0173 -1.2951 -0.2682 -0.0397 -0.0462 -0.3478 -1.2593 -0.3750 -1.6883 -1.0731 -0.2132 -0.0001 -0.0352 -2.9506 -0.7322 -3.6380 -1.3681 -1.9038 -0.1350 -0.1974 -0.7697 -0.1796 -0.1884 -0.0679
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf biosynthetic_enzymes lyso-paf_acetyltransferase lyso-paf-at 1-alkyl-2-acetyl-sn-glycerol_cholinephosphotransferase paf-cpt catabolic_isoenzymes paf-acetylhydrolase paf-ah lipoprotein-associated_phospholipase_a2 lp-pla2 leukocytes
H-1268	-0.7046698331832886	▁PA f ▁bio syn the tic _ ▁enzym es lys o - pa f ▁a ce tyl transfer ase lys o - pa f - at ▁di thi oth rei tol ▁d t - in sensitiv e ▁CD p _ ▁cho line _ phos pho transfer ase ▁p f - c p ▁cata bo lic _ ▁iso en zy mes ▁p f - ace tyl hydro lase ▁p f - AH ▁lipo prote in - as soci ated _ phos pho lipa se ▁l p - PLA
D-1268	-0.7046698331832886	PAf biosynthetic_ enzymeslyso-paf acetyltransferaselyso-paf-at dithiothreitol dt-insensitive CDp_ choline_phosphotransferase pf-cp catabolic_ isoenzymes pf-acetylhydrolase pf-AH lipoprotein-associated_phospholipase lp-PLA
P-1268	-0.3279 -0.0724 -0.6350 -0.0027 -0.3681 -1.7720 -1.8411 -0.3687 -0.0752 -1.6651 -0.0252 -0.0221 -0.4086 -0.0606 -0.8483 -0.2076 -0.6054 -0.7260 -1.3598 -2.1414 -0.0110 -0.0113 -0.2852 -0.0483 -0.9112 -1.1167 -0.0665 -0.0208 -1.4740 -0.1837 -0.4281 -0.0803 -0.0626 -2.1223 -0.0395 -0.0082 -0.0174 -0.1427 -0.1327 -4.4095 -2.4518 -0.0165 -2.8164 -3.9522 -1.2229 -1.8786 -1.3276 -1.6713 -0.1789 -0.3719 -0.1485 -0.7942 -2.1829 -0.0187 -0.7211 -0.5187 -0.6005 -0.3092 -0.0018 -0.0372 -2.4115 -0.1522 -0.0632 -0.3956 -0.2060 -0.2838 -0.0679 -1.2870 -0.2739 -0.0615 -0.6086 -0.0143 -1.5465 -0.5974 -1.0398 -0.1047 -0.0094 -0.4581 -0.9576 -0.5087 -0.3569 -0.1068 -0.2206 -1.5203 -0.0171 -0.1548 -0.2331 -2.6247 -0.1070
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine baseline follow-up exercise_capacity mets mets peak_oxygen_uptake peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1175	-1.2072705030441284	▁i va bra dine _ group ▁follow - up _ ▁exercise _ indu ce
D-1175	-1.2072705030441284	ivabradine_group follow-up_ exercise_induce
P-1175	-0.0257 -0.0407 -0.6116 -0.0356 -4.5818 -0.7780 -2.0303 -0.0201 -0.0165 -0.9197 -0.9871 -0.8622 -0.0529 -2.4679 -5.7780 -0.1081
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate_analysis chf odds_ratio chest hypertension genes rac2 doxorubicin_efflux_transporter abcc2
H-1455	-0.902559757232666	▁CHF ▁o ds _ ra tion ▁h ct ▁che st ▁radi ation ▁hyper tension ▁ NAD _ h - oxid ase ▁sub un it _ RAC 2 ▁h f ▁do xor ubi cin _ eff lux _ ▁transporter
D-1455	-0.902559757232666	CHF ods_ration hct chest radiation hypertension NAD_h-oxidase subunit_RAC2 hf doxorubicin_efflux_ transporter
P-1455	-2.1569 -5.1656 -0.0404 -2.5889 -0.1843 -1.7891 -0.0850 -1.4438 -2.1552 -0.0937 -0.1605 -0.0171 -0.0019 -0.0004 -1.6124 -0.0656 -3.8973 -0.5464 -0.2112 -0.0032 -2.4657 -1.6476 -0.1224 -0.0641 -0.6588 -0.6568 -0.0630 -0.1795 -1.8257 -0.7049 -0.6335 -0.0911 -0.0836 -0.5575 -0.2652 -0.1006 -1.4319 -0.9879 -1.1337 -0.2101
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline follow-up nyha_classification patients patient change patient quality_of_life duke_activity_status_index kansas_city_cardiomyopathy_questionnaire 6_min_walk_test
H-1958	-1.1485793590545654	▁NY HA ▁classifica tion ▁class _ III ▁class _ ▁II ▁patient ▁quality _ of _ ▁life ▁Duke _ ▁Activ ity _ status _ ▁Index ▁Kansas _ City _ ▁Card i om yo pathy _ ▁Question naire
D-1958	-1.1485793590545654	NYHA classification class_III class_ II patient quality_of_ life Duke_ Activity_status_ Index Kansas_City_ Cardiomyopathy_ Questionnaire
P-1958	-0.8804 -0.9997 -2.2619 -0.0193 -0.8517 -0.6164 -2.5329 -3.1888 -0.5004 -1.0789 -4.2524 -3.4232 -0.1861 -0.9532 -0.2728 -2.5389 -0.1613 -0.6751 -0.4907 -0.0517 -0.1824 -0.6242 -0.6234 -2.2756 -0.8875 -1.1616 -1.7799 -0.8442 -2.1921 -0.1175 -0.0897 -1.7067 -0.0827 -2.7069 -1.1162 -0.0007 -1.1320 -0.1867
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo dopamine dopamine placebo change cystatin_c dopamine placebo
H-80	-1.4267473220825195	▁low - dos e _ ▁dop amine ▁cum ul ative _ ▁urin e _ ▁volume dop amine
D-80	-1.4267473220825195	low-dose_ dopamine cumulative_ urine_ volumedopamine
P-80	-2.7559 -0.0496 -2.2857 -0.4265 -2.7422 -1.3324 -0.4052 -1.6245 -0.0227 -0.0505 -1.1658 -0.8424 -0.6033 -3.1257 -0.5350 -3.1350 -0.1686 -5.6828 -0.1544
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard_ratio confidence_interval baseline glomerular_filtration_rate chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks new_york_heart_association_class atrial_fibrillation congestive_hf mortality
H-66	-1.074204683303833	▁fréquence ▁h z ▁figure ▁base line _ ▁glo mer ular _ ▁filtr ation ▁h z ▁chronic _ ▁ob struct ive _ ▁pulmonar y ▁disease ▁diabetes ▁vent ri cular _ ▁e je ction _ fraction ▁ fraction ▁i CD _ ▁shock s ▁New ▁York _ ▁Heart _ association ▁at rial _ ▁fi bril lation ▁con ges tive _ HF
D-66	-1.074204683303833	fréquence hz figure baseline_ glomerular_ filtration hz chronic_ obstructive_ pulmonary disease diabetes ventricular_ ejection_fraction fraction iCD_ shocks New York_ Heart_association atrial_ fibrillation congestive_HF
P-66	-4.8854 -3.7470 -1.5190 -3.3382 -4.6165 -0.1508 -0.5117 -1.8412 -0.0474 -0.1105 -1.4674 -0.4188 -0.0170 -5.2864 -0.6810 -2.7461 -0.2653 -1.7619 -0.1468 -0.0603 -0.5195 -0.1032 -0.1475 -1.1276 -0.3364 -1.2336 -0.2593 -0.1456 -0.4505 -1.2948 -0.2596 -0.0297 -0.9003 -0.0016 -5.4337 -0.0131 -1.1616 -1.9978 -3.2749 -0.6194 -0.0341 -0.3280 -1.2837 -1.1244 -0.8545 -1.0283 -0.8140 -0.4459 -0.1469 -0.2146 -1.7408 -0.0300 -0.0185 -0.4513 -0.1670 -0.1520 -0.4458 -1.3591 -0.6782 -0.2065
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable_analysis end_point peak_oxygen_uptake hazard_ratio confidence_interval ventilatory_efficiency_slope hemoglobin left_ventricular_ejection_fraction renal_function renal_disease sodium
H-1761	-0.9693894982337952	▁oxygen _ up take ▁hazard ▁ratio ▁ventilator y _ ▁efficiency ▁s lope ▁hem o glob in ▁vent ri cular _ ▁e je ction _ fraction ▁renal
D-1761	-0.9693894982337952	oxygen_uptake hazard ratio ventilatory_ efficiency slope hemoglobin ventricular_ ejection_fraction renal
P-1761	-2.7711 -2.2128 -0.3832 -0.3777 -0.2204 -0.7162 -3.1413 -0.2221 -0.4575 -1.4372 -1.5133 -0.0134 -0.2638 -0.1366 -0.0125 -0.7612 -1.8775 -0.3942 -0.2454 -0.5845 -1.3656 -0.4858 -0.0445 -1.1976 -0.0005 -0.2888 -5.8294 -0.1885
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute_walked_distance kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire beck_depression_inventory flow-mediated_dilatation fes placebo b-type_natriuretic_peptide mitral
H-1331	-0.9185274839401245	▁Kansas _ city _ card i om yo pathy _ ▁Question naire ▁Minnesota _ ▁Living _ ▁with _ ▁Heart _ ▁Fail ure ▁questions naire ▁Beck _ de pression ▁in ven tory ▁Z ung ▁flow - media ted _ di la tation _ ▁diameter ▁F es ▁na tri ure tic _ pe pti de ▁mit ral _ e _ ▁wa ve
D-1331	-0.9185274839401245	Kansas_city_cardiomyopathy_ Questionnaire Minnesota_ Living_ with_ Heart_ Failure questionsnaire Beck_depression inventory Zung flow-mediated_dilatation_ diameter Fes natriuretic_peptide mitral_e_ wave
P-1331	-0.2356 -2.0769 -1.0729 -1.1407 -2.7532 -0.0866 -0.1805 -1.3423 -0.0683 -4.0114 -1.2076 -0.0004 -0.1085 -1.5914 -0.9332 -0.4627 -1.3924 -0.1805 -0.2778 -0.4047 -0.1567 -0.0746 -4.1947 -1.5362 -0.3658 -1.8194 -0.0144 -0.1803 -1.3145 -0.6379 -0.0593 -0.8616 -0.1450 -1.2118 -0.0991 -0.3315 -1.9175 -0.1027 -1.5506 -0.1375 -0.0144 -0.7020 -0.1020 -1.5779 -0.4015 -1.8693 -0.0258 -0.0752 -2.0269 -1.0074 -0.3024 -0.2113 -0.0927 -2.2856 -0.0384 -1.3743 -2.0463 -1.1241 -4.5310 -0.0136 -0.7249 -0.1631
2021-01-18 18:22:43 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-18 18:22:43 | INFO | fairseq_cli.generate | Translated 2,024 sentences (31,728 tokens) in 175.9s (11.51 sentences/s, 180.35 tokens/s)
2021-01-18 18:22:43 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 23.24, 55.5/34.3/23.4/16.2 (BP=0.797, ratio=0.815, syslen=31728, reflen=38932)
